2	4687242	Increase from baseline in the mean VO2 max after 8 weeks	There was a greater increase from baseline (P < 0.0001) in the mean VO2 max with KSM-66 Ashwagandha (n = 24) compared to placebo (n = 25) at 8 weeks (4.91 and 1.42, respectively) and at 12 weeks (5.67 and 1.86 respectively).
2	4687242	Quality of Life scores at 12 weeks	The quality of life scores for all subdomains significantly improved to a greater extent in the Ashwagandha group at 12 weeks compared to placebo (P < 0.05).  
1	4520847	increase in IL-6 levels	The changes in serum IL-6 after surgery did not correlate with the value of intra-abdominal pressure.  
2	3898240	Serum Lutein	In the ≥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly HDL3, (α-carotene, p = 0.008; β-cryptoxanthin, p = 0.042; lutein, p = 0.012; lycopene, p = 0.016), as did the activities of paraoxonase-1 and lecithin cholesterol acyltransferase in HDL3 (p = 0.006 and 0.044, respectively).  
2	3898240	High density lipoproteins 3 Lecithin–cholesterol acyltransferase	In the ≥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly HDL3, (α-carotene, p = 0.008; β-cryptoxanthin, p = 0.042; lutein, p = 0.012; lycopene, p = 0.016), as did the activities of paraoxonase-1 and lecithin cholesterol acyltransferase in HDL3 (p = 0.006 and 0.044, respectively).  
2	3898240	Serum α-carotene	In the ≥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly HDL3, (α-carotene, p = 0.008; β-cryptoxanthin, p = 0.042; lutein, p = 0.012; lycopene, p = 0.016), as did the activities of paraoxonase-1 and lecithin cholesterol acyltransferase in HDL3 (p = 0.006 and 0.044, respectively).  
2	3898240	Serum β-cryptoxanthin	In the ≥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly HDL3, (α-carotene, p = 0.008; β-cryptoxanthin, p = 0.042; lutein, p = 0.012; lycopene, p = 0.016), as did the activities of paraoxonase-1 and lecithin cholesterol acyltransferase in HDL3 (p = 0.006 and 0.044, respectively).  
2	3898240	High density lipoproteins 3 Lycopene	In the ≥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly HDL3, (α-carotene, p = 0.008; β-cryptoxanthin, p = 0.042; lutein, p = 0.012; lycopene, p = 0.016), as did the activities of paraoxonase-1 and lecithin cholesterol acyltransferase in HDL3 (p = 0.006 and 0.044, respectively).  
2	3898240	High density lipoproteins 3 Paraoxonase 1	In the ≥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly HDL3, (α-carotene, p = 0.008; β-cryptoxanthin, p = 0.042; lutein, p = 0.012; lycopene, p = 0.016), as did the activities of paraoxonase-1 and lecithin cholesterol acyltransferase in HDL3 (p = 0.006 and 0.044, respectively).  
1	2464595	overall complications	Major and minor complications were similar in the two groups.  
1	2464595	the time to drain removal	Thirty patients were then randomized; the median time to drain removal in the control group (n = 14) was 30 days (range, 13–74) compared to 29 days (range, 11–45) in the fibrin sealant group (n = 16; P = 0.6).
1	4627811	maximal oxygen uptake	Training improved maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse (all P<0.05), whilst no differences were present between high-intensity interval training and continuous training (N.S.).
2	4627811	maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse	Training improved maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse (all P<0.05), whilst no differences were present between high-intensity interval training and continuous training (N.S.).
2	5735476	Time for rescue analgesia	Time for rescue analgesia in Group D5-377.46 ± 60.05, in Group D10-401.60 ± 61.11, and in Group D15-517.96 ± 97.30, which is statistically highly significant (P < 0.000).  
2	5735476	The time taken for complete sensory recovery	The time taken for complete sensory recovery in Group D5-319.83 ± 61.41, Group D10-336.13 ± 61.38, and Group D15-415.20 ± 96.6, which is statistically highly significant (P = 0.000).
2	5735476	The time taken for two-segment sensory regression	The time taken for two-segment sensory regression Group D5-96.66 ± 33.67, Group D10-116.80 ± 36.27, and Group D15 120.96 ± 30.24, (P = 0.014).
0	5735476	The onset time of sensory block	The onset time of sensory block in Group D5-2.76 ± 1.32, Group D10-2.45 ± 1.50, and Group D15-1.86±0.93, which is statistically significant (P = 0.025).
2	3321528	wrist flexion, hip flexion, knee extension, and ankle dorsiflexion	Twenty four patients in the electrical muscle stimulation group and 28 patients in the control group were finally evaluated. electrical muscle stimulation patients achieved higher Medical Research Council scores than controls (P ≤ 0.05) in wrist flexion, hip flexion, knee extension, and ankle dorsiflexion.
2	3321528	the total Medical Research Council score of the legs	Collectively, the electrical muscle stimulation group performed higher (P < 0.01) in the legs and overall.
1	4472927	TNF-α	Furthermore, the serum IL-10 and E-selectin levels in group B were significantly higher than those in group C (serum IL-10: P<0.001; E-selectin: P<0.05); however, the serum TNF-α levels did not differ among groups (all P>0.05).
0	4472927	E-selectin	The serum IL-10 and E-selectin levels in group A were significantly lower than those in group B (serum IL-10: P<0.05; E-selectin: P<0.05).
1	4472927	E-selectin	The serum IL-10 in group A was significantly higher than that in group C (P<0.01); the serum E-selectin levels in group A did not significantly differ compared with those in group C (P>0.05).
2	4472927	E-selectin	Furthermore, the serum IL-10 and E-selectin levels in group B were significantly higher than those in group C (serum IL-10: P<0.001; E-selectin: P<0.05); however, the serum TNF-α levels did not differ among groups (all P>0.05).
0	4472927	IL-10	The serum IL-10 and E-selectin levels in group A were significantly lower than those in group B (serum IL-10: P<0.05; E-selectin: P<0.05).
2	4472927	IL-10	The serum IL-10 in group A was significantly higher than that in group C (P<0.01); the serum E-selectin levels in group A did not significantly differ compared with those in group C (P>0.05).
0	5282794	pain response	Infants born by vaginal operative delivery displayed a lower pain response after plastic cup than metal cup ventouse delivery (p < 0.001), but the pain response was generally lower than expected and they recovered fully within 72 h.  ABSTRACT.CONCLUSIONS. 
0	3108665	Postoperative complications	Administration of somatostatin reduced the exocrine granule number, and the patients suffered from fewer postoperative complications.  
1	4206772	6-min walk test (6-min walk test) distance at week 24 - patients with Morquio A syndrome (mucopolysaccharidosis IVA)	At week 24, the estimated mean effect on the 6-min walk test versus placebo was 22.5 m (95 % CI 4.0, 40.9; P = 0.017) for weekly and 0.5 m (95 % CI −17.8, 18.9; P = 0.954) for qow.
2	4206772	6-min walk test (6-min walk test) distance at week 24 - patients with Morquio A syndrome (mucopolysaccharidosis IVA)	At week 24, the estimated mean effect on the 6-min walk test versus placebo was 22.5 m (95 % CI 4.0, 40.9; P = 0.017) for weekly and 0.5 m (95 % CI −17.8, 18.9; P = 0.954) for qow.
0	5120251	Decrease of platelets	The decrease in platelet level in the intervention group was significantly lower than that in the control group (P = 0.03).  
0	5120251	Blood loss	Blood loss in the intervention group with the administration of tranexamic acid was significantly lesser than that in the control group (P = 0.01).
0	5120251	Hemoglobin decrease	The present study showed that local administration of tranexamic acid significantly reduces bleeding after prostatectomy surgery and is effective in preventing postoperative hemoglobin decrease.
2	4532714	weekly volumes of physical activity	Patients randomized to personalized audio-playlists with tempo-pace synchrony achieved higher weekly volumes of physical activity than did their non-music usual-care comparators (475.6 min vs. 370.2 min, P < 0.001).
2	4532714	utilizing audio-playlist devices	Patients randomized to music with rhythmic auditory stimulation utilized their audio-playlist devices more frequently than did non-RAS music counterparts (P < 0.001).  
1	4402460	Hypoxia	One dose of bevacizumab changed the expression of 14 genes and led to a significant decrease in microvessel density and in the proportion of pericyte-covered blood vessels, and a small but nonsignificant increase in hypoxia.
0	4402460	Microvessel density	One dose of bevacizumab changed the expression of 14 genes and led to a significant decrease in microvessel density and in the proportion of pericyte-covered blood vessels, and a small but nonsignificant increase in hypoxia.
2	4569275	Estimated infection hazard ratios for men	With the additional 1286 person years of 503-S follow-up, the estimated HR over Phambili and HVTN 503-S follow-up was 1.52 (95% CI 1.08–2.15, p = 0.02, 82 vaccine/54 placebo infections). The HR was significant for men (HR = 2.75, 95% CI 1.49, 5.06, p = 0.001) but not for women (HR = 1.12, 95% CI 0.73, 1.72, p = 0.62).  
1	4569275	Estimated infection hazard ratios for women	With the additional 1286 person years of 503-S follow-up, the estimated HR over Phambili and HVTN 503-S follow-up was 1.52 (95% CI 1.08–2.15, p = 0.02, 82 vaccine/54 placebo infections). The HR was significant for men (HR = 2.75, 95% CI 1.49, 5.06, p = 0.001) but not for women (HR = 1.12, 95% CI 0.73, 1.72, p = 0.62).  
0	4662763	Shear bond strength	The mean shear bond strength value in group one (pH 3.8) was significantly lower than that in other groups (P<0.05). The differences between other groups were not significant (P>0.05).  
1	4662763	Shear bond strength	The mean shear bond strength value in group one (pH 3.8) was significantly lower than that in other groups (P<0.05). The differences between other groups were not significant (P>0.05).  
0	4662763	Shear bond strength	The mean shear bond strength value in group one (pH 3.8) was significantly lower than that in other groups (P<0.05).
1	4662763	Shear bond strength	The mean shear bond strength value in group one (pH 3.8) was significantly lower than that in other groups (P<0.05). The differences between other groups were not significant (P>0.05).  
0	4662763	Shear bond strength	The mean shear bond strength value in group one (pH 3.8) was significantly lower than that in other groups (P<0.05).
1	4662763	Shear bond strength	The mean shear bond strength value in group one (pH 3.8) was significantly lower than that in other groups (P<0.05). The differences between other groups were not significant (P>0.05).  
0	4141382	VAS sedation	VAS for sedation on reversal of anesthesia showed the following association: Group CSuNeo = Group CSuNeoAdr < Group CSu = Group CSuAdr = Group IVSu (P < 0.005).
1	5966460	Protein levels	Compared to placebo, Griffithsin gels were not associated with any significant changes to protein levels at any time point (FDR < 5%), but increased abundances of two common and beneficial microbial taxa after 24 hours were observed in HEC-GRFT gel (p < 2E-09).
0	3996149	blood cholesterol - type 2 diabetes patients	Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and tumor necrosis factor-α, high sensitive C-reactive protein, interleukin-6 significantly (P < 0.01).
0	3996149	blood cholesterol - type 2 diabetes patients	Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and tumor necrosis factor-α, high sensitive C-reactive protein, interleukin-6 significantly (P < 0.01).
0	3996149	LDL-C - type 2 diabetes patients	Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and tumor necrosis factor-α, high sensitive C-reactive protein, interleukin-6 significantly (P < 0.01).
0	3996149	LDL-C - type 2 diabetes patients	Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and tumor necrosis factor-α, high sensitive C-reactive protein, interleukin-6 significantly (P < 0.01).
0	3996149	interleukin-6 - type 2 diabetes patients	Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and tumor necrosis factor-α, high sensitive C-reactive protein, interleukin-6 significantly (P < 0.01).
0	3996149	interleukin-6 - type 2 diabetes patients	Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and tumor necrosis factor-α, high sensitive C-reactive protein, interleukin-6 significantly (P < 0.01).
0	3996149	triglyceride - type 2 diabetes patients	Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and tumor necrosis factor-α, high sensitive C-reactive protein, interleukin-6 significantly (P < 0.01).
0	3996149	triglyceride - type 2 diabetes patients	Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and tumor necrosis factor-α, high sensitive C-reactive protein, interleukin-6 significantly (P < 0.01).
2	3043099	Insulin area under the curve	Following the intervention, there was a significant reduction in insulin area under the curve in Mexican Americans (29%) and nonHispanic whites (32%), however, the insulin area under the curve remained higher (p<0.05) for Mexican Americans (post  = 1635 μU*180 min/mL) than for nonHispanic whites (post = 1211 μU*180 min/mL).
2	3043099	Insulin area under the curve	Pre intervention insulin area under the curve was 28% higher (p<0.05) in Mexican Americans (insulin area under the curve pre  =  2298 μU*180 min/mL) than in nonHispanic whites (insulin area under the curve = 1795 μU*180 min/mL).
0	3043099	Improvement in Low density lipoprotein-cholesterol and small dense LDL particles concentrations	Plasma cholesterol and TG concentrations significantly improved in both groups, but concentrations of low density lipoprotein-cholesterol and small dense LDL particles significantly improved only in the nonHispanic whites.  
2	3849694	The effectiveness of the intervention	The effectiveness of the intervention (vs control) was more pronounced among participants with a low (vs high) education level (T2-T3: B=–0.32, SE 0.16, P=.049; T2-T4: B=–0.42, SE 0.21, P=.049), participants with high (vs low) positive outcome expectations (T2-T3: B=–0.12, SE 0.05, P=.02) and participants with anxiety disorder (vs mood disorder) (T2-T3: B=–0.43, SE 0.21, P=.04).
2	3849694	The effectiveness of the intervention	The effectiveness of the intervention (vs control) was more pronounced among participants with a low (vs high) education level (T2-T3: B=–0.32, SE 0.16, P=.049; T2-T4: B=–0.42, SE 0.21, P=.049), participants with high (vs low) positive outcome expectations (T2-T3: B=–0.12, SE 0.05, P=.02) and participants with anxiety disorder (vs mood disorder) (T2-T3: B=–0.43, SE 0.21, P=.04).
1	5125721	Blood glucose	The primary outcomes were that Tartary buckwheat significantly decreased the rela tive changes in urinary albumin to creatinine ratio (2.43–2.35, logarithmic transformed mg/g creatinine) and urea nitrogen (5.12–4.91 mmol/L) in the Tartary buckwheat intervention group vs the diet control group at 4 weeks (P<0.05), without obvious effect on blood glucose during the 4-week study.
0	5125721	Urea nitrogen	The primary outcomes were that Tartary buckwheat significantly decreased the rela tive changes in urinary albumin to creatinine ratio (2.43–2.35, logarithmic transformed mg/g creatinine) and urea nitrogen (5.12–4.91 mmol/L) in the Tartary buckwheat intervention group vs the diet control group at 4 weeks (P<0.05), without obvious effect on blood glucose during the 4-week study.
2	2908852	Intraocular pressure after 3 months	intraocular pressure in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection.  
1	3515338	Total mental health care costs	Mean total costs were €4795 in the Problem-Solving Treatment group and €6857 in the usual care group. Costs were not statistically significantly different between the two groups (95% CI -4698;359).
1	3515338	clinical outcomes at 9 months	There were no statistically significant differences in clinical outcomes at 9 months.
2	5156970	relief of overall symptoms	The onset of relief occurred significantly sooner, and duration of relief was significantly longer in azithromycin group. Movement, abdominal pain, bloating, and gas were significantly better in azithromycin group.
0	5156970	daily bloating and gas in all 12 weeks	Significantly more patients in azithromycin group felt relief in bloating and gas and had greater consistency relief in almost all weeks.  
0	3633335	Vomiting	We found that the incidence of vomiting was lower in group II (17.5%), group IV (7.5%), and group VI (10%) compared with group I (55%), group III (27.5%), and group V (30%), respectively (P < 0.05).
0	3633335	Vomiting	We conclude that compared with sevoflurane anesthesia alone, anesthesia with either propofol alone or propofol combined with sevoflurane resulted in a reduced incidence of vomiting and nausea during the first 24 h after surgery. Administration of ondansetron effectively reduced the incidence of vomiting but not that of nausea for all three types of general anesthesia.
0	3633335	Vomiting	The incidence of vomiting was also lower in group III (27.5%) and group V (30%) when compared with group I (55%) (P < 0.05).
0	3633335	Vomiting	We conclude that compared with sevoflurane anesthesia alone, anesthesia with either propofol alone or propofol combined with sevoflurane resulted in a reduced incidence of vomiting and nausea during the first 24 h after surgery.
0	3633335	Nausea	Groups III and V had a lower incidence of nausea than group I (P < 0.05).  
0	3633335	Nausea	Two hundred and forty patients were randomly allocated into six groups: Group I, anesthesia was maintained with sevoflurane; Group II, anesthesia was maintained with sevoflurane and 8 mg of ondansetron; Group III, anesthesia was maintained with propofol; Group IV, anesthesia was maintained with propofol and 8 mg of ondansetron; Group V, anesthesia was maintained with sevoflurane and propofol; Group VI, anesthesia was maintained with sevoflurane combined with propofol and 8 mg of ondansetron.  
0	3633335	Nausea	Two hundred and forty patients were randomly allocated into six groups: Group I, anesthesia was maintained with sevoflurane; Group II, anesthesia was maintained with sevoflurane and 8 mg of ondansetron; Group III, anesthesia was maintained with propofol; Group IV, anesthesia was maintained with propofol and 8 mg of ondansetron; Group V, anesthesia was maintained with sevoflurane and propofol; Group VI, anesthesia was maintained with sevoflurane combined with propofol and 8 mg of ondansetron.  
0	3633335	Vomiting	We found that the incidence of vomiting was lower in group II (17.5%), group IV (7.5%), and group VI (10%) compared with group I (55%), group III (27.5%), and group V (30%), respectively (P < 0.05).
2	3276927	relieving factors in reversible inguinal hernia	The relieving factors showed significant increase with P≤0.001.  
2	3276927	effective in the treatment of reversible inguinal hernia	Yoga therapy with selected asanas is effective in the treatment of reversible inguinal hernia.
0	3276927	frequency of occurrence in reversible inguinal hernia	The pre and post interventional data were compared statistically and found significant reduction of symptoms with P≤0.001 in pain, frequency of occurrence and aggravating factors.
0	3276927	pain in reversible inguinal hernia	The pre and post interventional data were compared statistically and found significant reduction of symptoms with P≤0.001 in pain, frequency of occurrence and aggravating factors.
0	3276927	aggravating factors in reversible inguinal hernia	The pre and post interventional data were compared statistically and found significant reduction of symptoms with P≤0.001 in pain, frequency of occurrence and aggravating factors.
1	3208342	TQ-score improvement	Results: Directly after therapy there was a significant improvement of the TQ-score in both groups. Comparison of both groups revealed a trend toward more pronounced effects for the combined group (effect size: Cohen's d = 0.176), but this effect did not reach significance.
1	3208342	Response rate	Results: Directly after therapy there was a significant improvement of the TQ-score in both groups. Comparison of both groups revealed a trend toward more pronounced effects for the combined group (effect size: Cohen's d = 0.176), but this effect did not reach significance.
2	3880665	Body mass	Body mass and body mass index increased (P < 0.05) after 8 weeks aerobic exercise compared to the control group.
1	3880665	Body fat percentage	For waist to hip ratio (waist to hip ratio), body fat percentage and maximal oxygen consumption there were no significant differences between the exercise group and the control group.
1	3880665	Body fat percentage	There were virtually no changes in body fat percentage, fasting glucose, insulin, insulin resistance and retinol binding protein 4 levels after 8 weeks training.  
1	3880665	Fasting glucose	There were virtually no changes in body fat percentage, fasting glucose, insulin, insulin resistance and retinol binding protein 4 levels after 8 weeks training.  
1	3880665	Insulin resistance	There were virtually no changes in body fat percentage, fasting glucose, insulin, insulin resistance and retinol binding protein 4 levels after 8 weeks training.  
1	3880665	Waist to hip ratio	For waist to hip ratio (waist to hip ratio), body fat percentage and maximal oxygen consumption there were no significant differences between the exercise group and the control group.
1	3880665	Maximal oxygen consumption	For waist to hip ratio (waist to hip ratio), body fat percentage and maximal oxygen consumption there were no significant differences between the exercise group and the control group.
0	4412792	Glomerulosclerosis at day 14	Both glomerulosclerosis and urinary albumin-to-creatinine ratio were less in the ACE-inhibition arm at day 14.
0	4412792	Urinary albumin-to-creatinine ratio at day 14	Both glomerulosclerosis and urinary albumin-to-creatinine ratio were less in the ACE-inhibition arm at day 14.
1	4412792	Podocyte proliferation	Podocyte proliferation did not occur at any time in any group.
2	2645358	Weight loss	At 12 months, the intervention group had greater weight loss (-5.6 ± 6.8% vs. -1.2 ± 4.6%, p < .001) and larger decreases in body size dissatisfaction (effect size of 1.08 vs. .41, p < .001) than the comparison group.
0	2645358	Body size dissatisfaction	At 12 months, the intervention group had greater weight loss (-5.6 ± 6.8% vs. -1.2 ± 4.6%, p < .001) and larger decreases in body size dissatisfaction (effect size of 1.08 vs. .41, p < .001) than the comparison group.
1	2788265	Progression-free survival	Median progression-free survival was estimated with 4.0, 5.6, and 6.0 months (P=0.21).
1	3228981	Abdominal pain/discomfort frequency score	Compared to baselines in per protocol populations, the reduced abdominal pain/discomfort frequency scores in otilonium bromide and mebeverine were 0.55 ± 1.20 (P = 0.011) and 0.37 ± 1.11 (P = 0.042), respectively, to show similarly reduced scores.
1	3228981	Abdominal bloating	Besides, the improved abdominal pain/discomfort frequency scores at 4th week visit, final alleviations in abdominal pain intensity, flatulence, abdominal bloating and satisfied stool frequency with global assessments filled by both patients and investigators were significantly achieved by both treatments, and otilonium bromide was not inferior to mebeverine in treating these parameters.  
1	3228981	Flatulence	Besides, the improved abdominal pain/discomfort frequency scores at 4th week visit, final alleviations in abdominal pain intensity, flatulence, abdominal bloating and satisfied stool frequency with global assessments filled by both patients and investigators were significantly achieved by both treatments, and otilonium bromide was not inferior to mebeverine in treating these parameters.  
1	3228981	Satisfied stool frequency	Besides, the improved abdominal pain/discomfort frequency scores at 4th week visit, final alleviations in abdominal pain intensity, flatulence, abdominal bloating and satisfied stool frequency with global assessments filled by both patients and investigators were significantly achieved by both treatments, and otilonium bromide was not inferior to mebeverine in treating these parameters.  
1	2853089	declared uptake of the trial results - Breast cancer patients participating in a trial on the efficacy of Trastuzumab	The Internet group's declared uptake of the trial results was only slightly higher (47.1% vs 33.9% P=0.166); however, they understood the results significantly more accurately (18.8% vs 5.6% P=0.039).  
2	2853089	accurately understanding the results - Breast cancer patients participating in a trial on the efficacy of Trastuzumab	The Internet group's declared uptake of the trial results was only slightly higher (47.1% vs 33.9% P=0.166); however, they understood the results significantly more accurately (18.8% vs 5.6% P=0.039).  
2	5399146	The absolute plasma concentration of activated FVII	The absolute plasma concentration of activated FVII was higher (P<0.05) among the able-bodied compared with the tetraplegic groups.
0	4639584	Weight after 8 weeks	At the end of the 8 weeks, weight and BMI further decreased in the group consuming the fiber-enriched diet (p<0.01).
0	4639584	Insulin resistance	Insulin resistance, estimated with the Homeostasis Model Assessment index and the Lipid Accumulation Product index, improved in all subjects after the fiber-enriched flour diet (p = 0.03, p = 0.02, respectively).
0	3786468	waist-hip ratio of women	Green tea suppressed waist-hip ratio of women from a significant increase and suppressed mean arterial pressure of men and women from a significant decrease after week 14.
0	3786468	alanine aminotransferase level in women	It reduced alanine aminotransferase level in women by 13.0% (P < 0.1) while increasing the antioxidant potential of men and women sera by 2.7% (P < 0.1) and 5.1% (P < 0.1).
1	2909923	Respiratory exchange ratio	Plasma glucose, blood lactate, and respiratory exchange ratio during the 2-hour ride, as well as VO2 peak, were not affected by creatine supplementation.
1	2909923	Plasma glucose	Plasma glucose, blood lactate, and respiratory exchange ratio during the 2-hour ride, as well as VO2 peak, were not affected by creatine supplementation.
1	2909923	Blood lactate	Plasma glucose, blood lactate, and respiratory exchange ratio during the 2-hour ride, as well as VO2 peak, were not affected by creatine supplementation.
1	2909923	VO2 peak	Plasma glucose, blood lactate, and respiratory exchange ratio during the 2-hour ride, as well as VO2 peak, were not affected by creatine supplementation.
2	2909923	Muscle creatine phosphate	There was a 24.5 ± 10.0% increase in resting muscle total creatine and 38.4 ± 23.9% increase in muscle creatine phosphate in the creatine group (P < 0.05).
0	3788226	Atlantooccipital distance	The atlantooccipital distance (atlantooccipital distance) traversed while using Truview laryngoscope was significantly less than with Macintosh blade (26%; P = 0.001).
2	3788226	Appropriate laryngoscopic view	Truview blade produced a better laryngoscopic view (P = 0.005) than Macintosh blade, but had a longer time to laryngoscopy (P = 0.04).  
2	3788226	Laryngoscopy time	Truview blade produced a better laryngoscopic view (P = 0.005) than Macintosh blade, but had a longer time to laryngoscopy (P = 0.04).  
0	3788226	Cervical spine movement at C0-C1	However, the movement was significantly less with Truview compared to the Macintosh laryngoscope at C0–C1 (21%; P = 0.005) and C1–C2 levels (32%; P = 0.009).
0	3788226	Cervical spine movement at C1-C2	Significant cervical spine movement occurred at all segments when compared to the baseline with both the Macintosh and Truview laryngoscopes (P < 0.001). However, the movement was significantly less with Truview compared to the Macintosh laryngoscope at C0–C1 (21%; P = 0.005) and C1–C2 levels (32%; P = 0.009).
2	3661884	strength in the exercises for leg extension (leg extension) and Low Row (Low Row)	Both groups showed significant increases in strength (SSGpre vs. SSGpost; PIGpre vs. PIGpost) in the same exercises for leg extension (leg extension) and Low Row (Low Row). Specifically, in the static stretching group group, the parameters for leg extension were (p = 0.0015 and ES = 2.28 - Large), and the parameters for Low Row were (p = 0.002 and ES = 1.95 - Large).
1	3661884	strength in the exercises for leg extension (leg extension) and Low Row (Low Row)	No differences were found between the groups (SSGpost vs. PIGpost).
2	3661884	flexibility of joints	Both groups showed significant increases in flexibility but in different joints (SSGpre vs. SSGpost; PIGpre vs. PIGpost). In the static stretching group group, only three joints showed significant increases in flexibility: shoulder extension (p = 0.004 and ES = 1.76 - Large), torso flexion (p = 0.002 and ES = 2.36 - Large), and hip flexion (p = 0.001 and ES = 1.79 -Large). In the passive interval group group, only three joints showed increases in flexibility: horizontal shoulder abduction (p = 0.003 and ES = 2.07 - Large), hip flexion (p = 0.001 and ES = 2.39 – Large), and hip extension (p = 0.02 and ES = 1.79 - Large).
1	3661884	cortisol secretion or growth hormone concentration	Hormonal profiles showed no significant differences in cortisol secretion or growth hormone concentration.
2	5850185	TUG completion time at A2	The subjects in the bilateral TENS+TOT group showed greater improvement in paretic ankle dorsiflexion strength (β=1.32; P=0.032) and in the completion time for the Timed Up and Go test (β=−1.54; P=0.004) than those in the unilateral TENS+TOT group.
0	5790265	Incidence of recurrent syncope after 12 months	Incidence of recurrent syncope after 12 months (6.5% vs. 41.2%, P<0.01) and rate of positive head-up tilt table testing after 30 days (9.7% vs.79.4%, P<0.01) were significantly lower in modified Valsalva maneuver group than in NVM group.
0	2920889	Depression or Anxiety or Adjustment Disorder with Depressed Mood, Anxiety, or Mixed Anxiety and Depressed Mood	In women without a psychiatric history (232/364; 64%), 36/125 (29%) were diagnosed with Depression or Anxiety or Adjustment Disorder with Depressed Mood, Anxiety, or Mixed Anxiety and Depressed Mood in the control group, compared with 16/107 (15%) in the intervention group.
2	3292461	Improvement in physical activity and energy expenditure	After 12 weeks, women in the intervention group had significantly increased their physical activity and energy expenditure per week (4394 vs. 1651 calorie, p < 0.001).
2	3292461	Improvement in waist circumference and hip circumference	Significant differences between-group in weight (P = 0.001), Body Mass Index (P = 0.001), waist circumference (P = 0.001), hip circumference (P = 0.032) and waist-hip ratio (P = 0.02) were presented after the intervention.
2	3292461	Improvement in body mass index	Significant differences between-group in weight (P = 0.001), Body Mass Index (P = 0.001), waist circumference (P = 0.001), hip circumference (P = 0.032) and waist-hip ratio (P = 0.02) were presented after the intervention.
2	3292461	Improvement in waist-hip ratio	Significant differences between-group in weight (P = 0.001), Body Mass Index (P = 0.001), waist circumference (P = 0.001), hip circumference (P = 0.032) and waist-hip ratio (P = 0.02) were presented after the intervention.
2	4685630	Service costs	Service costs were significantly higher for Pre-School Autism Communication Trial + treatment as usual (mean difference £4,489, p < 0.001), but the difference in societal costs was smaller and non-significant (mean difference £1,385, p = 0.788) due to lower informal care rates for Pre-School Autism Communication Trial + treatment as usual.  
1	4685630	Clinically meaningful symptom	Clinically meaningful symptom improvement was evident for 53 % of Pre-School Autism Communication Trial + treatment as usual versus 41 % of treatment as usual (odds ratio 1.91, p = 0.074).
2	4685630	Service costs	Service costs were significantly higher for Pre-School Autism Communication Trial + treatment as usual (mean difference £4,489, p < 0.001), but the difference in societal costs was smaller and non-significant (mean difference £1,385, p = 0.788) due to lower informal care rates for Pre-School Autism Communication Trial + treatment as usual.  
0	4872285	Cardiovascular death	Heart failure hospitalization or cardiovascular death occurred in a significantly lower percentage of patients treated with empagliflozin [265/4687 patients (5.7%)] than with placebo [198/2333 patients (8.5%)] [hazard ratio, HR: 0.66 (95% confidence interval: 0.55–0.79); P < 0.001], corresponding to a number needed to treat to prevent one heart failure hospitalization or cardiovascular death of 35 over 3 years.
0	4872285	Heart failure hospitalization	Heart failure hospitalization or cardiovascular death occurred in a significantly lower percentage of patients treated with empagliflozin [265/4687 patients (5.7%)] than with placebo [198/2333 patients (8.5%)] [hazard ratio, HR: 0.66 (95% confidence interval: 0.55–0.79); P < 0.001], corresponding to a number needed to treat to prevent one heart failure hospitalization or cardiovascular death of 35 over 3 years.
0	4872285	Heart failure hospitalization	Empagliflozin improved other heart failure outcomes, including hospitalization for or death from heart failure [2.8 vs. 4.5%; HR: 0.61 (0.47–0.79); P < 0.001] and was associated with a reduction in all-cause hospitalization [36.8 vs. 39.6%; HR: 0.89 (0.82–0.96); P = 0.003].
0	4872285	Heart failure hospitalization	Heart failure hospitalization or cardiovascular death occurred in a significantly lower percentage of patients treated with empagliflozin [265/4687 patients (5.7%)] than with placebo [198/2333 patients (8.5%)] [hazard ratio, HR: 0.66 (95% confidence interval: 0.55–0.79); P < 0.001], corresponding to a number needed to treat to prevent one heart failure hospitalization or cardiovascular death of 35 over 3 years.
0	4872285	Heart failure hospitalization	Empagliflozin improved other heart failure outcomes, including hospitalization for or death from heart failure [2.8 vs. 4.5%; HR: 0.61 (0.47–0.79); P < 0.001] and was associated with a reduction in all-cause hospitalization [36.8 vs. 39.6%; HR: 0.89 (0.82–0.96); P = 0.003].
0	4872285	Cardiovascular death	Heart failure hospitalization or cardiovascular death occurred in a significantly lower percentage of patients treated with empagliflozin [265/4687 patients (5.7%)] than with placebo [198/2333 patients (8.5%)] [hazard ratio, HR: 0.66 (95% confidence interval: 0.55–0.79); P < 0.001], corresponding to a number needed to treat to prevent one heart failure hospitalization or cardiovascular death of 35 over 3 years.
0	4872285	All-cause hospitalization	Empagliflozin improved other heart failure outcomes, including hospitalization for or death from heart failure [2.8 vs. 4.5%; HR: 0.61 (0.47–0.79); P < 0.001] and was associated with a reduction in all-cause hospitalization [36.8 vs. 39.6%; HR: 0.89 (0.82–0.96); P = 0.003].
0	5568359	concerning body mass index (body mass index)	The intervention group (n = 165) showed reductions compared to the control group (n = 177) concerning body mass index (body mass index) (0.3 kg/m2, p = .031), WC (2.1 cm, p ≤ .001) and waist hip ratio (.002, p ≤ .001) at the 1-year follow-up.
0	5568359	waist hip ratio (waist hip ratio)	The intervention group (n = 165) showed reductions compared to the control group (n = 177) concerning body mass index (body mass index) (0.3 kg/m2, p = .031), WC (2.1 cm, p ≤ .001) and waist hip ratio (.002, p ≤ .001) at the 1-year follow-up.
1	5568359	serum cholesterol, fasting plasma glucose, glycated haemoglobin (HbA1c), systolic/diastolic blood pressure	No differences between the intervention and control groups were found in other variables.
0	5568359	weight, body mass index, WC, waist hip ratio, HbA1c, and diet	Intervention group, compared to baseline, had reduced weight, body mass index, WC, waist hip ratio, HbA1c, and diet, while the men in the control group had reduced their alcohol consumption.  
2	4870813	number of parishes offering small media interventions - evidence-based strategies (evidence-based strategies) for cancer control	The only statistically significant difference between "capacity enhancement" and "standard dissemination" groups was the number of parishes offering small media interventions (90 % in "capacity enhancement", 64 % in "standard dissemination"; p < 0.05).  
2	4662683	recovery	Onset time of swallowing therapy after stroke was effective on swallowing recovery on the main outcome variables. So that in first group patients, recovery was rather than other groups P < 0.050.
0	4662683	number of patients experienced pneumonia	Furthermore, the frequency of pneumonia in the early group was less than other groups and in the early group no patients experienced pneumonia P = 0.002.   
1	5285426	Sexual function scores in females	In females, there was no difference between the two groups in any of the components of urological or sexual function.
1	5285426	Urological function scores in females	In females, there was no difference between the two groups in any of the components of urological or sexual function.
2	5285426	Male sexual function scores	Composite male urological and sexual function score changes from baseline were better in the robotic cohort (p < 0.001).
1	5331547	(serum C-reactive protein (C-reactive protein)	In subjects with high systemic inflammation at baseline (serum C-reactive protein (C-reactive protein) ≥3.0 mg/mL) who were supplemented with the fruit and vegetable juice concentrate (n = 16), these effects were greater, with decreased total cholesterol, low-density lipoprotein cholesterol and plasma TNFα and increased total lean mass; plasma C-reactive protein was unchanged by the fruit and vegetable juice concentrate following both analyses.
1	4139980	Need of erythropoietin	Erythropoietin requirements also had no significant differences.  
0	5718865	Episiotomy	Frequency of episiotomy was 69.47% in the intervention group and 92.31% in the control group, and the difference was statistically significant (p<0.05).
1	5122613	Adverse events	No adverse effects related to study products were observed.  
2	5122613	Improvement in faeces consistency	Stool consistency was improved only in the digestion-resistant maltodextrin group (p < 0.01).
1	5264222	therapeutic equivalence - Patients with moderate to severe rheumatoid arthritis (rheumatoid arthritis) despite methotrexate (methotrexate) treatment	The 95% CI of the adjusted treatment difference was −9.41% to 4.98%, which is completely contained within the predefined equivalence margin of −15% to 15%, indicating therapeutic equivalence between SB4 and etanercept.
0	5264222	incidence of antidrug antibody development up to week 24 - Patients with moderate to severe rheumatoid arthritis (rheumatoid arthritis) despite methotrexate (methotrexate) treatment	The incidence of treatment-emergent adverse events was comparable (55.2% vs 58.2%), and the incidence of antidrug antibody development up to week 24 was lower in SB4 compared with etanercept (0.7% vs 13.1%).  
1	5264222	incidence of treatment-emergent adverse events - Patients with moderate to severe rheumatoid arthritis (rheumatoid arthritis) despite methotrexate (methotrexate) treatment	The incidence of treatment-emergent adverse events was comparable (55.2% vs 58.2%), and the incidence of antidrug antibody development up to week 24 was lower in SB4 compared with etanercept (0.7% vs 13.1%).  
2	2690844	Smaller incision	Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance.
0	2690844	Pain on day three after surgery	More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.
0	2690844	Pain on day one after surgery	More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.
0	2690844	Incisional hernia apparition at follow-up	Two percent (1/60) of patients that had undergone the procedure through a transverse incision presented with an incisional hernia as opposed to 14% (9/63) of patients from the midline incision group (P = 0.017).
1	2690844	Analgesics use	The use of analgesics did not differ between the two groups.  
0	2690844	Scar length	Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance.
0	2690844	Pain on day two after surgery	More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.
0	4893758	Duration of procedure	Remifentanil group had lower duration of procedure (2.5 ± 1.6 versus 4.6 ± 1.8 minutes, p < 0.001), higher pain reduction (53.7 ± 13.3 versus 33.5 ± 19.6, p < 0.001), lower failure rate (1 (2.1%) versus 15 (31.3%), p < 0.001), higher satisfaction (p = 0.005).
2	4893758	Satisfaction	Remifentanil group had lower duration of procedure (2.5 ± 1.6 versus 4.6 ± 1.8 minutes, p < 0.001), higher pain reduction (53.7 ± 13.3 versus 33.5 ± 19.6, p < 0.001), lower failure rate (1 (2.1%) versus 15 (31.3%), p < 0.001), higher satisfaction (p = 0.005).
0	4893758	Pain	Remifentanil group had lower duration of procedure (2.5 ± 1.6 versus 4.6 ± 1.8 minutes, p < 0.001), higher pain reduction (53.7 ± 13.3 versus 33.5 ± 19.6, p < 0.001), lower failure rate (1 (2.1%) versus 15 (31.3%), p < 0.001), higher satisfaction (p = 0.005).
0	4893758	Failure rate	Remifentanil group had lower duration of procedure (2.5 ± 1.6 versus 4.6 ± 1.8 minutes, p < 0.001), higher pain reduction (53.7 ± 13.3 versus 33.5 ± 19.6, p < 0.001), lower failure rate (1 (2.1%) versus 15 (31.3%), p < 0.001), higher satisfaction (p = 0.005).
0	2830179	pain during movement	Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1)) and at rest (-2.0 (-3.8 to -0.2)) and significantly greater improvements in Qualeffo physical function (-4.8 (-9.2 to -0.5)) and the Timed Loaded Standing test (46.7 (16.1 to 77.3) secs).
0	2830179	Pain on rest (0-10)	Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1)) and at rest (-2.0 (-3.8 to -0.2)) and significantly greater improvements in Qualeffo physical function (-4.8 (-9.2 to -0.5)) and the Timed Loaded Standing test (46.7 (16.1 to 77.3) secs).
2	5086025	Intuitive eating total score	From pre- to postintervention, there were statistically significant within-group increases in intuitive eating (IES-2 total score P<.001; all IES-2 subscale scores: P ≤.01), psychological flexibility (P=.01), and general mental health (P<.001) as well as significant decreases in binge eating (P=.01).
2	5086025	Psychological flexibility	From pre- to postintervention, there were statistically significant within-group increases in intuitive eating (IES-2 total score P<.001; all IES-2 subscale scores: P ≤.01), psychological flexibility (P=.01), and general mental health (P<.001) as well as significant decreases in binge eating (P=.01).
2	5086025	General mental health	From pre- to postintervention, there were statistically significant within-group increases in intuitive eating (IES-2 total score P<.001; all IES-2 subscale scores: P ≤.01), psychological flexibility (P=.01), and general mental health (P<.001) as well as significant decreases in binge eating (P=.01).
0	5086025	Binge eating	From pre- to postintervention, there were statistically significant within-group increases in intuitive eating (IES-2 total score P<.001; all IES-2 subscale scores: P ≤.01), psychological flexibility (P=.01), and general mental health (P<.001) as well as significant decreases in binge eating (P=.01).
1	5086025	body mass index	There were no significant within-group changes in body mass index from pre- to postintervention and postintervention to 3-month follow-up (P=.46 and P=.93, respectively).  
1	4128673	leukopenia	No statistically significant differences were found in graft survival, patient survival or infections between the two groups, though there was a non-significant increase in leukopenia (43%v s. 30%), CMV (8% vs. 0) and BK (4% vs. 0) infections in sATG group vs. lowATG.
2	4895766	Healing of diabetic wounds	In Group A, diabetic wounds treated with Katupila paste got healed within 28 days with minimal scar formation without any complications, whereas in Group B, wound was healed completely only in two patients within 28 days.
1	4895766	Adverse reactions	In both the groups, no patients reported any adverse drug reaction during the entire course of treatment as well as in follow-up period.  
1	5446666	well-being at 4 weeks	Results demonstrated no significant effect of "The Toolbox" intervention on participant well-being at 4 weeks compared with the control group (P=.66).
1	5446666	Subscales of Mental Health Continuum-Short Form (Mental Health Continuum-Short Form)	There were also no significant differences between the intervention and control groups at 4 weeks on any of the subscales of the Mental Health Continuum-Short Form (psychological: P=.95, social: P=.42, emotional: P=.95).
2	5446666	mood, energy, rest, and sleep	Repeat engagement with the study platform resulted in a significant difference in mood, energy, rest, and sleep trajectories between intervention and control groups as measured by ecological momentary assessments (P<.01).  
2	4533227	invest more effort	Overall, however, dopamine had a motivating effect on participants' choice behaviour – patients with Parkinson's disease chose to invest more effort for a given reward when they were in the ON relative to OFF dopamine state.
0	3697207	Plantar fascia thickness	Over the study period, plantar fascia thickness significantly reduced in the extracorporeal shock wave therapy group (4.1 ± 1.3 to 3.6 ± 1.2 mm, P < 0.001), but slightly increased in the sham group (4.1 ± 0.8 to 4.5 ± 0.9 mm, P = 0.03).
0	3697207	Pain	Both groups showed significant pain improvement over the course of the study (P < 0.001), though pain scores were significantly more reduced in the extracorporeal shock wave therapy than the sham group (-4.2 ± 2.9 vs. -2.7 ± 1.8, P = 0.049).  
0	3954418	odds of cessation at 1 month	At 1 month, odds of cessation were greater among those who completed full time education at >16 years of age (odds ratio [odds ratio] = 1.82, 95% confidence interval CI = 1.24–2.67, p = .002) but they were lower in women with higher baseline cotinine levels (odds ratio = 0.93, 95% CI = 0.90–0.95, p < .001).
0	4826692	Secondary brain insults	The incidence of secondary brain insults at the end of week 2 was 8.97% in the treatment group and 23.75% in the control group, and the difference was significant (P < 0.001).
2	4826692	Favorable prognosis	The incidence of a favorable prognosis was 48.72% in the treatment group and 32.72% in the control group, and the difference was significant (P < 0.01) at the end of week 2.
2	2602945	exam room utilization time	Exam room utilization was lower for late patients (28.9% versus 44.7%, P = .03) with physician utilization lower in clinics with 3 or more late patients when compared to clinics with 2 or fewer (59.7% versus 68.7%, P = .004). 
2	2602945	patient wait time for physician arrival once in the exam room	" On-time patients were found to have a longer wait time once in the exam room for the physician than those that were late (14.8 ± 9.2 minutes versus 11.0 ± 8.4 minutes, P = .005); however, those patients spent a significantly longer time with the physician (10.7 ± 6.0 minutes versus 8.9 ± 5.8 minutes, P = .041).
2	2602945	time spent with the physician	" On-time patients were found to have a longer wait time once in the exam room for the physician than those that were late (14.8 ± 9.2 minutes versus 11.0 ± 8.4 minutes, P = .005); however, those patients spent a significantly longer time with the physician (10.7 ± 6.0 minutes versus 8.9 ± 5.8 minutes, P = .041).
0	3529678	Processed meat, serves/week	From baseline to six weeks, improvements were observed for minutes moderate-vigorous physical activity (150.7 minutes), processed meat intake (−1.2 serves/week), vegetable intake (1 serve/day), alcohol intake (−0.4 standard drinks/day), body mass index (−1.4 kg/m2), and waist circumference (−5.1 cm).
0	3529678	Waist circumference, cm	From baseline to six weeks, improvements were observed for minutes moderate-vigorous physical activity (150.7 minutes), processed meat intake (−1.2 serves/week), vegetable intake (1 serve/day), alcohol intake (−0.4 standard drinks/day), body mass index (−1.4 kg/m2), and waist circumference (−5.1 cm).
0	3529678	Waist circumference, cm	Further, compared with baseline, participants were more likely to meet Australian recommendations post-intervention for: moderate-vigorous physical activity (27.3 vs 59.1%); fruit intake (68.2 vs 81.8%); vegetable intake (4.6 vs 18.2%); alcohol consumption (59.1 vs 72.7%); body mass index (31.8 vs 45.5%) and waist circumference (18.2 vs 27.3%).
1	2724496	Mycophenolic acid exposure	The Mycophenolic acid exposure tended to be higher among belatacept patients than in CsA patients at week 1 (P = 0.057).
0	4947329	Osteocalcin	Daily doses of prednisone up to 60 mg resulted in dose- and time-dependent decreases in plasma osteocalcin, plasma procollagen type 1 N-propeptide, serum cortisol, and absolute blood eosinophil counts.
2	3248601	intubation time in hypertensive patients	The intubation time was shorter in the conventional laryngoscopy group than in the intubating laryngeal mask airway group (16.33±10.8 vs. 43.04±19.8 s, respectively) (p<0.001).
2	3248601	Systolic BP (SPB) measurements in hypertensive patients	The systolic and diastolic blood pressures in the intubating laryngeal mask airway group were higher than those in the conventional laryngoscopy group at 1 and 2 min following intubation (p<0.05).
2	3248601	Diastolic BP (DPB) measurements in hypertensive patients	The systolic and diastolic blood pressures in the intubating laryngeal mask airway group were higher than those in the conventional laryngoscopy group at 1 and 2 min following intubation (p<0.05).
0	2570683	the proportions of malaria cases among all health facility attendance (all causes diseases)	During the study period, the proportions of malaria cases among all health facility attendance (all causes diseases) were 21.0%, (445/2,111, 95% CI [19.3%–22.7%]) and 70.7% (2,595/3,671, 95% CI 68.5%–71.5%), respectively in the intervention and control arms (p << 0.0001).
0	3021887	weight	Results showed that rimonabant group lost more weight than placebo, (LSM ± SEM of −4.7 ± 0.3 kg vs. −1.7 ± 0.3 kg, P < .0001).
2	3021887	HDL-cholesterol	Rimonabant also significantly increased HDL-cholesterol, decreased triglycerides and waist circumference,by 7.1%, 10.6%, and 2.8 cm, respectively (P < .0001).
2	3021887	HDL-cholesterol	Rimonabant also significantly increased HDL-cholesterol, decreased triglycerides and waist circumference,by 7.1%, 10.6%, and 2.8 cm, respectively (P < .0001).
0	3021887	The mean waist circumference	Rimonabant also significantly increased HDL-cholesterol, decreased triglycerides and waist circumference,by 7.1%, 10.6%, and 2.8 cm, respectively (P < .0001).
0	3021887	The mean waist circumference	Rimonabant also significantly increased HDL-cholesterol, decreased triglycerides and waist circumference,by 7.1%, 10.6%, and 2.8 cm, respectively (P < .0001).
1	4163237	Postoperative nausea and vomiting	Results: The frequency of Postoperative nausea and vomiting in the low pressure and standard pressure groups did not demonstrate statistically significant different (P > 0.05).
0	4163237	Shoulder pain when leaving the recovery room	Nevertheless the frequency of shoulder pain after 4 hours at the low pressure group compared with standard pressure group was significantly different (P < 0.023).   
0	4163237	Shoulder pain when leaving the recovery room	Conclusions: The use of low pressure gas compared to standard pressure gas to create pneumoperitoneum could not reduce the Postoperative nausea and vomiting whereas the frequency of shoulder pain in low pressure group was reduced.
0	4163237	Shoulder pain 4 hours after the surgery	Nevertheless the frequency of shoulder pain after 4 hours at the low pressure group compared with standard pressure group was significantly different (P < 0.023).   
0	4163237	Shoulder pain 4 hours after the surgery	Conclusions: The use of low pressure gas compared to standard pressure gas to create pneumoperitoneum could not reduce the Postoperative nausea and vomiting whereas the frequency of shoulder pain in low pressure group was reduced.
0	4425923	receiving the treatment for cancer among oncologists and pulmonologists	Among oncologists and pulmonologists, 78% (95% CI: 72-85) would offer the treatment to the non-smoker and 66% (95% CI: 58-74) to the smoker (Chi-2 = 5.4, df = 1, p = 0.019).
2	5812876	Step counts	There were significantly higher step counts on average in the aerobics group compared to the control group over assessments.
0	3838646	Scar length	There was no significant differences regarding age and sex in the two groups. The scar length, operation duration and time before return to daily activities were significantly lower in the Knifelight group.
1	3838646	Pain	Although the mean visual analogue scale of Knifelight group found to be lower than the other, it was not statistically significant.  
0	3838646	Operation duration	The scar length, operation duration and time before return to daily activities were significantly lower in the Knifelight group.
0	3838646	Time to return to daily activities	The scar length, operation duration and time before return to daily activities were significantly lower in the Knifelight group.
2	5682702	Score on knowledge-based questions 3 months after intervention	The post hoc Wilcoxon signed-rank test with Bonferroni correction showed statistically significant improvement in the knowledge-based questions between pre- and post-seminar questionnaire (P = 0.002) and between preseminar and 3-month follow-up (P = 0.003).  
2	3281341	plasma level of β-endorphin after 2-week omeprazole administration	The level of plasma β-endorphin after the administration of omeprazole was significantly greater than at the start of the study and following the placebo. Responders to omeprazole had an average lower β-endorphin plasma concentration than subjects who failed to respond to this therapy. Subjects with symptoms in class III (according to the Canadian Cardiovascular Society classification) after omeprazole administration had a greater β-endorphin plasma level than subjects in class II for anginal symptom severity.  
2	3281341	β-endorphin plasma concentration in patients with coronary artery disease	Fourteen-day therapy with a double omeprazole dose significantly increases the β-endorphin plasma concentration in patients with coronary artery disease.
0	3296686	hepatitis C virus RNA at day-14	Pioglitazone was effective in decreasing serum hepatitis C virus RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0.001).
2	5747224	physical outcomes awareness -training effects on physical and psychological outcomes awareness of smoking in teenagers	According to the results, the mean of posttest scores had increased rather than pretest scores, and generally, a significant difference was observed (P ≤ 0.001). These results were significant in the aspect of both physical and psychological outcomes awareness.
2	5747224	training effects on physical and psychological outcomes awareness of smoking in teenagers	According to the results, the mean of posttest scores had increased rather than pretest scores, and generally, a significant difference was observed (P ≤ 0.001). These results were significant in the aspect of both physical and psychological outcomes awareness.
1	4609664	Cracks	There was no significant difference between Reciproc and control group (P>0.05).   
0	4609664	Cracks	Mtwo and ProTaper Universal caused cracks significantly more than Reciproc (P<0.05).
0	4609664	Cracks	Mtwo and ProTaper Universal caused cracks significantly more than Reciproc (P<0.05).
2	4609664	Cracks	No cracks were observed in the control group. All engine-driven systems caused dentinal cracks.
2	4609664	Cracks	No cracks were observed in the control group. All engine-driven systems caused dentinal cracks.
1	4300351	Treatment failure	Overall, treatment failed in 20 patients (20/107, 18.7%): in 10 individuals from the A + BE group (10/52; 18.2%) and in 10 individuals from the A + HC group (10/55; 19.2%) (p > 0.05).
1	4300351	Bleeding recurrence	Ten individuals (9.3%) experienced recurrent bleeding during hospitalisation: 4 patients from the A + BE group and 6 patients from the A + HC group (p > 0.05).
1	4300351	Need of surgery	Surgical intervention was required in 4 individuals (3.7%): 2 patients in the A + BE group and 2 patients treated with A + HC (p > 0.05).
1	4300351	Number of blood units transfused	No significant intergroup differences were documented with regards to the mean number of transfused blood units and the mean length of hospital stay.  
1	4300351	Failure to obtain haemostasis	Primary haemostasis was not obtained in 7 patients (6.5%): in 4 patients in the A + BE group and in 3 patients in the A + HC group (p > 0.05).
2	3685524	Augmentation pressure	Central arterial stiffness, measured as augmentation index, augmentation pressure and pulse wave velocity, was higher after wood smoke exposure as compared to filtered air (p < 0.01 for all), and heart rate was increased (p < 0.01) although there was no effect on blood pressure.
2	3685524	Pulse wave velocity	Central arterial stiffness, measured as augmentation index, augmentation pressure and pulse wave velocity, was higher after wood smoke exposure as compared to filtered air (p < 0.01 for all), and heart rate was increased (p < 0.01) although there was no effect on blood pressure.
2	3685524	Augmentation index	Central arterial stiffness, measured as augmentation index, augmentation pressure and pulse wave velocity, was higher after wood smoke exposure as compared to filtered air (p < 0.01 for all), and heart rate was increased (p < 0.01) although there was no effect on blood pressure.
2	3685524	Heart rate	Central arterial stiffness, measured as augmentation index, augmentation pressure and pulse wave velocity, was higher after wood smoke exposure as compared to filtered air (p < 0.01 for all), and heart rate was increased (p < 0.01) although there was no effect on blood pressure.
0	5295657	The mean LDL/HDL ratio	The mean LDL/HDL ratio decreased during the study (P < 0.001); however, there was not any significant difference between the two groups (P > 0.05).
1	5295657	fasting blood sugar (fasting blood sugar)	The mean of fasting blood sugar did not change between and within groups (P > 0.05).    
1	5295657	The mean LDL/HDL ratio	The mean LDL/HDL ratio decreased during the study (P < 0.001); however, there was not any significant difference between the two groups (P > 0.05).
2	5295657	high density lipoprotein cholesterol rate	The high density lipoprotein cholesterol rate was higher in intervention group compared to control group (P < 0.05).
1	3233526	pregnancy	No significant difference was observed with respect to pregnancy or birth outcome across the groups.
1	3233526	pregnancy	Twice-weekly supplementation is as effective as daily supplementation, and may represent an acceptable compromise in iron supplementation regimens for nonanemic pregnant women.
1	3233526	pregnancy	No significant difference was observed with respect to pregnancy or birth outcome across the groups.
1	3233526	birth outcome	No significant difference was observed with respect to pregnancy or birth outcome across the groups.
1	3233526	birth outcome	No significant difference was observed with respect to pregnancy or birth outcome across the groups.
1	3233526	birth outcome	No significant difference was observed with respect to pregnancy or birth outcome across the groups.
2	3233526	ferritin levels at week 28	There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.
2	3233526	ferritin levels at week 28	Two hundred and ten women with singleton pregnancies, no known disease, and hemoglobin levels >11.0 g/dL were randomly assigned to one of three groups, ie, Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).
2	3233526	ferritin levels at week 28	There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.
2	3233526	ferritin levels at week 28	Two hundred and ten women with singleton pregnancies, no known disease, and hemoglobin levels >11.0 g/dL were randomly assigned to one of three groups, ie, Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).
1	3233526	ferritin levels at week 38	There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 μg/L).
1	3233526	ferritin levels at week 38	Two hundred and ten women with singleton pregnancies, no known disease, and hemoglobin levels >11.0 g/dL were randomly assigned to one of three groups, ie, Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).
1	3233526	ferritin levels at week 38	There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 μg/L).
1	3233526	ferritin levels at week 38	There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 μg/L).
2	3882495	Resistance through the 22G cannula	The mean difference in resistance between Cannula P and I was: 307 mmHg.L-1.hr-1 (95% CI: 289–325, p < 0.001) for 22G; 135 mmHg.
2	3882495	Static resistance for 18G cannula	The mean difference in the force needed to displace the catheter away from its needle was: 1.41 N (95% CI: 1.09-1.73, p < 0.001) for 22G; 0.19 N (95% CI: -0.04-0.41, p = 0.12) for 20G; and 1.96 N (95% CI: 1.40-2.52, p < 0.001) for 18G.
2	3882495	Resistance through the 20G cannula	L-1.hr-1 (95% CI: 289–325, p < 0.001) for 22G; 135 mmHg.L-1.hr-1 (95% CI: 125–144, p < 0.001) for 20G; and 27 mmHg.
2	3882495	Resistance through the 18G cannula	L-1.hr-1 (95% CI: 125–144, p < 0.001) for 20G; and 27 mmHg.L-1.hr-1 (95% CI: 26–28, p < 0.001) for 18G.
2	3882495	Static resistance for 22G cannula	The mean difference in the force needed to displace the catheter away from its needle was: 1.41 N (95% CI: 1.09-1.73, p < 0.001) for 22G; 0.19 N (95% CI: -0.04-0.41, p = 0.12) for 20G; and 1.96 N (95% CI: 1.40-2.52, p < 0.001) for 18G.
2	5752784	incidences of Post-operative nausea and vomiting (Post-operative nausea and vomiting)	Overall incidences of Post-operative nausea and vomiting in the study 24 h postoperatively were 23.4% in PD, 27.2% in P group and 56.14% in D group (P < 0.001).
0	4222592	the AUC(0-3h) for blood insulin	Compared to the Avocado Inclusive meal, the AUC(0-3h) for blood insulin was higher in the Control and Avocado Added meals (P=0.04 and P=0.05, respectively).  
0	4222592	desire to eat for the AUC(0-3h)	For the AUC(0-3h), the Avocado Added test meal increased satisfaction by 26% (P=0.02) and decreased the desire to eat by 40% (P=0.01) as compared to the Control test meal.
0	4222592	desire to eat for the AUC(0-5h)	Compared to the Control test meal, the Avocado Added test meal increased satisfaction by 23% (P=0.05) and decreased the desire to eat by 28% (P=0.04) for the AUC(0-5h).
2	4222592	self-reported subjective feelings of satisfaction for the AUC(0-3h)	For the AUC(0-3h), the Avocado Added test meal increased satisfaction by 26% (P=0.02) and decreased the desire to eat by 40% (P=0.01) as compared to the Control test meal.
0	4450208	the use of aggressive strategies as an interpersonal conflict-resolution technique	In the follow-up phase, the positive effects of the intervention were generally maintained and, moreover, the use of aggressive strategies as an interpersonal conflict-resolution technique was significantly reduced.
2	4450208	assertive social interaction strategies, attention, and emotional clarity	Regarding the effect of the program on both genders, the change was very similar, but the boys increased assertive social interaction strategies, attention, and emotional clarity significantly more than the girls.
2	4450208	pretest–posttest change	The pretest–posttest ANCOVAs showed that the program significantly increased: (1) emotional intelligence (attention, clarity, emotional repair); (2) assertive cognitive social interaction strategies; (3) internal control of anger; and (4) the cognitive ability to analyze negative feelings.
2	4450208	attention, clarity, emotional repair, assertive cognitive social interaction strategies, internal control of anger and the cognitive ability to analyze negative feelings	The pretest–posttest ANCOVAs showed that the program significantly increased: (1) emotional intelligence (attention, clarity, emotional repair); (2) assertive cognitive social interaction strategies; (3) internal control of anger; and (4) the cognitive ability to analyze negative feelings.
1	3488813	Clinical depression	There was no significant difference in clinical depression ratings at 7 days between the escitalopram and placebo-treated patients.  
1	2206488	IL-6r (ng/ml)	There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.
0	2206488	Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I	In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.
0	2206488	Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I	In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).
1	2206488	IL-6 (pg/ml)	There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.
2	2206488	Cardiac index	Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.  ABSTRACT.CONCLUSION. 
0	2206488	systemic vascular resistance	Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.  ABSTRACT.CONCLUSION. 
2	4506382	circulating endothelial cells (circulating endothelial cells) after 4 and 6 weeks	The number of circulating endothelial cells increased during treatment with bevacizumab plus lomustine, but not during treatment in the single-agent arms.
1	4506382	circulating endothelial cells (circulating endothelial cells) after 4 and 6 weeks	The number of circulating endothelial cells increased during treatment with bevacizumab plus lomustine, but not during treatment in the single-agent arms.
1	4506382	circulating endothelial cells (circulating endothelial cells) after 4 and 6 weeks	The number of circulating endothelial cells increased during treatment with bevacizumab plus lomustine, but not during treatment in the single-agent arms.
1	5808689	numbers of positively response to the following question about the hospitalization: "Are you satisfied with the planning before discharge from the hospital?�	The response rate was 61%. In unadjusted analyses, significantly more patients in the intervention group responded positively to the following three questions about the hospitalization: "Did you get the nursing from the ward staff that you needed?" (p=0.003), "Are you satisfied with the information you received on your diseases and medication?" (p=0.016), and "Are you satisfied with the planning before discharge from the hospital?" (p=0.032). After adjusted analyses by multiple regression, a significant difference in favor of the intervention remained for the first question (p=0.027).  
2	5808689	numbers of positively response to the following question about the hospitalization: "Did you get the nursing from the ward staff that you needed?�	In unadjusted analyses, significantly more patients in the intervention group responded positively to the following three questions about the hospitalization: "Did you get the nursing from the ward staff that you needed?" (p=0.003), "Are you satisfied with the information you received on your diseases and medication?
1	4164149	Positive β-hCG at start	In addition, rates of initial positive β-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% confidence interval −9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% confidence interval −10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% confidence interval −7.6, 4.0), live birth (41.1 versus 43.1%; 95% confidence interval −8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% confidence interval −8.4, 5.4) were comparable.
1	4164149	Pregnancy with fetal cardiac activity (in uterus)	In addition, rates of initial positive β-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% confidence interval −9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% confidence interval −10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% confidence interval −7.6, 4.0), live birth (41.1 versus 43.1%; 95% confidence interval −8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% confidence interval −8.4, 5.4) were comparable.
1	4164149	Babies born alive	In addition, rates of initial positive β-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% confidence interval −9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% confidence interval −10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% confidence interval −7.6, 4.0), live birth (41.1 versus 43.1%; 95% confidence interval −8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% confidence interval −8.4, 5.4) were comparable.
1	4164149	Babies taken home	In addition, rates of initial positive β-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% confidence interval −9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% confidence interval −10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% confidence interval −7.6, 4.0), live birth (41.1 versus 43.1%; 95% confidence interval −8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% confidence interval −8.4, 5.4) were comparable.
1	4164149	Pregnancy rate	Using a per-protocol analysis, which included all patients who received an embryo transfer (Prolutex = 392; Endometrin = 390), the ongoing pregnancy rate per retrieval for subcutaneous versus vaginal progesterone was 41.6 versus 44.4%, with a difference between groups of −2.8% (95% confidence interval −9.7, 4.2), consistent with the non-inferiority of subcutaneous progesterone for luteal phase support.
1	4164149	Implantation	In addition, rates of initial positive β-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% confidence interval −9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% confidence interval −10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% confidence interval −7.6, 4.0), live birth (41.1 versus 43.1%; 95% confidence interval −8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% confidence interval −8.4, 5.4) were comparable.
2	2920262	Improvement in SF-36 physical component score	In the RCT, the physical component score of the SF36 improved in the singers (n = 15) compared to the controls (n = 13); +7.5(14.6) vs. -3.8(8.4) p = 0.02.
2	2920262	Improvement in HAD anxiety score	Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03.
2	4832354	informed about the treatment choice, aware of options, knowledgeable about treatment benefits, and knowledgeable about treatment risks/side effects	P‐DA users perceived themselves to be significantly more 1) informed about the treatment choice (P = .008), 2) aware of options (P = .009), 3) knowledgeable about treatment benefits (P = .020), and 4) knowledgeable about treatment risks/side effects (P = .001) in comparison with controls.
1	4004388	Overall clinical response	Overall clinical response was reported in 61.5% of the mistletoe preparation arm versus 30% in bleomycin arm (p = 0.2138), 95% CI = (–0.1203, 0.6325).
2	4235088	psychometric hepatic encephalopathy score (psychometric hepatic encephalopathy score)	psychometric hepatic encephalopathy score significantly improved after medication in all the three groups (Gp-LPr: −3.8 ± 3.9 to −1.6 ± 3.0; Gp-L: −4.8 ± 4.1 to −1.6 ± 2.9; and group of patients received probiotic alone: −4.9 ± 3.7 to −2.1 ± 2.5, P < 0.001).
2	4733270	Probability of having an injury	The significant behavior disorder predictors for unintentional injury in boys were schizoid behavior problem (OR = 2.43), anxiety/depression (OR = 2.76) and hyperactive (OR = 2.42). The predictors for unintentional injury in girls were anxiety/depression (OR = 2.12) and delinquent behavior (OR = 2.81).  
2	4733270	Probability of having an injury	The significant behavior disorder predictors for unintentional injury in boys were schizoid behavior problem (OR = 2.43), anxiety/depression (OR = 2.76) and hyperactive (OR = 2.42).
2	5777197	Risk of death in the first four months	Hazard of death in the first four months was greatest in subjects receiving continuous high-dose lenalidomide; hazards of death thereafter were similar.
2	5777197	Risk of death after 4 months	Hazard of death in the first four months was greatest in subjects receiving continuous high-dose lenalidomide; hazards of death thereafter were similar.
1	5643294	Pain visual analog scale scores at rest after 24 hours	ABSTRACT.RESULTS. visual analog scale scores both at rest and on movement at 24 h and 48 h were similar between the two groups.
1	5643294	Pain visual analog scale scores on movement after 24 hours	ABSTRACT.RESULTS. visual analog scale scores both at rest and on movement at 24 h and 48 h were similar between the two groups.
0	5643294	Time to bowel recovery	Mean arterial pressure was significantly lower at 6, 12, and 24 h (P < 0.05 for all); heart rate was significantly lower at 0, 6, 12, and 24 h (P < 0.05 for all); time to bowel recovery and length of hospitalization after surgery (P < 0.05 for both) were significantly shortened; and cumulative sufentanil consumption was significantly lower at 6, 12, 24, and 36 h (P < 0.05 for all) in the ropivacaine group than in the control group, although the incidence of nausea and vomiting showed no significant difference between the two groups.
0	5643294	Time to bowel recovery	Mean arterial pressure was significantly lower at 6, 12, and 24 h (P < 0.05 for all); heart rate was significantly lower at 0, 6, 12, and 24 h (P < 0.05 for all); time to bowel recovery and length of hospitalization after surgery (P < 0.05 for both) were significantly shortened; and cumulative sufentanil consumption was significantly lower at 6, 12, 24, and 36 h (P < 0.05 for all) in the ropivacaine group than in the control group, although the incidence of nausea and vomiting showed no significant difference between the two groups.
0	5643294	Length of hospitalization	Mean arterial pressure was significantly lower at 6, 12, and 24 h (P < 0.05 for all); heart rate was significantly lower at 0, 6, 12, and 24 h (P < 0.05 for all); time to bowel recovery and length of hospitalization after surgery (P < 0.05 for both) were significantly shortened; and cumulative sufentanil consumption was significantly lower at 6, 12, 24, and 36 h (P < 0.05 for all) in the ropivacaine group than in the control group, although the incidence of nausea and vomiting showed no significant difference between the two groups.
0	5643294	Length of hospitalization	Mean arterial pressure was significantly lower at 6, 12, and 24 h (P < 0.05 for all); heart rate was significantly lower at 0, 6, 12, and 24 h (P < 0.05 for all); time to bowel recovery and length of hospitalization after surgery (P < 0.05 for both) were significantly shortened; and cumulative sufentanil consumption was significantly lower at 6, 12, 24, and 36 h (P < 0.05 for all) in the ropivacaine group than in the control group, although the incidence of nausea and vomiting showed no significant difference between the two groups.
0	5643294	Sufentanil consumption	Mean arterial pressure was significantly lower at 6, 12, and 24 h (P < 0.05 for all); heart rate was significantly lower at 0, 6, 12, and 24 h (P < 0.05 for all); time to bowel recovery and length of hospitalization after surgery (P < 0.05 for both) were significantly shortened; and cumulative sufentanil consumption was significantly lower at 6, 12, 24, and 36 h (P < 0.05 for all) in the ropivacaine group than in the control group, although the incidence of nausea and vomiting showed no significant difference between the two groups.
1	5643294	Nausea and vomiting	Mean arterial pressure was significantly lower at 6, 12, and 24 h (P < 0.05 for all); heart rate was significantly lower at 0, 6, 12, and 24 h (P < 0.05 for all); time to bowel recovery and length of hospitalization after surgery (P < 0.05 for both) were significantly shortened; and cumulative sufentanil consumption was significantly lower at 6, 12, 24, and 36 h (P < 0.05 for all) in the ropivacaine group than in the control group, although the incidence of nausea and vomiting showed no significant difference between the two groups.
2	4837927	Roland-Morris Disability Questionnaire improvement	Pain intensity and Roland-Morris Disability Questionnaire scores improved significantly in both groups at 5 days compared with baseline. Considering the degree of treatment effect (the change from baseline to day 5), the Kinesio taping group was significantly superior than the control group in all outcome measures (for all, P<0.001).  
2	4941128	Overall Unified Parkinson's Disease Rating Scale improvement	Unified Parkinson's Disease Rating Scale scores were 43% (p=0.04; Cohen's d=1.62) better with Adaptive deep brain stimulation than without stimulation.
2	3253463	P300 amplitude	We found that the ginger-treated groups had significantly decreased P300 latencies, increased N100 and P300 amplitudes, and exhibited enhanced working memory.
2	3253463	P300 amplitude	We found that the ginger-treated groups had significantly decreased P300 latencies, increased N100 and P300 amplitudes, and exhibited enhanced working memory.
0	3253463	P300 latency	We found that the ginger-treated groups had significantly decreased P300 latencies, increased N100 and P300 amplitudes, and exhibited enhanced working memory.
2	3253463	N100 amplitude	We found that the ginger-treated groups had significantly decreased P300 latencies, increased N100 and P300 amplitudes, and exhibited enhanced working memory.
2	3253463	Working memory	We found that the ginger-treated groups had significantly decreased P300 latencies, increased N100 and P300 amplitudes, and exhibited enhanced working memory.
2	5324269	25(OH)D3 level	Baseline 25(OH)D3 level was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups, respectively.
2	5324269	25(OH)D2 AUC140	25(OH)D2 AUC140 was higher in daily than 2-weekly (17%, p = 0.006) and 4-weekly (20%, p = 0.001) D2-treated groups.
1	4555141	Executive IQ scores	In 2012, a subsample of 184 children from the original cohort (now aged 36–48 months) was randomly selected to participate in a follow-up trial and was assessed for intelligence, working memory, inhibition, and executive function. The tests showed no significant differences between the supplementation groups though there were some gender differences, with girls displaying higher scores than boys across both groups on the Wechsler Preschool and Primary Scale of Intelligence (Wechsler Preschool and Primary Scale of Intelligence) Verbal IQ sentences subtest, the Day-Night cognitive test and on the Brief Infant-Toddler Social Emotional Assessment (Brief Infant-Toddler Social Emotional Assessment) social competency, and boys scoring higher than girls in problem behaviour.
0	5308129	length of hospital stay	Overall, PEG-lactulose regimen was associated with a decrease in length of hospital stay compared with lactulose treatment (p =0.03) but in subgroup analysis we found that PEG-lactulose regimen could only decrease the length of hospital stay in women significantly (p =0.01).   
1	4060171	improvement of medical compliance in patients with schizophrenia	When accounting for missing values with a multiple imputation approach, we found a tendency toward a difference in both the compliance scale and PANSS favoring the system-oriented therapy, although it did not reach statistical significance.
1	4060171	effect on compliance	When accounting for missing values with a multiple imputation approach, we found a tendency toward a difference in both the compliance scale and PANSS favoring the system-oriented therapy, although it did not reach statistical significance.
2	4950806	The percentage changes in lumbar bone mineral density	The percentage change in lumbar bone mineral density from baseline to the end of treatment was −0.4±4.0% for the alfacalcidol group vs. 6.8±6.3% for the alendronate group (P=0.015).
1	4950806	bone-specific alkaline-phosphatase (U/l),NTX (nmol BCE/l)	No significant percentage change of bone-specific alkaline-phosphatase and NTX between the two groups was observed.
2	4374075	patients who achieved an HbA1c of <7.0% at week 14	The proportion of patients achieving target HbA1c <7.0% was significantly higher with vildagliptin/metformin single-pill combination compared with vildagliptin/placebo single-pill combination (45.8% vs. 13.5%, P <0.001).
1	5732563	rate of pain relief (VRS/minute)	The estimated difference in the rate of pain relief (VRS/minute) was 0.04 (95% CI: −0.01 to 0.11; p=0.109), and the estimated difference in onset of sensory blockade (sensory level/minute) was 0.63 (95% CI: −0.02 to 0.15; p=0.166).
1	5732563	The time to Verbal rating scale ≤3 and level of sensory block 20 minutes after dosing	The time to Verbal rating scale ≤3 and level of sensory block 20 minutes after dosing were also similar between groups.
1	5732563	adverse events	This investigation observed that epidural needle and catheter injection of medications result in similar onset of analgesia and sensory blockade, quality of labor analgesia, patient satisfaction, and complication rates.
0	4377530	rates of urinary tract infection (urinary tract infection) in rabbits	The Nelatone catheters, compared with the Foley ones, had a lower risk of urinary tract infection in the long term use.
0	4377530	rates of urinary tract infection (urinary tract infection) in rabbits	At the end of the study, four cases in the Nelatone group and 12 cases in the Foley group presented with urinary tract infection (P = 0.01).
1	4048120	Modified gingival index	Peri-implant health showed no statistically significant differences for any of the studied parameters (crevicular fluid volume, plaque index, gingival retraction, keratinized mucosa, probing depth, modified gingival index and presence of mucositis) at the twelve-month follow-up.     
1	4048120	Bone loss	Bone loss was 0.54 ± 0.39 mm for immediate implants and 0.66 ± 0.25 mm for delayed implants (p=0.201). No implants failed in either group. 
1	4048120	Gingival retraction and probing depth	Peri-implant health showed no statistically significant differences for any of the studied parameters (crevicular fluid volume, plaque index, gingival retraction, keratinized mucosa, probing depth, modified gingival index and presence of mucositis) at the twelve-month follow-up.     
2	2887151	Median peak (4 hours after administration), Anti-factor Xa activity levels	Median peak (4 hours after administration), Anti-factor Xa activity levels increased significantly with an increase in enoxaparin dose, from 0.13 IU/ml at 40 mg, to 0.14 IU/ml at 50 mg, 0.27 IU/ml at 60 mg, and 0.29 IU/ml at 70 mg (P = 0.002).
2	3475525	Correct selection of the healthier product	The MTL+caloric intake group (mean [standard deviation], 73.3% [6.9%]) and Choices group (72.5% [13.2%]) significantly outperformed the no label group (67.8% [10.3%]) and the TL+SNL group (65.8% [7.3%]) in selecting the more healthful product on the healthier product quiz.
2	3475525	Scores on the saturated fat, sugar, and sodium quizzes	The multiple traffic light and MTL+caloric intake groups achieved average scores of more than 90% on the saturated fat, sugar, and sodium quizzes, which were significantly better than the no label and Choices group average scores, which were between 34% and 47%.  
2	5685077	Total energy expenditure	Total energy expenditure was significantly greater (p < 0.05) during WALK (149.5 ± 30.6 kcal) compared to DRUM (118.7 ± 18.8 kcal) and HANDHELD (44.9±11.6 kcal), and greater during DRUM compared to HANDHELD.
2	5685077	Total energy expenditure	Total energy expenditure was significantly greater (p < 0.05) during WALK (149.5 ± 30.6 kcal) compared to DRUM (118.7 ± 18.8 kcal) and HANDHELD (44.9±11.6 kcal), and greater during DRUM compared to HANDHELD.
2	5685077	Total energy expenditure	Total energy expenditure was significantly greater (p < 0.05) during WALK (149.5 ± 30.6 kcal) compared to DRUM (118.7 ± 18.8 kcal) and HANDHELD (44.9±11.6 kcal), and greater during DRUM compared to HANDHELD.
1	5685077	Total energy expenditure	Total energy expenditure was not significantly different between HANDHELD (44.9 ± 11.6 kcal) and control (38.2 ± 6.0 kcal).
2	3937058	documentation for the previously given, 'historical' vaccine doses	Clinics that received in-person and webinar consultations reported similar levels of participation on key programmatic activities with one exception: more webinar clinics reported improving documentation of previously administered, 'historical' vaccine doses.
0	3937058	cost of intervention	Delivery cost per clinic was $152 for in-person consultations versus $100 for webinar consultations.  
0	3937058	cost of intervention	In-person and webinar delivery modes were both well received, but webinar Assessment, Feedback, Incentives, and eXchange consultations cost substantially less.
1	3937058	confidence to use reminder/recall systems	Both in-person and webinar clinics showed sustained improvement in confidence to use reminder/recall systems (both p < 0.05).
2	3937058	participants' confidence for giving reminder/recalls	Both in-person and webinar clinics showed sustained improvement in confidence to use reminder/recall systems (both p < 0.05).
2	4382580	Range of motion of trunk extension	After the intervention, significant improvements were observed regarding the Lequesne index (p-value = 0.0217), Oswestry Disability Index (p-value = 0.0112), range of motion of trunk extension (p-value = 0.0320), trunk flexion muscle strength (p-value = 0.0459), hip extension and abduction muscle strength (p-value = 0.0062 and p-value = 0.0257, respectively).
2	4382580	Hip extension	After the intervention, significant improvements were observed regarding the Lequesne index (p-value = 0.0217), Oswestry Disability Index (p-value = 0.0112), range of motion of trunk extension (p-value = 0.0320), trunk flexion muscle strength (p-value = 0.0459), hip extension and abduction muscle strength (p-value = 0.0062 and p-value = 0.0257, respectively).
1	4382580	Hip abduction	After the intervention, significant improvements were observed regarding the Lequesne index (p-value = 0.0217), Oswestry Disability Index (p-value = 0.0112), range of motion of trunk extension (p-value = 0.0320), trunk flexion muscle strength (p-value = 0.0459), hip extension and abduction muscle strength (p-value = 0.0062 and p-value = 0.0257, respectively). Range of motion of trunk and hip flexion, extension, adduction and abduction, trunk extensor muscle strength and all surface electromyography variables showed no significant statistical difference.  
2	4682219	CIN3+ association	CIN3+ was significantly associated with HPV 16 (Odds Ratio [Odds Ratio] 5.11; 95 % confidence interval [confidence interval] 2.30, 11.37), but not HPV 18 (Odds Ratio 2.62; 95 % confidence interval 0.73, 9.49), vs. non-HPV 16/18 HPV at baseline.
2	4682219	CIN3+ association	CIN3+ was significantly associated with HPV 16 (Odds Ratio [Odds Ratio] 5.11; 95 % confidence interval [confidence interval] 2.30, 11.37), but not HPV 18 (Odds Ratio 2.62; 95 % confidence interval 0.73, 9.49), vs. non-HPV 16/18 HPV at baseline.
1	4682219	positive for round 1 CIN3+	HC2 and COBAS were concordant positive for 91 % of round 1 CIN2 and 98 % of CIN3+.
1	4682219	positive for round 1 CIN2	HC2 and COBAS were concordant positive for 91 % of round 1 CIN2 and 98 % of CIN3+.
1	3693661	The mean of weight, body mass index (BMI), waist-to-hip ratio (WHR), body fat, protein, mineral and total water	The mean of weight, BMI, WHR, body fat, protein, mineral and total water showed no difference between groups (P > 0.05).
0	3693661	Potassium, creatinine, urea and uric acid	Potassium, creatinine, urea and uric acid had been decreased significantly in both groups (P < 0.05).
0	3693661	weight, BMI, WHR	The mean differences were as follows: significant weight loss, BMI, WHR, in two groups at the end of Ramadan (P < 0.05).
1	3693661	FBS, sodium, phosphorus and osmolarity levels	Variations within group had been changed in FBS; sodium, phosphorus and osmolarity levels were not changed significantly.  
1	4148632	Membrane exposure	Membrane exposure was not observed in any cases.
1	4148632	Probing pocket depth	Membrane exposure was not observed in any cases. Significant probing depth reduction, attachment-level gain and bone fill were observed for both test and control groups compared to baseline at 3 months after surgery (P<0.05). However, there were no statistically significant differences in clinical improvement and radiographic bone fill between treatment protocols (P>0.05).  
1	4148632	Clinical improvement	However, there were no statistically significant differences in clinical improvement and radiographic bone fill between treatment protocols (P>0.05).  
1	4148632	Radiographic bone fill	However, there were no statistically significant differences in clinical improvement and radiographic bone fill between treatment protocols (P>0.05).  
2	4796446	Wound healing mean score improvement after 24 hours	Also, a significant difference was observed between the two groups with respect to the wound healing score 24 hours after the operation (P=0.003).
1	4796446	Getting a score of 0 after 8 days	After 8 days, however, the difference in the wound healing score was not significant (P=0.283).
1	4676931	Beck Depression Inventory score (12 weeks)	At week 12 there was no significant difference between groups for the reduction in total BDI-IA score (primary efficacy variable).
2	4676931	Parkinson's disease quality of life questionnaire - cognition score improvement	Post hoc analyses showed the statistical superiority of rasagiline versus placebo in the Unified Parkinson's Disease Rating Scale Part I depression item (P = 0.04) and PDQ-39 mobility (P = 0.007) and cognition domains (P = 0.026).  
2	4676931	Unified Parkinson's Disease Rating Scale Part II score improvement	Rasagiline significantly improved Unified Parkinson's Disease Rating Scale Parts I (P = 0.03) and II (P = 0.003) scores versus placebo at week 12.
2	4676931	Parkinson's disease quality of life questionnaire - mobility score improvement	Post hoc analyses showed the statistical superiority of rasagiline versus placebo in the Unified Parkinson's Disease Rating Scale Part I depression item (P = 0.04) and PDQ-39 mobility (P = 0.007) and cognition domains (P = 0.026).  
2	4676931	Unified Parkinson's Disease Rating Scale Part I score improvement	Rasagiline significantly improved Unified Parkinson's Disease Rating Scale Parts I (P = 0.03) and II (P = 0.003) scores versus placebo at week 12.
0	2427034	23S rRNA	The presence of 23S rRNA due to H. pylori infection in the omeprazole group remained lower than that in the placebo group 7.3 yrs after OA-therapy [51.1% (157/307) vs. 83.9% (260/310), p = 0.0000]. In the OA and CLR group, the 23S rRNA detection rate was 26.8% (41/153) three yrs after OAC-treatment.
2	2427034	A2143G mutation	The A2143G mutation rate among the 23S rRNA-positive subjects in the OA and CLR group [31.7% (13/41)] was significantly higher than that in the omeprazole group [10.2% (16/157)] and the placebo group [13.8% (36/260)].
2	2427034	AAGGG → CTTCA sequence alterations	The frequency of the AAGGG → CTTCA (2222–2226) and AACC → GAAG (2081–2084) sequence alterations in the OA and CLR group was also significantly higher than those in the omeprazole group and the placebo group.  
2	2427034	AAGGG → CTTCA sequence alterations	The frequency of the AAGGG → CTTCA (2222–2226) and AACC → GAAG (2081–2084) sequence alterations in the OA and CLR group was also significantly higher than those in the omeprazole group and the placebo group.  
0	2427034	23S rRNA	The presence of 23S rRNA due to H. pylori infection in the omeprazole group remained lower than that in the placebo group 7.3 yrs after OA-therapy [51.1% (157/307) vs. 83.9% (260/310), p = 0.0000].
2	2427034	A2143G mutation	The A2143G mutation rate among the 23S rRNA-positive subjects in the OA and CLR group [31.7% (13/41)] was significantly higher than that in the omeprazole group [10.2% (16/157)] and the placebo group [13.8% (36/260)].
1	5944439	Estradiol levels	Estradiol levels were statistically different with respect to time points within treatment groups (p<0.0001), but not between groups (p=0.43), or pregnancy outcomes (p=0.2595).
1	5944439	Retrieved oocytes	No differences were found in retrieved oocytes numbers, fertilization rate or embryos obtained.
1	5944439	Fertilization rate	Progesterone profiles were similar between groups. No differences were found in retrieved oocytes numbers, fertilization rate or embryos obtained.
1	5944439	Embryos obtained	Progesterone profiles were similar between groups. No differences were found in retrieved oocytes numbers, fertilization rate or embryos obtained.
1	5944439	Progesterone profile	Progesterone profiles were similar between groups.
0	5776520	mitochondrial membrane potentials	At day 1, 3 and 5 after operation, the mitochondrial membrane potentials of the two groups were decreased in different degrees, but the decrease range in the dexmedetomidine group was smaller than that in the propofol + remifentanil group, and the differences were statistically significant (P<0.05).
2	5776520	decrease in activities of mitochondrial respiratory chain complex I–IV	The activities of mitochondrial respiratory chain complex I–IV in the propofol + remifentanil group at day 1 after operation were significantly decreased compared with those before operation, and the differences were statistically significant (P<0.05). The decrease in activities of mitochondrial respiratory chain complex I–IV in the propofol + remifentanil group at day 1 after operation was more significant than that in the dexmedetomidine group, and the difference was statistically significant (P<0.05).
1	3941354	Retrieved oocytes	Results: There were no statistically significant differences in the number of retrieved oocyte (p=0.545), fertilization (p=0.876), implantation (p=0.716) and pregnancy rate (p=0.727) between the two groups.   
1	3941354	Implantation rate	Results: There were no statistically significant differences in the number of retrieved oocyte (p=0.545), fertilization (p=0.876), implantation (p=0.716) and pregnancy rate (p=0.727) between the two groups.   
1	3941354	Fertilization rate	Results: There were no statistically significant differences in the number of retrieved oocyte (p=0.545), fertilization (p=0.876), implantation (p=0.716) and pregnancy rate (p=0.727) between the two groups.   
1	3941354	Pregnancy rate	Results: There were no statistically significant differences in the number of retrieved oocyte (p=0.545), fertilization (p=0.876), implantation (p=0.716) and pregnancy rate (p=0.727) between the two groups.   
2	3929816	Pathologic changes in the kidneys	Histopathologic evaluations revealed more pathological changes at the kidney of all the dogs in test group in comparison to control group.  
0	4677000	pain in the paediatric population	In addition, adverse events and local tolerability were evaluated. In group I, pain was reduced significantly after treatment with verum compared to placebo at both time points. In group II, the individual pain rating shift showed statistically significant lower pain after treatment.
0	5483302	Small dense low-density lipoprotein cholesterol (sd-LDL-C) level at 52wks	The reduction of LDL-C was larger in the EAT group (28.3%) than in the double-dose statin group (9.2%) at 52 weeks as well as the primary endpoint of 12 weeks.
1	3134103	Blood loss after 2 days	Blood loss between groups at 48 (366 ± 318 mL versus 412 ± 363 mL, P = .382) and 72 (194 ± 300 mL versus 176 ± 224 mL, P = .643) hours was not significantly different.
1	3134103	Blood loss after 3 days	Mean blood loss in the first 24 hours was 962 ± 595 mL in the treatment group (n = 79) and 1,178 ± 788 mL in the control group (n = 106), P = .040. Blood loss between groups at 48 (366 ± 318 mL versus 412 ± 363 mL, P = .382) and 72 (194 ± 300 mL versus 176 ± 224 mL, P = .643) hours was not significantly different.
0	3134103	Blood loss during day 1	Mean blood loss in the first 24 hours was 962 ± 595 mL in the treatment group (n = 79) and 1,178 ± 788 mL in the control group (n = 106), P = .040.
2	3309311	differences in the disc herniation, HDD, annulus tear, and high intensity zone	The findings of disc herniation, annular tear, high intensity zone, and lumbar disc degeneration were more prevalent in A group than in B group (p<0.01). high intensity zone findings were more prevalent in A group than in group B or group C (p<0.05).  
2	3309311	The proportion of high intensity zone incidence	high intensity zone findings were more prevalent in A group than in group B or group C (p<0.05).  
2	3309311	The proportion of high intensity zone incidence	high intensity zone findings were more prevalent in A group than in group B or group C (p<0.05).  
1	3482439	intraoperative femoral shaft fractures	The mean surgical time was statistically significantly shorter and fluoroscopy time longer for the group B. No intraoperative femoral shaft fractures occurred.
1	5358738	Skin-to-Skin Contact % points	At 4 months post-intervention an increase of 20 percentage points (p.p.) for complete Active Management of Third Stage of Labor (Active Management of Third Stage of Labor) (p = 0.044), and 16 p.p. increase for Skin-to-Skin Contact (p = 0.067); at 12 months a 25 p.p.
2	5358738	Delayed Cord Clamping % points	increase for Skin-to-Skin Contact (p = 0.067); at 12 months a 25 p.p. increase of the 1st step of Active Management of Third Stage of Labor (p = 0.026) and a 42 p.p. increase of Delayed Cord Clamping (p = 0.004); at 4 months a 30 (p = 0.001) and at 8 months a 22 (p = 0.010) p.p.
0	5358738	Uterine Sweeping % points	increase of Delayed Cord Clamping (p = 0.004); at 4 months a 30 (p = 0.001) and at 8 months a 22 (p = 0.010) p.p. decrease for Uterine Sweeping.  
0	3346068	cumulative pain	In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms.
0	524504	induction-delivery interval	The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).
2	524504	number of women who deliver within 12 hours	With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).
2	524504	number of women who deliver within 24 hours	With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).
2	524504	spontaneous rupture of membranes	With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).
0	524504	administration of oxytocin augmentation	With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).
1	524504	Caesarean section rate	Although not statistically significant, a lower Caesarean section (Caesarean section) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (fetal heart rate) tracings (22.5% vs. 12%, p > 0.05).
1	524504	abnormal fetal heart rate	Although not statistically significant, a lower Caesarean section (Caesarean section) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (fetal heart rate) tracings (22.5% vs. 12%, p > 0.05).
0	5073301	composite appetite score	HP-Legume induced lower composite appetite score, hunger, prospective food consumption, and higher fullness compared to HP-Meat and LP-Legume (p<0.05).
2	5073301	fullness	Furthermore, HP-Legume induced higher fullness than LP-Legume (p<0.05).
2	5073301	fullness	HP-Legume induced lower composite appetite score, hunger, prospective food consumption, and higher fullness compared to HP-Meat and LP-Legume (p<0.05).
0	5073301	lower energy intake	A 12% and 13% lower energy intake, respectively, was seen after HP-Legume compared to HP-Meat or LP-Legume (p<0.01).  
2	5073301	satiety	Furthermore, satiety was higher after HP-Legume than HP-Meat (p<0.05).
2	5101386	two quality of life domains (role-physical and general health perceptions)	Preliminary results revealed significantly larger improvements in two quality of life domains (role-physical and general health perceptions) in the health education program plus yoga group versus health education program alone (ps < 0.05).
1	3698010	Vaccine-related serious adverse events	No vaccine-related serious adverse events were reported.  
0	3698010	Fever ≥39°C	After the toddler dose, paracetamol effectively reduced fever >39°C, reaching statistical significance in the per protocol population only (efficacy 79%; 95% confidence interval: 3.9, 97.7).
1	3698010	Fever ≥38°C	In the intent-to-treat population, paracetamol reduced the incidence of fever ≥38°C, but this reduction was only significant for the infant series, with computed efficacy of 43.0% (95% confidence interval [confidence interval]: 17.4, 61.2), and not significant after the toddler dose (efficacy 15.9%; 95% confidence interval: −19.9, 41.3); results were similar in the per protocol (per protocol) population.
1	3698010	Vaccine-related serious adverse events	No vaccine-related serious adverse events were reported.  
0	3778304	5-year overall survival rate	The 5-year overall survival and disease-specific survival rates for patients with critical weight loss during radiotherapy were 62% and 82%, compared with 70% and 89% for patients without critical weight loss (P=0.01; P=0.001).
0	3778304	5-year overall survival rate	Before radiotherapy, 70% of patients had no weight loss, 16% had ⩽5% weight loss, 9% had >5–10% weight loss, and 5% had >10% weight loss. Five-year overall survival and disease-specific survival rates for these groups were 71%, 59%, 47%, and 42% (P<0.001), and 86%, 86%, 81%, and 71%, respectively (P<0.001).
0	3778304	5-year disease-specific survival rate	The 5-year overall survival and disease-specific survival rates for patients with critical weight loss during radiotherapy were 62% and 82%, compared with 70% and 89% for patients without critical weight loss (P=0.01; P=0.001).
0	3778304	5-year disease-specific survival rate	Five-year overall survival and disease-specific survival rates for these groups were 71%, 59%, 47%, and 42% (P<0.001), and 86%, 86%, 81%, and 71%, respectively (P<0.001).
1	3411720	magnitude of the effect of zinc on rates of respiratory illness	We found no evidence that concurrent supplementation with multi-nutrients influenced the magnitude of the effect of zinc on rates of diarrhea, respiratory illness, fever without localizing signs, or other illness (guardian-reported illness with symptoms involving skin, ears, eyes and abscesses, but excluding trauma or burns).
1	3411720	magnitude of the effect of zinc on rates of fever without localizing signs	We found no evidence that concurrent supplementation with multi-nutrients influenced the magnitude of the effect of zinc on rates of diarrhea, respiratory illness, fever without localizing signs, or other illness (guardian-reported illness with symptoms involving skin, ears, eyes and abscesses, but excluding trauma or burns).
0	3411720	rate of diarrhea	Zinc supplementation reduced the hazard rate of diarrhea by 24% (4%–40%). By contrast, multi-nutrients seemed to increase this rate (HR; 95% CI: 1.19; 0.94–1.50), particularly in children with asymptomatic Giardia infection at baseline (2.03; 1.24–3.32).
0	3411720	rate of diarrhea	We found no evidence that the efficacy of zinc supplements in reducing diarrhea rates is enhanced by concurrent supplementation with other micronutrients.
1	3411720	number of clinic visits	Zinc also protected against episodes of fever without localizing signs (0.75; 0.57–0.96), but we found no evidence that it reduced the overall number of clinic visits.  
1	3411720	magnitude of the effect of zinc on rates of diarrhea	We found no evidence that concurrent supplementation with multi-nutrients influenced the magnitude of the effect of zinc on rates of diarrhea, respiratory illness, fever without localizing signs, or other illness (guardian-reported illness with symptoms involving skin, ears, eyes and abscesses, but excluding trauma or burns).
1	4893238	Mean tissue PGE2	In the rebamipide group, the mean tissue PGE2 concentration was 999 ± 109 pg/mL before treatment, and 168 ± 13 pg/mL after treatment (p < 0.001). There was no difference in mean tissue PGE2 between the two groups (difference = 5; 95%CI from −334.870 to 345.650; p = 0.975).
1	4893238	Cryer score	At the end of the study, median Cryer score was 4 in both groups (Difference = 0; 95%CI = −1 to 0; p = 0.728).
1	4893238	Median histopathological scores	No significant change was observed at the histopathological evaluation, despite the evident macroscopic damage induced by naproxen.  
2	3785973	Asthma-related quality of life	In this study, Internet-based self-management support has been demonstrated to improve asthma-related quality of life, asthma control, lung function, and the number of symptom-free days as compared to usual care.
2	3785973	Asthma control	At 30 months after baseline, a sustained and significant difference in terms of asthma-related quality of life of 0.29 (95% CI 0.01-0.57) and asthma control of -0.33 (95% CI -0.61 to -0.05) was found in favor of the Internet-based self-management group.
1	3785973	Inhaled corticosteroid dosage	No such differences were found for inhaled corticosteroid dosage or for lung function, measured as forced expiratory volume in 1 second.  
1	3785973	FEV 1	No such differences were found for inhaled corticosteroid dosage or for lung function, measured as forced expiratory volume in 1 second.  
0	4676914	Weight gain	Weight gain was low (<1 kg) in both groups, with less gain with glargine 300 U/ml [least squares mean difference −0.28 kg (95% confidence interval −0.55 to −0.01); p = 0.039].
0	4676914	annualized rate (events per participant-year) of confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe hypoglycaemia at any time of day (24 h) over the 6-month	Annualized rates of confirmed (≤3.9 mmol/l) or severe hypoglycaemia were lower with glargine 300 U/ml than with glargine 100 U/ml during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference).
1	3506492	Acute kidney injury	erythropoietin treatment did not significantly modify the difference in uNGAl between 48 hours and randomization compared to placebo [2.5 ng/ml (−17.3; 22.5) vs 0.7 ng/ml (−31.77; 25.15), p = 0.77] and the incidence of acute kidney injury was similar.
1	3506492	Urinary neutrophil gelatinase-associated lipocalin	erythropoietin treatment did not significantly modify the difference in uNGAl between 48 hours and randomization compared to placebo [2.5 ng/ml (−17.3; 22.5) vs 0.7 ng/ml (−31.77; 25.15), p = 0.77] and the incidence of acute kidney injury was similar.
1	3506492	Cytokines	Inflammatory cytokines levels were not influenced by erythropoietin treatment.
1	3506492	Mortality	Mortality and hospital stays were similar between the groups and no adverse event was recorded.  
1	3506492	Total hospital stay	Mortality and hospital stays were similar between the groups and no adverse event was recorded.  
1	3506492	ICU stay	Inflammatory cytokines levels were not influenced by erythropoietin treatment. Mortality and hospital stays were similar between the groups and no adverse event was recorded.  
2	5622764	average daily risk range	There was an increase in basic measures of glycaemic control (maximal glucose value 341 ± 15 vs. 378 ± 13 mg/dL for placebo and β-glucan, p = 0.004), and average daily risk range (62 ± 5 vs. 79 ± 4 mg/dL for placebo and β-glucan, p = 0.003) favouring placebo over β-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures.
2	5622764	maximal glucose value	There was an increase in basic measures of glycaemic control (maximal glucose value 341 ± 15 vs. 378 ± 13 mg/dL for placebo and β-glucan, p = 0.004), and average daily risk range (62 ± 5 vs. 79 ± 4 mg/dL for placebo and β-glucan, p = 0.003) favouring placebo over β-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures.
1	4689777	Nausea score	The nausea score tended to increase from day 3 in both groups, but no significant intergroup difference was observed.
1	4689777	Complete response rate in acute phase	No significant intergroup differences in the complete response rate or the complete control rate were found over the entire period.
1	4689777	Complete response rate during the first stage of the late phase	No significant intergroup differences in the complete response rate or the complete control rate were found over the entire period.
1	4689777	Complete response rate during the second stage of the late phase	No significant intergroup differences in the complete response rate or the complete control rate were found over the entire period.
1	4689777	Complete control rate	No significant intergroup differences in the complete response rate or the complete control rate were found over the entire period.
1	5892275	Fasting plasma C-Peptide	There were no significant differences in daily dosages of insulin, fasting plasma C-P and 2 h postprandial C-P and insulin, and fructosamine at the baseline and endpoint between the groups Asp and Lis.
1	5892275	2 h postprandial C-Peptide	There were no significant differences in daily dosages of insulin, fasting plasma C-P and 2 h postprandial C-P and insulin, and fructosamine at the baseline and endpoint between the groups Asp and Lis.
1	5892275	Fructosamine	There were no significant differences in daily dosages of insulin, fasting plasma C-P and 2 h postprandial C-P and insulin, and fructosamine at the baseline and endpoint between the groups Asp and Lis.
1	5892275	Mean amplitude of glycemic excursions	No significant differences were seen in the 24 h mean amplitude of glycemic excursions (mean amplitude of glycemic excursions), 24 h mean blood glucose (mean blood glucose), the standard deviation of the mean blood glucose (SDBG), fasting blood glucose, number of glycemic excursion (number of glycemic excursion), and the incidence of hypoglycemia between the two groups.
1	5892275	Dosages of insulin	There were no significant differences in daily dosages of insulin, fasting plasma C-P and 2 h postprandial C-P and insulin, and fructosamine at the baseline and endpoint between the groups Asp and Lis.
1	5892275	Blood glucose	No significant differences were seen in the 24 h mean amplitude of glycemic excursions (mean amplitude of glycemic excursions), 24 h mean blood glucose (mean blood glucose), the standard deviation of the mean blood glucose (SDBG), fasting blood glucose, number of glycemic excursion (number of glycemic excursion), and the incidence of hypoglycemia between the two groups.
2	4080584	total score	For Health-Related Quality of Life, after adjustment for baseline scores, the intervention group showed significantly higher scores on all three PedsQL scores (physical functioning: M ± SE = 83.9 ± 0.7, p = .005; psychosocial: 79.9 ± 0.8, p = .001; total score: 81.3 ± 0.7, p = .001) than the control group (80.9 ± 0.8; 76.1 ± 0.9 and 77.8 ± 0.8).
2	4080584	physical functioning	For Health-Related Quality of Life, after adjustment for baseline scores, the intervention group showed significantly higher scores on all three PedsQL scores (physical functioning: M ± SE = 83.9 ± 0.7, p = .005; psychosocial: 79.9 ± 0.8, p = .001; total score: 81.3 ± 0.7, p = .001) than the control group (80.9 ± 0.8; 76.1 ± 0.9 and 77.8 ± 0.8).
2	4080584	psychosocial functioning	For Health-Related Quality of Life, after adjustment for baseline scores, the intervention group showed significantly higher scores on all three PedsQL scores (physical functioning: M ± SE = 83.9 ± 0.7, p = .005; psychosocial: 79.9 ± 0.8, p = .001; total score: 81.3 ± 0.7, p = .001) than the control group (80.9 ± 0.8; 76.1 ± 0.9 and 77.8 ± 0.8).
2	4080584	PedsQL	The three-group analysis found intervention non-completers had significantly higher PedsQL scores (84.0 ± 0.8, p = .021; 80.4 ± 0.9, p = .003; 81.7 ± 0.8, p = .002;) than controls (80.9 ± 0.8, 76.1 ± 0.9 and 77.8 ± 0.8).
2	4080584	PedsQL	For Health-Related Quality of Life, after adjustment for baseline scores, the intervention group showed significantly higher scores on all three PedsQL scores (physical functioning: M ± SE = 83.9 ± 0.7, p = .005; psychosocial: 79.9 ± 0.8, p = .001; total score: 81.3 ± 0.7, p = .001) than the control group (80.9 ± 0.8; 76.1 ± 0.9 and 77.8 ± 0.8).
2	4080584	PedsQL	The three-group analysis found intervention non-completers had significantly higher PedsQL scores (84.0 ± 0.8, p = .021; 80.4 ± 0.9, p = .003; 81.7 ± 0.8, p = .002;) than controls (80.9 ± 0.8, 76.1 ± 0.9 and 77.8 ± 0.8).
0	2703617	Waiting time of urgent patients	The mean waiting timess of urgent patients (Canadian Triage Acuity Scale 2/3) were also significantly reduced after the fast track area was opened (P < 0.001).
0	2703617	Patient that left without being seen	The LWBS rate was reduced from 4.7% to 0.7% (95% CI 3.37 to 4.64; P < 0.001).
1	2703617	Mortality	Opening a fast track area had no significant impact on mortality rates (P = 0.88).  
0	2703617	Waiting time of Canadian Triage Acuity Scale 4	Mean waiting timess of Canadian Triage Acuity Scale (Canadian Triage Acuity Scale) 4 patients decreased by 22 min (95% CI 21 min to 24 min, P < 0.001).
0	2703617	Waiting time of Canadian Triage Acuity Scale 5	Similarly, mean waiting timess of Canadian Triage Acuity Scale 5 patients decreased by 28 min (95% CI 19 min to 37 min, P < 0.001) post fast track area.
2	5008205	Gastrointestinal adverse events	Gastrointestinal adverse events were more common with dulaglutide 1.5 and 0.75 mg versus sitagliptin (nausea 17 and 15% vs 7%, diarrhoea 16 and 12% vs 6%, vomiting 14 and 8% vs 4% respectively).
2	5662620	Subjective well-being	The findings showed significant increases in subjective well-being and positive learning behaviors among the intervention participants, with no significant changes in the control group.
2	5662620	Positive learning behaviors	The findings showed significant increases in subjective well-being and positive learning behaviors among the intervention participants, with no significant changes in the control group.
0	5556332	universal pain assessment tool scores	Patients in the PAN group had significantly lower universal pain assessment tool scores at 0, 2, 4, 6, 12, 24 and 48 hours after the surgery than those in the control group (P = 0.008, 0.021, 0.008, 0.047, 0.004, 0.001, and 0.001).
0	5556332	Consumption of morphine after the surgery	The mean dose of postoperative morphine consumption in the PAN group was 37% less than the control group (P = 0.001).
1	5556332	Rate of complications	The complications were not significantly different between the two groups.  
1	3591547	The average returning time of respiration after discontinuing of the drugs	The time of spontaneous respiration in Alfentanil group was 2 minutes and in Remifentanil group was 3.3 minutes, the difference was not statistically significant (P=0.08).
0	3591547	nausea and vomiting	During recovery, incidence of nausea and vomiting in Remifentanil group (30% of patients) was significantly more than Alfentanil group (5% of patients) (P=0.045).  
2	3407981	Glucose levels obtained 30 min post-feeding	Blood glucose levels (30 min after beverage ingestion) differed across all treatments (carbohydrate-only > high-carbohydrate/low-protein > low-carbohydrate/high-protein; p < 0.05), and serum insulin was higher following carbohydrate-only and high-carbohydrate/low-protein ingestion versus low-carbohydrate/high-protein.
2	3407981	serum insulin during recovery from cycling exercise	Blood glucose levels (30 min after beverage ingestion) differed across all treatments (carbohydrate-only > high-carbohydrate/low-protein > low-carbohydrate/high-protein; p < 0.05), and serum insulin was higher following carbohydrate-only and high-carbohydrate/low-protein ingestion versus low-carbohydrate/high-protein.
2	3407981	Glucose levels obtained 30 min post-feeding	Blood glucose levels (30 min after beverage ingestion) differed across all treatments (carbohydrate-only > high-carbohydrate/low-protein > low-carbohydrate/high-protein; p < 0.05), and serum insulin was higher following carbohydrate-only and high-carbohydrate/low-protein ingestion versus low-carbohydrate/high-protein.
2	3407981	Glucose levels obtained 30 min post-feeding	Blood glucose levels (30 min after beverage ingestion) differed across all treatments (carbohydrate-only > high-carbohydrate/low-protein > low-carbohydrate/high-protein; p < 0.05), and serum insulin was higher following carbohydrate-only and high-carbohydrate/low-protein ingestion versus low-carbohydrate/high-protein.
2	3682293	postoperative sedation have any beneficial effects on myocardial injury in cardiac surgery patients after on-pump valve replacement.	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1 was significantly lower in the sevoflurane group compared with the propofol group (unadjusted difference, -0.4; 95% CI, -0.7 to -0.1; P < 0.01; adjusted difference, -0.2; 95% CI, -0.4 to -0.02; P = 0.03, respectively).  
0	3682293	Concentration of troponin T	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1 was significantly lower in the sevoflurane group compared with the propofol group (unadjusted difference, -0.4; 95% CI, -0.7 to -0.1; P < 0.01; adjusted difference, -0.2; 95% CI, -0.4 to -0.02; P = 0.03, respectively).  
1	4890862	Externalizing problems	No effects were observed for girls or for the continuous measures of Total, Internalizing, and Externalizing problems.
1	4890862	Internalizing problems	No effects were observed for girls or for the continuous measures of Total, Internalizing, and Externalizing problems.
1	4890862	Total problems	No effects were observed for girls or for the continuous measures of Total, Internalizing, and Externalizing problems.
2	4255428	alcohol use in pregnancy	The program identified alcohol use in pregnancy among 21% of users, a higher rate than the 13% (p < .01) found via screening by clinic staff.  
1	420060	Remifentanil incidence of adverse events - ICU patients with various degrees of renal impairment	There were no statistically significant differences between the renal function groups in the incidence of adverse events, and no deaths were attributable to remifentanil use.  
0	420060	Propofol consumption - ICU patients with various degrees of renal impairment	Propofol consumption was lower with the remifentanil based technique than with hypnotic based sedative techniques.
2	2074536	Survival rate after 2 years in non-small cell lung cancer patients	The trial in non-small-cell lung cancer included 563 patients and showed improvement in survival; 30% of the Continuous hyperfractionated accelerated radiation therapy patients were alive at 2 years compared with 20% in the control group (P = 0.006).
1	2074536	Long-term morbidity	The early mucosal reactions appeared sooner and were more troublesome with Continuous hyperfractionated accelerated radiation therapy, however they quickly settled; so far no difference in long-term morbidity has emerged.
1	2074536	Disease-free interval in patients with head and neck cancer	In the 918 head and neck cases, there was only a small, non-significant improvement in the disease-free interval.
0	5668634	Fatigue severity	Multiple group latent growth curve analysis, corrected for individual time between assessments, showed that fatigue severity decreased significantly more in the Ambulant Activity Feedback and eMBCT groups compared to the psycho-educational group.
0	5668634	Fatigue severity	Multiple group latent growth curve analysis, corrected for individual time between assessments, showed that fatigue severity decreased significantly more in the Ambulant Activity Feedback and eMBCT groups compared to the psycho-educational group.
1	4221328	Acute kidney injury	None of the patients developed an acute kidney injury during the study and no significant differences were found between the serum neutrophil gelatinase-associated lipocalin levels of the groups during the perioperative period.  
1	4221328	Levels of neutrophil gelatinase-associated lipocalin	None of the patients developed an acute kidney injury during the study and no significant differences were found between the serum neutrophil gelatinase-associated lipocalin levels of the groups during the perioperative period.  
0	2774638	Estimation of underreported calcium as daily calcium intake increased	As daily calcium intake increased, the 24-hour recall increasingly underreported calcium (r = 0.41, P < .001) compared with the calcium-focused food frequency questionnaire.
2	2774638	Estimation of total daily calcium intake	The calcium-focused food frequency questionnaire estimated greater total daily calcium intake than did the 24-hour recall (mean [SD], 1,021 [624] mg/d vs 800 [433] mg/d, P < .001).
2	3339727	stable hemodynamic profile	Fentanyl in the lower dose provides a more stable hemodynamic profile.
0	3339727	decrease in systolic blood pressure	There was no statistically significant difference in any parameter in the two groups except for a significant fall in systolic and mean arterial pressure in fentanyl 2 mcg/kg group.  
1	4822094	Aronchick Scale score	There was no significant difference in bowel cleansing quality, measured by the endoscopist blinded to preparation, between plus magnesium citrate, plus magnesium citrate plus enema, and enema alone as measured by the modified Ottawa Bowel Preparation Scale (P=0.34) or the Aronchick Scale (P=0.13).
1	4822094	Aronchick Scale score	There was no significant difference in bowel cleansing quality, measured by the endoscopist blinded to preparation, between plus magnesium citrate, plus magnesium citrate plus enema, and enema alone as measured by the modified Ottawa Bowel Preparation Scale (P=0.34) or the Aronchick Scale (P=0.13).
2	4822094	Abdominal pain	Both oral plus magnesium citrate regimens were associated with higher incidence of nausea, abdominal pain, bloating, and interrupted sleep than enema alone (P<0.05).  
2	4822094	Bloating	Both oral plus magnesium citrate regimens were associated with higher incidence of nausea, abdominal pain, bloating, and interrupted sleep than enema alone (P<0.05).  
1	4822094	Ottawa Bowel Preparation Scale score	There was no significant difference in bowel cleansing quality, measured by the endoscopist blinded to preparation, between plus magnesium citrate, plus magnesium citrate plus enema, and enema alone as measured by the modified Ottawa Bowel Preparation Scale (P=0.34) or the Aronchick Scale (P=0.13).
2	4822094	Nausea	Both oral plus magnesium citrate regimens were associated with higher incidence of nausea, abdominal pain, bloating, and interrupted sleep than enema alone (P<0.05).  
1	5773988	Probing pocket depth reduction	probing pocket depth reduction and clinical attachment level gain were significant in all the groups after 6 months whereas, on intergroup comparisons, insignificant finding was observed both at baseline and after 6 months.
0	5773988	Buccolingual measurements	Coronoapical bone status decreased significantly in all groups, buccolingual measurements decreased significantly in TG1 and TG2, but no such trend was seen in CG.
1	3877985	oxytocin levels	During treatment, plasma oxytocin did not differ between SRI and placebo treatment.
1	3403627	Pain scores	No differences were found in pain scores between the groups at all points.
2	3403627	Passive knee motion at 3 days after surgery	On the 3rd day after surgery, the passive knee motion in the acupressure group patients was significantly better than in the sham control group patients (P < 0.05), controlling for BMI.
0	3403627	Use of analgesic drugs	However, analgesic drug usage in the acupressure group patients was significantly lower than in the sham control group (P < 0.05), controlling for BMI, age, and pain score.
1	5029935	Mortality rates	Higher Long-term oxygen therapy duration analyzed as a continuous variable was not associated with any change in mortality rate (hazard ratio [hazard ratio] 1.00; (95% confidence interval [confidence interval], 0.98 to 1.02) per 1 h/day increase above 15 h/day.
1	5029935	Mortality rates	Mortality was similar between the groups for all-cause, respiratory and cardiovascular mortality.
1	5029935	Survival benefit in hypoxemic chronic obstructive pulmonary disease	In hypoxemic chronic obstructive pulmonary disease, Long-term oxygen therapy 24 h/day was not associated with a survival benefit compared with treatment 15–16 h/day.
1	4461648	percentage of time with Pcuff 20–30 cmH2O versus Pcuff <20 cmH2O	The percentage of time spent with Pcuff 20–30 cmH2O (median (IQR) 34 % (17–57) versus 50 % (35–64), p = 0.184) and the percentage of time spent with Pcuff <20 cmH2O (23 % (5–63) versus 43 % (16–60), p = 0.5) were similar during continuous control of Pcuff and routine care, respectively.
2	4129110	intend to continue	high-intensity functional training participants spent significantly less time exercising per week, yet were able to maintain exercise enjoyment and were more likely to intend to continue.
1	4129110	body mass index	No significant changes in body mass index or body composition were found.
0	4129110	Time spent completing daily workouts	Workouts were shorter for high-intensity functional training than and resistance training (p < .001).  
0	4129110	Workouts	Workouts were shorter for high-intensity functional training than and resistance training (p < .001).  
2	2656477	self-efficacy related to social pressure and restraint in overweight and obese endometrial cancer survivors.	There was a significant improvement for self-efficacy related to social pressure (p = .03) and restraint (p = .02) in the LI group.
2	3590825	Torque values (concentric contractions)	Analysis of variance showed a significant increase in plantar-flexor eccentric and concentric torque (p < 0.05) of trained and untrained groups, and an increase in dorsiflexion range of motion (p < 0.05) at both angular velocities for the untrained group only.
2	3590825	Torque values (eccentric contractions)	Analysis of variance showed a significant increase in plantar-flexor eccentric and concentric torque (p < 0.05) of trained and untrained groups, and an increase in dorsiflexion range of motion (p < 0.05) at both angular velocities for the untrained group only.
2	3590825	Torque values (concentric contractions)	Analysis of variance showed a significant increase in plantar-flexor eccentric and concentric torque (p < 0.05) of trained and untrained groups, and an increase in dorsiflexion range of motion (p < 0.05) at both angular velocities for the untrained group only.
1	3657931	mean dose of propofol required for induction	No significant difference in the induction dose of propofol was observed when assessed clinically (loss of verbal response) or by bispectral index monitoring.
1	3657931	dosage of propofol required by females	The mean dose of propofol used in groups A and B were 1.85±0.48 mg/kg and 1.79±0.41 mg/kg, respectively. The dosage used in group B were less but not clinically significant (P=0.575). On comparing the dosage of propofol in males among the groups there was a significantly lower dosage of propofol required in group B (2.06±0.45 mg/kg and 1.83±0.32 mg/kg, respectively, P=0.016). This decrease however was not seen in female patients dosage being 1.65±0.44 mg/kg and 1.75±0.49 mg/kg, respectively (P=0.372).
0	4713214	required tolterodine	Finally, less patients in Resiniferatoxin group required tolterodine, compared with control, P=0.009.
1	4713214	catheter related bladder discomfort On the fifth day after surgery	Interestingly, the difference of catheter related bladder discomfort incidence between Group Resiniferatoxin (50%) and control (75%) diminished 5 days after TURP, P=0.135.  
1	5630555	The titers of glutamic acid decarboxylase autoantibodies	Although the titers of glutamic acid decarboxylase autoantibodies were not significantly different between the S and P groups during the study, the change ratio of the glutamic acid decarboxylase autoantibodies titers from baseline was significantly inversely correlated with the change ratio of the ∑C-peptide values from baseline in the S group (p = 0.003); in particular, when the glutamic acid decarboxylase autoantibodies titers decreased from baseline, the ∑C-peptide values frequently increased.  
1	5630555	the ∑C-peptide values during the oral glucose tolerance test	On average, the ∑C-peptide values during the oral glucose tolerance test through the follow-up periods showed a nonsignificant increase in the S group (n = 6, n = 5 at 48 months) compared to the P group (n = 5, n = 2 at 48 months).
0	4808857	Snacks intake	Statistical tests performed revealed that compared to control group, participants in intervention group increased fruit intake and decreased intake of snacks high in sugar and fat significantly (p < 0.05).
2	4808857	Nutrition knowledge	Nutritional Knowledge and attitudinal scores also increased significantly in the intervention group (p < 0.05).
1	4808857	Vegetable intake	No intervention effect was found for vegetables intake, Energy Intake, BMI and Physical Activity Level (p > 0.05).
1	4808857	Energy intake	No intervention effect was found for vegetables intake, Energy Intake, BMI and Physical Activity Level (p > 0.05).
1	4808857	BMI	No intervention effect was found for vegetables intake, Energy Intake, BMI and Physical Activity Level (p > 0.05).
1	3688436	Young Mania Rating Scale (Young Mania Rating Scale) on the first day	The total Young Mania Rating Scale difference on the first day approached the conventional significance level (1.97 units, t = 1.84, P = 0.07).
1	3688436	Young Mania Rating Scale and the Brief Psychiatric Rating Scale scale over the course of 4 weeks	Over the course of 4 weeks, we failed to find that donepezil produced any significant difference in the Young Mania Rating Scale (6.71 units difference, t = −1.44, P = 0.16) or the Brief Psychiatric Rating Scale scale (1.29 units difference, t = −0.33, P = 0.75) as compared to placebo.
2	1868720	Sickness absence	Sickness absence was higher in the 'at risk' (N = 212) group (42%) compared to the 'not at risk' (N = 2503) group (25%) (OR 2.17 CI 1.63–2.89; p = 0.000).
2	1868720	The percentage of participating employees reporting sickness absence	Sickness absence was higher in the 'at risk' (N = 212) group (42%) compared to the 'not at risk' (N = 2503) group (25%) (OR 2.17 CI 1.63–2.89; p = 0.000).
1	5562134	Skin temperature	Skin and room temperatures showed no differences between the two groups (p>0.05).
0	5562134	Decrease in core temperature	Results: G1 was decreased by a lesser extent than G2 in core temperature, apparently higher at 30 and 60 minutes after induction.
1	5562134	Room temperature	Skin and room temperatures showed no differences between the two groups (p>0.05).
1	4332717	Incidence of grade II-IV acute GVHD at 180 days	The 180-day cumulative incidences of grade II-IV acute GVHD (primary endpoint) were 12.2% versus 8.9% in Flu-TBI and TLI-ATG patients, respectively (P = 0.5).
0	4332717	Incidence of relapse/progression at four years	Four-year cumulative incidences of relapse/progression were 22% and 50% in Flu-TBI and TLI-ATG patients, respectively (P = 0.017).
2	4332717	Incidence of moderate/severe chronic GVHD at 2 years	Two-year cumulative incidences of moderate/severe chronic GVHD were 40.8% versus 17.8% in Flu-TBI and TLI-ATG patients, respectively (P = 0.017).
1	4332717	Incidence of nonrelapse mortality	Four-year cumulative incidences of nonrelapse mortality were 24% and 13% in Flu-TBI and TLI-ATG patients, respectively (P = 0.5).
1	4332717	4-year overall survival and progression-free survival	Finally, 4-year overall (OS) and progression-free survivals (progression-free survivals) were 53% and 54%, respectively, in the Flu-TBI arm, versus 54% (P = 0.9) and 37% (P = 0.12), respectively, in the TLI-ATG arm.  
0	5673730	HbA1C	There were two intrauterine deaths and significantly higher HbA1C at term in Group-B. (P=0.03).
0	5673730	numbers of babies were delivered after 38 weeks of pregnancy	Significant numbers of babies were delivered after 38 weeks of pregnancy in Group-B (P=0.021).
0	5673730	newborns weight	When groups were compared, newborns in Group-B were significantly more in weight (p=0.01).
1	5673730	fasting blood sugar (FBS) at term	FBS at term was non-significant (p=0.079) and there was more number of cesarean sections due to feto-maternal disproportion in Group-B (28% vs.2%).
0	5673730	number of cesarean sections due to feto-maternal disproportion	FBS at term was non-significant (p=0.079) and there was more number of cesarean sections due to feto-maternal disproportion in Group-B (28% vs.2%).
1	4984426	pain ratings	There were no significant differences in pain ratings between treatments.
1	4984426	Clinical Opiate Withdrawal Scale(COWS) - 24-hour period	The mean maximum Clinical Opiate Withdrawal Scale scores were similar, and numerically lower on buccal buprenorphine.
1	4871571	adverse events	The vaccine was safe and well tolerated except for one episode of asymptomatic hypoglycaemia that was classified as severe adverse event.
1	5099199	eradication rates by intention-to-treat (intention-to-treat)	The eradication rates of S10 and therapy for 14 days were 87.2% (567/650, 95% CI 84.4% to 89.6%) and 85.7% (557/650, 95% CI 82.8% to 88.2%) in the intention-to-treat analysis, respectively, and were 91.6% (556/607, 95% CI 89.1% to 93.4%) and 91.0% (548/602, 95% CI 88.5% to 93.1%) in the per-protocol analysis, respectively.
1	5099199	eradication rates by intention-to-treat (intention-to-treat)	S10 was not superior to therapy for 14 days in areas with low clarithromycin resistance.  
1	5099199	eradication rates by per-protocol (per-protocol)	The eradication rates of S10 and therapy for 14 days were 87.2% (567/650, 95% CI 84.4% to 89.6%) and 85.7% (557/650, 95% CI 82.8% to 88.2%) in the intention-to-treat analysis, respectively, and were 91.6% (556/607, 95% CI 89.1% to 93.4%) and 91.0% (548/602, 95% CI 88.5% to 93.1%) in the per-protocol analysis, respectively.
1	5099199	compliance to treatment	There were no differences in compliance or adverse effects.
0	3798949	Savings in drugs and dispensing costs	When compared with standard of care, the average treatment cost per patient was an excess of £431 for a non-commercial trial (range £6393 excess to £6005 saving) and a saving of £9294 for a commercial trial (range £0 to £71 480).
0	3798949	Savings in drugs and dispensing costs	On an average, non-commercial trial protocols were associated with a small per patient excess treatment cost, whereas commercial trials were associated with a substantially higher cost saving.
0	3640161	Time to first postoperative analgesic requirement	The time to the first postoperative analgesic requirement was significantly shorter in group RH than in the other two groups.
0	3640161	Time to first postoperative analgesic requirement	The time to the first postoperative analgesic requirement was significantly shorter in group RH than in the other two groups. The desflurane requirement was significantly greater in group C than in the other groups.
2	3640161	Hypotension/bradycardia	The frequency of hypotension and bradycardia was significantly higher, but shivering and postoperative nausea and vomiting were significantly lower in group DRH than in the other two groups.  
1	3315554	Renal function parameters	Renal function parameters were similar between study arms although a small increase in neutrophil gelatinase-associated lipocalin was detected among TDF-treated patients.  
0	3315554	Hip bone mass density at weeks 24 and 48	In TDF/FTC-treated patients we observed significant reductions from baseline in hip and lumbar spine bone mass density at week 24 (−1.8% and −2.5%) and week 48 (−2.1% and −2.1%), whereas bone mass density was stable in patients in the ABC/3TC arm.
0	3315554	Lumbar spine bone mass density at weeks 24 and 48	In TDF/FTC-treated patients we observed significant reductions from baseline in hip and lumbar spine bone mass density at week 24 (−1.8% and −2.5%) and week 48 (−2.1% and −2.1%), whereas bone mass density was stable in patients in the ABC/3TC arm.
2	3315554	Bone turnover biomarkers (except osteoprotegerin)	All bone turnover biomarkers except osteoprotegerin increased in the TDF/FTC arm compared with the ABC/3TC arm, but early changes did not predict subsequent loss of bone mass density.
1	4023937	diarrhea incidence	There were no differences between village groups in diarrhea incidence either reported at the home or presenting to clinic.
1	4023937	median number of oral rehydration solution sachets	There were no differences in oral rehydration solution use between zinc (59.6%) and comparison villages (58.8%).
0	4392433	urgent coronary revascularization	Vorapaxar also significantly reduced the composite of cardiovascular death, myocardial infarction, stroke, and urgent coronary revascularization (10.1% versus 11.8%, HR, 0.83; 95% CI 0.76 to 0.90; P<0.001), as well as the rate of cardiovascular death or myocardial infarction (P<0.001).
2	4392433	long�term secondary prevention of thrombotic cardiovascular events	In patients with prior myocardial infarction or peripheral artery disease who have not had a previous stroke or transient ischemic attack, vorapaxar added to standard therapy is effective for long‐term secondary prevention of thrombotic cardiovascular events, while increasing moderate or severe bleeding.  
2	4392433	moderate or severe bleeding	In patients with prior myocardial infarction or peripheral artery disease who have not had a previous stroke or transient ischemic attack, vorapaxar added to standard therapy is effective for long‐term secondary prevention of thrombotic cardiovascular events, while increasing moderate or severe bleeding.  
2	4392433	moderate or severe bleeding	The safety endpoint of GUSTO moderate or severe bleeding, was increased in the vorapaxar group (3.7 versus 2.4, HR, 1.55; 95% CI 1.30 to 1.86, P<0.001).
0	4392433	cardiovascular death	Vorapaxar also significantly reduced the composite of cardiovascular death, myocardial infarction, stroke, and urgent coronary revascularization (10.1% versus 11.8%, HR, 0.83; 95% CI 0.76 to 0.90; P<0.001), as well as the rate of cardiovascular death or myocardial infarction (P<0.001).
0	4392433	Myocardial Infarction	Vorapaxar also significantly reduced the composite of cardiovascular death, myocardial infarction, stroke, and urgent coronary revascularization (10.1% versus 11.8%, HR, 0.83; 95% CI 0.76 to 0.90; P<0.001), as well as the rate of cardiovascular death or myocardial infarction (P<0.001).
0	4392433	stroke	Vorapaxar also significantly reduced the composite of cardiovascular death, myocardial infarction, stroke, and urgent coronary revascularization (10.1% versus 11.8%, HR, 0.83; 95% CI 0.76 to 0.90; P<0.001), as well as the rate of cardiovascular death or myocardial infarction (P<0.001).
2	2249589	Costs	Total direct healthcare costs in the arthroscopy group were estimated to exceed on average those of the control group by €901 per patient (p < 0.001).  
1	2249589	Kujala score on patellofemoral pain	The mean improvement in the Kujala score was 12.9 (95% confidence interval (confidence interval) 8.2–17.6) in the arthroscopy group and 11.4 (95% confidence interval 6.9–15.8) in the control group. However, there was no difference between the groups in mean improvement in the Kujala score (group difference 1.1 (95% confidence interval -7.4 - 5.2)) or in any of the VAS scores.
1	5131536	Pathological complete response	The pathological complete response was found in 3 (4.4%) cases after radiotherapy and 8 (11.1%) after chemoradiotherapy (P = 0.112).
1	5131536	Downstaging (stage 0 and I)	Downstaging (stage 0 and I) was observed in 21 (30.9%) cases in radiotherapy group vs. 27 (37.5%) cases in chemoradiotherapy group (P = 0.409).
1	5131536	3-years overall survival	3-years overall survival (overall survival) was 78% in radiotherapy group vs. 82.4% in chemoradiotherapy group (P = 0.145), while disease-free survival (disease-free survival) differed significantly – 59% in radiotherapy group vs. 75.1% in chemoradiotherapy group (P = 0,022).
2	5131536	Disease-free survival	3-years overall survival (overall survival) was 78% in radiotherapy group vs. 82.4% in chemoradiotherapy group (P = 0.145), while disease-free survival (disease-free survival) differed significantly – 59% in radiotherapy group vs. 75.1% in chemoradiotherapy group (P = 0,022).
1	4156403	National Lung Screening Trial thyroid cancer risk	In National Lung Screening Trial, randomization to lung CT scan was associated with a non-significant increase in thyroid cancer risk (hazard ratios  = 1.61; 95% confidence intervals: 0.96–2.71).
0	4156403	PLCO thyroid cancer risk in men	In PLCO, randomization to cancer screening compared with usual care was associated with a significant decrease in thyroid cancer risk for men (hazard ratios  = 0.61; 95% confidence intervals: 0.49–0.95) but not women (hazard ratios  = 0.91; 95% confidence intervals: 0.66–1.26).
1	4156403	PLCO thyroid cancer risk in women	In PLCO, randomization to cancer screening compared with usual care was associated with a significant decrease in thyroid cancer risk for men (hazard ratios  = 0.61; 95% confidence intervals: 0.49–0.95) but not women (hazard ratios  = 0.91; 95% confidence intervals: 0.66–1.26).
1	2363351	Overall survival at 3 years	Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached).
2	2363351	Progression-free survival after 3 years	Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82).
1	2363351	Full clinical responses	Complete clinical responses were observed in 68% with interferon-γ versus 56% in controls (n.s.).
1	2363351	Toxicity	Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of interferon-γ.
2	5564145	Success rate	The DC of 4 % articaine had a significantly higher success rate (83.3%) than did the SC (53.3%; P < 0.05).
2	5564145	Duration of soft tissue anesthesia	The duration of soft tissue anesthesia was longer in the DC group.
0	5564145	Pain during the surgery	The intra-operative pain was higher in the SC group with a significant (P < 0.05) requirement for a supplementary local anesthetic.  
1	3806550	Perceived involvement in medical decision making	No differences were found between the intervention and control conditions on perceived involvement in medical decision making (Combined Outcome Measure for Risk Communication and Treatment Decision-making Effectiveness satisfaction with communication: F1,68=0.422, P=.52; Combined Outcome Measure for Risk Communication and Treatment Decision-making Effectiveness confidence in decision: F1,67=0.086, P=.77).
2	4497728	lower limb proprioception function	Compared with controls, significant improvements in Baduanjin exercise group at the end of 12-week intervention period were found on lower limb proprioception function (the rate of average trace error on right lower limb (%): control 23.50±5.50, Baduanjin 21.92±6.54, P=0.004; the rate of average trace error on left lower limb (%): control 22.32±6.62, Baduanjin 20.63±4.62, P=0.046), cardiorespiratory endurance (step test index: control 47.66±5.94, Baduanjin 50.07±9.30, P=0.025), flexibility (control 14.35±7.26cm, Baduanjin 15.39±6.43cm, P=0.009) and explosive force of lower limb (standing long jump test (m): control 1.77±0.24, Baduanjin 1.79±0.22, P=0.005 for adjustment baseline) in physical outcomes, and attention (Schulte Grid test (second): control 210.4±51.15, Baduanjin 192.4±47.14, P=0.034) in mental outcome.
2	4497728	the rate of average trace error on left lower limb	Compared with controls, significant improvements in Baduanjin exercise group at the end of 12-week intervention period were found on lower limb proprioception function (the rate of average trace error on right lower limb (%): control 23.50±5.50, Baduanjin 21.92±6.54, P=0.004; the rate of average trace error on left lower limb (%): control 22.32±6.62, Baduanjin 20.63±4.62, P=0.046), cardiorespiratory endurance (step test index: control 47.66±5.94, Baduanjin 50.07±9.30, P=0.025), flexibility (control 14.35±7.26cm, Baduanjin 15.39±6.43cm, P=0.009) and explosive force of lower limb (standing long jump test (m): control 1.77±0.24, Baduanjin 1.79±0.22, P=0.005 for adjustment baseline) in physical outcomes, and attention (Schulte Grid test (second): control 210.4±51.15, Baduanjin 192.4±47.14, P=0.034) in mental outcome.
2	4497728	cardiorespiratory endurance	Compared with controls, significant improvements in Baduanjin exercise group at the end of 12-week intervention period were found on lower limb proprioception function (the rate of average trace error on right lower limb (%): control 23.50±5.50, Baduanjin 21.92±6.54, P=0.004; the rate of average trace error on left lower limb (%): control 22.32±6.62, Baduanjin 20.63±4.62, P=0.046), cardiorespiratory endurance (step test index: control 47.66±5.94, Baduanjin 50.07±9.30, P=0.025), flexibility (control 14.35±7.26cm, Baduanjin 15.39±6.43cm, P=0.009) and explosive force of lower limb (standing long jump test (m): control 1.77±0.24, Baduanjin 1.79±0.22, P=0.005 for adjustment baseline) in physical outcomes, and attention (Schulte Grid test (second): control 210.4±51.15, Baduanjin 192.4±47.14, P=0.034) in mental outcome.
2	4497728	flexibility	Compared with controls, significant improvements in Baduanjin exercise group at the end of 12-week intervention period were found on lower limb proprioception function (the rate of average trace error on right lower limb (%): control 23.50±5.50, Baduanjin 21.92±6.54, P=0.004; the rate of average trace error on left lower limb (%): control 22.32±6.62, Baduanjin 20.63±4.62, P=0.046), cardiorespiratory endurance (step test index: control 47.66±5.94, Baduanjin 50.07±9.30, P=0.025), flexibility (control 14.35±7.26cm, Baduanjin 15.39±6.43cm, P=0.009) and explosive force of lower limb (standing long jump test (m): control 1.77±0.24, Baduanjin 1.79±0.22, P=0.005 for adjustment baseline) in physical outcomes, and attention (Schulte Grid test (second): control 210.4±51.15, Baduanjin 192.4±47.14, P=0.034) in mental outcome.
2	4497728	explosive force of lower limb	Compared with controls, significant improvements in Baduanjin exercise group at the end of 12-week intervention period were found on lower limb proprioception function (the rate of average trace error on right lower limb (%): control 23.50±5.50, Baduanjin 21.92±6.54, P=0.004; the rate of average trace error on left lower limb (%): control 22.32±6.62, Baduanjin 20.63±4.62, P=0.046), cardiorespiratory endurance (step test index: control 47.66±5.94, Baduanjin 50.07±9.30, P=0.025), flexibility (control 14.35±7.26cm, Baduanjin 15.39±6.43cm, P=0.009) and explosive force of lower limb (standing long jump test (m): control 1.77±0.24, Baduanjin 1.79±0.22, P=0.005 for adjustment baseline) in physical outcomes, and attention (Schulte Grid test (second): control 210.4±51.15, Baduanjin 192.4±47.14, P=0.034) in mental outcome.
2	4497728	attention	Compared with controls, significant improvements in Baduanjin exercise group at the end of 12-week intervention period were found on lower limb proprioception function (the rate of average trace error on right lower limb (%): control 23.50±5.50, Baduanjin 21.92±6.54, P=0.004; the rate of average trace error on left lower limb (%): control 22.32±6.62, Baduanjin 20.63±4.62, P=0.046), cardiorespiratory endurance (step test index: control 47.66±5.94, Baduanjin 50.07±9.30, P=0.025), flexibility (control 14.35±7.26cm, Baduanjin 15.39±6.43cm, P=0.009) and explosive force of lower limb (standing long jump test (m): control 1.77±0.24, Baduanjin 1.79±0.22, P=0.005 for adjustment baseline) in physical outcomes, and attention (Schulte Grid test (second): control 210.4±51.15, Baduanjin 192.4±47.14, P=0.034) in mental outcome.
1	4497728	Lumbar muscle strength	Lumbar muscle strength in Baduanjin group had been moderately enhanced but no significant difference compared to controls.
1	4497728	vital capacity, blood pressure, heart rate, hand grip force, self-symptom intensity, stress, self-efficacy, quality of life, and quality of sleep	No significant changes in other physical and mental outcomes, including vital capacity, blood pressure, heart rate, hand grip force, self-symptom intensity, stress, self-efficacy, quality of life, and quality of sleep, were found between groups.
1	4497728	adverse event	No adverse event was reported during the study period.  
0	4803984	The mean length of the first and second stages of labor	The mean length of the first and second stages of labor was respectively 157.0±29.5 and 58.9±25.8 minutes in the supportive care group, 161.7±37.3 and 56.1±31.4 minutes in the acupressure group, ad 281.0±79.8 and 128.4±44.9 minutes in the control group.
1	5716426	tapping task	On average, all children learnt the tapping sequence, however, there were no group differences and no effect of the intervention on the tapping task.
2	5716426	manual dexterity scores after intervention	Children in the intervention group significantly improved their manual dexterity scores in the MABC-2 compared to the control group.
2	5754508	macrophage activation	We observed a significant two-fold increase in plasma sCD163 levels following lipopolysaccharides exposure (P < 0.001), and sCD163 concentrations correlated positively with the plasma concentration of free fatty acids, Rapalmitate, lipid oxidation rates and phosphorylation of the hormone-sensitive lipase at serine 660 in adipose tissue (P < 0.05, all). Furthermore, sCD163 concentrations correlated positively with plasma concentrations of cortisol, glucagon, tumour necrosis factor (TNF)-α, interleukin (IL)-6 and IL-10 (P < 0.05, all).  
2	5754508	concentration of sCD163	We observed a significant two-fold increase in plasma sCD163 levels following lipopolysaccharides exposure (P < 0.001), and sCD163 concentrations correlated positively with the plasma concentration of free fatty acids, Rapalmitate, lipid oxidation rates and phosphorylation of the hormone-sensitive lipase at serine 660 in adipose tissue (P < 0.05, all).
2	3580611	The 30-day rate of stroke or death	The 30-day rate of stroke or death was 14.7% in the percutaneous transluminal angioplasty and stenting group (nonfatal stroke, 12.5%; fatal stroke, 2.2%) and 5.8% in the medical-management group (nonfatal stroke, 5.3%; non-stroke-related death, 0.4%) (P = 0.002).
2	3580611	The probability of the occurrence of a primary end-point event	The probability of the occurrence of a primary end-point event over time differed significantly between the two treatment groups (P = 0.009), with 1-year rates of the primary end point of 20.0% in the percutaneous transluminal angioplasty and stenting group and 12.2% in the medical-management group.  
2	3580611	risk of death and stroke	The 30-day rate of stroke or death was 14.7% in the percutaneous transluminal angioplasty and stenting group (nonfatal stroke, 12.5%; fatal stroke, 2.2%) and 5.8% in the medical-management group (nonfatal stroke, 5.3%; non-stroke-related death, 0.4%) (P = 0.002).
1	4114185	Fugl-Meyer motor assessment scores	Fugl-Meyer Motor Assessment score improved in all groups, but no intergroup differences were found at any time points.
1	4114185	Fugl-Meyer motor assessment scores	Fugl-Meyer Motor Assessment score improved in all groups, but no intergroup differences were found at any time points.
1	4114185	Fugl-Meyer motor assessment scores	Fugl-Meyer Motor Assessment score improved in all groups, but no intergroup differences were found at any time points.
1	4636858	Multiple sclerosis plaques	MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611).
1	4636858	Multiple sclerosis plaques	MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782).
1	4636858	Multiple sclerosis plaques after 6 months	Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611).
1	4636858	Expanded disability status scale	The mean value of Expanded disability status scale showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953).
0	5387905	Mean pain visual analogue scales scores at 4 and 6 hours after the procedure	There were significant decreases in mean pain visual analogue scales scores for diclofenac potassium group compared to paracetamol and ibuprofen groups at 4 hours postoperatively (one-way Analysis of Variance: p=0.0001, p=0.001) and 6 hours postoperatively (p=0.04, p=0.005).
1	5320771	Wexner scores	Comparing Wexner scores in the cell group and the control group showed no significant difference.
0	3304380	Inflammatory indices	More precise analysis of data revealed that scaling and root planning in association with Frankincense application (either extract or powder) can lead to remarkable decrease in inflammatory indices in comparison to the groups without scaling and root planning and drug therapy (p<0.001).
1	3304380	Changes in gingival index, alteration in plaque index, bleeding index, and probing pocket depth.	In addition, no significant difference was observed between powder or extract therapy (p >0.05) and between patients received either scaling and root planning or treatment alone (p=0.169).  
1	3304380	Changes in gingival index, alteration in plaque index, bleeding index, and probing pocket depth.	In addition, no significant difference was observed between powder or extract therapy (p >0.05) and between patients received either scaling and root planning or treatment alone (p=0.169).  
2	4415997	Usage of sexually-transmitted infections services	Exposure was associated with over twice the odds of using STI services (AOR 2.47; 95%CI 1.78–3.42), 89% greater odds of using perinatal services (AOR 1.89; 95%CI 1.37–2.60) and 56% greater odds of using antenatal services (AOR 1.56; 95%CI 1.10–2.20) among participants in intervention versus comparison communities, after adjustment for baseline differences.  
2	4415997	Usage of peri/postnatal services	Exposure was associated with over twice the odds of using STI services (AOR 2.47; 95%CI 1.78–3.42), 89% greater odds of using perinatal services (AOR 1.89; 95%CI 1.37–2.60) and 56% greater odds of using antenatal services (AOR 1.56; 95%CI 1.10–2.20) among participants in intervention versus comparison communities, after adjustment for baseline differences.  
2	4415997	Usage of antenatal services	Exposure was associated with over twice the odds of using STI services (AOR 2.47; 95%CI 1.78–3.42), 89% greater odds of using perinatal services (AOR 1.89; 95%CI 1.37–2.60) and 56% greater odds of using antenatal services (AOR 1.56; 95%CI 1.10–2.20) among participants in intervention versus comparison communities, after adjustment for baseline differences.  
1	3466131	overall survival (OS)	After a median follow-up of 42 months, median progression-free survival was 10.2 and 10.8 months (p = 0.74), while median OS was 20.0 and 25.3 months (p = 0.099), for groups A and B, respectively.
1	3466131	neutropenia and diarrhea	Most frequent grade 3–4 toxicities (group A vs group B) were neutropenia (13% vs 22%, p = 0.053) and diarrhea (19% vs 11%, p = 0.082).
1	3466131	progression-free survival (progression-free survival)	After a median follow-up of 42 months, median progression-free survival was 10.2 and 10.8 months (p = 0.74), while median OS was 20.0 and 25.3 months (p = 0.099), for groups A and B, respectively.
2	5615441	learning achievement	Repeated testing yielded an additional positive effect: while the covariate (baseline score) exhibits no relation to the post-intervention score, F(1, 106) = 2.88, p > .05, there was a significant effect of the intervention (repeated tests scenario) on learning achievement, F(1106) = 12.72, p < .05, d = .94, r = .42 (95% CI:
2	4763545	SaO2	At both temperatures, SaO2 and PaO2, but not tHb, were increased by HOX.
1	4763545	Perception of exertion	Tskin and perception of exertion and thermal discomfort were higher at 33°C than 21°C (p < 0.01), but independent of FinO2.
1	4763545	Thermal discomfort	Tskin and perception of exertion and thermal discomfort were higher at 33°C than 21°C (p < 0.01), but independent of FinO2.
1	4763545	Muscle activity	Tcore and muscle activity were the same under all conditions (p > 0.07).
1	4763545	Muscle activity	In conclusion, during 30 min of submaximal cycling at 21°C or 33°C, Tcore, Tskin and Tbody, tHb, muscle activity and ratings of perceived exertion and thermal discomfort were the same under normoxic and hyperoxic conditions.
1	4763545	Core temperature	Tcore and muscle activity were the same under all conditions (p > 0.07).
2	5636096	patients with an abnormal continuous reaction time test index	The patients with an abnormal continuous reaction time test index who were randomized to receive the active intervention normalized or improved their continuous reaction time test index (mean change 0.92 ± 0.29, p = 0.01).
2	5636096	portosystemic encephalopathy (portosystemic encephalopathy) test	Additionally, their portosystemic encephalopathy improved (change 3.85 ± 1.83, p = 0.03).
2	5636096	portosystemic encephalopathy (portosystemic encephalopathy) test	The patients with an abnormal continuous reaction time test index who were randomized to receive the active intervention normalized or improved their continuous reaction time test index (mean change 0.92 ± 0.29, p = 0.01).
0	3376507	Body mass index	Intention-to-treat analysis showed that both intervention groups reduced their body mass index compared with the controls (basic: –0.72, SD 1.1 kg/m2, enhanced: –1.0, SD 1.4, control: 0.15, SD 0.82; P < .001) and lost significant weight (basic: –2.1, SD 3.3 kg, enhanced: –3.0, SD 4.1, control: 0.4, SD 2.3; P < .001) with changes in waist circumference (basic: –2.0, SD 3.5 cm, enhanced: –3.2, SD 4.7, control: 0.5, SD 3.0; P < .001) and waist-to-height ratio (basic: –0.01, SD 0.02, enhanced: –0.02, SD 0.03, control: 0.0, SD 0.02; P < .001), but no differences were observed between the basic and enhanced groups.
2	3376507	Improvement in waist-to-height ratio	Intention-to-treat analysis showed that both intervention groups reduced their body mass index compared with the controls (basic: –0.72, SD 1.1 kg/m2, enhanced: –1.0, SD 1.4, control: 0.15, SD 0.82; P < .001) and lost significant weight (basic: –2.1, SD 3.3 kg, enhanced: –3.0, SD 4.1, control: 0.4, SD 2.3; P < .001) with changes in waist circumference (basic: –2.0, SD 3.5 cm, enhanced: –3.2, SD 4.7, control: 0.5, SD 3.0; P < .001) and waist-to-height ratio (basic: –0.01, SD 0.02, enhanced: –0.02, SD 0.03, control: 0.0, SD 0.02; P < .001), but no differences were observed between the basic and enhanced groups.
2	3376507	Weight loss	Intention-to-treat analysis showed that both intervention groups reduced their body mass index compared with the controls (basic: –0.72, SD 1.1 kg/m2, enhanced: –1.0, SD 1.4, control: 0.15, SD 0.82; P < .001) and lost significant weight (basic: –2.1, SD 3.3 kg, enhanced: –3.0, SD 4.1, control: 0.4, SD 2.3; P < .001) with changes in waist circumference (basic: –2.0, SD 3.5 cm, enhanced: –3.2, SD 4.7, control: 0.5, SD 3.0; P < .001) and waist-to-height ratio (basic: –0.01, SD 0.02, enhanced: –0.02, SD 0.03, control: 0.0, SD 0.02; P < .001), but no differences were observed between the basic and enhanced groups.
2	3376507	Changes in waist circumference	Intention-to-treat analysis showed that both intervention groups reduced their body mass index compared with the controls (basic: –0.72, SD 1.1 kg/m2, enhanced: –1.0, SD 1.4, control: 0.15, SD 0.82; P < .001) and lost significant weight (basic: –2.1, SD 3.3 kg, enhanced: –3.0, SD 4.1, control: 0.4, SD 2.3; P < .001) with changes in waist circumference (basic: –2.0, SD 3.5 cm, enhanced: –3.2, SD 4.7, control: 0.5, SD 3.0; P < .001) and waist-to-height ratio (basic: –0.01, SD 0.02, enhanced: –0.02, SD 0.03, control: 0.0, SD 0.02; P < .001), but no differences were observed between the basic and enhanced groups.
0	3780629	disability, anxiety, and repetitive negative thinking	Results: Intent-to-treat marginal models using restricted maximum likelihood estimation demonstrated significant reductions in primary measures of depressive symptoms and distress corresponding to medium-large effect sizes (Cohen's d = 0.62–2.40) following CBM-I and the combined (CBM-I + Internet-based cognitive behavioral therapy) intervention.
0	3780629	disability, anxiety, and repetitive negative thinking	Significant reductions were also observed following the combined intervention on secondary measures associated with depression: disability, anxiety, and repetitive negative thinking (Cohen's d = 1.51–2.23). Twenty-seven percent of patients evidenced clinically significant change following CBM-I, and this proportion increased to 65% following the combined intervention.
0	3780629	primary measures of depressive symptoms and distress	Results: Intent-to-treat marginal models using restricted maximum likelihood estimation demonstrated significant reductions in primary measures of depressive symptoms and distress corresponding to medium-large effect sizes (Cohen's d = 0.62–2.40) following CBM-I and the combined (CBM-I + Internet-based cognitive behavioral therapy) intervention.
0	3780629	primary measures of depressive symptoms and distress	Results: Intent-to-treat marginal models using restricted maximum likelihood estimation demonstrated significant reductions in primary measures of depressive symptoms and distress corresponding to medium-large effect sizes (Cohen's d = 0.62–2.40) following CBM-I and the combined (CBM-I + Internet-based cognitive behavioral therapy) intervention.
1	3822756	Interleukin-10	Neither angiotensin-converting enzyme inhibition nor ARB significantly affectedplasminogen activator inhibitor-1 (PAI-1), interleukin (IL)-6, IL-8, or IL-10 concentrations.
2	3822756	Bradykinin	This study tested the hypothesis that angiotensin-converting enzyme inhibition enhances fibrinolysis and inflammation to greater extent than ARB in patients undergoing CPB.One week to five days prior to surgery, patients were randomized to ramipril 5mg/day,candesartan 16mg/day or placebo.angiotensin-converting enzyme inhibition increased intraoperative bradykinin and tissue-type plasminogen activator (tissue-type plasminogen activator) concentrations compared to ARB.
2	3822756	Tissue-type plasminogen activator	This study tested the hypothesis that angiotensin-converting enzyme inhibition enhances fibrinolysis and inflammation to greater extent than ARB in patients undergoing CPB.One week to five days prior to surgery, patients were randomized to ramipril 5mg/day,candesartan 16mg/day or placebo.angiotensin-converting enzyme inhibition increased intraoperative bradykinin and tissue-type plasminogen activator (tissue-type plasminogen activator) concentrations compared to ARB.
0	3822756	Need of plasma transfusion	Both angiotensin-converting enzyme inhibition and ARB decreased plasma transfusion compared to placebo, but only angiotensin-converting enzyme inhibition decreased length of stay.
1	3822756	Interleukin-6	Neither angiotensin-converting enzyme inhibition nor ARB significantly affectedplasminogen activator inhibitor-1 (PAI-1), interleukin (IL)-6, IL-8, or IL-10 concentrations.
0	3822756	Need of plasma transfusion	Both angiotensin-converting enzyme inhibition and ARB decreased plasma transfusion compared to placebo, but only angiotensin-converting enzyme inhibition decreased length of stay.
1	3822756	Plasminogen activator inhibitor-1	Neither angiotensin-converting enzyme inhibition nor ARB significantly affectedplasminogen activator inhibitor-1 (PAI-1), interleukin (IL)-6, IL-8, or IL-10 concentrations.
1	2129145	Caloric intake	No significant differences were observed in caloric or macronutrient intake.
1	2129145	Body mass gains	Coleus Forskohlii tended to mitigate gains in body mass (-0.7 ± 1.8, 1.0 ± 2.5 kg, p = 0.10) and scanned mass (-0.2 ± 1.3, 1.7 ± 2.9 kg, p = 0.08) with no significant differences in fat mass (-0.2 ± 0.7, 1.1 ± 2.3 kg, p = 0.16), fat free mass (-0.1 ± 1.3, 0.6 ± 1.2 kg, p = 0.21), or body fat (-0.2 ± 1.0, 0.4 ± 1.4%, p = 0.40).
1	2129145	Scanned mass	Coleus Forskohlii tended to mitigate gains in body mass (-0.7 ± 1.8, 1.0 ± 2.5 kg, p = 0.10) and scanned mass (-0.2 ± 1.3, 1.7 ± 2.9 kg, p = 0.08) with no significant differences in fat mass (-0.2 ± 0.7, 1.1 ± 2.3 kg, p = 0.16), fat free mass (-0.1 ± 1.3, 0.6 ± 1.2 kg, p = 0.21), or body fat (-0.2 ± 1.0, 0.4 ± 1.4%, p = 0.40).
1	2129145	Fat mass	Coleus Forskohlii tended to mitigate gains in body mass (-0.7 ± 1.8, 1.0 ± 2.5 kg, p = 0.10) and scanned mass (-0.2 ± 1.3, 1.7 ± 2.9 kg, p = 0.08) with no significant differences in fat mass (-0.2 ± 0.7, 1.1 ± 2.3 kg, p = 0.16), fat free mass (-0.1 ± 1.3, 0.6 ± 1.2 kg, p = 0.21), or body fat (-0.2 ± 1.0, 0.4 ± 1.4%, p = 0.40).
1	2129145	Body fat	Coleus Forskohlii tended to mitigate gains in body mass (-0.7 ± 1.8, 1.0 ± 2.5 kg, p = 0.10) and scanned mass (-0.2 ± 1.3, 1.7 ± 2.9 kg, p = 0.08) with no significant differences in fat mass (-0.2 ± 0.7, 1.1 ± 2.3 kg, p = 0.16), fat free mass (-0.1 ± 1.3, 0.6 ± 1.2 kg, p = 0.21), or body fat (-0.2 ± 1.0, 0.4 ± 1.4%, p = 0.40).
0	2129145	Hunger	Subjects in the Coleus Forskohlii group tended to report less fatigue (p = 0.07), hunger (p = 0.02), and fullness (p = 0.04).
1	5432698	Inotropic support requirements	There was no statistically significant difference in requirements of inotropic support between the groups.
0	5432698	Ventilation time	Mean ventilation time in GIK group was 5.06±2.39 hours versus 6.55±3.58 hours in non-GIK group (p-value 0.002).
0	5432698	Ventilation time	A total number of one hundred and sixty (160) patients were randomized into two equal groups; GIK Group and non-GIK group.
0	5432698	Ventilation time	So this study was conducted to evaluate the effectiveness of Glucose-insulin-potassium (GIK) solutions in non-diabetic patients undergoing coronary artery bypass grafting.  
0	5432698	Inotropic support duration	The mean duration of inotropic support in GIK group was only 5.50±6.88 hours in GIK group and 8.64±7.74 hours in non-GIK group (p-value 0.008).
1	5432698	Neurologic complications	We did not found any detrimental effect of GIK infusion on non-cardiac complications e.g. renal, pulmonary and neurologic complications.  
0	5432698	ICU stay	Similarly, ICU stay period was also shorter in GIK group (p-value 0.01).
0	4069731	Duration of diarrhea	Median (inter quartile range) duration of diarrhoea was significantly shorter in children in Lactobacillus GG group [60 (54-72) h vs. 78 (72-90) h; P<0.001].
2	4069731	Improvement in faeces consistency	Also, there was faster improvement in stool consistency in children receiving Lactobacillus GG than control group [36 (30-36) h vs. 42 (36-48) h; P<0.001].
0	4069731	Number of stools per day	There was significant reduction in average number of stools per day in Lactobacillus GG group (P<0.001) compared to the control group.
2	5062220	Time to tracheal extubation	Mean time to tracheal extubation was significantly longer in bispectral index group (9.63 ± 3.02 min) as compared to end-tidal anesthetic gas group (5.29 ± 1.51 min), mean difference 4.34 min with 95% confidence interval (3.106, 5.982) (P < 0.05).  
2	5384512	Satisfying sexual events/month	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).
2	5384512	Sexual function index total score	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).
2	5384512	Sexual distress improvement	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).
2	5384512	Satisfying sexual events/month	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).
2	5384512	Sexual function index total score	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).
2	5384512	Sexual distress improvement	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).
1	4092903	Ruminal pH	Ruminal temperature and pH were not significantly affected by mulberry leaf pellet supplementation while NH3-N concentration was increased (p<0.05) and maintained at a high level (18.5 mg/dl) with supplementation of mulberry leaf pellet at 600 g/hd/d.
2	4092903	Total viable rumen bacteria	Similarly, viable total bacteria in the rumen and cellulolytic bacteria were enriched by mulberry leaf pellet supplementation at 600 g/hd/d.
1	4092903	Ruminal temperature	Ruminal temperature and pH were not significantly affected by mulberry leaf pellet supplementation while NH3-N concentration was increased (p<0.05) and maintained at a high level (18.5 mg/dl) with supplementation of mulberry leaf pellet at 600 g/hd/d.
2	4092903	Ruminal ammoniacal nitrogen	Ruminal temperature and pH were not significantly affected by mulberry leaf pellet supplementation while NH3-N concentration was increased (p<0.05) and maintained at a high level (18.5 mg/dl) with supplementation of mulberry leaf pellet at 600 g/hd/d.
2	5702366	trough forced expiratory volume in 1 s at week 8 in intent-to-treat (patients with COPD)	umeclidinium/vilanterol treatment was noninferior in the per-protocol population and superior in the intent-to-treat population to tiotropium/olodaterol treatment with regard to trough forced expiratory volume in 1 s at week 8 [forced expiratory volume in 1 s change from baseline 180 mL vs 128 mL; difference 52 mL (95% confidence interval 28–77 mL); p < 0.001].
2	5702366	trough forced expiratory volume in 1 s at week 8 in intent-to-treat (patients with COPD)	Patients receiving umeclidinium/vilanterol had twofold increased odds of experiencing a clinically meaningful increase (100 mL or more) from baseline in trough forced expiratory volume in 1 s at week 8 compared with patients receiving tiotropium/olodaterol (odds ratio 2.05; 95% confidence interval 1.34–3.14).
2	5702366	odds of experiencing a clinically meaningful increase (100 mL or more) from baseline in trough forced expiratory volume in 1 s at week 8 (patients with COPD)	Patients receiving umeclidinium/vilanterol had twofold increased odds of experiencing a clinically meaningful increase (100 mL or more) from baseline in trough forced expiratory volume in 1 s at week 8 compared with patients receiving tiotropium/olodaterol (odds ratio 2.05; 95% confidence interval 1.34–3.14).
1	5809709	Time to first flatus	There was no significant difference in time to first bowel movement (80.1 ± 42.2 vs. 82.5 ± 40.4 hours; P = 0.830), time to first flatus (64.7 ± 38.5 vs. 70.0 ± 31.2 hours; P = 0.568), length of hospital stay (9 [8–13] vs. 11 [9–14) days; P = 0.531], nor postoperative pain scores in the lidocaine vs. control groups.
1	5809709	Postoperative pain	There was no significant difference in time to first bowel movement (80.1 ± 42.2 vs. 82.5 ± 40.4 hours; P = 0.830), time to first flatus (64.7 ± 38.5 vs. 70.0 ± 31.2 hours; P = 0.568), length of hospital stay (9 [8–13] vs. 11 [9–14) days; P = 0.531], nor postoperative pain scores in the lidocaine vs. control groups.
1	5809709	Time to first bowel movement	There was no significant difference in time to first bowel movement (80.1 ± 42.2 vs. 82.5 ± 40.4 hours; P = 0.830), time to first flatus (64.7 ± 38.5 vs. 70.0 ± 31.2 hours; P = 0.568), length of hospital stay (9 [8–13] vs. 11 [9–14) days; P = 0.531], nor postoperative pain scores in the lidocaine vs. control groups.
1	5809709	Hospital stay	There was no significant difference in time to first bowel movement (80.1 ± 42.2 vs. 82.5 ± 40.4 hours; P = 0.830), time to first flatus (64.7 ± 38.5 vs. 70.0 ± 31.2 hours; P = 0.568), length of hospital stay (9 [8–13] vs. 11 [9–14) days; P = 0.531], nor postoperative pain scores in the lidocaine vs. control groups.
0	5809709	Cumulative opioid consumption	Cumulative opioid consumption was significantly lower in the lidocaine vs. the control group from 24 hours onwards. At 72 hours, cumulative opioid consumption (μg fentanyl) in the lidocaine group (1,570 [825–3,587]) was over 40% lower than in the placebo group (2,730 [1,778–5,327]; P = 0.039).  
0	4140238	ocular itching	A statistically significant reduction in ocular itching was observed for bepotastine besilate ophthalmic solution 1.5% treatment compared to placebo at all time points (P<0.0001), while measures for onset and 8-hour persistence of action also reached clinical significance (ie, ≥1.0 unit difference) at a majority of time points.
2	4494428	Transport duration - effect on serum cortisol concentration	Hogs transported 6 h had increased cortisol concentrations (103.0 vs. 95.5 ng/mL; P < 0.001) and decreased L* (52.49 vs. 52.69; P = 0.09), b* (6.28 vs. 6.36; P = 0.03), and hue angle (20.70 vs. 20.95; P = 0.03) compared to hogs transported 3 h. Hogs subjected to 6 h of lairage had increased 24-h pH (5.69 vs. 5.66; P = 0.005), a* (16.64 vs. 16.48; P < 0.0001), b* (6.42 vs. 6.22; P < 0.0001), saturation (17.85 vs. 17.64; P < 0.0001), and hue angle (21.01 vs. 20.65; P = 0.002) and decreased L* (52.49 vs. 52.69; P = 0.07) when compared to hogs subjected to 3 h of lairage.
2	5923799	Stork test of balance	Results: Results of the Stork test of balance were significantly higher in the Taekwondo group after intervention (p < 0.05).
2	5923799	sociability score	Furthermore, sociability and 'being left out' score, a sub-variable of sociability, was significantly lower (p < 0.05) after the intervention, while sociability score was significantly higher (p < 0.05).
2	5923799	vigor	In terms of sub-variables, profile of mood states, tension, and depression scores were significantly lower (p < 0.05) after the intervention, while the vigor score was significantly higher in the intervention group than those in the control group (p < 0.05).
0	5923799	tension, depression	In terms of sub-variables, profile of mood states, tension, and depression scores were significantly lower (p < 0.05) after the intervention, while the vigor score was significantly higher in the intervention group than those in the control group (p < 0.05).
2	3546023	Urine cotinine levels	Urine cotinine levels and serum α1-antitrypsin were significantly higher in smokers compared to nonsmokers.
2	3546023	serum α1-antitrypsin	Urine cotinine levels and serum α1-antitrypsin were significantly higher in smokers compared to nonsmokers.
2	3546023	The percentage of B cells	Natural killer cells were decreased; CD4+ cells and B cells were increased in smokers compared to nonsmokers but were unaffected with vitamin E supplementation except in the percentage of B cells which were increased in nonsmokers supplemented palmvitee compared to placebo.
2	3546023	CD4+/CD8+ ratio	Natural killer cells were decreased; CD4+ cells and B cells were increased in smokers compared to nonsmokers but were unaffected with vitamin E supplementation except in the percentage of B cells which were increased in nonsmokers supplemented palmvitee compared to placebo. CD4+/CD8+ ratio was increased in smokers compared to nonsmokers.
2	3971783	O2sat, PaO2	Likewise, O2sat, PaO2 in the case group were higher than the control group (P < 0.0001).
0	3971783	PaCO2 and Respiratory rates	After intervention the means of PaCO2 and respiratory rates in the control group were significantly higher than the case group (P < 0.0001).
0	3971783	The nocturnal enuresis	The nocturnal enuresis decreased significantly in the case group, compared to the control group (P < 0.0001).  
2	4018698	Mean arterial pressure	Mean arterial pressure was significantly lower in the epidural group compared with the paravertebral group from 2 hours after start of the infusion until 48 hrs.
0	4018698	Procedure time	Regional anesthesia procedure time was significantly longer in the epidural group (P < 0.001).
1	4018698	Postoperative complications frequency	There was no significant difference between the 2 groups regarding frequency of postoperative complications and catheter-related problems.  
1	4018698	Catheter-related problems	There was no significant difference between the 2 groups regarding frequency of postoperative complications and catheter-related problems.  
0	3198285	low–glycemic index	The low–glycemic index group achieved a modestly lower glycemic index than the HF group (mean ± SEM 47 ± 1 vs. 53 ± 1; P < 0.001).
1	3198285	birth weight, birth weight centile, prevalence of macrosomia, insulin treatment, adverse pregnancy outcomes	At birth, there was no significant difference in birth weight (low–glycemic index 3.3 ± 0.1 kg vs. HF 3.3 ± 0.1 kg; P = 0.619), birth weight centile (low–glycemic index 52.5 ± 4.3 vs. HF 52.2 ± 4.0; P = 0.969), prevalence of macrosomia (low–glycemic index 2.1% vs. HF 6.7%; P = 0.157), insulin treatment (low–glycemic index 53% vs. HF 65%; P = 0.251), or adverse pregnancy outcomes.  
2	4280732	Most preferred method; normal vaginal delivery	Analysis of delivery method showed that in mothers, couples, and control groups, normal vaginal delivery was the most preferred method in that order, w hich was significant (P = 0.017).  
1	5682159	Overall satisfaction of the patients	In this first direct comparison of CPM-26 and VYC-20, the majority of subjects were satisfied with both treatments throughout the study. Patient-reported outcome measures identified a trend in favor of CPM-26.
2	3559346	Tenofovir serum concentrations	Serum concentrations after vaginal dosing were 56-fold lower than after oral dosing (p<0.001).
0	3559346	Tenofovir Vaginal tissue concentrations	Vaginal tissue tenofovir diphosphate was ≥130-fold higher with vaginal compared to oral dosing (p<0.001).
0	3559346	Tenofovir rectal fluid concentrations	Rectal fluid tenofovir concentrations in vaginal dosing periods were higher than concentrations measured in the oral only dosing period (p<0.03).  
0	2748711	Matrix metalloproteinases in cerebrospinal fluid in early treatment	Dexamethasone significantly reduced cerebrospinal fluid MMP-9 concentrations in early follow up samples (median 5 days (range 3–8) of treatment), but had no significant influence on other MMPs/TIMPs.
0	2361515	Diarrhoea of some grade	In all, 14 patients (29%) from arm A and 24 patients (52%) from arm B had some grade of diarrhoea (P<0.03).
1	270000	chemical, clinical and continuing pregnancies, rate of live birth	Although patients receiving Bravelle(R) consistently reported a greater number of chemical, clinical and continuing pregnancies, as well as an increased rate of live birth, the data did not attain statistical significance (P > 0.05).
1	270000	adverse events	The overall incidence of adverse events was similar in both groups, but compared to Follistim(R), injections of Bravelle(R) were reported by patients to be significantly less painful (P < 0.001).  
0	270000	pain score	The overall incidence of adverse events was similar in both groups, but compared to Follistim(R), injections of Bravelle(R) were reported by patients to be significantly less painful (P < 0.001).  
2	5870330	fracture resistance	Furthermore, the fracture resistance of G4 and G5 was significantly higher than G3 and G6 (P < 0.05), where in both groups, the preparation of the occlusal extension mostly remained in the enamel layer.  
2	5870330	fracture resistance	G1 showed the highest fracture resistance value (1737.1 N) while G3 had the lowest mean value (522.9 N). Furthermore, the fracture resistance of G4 and G5 was significantly higher than G3 and G6 (P < 0.05), where in both groups, the preparation of the occlusal extension mostly remained in the enamel layer.  
2	3713866	Salivary secretion	The difference between saliva secretion rates before and after medications was not significant for bromhexine users at two steps of the study (P=0.35); however, it was significant for pilocarpine users (P=0.0001).
2	3713866	Salivary secretion	Pilocarpine is probably more effective in improving xerostomia and its associated problems compared with bromhexine, although the use of the latter was also shown to ease some of the consequences of radiotherapy in the head and neck region.
1	3713866	Salivary secretion	The difference between saliva secretion rates before and after medications was not significant for bromhexine users at two steps of the study (P=0.35); however, it was significant for pilocarpine users (P=0.0001).
0	3713866	Xerostomia	Users of both drugs showed significant differences in improvement of xerostomia, chewing, swallowing, tasting and mouth burning.    
0	3713866	Xerostomia	Users of both drugs showed significant differences in improvement of xerostomia, chewing, swallowing, tasting and mouth burning.    
0	4096387	Recurrence rate at 12 months	The success and recurrence rate at 12-month followup were, respectively, 38.3% (28/73) in group I versus 58.5% (41/70) in group II (P = 0.019; Fisher's exact test) and 30.2% (13/43) in group I versus 14.5% (7/48) in group II (P = 0.0047; Fisher's exact test).
0	4096387	Median visual analogue scale	At six-month followup, median visual analogue scale score was significantly higher in group I if compared with group II.
2	4096387	Success rate at 12 months	The success and recurrence rate at 12-month followup were, respectively, 38.3% (28/73) in group I versus 58.5% (41/70) in group II (P = 0.019; Fisher's exact test) and 30.2% (13/43) in group I versus 14.5% (7/48) in group II (P = 0.0047; Fisher's exact test).
2	4096387	Success rate at 12 months	The maintenance therapy with partially hydrolyzed guar gum in patients with healed chronic anal fissure after chemical sphincterotomy by topical application of glyceryl trinitrate 0.4% ointment seems associated with a significant reduction of recurrence rate and with a significant increase of success rate at 12-month followup.
2	4789479	Pain delay	In group 1, pain manifestation was significantly delayed in comparison with group 2.
1	4789479	Substance P expression	No statistically significant difference could be detected in substance P expression between the two groups.
1	4824463	Incidence of moderate or severe anaemia after the first episode of fever	After the first episode of febrile illness, the incidence of severe anaemia was the same in both arms (0.11 per child per year) and that of moderate anaemia was 0.16 (0.13–0.21) vs. 0.17 (0.14–0.21) per child year respectively.
1	4824463	Incidence of the overall episodes of malaria	Over 24-months, the incidence of all episodes of malaria following the first febrile illness was 0.64 (95% CI 0.49–0.82) and 0.76 (0.63–0.93) per child per year in the rapid diagnostic tests and clinical judgement arms respectively (adjusted rate ratio 1.13 (0.82–1.55).
0	4824463	Proportion of patients with fever receiving ACT	The proportion of fever cases receiving ACT was lower in the rapid diagnostic tests arm (72% vs 81%; p = 0.02).  
2	3657667	Overall costs	Home telemonitoring of blood pressure costs significantly more than usual care (mean difference per patient £115.32 (95% CI £83.49 to £146.63; p<0.001)).
2	5577662	Mean change in nodular consistency and hardness	Mean change in nodular consistency and hardness were significantly improved with collagenase clostridium histolyticum versus placebo at Weeks 4 and 8 (P ≤ 0.0139 for all).
1	2856148	days spend in the ICU	No significant difference between the two groups in duration of mechanical ventilation (6.20 ± 5.20 days vs. 7.47 ± 6.38 days, P > 0.05), duration of weaning (35.17 ± 16.98 and 47.05 ± 20.98 hours, P > 0.05) or duration of ICU stay (8.47 ± 4.79 and 10.80 ± 5.28 days, P > 0.05) in Gp I and Gp II, respectively.
1	2856148	Mortality at discharge from ICU	Lesser number of deaths in the Noninvasive ventilation group at discharge from ICU (3 vs. 5 patients, respectively) and at 30 days (5 vs. 9 patients, respectively), it did not achieve statistical significance (P > 0.05).  
1	2856148	duration of weaning	No significant difference between the two groups in duration of mechanical ventilation (6.20 ± 5.20 days vs. 7.47 ± 6.38 days, P > 0.05), duration of weaning (35.17 ± 16.98 and 47.05 ± 20.98 hours, P > 0.05) or duration of ICU stay (8.47 ± 4.79 and 10.80 ± 5.28 days, P > 0.05) in Gp I and Gp II, respectively.
1	2856148	time spent on mechanical ventilation	No significant difference between the two groups in duration of mechanical ventilation (6.20 ± 5.20 days vs. 7.47 ± 6.38 days, P > 0.05), duration of weaning (35.17 ± 16.98 and 47.05 ± 20.98 hours, P > 0.05) or duration of ICU stay (8.47 ± 4.79 and 10.80 ± 5.28 days, P > 0.05) in Gp I and Gp II, respectively.
0	5018291	Pain VAS score	Mean VAS scores in the first 30 min and total analgesic consumption in the first 24 h of post-operative period were significantly lower in groups BK1 and BK2 in comparison with the other groups (P < 0.05).
0	5018291	Pain VAS score	Mean VAS scores in the first 30 min and total analgesic consumption in the first 24 h of post-operative period were significantly lower in groups BK1 and BK2 in comparison with the other groups (P < 0.05).
0	5018291	Total analgesic consumption (first day)	Mean VAS scores in the first 30 min and total analgesic consumption in the first 24 h of post-operative period were significantly lower in groups BK1 and BK2 in comparison with the other groups (P < 0.05).
0	5018291	Total analgesic consumption (first day)	Mean VAS scores in the first 30 min and total analgesic consumption in the first 24 h of post-operative period were significantly lower in groups BK1 and BK2 in comparison with the other groups (P < 0.05).
2	5018291	Time to first rescue analgesics	Also, time to first rescue analgesics administration was longer in the same groups (P < 0.05).   
2	5018291	Time to first rescue analgesics	Mean VAS scores in the first 30 min and total analgesic consumption in the first 24 h of post-operative period were significantly lower in groups BK1 and BK2 in comparison with the other groups (P < 0.05). Also, time to first rescue analgesics administration was longer in the same groups (P < 0.05).   
0	5018291	Total analgesic consumption (first day)	Mean VAS scores in the first 30 min and total analgesic consumption in the first 24 h of post-operative period were significantly lower in groups BK1 and BK2 in comparison with the other groups (P < 0.05).
1	2762857	Cognition	Second, there were no effects of the cues on any of the measures of cognition, affect, vulnerability, or intentions.
1	2762857	Affect	Second, there were no effects of the cues on any of the measures of cognition, affect, vulnerability, or intentions.
1	2762857	Affect	First, the cues did not affect how long the women spent on the site or how long they spent reading the text.
0	2762857	Time looking at logo	However, women in the negative cues condition spent more time looking at a donation button than those in the positive cues condition spent looking at a TRUSTe seal (β = −.43, P < .001) but less time looking at a logo (β = .43, P < .001) or at certain other features of the site.
2	2762857	Site content recalling	Those in the negative cues condition also recalled more site content (β = −.22, P = .048).
1	2762857	Vulnerability	Second, there were no effects of the cues on any of the measures of cognition, affect, vulnerability, or intentions.
1	2762857	Intentions	Second, there were no effects of the cues on any of the measures of cognition, affect, vulnerability, or intentions.
0	2762857	Alcohol reduction	However, third, at follow-up, the positive cues had promoted greater alcohol reduction than the negative cues among those women who had previously reported drinking more heavily (β =  −.22, P = .02).
2	4830153	Physical quality of life	There was no significant difference between intervention and control groups in physical aspects of the quality of life before intervention (P = 0.423) while two groups were significantly different after intervention (P = 0.000) and quality of life of patients in the case group improved significantly.  
2	4878364	Gait speed	When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007), sit to stand performance (F(3.24) = 11.033, p = 0.002) and handgrip strength (F(3.697) = 26.359, p < 0.001).
2	4878364	Handgrip strength	When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007), sit to stand performance (F(3.24) = 11.033, p = 0.002) and handgrip strength (F(3.697) = 26.359, p < 0.001).
2	4878364	Sit to stand performance	When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007), sit to stand performance (F(3.24) = 11.033, p = 0.002) and handgrip strength (F(3.697) = 26.359, p < 0.001).
2	1475568	Daily weight monitoring at the end of treatment	At 12 months, more patients in the intervention group reported monitoring weights daily (79% vs. 29%, p < 0.0001).
1	2517154	Severity of pain	Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001).
1	3961020	heart rate (HR) , Systolic BP (SBP), saturation of peripheral oxygen(SpO2) , end-tidal carbon dioxide (ETCO2) and Diastolic BP	There was no significant statistical difference among groups with respect to hemodynamic parameters.  
0	3734718	Viral load	The highly active antiretroviral treatment arm was characterized by significant improvements in CD4 cell count (154.4 cells/μl/year, P<0.001) and reduction in plasma viral load within 3 to 6 months (-0.431+ 0.004 log10 IU/month, P<0.001).
1	3734718	Viral load	In contrast, the polyherbal formulation arm showed a profile of CD4 cell loss at remarkably slower kinetics (14.3 cells/μl/year, P=0.021) and insignificant reduction in the viral load.
2	3734718	CD4 count	The highly active antiretroviral treatment arm was characterized by significant improvements in CD4 cell count (154.4 cells/μl/year, P<0.001) and reduction in plasma viral load within 3 to 6 months (-0.431+ 0.004 log10 IU/month, P<0.001).
1	4825255	Visual Analogue Scale pain during 3-4 cm dilatation	However, this was not significantly different between the two groups at 3-4 cm cervical dilation and the second stage of childbirth.
1	4825255	Visual Analogue Scale pain during second stage of labor	The Visual Analogue Scale suggested that in the transitional stages (8-10 cm cervical dilation), the level of pain felt by the experimental group was meaningfully lower than that felt by the control group (p=0.03). However, this was not significantly different between the two groups at 3-4 cm cervical dilation and the second stage of childbirth.
0	4825255	McGill scale's pain	The McGill scale's results for measuring pain levels, proved a meaningful difference between the experimental group and the control group (p=0.018).
0	4825255	Stress	The results of the t-test showed a meaningful difference in levels of stress felt by the experimental group compared to control group (p=0.002).
0	4825255	Visual Analogue Scale pain during 8-10 cm dilatation	The Visual Analogue Scale suggested that in the transitional stages (8-10 cm cervical dilation), the level of pain felt by the experimental group was meaningfully lower than that felt by the control group (p=0.03).
1	3263747	mean number of attacks per day	The decrease in mean number of attacks per day was 0.75 with SJW and 1.01 with placebo, P = 0.06.
0	4759860	subjective feelings of muscle fatigue immediately after exercise	Moreover, L-citrulline significantly improved subjective feelings of muscle fatigue and concentration immediately after exercise.  
2	4759860	increased plasma L-arginine levels	L-Citrulline supplementation significantly increased plasma L-arginine levels and reduced completion time by 1.5 % (p < 0.05) compared with placebo.
2	4759860	subjective feelings of concentration immediately after exercise	Moreover, L-citrulline significantly improved subjective feelings of muscle fatigue and concentration immediately after exercise.  
1	5292678	The overall response rate	The overall response rate was 69% (complete remission (complete remission) 60% CRi 9%), with no difference between daunorubicin/ara-C (71%) and daunorubicin/clofarabine (66%).
1	5292678	cumulative incidence of relapse survival from relapse; relapse-free or overall survival	There were no differences in cumulative incidence of relapse (74% vs 68% hazard ratio (hazard ratio) 0.93 (0.77–1.14), P=0.5); survival from relapse (7% vs 9% hazard ratio 0.96 (0.77–1.19), P=0.7); relapse-free (31% vs 32% hazard ratio 1.02 (0.83–1.24), P=0.9) or overall survival (23% vs 22% hazard ratio 1.08 (0.93–1.26), P=0.3).
1	5292678	overall survival	There were no differences in cumulative incidence of relapse (74% vs 68% hazard ratio (hazard ratio) 0.93 (0.77–1.14), P=0.5); survival from relapse (7% vs 9% hazard ratio 0.96 (0.77–1.19), P=0.7); relapse-free (31% vs 32% hazard ratio 1.02 (0.83–1.24), P=0.9) or overall survival (23% vs 22% hazard ratio 1.08 (0.93–1.26), P=0.3).
2	5022334	Surgery time	The mean operative time of the robotic group was longer than that of the conventional open approach group (118.8 ± 16.5 min vs. 90.7 ± 10.3 min, P < 0.05).
0	5022334	Visual analogue scale	The study showed significant differences between the two groups in terms of the visual analog scales (2.1 ± 1.0 vs. 3.8 ± 1.2, P < 0.05) and numerical scoring system (8.9 ± 0.8 vs. 4.8 ± 1.7, P < 0.05).
1	5022334	Amount of lymph nodes removed	The differences between the two groups in the estimated intraoperative blood loss, postoperative hospital stay time, numbers of lymph node removed, postoperative thyroglobulin levels, and complications were not statistically significant (all P > 0.05).
2	5022334	Numerical scoring system	The study showed significant differences between the two groups in terms of the visual analog scales (2.1 ± 1.0 vs. 3.8 ± 1.2, P < 0.05) and numerical scoring system (8.9 ± 0.8 vs. 4.8 ± 1.7, P < 0.05).
1	5022334	Amount of blood lost	The differences between the two groups in the estimated intraoperative blood loss, postoperative hospital stay time, numbers of lymph node removed, postoperative thyroglobulin levels, and complications were not statistically significant (all P > 0.05).
0	3349215	VAS pain score after therapy	There was a significant difference between the test and control groups immediately after therapy (P < 0.05), while no effect 6 months later.
1	3349215	VAS pain score after 6 months	In both groups, the pain intensity (VAS score) decreased significantly immediately after therapy as compared to therapy. There was a significant difference between the test and control groups immediately after therapy (P < 0.05), while no effect 6 months later.
0	1876597	unadjusted risk of recurrent falciparum parasitemia	The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with dihydroartemisinin-piperaquine than for those treated with artemether-lumefantrine after 28 d (11% versus 29%; risk difference [risk difference] 18%, 95% confidence interval [confidence interval] 11%–26%) and 42 d (43% versus 53%; risk difference 9.6%, 95% confidence interval 0%–19%) of follow-up.
0	1876597	the risk of recurrent parasitemia due to possible recrudescence	Similarly, the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with dihydroartemisinin-piperaquine than for those treated with artemether-lumefantrine after 28 d (1.9% versus 8.9%; risk difference 7.0%, 95% confidence interval 2.5%–12%) and 42 d (6.9% versus 16%; risk difference 9.5%, 95% confidence interval 2.8%–16%).
1	400417	the proportion of patients achieving an American College of Rheumatology (American College of Rheumatology) 20 response at 24 weeks	Fewer than 20% of patients in each arm of the study achieved an American College of Rheumatology 20 response at 24 weeks (P = 0.71).
0	4859374	Interstage mortality rate	Interstage mortality for those not on digoxin was 12.3%, compared to 2.9% among those on digoxin, with an adjusted hazard ratio of 3.5 (95% CI, 1.1–11.7; P=0.04).
1	4859374	Interstage complications rate	There were no differences in complications between the 2 groups during the interstage period.  
2	3349250	Duration of median progression-free survival	In a randomised phase III trial of treatment-naive patients with metastatic renal cell carcinoma, sunitinib showed significant improvement in progression-free survival (progression-free survival) compared with interferon (IFN)-α.
2	5530360	Functional Assessment of Chronic Illness Therapy-Fatigue improvement	At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (Health Assessment Questionnaire-Disability Index <0.5; p≤0.001), reductions in fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue ≥3.56; p≤0.05), improvements in PtGA (p≤0.001) and pain (p≤0.001) and reductions in duration of morning joint stiffness (p<0.01).  
2	5530360	Health Assessment Questionnaire-Disability Index improvement	At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (Health Assessment Questionnaire-Disability Index <0.5; p≤0.001), reductions in fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue ≥3.56; p≤0.05), improvements in PtGA (p≤0.001) and pain (p≤0.001) and reductions in duration of morning joint stiffness (p<0.01).  
2	4776123	LCF	The lateralization of the left-FPN was retained especially well in the training group but decreased in the control group.
0	5620095	reflux of bile in the remnant stomach	Endoscopic findings showed a significant reduction of bile reflux in the remnant stomach in the Roux-en-Y group (P<0.001), and the histological findings showed that reflux gastritis was more significant in the Billroth-I group than in the Roux-en-Y group (P=0.026).  
1	5620095	clinicopathological findings	No significant differences in clinicopathological findings were observed between the 2 groups.
0	5620095	Gastritis in the remnant stomach	Endoscopic findings showed a significant reduction of bile reflux in the remnant stomach in the Roux-en-Y group (P<0.001), and the histological findings showed that reflux gastritis was more significant in the Billroth-I group than in the Roux-en-Y group (P=0.026).  
1	5620095	total surgery time	Although anastomosis time was significantly longer for the patients of the Roux-en-Y group (P<0.001), no difference was detected between the 2 groups in terms of the total surgery duration (P=0.112).
1	2671107	Fibrinolysis in Metabolic Syndrome	There was no effect of any treatment on fibrinolysis.  
2	4059551	negatively associated with good adherence	In multivariate analysis, the Bloemfontein site [odds ratio (odds ratio): 2.43; 95% confidence interval (confidence interval): 1.32 to 4.48] and liking the pill color (odds ratio: 2.93; 95% confidence interval: 1.18 to 7.27) were positively associated with good adherence, whereas using oral contraceptive pills at enrollment was negatively associated with good adherence (odds ratio: 0.37; 95% confidence interval: 0.18 to 0.74).  
0	2569033	LDL- C	Regular consumption of the soy drink enriched with plant sterols for 8 weeks significantly reduced LDL- C by 0.29 mmol/l or 7% compared to baseline (p < 0.05).
1	2569033	triglycerides	HDL cholesterol and triglycerides were not affected.
0	2569033	non-HDL-cholesterol	Mean reductions in total, LDL and non-HDL cholesterol were significantly greater than in the placebo group (p < 0.05).
0	2569033	Total cholesterol	Mean reductions in total, LDL and non-HDL cholesterol were significantly greater than in the placebo group (p < 0.05).
1	2569033	HDL cholesterol	HDL cholesterol and triglycerides were not affected.
2	4170550	Among the prefabricated posts lowest bond strength	Among the prefabricated posts highest bond strength was obtained for prefabricated stainless steel post and lowest for carbon fiber posts.
2	4170550	Among the prefabricated posts highest bond strength	The bond strength of all the prefabricated posts was significantly lower than the conventional cast post.
2	4170550	Among the prefabricated posts highest bond strength	Among the prefabricated posts highest bond strength was obtained for prefabricated stainless steel post and lowest for carbon fiber posts. There was no significant difference in the mean bond strength obtained for stainless steel and glass fiber post.  
0	4170550	bond strength	The bond strength of all the prefabricated posts was significantly lower than the conventional cast post.
2	4183584	Nonverbal behaviors	Results showed that schizophrenia patients with pro-social priming had significantly more nonverbal behaviors than schizophrenia patients with anti-social and non-social priming conditions.
2	4744782	caregiving self‐efficacy	Caregiving self‐efficacy scores for obtaining respite and for managing patient behavioral disturbances were significantly higher in the coaching condition.
0	4744782	Upset following behavior problems	For those providing in‐home care at post‐treatment, depressive symptoms, upset following disruptive behaviors, and negative mood states were statistically lower in the behavioral coaching condition than in the basic education and support condition.
1	5351968	Glycogen synthase kinase 3 phosphorylation	The phosphorylation of AMPK was elevated by exercise at 1 h post exercise, and this elevated level was sustained only in the whey protein group at 2 h. The phosphorylation of Akt, GSK3, and eIF2Bε were unchanged by treatments.
1	5351968	eIF2Bε phosphorylation	The phosphorylation of AMPK was elevated by exercise at 1 h post exercise, and this elevated level was sustained only in the whey protein group at 2 h. The phosphorylation of Akt, GSK3, and eIF2Bε were unchanged by treatments.
2	5351968	Muscle protein synthesis after exercise	muscle protein synthesis was significantly increased by CP compared with Placebo (p<0.05), and approached significance compared with whey protein at 1 h post exercise (p = 0.08).
1	5351968	Muscle protein synthesis after exercise	muscle protein synthesis was significantly increased by CP compared with Placebo (p<0.05), and approached significance compared with whey protein at 1 h post exercise (p = 0.08).
1	5351968	Protein kinase B phosphorylation	The phosphorylation of AMPK was elevated by exercise at 1 h post exercise, and this elevated level was sustained only in the whey protein group at 2 h. The phosphorylation of Akt, GSK3, and eIF2Bε were unchanged by treatments.
2	3921228	happiness	Significant pre-post scan decreases in anxiety ratings and increases in happiness ratings were evident in the experimental versus control group.
1	5787910	Mean acne severity	The average severity of acne in the two treatment groups did not differ significantly within any of the study periods.
2	2956327	initial body mass index (body mass index)	While there was no significant difference between website use categories in the amount of Phase I change in body weight (P = .45) or income (P = .78), minimal website users (n = 75) were significantly more likely to have attended fewer Phase I sessions (P = .001) and had a higher initial body mass index (body mass index) (P < .001).
2	2956327	Age, education.	Participants in the consistent user group (n = 212) were more likely to be older (P = .002), other than African American (P = .02), and more educated (P = .01).
1	4298088	Insertion was successful with one attempt	Insertion was successful with one attempt in 35 cases each for the W and C groups.
1	4298088	sealing pressure	Sealing pressure was slightly, but not significantly, higher in the W group than in the C group (W group 22.6±6.1 cm H2O; C group 20.7±6.1 cm H2O; p=0.15).  
2	3883318	Duration of parotid salivary flow following the use of transcutaneous electric nerve stimulation	Subjects belonging to group B were showing statistically significant increases in the duration of stimulated parotid salivary flow following the use of transcutaneous electric nerve stimulation.  
1	2447849	Total adherence	There were no significant differences between the groups with respect to total adherence or any of the satisfaction scales.
2	2447849	Difficulties with medication usage	More patients in the medical practice group reported difficulties using their medication compared to the researcher group (46 (35%) v 30 (21%); p = 0.015, Fisher's exact test).  
1	4007144	Partner physical violence	At follow-up, reported levels of physical and/or sexual intimate partner violence in the intervention arm had decreased compared to the control arm (ARR 0.52, 95% CI 0.18-1.51, not significant).
2	4007144	Participation in household tasks	Significant differences were found between men in the intervention and control arms' reported ability to control their hostility and manage conflict (ARR 1.3, 95% CI 1.06-1.58), and participation in gendered household tasks (ARR 2.47, 95% CI 1.24-4.90).  
1	4007144	Partner sexual violence	At follow-up, reported levels of physical and/or sexual intimate partner violence in the intervention arm had decreased compared to the control arm (ARR 0.52, 95% CI 0.18-1.51, not significant).
0	4007144	Hostility when managing conflicts	Significant differences were found between men in the intervention and control arms' reported ability to control their hostility and manage conflict (ARR 1.3, 95% CI 1.06-1.58), and participation in gendered household tasks (ARR 2.47, 95% CI 1.24-4.90).  
1	4409094	Thrombotic/thromboembolic events (Thrombotic/thromboembolic events) or deep vein thrombosis	No increased risk of deep vein thrombosis was identified, nor any Thrombotic/thromboembolic events reported in recombinant human C1INH treated or controls.  
2	4714728	mean scores of Constant–Murley score	Results indicated that patients in Group B showed higher mean scores (90.3±5.4) than Group A (80.4±11.5) in terms of Constant–Murley score (P=0.001).
2	4714728	activities	Group B patients scored higher in terms of pain (P=0.002), activities (P=0.02), range of motion (P<0.001), and strength (P=0.004).
2	4714728	strength	Group B patients scored higher in terms of pain (P=0.002), activities (P=0.02), range of motion (P<0.001), and strength (P=0.004).
0	5494586	P300 latency incremental values	Breakfasts B1 and B2 exhibited significantly lower glycemic and insulinemic responses as compared to A. Breakfast B3 exhibited significantly lower glycemic, but not insulinemic response, as compared to A. Final plasma ghrelin inhibition was more pronounced, albeit not significantly, in all breakfasts with respect to A. P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01), suggesting ameliorated cognitive performance.
2	5900060	Survival from noninvasive ventilation months	The noninvasive ventilation group presented longer survival (median 18.50 months, 95% CI 12.62–24.38 months) than the no-NIV group (3.00 months, 95% CI 0.82–5.18 months) (p<0.001) and also in those patients with severe bulbar dysfunction (13.00 months (95% CI 9.49–16.50 months) versus 3.00 months (95% CI 0.85–5.15 months), p<0.001).
2	4198846	Improvement in the Insight and Treatment Attitude Questionnaire	The total Insight and Treatment Attitude Questionnaire score also showed significant improvement in both groups over the three months and the degree of improvement was significantly greater in the Cognitive remediation therapy group than in the treatment as usual group group.  
2	4198846	Improvement in the Wisconsin Card Sorting Test	Both groups showed significant improvement in Wisconsin Card Sorting Test measures over the three-month trial but the improvement in the Cognitive remediation therapy group was significantly greater than that for the treatment as usual group group on all of the Wisconsin Card Sorting Test measures assessed.
1	4198846	Improvement in the Scale of Social Skills of chronic schizophrenia Inpatients	The total SSSI score improved significantly in both groups over the three months, but the improvement in the two groups was not significantly different.
1	2500257	Hospital stay	Notification was associated with reduced mortality (8% vs.17%, p = 0.05), further antibiotic use (median −2.5 days, p = 0.01), and trended toward reduced hospital stay and charges.
0	2500257	Further antibiotic use	Notification was associated with reduced mortality (8% vs.17%, p = 0.05), further antibiotic use (median −2.5 days, p = 0.01), and trended toward reduced hospital stay and charges.
0	2500257	Overall mortality	Notification was associated with reduced mortality (8% vs.17%, p = 0.05), further antibiotic use (median −2.5 days, p = 0.01), and trended toward reduced hospital stay and charges.
2	5863418	The mean Tumor necrosis factor-α value at 24 h	The concentration of Tumor necrosis factor-α was significantly higher in the experimental groups than in the control group at 24 h after force application.
0	5863418	Tumor necrosis factor-α levels after 168 h	Tumor necrosis factor-α levels were significantly decreased at 168 h after force application in the preadjusted edgewise appliance group.
2	3214443	The mean difference in the reduction of both SBP and DBP	All three intervention groups showed significant reduction in BP (SBP/DBP mmHg: 5.3/6.0 in NG II, 2.5/2.0 in NG III, and 2.3/2.4 in NG IV, respectively), while the Control Group showed no significant difference.
2	4602159	Cough	Cough (primary outcome) was significantly more frequent among those with topical compared with intravenous lidocaine (46% vs. 26%; P = 0.004).
1	4726501	The annual change in estimated glomerular filtration rate	There were no significant differences in annual changes in estimated glomerular filtration rate between the groups (aspirin, −0.8 ± 2.9; no aspirin, −0.9 ± 2.5 ml/min/1.73m2/year).  
0	4530661	systolic and diastolic blood pressure	Although soy milk did not have any effect on blood pressure, probiotic soymilk significantly decreased systolic (14.7 ± 0.48 vs. 13.05 ± 0.16, P = 0.001) and diastolic blood pressure (10 ± 0.7 vs. 9.1 ± 1, P = 0.031).  
1	4530661	BMI and waist to hip ratio	In this study, we failed to find any significant changes between probiotic soy milk and soy milk in term of body mass index (26.65 ± 0.68 vs. 26.33 ± 0.74, P = 0.300) and waist to hip ratio (1.49 ± 0.08 vs. 1.54 ± 0.1, P = 0.170).
1	3889827	Pre/postoperative alignment	Pre/postoperative alignment, surgical time, lateral laxity, and preoperative range of motion had no significant in two groups; however, postoperative flexion was superior in lateral approach group 123.8°, 109° in medial approach group.
1	3889827	Lateral laxity	Pre/postoperative alignment, surgical time, lateral laxity, and preoperative range of motion had no significant in two groups; however, postoperative flexion was superior in lateral approach group 123.8°, 109° in medial approach group.
1	3889827	Surgical time	Pre/postoperative alignment, surgical time, lateral laxity, and preoperative range of motion had no significant in two groups; however, postoperative flexion was superior in lateral approach group 123.8°, 109° in medial approach group.
0	2765950	Lipid hydroperoxide levels	LOOH levels decreased from 0.53 ± 0.19 to 0.40 ± 0.10 μmol/mL in the 29.5 mL dose group (P < 0.001) and from 0.55 ± 0.21 to 0.40 ± 0.14 μmol/mL in the 118 mL dose group (P < 0.001).
2	3552315	Improvement in psychopathology	The Parenting Matters group also demonstrated greater and more rapid improvement than in usual care alone in terms of overall psychopathology (Child Behaviour Checklist, P = 0.02), but there were no group differences in parenting.
0	3552315	Behaviour problems	ABSTRACT.RESULTS.. Behaviour problems (Eyberg Child Behaviour Inventory) decreased significantly more in the Parenting Matters condition compared with Usual Care alone, based on a significant time by treatment group effect in intent-to-treat, growth curve analyses (P = 0.033).
1	3793422	Bond strength	The surface treatment methods did not have any significant effect (P > 0.05) on any group but ethylene de amine tetra acetic acid group had the highest bond strength.  
1	3793422	Bond strength	Surface treatment with (ethanol, ethylene de amine tetra acetic acid, and ethylene de amine tetra acetic acid + ethanol) does not significantly appear to be effective in improving the bond strength of fiber posts into root dentine.
1	3793422	Bond strength	The surface treatment methods did not have any significant effect (P > 0.05) on any group but ethylene de amine tetra acetic acid group had the highest bond strength.  
1	3793422	Bond strength	The surface treatment methods did not have any significant effect (P > 0.05) on any group but ethylene de amine tetra acetic acid group had the highest bond strength.  
1	4153084	Pons glucose metabolism	MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain.
1	2211287	Changes in metabolic rate (metabolic rate) (kcal/min and kcal/min/kg fat free mass)	Changes in metabolic rate (kcal/min and kcal/min/kg fat free mass) from the baseline rate did not significantly differ in the underweight (n = 3) or in the overweight subjects (n = 5) following consumption of either meal at any time.
2	2211287	Changes in metabolic rate (metabolic rate) (kcal/min and kcal/min/kg fat free mass)	Changes in metabolic rate (kcal/min and kcal/min/kg fat free mass) from baseline were significantly higher in normal weight subjects (n = 11) across all times following consumption of the high protein, high fat meal versus the high protein, low fat meal.  
2	3085176	Resting metabolic rates (Resting metabolic rates)	The group receiving p-synephrine (50 mg) alone exhibited a 65 kcal increase in Resting metabolic rates as compared to the placebo group.
2	3085176	Resting metabolic rates (Resting metabolic rates)	The consumption of 600 mg naringin with 50 mg p-synephrine resulted in a 129 kcal increase in Resting metabolic rates relative to the placebo group.
2	3085176	Resting metabolic rates (Resting metabolic rates)	In the group receiving 100 mg hesperidin in addition to the 50 mg p-synephrine plus 600 mg naringin, the Resting metabolic rates increased by 183 kcal, an increase that was statistically significant with respect to the placebo control (p<0.02).
1	3085176	heart rate and blood pressure	None of the treatment groups exhibited changes in heart rate or blood pressure relative to the control group, nor there were no differences in self-reported ratings of 10 symptoms between the treatment groups and the control group.
1	3085176	self-report ratings for the 10 symptoms	None of the treatment groups exhibited changes in heart rate or blood pressure relative to the control group, nor there were no differences in self-reported ratings of 10 symptoms between the treatment groups and the control group.
0	5494175	'Atlantis' and 'Number recall', and spatial ability tests-'Triangle', problem solving Children's Category Test Level 1 test	At unstandardized and standardized multivariable analysis, children whose mothers reported alcohol consumption during pregnancy performed significantly poorer for memory-'Atlantis' (p = 0.03) and 'Number recall' (p = 0.0001), and spatial ability tests-'Triangle' (p = 0.03); they scored significantly higher errors at problem solving Children's Category Test Level 1 test (p = 0.002); all the results were adjusted for age, sex, schooling, stunting, father's education, mother's employment and the promotion of exclusive breastfeeding.
0	5494175	'Atlantis' and 'Number recall', and spatial ability tests-'Triangle', problem solving Children's Category Test Level 1 test	Children whose mothers reported alcohol consumption during pregnancy performed significantly poorly for memory and spatial abilities tests from small effect size difference for 'Atlantis' (0.27) and 'Triangle' (0.29) to moderate effect size difference for 'Number recall' (0.72) compared to children whose mothers did not consume alcohol during pregnancy; the exposed children scored significantly higher errors with a small effect size (0.37) at problem solving (Children's Category Test Level 1) test compared to unexposed children.  
1	5494175	'Conceptual Thinking', 'Face recognition', 'Story completion', and reasoning tests-'Rover', 'Block counting', and 'Pattern Reasoning'	No statistical association was found for visual abilities-'Conceptual Thinking', 'Face recognition', 'Story completion', and reasoning tests-'Rover', 'Block counting', and 'Pattern Reasoning'.  
1	4260664	Beck Depression Inventory-II score	The analyses revealed no significant difference between the two groups at post treatment, neither on Beck Depression Inventory-II, MADRS-S, nor Beck Anxiety Inventory.
1	4260664	Beck Anxiety Inventory	The analyses revealed no significant difference between the two groups at post treatment, neither on Beck Depression Inventory-II, MADRS-S, nor Beck Anxiety Inventory.
1	4260664	Montgomery Åsberg Depression Rating Scale score	The analyses revealed no significant difference between the two groups at post treatment, neither on Beck Depression Inventory-II, MADRS-S, nor Beck Anxiety Inventory.
0	3743198	Admission rate	The admission rate decreased by 8.3% in the intervention group (adjusted odds ratio 0.31, 95% confidence interval 0.13-0.70, p=0.005).
2	3034877	mean serum 25(OH)D	After 6 months, mean serum 25(OH)D increased to 53 nmol/l with 800 IU/day, to 50.5 nmol/l with 100,000 IU/3 months, and to 29.1 nmol/l with advised sunlight exposure (supplementation vs sunshine p < 0.001).
0	3034877	parathyroid hormone (parathyroid hormone) concentrations	Serum parathyroid hormone decreased significantly in all groups after 3 months, more in the supplementation groups than in the advised sunlight group (p < 0.05).
1	4162719	time to complete the difficult model	There was no significant difference in time to complete the simple model (hand-on-needle vs. hand-on-syringe, 18 seconds vs. 18 seconds, p=0.93), time to complete the difficult model (hand-on-needle vs. hand-on-syringe, 56 seconds vs. 50 seconds, p=0.63), needle visualization, or needle tip targeting accuracy.
2	4162719	residents preference	Most residents (60%) preferred the hand-on-syringe technique.  
1	4162719	time to complete the simple model	There was no significant difference in time to complete the simple model (hand-on-needle vs. hand-on-syringe, 18 seconds vs. 18 seconds, p=0.93), time to complete the difficult model (hand-on-needle vs. hand-on-syringe, 56 seconds vs. 50 seconds, p=0.63), needle visualization, or needle tip targeting accuracy.
2	4191553	the reduction in risk of 24-month incidence of new or worsening vertebral fracture	Denosumab significantly reduced the risk of new or worsening vertebral fracture by 65.7%, with incidences of 3.6% in denosumab and 10.3% in placebo at 24 months (hazard ratio 0.343; 95% confidence interval 0.194–0.606, P = .0001).
2	4994121	Stroke volume index	At the postoperative period, cardiac output and stroke volume index was higher in SG (mean±sd;29.1±6.3 vs. 18.4±4.9 mL/min−1/m−2 (P<0.0001)).
2	4994121	Cardiac index	Cardiac index was higher in SG (320.7±37.5 vs. 283.0±83.9 mL/min−1/m−2 (P=0.009)).
0	4994121	Postoperative inotrophyc requirement	The postoperative inotrophyc requirement was less in SG (5.6±2.7 vs. 10.4±2.0 mg/kg, P< 0.008), and postoperative cardiac enzyme levels were less in SG (P< 0.01).
0	4994121	Postoperative cardiac enzyme levels	The postoperative inotrophyc requirement was less in SG (5.6±2.7 vs. 10.4±2.0 mg/kg, P< 0.008), and postoperative cardiac enzyme levels were less in SG (P< 0.01).
0	4994121	Need for intra-aortic balloon pump	We used IABP in eight patients (22.8%) in SG and 17 patients (48.5%) in CG (P=0.0001).  
2	4730432	intention to seek information about clinical trials	A statistically significant increase in the intention to obtain clinical trial information at the three and six month time points was observed in the intervention group, but not the control group.
1	4730432	intention to seek information about clinical trials	A statistically significant increase in the intention to obtain clinical trial information at the three and six month time points was observed in the intervention group, but not the control group.
2	4056626	Mean arterial pressure (mean arterial pressure), intracranial pressure, SjO2 and mVMCA	In the control group Endotracheal suctioning stimulated the cough reflex, with a median cough score of 2 (interquartile range (interquartile range) 1 to 2). Furthermore, it caused an increase in mean arterial pressure (mean arterial pressure) (from 89.0 ± 11.6 to 96.4 ± 13.1 mmHg; P <0.001), intracranial pressure (from 11.0 ± 6.7 to 18.5 ± 8.9 mmHg; P <0.001), SjO2 (from 82.3 ± 7.5 to 89.1 ± 5.4; P = 0.01) and mVMCA (from 76.8 ± 20.4 to 90.2 ± 30.2 cm/sec; P = 0.04).
1	4056626	Mean arterial pressure (mean arterial pressure), cerebral perfusion pressure (cerebral perfusion pressure), SjO2 and mVMCA	In the intervention group, no significant variation of mean arterial pressure, cerebral perfusion pressure, mVMCA, and SjO2 were observed in any step; after Endotracheal suctioning, intracranial pressure increased if compared with baseline (15.1 ± 9.4 vs. 11.0 ± 6.4 mmHg; P <0.05).
2	4056626	intracranial pressure	In the intervention group, no significant variation of mean arterial pressure, cerebral perfusion pressure, mVMCA, and SjO2 were observed in any step; after Endotracheal suctioning, intracranial pressure increased if compared with baseline (15.1 ± 9.4 vs. 11.0 ± 6.4 mmHg; P <0.05).
1	3290117	Final tumor size	Final tumor size was 2.59 cm in the Neoadjuvant chemotherapy + BC group versus 3.16 cm for Neoadjuvant chemotherapy (P = 0.76) Mean Ki-67 for Neoadjuvant chemotherapy + BC was 7% versus 29% with Neoadjuvant chemotherapy (P = 0.14).
1	3290117	Mean Ki-67	Final tumor size was 2.59 cm in the Neoadjuvant chemotherapy + BC group versus 3.16 cm for Neoadjuvant chemotherapy (P = 0.76) Mean Ki-67 for Neoadjuvant chemotherapy + BC was 7% versus 29% with Neoadjuvant chemotherapy (P = 0.14).
1	3290117	C-peptide (ng/mL)	C-peptide (ng/mL) was equivalent between the two groups (4.55 Neoadjuvant chemotherapy + BC versus 4.74 Neoadjuvant chemotherapy, P = 0.85).  
1	3290117	C-peptide (ng/mL)	There were no initial differences between groups in regards to tumor size, C-peptide, BMI, and Ki–67.
0	3290117	mean BMI	The Neoadjuvant chemotherapy + BC (n = 5) group had a lower mean BMI at the conclusion of Neoadjuvant chemotherapy compared with those (n = 5) in the Neoadjuvant chemotherapy group (28.0 versus 35.8, P = 0.03).
2	3776379	sleep latency effects among patients with schizophrenia	A significant effect of acupuncture treatment was observed for seven objective sleep variables: sleep onset latency, sleep percentage, mean activity level, wake time after sleep onset, mean number of wake episodes, mean wake episode and longest wake episode.
2	3776379	beneficial effects on emotional measures among patients with schizophrenia	Overall, the findings of this pilot study suggest that acupuncture has beneficial effects as a treatment for insomnia and psychopathology symptoms among patients with schizophrenia.
2	5260131	Core temperature after reperfusion	Repeated measured ANOVA showed that core temperatures over time during the stages of the transplant were higher in the Humidification Group compared to the Control Group (p < 0.0001).
1	5260131	Need for inotropic support	There were no significant differences in the ETCO2, PaCO2, minute ventilation, or inotropic support.  
1	5260131	End-tidal CO2	There were no significant differences in the ETCO2, PaCO2, minute ventilation, or inotropic support.  
1	5260131	Partial pressure of CO2	There were no significant differences in the ETCO2, PaCO2, minute ventilation, or inotropic support.  
1	5518919	Montgomery–Åsberg Depression Rating Scale	At end-point, 9 (23%) of those in the probiotic group showed a ⩾60% change on the Montgomery–Åsberg Depression Rating Scale (responders), compared to 10 (26%) of those in the placebo group (χ12=0.107, p = ns).
1	5518919	Depression	No significant difference was found between the probiotic and placebo groups on any psychological outcome measure (Cohen's d range = 0.07–0.16) or any blood-based biomarker.
1	5518919	Depression	At end-point, 9 (23%) of those in the probiotic group showed a ⩾60% change on the Montgomery–Åsberg Depression Rating Scale (responders), compared to 10 (26%) of those in the placebo group (χ12=0.107, p = ns).
1	5518919	Anxiety	No significant difference was found between the probiotic and placebo groups on any psychological outcome measure (Cohen's d range = 0.07–0.16) or any blood-based biomarker.
0	3611073	Sensory block levels	Sensory block levels were significantly lower at all time points for the L group.
2	2769033	Weekly physical activity	At 12 months rates increased to 43% and 30% and at 24 months to 39.3% and 32.8% (P<0.001), respectively.
2	2769033	SF-36 mental health improvement	SF-36 physical functioning (P=0.03) and mental health (P<0.05) scores improved more in intervention compared with control participants, but role physical scores were significantly lower (P<0.01).
2	2769033	Falls	More falls (P<0.001) and injuries (P=0.03) were recorded in the intervention group.  
2	2769033	SF-36 physical functioning improvement	SF-36 physical functioning (P=0.03) and mental health (P<0.05) scores improved more in intervention compared with control participants, but role physical scores were significantly lower (P<0.01).
2	4477769	the mean score of satisfaction among the parents of the children	In addition, a significant difference was found between the scores of satisfaction for the control and experimental groups (p<0.001), and all parents of children in the experimental group expressed high satisfaction.  
2	4477769	the mean score of parent's educational satisfaction	In the Family-centered care group, the mean score of satisfaction among the parents of the children was 20 out of 90 before the intervention, but, after the Family-centered care method was used, it increased to 83.2 out of 90. In addition, a significant difference was found between the scores of satisfaction for the control and experimental groups (p<0.001), and all parents of children in the experimental group expressed high satisfaction.  
2	4535555	Late gadolinium enhancement	Late gadolinium enhancement remained the predominant signal with 56% encirclement in the robotic group vs. 45% in the standard group (P = 0.04).
1	4535555	mean late gadolinium enhancement encirclement at 6 months follow-up	At 6 months follow-up, arrhythmia-free patients had an almost similar mean late gadolinium enhancement encirclement (robotic 64%, standard 60%, P = 0.45) but in recurrences, late gadolinium enhancement was higher in the robotic group (43% vs. 30%, P = 0.001).
1	3767244	Salivary cortisol 1 hour after waking	There was a decrease in salivary cortisol at wake (P = 0.025) in the exercise group and a trend (P = 0.07) for a decrease 1 hour after waking.
0	3767244	Total fat if +20% body fat	Those in the exercise group below median body fat (20%) increased lean tissue mass (P = 0.014) only, while those above 20% decreased fat mass (P = 0.02), total fat (N = 0.009), and trunk fat (P = 0.001), while also increasing lean tissue mass (P = 0.027).
0	3767244	Salivary cortisol at wake	There was a decrease in salivary cortisol at wake (P = 0.025) in the exercise group and a trend (P = 0.07) for a decrease 1 hour after waking.
2	3767244	Lean tissue mass	The exercise group had a significant increase in lean tissue mass (lean tissue mass) (P < 0.001) following the intervention.
0	3767244	Fat mass if +20% body fat	Those in the exercise group below median body fat (20%) increased lean tissue mass (P = 0.014) only, while those above 20% decreased fat mass (P = 0.02), total fat (N = 0.009), and trunk fat (P = 0.001), while also increasing lean tissue mass (P = 0.027).
0	3767244	Trunk fat if +20% body fat	Those in the exercise group below median body fat (20%) increased lean tissue mass (P = 0.014) only, while those above 20% decreased fat mass (P = 0.02), total fat (N = 0.009), and trunk fat (P = 0.001), while also increasing lean tissue mass (P = 0.027).
0	3232074	Michigan diabetic neuropathy score	Michigan diabetic neuropathy score was decreased notably in ANGIPARSTM group.
2	1713239	Forced expiratory volume (forced expiratory volume in 1 second)	At 1 minute after inhalation, statistically significant decreases in Borg score were observed for budesonide/formoterol and salbutamol (p = 0.0233 and p < 0.0001, respectively, versus placebo), with similar rapid increases in forced expiratory volume in 1 second (both active treatments p < 0.0001 versus placebo).
0	3694465	Placement of hands in the abdominal region	None in the intervention group placed their hands in the abdominal region, compared to 5/18 in the control group (p = 0.045).
2	5668004	GLUT-1 expression	VEGF and GLUT-1 expression were significantly positively associated with complete response (complete response) to treatment in all leave-one-out iterations.
2	5668004	vascular endothelial growth factor (VEGF) expression	VEGF and GLUT-1 expression were significantly positively associated with complete response (complete response) to treatment in all leave-one-out iterations.
1	4684352	Body weight	Diet did not affect body weight, resting energy expenditure or skeletal muscle adenosine monophosphate-activated protein kinase phosphorylation.
1	4684352	Resting energy expenditure	Diet did not affect body weight, resting energy expenditure or skeletal muscle adenosine monophosphate-activated protein kinase phosphorylation.
1	4684352	Adenosine monophosphate-activated protein kinase phosphorylation	Diet did not affect body weight, resting energy expenditure or skeletal muscle adenosine monophosphate-activated protein kinase phosphorylation.
0	4684352	Ratio of fat to lean body mass	Dogs fed Mannoheptulose had significantly lower post-prandial respiratory quotient (p = 0.02) and ratio of fat to lean body mass (p = 0.02).
0	4684352	Post-prandial respiratory quotient	Dogs fed Mannoheptulose had significantly lower post-prandial respiratory quotient (p = 0.02) and ratio of fat to lean body mass (p = 0.02).
0	4684352	Physical activity during light time periods	Physical activity during light time periods (but not dark) was lower in dogs fed Mannoheptulose (p < 0.05) during weekends, but not on weekdays.
0	5062194	preoperative anxiety	Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.
2	5062194	postoperative satisfaction	Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.
1	5062194	neonatal outcome	There were no between-group differences regarding the neonatal outcome.  
1	4274965	stress levels	Subjective and physiological stress levels showed no age difference and no detrimental association with prospective memory.
2	4048141	Overall severity category shift from ≥ 4 to ≤ 2	A significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from baseline ≥ 4 to end of study ≤ 2 on Montgomery-Asberg Depression Rating Scale items of apparent sadness, reported sadness, inner tension, reduced sleep, and lassitude (odds ratio range, 1.5–2.0, P < .05).
2	4048141	Abscense of anxious depression	Additionally, a significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from anxious depression at baseline to no anxious depression at end of study (odds ratio = 1.5, P = .031).  
1	3577738	website use and terms of the number of pages visited and terms of time on the website	Participants in the experimental condition focused on the social presence elements, both in terms of frequency (F(1, 98) = 40.34, p<.001) and duration (F(1, 88) = 39.99, p<.001), but did not differ in website use in comparison with the control condition; neither in terms of the number of pages visited (t(456) = 1.44, p = .15), nor in terms of time on the website (t(456) = 0.01, p = .99).  
2	3577738	focused on the social presence elements in terms of frequency and duration	Participants in the experimental condition focused on the social presence elements, both in terms of frequency (F(1, 98) = 40.34, p<.001) and duration (F(1, 88) = 39.99, p<.001), but did not differ in website use in comparison with the control condition; neither in terms of the number of pages visited (t(456) = 1.44, p = .15), nor in terms of time on the website (t(456) = 0.01, p = .99).  
1	5518918	Healthcare costs	Healthcare costs were statistically non-significantly lower in the home-based group (€437 per patient, 95% confidence interval –562 to 1436, p = 0.39). From a societal perspective, a statistically non-significant difference of €3160 per patient in favour of the home-based group was found (95% confidence interval –460 to 6780, p = 0.09) and the probability that it was more cost-effective varied between 97% and 75% (willingness-to-pay of €0 and €100,000 per quality-adjusted life-years, respectively).  
1	5518918	Physical fitness	Physical fitness improved at discharge (p < 0.01) and at one-year follow-up (p < 0.01) in both groups, without differences between groups (home-based p = 0.31 and centre-based p = 0.87).
1	5518918	Health-related quality of life	We found no differences between home-based training with telemonitoring guidance and centre-based training on physical fitness, physical activity level or health-related quality of life.
2	5518918	Satisfaction	Although training adherence was similar between groups, satisfaction was higher in the home-based group (p = 0.02).
1	4149239	Gastric inhibitory polypeptide	There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups.
1	4149239	Glucagon-like peptide-1	There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups.
1	4149239	Flow mediated dilatation	ΔFMD was significantly improved after 12 weeks of treatment in both groups, and there was no significant difference in ΔFMD between the two groups.
1	4149239	Glycated hemoglobin	There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups.
1	4149239	Epidermal growth factor receptor	There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups.
2	5593355	Risk of cardiovascular death	On-treatment analysis showed similar results to the SERVE-HF intention-to-treat analysis, with an increased risk of cardiovascular death in heart failure with reduced ejection fraction patients with predominant central sleep apnoea treated with adaptive servo ventilation. Bias is inevitable and needs to be taken into account in any kind of on-treatment analysis in positive airway pressure studies.
1	4045752	The anti-HBs level	The anti-HBs level in the therapeutic paracetamol group (4958 mIU/mL) was not different (p = 0.34) from the level in the control group.
0	4045752	the anti-HBs level	One month after the second booster vaccination, the anti-HBs level in the prophylactic paracetamol group was significantly lower (p = 0.048) than the level in the control group (4257 mIU/mL vs. 5768 mIU/mL).
1	3474173	Improvement in quality of life	We observed no significant changes in quality of life between patients with or without the tool during the study period.  
1	3474173	Baseline characteristics	The groups were similar at inclusion in terms of characteristics, including global quality of life.
2	5588713	Neutrophils in blood	There was a significant dose-dependent increase in blood neutrophils (p = 0.046) after challenge with carbon nanoparticles. The individual top-dose of 100 μg showed a significant (p = 0.05) increase in terms of percentage neutrophils in blood as compared to placebo.  
1	4401879	fasting blood sugar, insulin and homeostatic model assessment of insulin resistance	Serumlevels of fasting blood sugar, insulin and homeostatic model assessment of insulin resistance slightly decreased in zinc group, but these changes were not statistically significant.
2	4401879	energy, protein, and fat and zinc intake	Serum zinc levels (P =0.012), energy (P=0.037), protein (P=0.019) and fat (P=0.017) intakes increased statistically significant in the zinc group after intervention but not in the placebo group.  
1	5029174	Sickness absence	Compared with the control group, the results indicated no reduction in sickness absence in the intervention group but fewer depressive symptoms, a heightened ability of the participants to distance themselves from work, more experience of work-related success, less depletion of emotional resources, and a greater satisfaction with life when participants had received the job coaching.
2	4562579	Fat-free leg mass	Leg fat-free mass decreased with Step-reduction (−124 ± 61 g) and increased in the Step-reduction + resistance exercise (+126 ± 68 g; P = 0.003).
2	4562579	Myofibrillar fractional synthetis rate	Myofibrillar FSR was lower (P < 0.0001) in the Step-reduction as compared with the Step-reduction + resistance exercise leg in the postabsorptive (0.026 ± 0.001%/h vs. 0.045 ± 0.001%/h) and postprandial states (0.055 ± 0.002%/h vs. 0.115 ± 0.003%/h).
1	3271555	ventilator-associated pneumonia (ventilator-associated pneumonia) rate	The ventilator-associated pneumonia rates in the control and intervention groups were 14.03 and 6.48 per 1000 ventilator days (P = 0.08).
1	3271555	Tracheobronchial colonization	Tracheobronchial colonization was seen in 86 (48.6%) of 177 in the control group and 73 (41.7%) of 175 among the intervention group (P = 0.195).
0	3586143	Vandetaninb area under the plasma concentration-time curve from time 0 to 504 hours	Results: Study A: coadministration of vandetanib with rifampicin resulted in a statistically significant reduction in AUC504 (geometric least square [GLS]mean ratio [vandetanib + rifampicin/vandetanib alone] 0.60; 90% CI 0.58, 0.63).
1	3586143	Vandetaninb maximum plasma concentration	There was no significant difference in Cmax of vandetanib (GLSmean ratio 1.03; 90% CI 0.95, 1.11).
2	3586143	Vandetaninb area under the plasma concentration-time curve from time 0 to 504 hours	Study B: coadministration of vandetanib with itraconazole resulted in a significant increase in AUC504 (GLSmean ratio [vandetanib + itraconazole/vandetanib alone] 1.09; 90% CI 1.01, 1.18) and no significant change in Cmax (GLSmean ratio 0.96; 90% CI 0.83, 1.11).
1	3586143	Vandetaninb maximum plasma concentration	Study B: coadministration of vandetanib with itraconazole resulted in a significant increase in AUC504 (GLSmean ratio [vandetanib + itraconazole/vandetanib alone] 1.09; 90% CI 1.01, 1.18) and no significant change in Cmax (GLSmean ratio 0.96; 90% CI 0.83, 1.11).
1	3586143	Vandetaninb maximum plasma concentration	There was no significant difference in Cmax of vandetanib (GLSmean ratio 1.03; 90% CI 0.95, 1.11).
1	4810948	Total antioxidant status	In the postoperative 24th h, total oxidant status and oxidative stress index were found to be significantly higher in open appendectomy group when compared to laparoscopic appendectomy group (P = 0.017 and 0.002) whereas no difference was detected in total antioxidant status level in the postoperative 24th h (P = 0.172).  
0	4810948	Oxidative stress index	In the postoperative 24th h, total oxidant status and oxidative stress index were found to be significantly higher in open appendectomy group when compared to laparoscopic appendectomy group (P = 0.017 and 0.002) whereas no difference was detected in total antioxidant status level in the postoperative 24th h (P = 0.172).  
0	4810948	C-reactive protein	There were no differences in preoperative values of WBC and C-reactive protein between laparoscopic appendectomy and open appendectomy groups (P = 0.523 and 0.424), however, in postoperative 24th h, C-reactive protein was reduced in laparoscopic appendectomy group (P = 0.031).
1	4810948	Total oxidant status	There were no differences in preoperative levels of total oxidant status, total antioxidant status, and oxidative stress index (oxidative stress index) between laparoscopic appendectomy and open appendectomy groups.
1	5634755	The mean blood glucose concentration	The mean blood glucose concentration in bitter gourd group was not statistically significant between time points, (P = .176).
1	4879328	waist circumference	Waist circumference, other physical activity outcomes and dietary outcomes, did not differ significantly between groups.  
2	4879328	weekly moderate physical activity sessions	Significant intervention effects, all favoring the intervention group, were observed at 6-months for change in weight (-1.35 kg, 95% confidence interval (confidence interval): -2.24, -0.46, P=.003), weekly moderate physical activity sessions (0.56 sessions/week, 95% confidence interval: 0.15, 0.96, P=.008) and accelerometer-assessed moderate-vigorous physical activity (24.16 minutes/week, 95% confidence interval: 5.07, 43.25, P=.007).
2	4879328	accelerometer-assessed moderate to vigorous physical activity (moderate-vigorous physical activity)	Significant intervention effects, all favoring the intervention group, were observed at 6-months for change in weight (-1.35 kg, 95% confidence interval (confidence interval): -2.24, -0.46, P=.003), weekly moderate physical activity sessions (0.56 sessions/week, 95% confidence interval: 0.15, 0.96, P=.008) and accelerometer-assessed moderate-vigorous physical activity (24.16 minutes/week, 95% confidence interval: 5.07, 43.25, P=.007).
0	3330821	Beck Depression Inventory-II (Beck Depression Inventory-II) after 4 months	The Beck Depression Inventory-II scores fell from the mean of 17.3 at baseline to 11.0 in the intervention group and to 15.7 in the control group after 4 months (p<0.001, Effect size = 0.69, 95%CI: 0.32 to 1.05).
2	4859395	constrictive remodeling	Low‐WSS regions were associated with greater plaque progression (P<0.0001) and constrictive remodeling (P=0.04); conversely, high‐WSS segments demonstrated plaque regression and excessive expansive remodeling.
0	3620516	acute medication intake	Preventive treatment with anodal Transcranial direct current stimulation turned out to be beneficial in migraine without aura patients: migraine attack frequency, migraine days, attack duration and acute medication intake significantly decreased during the treatment period compared to pre-treatment baseline (all p < 0.05), and this benefit persisted on average 4.8 weeks after the end of Transcranial direct current stimulation.  
0	3620516	migraine attack frequency, migraine days, attack duration	Preventive treatment with anodal Transcranial direct current stimulation turned out to be beneficial in migraine without aura patients: migraine attack frequency, migraine days, attack duration and acute medication intake significantly decreased during the treatment period compared to pre-treatment baseline (all p < 0.05), and this benefit persisted on average 4.8 weeks after the end of Transcranial direct current stimulation.  
0	4399299	Fasting liver triglycerides	Mean fasting liver triglyceride content decreased by 27% with vildagliptin, from 7.3 ± 1.0% (baseline) to 5.3 ± 0.9% (endpoint). There was no change in the placebo group. The between-group difference in change from baseline was significant (P = .013).
1	4399299	Insulin sensitivity	Insulin sensitivity during the euglycemic clamp was similar in each group at baseline (3.24 ± 0.30 vs 3.19 ± 0.38 mg/kg/min) and did not change (adjusted mean change of 0.26 ± 0.22 vs 0.32 ± 0.22 mg/kg/min; P = .86).
0	4399299	Fasting plasma glucose	Mean fasting plasma glucose concentration decreased over the study period with vildagliptin vs placebo by −1.0 mmol/L (P = .018), and there was a positive correlation between these decrements and liver triglyceride in the vildagliptin group at 3 months (r = 0.47; P = .02) and 6 months (r = 0.44; P = .03).
0	4399299	Alanine aminotransferase	Plasma alanine aminotransferase fell from 27.2 ± 2.8 to 20.3 ± 1.4 IU/L in the vildagliptin group (P = .0007), and there was a correlation between the decrements in alanine aminotransferase and liver triglyceride (r = 0.83; P < .0001).
1	4399299	Body weight	Mean body weight decreased by 1.6 ± 0.5 vs 0.4 ± 0.5 kg in the vildagliptin and placebo groups, respectively (P = .08).  
0	2717426	Peak blood glucose	In all patients, exogenous glucagon-like peptide-1 infusion reduced the overall glycaemic response during enteral nutrient stimulation (AUC30–270 min glucagon-like peptide-1 (2077 ± 144 mmol/l min) vs placebo (2568 ± 208 mmol/l min); P = 0.02) and the peak blood glucose (glucagon-like peptide-1 (10.1 ± 0.7 mmol/l) vs placebo (12.7 ± 1.0 mmol/l); P < 0.01).
1	2717426	Absolute insulin concentrations	The insulin/glucose ratio at 270 minutes was increased with glucagon-like peptide-1 infusion (glucagon-like peptide-1 (9.1 ± 2.7) vs. placebo (5.8 ± 1.8); P = 0.02) but there was no difference in absolute insulin concentrations.
0	2717426	Glucagon concentrations during infusion	There was a transient, non-sustained, reduction in plasma glucagon concentrations during glucagon-like peptide-1 infusion (t = 30 minutes glucagon-like peptide-1 (90 ± 12 pmol/ml) vs. placebo (104 ± 10 pmol/ml); P < 0.01).  
0	2717426	Glycaemic response	In all patients, exogenous glucagon-like peptide-1 infusion reduced the overall glycaemic response during enteral nutrient stimulation (AUC30–270 min glucagon-like peptide-1 (2077 ± 144 mmol/l min) vs placebo (2568 ± 208 mmol/l min); P = 0.02) and the peak blood glucose (glucagon-like peptide-1 (10.1 ± 0.7 mmol/l) vs placebo (12.7 ± 1.0 mmol/l); P < 0.01).
0	3613423	body fat percentage (%BF) underestimation at the endpoint in males in obese or overweight Chinese adults	Compared with dual energy X-ray absorptiometry, bioelectrical impedance analysis underestimated %BF [in males: 4.6, –2.4 to 11.7 (mean biases, 95% limit of agreement) at the baseline, 1.4, –7.4 to 10.2 at the endpoint, and 3.2, –4.8 to 11.3 in changes; in females: 5.1, –2.4 to 12.7; 2.2, –6.1 to 10.4; and 3.0, –4.8 to 10.7, respectively].
0	3613423	body fat percentage (%BF) underestimation in changes in males in obese or overweight Chinese adults	Compared with dual energy X-ray absorptiometry, bioelectrical impedance analysis underestimated %BF [in males: 4.6, –2.4 to 11.7 (mean biases, 95% limit of agreement) at the baseline, 1.4, –7.4 to 10.2 at the endpoint, and 3.2, –4.8 to 11.3 in changes; in females: 5.1, –2.4 to 12.7; 2.2, –6.1 to 10.4; and 3.0, –4.8 to 10.7, respectively].
2	5414544	HBV surface antigen positivity	Overall, HBV surface antigen positivity was associated with male sex (adjusted odds ratio = 1.54, P < 0.001) but not with age, WHO disease stage, or CD4+ cell count.
2	5414544	The rate of HBV surface antigen positivity	The rate of HBV surface antigen positivity was significantly higher in Zimbabwe than Uganda (12.2 vs. 7.7%, adjusted odds ratio = 1.54, P < 0.001) despite a similar prevalence of antibody to HBV core antigen (56.3 vs. 52.4%) in the two settings.
1	5244020	Blood pressure	Systolic and diastolic blood pressure (blood pressure), heart rate, lower urinary tract symptoms, and visual analog scales of pain magnitude and quality of life (quality of life) regarding urinary symptoms were measured before and after inhalation. Systolic blood pressure, diastolic blood pressure, heart rate, lower urinary tract symptoms, and quality of life satisfaction with urinary symptoms were similar in the three groups.
1	5244020	Blood pressure	Systolic blood pressure, diastolic blood pressure, heart rate, lower urinary tract symptoms, and quality of life satisfaction with urinary symptoms were similar in the three groups.
1	5244020	Heart rate	Systolic blood pressure, diastolic blood pressure, heart rate, lower urinary tract symptoms, and quality of life satisfaction with urinary symptoms were similar in the three groups.
0	5244020	Pain	Significant differences in pain magnitude and urinary residual sense of indwelling catheters were observed among the three groups, with inhalation of linalyl acetate being significantly more effective than inhalation of lavender or vehicle.
0	3172326	The total number of pethidine injections in first 24 hours postoperatively	The interval time for the first analgesic request was 23.1 ± 6.7 minutes for the case group and 18.1 ± 7.3 minutes for the control (P = 0.02). The total number of pethidine injections in the first 24 hours postoperatively was 0.6 ± 0.6 for the case group and 2.0 ± 0.8 for the controls (P = 0.032).
0	3172326	visual analogue scale (visual analogue scale).	For all of the evaluated times, the visual analogue scale score was significantly lower in the ketamine group compared to the control.
2	3172326	The interval time for the first analgesic request	The interval time for the first analgesic request was 23.1 ± 6.7 minutes for the case group and 18.1 ± 7.3 minutes for the control (P = 0.02).
0	5289293	Risk of death from prostate cancer	ProtecT men had a 45% lower risk of death from prostate cancer compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38–0.83; p = 0.0037), but mortality was similar in those treated radically.
1	5289293	Mortality rates	ProtecT men had a 45% lower risk of death from prostate cancer compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38–0.83; p = 0.0037), but mortality was similar in those treated radically.
1	4025600	reduction in absolute weight	Both low-fat diet and low-carbohydrate diet led to similar reductions in body weight, while beneficial effects on glycaemic control were observed in the low-carbohydrate diet group only.
0	4025600	interleukin-1 receptor antagonist and IL-6 levels	After 6 months, the levels of interleukin-1 receptor antagonist and IL-6 were significantly lower in the low-carbohydrate diet group than in the low-fat diet group, 978 (664–1385) versus 1216 (974–1822) pg/mL and 2.15 (1.65–4.27) versus 3.39 (2.25–4.79) pg/mL, both P < 0.05.  
2	3829814	Production of IFN-γ	Delivery of probiotic also suppressed production of sCD23 (p = 0.0081), TGF-β (p = 0.0283) and induced increased production of IFN-γ (p = 0.0351) in supernatants of cultured peripheral blood.  
0	3829814	Production of sCD23	Delivery of probiotic also suppressed production of sCD23 (p = 0.0081), TGF-β (p = 0.0283) and induced increased production of IFN-γ (p = 0.0351) in supernatants of cultured peripheral blood.  
0	3829814	Production of TGF-β	Delivery of probiotic also suppressed production of sCD23 (p = 0.0081), TGF-β (p = 0.0283) and induced increased production of IFN-γ (p = 0.0351) in supernatants of cultured peripheral blood.  
0	5459456	The stiffness	Overall, stiffness was significantly decreased in the ACVC and ACVC-HA groups compared with the control group and the Anterior cervical corpectomy and fusion group.
2	4568196	total cholesterol (total cholesterol)	hypocaloric diet without legumes significantly reduced Waist to hip ratio [P = 0.010 (3.2%)] and increased total cholesterol [P < 0.001 (6.3%)].
1	4568196	total antioxidant capacity (total antioxidant capacity)	Despite the significant effect of hypocaloric diet enriched with legumes on increasing total antioxidant capacity in 3 weeks [P = 0.050 (4%)], the level of total antioxidant capacity remained the same in 6 weeks.
1	5395991	The primary reattachment rate	The primary macular hole closure and reattachment rates were not significantly different in both groups (P=0.056, respectively).  
1	3464379	Adverse events	There were no adverse events.  
2	4398332	Stoned feeling	In comparison to placebo, cannabidiol improved emotional facial affect recognition at 60% emotional intensity; Δ-9-tetrahydrocannabinol was detrimental to the recognition of ambiguous faces of 40% intensity. The combination of THC+CBD produced no impairment. Relative to placebo, both Δ-9-tetrahydrocannabinol alone and combined THC+CBD equally increased feelings of being 'stoned'.
0	4398332	Facial affect recognition	A visual analogue scale (visual analogue scale) of feeling 'stoned' was also completed. In comparison to placebo, cannabidiol improved emotional facial affect recognition at 60% emotional intensity; Δ-9-tetrahydrocannabinol was detrimental to the recognition of ambiguous faces of 40% intensity.
2	4398332	Facial affect recognition	In comparison to placebo, cannabidiol improved emotional facial affect recognition at 60% emotional intensity; Δ-9-tetrahydrocannabinol was detrimental to the recognition of ambiguous faces of 40% intensity.
0	4398332	Facial affect recognition	In comparison to placebo, cannabidiol improved emotional facial affect recognition at 60% emotional intensity; Δ-9-tetrahydrocannabinol was detrimental to the recognition of ambiguous faces of 40% intensity. The combination of THC+CBD produced no impairment.
1	4398332	Stoned feeling	cannabidiol did not influence feelings of 'stoned'.
0	4234827	The duration of sedation	Mortality at day 90 was similar in both groups (25.7% versus 29.9%), but duration of sedation was shorter in the early tracheotomy group median 11 days (range 2 to 92) days compared to 14 days (range 0 to 79) in the late group (P <0.02).
1	4234827	Mortality at day 90	In these subgroup of patients (per-protocol analysis) no differences existed in mortality at day 90 between the two groups, but the early group had more ventilator-free days, less duration of sedation and less length of stay, than the late group.  
1	4234827	The crude 90-day mortality	Mortality at day 90 was similar in both groups (25.7% versus 29.9%), but duration of sedation was shorter in the early tracheotomy group median 11 days (range 2 to 92) days compared to 14 days (range 0 to 79) in the late group (P <0.02).
1	5504551	physical activity	Our study shows that the awareness of wearing an accelerometer has no influence on physical activity patterns in young people.
1	5504551	physical activity	Missing data led to the exclusion of 2 participants assigned to the blinded group. When data from the blinded group were compared with these from the nonblinded group, no differences were found in the duration of any of the following items: (i) wearing the accelerometer, (ii) total physical activity, (iii) sedentary activity, and (iv) moderate-to-vigorous activity.  
1	5504551	The duration of wearing the accelerometer	When data from the blinded group were compared with these from the nonblinded group, no differences were found in the duration of any of the following items: (i) wearing the accelerometer, (ii) total physical activity, (iii) sedentary activity, and (iv) moderate-to-vigorous activity.  
2	4341337	Physician-assessed overall nasal signs and symptoms improvement	Significant improvements in rTNSS, physician-assessed overall nasal signs and symptoms severity, and rhinoconjunctivitis quality-of-life questionnaires in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group.
2	4341337	Physician-assessed overall nasal signs and symptoms improvement	Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both seasonal allergic rhinitis and perennial allergic rhinitis patients.
1	4341337	Reflective total ocular symptom scores	rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown.
1	3602032	Undertreatment rate	The undertreatment rate did not differ significantly either (p = 0.390).
1	3602032	Recognition rates	No significant differences were found for recognition rates (58.0% vs. 48.1% intervention vs. control; OR [95%CI] 1.40 [0.73-2.68], p = 0.309).
1	2650992	The mean drainage duration	Overall, the fibrin glue and control groups were similar in terms of drainage duration, overall drain output, and incidence of seroma.
1	2650992	drainage duration	Overall, the fibrin glue and control groups were similar in terms of drainage duration, overall drain output, and incidence of seroma.
1	2650992	overall drain output	Overall, the fibrin glue and control groups were similar in terms of drainage duration, overall drain output, and incidence of seroma.
2	3262135	analgesic effects of low doses after knee surgery	The results of this randomised clinical trial demonstrate improved analgesia after administration of low doses of intra-articular Bupivacaine and Ropivacaine after arthroscopy of the knee.
2	3262135	analgesic effects of low doses after knee surgery	One-h NRS-scores at rest were higher in the NaCl group compared with the Bupivacaine group (P < 0.01), 1 h NRS-scores in flexion were higher in the NaCl group compared with the Bupivacaine (P < 0.01) and Ropivacaine (P < 0.01) groups.
2	3262135	analgesic effects of low doses after knee surgery	The results of this randomised clinical trial demonstrate improved analgesia after administration of low doses of intra-articular Bupivacaine and Ropivacaine after arthroscopy of the knee.
0	3262135	used NSAID's	NSAID consumption was lower in the Bupivacaine group compared with the NaCl group (P < 0.01).  
1	5536558	Inhibition of the maximal resting pressure	No significant differences were observed in the percentage inhibition of the maximal resting pressure among the three regional anaesthetic groups.
1	5536558	Inhibition of the maximal resting pressure	No significant differences were observed in the percentage inhibition of the maximal resting pressure among the three regional anaesthetic groups.
1	5536558	Inhibition of the maximal resting pressure	No significant differences were observed in the percentage inhibition of the maximal resting pressure among the three regional anaesthetic groups.
2	5536558	Inhibition of the maximal squeezing pressure	However, percentage inhibition of the maximal squeezing pressure was significantly greater in the saddle group (83.6 ± 13.7%) compared with the lumbar epidural group (58.4 ± 19.8%) and the caudal group (47.8 ± 16.9%).
2	5536558	Inhibition of the maximal squeezing pressure	However, percentage inhibition of the maximal squeezing pressure was significantly greater in the saddle group (83.6 ± 13.7%) compared with the lumbar epidural group (58.4 ± 19.8%) and the caudal group (47.8 ± 16.9%).
0	3996328	Lean tissue loss	Participants in the traditional group lost a significant amount of lean tissue (P = 0.007) in the nine months after intervention, while participants in the eccentric group did not (P = 0.32).
1	3787573	Timed Up and Go test	For the comparison between the groups, no statistically significant difference was found between the NMES + exercise and the exercise groups in NRS (P = 0.52), Timed Up and Go test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).
1	3787573	Western Ontario and McMaster Universities Osteoarthritis Index for pain	For the comparison between the groups, no statistically significant difference was found between the NMES + exercise and the exercise groups in NRS (P = 0.52), Timed Up and Go test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).
1	3787573	Numerical Rating Scale	For the comparison between the groups, no statistically significant difference was found between the NMES + exercise and the exercise groups in NRS (P = 0.52), Timed Up and Go test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).
1	3787573	Western Ontario and McMaster Universities Osteoarthritis Index for stiffness	For the comparison between the groups, no statistically significant difference was found between the NMES + exercise and the exercise groups in NRS (P = 0.52), Timed Up and Go test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).
1	3787573	Western Ontario and McMaster Universities Osteoarthritis Index for physical function	For the comparison between the groups, no statistically significant difference was found between the NMES + exercise and the exercise groups in NRS (P = 0.52), Timed Up and Go test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).
1	5519461	H. pylori eradication	The eradication rates of the EAC and RAC regimens were 79.8% (95% confidential interval: 71.7-89.0%) and 74.7% (66.0-83.4%), respectively, in a per protocol (per protocol) analysis (p=0.488). The eradication rates of the EAC and RAC regimens were not significantly different between patients with the homo EM genotype (p=0.999) or hetero IM or PM genotypes (p=0.286).
1	5519461	Eradication of H. pylori with homo EM genotype and those with hetero IM or PM genotype.	The eradication rates of the EAC and RAC regimens were not significantly different between patients with the homo EM genotype (p=0.999) or hetero IM or PM genotypes (p=0.286).
2	3932017	Pulse wave velocity (Pulse wave velocity)	Pulse wave velocity (Pulse wave velocity) and stiffness index (β) were remarkably greater (8.388 ± 3.254 m/s vs. 7.269 ± 1.332 m/s; 12.51 ± 14.16 vs.9.279 ± 2.871), while compliance coefficient (compliance coefficient) decreased significantly in the diabetes group (0.802 ± 0.3094 mm2/Kpa vs. 0.968 ± 0.3992 mm2/Kpa) (P < 0.05).
2	3932017	stiffness index (β)	Pulse wave velocity (Pulse wave velocity) and stiffness index (β) were remarkably greater (8.388 ± 3.254 m/s vs. 7.269 ± 1.332 m/s; 12.51 ± 14.16 vs.9.279 ± 2.871), while compliance coefficient (compliance coefficient) decreased significantly in the diabetes group (0.802 ± 0.3094 mm2/Kpa vs. 0.968 ± 0.3992 mm2/Kpa) (P < 0.05).
0	3932017	compliance coefficient (compliance coefficient)	Pulse wave velocity (Pulse wave velocity) and stiffness index (β) were remarkably greater (8.388 ± 3.254 m/s vs. 7.269 ± 1.332 m/s; 12.51 ± 14.16 vs.9.279 ± 2.871), while compliance coefficient (compliance coefficient) decreased significantly in the diabetes group (0.802 ± 0.3094 mm2/Kpa vs. 0.968 ± 0.3992 mm2/Kpa) (P < 0.05).
1	3932017	carotid IMT	There was no significant difference in carotid IMT (626.5 ± 169.1 μm vs. 568.5 ± 122.6 μm, P = 0.1506) between two groups.
0	3348575	Systolic blood pressure	On ambulatory BP monitoring, the week 14 mean changes from baseline in diastolic and systolic blood pressure were also significantly greater with azilsartan over a 24-h period, and during the daytime, night-time and early morning.
0	3348575	Systolic blood pressure	These data demonstrate that once-daily azilsartan provides a more potent 24-h sustained antihypertensive effect than that of candesartan but with equivalent safety.
0	3348575	Diastolic blood pressure	On ambulatory BP monitoring, the week 14 mean changes from baseline in diastolic and systolic blood pressure were also significantly greater with azilsartan over a 24-h period, and during the daytime, night-time and early morning.
0	3348575	Diastolic blood pressure	These data demonstrate that once-daily azilsartan provides a more potent 24-h sustained antihypertensive effect than that of candesartan but with equivalent safety.
2	4754570	Microleakage at gingival vs incisal margin	All groups showed greater microleakage at the gingival in comparison to the incisal margin and the differences were significant among groups with transillumination (P<0.001).
2	4754570	Microleakage at gingival vs incisal margin	All groups showed greater microleakage at the gingival in comparison to the incisal margin and the differences were significant among groups with transillumination (P<0.001).
1	4754570	Microleakage at gingival vs incisal margin	All groups showed greater microleakage at the gingival in comparison to the incisal margin and the differences were significant among groups with transillumination (P<0.001). No significant differences were observed in the microleakage scores at the gingival and incisal margins in any of the interfaces (P>0.05).
2	5654031	Analgesic consumption	The total amount of analgesic consumption was significantly higher in Group I compared with Groups T and C (p=0.003).
2	5654031	Analgesic consumption	The total amount of analgesic consumption was significantly higher in Group I compared with Groups T and C (p=0.003).
2	5654031	Pain score after 1 hour	Pain scores at 1, 4, and 8 hours were significantly higher in Group I compared with the other 2 groups; however, pain scores in Group I at 16 hours were significantly higher only compared with Group C (p<0.05).  
2	5654031	Pain score after 1 hour	Pain scores at 1, 4, and 8 hours were significantly higher in Group I compared with the other 2 groups; however, pain scores in Group I at 16 hours were significantly higher only compared with Group C (p<0.05).  
2	5073953	Gestational age at birth	LMP-based gestational age was higher than crown-rump length by a mean (SD) of 2.8 (10.7) days; differences varied by maternal education and preterm birth (P < 0.05).
2	3617313	Geometric mean titer against diphtheria	After the vaccination, the geometric mean titer (geometric mean titer) against diphtheria was significantly higher in Group GC1107-T5.0 (6.53) and GC1107-T7.5 (6.11) than in the control group (3.96).
2	3617313	Geometric mean titer against diphtheria	After the vaccination, the geometric mean titer (geometric mean titer) against diphtheria was significantly higher in Group GC1107-T5.0 (6.53) and GC1107-T7.5 (6.11) than in the control group (3.96).
1	3617313	Adverse reaction severity	No significant differences in the number of adverse reactions, prevalence and degree of severity of the solicited and unsolicited adverse reactions were observed among the three groups.
1	3617313	Number of averse reactions	No significant differences in the number of adverse reactions, prevalence and degree of severity of the solicited and unsolicited adverse reactions were observed among the three groups.
2	5702778	Microhardness changes	The microhardness changes in all experimental groups except Group 3 (low-level carbonated water with calcium ions) were significantly greater than those in the Control group.
2	5702778	Microhardness changes	The microhardness changes in all experimental groups except Group 3 (low-level carbonated water with calcium ions) were significantly greater than those in the Control group.
2	5702778	Microhardness changes	The microhardness changes in all experimental groups except Group 3 (low-level carbonated water with calcium ions) were significantly greater than those in the Control group.
1	5702778	Microhardness changes	The microhardness changes in all experimental groups except Group 3 (low-level carbonated water with calcium ions) were significantly greater than those in the Control group.
2	2800022	Vitamin D concentration	At 6 and 12 months of age, 25OHD3 was significantly higher in group S than in group B (P<0.001).
2	2800022	Bone mineral density	Regardless of vitamin D supplementation, bone mineral density was lower in group B and S than in group A (P<0.05).
2	2800022	Bone mineral density	Regardless of vitamin D supplementation, bone mineral density was lower in group B and S than in group A (P<0.05).
2	2800022	Calcium and phosphorus intake	Total intake of vitamin D differed among 3 groups (P<0.001, A>S>B), but total intake of calcium and phosphorus were higher in group A than in group B and S (P<0.001).
2	2800022	Calcium and phosphorus intake	Total intake of vitamin D differed among 3 groups (P<0.001, A>S>B), but total intake of calcium and phosphorus were higher in group A than in group B and S (P<0.001).
0	3511949	visual analog scale (visual analog scale) scores at the end of 12th week	After the intra-articular injection, there was statistically significant decrease in visual analog scale (visual analog scale) scores in Groups M and T, when compared to Group C. The decrease of visual analog scale scores seen at the first 2 weeks continued steadily up to the end of 12th week.
0	3511949	Patients who needed NSAID supplementation	Significantly less supplementary analgesics was used in the morphine and steroid groups.  
1	5863413	Pain	However, on comparison of the reduction in pain and erythema scores between the two groups, the difference was found to be statistically insignificant (P = 0.255).  
1	5863413	Erythema	However, on comparison of the reduction in pain and erythema scores between the two groups, the difference was found to be statistically insignificant (P = 0.255).  
1	5863413	Pain	However, on comparison of the reduction in pain and erythema scores between the two groups, the difference was found to be statistically insignificant (P = 0.255).  
1	5863413	Pain	However, on comparison of the reduction in pain and erythema scores between the two groups, the difference was found to be statistically insignificant (P = 0.255).  
0	5863413	Erythema	The patients in both the study and control groups showed a statistically significant reduction (P = 0.000 for the study group and P = 0.000 for the control group) in pain and erythema scores from baseline to second follow-up visit.
1	3747414	Deqi sensation	As a result, needle penetration, VAS ratings for either needle and Deqi sensation were not significantly different between two kinds of needles.
1	3747414	visual analogue scale (VAS) ratings	As a result, needle penetration, VAS ratings for either needle and Deqi sensation were not significantly different between two kinds of needles.
1	3747414	needle penetration	As a result, needle penetration, VAS ratings for either needle and Deqi sensation were not significantly different between two kinds of needles.
2	5766333	The satisfaction scores	The satisfaction scores of the endoscopists, which were measured using a visual analogue scale, were significantly higher in the Combination group than in the propofol group (88 vs. 69, P  = 0.003).
1	3938677	Lactadherin+ CD144+	CD144 (VE-cadherin) or HMGB1 release did not significantly change during active smoking.  
1	1896161	computerized quantification of wheezing and crackles in infants	There was no significant change in objective quantification of wheezes and crackles or in the total clinical scores either within the groups or between the groups.
0	2723123	Dentin mineral loss	Statistically significant differences for mineral loss and lesion depth were found between the toothpaste and the mouth rinse as well as between the toothpaste and the control group, but not between the mouth rinse and the control group.  
0	2723123	Dentin mineral loss	Within the limitations of this study, the results suggest that treatment of demineralised dentin with a toothpaste containing 5000 ppm fluoride may considerably reduce mineral loss and lesion depth on exposed dentin.
0	2723123	Depth of the lesion	Statistically significant differences for mineral loss and lesion depth were found between the toothpaste and the mouth rinse as well as between the toothpaste and the control group, but not between the mouth rinse and the control group.  
0	2723123	Depth of the lesion	Within the limitations of this study, the results suggest that treatment of demineralised dentin with a toothpaste containing 5000 ppm fluoride may considerably reduce mineral loss and lesion depth on exposed dentin.
0	5524909	Calbindin-28k	Cerebral ischaemia was associated with reduced numbers of calbindin-28k, calretinin, parvalbumin and GAD positive striatal neurons (P < 0.05 ischaemia + vehicle, n = 6 vs. sham ischaemia, n = 6) but not ChAT or nNOS positive neurons.
2	5524909	Calretinin	Long infusion of peptide (n = 6) was associated with increased survival of calbindin-28k, calretinin, parvalbumin and GAD positive neurons (P < 0.05 vs. ischaemia + vehicle).
0	5524909	Calretinin	Cerebral ischaemia was associated with reduced numbers of calbindin-28k, calretinin, parvalbumin and GAD positive striatal neurons (P < 0.05 ischaemia + vehicle, n = 6 vs. sham ischaemia, n = 6) but not ChAT or nNOS positive neurons.
2	5524909	Calbindin-28k	Long infusion of peptide (n = 6) was associated with increased survival of calbindin-28k, calretinin, parvalbumin and GAD positive neurons (P < 0.05 vs. ischaemia + vehicle).
2	3179931	returned fecal occult blood test (fecal occult blood test) cards	At 6 months after card distribution, 64.6% patients in the intervention group returned fecal occult blood test cards compared with 48.4% in the control group (P < 0.001).
1	4121500	heart rate	Between two groups, Bispectral index values showed a significant differences only at T10, Bispectral index of group H was lower than that of group L. Ramsay score showed no significant differences except in TL; the score of group L was significantly lower than that of group H. Other vital signs and complications showed a minimal differences between two groups.  
2	4121500	Bispectral index (Bispectral index) after 10 minutes interval	Between two groups, Bispectral index values showed a significant differences only at T10, Bispectral index of group H was lower than that of group L. Ramsay score showed no significant differences except in TL; the score of group L was significantly lower than that of group H. Other vital signs and complications showed a minimal differences between two groups.  
2	3759706	Cold contact urticaria (Cold contact urticaria) change in critical temperature thresholds (critical temperature thresholds)	Bilastine 20 mg was highly effective (P < 0.0001) in reducing critical temperature thresholds.
2	3759706	Cold contact urticaria (Cold contact urticaria) change in critical temperature thresholds (critical temperature thresholds)	Bilastine 20 mg was highly effective (P < 0.0001) in reducing critical temperature thresholds. Up-dosing to 80 mg significantly (P < 0.04) increased its effectiveness.
0	3759706	histamine assessed 1–3 h after cold challenge	Microdialysis levels of histamine, IL-6 and IL-8 assessed 1–3 h after cold challenge were significantly (P < 0.05) decreased following up-dosing with 80 mg bilastine.
0	3759706	IL-8 assessed 1–3 h after cold challenge	Microdialysis levels of histamine, IL-6 and IL-8 assessed 1–3 h after cold challenge were significantly (P < 0.05) decreased following up-dosing with 80 mg bilastine.
0	3759706	IL-6 assessed 1–3 h after cold challenge	Microdialysis levels of histamine, IL-6 and IL-8 assessed 1–3 h after cold challenge were significantly (P < 0.05) decreased following up-dosing with 80 mg bilastine.
1	3192699	Attending the antenatal clinic with their partner	For the primary outcome, the percentage of trial participants who attended the antenatal clinic with their partners were 16.2% (86/530) and 14.2% (75/530) in the intervention and non-intervention groups, respectively (OR = 1.2; 95% CI: 0.8, 1.6).
1	3192699	Getting tested for HIV	For the secondary outcome, most of the 161 male partners attended the antenatal clinic; 82 of 86 (95%) in the intervention group and 68 of 75 (91%) in the non-intervention group were tested for HIV (OR = 2.1; 95% CI: 0.6 to 7.5).  
1	2409966	increased HIV risk behavior	In the context of a RCT, circumcision did not result in increased HIV risk behavior.
2	3046916	Overall total per patient costs (including intervention costs)	Overall total per patient costs (including intervention costs) were significantly higher in the cognitive behaviour therapy group compared with the treatment as usual group at 10 month follow up (difference £427, 95% CI: £56 - £787, p < 0.001).
2	3046916	Reductions in The Beck Depression Inventory II (Beck Depression Inventory II) scores	Reductions in Beck Depression Inventory II scores were significantly greater in the cognitive behaviour therapy group (difference 3.6 points, 95% CI: 0.7-6.5 points, p = 0.018).
0	3314673	Global Severity Index of the SCL 90-r	There was a significant decrease of 2.8 points on the Symptom Checklist 90- Revised Global Severity Index (p<0.05).  
0	5122238	incidence and intensity of shivering	The investigation of the incidence of inter- and post-operative shivering in patients in the three groups revealed that within the study period, 31 patients suffered from shivering among which 9, 5, and 17 cases were in 1 mg/kg hydrocortisone group, 2 mg/kg hydrocortisone group, and placebo group, respectively, and according to the Chi-square test, the difference among the three groups was significant (P = 0.004).  
2	4839625	thermal care	Significant post-intervention differences were: delivery place [adjusted Odds Ratio aOR: 17.94(95%CI: 6.26–51.37); p<0.001], cord care [aOR: 3.05(95%CI: 1.81–5.12); p<0.001] thermal care [aOR: 7.58(95%CI: 2.52–22.82); p<0.001], and timely care-seeking for newborn illness [aOR: 4.93(95%CI: 1.59–15.31); p = 0.006].  
0	3224529	fragmentation index	Proportions of rapid eye movement sleep duration were different in the two ventilatory modes (4.5% (range, 3-11%) in pressure support ventilation and 16.5% (range, 13-29%) during neurally adjusted ventilatory assist (p = 0.001)), as well as the fragmentation index, with 40 ± 20 arousals and awakenings per hour in pressure support ventilation and 16 ± 9 during neurally adjusted ventilatory assist (p = 0.001).
0	3224529	episodes of central apnea and ineffective efforts	There were large differences in ineffective efforts (24 ± 23 per hour of sleep in pressure support ventilation, and 0 during neurally adjusted ventilatory assist) and episodes of central apnea (10.5 ± 11 in pressure support ventilation vs. 0 during neurally adjusted ventilatory assist).
2	3224529	Proportions of rapid eye movement sleep duration	Proportions of rapid eye movement sleep duration were different in the two ventilatory modes (4.5% (range, 3-11%) in pressure support ventilation and 16.5% (range, 13-29%) during neurally adjusted ventilatory assist (p = 0.001)), as well as the fragmentation index, with 40 ± 20 arousals and awakenings per hour in pressure support ventilation and 16 ± 9 during neurally adjusted ventilatory assist (p = 0.001).
0	5434591	Migration by radiostereometric analysis maximal total point motion after 2 years	The primary effect variable, maximal total point motion after 12 months, showed that migration in the denosumab group was statistically significantly less than in the controls. Denosumab maximal total point motion 12 months was reduced by one-third (denosumab: median 0.24 mm, 10% and 90% percentiles: 0.15 and 0.41; placebo: median 0.36 mm, 10% and 90% percentiles: 0.20 and 0.62). The secondary maximal total point motion variables (6 and 24 months) also showed a statistically significant reduction in migration. There was no significant difference in maximal total point motion for the period 12–24 months.
0	5434591	Migration by radiostereometric analysis maximal total point motion after 1 year	The primary effect variable, maximal total point motion after 12 months, showed that migration in the denosumab group was statistically significantly less than in the controls.
1	5434591	Migration by secondary maximal total point motion variables after 2 years	There was no significant difference in maximal total point motion for the period 12–24 months.
1	5434591	Knee osteoarthritis outcome score after 1 year	knee osteoarthritis outcome score sub-variables were similiar between denosumab and placebo after 12 and 24 months.  
1	5434591	Knee osteoarthritis outcome score after 2 years	knee osteoarthritis outcome score sub-variables were similiar between denosumab and placebo after 12 and 24 months.  
1	5296807	Brain relaxation scores	The brain relaxation scores were comparable among the two groups (P = 0.27).
1	5296807	Arterial pressure	The mean arterial pressure was comparable between the groups.
1	5296807	Heart rate during surgery	The intraoperative heart rate was comparable; however, in the post-operative period, it remained higher in Group B for 30 min after extubation (P = 0.02).
0	5296807	Heart rate 30 minutes after extubation	The intraoperative heart rate was comparable; however, in the post-operative period, it remained higher in Group B for 30 min after extubation (P = 0.02).
2	4937273	Low‐density lipoprotein cholesterol reduction	Maximal mean Low‐density lipoprotein cholesterol reductions from day −1 baseline (prealirocumab) occurred on day 71 in all groups: alirocumab plus placebo, 47.4%; alirocumab plus ezetimibe, 56.6%; and alirocumab plus fenofibrate, 54.3%.
0	4235563	depression in Myocardial infarction (Myocardial Infarction) patients - at discharge	There was no significant difference between the control and experimental groups before the intervention, but after the intervention, anxiety and depression in the experimental group was significantly less than that in the control group (p<0.05).    
1	4235563	before intervention in Myocardial infarction (Myocardial Infarction) patients	There was no significant difference between the control and experimental groups before the intervention, but after the intervention, anxiety and depression in the experimental group was significantly less than that in the control group (p<0.05).    
0	4235563	anxiety in Myocardial infarction (Myocardial Infarction) patients - 3 months after discharge	There was no significant difference between the control and experimental groups before the intervention, but after the intervention, anxiety and depression in the experimental group was significantly less than that in the control group (p<0.05).    
0	4235563	depression in Myocardial infarction (Myocardial Infarction) patients - 3 months after discharge	There was no significant difference between the control and experimental groups before the intervention, but after the intervention, anxiety and depression in the experimental group was significantly less than that in the control group (p<0.05).    
0	4235563	anxiety in Myocardial infarction (Myocardial Infarction) patients - at discharge	There was no significant difference between the control and experimental groups before the intervention, but after the intervention, anxiety and depression in the experimental group was significantly less than that in the control group (p<0.05).    
0	3604641	high-molecular-weight (high-molecular-weight) adiponectin	There was also a smaller increase in high-molecular-weight (high-molecular-weight) adiponectin with MSDC-0160 than with pioglitazone (P < 0.0001), suggesting that MSDC-0160 produces less expansion of white adipose tissue.
1	3604641	The decreases in glycated hemoglobin (HbA1c)	The decreases in glycated hemoglobin (HbA1c) observed with the two higher doses of MSDC-0160 were not different from those associated with pioglitazone.
0	3604641	hematocrit, red blood cells, and total hemoglobin	By contrast, fluid retention as evidenced by reduction in hematocrit, red blood cells, and total hemoglobin was 50% less in the MSDC-0160–treated groups.
2	4482193	mean serum albumin	Statistically significant improvement was reported in the transplanted patients (G-1) as regards the mean serum albumin, bilirubin and INR levels which started to improve after 2 weeks of treatment and continued to improve till the 6th month in the single infusion group.
1	5629940	ACR20 results	ACR20 response at week 24 was 74.6% (ABP 501) and 72.4% (adalimumab). At week 24, the risk ratio of ACR20 (90% CI) between groups was 1.039 (0.954, 1.133), confirming the primary hypothesis.
1	5629940	Adverse events	There were no clinically meaningful differences in adverse events and laboratory abnormalities.
1	5629940	Disease Activity Score 28-joint count-C reactive protein	Changes from baseline in Disease Activity Score 28-joint count-C reactive protein, ACR50 and ACR70 were similar.
1	5629940	ACR50 results	Changes from baseline in Disease Activity Score 28-joint count-C reactive protein, ACR50 and ACR70 were similar.
1	5629940	Laboratory tests	There were no clinically meaningful differences in adverse events and laboratory abnormalities.
1	5629940	ACR70 results	Changes from baseline in Disease Activity Score 28-joint count-C reactive protein, ACR50 and ACR70 were similar.
1	2503659	Cure rate	In two identical phase III trials comparing telavancin versus vancomycin at the doses of the FAST 2 study for complicated skin and skin structure infections, the clinical cure rates were 88.3% and 87.1%, respectively.
1	4958948	FGF-19 levels	Serum levels of BA species and total GLP-1 decreased, while FGF-19 remained stable.
1	5021748	heparin dosages required to produce an activated clotting time 15 min after the initial bolus that was identical to the control (110U/kg)	The initial bolus heparin dosages required to produce an activated clotting time 15 min after the initial bolus that was identical to the control (333 ± 32 s) were 120 U/kg (318 ± 29 s) and 130 U/kg (339 ± 43 s) for dabigatran, 130 U/kg (314 ± 31 s) for rivaroxaban and 130 U/kg (317 ± 39 s) for apixaban.
1	5021748	heparin dosages required to produce an activated clotting time 15 min after the initial bolus that was identical to the control (110U/kg)	The NOAC groups required significantly larger doses of total heparin than the warfarin group.  
1	5021748	heparin dosages required to produce an activated clotting time 15 min after the initial bolus that was identical to the control (110U/kg)	The results of the comparison with warfarin (the control) indicated that dosages of 120 or 130 U/kg for dabigatran, and 130 U/kg for rivaroxaban and apixaban, were adequate initial heparin dosages.
1	2253708	7-day point prevalence abstinence	Using complete case analysis, the tailored letters intervention was significantly more effective than brief advice for 24-hour [odds ratio (odds ratio) = 1.4; P = 0.047] but not for 7-day point prevalence abstinence (odds ratio = 1.4; P = 0.068) for prolonged abstinence, or for alternative assumptions about participants lost to follow-up.  
2	2253708	24-hour point prevalence abstinence	Using complete case analysis, the tailored letters intervention was significantly more effective than brief advice for 24-hour [odds ratio (odds ratio) = 1.4; P = 0.047] but not for 7-day point prevalence abstinence (odds ratio = 1.4; P = 0.068) for prolonged abstinence, or for alternative assumptions about participants lost to follow-up.  
2	5133075	Insulin incremental area under the curve	The area under the curve (p < 0.001) and incremental area under the curve (p = 0.001) for insulin was significantly higher after the red meat/refined grain diet than after the dairy/chicken/nuts/whole grain diet.
1	5471294	Ongoing pregnancy (Ongoing pregnancy) rate	Similarly, the Ongoing pregnancy rate was 37% in the treatment group and 31% in the control group [odds ratio 1.3 (95% CI 0.8–2.0), P < 0.23].
1	5471294	live birth (live birth) rate	The live birth rate was 36% in the treatment group and 31% in the control group [odds ratio: 1.3 (95% CI 0.8–2.0), P < 0.27].  
2	5471294	follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone (P)	Although serum concentrations of FSH, LH, E2, and P on day oocyte pick-up + 7 were significantly higher in the study group compared to the control group, the implantation rate was not statistically different between the treatment group (27%) and the control group (23%) [odds ratio (odds ratio) 1.2 (95% CI 0.9–1.7), P < 0.27].
1	5471294	implantation rate (implantation rate)	Although serum concentrations of FSH, LH, E2, and P on day oocyte pick-up + 7 were significantly higher in the study group compared to the control group, the implantation rate was not statistically different between the treatment group (27%) and the control group (23%) [odds ratio (odds ratio) 1.2 (95% CI 0.9–1.7), P < 0.27].
0	2396624	internalized social stigma score after 2 months - in new AFB positive tuberculosis (tuberculosis) patients	After 15 days, internalized stigma scores were equivalent in both groups. After 2 months, difference between scores was statistically significant, revealing a decreased internalized stigma in the intervention group and not in the control group.  
1	2396624	internalized social stigma score on day 15 - in new AFB positive tuberculosis (tuberculosis) patients	After 15 days, internalized stigma scores were equivalent in both groups.
1	2447617	The mean intracranial pressure values 72 hours and 7 days after injury	The mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).
2	2447617	The modified Functional Independence Measure scores	The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01).
1	2447617	Instances of complications and adverse events	Instances of complications and adverse events associated with the administration of progesterone were not found.  
0	2447617	The mortality rate	The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05).
1	4112748	the time to maximum concentration	Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P<0.0001).
2	4112748	The proportion of patients who were pain-free at 4 hours without rescue medication	The proportion of patients who were pain-free at 4 hours without rescue medication was higher in the frovatriptan-treated group, (38.9 versus 5.6%, P=0.045).
0	4112748	adverse events	Fewer adverse events were observed for frovatriptan compared to rizatriptan (one versus eight, P=0.021).  
0	5729670	Mean blood glucose	The mean blood glucose in the experimental and the control group was 170.32 ± 33.46 mg/dl and 221.05 ± 49.72, respectively (P = 0.0001).
0	5729670	Mean amplitude of glycemic excursion	The parameters for glycemic variability were all significantly lower in patients in the experimental group.
2	3420321	isometric knee extension test hold-time	isometric knee extension test hold-time increased by 9.7 ± 9.4 s (13.2%) and impulse by 3.7 ± 1.3 kN·s-1 (13.9%) following β-alanine supplementation. These changes were significantly greater than those in the placebo group (isometric knee extension test: t(11) = 2.9, p ≤0.05; impulse: t(11) = 3.1, p ≤ 0.05).
1	3420321	maximal voluntary isometric contraction (maximal voluntary isometric contraction)	There were no significant changes in maximal voluntary isometric contraction force in either group.  
0	5306110	Risk of death by cardiovascular causes	The risk of cardiovascular death was reduced by 38% relative to the placebo group (HR 0.62; 95% CI: 0.49–0.77; P < 0.001) and the risk of death from any cause by 32% (HR 0.68; 95% CI: 0.57–0.82; P < 0.001).
0	5306110	Risk of hospitalization due to heart failure or renal adverse events.	Furthermore, empagliflozin was associated with reduced risk of hospitalization for heart failure and of renal adverse events.
0	5306110	Risk of major adverse cardiovascular events	The risk of major adverse cardiovascular events (MACE: first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) was reduced by 14% relative to placebo (HR 0.86; 95.02% CI: 0.74–0.99; P = 0.04 for superiority).
0	5306110	Risk of death by any cause	The risk of cardiovascular death was reduced by 38% relative to the placebo group (HR 0.62; 95% CI: 0.49–0.77; P < 0.001) and the risk of death from any cause by 32% (HR 0.68; 95% CI: 0.57–0.82; P < 0.001).
2	4222660	Decrease in average Sugar Sweetened Beverages Consumption	Significant positive intervention effects were found for average Since sugar-sweetened beverages consumption (B -0.19 litres, 95% CI -0.28;-0.10; parent report), average Since sugar-sweetened beverages servings (B -0.54 servings, 95% CI -0.82;-0.26; parent report) and bringing Since sugar-sweetened beverages to school (OR 0.51, 95% CI 0.36;0.72; observation report).  
2	4222660	Decrease in average Sugar Sweetened Beverages Consumption	This study supports the effectiveness of the water campaign intervention in reducing children's Since sugar-sweetened beverages consumption.
2	5986443	Skeletal muscle mass	A time vs. group interaction (p < 0.05) was observed with whey protein pre-RT and placebo post-RT and placebo pre-RT and whey protein post-RT presenting greater increases compared with PLA-PLA for skeletal muscle mass (whey protein pre-RT and placebo post-RT = 3.4%; placebo pre-RT and whey protein post-RT = 4.2%; PLA-PLA = 2.0%), strength (whey protein pre-RT and placebo post-RT = 8.1%; placebo pre-RT and whey protein post-RT = 8.3%; PLA-PLA = 7.0%), and the 10-m walk test (whey protein pre-RT and placebo post-RT = −10.8%; placebo pre-RT and whey protein post-RT = −11.8%; PLA-PLA = −4.3%).
1	5124283	Macrophage migration inhibitory factor	However, the plasma CXCL4L1, CXCL1, macrophage migration inhibitory factor (migration inhibitory factor) and human plasminogen activator inhibitor 1 (plasminogen activator inhibitor 1) levels did not significantly change following anthocyanin supplementation.  
0	5124283	CXCL7	Anthocyanin supplementation for 24 weeks significantly decreased the plasma CXCL7 (–12.32% vs. 4.22%, P = 0.001), CXCL5 (–9.95% vs. 1.93%, P = 0.011), CXCL8 (–6.07% vs. 0.66%, P = 0.004), CXCL12 (–8.11% vs. 5.43%, P = 0.023) and CCL2 levels (–11.63% vs. 12.84%, P = 0.001) compared with the placebo.
0	5124283	CXCL12	Anthocyanin supplementation for 24 weeks significantly decreased the plasma CXCL7 (–12.32% vs. 4.22%, P = 0.001), CXCL5 (–9.95% vs. 1.93%, P = 0.011), CXCL8 (–6.07% vs. 0.66%, P = 0.004), CXCL12 (–8.11% vs. 5.43%, P = 0.023) and CCL2 levels (–11.63% vs. 12.84%, P = 0.001) compared with the placebo.
1	5124283	Plasminogen activator inhibitor 1	However, the plasma CXCL4L1, CXCL1, macrophage migration inhibitory factor (migration inhibitory factor) and human plasminogen activator inhibitor 1 (plasminogen activator inhibitor 1) levels did not significantly change following anthocyanin supplementation.  
2	5433398	Median Multiple Sclerosis Impact Scale (MSIS) 29 score	Median MSIS 29 score decreased over six months in the control group (−4.89) and increased in the integrated multidisciplinary group (+2.00), with a significant difference between the two groups (p = 0.03).
2	5433398	Median Multiple Sclerosis Impact Scale (MSIS) 29 score	Median MSIS 29 score decreased over six months in the control group (−4.89) and increased in the integrated multidisciplinary group (+2.00), with a significant difference between the two groups (p = 0.03).
1	4319305	amount of debris	The WaveOne group presented a larger amount of debris than the Reciproc Group, however, without statistically significant difference (P > 0.05).
0	4748685	Systolic blood pressure	The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.
0	4748685	LDL values	The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.
2	4748685	Self-reported consumption of fruits and vegetables	Furthermore, we detected a statistically significant increase in self-reported fruit and vegetable consumption (pseudo-median of the differences = 5.4 servings/week; p = 0.04; 95 % CI = [0.5, 10.5]) and a decrease in sweets consumption (pseudo-median of the differences = –2 servings/week; p = 0.04; 95 % CI = [–4, –0.00001]) in the intervention group.
0	4748685	Self-reported consumption of sweets	Furthermore, we detected a statistically significant increase in self-reported fruit and vegetable consumption (pseudo-median of the differences = 5.4 servings/week; p = 0.04; 95 % CI = [0.5, 10.5]) and a decrease in sweets consumption (pseudo-median of the differences = –2 servings/week; p = 0.04; 95 % CI = [–4, –0.00001]) in the intervention group.
0	4748685	Triglyceride levels	The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.
1	2911596	Decrease in Surgical Stress Index after fentanyl boluses	During surgery, the decrease of Surgical Stress Index after fentanyl boluses was similar in sevoflurane and isoflurane groups but Surgical Stress Index values were higher in sevoflurane than in isoflurane group.
2	4749757	Improvement in the 12-item MS Walking Scale (MSWS-12) Score during 24 weeks	PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, Timed Up and Go speed and Berg Balance Scale total score versus placebo over 24 weeks.
2	4749757	Improvement in the 12-item MS Walking Scale (MSWS-12) Score during 24 weeks	A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds ⩾7 (p = 0.0275), ⩾8 (p = 0.0153) and ⩾9 points (p = 0.0088) and Timed Up and Go speed thresholds ⩾10% (p = 0.0021) and ⩾15% (p = 0.0262).
2	4749757	Improvement in Timed Up and Go (Timed Up and Go) speed during 24 weeks	PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, Timed Up and Go speed and Berg Balance Scale total score versus placebo over 24 weeks.
2	4749757	Improvement in Berg Balance Scale (Berg Balance Scale) Score during 24 weeks	PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, Timed Up and Go speed and Berg Balance Scale total score versus placebo over 24 weeks.
0	5593818	risk of converting from pre-diabetes to diabetes	The risk of converting from pre-diabetes to diabetes was 0.58-fold less in the JQJT tablets group than in the placebo group [HR (95% CI): 0.58 (0.384, 0.876), P = 0.010].
2	5593818	probability of achieving normalized blood glucose	Furthermore, the probability of achieving normalized blood glucose was 1.41-fold greater in the JQJT tablets group than in the placebo group [HR (95% CI): 1.41 (1.002, 1.996), P = 0.0049].
1	5721317	With survival for any reason	Implant survival rates at 10 years, with survival for any reason as the endpoint of interest, were 93.7% (95% confidence interval, 86.4% and 97.1%) and 89.8% (95% confidence interval, 81.9% - 94.4%) for the gap balancing group and the measured resection group, respectively (p = 0.302).  
2	5721317	Knee Society Knee Score (Knee Score) 10 years postoperatively using the two one-sided test (two one-sided test)	Mean Knee Score was 82 (95% confidence interval (confidence interval), 80 – 83) and 77 (95% confidence interval, 76 – 79) in the gap balancing and measured resection group, respectively. The two one-sided test test and linear mixed model both revealed statistical significance (p < 0.001).
2	5054611	oropharyngeal seal pressure in right position	The oropharyngeal seal pressure achieved with the Laryngeal Tube Suction Disposable was higher than the Supreme Laryngeal Mask Airway in, (extension (p=0.0150) and right position (p=0.0268 at 60 cm H2O intracuff pressures and nearly significant in neutral position (p = 0.0571).
2	5054611	oropharyngeal seal pressure in extension	The oropharyngeal seal pressure achieved with the Laryngeal Tube Suction Disposable was higher than the Supreme Laryngeal Mask Airway in, (extension (p=0.0150) and right position (p=0.0268 at 60 cm H2O intracuff pressures and nearly significant in neutral position (p = 0.0571).
2	5054611	The oropharyngeal seal pressure during neck extension	The oropharyngeal seal pressure was significantly higher with the Laryngeal Tube Suction Disposable during neck extension as compared to Supreme Laryngeal Mask Airway (p= 0.015).
2	5054611	The oropharyngeal seal pressure during neck extension	The oropharyngeal seal pressure achieved with the Laryngeal Tube Suction Disposable was higher than the Supreme Laryngeal Mask Airway in, (extension (p=0.0150) and right position (p=0.0268 at 60 cm H2O intracuff pressures and nearly significant in neutral position (p = 0.0571).
2	5444773	Surfactant protein B expression	In the presence of Intra-abdominal hypertension, pressure support ventilation improved oxygenation; decreased alveolar collapse, interstitial edema, and diffuse alveolar damage; and increased expression of surfactant protein B as compared to pressure-controlled ventilation.
0	5444773	Mean airway pressure	Regardless of whether Intra-abdominal hypertension was present, pressure support ventilation resulted in lower mean airway pressure (with no differences in peak airway or peak and mean transpulmonary pressures) and less mRNA expression of biomarkers associated with lung inflammation (IL-6) and fibrogenesis (type III procollagen) than pressure-controlled ventilation.
0	5444773	mRNA expression of IL-6 and type III procollagen	Regardless of whether Intra-abdominal hypertension was present, pressure support ventilation resulted in lower mean airway pressure (with no differences in peak airway or peak and mean transpulmonary pressures) and less mRNA expression of biomarkers associated with lung inflammation (IL-6) and fibrogenesis (type III procollagen) than pressure-controlled ventilation.
0	5444773	Alveolar collapse, interstitial edema, or DAD score in animals with Intra-abdominal hypertension	In the presence of Intra-abdominal hypertension, pressure support ventilation improved oxygenation; decreased alveolar collapse, interstitial edema, and diffuse alveolar damage; and increased expression of surfactant protein B as compared to pressure-controlled ventilation.
2	5467351	fasting insulin and homeostasis model assessment estimate of insulin resistance (homeostasis model assessment estimate of insulin resistance)	As regards the metabolic parameters, in both groups, we found a significant increase in fasting insulin (p < 0.001 and p = 0.026) and homeostasis model assessment estimate of insulin resistance (p < 0.001 and p = 0.019).
0	5467351	insulin sensitivity index (insulin sensitivity index) and oral disposition index (disposition index)	A significant increase in fasting glucose (p = 0.001) and a decrease in insulin sensitivity index (p < 0.001) and disposition index (p = 0.002) were only found in group A.   ABSTRACT.CONCLUSIONS.  
2	5467351	fasting glucose	A significant increase in fasting glucose (p = 0.001) and a decrease in insulin sensitivity index (p < 0.001) and disposition index (p = 0.002) were only found in group A.   ABSTRACT.CONCLUSIONS.  
1	5937795	oocysts shedding	Calves in confinement had no significant differences in mean log oocysts enumerated per gram of fecal dry matter between Complete Fecal Collection and Interval Collection samples (P = 0.6), nor were there diurnal variations in oocyst shedding (P = 0.1).
2	5937795	supportive care	Confinement housed calves shed significantly more oocysts (P = 0.05), had higher plasma cortisol (P = 0.001), and required more supportive care (P = 0.0009) than calves in box stalls.  
2	5937795	plasma cortisol	Confinement housed calves shed significantly more oocysts (P = 0.05), had higher plasma cortisol (P = 0.001), and required more supportive care (P = 0.0009) than calves in box stalls.  
1	4185107	overall rate of early postoperative complications	There were no statistically significant differences in the overall rate of early postoperative complications between the study and control group: 25.6 and 34.1 % respectively; p = 0.245, relative risk (relative risk) 0.750 [95 % confidence interval (confidence interval) 0.471–1.195].
1	4185107	The reoperation rate	The reoperation rate was similar in both groups: 12.8 versus 9.4 %; p = 0.628; relative risk 1.359; (95 % confidence interval 0.575–3.212).
1	4185107	The total rate of surgical site infections and organ space surgical site infections (surgical site infections)	The total rate of surgical site infections and organ space surgical site infections were 22.2 and 15.8 % without differences between the study and control group.
2	5103135	IVEF	After treatment, peak E, E/A and IVEF were increased by 41%, 44% and 16% respectively, but peak A, LVPWT/mm and IVST/mm were significantly reduced.
0	5103135	Limitation of motion	The differences in the respiratory symptoms, limitation of motion, disease impacts and SGRQ total scores were statistically significant compared with those before treatment (P<0.05) and those of the control group (P<0.05).  
0	5103135	Disease impacts	The differences in the respiratory symptoms, limitation of motion, disease impacts and SGRQ total scores were statistically significant compared with those before treatment (P<0.05) and those of the control group (P<0.05).  
2	5103135	peak E	After treatment, peak E, E/A and IVEF were increased by 41%, 44% and 16% respectively, but peak A, LVPWT/mm and IVST/mm were significantly reduced.
2	5103135	E/A	The oxygen partial pressure (PaO2) and partial pressure of carbon dioxide (PaCO2) of the treatment group after treatment were significantly different from those before treatment. After treatment, peak E, E/A and IVEF were increased by 41%, 44% and 16% respectively, but peak A, LVPWT/mm and IVST/mm were significantly reduced.
0	5103135	Respiratory symptoms	The differences in the respiratory symptoms, limitation of motion, disease impacts and SGRQ total scores were statistically significant compared with those before treatment (P<0.05) and those of the control group (P<0.05).  
2	4968829	VO2max in older and younger subjects	Rowing VO2max was higher than cycling VO2max in both groups (p<0.05).
2	4304200	fiber intake at 12r months	The intervention resulted in significant improvements in fiber intake (M between-group difference = 5.7 g/day, p < .001) but not fat consumption (−2.3 g/day, p = 0.13), that were predictive of weight loss at both four months (M between-group difference = −1.98 kg, p < .01; R2 = 0.2, p < 0.005), and 12 months (M difference = −1.85 kg, p = 0.1; R2 = 0.1, p < 0.01).
2	4304200	fiber intake at four months	The intervention resulted in significant improvements in fiber intake (M between-group difference = 5.7 g/day, p < .001) but not fat consumption (−2.3 g/day, p = 0.13), that were predictive of weight loss at both four months (M between-group difference = −1.98 kg, p < .01; R2 = 0.2, p < 0.005), and 12 months (M difference = −1.85 kg, p = 0.1; R2 = 0.1, p < 0.01).
1	4304200	fat consumption at four months	The intervention resulted in significant improvements in fiber intake (M between-group difference = 5.7 g/day, p < .001) but not fat consumption (−2.3 g/day, p = 0.13), that were predictive of weight loss at both four months (M between-group difference = −1.98 kg, p < .01; R2 = 0.2, p < 0.005), and 12 months (M difference = −1.85 kg, p = 0.1; R2 = 0.1, p < 0.01).
0	5332296	insulin levels among women in the middle Indigenous American ancestry tertile	Compared to the U.S. diet, the traditional Mexican diet tended to reduce glucose, insulin, IGF-1, IGFBP-3, and HOMAIR among women in the middle Indigenous American ancestry group (Indigenous American ancestry ≤45–62%); while having no effect on biomarkers related to inflammation.  
0	3364603	Serum nonesterified fatty acid	In forty-nine (27, group A; 22, group B) patients completing all tests, the mean value of the natural logarithmic-scaled reactive hyperemia index (L_RHI) increased and those of serum nonesterified fatty acid (nonesterified fatty acid), malondialdehyde, and soluble vascular cell adhesion molecule 1 decreased significantly during the KBG-treatment period, but not during the control period, and 4-week changes of L_RHI, nonesterified fatty acid, and malondialdehyde between the 2 periods showed significance.
0	3364603	Malondialdehyde	In forty-nine (27, group A; 22, group B) patients completing all tests, the mean value of the natural logarithmic-scaled reactive hyperemia index (L_RHI) increased and those of serum nonesterified fatty acid (nonesterified fatty acid), malondialdehyde, and soluble vascular cell adhesion molecule 1 decreased significantly during the KBG-treatment period, but not during the control period, and 4-week changes of L_RHI, nonesterified fatty acid, and malondialdehyde between the 2 periods showed significance.
2	3364603	Logarithmic-scaled reactive hyperemia index	In forty-nine (27, group A; 22, group B) patients completing all tests, the mean value of the natural logarithmic-scaled reactive hyperemia index (L_RHI) increased and those of serum nonesterified fatty acid (nonesterified fatty acid), malondialdehyde, and soluble vascular cell adhesion molecule 1 decreased significantly during the KBG-treatment period, but not during the control period, and 4-week changes of L_RHI, nonesterified fatty acid, and malondialdehyde between the 2 periods showed significance.
0	5341660	Intraoperative rescue sedation by propofol and postoperative rescue analgesia by acetaminophen	Intraoperative rescue sedation by propofol and postoperative rescue analgesia by acetaminophen showed a highly significant decrease (P < 0.01) in group D compared with group M. Furthermore, the time of postanesthesia care unit stay was significantly less (P < 0.01) in group D (49.03 ± 12.8 min) compared to group M (62.5 ± 18.34 min).
0	5341660	the time of the postanesthesia care unit (postanesthesia care unit) stay	Intraoperative rescue sedation by propofol and postoperative rescue analgesia by acetaminophen showed a highly significant decrease (P < 0.01) in group D compared with group M. Furthermore, the time of postanesthesia care unit stay was significantly less (P < 0.01) in group D (49.03 ± 12.8 min) compared to group M (62.5 ± 18.34 min).
2	5341660	bradycardia	Although significant bradycardia was noted in group D (23% of patients) during the procedure (P = 0.02), no cases were reported in group M. Patient satisfaction was significantly higher in group D (P < 0.1).  
1	3132856	Pain duration on IBS-Undifferentiated	Treatment of irritable bowel syndrome patients with mesalazine significantly reduced intensity and duration of pain in all subtypes of irritable bowel syndrome, except for duration of pain in the subtype "undifferentiated", where the difference was not significant.
0	3132856	Pain duration on IBS-Diarrhea	Treatment of irritable bowel syndrome patients with mesalazine significantly reduced intensity and duration of pain in all subtypes of irritable bowel syndrome, except for duration of pain in the subtype "undifferentiated", where the difference was not significant.
0	3333807	Plasma renin activity	Plasma renin activity, angiotensin I, and angiotensin II decreased from baseline to month 20 (plasma renin activity (ng/mL/h): 2.3 ± 2.6 to 0.3 ± 0.4 (P < 0.05), angiotensin I (pg/mL): 909.1 ± 902.5 to 41.5 ± 14.8 (P < 0.05), angiotensin II (pg/mL): 41.5 ± 45.8 to 11.0 ± 4.9 (P < 0.05)).  
0	3333807	Angiotensin I	Plasma renin activity, angiotensin I, and angiotensin II decreased from baseline to month 20 (plasma renin activity (ng/mL/h): 2.3 ± 2.6 to 0.3 ± 0.4 (P < 0.05), angiotensin I (pg/mL): 909.1 ± 902.5 to 41.5 ± 14.8 (P < 0.05), angiotensin II (pg/mL): 41.5 ± 45.8 to 11.0 ± 4.9 (P < 0.05)).  
0	3333807	Angiotensin II	Plasma renin activity, angiotensin I, and angiotensin II decreased from baseline to month 20 (plasma renin activity (ng/mL/h): 2.3 ± 2.6 to 0.3 ± 0.4 (P < 0.05), angiotensin I (pg/mL): 909.1 ± 902.5 to 41.5 ± 14.8 (P < 0.05), angiotensin II (pg/mL): 41.5 ± 45.8 to 11.0 ± 4.9 (P < 0.05)).  
2	4831612	cleaning efficacy in the coronal third	Considering cleanliness, at coronal third Reciproc was better than K-file (P < 0.001), but not more effective than Mtwo (P = 0.080).
1	4831612	shaping ability	Regarding shaping ability, no differences were found between Reciproc and Mtwo (P = 1.00).
2	4831612	shaping ability	Meanwhile, both displayed better shaping efficacy than K-file (P < 0.05).
0	4831612	preparation time	Between each two groups, there were differences in preparation time (P < 0.05), with Reciproc being the fastest.
1	4831612	cleanliness	Considering cleanliness, at coronal third Reciproc was better than K-file (P < 0.001), but not more effective than Mtwo (P = 0.080).
2	4831612	cleaning efficacy in the middle third	In the middle third, only Reciproc exhibited better cleaning efficacy than K-file (P = 0.005).
1	4884360	carbon monoxide-confirmed continuous abstinence rates (continuous abstinence rates)	The continuous abstinence ratess for weeks 5–52 were 10.0 %, 12.4 %, and 15.3 % in the NRT, nicotine replacement therapy, and varenicline groups, respectively; no group differences were observed.
1	4884360	Adverse events	The frequency of serious adverse events did not differ between groups.  
1	4884360	The frequency of serious adverse events	The frequency of serious adverse events did not differ between groups.  
1	5595267	Schirmer test score	But, the differences for the Schirmer test score and tear break up time score was not significant (p = 0.115, p = 0.013, respectively).  
1	5595267	Conjunctival score	In comparing two groups before the intervention, the ocular surface disease index scores, the tear break up time scores, the conjunctival and corneal staining scores and the Schirmer scores did not show statistically significant differences (p = 0.339, p = 0.640, p = 0.334, p = 0.807 and p = 0.676, respectively). After 4 weeks, the ocular surface disease index scores, conjunctival and corneal staining scores showed improvement in compare to those before the intervention (p < 0.001). But, the differences for the Schirmer test score and tear break up time score was not significant (p = 0.115, p = 0.013, respectively).  
1	5595267	Tear break up time	But, the differences for the Schirmer test score and tear break up time score was not significant (p = 0.115, p = 0.013, respectively).  
0	5550381	Loss of Brain volume	brain volume loss was lower for teriflunomide 14 mg vs placebo at year 1 (36.9% relative reduction, p = 0.0001) and year 2 (30.6% relative reduction, p = 0.0001).
0	5550381	Loss of Brain volume	brain volume loss was lower for teriflunomide 14 mg vs placebo at year 1 (36.9% relative reduction, p = 0.0001) and year 2 (30.6% relative reduction, p = 0.0001).
0	5550381	Loss of Brain volume	Teriflunomide 7 mg was also associated with significant reduction in brain volume loss vs placebo over the 2-year study.
0	5550381	Loss of Brain volume	brain volume loss was lower for teriflunomide 14 mg vs placebo at year 1 (36.9% relative reduction, p = 0.0001) and year 2 (30.6% relative reduction, p = 0.0001).
0	4782022	Bone alkaline phosphatase after 36 months	bone alkaline phosphatase remained significantly higher compared to baseline at 12, 24 and 36 months in patients receiving chemotherapy, resulting in a significant difference between treatment groups at 36 months (CT+G 5.845 vs chemotherapy 8.5 p=0.0006).
2	4782022	N-terminal telopeptide after 6 months	In the overall population, there was a significant increase in NTX at 6 months compared to baseline in patients treated with CT+G (40.81 vs 57.82 p=0.0074) with normalisation of levels thereafter.
1	4387644	Demographic characteristics	No significant difference was found in the demographic characteristics of the three groups of women.
1	4387644	Systolic and diastolic blood pressure	In this case, Tukey's test showed significant improvement of systolic and diastolic blood pressure in stretching exercise group. Walking and control groups showed no change or significant reduction (P < 0.05). No significant difference was found between the walking and control groups (P > 0.05).  
2	4387644	Improvement of systolic and diastolic blood pressure	In this case, Tukey's test showed significant improvement of systolic and diastolic blood pressure in stretching exercise group. Walking and control groups showed no change or significant reduction (P < 0.05).
0	3893543	epileptiform discharges after 1, 2, and 6 month	Significant decreases in epileptiform discharges were also observed after 1, 2, and 6 months of listening to Mozart K.448 when compared with EEGs before listening to music.
0	3893543	The seizure recurrence rate over 24 months	The seizure recurrence rate was estimated to be significantly lower in the treatment group than the control group over 24 months (37.2% vs. 76.8%, p = 0.0109).
2	1198254	total fecal counts of lactobacilli	ME-3 was well tolerated and a significant increase in total faecal lactobacilli yet no predominance of ME-3 was detected in all study groups.
2	1198254	Total Antioxidative Activity	Faecal recovery of ME-3 was documented by molecular methods only in fermented milk group, however the significant improvement of blood Total Antioxidative Activity (Total Antioxidative Activity) and Total Antioxidative Status (Total Antioxidative Status) indices was seen both in case of fermented goat milk and capsules", yet glutathione re-ox ratio values decreased only in case of fermented by ME-3 goat milk.  
2	4558453	Sense of presence in virtual immersive environment	Furthermore, these changes indicated that exercise augments the demands of virtual environment exposures and this likely contributed to an enhanced sense of presence.
2	5415292	accessing the program	Non-Hispanics were twice as likely to access the program as Hispanics (adjusted odds ratio = 2.1, 95% confidence interval = 1.2-3.8, P < .05).
1	5415292	referral approaches	Both referral approaches were equally effective.
1	3771300	index lesion cure rate after 6 months follow-up	The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099).
2	3771300	final cure rate	When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046).
1	2714198	Survival time	Results: No difference in survival time was observed across the different groups.
2	4996255	the number of steps to use, time taken to use and ease of use	Across the two Phase IIIa active comparator studies, patients consistently stated a preference for the ElliptaTM dry powder inhaler over HandiHaler® regarding the number of steps to use (59% vs 17%), time taken to use (62% vs 14%), and ease of use (63% vs 15%) regardless of which inhaler contained active drug.
0	2785868	Hip fracture frequency	After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).  
0	2785868	Hip fracture frequency	After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).  
0	3628658	Hospital stay	The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.
0	3628658	Loss of blood during surgery	The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.
0	3628658	Surgery time	The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.
1	3628658	Harris hip values and union time of fractures	There was not statistical significance on union time and Harris values in the two position groups.
0	3628658	Incision lenght	The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.
2	2752780	Treatment response rate	We found greater treatment response rate (defined as ≥50% reduction in headache index) in patients with biofeedback-assisted autogenic training than in monitoring group.
0	3253336	Risk of symptomatic hypoglycaemia	The risk of symptomatic hypoglycaemia was significantly decreased with sitagliptin relative to sulphonylurea treatment (Mantel–Haenszel relative risk ratio [95% CI] = 0.51 [0.34, 0.75]; p < 0.001).
1	5465806	The z-scores for endothelial dysfunction and low-grade inflammation	The z-scores for endothelial dysfunction (−0·02; 95 % CI −0·15, 0·11) and low-grade inflammation (−0·04; 95 % CI −0·16, 0·07) were also not significantly changed after Plant sterols intake compared with placebo.
1	5465806	individual biomarkers of endothelial dysfunction and low-grade inflammation	The intake of Plant sterols did not significantly change the individual biomarkers of endothelial dysfunction and low-grade inflammation.
2	4249579	maximum observed plasma concentration after oral administration (combined versus primaquine alone for maximum concentration) and predicted area under the plasma concentration time curve after the last dose from zero time to infinity (AUC0–last)values	Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [confidence interval]) of primaquine combined versus primaquine alone for maximum concentration (combined versus primaquine alone for maximum concentration), area under the concentration-time curve from 0 h to the end of the study (AUC0–last), and area under the concentration-time curve from 0 h to infinity (AUC0–∞) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively.
1	5910333	50-ft Speed Walk improvement	50ftSW did not change (P = 0.15).
2	5910333	6-Minute Walk improvement	Only the clinic arm increased the 6 MW (172.4 ft, P = 0.02) and SF-12 PCS (6.2 points, P < 0.001).
2	5910333	SF-12 Physical Component Summary improvement	Only the clinic arm increased the 6 MW (172.4 ft, P = 0.02) and SF-12 PCS (6.2 points, P < 0.001).
2	5910333	SF-12 Physical Component Summary improvement	Only the clinic arm increased the 6 MW (172.4 ft, P = 0.02) and SF-12 PCS (6.2 points, P < 0.001).
2	5910333	6-Minute Walk improvement	Only the clinic arm increased the 6 MW (172.4 ft, P = 0.02) and SF-12 PCS (6.2 points, P < 0.001).
1	4139977	Improvement in bowel habit	Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910).
1	4139977	decrease in abdominal pain and distension severity	After treatment, there was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05).
0	4414618	cortical silent period duration	By applying transcranial magnetic stimulation over the primary motor cortex, we found that while motor evoked potentials amplitude remained stable throughout the procedure in both groups, the cortical silent period duration was shorter in the experimental group after the nocebo procedure.
2	3233513	FEV1 60-min increase	End of study increases in FEV1 60-min post-dose were significantly greater (p < 0.001 for both) with formoterol 4.5 and 9 μg bid (113% of baseline for both) than with placebo, as were all secondary outcome measures.
2	3233513	FEV1 60-min increase	End of study increases in FEV1 60-min post-dose were significantly greater (p < 0.001 for both) with formoterol 4.5 and 9 μg bid (113% of baseline for both) than with placebo, as were all secondary outcome measures.
2	3233513	St George's Respiratory Questionnaire score improvement	The proportion of patients with an improvement in St George's Respiratory Questionnaire score of ≥ 4 was 50.2% for formoterol 4.5 μg (p = 0.0682 vs. placebo), 59.2% (p = 0.0004) for 9 μg, and 41.3% for placebo.
0	3233513	Use of salbutamol as reliever	Reduction in reliever medication use was significantly greater with formoterol vs. placebo (9 μg: -0.548, p < 0.001; 4.5 μg: -0.274, p = 0.027), with 9 μg being significantly superior to 4.5 μg (-0.274, p = 0.029).
1	3233513	Adverse events	Formoterol was well tolerated with the incidence and type of adverse events not being different for the three groups.  
0	3233513	Use of salbutamol as reliever	Reduction in reliever medication use was significantly greater with formoterol vs. placebo (9 μg: -0.548, p < 0.001; 4.5 μg: -0.274, p = 0.027), with 9 μg being significantly superior to 4.5 μg (-0.274, p = 0.029).
0	3233513	Use of salbutamol as reliever	Reduction in reliever medication use was significantly greater with formoterol vs. placebo (9 μg: -0.548, p < 0.001; 4.5 μg: -0.274, p = 0.027), with 9 μg being significantly superior to 4.5 μg (-0.274, p = 0.029).
1	3599990	Differences between self-reported and measured body mass index	Mean differences between self-reported and measured weight (p = 0.4004), height (p = 0.5342) and body mass index (body mass index) (p = 0.4409) were not statistically different between the informed and uninformed group.
1	3599990	Differences between self-reported and measured height	Mean differences between self-reported and measured weight (p = 0.4004), height (p = 0.5342) and body mass index (body mass index) (p = 0.4409) were not statistically different between the informed and uninformed group.
1	3599990	Differences between self-reported and measured weight	Mean differences between self-reported and measured weight (p = 0.4004), height (p = 0.5342) and body mass index (body mass index) (p = 0.4409) were not statistically different between the informed and uninformed group.
2	3856598	survival	bone marrow-derived mononuclear cells therapy led to improved survival in the cecal ligation and puncture group, reduced lung elastance, alveolar collapse, tissue and bronchoalveolar lavage fluid cellularity, collagen fiber content, and interleukin-1β and increased chemokine (keratinocyte-derived chemokine and monocyte chemotactic protein-1) expression in lung tissue regardless of the experimental acute respiratory distress syndrome model.
0	3856598	interleukin-1β	bone marrow-derived mononuclear cells therapy led to improved survival in the cecal ligation and puncture group, reduced lung elastance, alveolar collapse, tissue and bronchoalveolar lavage fluid cellularity, collagen fiber content, and interleukin-1β and increased chemokine (keratinocyte-derived chemokine and monocyte chemotactic protein-1) expression in lung tissue regardless of the experimental acute respiratory distress syndrome model.
0	3856598	alveolar collapse	bone marrow-derived mononuclear cells therapy led to improved survival in the cecal ligation and puncture group, reduced lung elastance, alveolar collapse, tissue and bronchoalveolar lavage fluid cellularity, collagen fiber content, and interleukin-1β and increased chemokine (keratinocyte-derived chemokine and monocyte chemotactic protein-1) expression in lung tissue regardless of the experimental acute respiratory distress syndrome model.
0	3856598	collagen fiber content	bone marrow-derived mononuclear cells therapy led to improved survival in the cecal ligation and puncture group, reduced lung elastance, alveolar collapse, tissue and bronchoalveolar lavage fluid cellularity, collagen fiber content, and interleukin-1β and increased chemokine (keratinocyte-derived chemokine and monocyte chemotactic protein-1) expression in lung tissue regardless of the experimental acute respiratory distress syndrome model.
0	4598102	PANSS-total scores at week 4 and 8	PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003) and week 8 (P = 0.007) compared with the control group.
0	4598102	PANSS-negative scores at week 4 and 8	PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005) and week 8 (P< 0.001) compared with the control group.
1	4598102	Changes in levels of lipids (except low density lipoproteins) or fasting glucose	There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins.
1	4598102	Adverse reactions	There was no significant difference in the incidence of adverse reactions between the two groups.  
0	4598102	Prolactin levels in serum	Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001), week 4 (P< 0.001), week 6 (P< 0.001) and week 8 (P< 0.001) compared with the control group.
1	4517637	fractional albumin synthesis rate (FSRalb)	Between groups, there was no difference in FSRalb.
1	4517637	effect on protein kinetics	Due to underpowering of our study, we could not draw conclusions on the primary outcome parameters.
1	2039813	Flow-mediated vasodilatation after 36 months	Change in flow-mediated vasodilatation after 36 month treatment was 0.55% (95% confidence interval −0.36, 1.47; p = 0.23) higher in perindopril than in placebo group.
1	2039813	Flow-mediated vasodilatation after 6 months	The rate of change in flow-mediated vasodilatation per 6 months was 0.14% (SE 0.05, p = 0.02) in perindopril and 0.02% (SE 0.05, p = 0.74) in placebo group (0.12% difference in rate of change p = 0.07).  
1	2782153	clinical efficacy (infants birth weight <1,500 g) - treatment of respiratory distress syndrome (respiratory distress syndrome)	We concluded that Newfactan® was comparable to Surfacten® in the clinical efficacy in the treatment of respiratory distress syndrome in both birth weight groups.
1	2782153	clinical efficacy (infants birth weight >1,500 g) - treatment of respiratory distress syndrome (respiratory distress syndrome)	We concluded that Newfactan® was comparable to Surfacten® in the clinical efficacy in the treatment of respiratory distress syndrome in both birth weight groups.
2	3742017	performed on Kaufman Assessment Battery for Children-Second Edition Composite Index Simultaneous Processing and on subtest Rover	E-performed significantly better than C-group children on the Kaufman Assessment Battery for Children-Second Edition (Kaufman Assessment Battery for Children-Second Edition) and trended towards better scores on the Rey-Osterrieth Complex Figure Test.
2	4889691	The hospital discharge rate of the patients with out-of-hospital cardiac arrest	The hospital discharge rate of the patients with out-of-hospital cardiac arrest was significantly higher in the AutoPulse cardiopulmonary resuscitation group than in the Manual cardiopulmonary resuscitation group (18.8% vs. 6.3%; p = 0.03).
2	4889691	return of spontaneous circulation (return of spontaneous circulation)	The return of spontaneous circulation rate of patients with out-of-hospital cardiac arrest was significantly higher in the AutoPulse cardiopulmonary resuscitation group than in the Manual cardiopulmonary resuscitation group (44.9% vs. 23.4%; p = 0.009).
2	4889691	The 24-h survival rate of out-of-hospital cardiac arrest	The 24-h survival rate of out-of-hospital cardiac arrest patients was significantly higher in the AutoPulse cardiopulmonary resuscitation group than in the Manual cardiopulmonary resuscitation group (39.1% vs. 21.9%; p = 0.03).
1	4889691	The proportion of patients with out-of-hospital cardiac arrest and a cerebral performance category score of 1 or 2 points at hospital discharge	The proportion of patients with out-of-hospital cardiac arrest and a cerebral performance category score of 1 or 2 points at hospital discharge was higher in the AutoPulse cardiopulmonary resuscitation group than in the Manual cardiopulmonary resuscitation group, but the difference was not statistically significant (16.2% vs. 13.4%, p = 1.00).  
1	3712263	Apical dye penetration	RESULTS: No statistical differences in mean apical dye penetration between groups LGP/AH26, SGP/MTA and SGP/NEC were found; SGP/NEC group showed significantly less coronal dye penetration (P<0.001).   
1	3712263	Apical dye penetration	RESULTS: No statistical differences in mean apical dye penetration between groups LGP/AH26, SGP/MTA and SGP/NEC were found; SGP/NEC group showed significantly less coronal dye penetration (P<0.001).   
1	3712263	Apical dye penetration	RESULTS: No statistical differences in mean apical dye penetration between groups LGP/AH26, SGP/MTA and SGP/NEC were found; SGP/NEC group showed significantly less coronal dye penetration (P<0.001).   
0	3712263	Coronal dye penetration	RESULTS: No statistical differences in mean apical dye penetration between groups LGP/AH26, SGP/MTA and SGP/NEC were found; SGP/NEC group showed significantly less coronal dye penetration (P<0.001).   
1	4710971	General Movement Optimality secondary outcome	The GMOS (secondary outcome) did not change from session to session (main effect session: p = 0.262) in the intervention group or the control group.
1	4710971	General Movement Assessment (General Movement Assessment)	Between groups no difference in the global General Movement Assessment (primary outcome) could be observed.  
2	2360567	Tumour-specific survival after 5 years	Tumour-specific survival in the interleukin-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04).
2	2360567	Tumour-specific survival after 1 year	Tumour-specific survival in the interleukin-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04).
2	3651817	mean values of AUC0-t(last)	Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC0-t(last) values: 282, 236, 204 and 81.6 hr*ng/L).
2	4488565	efficacy of treating patients with chronic functional constipation	This study confirms the efficacy and tolerability of an Iranian herbal preparation, Lax-Asab, in treating patients with chronic functional constipation.
2	4488565	mean of weekly defecation frequency increase	The mean of weekly defecation frequency increased in both groups; from 1.8 ± 0.41 to 4.8 ± 1.12 times in patients who received Lax-Asab and from 1.7 ± 0.44 to 2.2 ± 0.61 times in patients who received placebo. A time–treatment interaction showed that this increase was significantly higher in the intervention group.
1	4488565	side effects observed	There was no statistically significant difference between the two groups with regard to the side effects observed.
2	4334043	the average duration of surgery	In group A, the average duration of surgery was 71 minutes, when compared to 60 minutes in group B (P < 0.001).
0	4237982	Total adipose tissue in women	Mean intensive lifestyle intervention changes were different from diabetes support and education (P < 0.001 for total AT, subcutaneous AT, and intermuscular AT and P < 0.01 for visceral AT in females).
0	4237982	Subcutaneous adipose tissue in women	Mean intensive lifestyle intervention changes were different from diabetes support and education (P < 0.001 for total AT, subcutaneous AT, and intermuscular AT and P < 0.01 for visceral AT in females).
0	4237982	Intermuscular adipose tissue in women	Mean intensive lifestyle intervention changes were different from diabetes support and education (P < 0.001 for total AT, subcutaneous AT, and intermuscular AT and P < 0.01 for visceral AT in females).
0	4237982	Visceral adipose tissue in women	Mean intensive lifestyle intervention changes were different from diabetes support and education (P < 0.001 for total AT, subcutaneous AT, and intermuscular AT and P < 0.01 for visceral AT in females).
1	4018592	Weight until week 28 of pregnancy	Women taking multivitamin-mineral supplements gained marginally less weight until week 28 than those taking multivitamin supplements (weight at week 28 of gestation: 67.5 ± 11.4 vs. 71.6 ± 10.3 kg, P = 0.06).
0	4018592	BMI at week 28 of pregnancy	Mean body mass index at week 28 (25.8 ± 4.0 vs. 28.4 ± 3.7 kg/m2, P = 0.001) as well as at delivery (28.0 ± 3.9 vs. 30.1 ± 3.8 kg/m2, P = 0.006) was lower among women taking multivitamin-mineral supplements than those taking multivitamin supplements.
1	4018592	Newborns' height and Apgar score	Although no significant difference was seen in newborns' height and Apgar score between the two groups, mean birth weight (3.3 ± 0.4 vs. 3.1 ± 0.4 kg, P = 0.04) and head circumference (35 ± 1.4 vs. 34 ± 1.3 cm, P < 0.0001) of the infants whose mothers receiving multivitamin-mineral supplements were higher than those whose mothers received multivitamins.
0	4018592	BMI at delivery	Mean body mass index at week 28 (25.8 ± 4.0 vs. 28.4 ± 3.7 kg/m2, P = 0.001) as well as at delivery (28.0 ± 3.9 vs. 30.1 ± 3.8 kg/m2, P = 0.006) was lower among women taking multivitamin-mineral supplements than those taking multivitamin supplements.
2	4018592	Newborn's weight and head circumference at birth	Although no significant difference was seen in newborns' height and Apgar score between the two groups, mean birth weight (3.3 ± 0.4 vs. 3.1 ± 0.4 kg, P = 0.04) and head circumference (35 ± 1.4 vs. 34 ± 1.3 cm, P < 0.0001) of the infants whose mothers receiving multivitamin-mineral supplements were higher than those whose mothers received multivitamins.
0	4467620	accuracy of the cognitive tasks	The accuracy of the cognitive tasks was lower during exercise than that at rest in the Hot and Hot + Cooling condition (p < 0.05).
0	4467620	accuracy of the cognitive tasks	The accuracy of the cognitive tasks was lower during exercise than that at rest in the Hot and Hot + Cooling condition (p < 0.05).
1	4467620	differences in the accuracy	There were no differences in the accuracy between the Hot and Hot + Cooling conditions (p = 0.98).
2	2899760	Fusion rate	Fusion rate in the Smith–Robinson group was 92%, and in the Trabecular MetalTM group 69% (P < 0.05).
1	2899760	clinical outcomes	There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused.
2	2899760	Radiological fusion	In our study, Trabecular Metal showed a lower fusion rate than the Smith–Robinson technique with autograft after single-level anterior cervical fusion without plating.
2	5610004	concordance index in the non-small-cell lung cancer group	The concordance index was higher for the non-small-cell lung cancer cohort nomogram than for the TNM staging system (0.67 vs. 0.64, P = 0.01) and higher for the small-cell lung cancer nomogram than for the clinical staging system (limited vs. extensive) (0.60 vs. 0.53, P = 0.12).  
1	5122106	weight loss	At the end of the study, participants had a significant weight loss (2.96 ± 1.6 kg, P < 0.001) that was slightly more in the case group (3.15 ± 1.5 kg vs. 2.75 ± 1.7, P = 0.375).
1	5122106	abdominal fat thickness	Similarly, abdominal fat thickness decreased significantly in the participants (2.3 ± 1.1 cm, P < 0.001), although changes were not significantly different between two groups (2.53 vs. 2.04 cm, P = 0.139).  
0	5122106	Abdominal circumference	Abdominal circumference also decreased significantly in the participants (11.3 ± 6.7 cm, P < 0.001), but the changes were more significant in the case group (13.9 vs. 6.5 cm, P = 0.004).
2	3154347	Mineral density	In a per protocol analysis after 6 months, L3 bone mineral density has increased statistically significantly in the vitamin K group compared to the control group (0.01 ± 0.03 g/cm2 vs -0.008 ± 0.04 g/cm2, P = 0.049).
0	3154347	Undercarboxylated osteocalcin	In a per protocol analysis after 6 months, L3 bone mineral density has increased statistically significantly in the vitamin K group compared to the control group (0.01 ± 0.03 g/cm2 vs -0.008 ± 0.04 g/cm2, P = 0.049). undercarboxylated osteocalcin concentration was also significantly decreased in the vitamin K group (-1.6 ± 1.6 ng/dL vs -0.4 ± 1.1 ng/dL, P = 0.008).
2	5424452	training had the most beneficial effect	The mean percentage values of post-training changes to study parameters suggest that the training had the most beneficial effect in Groups I (60 Hz/4 mm) and IV (60 Hz/2 mm) (p<0.05).
2	5424452	total work for knee flexors at high angular velocity	After 4 weeks of whole-body vibration training, a significant increase was noted regarding the mean values of peak torque, average peak torque and total work for knee flexors at high angular velocity in Groups I (60 Hz/4 mm) and V (40 Hz/2 mm) (p<0.05).
2	5424452	average peak torque	After 4 weeks of whole-body vibration training, a significant increase was noted regarding the mean values of peak torque, average peak torque and total work for knee flexors at high angular velocity in Groups I (60 Hz/4 mm) and V (40 Hz/2 mm) (p<0.05).
2	5424452	mean values of peak torque	After 4 weeks of whole-body vibration training, a significant increase was noted regarding the mean values of peak torque, average peak torque and total work for knee flexors at high angular velocity in Groups I (60 Hz/4 mm) and V (40 Hz/2 mm) (p<0.05).
0	4558893	Body weight	Between-group differences were significantly in favor of exenatide for body weight (P < 0.0001), waist circumference (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.023), HDL-cholesterol (P = 0.001), and high-sensitivity C-reactive protein (P = 0.004).
0	4558893	Systolic blood pressure	Between-group differences were significantly in favor of exenatide for body weight (P < 0.0001), waist circumference (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.023), HDL-cholesterol (P = 0.001), and high-sensitivity C-reactive protein (P = 0.004).
0	4558893	High sensitivity C-reactive protein	Between-group differences were significantly in favor of exenatide for body weight (P < 0.0001), waist circumference (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.023), HDL-cholesterol (P = 0.001), and high-sensitivity C-reactive protein (P = 0.004).
0	4558893	Waist circumference	Between-group differences were significantly in favor of exenatide for body weight (P < 0.0001), waist circumference (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.023), HDL-cholesterol (P = 0.001), and high-sensitivity C-reactive protein (P = 0.004).
0	4558893	Diastolic blood pressure	Between-group differences were significantly in favor of exenatide for body weight (P < 0.0001), waist circumference (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.023), HDL-cholesterol (P = 0.001), and high-sensitivity C-reactive protein (P = 0.004).
2	4558893	HDL-cholesterol	Between-group differences were significantly in favor of exenatide for body weight (P < 0.0001), waist circumference (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.023), HDL-cholesterol (P = 0.001), and high-sensitivity C-reactive protein (P = 0.004).
1	4143738	colon preperation	The colon prep was adequate in 94.4% in AM group and in 90.2% cases in PM group (P=0.2).
0	4143738	flush need	Sleep quality and the need for flush was lower in the AM group (P=0.004 and P=0.03).
2	4143738	suction fluid during the procedure	The mean volume of suction fluid was higher in the AM group (P=0.01).
1	3883373	Recurrent urinary tract infections	During the course of three years, 39% in group I and 50% of participants in group II experienced recurrent urinary tract infectionss (P=0.4).
0	3883373	Febrile urianry tract infections	Also, incidence of afebrile UTIs did not significantly differ (0.51±1.30 and 0.81±1.41 respectively, P =0.3); however, the incidence of febrile UTIs in particular were lower in group I (0.00±0.00 versus 0.13±0.40, P =0.03) in the last year.  
1	3883373	Afebrile urianry tract infections	Also, incidence of afebrile UTIs did not significantly differ (0.51±1.30 and 0.81±1.41 respectively, P =0.3); however, the incidence of febrile UTIs in particular were lower in group I (0.00±0.00 versus 0.13±0.40, P =0.03) in the last year.  
1	5908397	Percentage of treatment failure on day 10 - severe pneumonia in children	Percentage of treatment failure were similar in placebo and zinc arms both on day 5 (14.0% vs 14.1%) and day 10 (5.2% vs 5.9%).
1	5908397	time to resolution for all respiratory symptoms of severity - severe pneumonia in children	The time to resolution for all respiratory symptoms of severity was not significantly different between placebo and zinc arms (42.3 vs 30.9 hours respectively; P = 0.242).
1	5908397	Percentage of treatment failure on day 5 - severe pneumonia in children	Percentage of treatment failure were similar in placebo and zinc arms both on day 5 (14.0% vs 14.1%) and day 10 (5.2% vs 5.9%).
0	5908397	time to recovery from lower chest wall indrawing (LCWI) - severe pneumonia in children	The time to recovery from lower chest wall indrawing and sternal retraction was longer in the placebo compared to zinc arm (24.4 vs 23.0 hours; P = 0.011 and 18.7 vs 11.0 hours; P = 0.006 respectively).
0	5340016	The clinical response rates	The overall clinical response rate was significantly higher in the paclitaxel–epirubicin arm than in the 5-fluorouracil–epirubicin–cyclophosphamide arm (76.06% vs. 59.95%, P = 0.001).
2	5340016	the post-chemotherapy pathologic T and N stages	Consistently, the post-chemotherapy pathologic T and N stages were significantly lower in the paclitaxel–epirubicin arm than in the 5-fluorouracil–epirubicin–cyclophosphamide arm (P < 0.001).
1	5340016	pathologic complete response (pathologic complete response in both the breast and lymph nodes) rates	However, the pathologic complete response rate was similar in the two arms (10.61% vs. 12.31%, P = 0.665).
0	5340016	The frequency of neutropenia	Most adverse events were comparable in both arms, with more severe neutropenia in the paclitaxel–epirubicin arm than in the 5-fluorouracil–epirubicin–cyclophosphamide arm (11.97% vs. 5.96%, P = 0.031).  
2	5452353	Level of VO2 max after 5 minutes into cycling time trial to exhaustion at 100%VO2max	VO2 measured at five minutes into the TTE100% was significantly increased in ALTPOMx vs. ALTPLAC (+3.8 ml.min−1kg−1, 95% CI, −5.7, 9.5, F1,7 = 29.2, p = 0.001, ES = 0.6) but unchanged in SEAPOMx vs. SEAPLAC (p > 0.05).
1	5452353	Level of VO2 max after 5 minutes into cycling time trial to exhaustion at 100%VO2max	VO2 measured at five minutes into the TTE100% was significantly increased in ALTPOMx vs. ALTPLAC (+3.8 ml.min−1kg−1, 95% CI, −5.7, 9.5, F1,7 = 29.2, p = 0.001, ES = 0.6) but unchanged in SEAPOMx vs. SEAPLAC (p > 0.05).
2	5980459	pH of abomasal outflow fluid for 4 hours	Abomasal outflow fluid pH was higher in steers treated with famotidine for up to 4 hours after a single dose but the effect decreased with subsequent doses.
1	4804512	Pain during 30° flexion	There was no difference in primary outcome between Group Ropivacaine and Group Placebo (Visual Analogue Scale 27 mm vs. 31 mm, p = 0.41; difference −5 mm (95 % CI: −15 mm - +5 mm).
1	4804512	Time to mobilisation	Secondary outcomes were pain at rest, pain during movement, oxycodone consumption (0–24 h), time to mobilisation, ability to mobilise, and length of stay.
1	4804512	Time to mobilisation	TITLE: Effect of lateral femoral cutaneous nerve-block on pain after total hip arthroplasty: a randomised, blinded, placebo-controlled trial    ABSTRACT.BACKGROUND. 
1	4804512	Time to mobilisation	No differences in any of the secondary outcomes were observed.
2	4640056	Total adaptation	Independent t-test showed statistically significant differences between the two groups in the post-test stage in terms of the total score of adaptation (P = 0.001) as well as physiologic (P = 0.0001) and role function modes (P = 0.004).
2	4640056	Total adaptation	The total score of adaptation (139.43 ± 5.45 to 127.54 ± 14.55, P = 0.006) as well as the scores of physiologic (60.26 ± 5.45 to 53.73 ± 7.79, P = 0.001) and role function (20.30 ± 2.42 to 18.13 ± 3.18, P = 0.01) modes in the intervention group significantly increased, whereas the scores of self-concept (42.10 ± 4.71 to 39.40 ± 5.67, P = 0.21) and interdependence (16.76 ± 2.22 to 16.30 ± 2.57, P = 0.44) modes in the two stages did not have a significant difference.  
1	4640056	Self-concept score	The total score of adaptation (139.43 ± 5.45 to 127.54 ± 14.55, P = 0.006) as well as the scores of physiologic (60.26 ± 5.45 to 53.73 ± 7.79, P = 0.001) and role function (20.30 ± 2.42 to 18.13 ± 3.18, P = 0.01) modes in the intervention group significantly increased, whereas the scores of self-concept (42.10 ± 4.71 to 39.40 ± 5.67, P = 0.21) and interdependence (16.76 ± 2.22 to 16.30 ± 2.57, P = 0.44) modes in the two stages did not have a significant difference.  
1	4640056	Interdependence score	The total score of adaptation (139.43 ± 5.45 to 127.54 ± 14.55, P = 0.006) as well as the scores of physiologic (60.26 ± 5.45 to 53.73 ± 7.79, P = 0.001) and role function (20.30 ± 2.42 to 18.13 ± 3.18, P = 0.01) modes in the intervention group significantly increased, whereas the scores of self-concept (42.10 ± 4.71 to 39.40 ± 5.67, P = 0.21) and interdependence (16.76 ± 2.22 to 16.30 ± 2.57, P = 0.44) modes in the two stages did not have a significant difference.  
2	4640056	Physiologic score	Independent t-test showed statistically significant differences between the two groups in the post-test stage in terms of the total score of adaptation (P = 0.001) as well as physiologic (P = 0.0001) and role function modes (P = 0.004).
2	4640056	Physiologic score	The total score of adaptation (139.43 ± 5.45 to 127.54 ± 14.55, P = 0.006) as well as the scores of physiologic (60.26 ± 5.45 to 53.73 ± 7.79, P = 0.001) and role function (20.30 ± 2.42 to 18.13 ± 3.18, P = 0.01) modes in the intervention group significantly increased, whereas the scores of self-concept (42.10 ± 4.71 to 39.40 ± 5.67, P = 0.21) and interdependence (16.76 ± 2.22 to 16.30 ± 2.57, P = 0.44) modes in the two stages did not have a significant difference.  
2	4640056	Role function score	The total score of adaptation (139.43 ± 5.45 to 127.54 ± 14.55, P = 0.006) as well as the scores of physiologic (60.26 ± 5.45 to 53.73 ± 7.79, P = 0.001) and role function (20.30 ± 2.42 to 18.13 ± 3.18, P = 0.01) modes in the intervention group significantly increased, whereas the scores of self-concept (42.10 ± 4.71 to 39.40 ± 5.67, P = 0.21) and interdependence (16.76 ± 2.22 to 16.30 ± 2.57, P = 0.44) modes in the two stages did not have a significant difference.  
2	4640056	Role function score	TITLE: Roy’s Adaptation Model-Guided Education and Promoting the Adaptation of Veterans With Lower Extremities Amputation    ABSTRACT.BACKGROUND:. 
2	4640056	Role function score	Independent t-test showed statistically significant differences between the two groups in the post-test stage in terms of the total score of adaptation (P = 0.001) as well as physiologic (P = 0.0001) and role function modes (P = 0.004).
1	2678276	progression-free survival (progression-free survival) in metastatic colorectal cancer (metastatic colorectal cancer)	At the median follow up of 17 (range 1–39) months, the median progression-free survival was 10.3 months in the XELIRI and 9.3 months in the FOLFIRI arm (p = 0.78), the median overall survival was 30.7 months in the XELIRI arm and 16.6 months in the FOLFIRI arm (p = 0.16).  
1	2678276	progression-free survival (progression-free survival) in metastatic colorectal cancer (metastatic colorectal cancer)	In addition, the XELIRI regimen showed similar progression-free survival and overall survival with acceptable toxicity compared to the FOLFIRI regimen.  
1	2678276	overall survival (overall survival) in metastatic colorectal cancer (metastatic colorectal cancer)	At the median follow up of 17 (range 1–39) months, the median progression-free survival was 10.3 months in the XELIRI and 9.3 months in the FOLFIRI arm (p = 0.78), the median overall survival was 30.7 months in the XELIRI arm and 16.6 months in the FOLFIRI arm (p = 0.16).  
1	2678276	rate of radical (R0) surgical resection in metastatic colorectal cancer (metastatic colorectal cancer)	The rate of radical R0 resection was 24% in both arms of patients.
1	2678276	At the end of treatment, patients without evidence of the disease in metastatic colorectal cancer (metastatic colorectal cancer)	At the end of treatment, 37% of patients in the XELIRI and 26% of patients in the FOLFIRI arm were without evidence of the disease (CR+R0 resection) (p = 0.56).
1	4667210	the appearance time of the monosodium glutamate symptom complex	Although there was no significant difference in the appearance time of the monosodium glutamate symptom complex between subjects orally administered G101 and those administered the placebo, its disappearance in < 3 h was observed in 69.9% of subjects in the G101 treatment group and in 38.0% of subjects in the placebo group (P = 0.0841).  
0	4667210	The intensity of the monosodium glutamate symptom complex (characterized by unpleasant reactions such as numbness, tingling, headaches, muscle tightness, general weakness, and flushing )	The intensity of the monosodium glutamate symptom complex was significantly reduced in respondents of the G101 intake group (2.87 ± 0.73) compared to that in those treated with the placebo (3.63 ± 1.03) (P = 0.0016).
2	2778406	weight loss, first 6 months	In the first six months, adherence to attendance, self-monitoring and the energy goal were significantly associated with greater weight loss (P < 0.05).
2	2778406	weight loss, first 6 months	In the first six months, adherence to attendance, self-monitoring and the energy goal were significantly associated with greater weight loss (P < 0.05).
2	2778406	weight loss, first 6 months	In the first six months, adherence to attendance, self-monitoring and the energy goal were significantly associated with greater weight loss (P < 0.05).
2	2865639	washing	However, women in the intervention group were significantly more likely to report washing or wiping during follow-up compared to those in the control group.
2	2865639	wiping	However, women in the intervention group were significantly more likely to report washing or wiping during follow-up compared to those in the control group.
0	5117579	The incidence of hypotension	The incidence of hypotension was significantly lower in Group A (16.1%) than in Group B (48.4%) during infusion of dexmedetomidine (p = 0.01).
1	5117579	The incidence of bradycardia and desaturation	The incidence of bradycardia and desaturation did not significantly differ between the two groups.
0	5117579	The need for treatment of hypotension	The need for treatment of hypotension is higher in Group B than Group A (p = 0.02).
0	2796659	Hamilton Anxiety Rating Scale (Hamilton Anxiety Rating Scale)	At 2-weeks post treatment 6 of 10 patients had a remission (a score ≤ 10) on the HAM-D and 7 of 10 achieved this on the HAM-A. Patients experienced highly significant reductions in both HAM-D and Hamilton Anxiety Rating Scale scores following treatment, with the greatest reductions occurring at 2 weeks.
2	4223282	women's ability to refuse sex	Only some achieved statistical significance. Women in intervention communities were significantly more likely to report being able to refuse sex with their partners (aRR 1.16, 95% CI 1.00–1.35), joint decision-making (aRR 1.37, 95% CI 1.06–1.78) and more open communication on a number of indicators.
2	4223282	male reports of undergoing HIV testing	Men in intervention communities were significantly more likely than controls to report a broad range of HIV-protective behaviours, including higher levels of condom use (aRR 2.03, 95% CI 1.22–3.39), HIV testing (aRR 1.50, 95% CI 1.13–2.00) and fewer concurrent partners (aRR 0.60, 95% CI 0.37–0.97).
2	4223282	women making decisions jointly with their partner	Women in intervention communities were significantly more likely to report being able to refuse sex with their partners (aRR 1.16, 95% CI 1.00–1.35), joint decision-making (aRR 1.37, 95% CI 1.06–1.78) and more open communication on a number of indicators.
2	5986454	Improvement in Uchida–Kraepelin test score	Subjects showed a significant improvement in performance in the Uchida–Kraepelin test, the primary outcome measured, when they consumed the acidified milk protein drink compared with the placebo control condition.
1	5986454	Subjective feelings and body temperature	There was no significant difference in subjective feelings and body temperature between the test drink conditions.
2	5986454	Vagally-mediated heart rate variability indices	In addition, consumption of the acidified milk protein drink, compared with the placebo control, was associated with increases in vagally-mediated heart rate variability indices which, from recent theoretical perspectives, may reflect a higher ability to modulate cognitive and behavioral processes.
0	4893393	intensity of pain	Intravenous lidocaine was superior regarding the reduction of the intensity of pain, the allodynia, and the hyperalgesia compared to placebo.
1	3381083	Uncorrected visual acuity ≥ 20/20 and ≥ 20/40	Uncorrected visual acuity ≥ 20/20 and ≥ 20/40 was achieved in 90.9% versus 93.4% (P = 0.08), and 98.9% versus 99.5% (P = 0.36) of eyes in the alcohol and mechanical groups, respectively.
1	3381083	Final refractive error within 1D of emmetropia	Final refractive error within 1D of emmetropia was achieved in 90% versus 92.2% of eyes in the alcohol and mechanical groups, respectively (P = 0.23).
0	3381083	Time needed for debridement	Alcohol-assisted debridement required less time than mechanical debridement (96±18 vs. 118±26 seconds, P=0.035).
1	3381083	Mean spherical equivalent	Mean spherical equivalent was −4.37±2.3 D in the alcohol group and −3.8±1.3 D in the mechanical group (P = 0.78).
1	3381083	Postoperative pain	There was no significant difference in postoperative pain between the study groups (P = 0.22).
2	3376511	Perception of efficiency	The findings demonstrate that having less user control (ie, a tunneled version of the website) had a negative effect on users' perception of efficiency (F1,452 = 97.69, P < .001), but a positive effect on number of pages visited (F1,452 = 171.49, P < .001), time on the website (F1,452 = 6.32, P = .01), and knowledge gained from the website (F1,452 = 134.32, P < .001).
0	3376511	Time spent on the site	The findings demonstrate that having less user control (ie, a tunneled version of the website) had a negative effect on users' perception of efficiency (F1,452 = 97.69, P < .001), but a positive effect on number of pages visited (F1,452 = 171.49, P < .001), time on the website (F1,452 = 6.32, P = .01), and knowledge gained from the website (F1,452 = 134.32, P < .001).
0	3376511	Pages visited	The findings demonstrate that having less user control (ie, a tunneled version of the website) had a negative effect on users' perception of efficiency (F1,452 = 97.69, P < .001), but a positive effect on number of pages visited (F1,452 = 171.49, P < .001), time on the website (F1,452 = 6.32, P = .01), and knowledge gained from the website (F1,452 = 134.32, P < .001).
0	3376511	Knowledge gained on the site	The findings demonstrate that having less user control (ie, a tunneled version of the website) had a negative effect on users' perception of efficiency (F1,452 = 97.69, P < .001), but a positive effect on number of pages visited (F1,452 = 171.49, P < .001), time on the website (F1,452 = 6.32, P = .01), and knowledge gained from the website (F1,452 = 134.32, P < .001).
1	2967098	Improvement rate	Comparison of the improvement rate in both study groups revealed no significant difference.
2	3329148	H. pylori eradication rate	The H. pylori eradication rate of group A was slightly higher than group B (P < 0.05) and both of them were obviously higher than group C (P < 0.05).
2	3329148	H. pylori eradication rate	The H. pylori eradication rate of group A was slightly higher than group B (P < 0.05) and both of them were obviously higher than group C (P < 0.05).
1	3329148	total score descending of symptoms	There was no significant difference in total score descending of symptoms between each group (P > 0.05).
1	5548257	Pulmonary function	Conclusion: Pulmonary function and exercise capacity did not improve with vitamin D supplementation in chronic obstructive pulmonary disease patients.
1	5548257	exercise capacity	Conclusion: Pulmonary function and exercise capacity did not improve with vitamin D supplementation in chronic obstructive pulmonary disease patients.
1	5548257	exercise capacity	The vitamin D supplementation did not have any significant effect on the exercise capacity (p-value=0.175) or the saturation of oxygen (p-value = 0.635).
1	5548257	saturation of oxygen during 6MWT	The vitamin D supplementation did not have any significant effect on the exercise capacity (p-value=0.175) or the saturation of oxygen (p-value = 0.635).
1	5548257	mean forced expiratory volume in one second (FEV1)	Results: The mean FEV1 (p-value = 0.866), forced vital capacity (p-value = 0.475) and vital capacity (p-value = 0.425) were not significantly different before and after intervention.
1	5548257	vital capacity (vital capacity)	Results: The mean FEV1 (p-value = 0.866), forced vital capacity (p-value = 0.475) and vital capacity (p-value = 0.425) were not significantly different before and after intervention.
1	5548257	forced vital capacity (forced vital capacity)	Results: The mean FEV1 (p-value = 0.866), forced vital capacity (p-value = 0.475) and vital capacity (p-value = 0.425) were not significantly different before and after intervention.
2	5859768	Cervicobrachial pain intensity	Indeed, Bonferroni ́s correction showed statistically significant differences for cervicobrachial pain intensity (P < .01; 95% CI = 0.22 - 3.26) and Quick DASH reduction (P < .01; 95% CI = 8.48 - 24.67) in favor of the oral ibuprofen treatment at all measurement moments after baseline.  
1	5859768	Improvement in motion range	Results: Repeated-measures ANOVA intergroup statistically significant differences were shown for cervicobrachial pain intensity (F(2,72) = 22.343; P < .001; Eta2 = 0.383) and Quick DASH (F(2,72) = 15.338; P < .001; Eta2 = 0.299), although not for cervical range of motion (F(2,72) = 1.434; P = .245; Eta2 = 0.038).
0	5633216	plaque index and gingival index	The results showed that plaque index and gingival index significantly reduced in two groups (p<0.001).
1	5633216	terms of bleeding index	Similar results were observed in terms of bleeding index with the difference that the two groups did not differ significantly from each other (p=0.879).
1	5916905	Insulin sensitivity after meals	After BM-intervention, fat mass increased (+1.0 ± 1.8 kg; p < 0.05) and postprandial insulin sensitivity tended to decrease (ΔMatsudaISI: −0.89 ± 2.3; p = 0.06).
1	5916905	Insulin sensitivity after meals	Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all p > 0.05).
1	5916905	Basal insulin sensitivity	Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all p > 0.05).
1	5916905	Secretion of insulin	Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all p > 0.05).
1	5916905	Triglycerides levels	Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all p > 0.05).
1	5916905	Daylong glycemia	Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all p > 0.05).
2	5010179	Recurrence-free survival	UFT/LV significantly prolonged the recurrence-free survival compared with surgery alone with the hazard ratio of 0.56 (95% confidence interval, 0.38–0.83; P = 0.003).
1	4416300	Waist circumference	The mean 10-week change for most metabolic syndrome components favored melatonin over placebo (except fasting glucose): waist circumference -0.9 vs. +1.0 cm (p = 0.15); triglycerides -66.3 vs. -4.2 mg/dL (p = 0.17); HDL cholesterol -0.2 vs. -1.1 mg/dL (p = 0.59); fasting glucose +0.3 vs. -3.1 mg/dL (p = 0.29); systolic blood pressure -2.7 vs. +4.7 mmHg (p = 0.013); and diastolic blood pressure -1.1 vs. +1.1 mmHg (p = 0.24).
1	4416300	Triglycerides	The mean 10-week change for most metabolic syndrome components favored melatonin over placebo (except fasting glucose): waist circumference -0.9 vs. +1.0 cm (p = 0.15); triglycerides -66.3 vs. -4.2 mg/dL (p = 0.17); HDL cholesterol -0.2 vs. -1.1 mg/dL (p = 0.59); fasting glucose +0.3 vs. -3.1 mg/dL (p = 0.29); systolic blood pressure -2.7 vs. +4.7 mmHg (p = 0.013); and diastolic blood pressure -1.1 vs. +1.1 mmHg (p = 0.24).
1	4416300	HDL cholesterol	The mean 10-week change for most metabolic syndrome components favored melatonin over placebo (except fasting glucose): waist circumference -0.9 vs. +1.0 cm (p = 0.15); triglycerides -66.3 vs. -4.2 mg/dL (p = 0.17); HDL cholesterol -0.2 vs. -1.1 mg/dL (p = 0.59); fasting glucose +0.3 vs. -3.1 mg/dL (p = 0.29); systolic blood pressure -2.7 vs. +4.7 mmHg (p = 0.013); and diastolic blood pressure -1.1 vs. +1.1 mmHg (p = 0.24).
0	4416300	Systolic blood pressure	The mean 10-week change for most metabolic syndrome components favored melatonin over placebo (except fasting glucose): waist circumference -0.9 vs. +1.0 cm (p = 0.15); triglycerides -66.3 vs. -4.2 mg/dL (p = 0.17); HDL cholesterol -0.2 vs. -1.1 mg/dL (p = 0.59); fasting glucose +0.3 vs. -3.1 mg/dL (p = 0.29); systolic blood pressure -2.7 vs. +4.7 mmHg (p = 0.013); and diastolic blood pressure -1.1 vs. +1.1 mmHg (p = 0.24).
1	4416300	Fasting glucose	The mean 10-week change for most metabolic syndrome components favored melatonin over placebo (except fasting glucose): waist circumference -0.9 vs. +1.0 cm (p = 0.15); triglycerides -66.3 vs. -4.2 mg/dL (p = 0.17); HDL cholesterol -0.2 vs. -1.1 mg/dL (p = 0.59); fasting glucose +0.3 vs. -3.1 mg/dL (p = 0.29); systolic blood pressure -2.7 vs. +4.7 mmHg (p = 0.013); and diastolic blood pressure -1.1 vs. +1.1 mmHg (p = 0.24).
0	5440738	depressive symptom severity	Both patients assigned to the text messaging adjunct (B=−.29, 95% CI −0.38 to −0.19, z=−5.80, P<.001) and patients assigned to the control conditions (B=−.20, 95% CI −0.32 to −0.07, z=−3.12, P=.002) experienced significant decreases in depressive symptom severity over the course of treatment; however, the conditions did not significantly differ in their degree of symptom reduction.  
1	5440738	attending of sessions	Patients assigned to the text messaging adjunct also generally attended more sessions (median=6 sessions) during this period than patients assigned to the control condition (median =2.5 sessions), but the effect was not significant (Wilcoxon-Mann-Whitney z=−1.65, P=.10).
2	5440738	time staying in therapy	Intent-to-treat analyses on therapy attendance during 16 sessions of weekly therapy found that patients assigned to the text messaging adjunct stayed in therapy significantly longer (median of 13.5 weeks before dropping out) than patients assigned to the control condition (median of 3 weeks before dropping out; Wilcoxon-Mann-Whitney z=−2.21, P=.03).
0	5440738	depressive symptom severity	Both patients assigned to the text messaging adjunct (B=−.29, 95% CI −0.38 to −0.19, z=−5.80, P<.001) and patients assigned to the control conditions (B=−.20, 95% CI −0.32 to −0.07, z=−3.12, P=.002) experienced significant decreases in depressive symptom severity over the course of treatment; however, the conditions did not significantly differ in their degree of symptom reduction.  
1	5440738	the degree of symptom reduction	Both patients assigned to the text messaging adjunct (B=−.29, 95% CI −0.38 to −0.19, z=−5.80, P<.001) and patients assigned to the control conditions (B=−.20, 95% CI −0.32 to −0.07, z=−3.12, P=.002) experienced significant decreases in depressive symptom severity over the course of treatment; however, the conditions did not significantly differ in their degree of symptom reduction.  
2	3526879	lean mass (lean mass)	The values (mean ± standard deviation [standard deviation]) of relative changes to body weight (−8.0% ± 0.8%), body fat (−21.4% ± 2.1%), lean mass (3.0% ± 0.3%), and fat mass (−31.2% ± 3.0%) to the OT group were higher (P < 0.05) than in the AWT (body weight: −2.0% ± 1.1%; body fat: −4.6% ± 1.8%; fat mass: −7.0% ± 2.8%; lean mass: 0.2% ± 1.1%) and OWT (body weight: −4.5% ± 1.0%; body fat: −11.0% ± 2.2%; fat mass: −16.1% ± 3.2%; lean mass: −0.2% ± 1.0%) groups; additionally, no differences were found for C groups.
0	3816860	Glycated hemoglobin	The between-group difference in the change in HbA1c from baseline to week 24 was −0.61% (−6.7 mmol/mol) in favor of linagliptin (95% CI −0.88 to −0.34% [−9.6 to −3.7 mmol/mol]; P < 0.0001).
2	5437665	Fatigue score at week 4	At the end of study, the fatigue score was significantly increased in patients treated with simvastatin, whereas no significant change was observed in patients receiving red yeast rice.
0	5437665	Level of physical activity	In addition, the physical activity level was significantly decreased in patients from simvastatin group when compared to those from red yeast rice group.
1	5437665	Effects in reduction of lipids levels	Similar lipid-lowering effects were observed in two groups.
1	4756047	Hypoglycemia	Changes in hypoglycemia rates from baseline were not significantly different between the age groups and there was no weight increase in either age group.  
1	4756047	Body weight	Changes in hypoglycemia rates from baseline were not significantly different between the age groups and there was no weight increase in either age group.  
2	2954378	Laboratory forced expiratory volume in 1 s	The variability of the median day-to-day forced expiratory volume in 1 s (forced expiratory volume in 1 s) was 72.5 mL (25th percentile of 40 mL and 75th percentile of 130 mL). The daily forced expiratory volume in 1 s variation was 70 mL (25th percentile of 50 mL and 75th percentile of 100 mL). The overall laboratory forced expiratory volume in 1 s variability was larger after the steroid course (P < 0.001), but not clinically significant.
2	4247720	rate of retention	The rate of memory retention, computed by dividing Logical Memory delayed recall by immediate recall, showed a significant interaction (p < .05) in analysis of covariance.
2	4247720	rate of retention	Simple main effects showed that the rate of memory retention of the intervention group improved after the program completion (p < .05).
2	4247720	the rate of memory retention	Simple main effects showed that the rate of memory retention of the intervention group improved after the program completion (p < .05).
2	5515187	average of physical activity	After 6 months intervention self-efficacy (< 0.001) and physical activity (< 0.001) improvement of in the intervention group was significantly different in comparison with the control group.
0	5515187	systolic and diastolic blood pressure	After 6 months, there was a significant reduction in systolic (P < 0.001) and diastolic blood pressure (P = 0.010) in the intervention group.  
0	4845107	low‐density lipoprotein‐particle number	Switching to ezetimibe/simvastatin 10/20 mg reduced low‐density lipoprotein‐particle number numerically more than did statin dose‐doubling and was comparable with rosuvastatin 10 mg (−133.3, −94.4, and −56.3 nmol/L, respectively; P>0.05).
1	4845107	low‐density lipoprotein‐particle number	Switching to ezetimibe/simvastatin 10/20 mg reduced low‐density lipoprotein‐particle number numerically more than did statin dose‐doubling and was comparable with rosuvastatin 10 mg (−133.3, −94.4, and −56.3 nmol/L, respectively; P>0.05).
1	5593173	Torrance test (the Torrance test)	The placebo group showed higher originality than the control group both in the creative foraging game (p<0.04, effect size = 0.5) and in the alternate uses test (p<0.05, effect size = 0.4), but not in the Torrance test.
2	4881703	Analgesia improvement after 3 hours	ABSTRACT.RESULTS:. Tapentadol group patients had significantly better analgesia 3 h after the drug and "on coughing" than tramadol group.
1	4881703	Blood creatinine	The difference in their effects on blood creatinine levels, temperature, hemodynamics, oxygen saturation, and respiratory rate were not clinically significant. Tapentadol produced lesser drowsiness and lesser vomiting than tramadol.  
1	4881703	Temperature	The difference in their effects on blood creatinine levels, temperature, hemodynamics, oxygen saturation, and respiratory rate were not clinically significant.
1	4881703	Respiratory rate	The difference in their effects on blood creatinine levels, temperature, hemodynamics, oxygen saturation, and respiratory rate were not clinically significant. Tapentadol produced lesser drowsiness and lesser vomiting than tramadol.  
1	4881703	Oxygen saturation	The difference in their effects on blood creatinine levels, temperature, hemodynamics, oxygen saturation, and respiratory rate were not clinically significant. Tapentadol produced lesser drowsiness and lesser vomiting than tramadol.  
0	5703870	Reduction of thickness and covering grade of the plaque-like biofilm	Although, both essential oils antiseptics presented a similar bactericidal activity, the alcohol-free formulation of EO rinses led to more significant reductions in the thickness and covering grade of the plaque-like biofilm than the that contains EO with alcohol rinses (thickness = 7.90 vs. 9.92 μm, P = 0.012; covering grade = 33.36 vs. 46.61%, P = 0.001).
2	5703870	Overall effectiveness after 4 days	After 4 days, the that contains EO with alcohol and alcohol-free formulation of EO solutions were significantly more effective than the WATER, reducing the bacterial viability, thickness, and covering grade of the plaque-like biofilm (P < 0.001).
1	5703870	Bacterial viability	After 4 days, the that contains EO with alcohol and alcohol-free formulation of EO solutions were significantly more effective than the WATER, reducing the bacterial viability, thickness, and covering grade of the plaque-like biofilm (P < 0.001). Although, both essential oils antiseptics presented a similar bactericidal activity, the alcohol-free formulation of EO rinses led to more significant reductions in the thickness and covering grade of the plaque-like biofilm than the that contains EO with alcohol rinses (thickness = 7.90 vs. 9.92 μm, P = 0.012; covering grade = 33.36 vs. 46.61%, P = 0.001).
1	5703870	Reduction of thickness of the plaque-like biofilm after a single mouthwash	The mean thickness of the plaque-like biofilm after rinsing was not affected by any of the essential oils formulations and ranged from 18.58 to 20.19 μm.
2	4815378	Mean weight changes of neonates 7 weeks	Mean weight changes of neonates 7 weeks after the intervention compared to those in the beginning of the intervention were significantly more in palady group compared to the cup group (cup = 146.7 and palady = 198.8; P < 0.001).  
0	4815378	Mean hospitalization time	Mean hospitalization time (cup = 39.01 and palady = 30.4; P < 0.001) and mean time interval to reach full oral feeding (cup = 33.7 and palady = 24.1; P < 0.001) were significantly lower in palady group compared to cup group.
1	4941182	Rates of safety events	Rates of safety events of special interest were generally similar between tofacitinib doses and subpopulations; however, patients receiving glucocorticoids had more serious adverse events, discontinuations due to adverse events, serious infection events and herpes zoster.
2	4941182	improvements in efficacy parameters at month 3	Across subpopulations, improvements in efficacy parameters at month 3 were generally significantly greater for both tofacitinib doses versus placebo.
2	4516063	bond strength values	Comparing the shear bond strength values, All Bond 2 (Group III) demonstrated fairly higher bond strength values at different levels of dentin. Generally comparing All Bond 2 with the other two experimental groups revealed highly significant statistical results.  
2	3101755	the mean and maximum duration of analgesia	A significant increase in the mean and maximum duration of analgesia in Group A in comparison with Group B (P<0.05) was observed.
0	3101755	Total epidural dose of fentanyl and bupivacaine	Total epidural dose of fentanyl and bupivacaine required in Group A was significantly lower in comparison with Group B in 24 hours.  
1	165418	glycemic control	A trend towards a superior improvement in glycemic control was found in the paroxetine group (p = 0.08).
1	165418	Quality of life	At the end of the study no significant difference between groups in improvement of quality of life was found.
1	165418	investigator-rated aspects of mental health	A superior increase in sex-hormone-binding-globuline (sex-hormone-binding-globuline) levels was evidenced in the paroxetine group (p = 0.01) as a sign of improved insulin sensitivity. There was also a trend for superior efficacy of paroxetine in investigator-rated anxiety and depression. This notion was supported by a trend for superior decrease of serum cortisol levels in the paroxetine group (p = 0.06).  
2	165418	Insulin sensitivity	Paroxetine has a beneficial effect on measures of insulin sensitivity and may improve glycemic control.
2	165418	Insulin sensitivity	A superior increase in sex-hormone-binding-globuline (sex-hormone-binding-globuline) levels was evidenced in the paroxetine group (p = 0.01) as a sign of improved insulin sensitivity.
2	5774613	12-month primary patency	Results: Patients treated with drug-coated balloons exhibited superior 12-month primary patency (89%) compared to patients treated with percutaneous transluminal angioplasty (48%, p<0.001).
0	5774613	Clinically-driven target lesion revascularization rate	The 12-month clinically-driven target lesion revascularization rate was 3% for drug-coated balloon vs 19% for percutaneous transluminal angioplasty (p=0.012).
1	5187654	wave I	There was no significant difference obtained for any of the parameters for wave I. In CE-Chirp ABR, the latencies for all three waves were significantly prolonged in the experimental group.
1	3600348	Positive predictive value for extubation failure	In the Automatic tube compensation group (n = 17), 11 (65%) patients passed the spontaneous breathing trial with subsequent extubation failure (9%). While in pressure support ventilation group (n = 19), 10 (53%) patients passed the spontaneous breathing trial with subsequent extubation failure (10%). This represented a positive predictive value for Automatic tube compensation of 91% and pressure support ventilation of 90% (P = 0.52).
0	4876157	Onset of action speed	The onset of action of 0.2% lidocaine in a one-per-mil tumescent solution is statistically shorter than 2% plain lidocaine (P=0.04); while its duration of action is statistically longer than 2% plain lidocaine (P<0.001).  
2	4876157	Duration of action	The onset of action of 0.2% lidocaine in a one-per-mil tumescent solution is statistically shorter than 2% plain lidocaine (P=0.04); while its duration of action is statistically longer than 2% plain lidocaine (P<0.001).  
1	5331772	Density of type 1 monocytes chemo tactic protein (MCP-1)	In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (intercellular adhesion molecule-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (interleukin-10) (P = 0.164).  
1	5331772	Intercellular adhesion molecule-1 (intercellular adhesion molecule-1)	In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (intercellular adhesion molecule-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (interleukin-10) (P = 0.164).  
1	5331772	Serum interleukin-10 (interleukin-10)	In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (intercellular adhesion molecule-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (interleukin-10) (P = 0.164).  
2	5377263	Th1 and Th1/Th2	Compared with patients in the control group, the levels of Th1 and Th1/Th2 in the observation group significantly increased, yet their Th2 decreased.
2	5377263	IL-2 and TNF-α	Compared with patients in the control group, the levels of Th1 and Th1/Th2 in the observation group significantly increased, yet their Th2 decreased. The levels of IL-2 and TNF-α were also observed to be significantly elevated, yet IL-10 decreased.
2	5377263	TLR-4 and alkaline phosphatase levels	Compared with patients in the control group, the levels of Th1 and Th1/Th2 in the observation group significantly increased, yet their Th2 decreased.
2	5377263	TLR-4 and alkaline phosphatase levels	Furthermore, their TLR-4 and alkaline phosphatase levels were significantly higher.
0	3542441	body weight gain and food efficiency ratio	Aged garlic extract (P < 0.01), Exercise, and Exercise+AGE (P < 0.001) attenuated body weight gain and food efficiency ratio compared to high-fat diet.
0	3542441	Visceral fat and liver weight gain	Visceral fat and liver weight gain were attenuated (P < 0.05) with all three interventions with a greater effect on visceral fat in the Exercise+AGE than Aged garlic extract (P < 0.001). In reducing visceral fat (P < 0.001), epididymal fat (P < 0.01) and liver weight (P < 0.001), Exercise+AGE was effective, but exercise showed a stronger suppressive effect than Aged garlic extract. Exercise+AGE showed further additive effects on reducing visceral fat and liver weight (P < 0.001).
0	3542441	body weight gain and food efficiency ratio	Aged garlic extract (P < 0.01), Exercise, and Exercise+AGE (P < 0.001) attenuated body weight gain and food efficiency ratio compared to high-fat diet.
0	3542441	body weight gain and food efficiency ratio	Aged garlic extract (P < 0.01), Exercise, and Exercise+AGE (P < 0.001) attenuated body weight gain and food efficiency ratio compared to high-fat diet.
2	5667629	Forced expiratory volume at 1 second improvement	The improvements in Forced expiratory volume at 1 second, visual analog scale, and Oswestry Disability Index were significantly greater in the experimental group than in the control group (P<0.01).
2	5667629	Oswestry Disability Index improvement	The improvements in Forced expiratory volume at 1 second, visual analog scale, and Oswestry Disability Index were significantly greater in the experimental group than in the control group (P<0.01).
2	5667629	Pain visual analog scale improvement	The improvements in Forced expiratory volume at 1 second, visual analog scale, and Oswestry Disability Index were significantly greater in the experimental group than in the control group (P<0.01).
1	3864139	Epistaxis (Overall)	The overall incidence of postoperative nasal bleeding throughout the observation period was similar between the two groups.
0	3864139	Epistaxis first episode (outside operation room)	However, outside the operation room, the incidence of the first episode of postoperative nasal bleeding in the laryngeal mask airway group was higher than that in the endotracheal tube group (difference: −26.5%; 95% CI: −42.2% to −10.7%; P < 0.001).
2	5301061	Religious dimension improvement right after test	However in the posttest step and follow-up stage, the mean scores of spiritual wellbeing, the religious dimension, and the existential aspect of spiritual wellbeing in the experimental group was significantly higher than in the control group (P < 0.001).  
2	5301061	Religious dimension improvement 1 month after test	However in the posttest step and follow-up stage, the mean scores of spiritual wellbeing, the religious dimension, and the existential aspect of spiritual wellbeing in the experimental group was significantly higher than in the control group (P < 0.001).  
2	5301061	Spiritual existential aspect 1 month after test	However in the posttest step and follow-up stage, the mean scores of spiritual wellbeing, the religious dimension, and the existential aspect of spiritual wellbeing in the experimental group was significantly higher than in the control group (P < 0.001).  
2	5301061	Spiritual well-being right after test	However in the posttest step and follow-up stage, the mean scores of spiritual wellbeing, the religious dimension, and the existential aspect of spiritual wellbeing in the experimental group was significantly higher than in the control group (P < 0.001).  
2	5301061	Spiritual well-being 1 month after test	However in the posttest step and follow-up stage, the mean scores of spiritual wellbeing, the religious dimension, and the existential aspect of spiritual wellbeing in the experimental group was significantly higher than in the control group (P < 0.001).  
2	5301061	Spiritual existential aspect right after test	However in the posttest step and follow-up stage, the mean scores of spiritual wellbeing, the religious dimension, and the existential aspect of spiritual wellbeing in the experimental group was significantly higher than in the control group (P < 0.001).  
2	4701161	megalin mRNA in adults	Vitamin A-Retinoic Acid supplementation increased total retinol in plasma, liver and lung, with a dose-by-dose accumulation in neonatal liver and lung, while transcripts for Lrat in liver, megalin in kidney, Cyp26A1/B1 in liver and lung, respectively, and Stra6 in lung, were all increased, suggesting pathways of Vitamin A uptake, storage and RA oxidation were each augmented after Vitamin A-Retinoic Acid. Vitamin A-Retinoic Acid decreased hepatic expression of Rbp4, responsible for Vitamin A trafficking from liver to plasma, and, in lung, of Raldh-1 and Raldh-2, which function in RA production.
2	4701161	Stra6 expression	Vitamin A-Retinoic Acid supplementation increased total retinol in plasma, liver and lung, with a dose-by-dose accumulation in neonatal liver and lung, while transcripts for Lrat in liver, megalin in kidney, Cyp26A1/B1 in liver and lung, respectively, and Stra6 in lung, were all increased, suggesting pathways of Vitamin A uptake, storage and RA oxidation were each augmented after Vitamin A-Retinoic Acid.
1	2758835	Global perceived effect and Headache Impact Test score (primary outcomes)	Primary outcome measures were global perceived effect (global perceived effect) and the impact of the headache using the Headache Impact Test (HIT-6).
1	2758835	Global perceived effect and Headache Impact Test score (primary outcomes)	Significant improvements on primary and secondary outcome measures were recorded in both treatment groups. No significant differences between both treatment groups were found.
1	2758835	Reduction in headache frequency, pain intensity, medication intake, absenteeism, and use of additional professional help (secondary outcomes)	Significant improvements on primary and secondary outcome measures were recorded in both treatment groups. No significant differences between both treatment groups were found.
2	5791393	Pain intensity	Intensity of pain measured by the Visual Analog Scale was higher in Group II.
1	5791393	Fever	Catheterisation does not influence: the number of additional doses of ketoprofen and pethidine administered during the 1st day after the operation, the duration of hospitalization, the occurrence of fever, significant bacteriuria, the postoperative acute urinary retention and the post-void residual urine volume.  
1	5791393	Acute urinary retention and post-void residual urine volume	Catheterisation does not influence: the number of additional doses of ketoprofen and pethidine administered during the 1st day after the operation, the duration of hospitalization, the occurrence of fever, significant bacteriuria, the postoperative acute urinary retention and the post-void residual urine volume.  
1	3051215	mean changes in body weight, BMI, and waist circumference	The treatment group had a tendency towards more reduction in anthropometry as compared to the placebo group, in body weight reduction (- 7.0 kg vs. - 4.6 kg), body mass index (- 2.51 kg/m2 vs. - 1.59 kg/m2), and waist circumference (- 7.3 cm vs. - 4.4 cm). These reductions were not statistically significant.
0	3781502	Gastrointestinal events	In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P < 0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P < 0.05).  
1	3781502	Mean HbA1c	Lixisenatide once daily demonstrated noninferiority in HbA1c reduction versus exenatide twice daily. The least squares mean change was −0.79% (mean decrease 7.97 to 7.17%) for lixisenatide versus −0.96% (mean decrease 7.96 to 7.01%) for exenatide, and treatment difference was 0.17% (95% CI, 0.033–0.297), meeting a predefined noninferiority upper CI margin of 0.4%.
1	4127855	Mean operative time	Mean operative time, mean duration of urethral catheter, and mean duration of drain removal were comparable in both the groups.
0	4127855	Lower urinary tract symptoms	However bothersome irritative lower urinary tract symptoms (lower urinary tract symptoms) and hematuria were significantly more in group B patients (P < 0.0001 and <0.013 respectively).  
1	4127855	Mean duration of urethral catheter	Mean operative time, mean duration of urethral catheter, and mean duration of drain removal were comparable in both the groups.
1	4127855	Mean duration of drain removal	Mean operative time, mean duration of urethral catheter, and mean duration of drain removal were comparable in both the groups.
0	4127855	Hematuria	However bothersome irritative lower urinary tract symptoms (lower urinary tract symptoms) and hematuria were significantly more in group B patients (P < 0.0001 and <0.013 respectively).  
2	4327560	Progression-free survival in Chemo-naive Patients	Everolimus significantly prolonged median progression-free survival regardless of prior chemotherapy use (prior chemotherapy: 11.0 vs 3.2 months; hazard ratio, 0.34; 95% confidence interval, 0.25–0.48; P < 0.0001) (chemonaive: 11.4 vs 5.4 months; hazard ratio, 0.42; 95% confidence interval, 0.29–0.60; P < 0.0001).
1	5018700	Mean blood pressure	The 2 oxycodone groups showed no significant differences in mean blood pressure, heart rate, SpO2, and bispectral index compared to Group F at the time points assessed.
1	5018700	Heart rate	The 2 oxycodone groups showed no significant differences in mean blood pressure, heart rate, SpO2, and bispectral index compared to Group F at the time points assessed.
1	5018700	Bispectral index	The 2 oxycodone groups showed no significant differences in mean blood pressure, heart rate, SpO2, and bispectral index compared to Group F at the time points assessed.
1	5018700	Rate of complications	The incidence of complications was comparable among the groups.  
1	5018700	Peripheral oxygen saturation	The 2 oxycodone groups showed no significant differences in mean blood pressure, heart rate, SpO2, and bispectral index compared to Group F at the time points assessed.
2	5851630	absolute beta power (absolute beta power) after exercise	However, in the ET+TA treatment, absolute beta power values were greater after exercise, except for Fp1.
2	5499864	preference for using long-acting injectable [LAI] medication	For 3 nonadherent patient vignettes, respondents in the experimental group were more likely to choose a long-acting injectable antipsychotic compared with those in the control group (77.7% experimental vs 25.8% control; P<0.001).
2	3309323	Movement time of the elbow	After pre- and post-training experimental group, movement time, mean velocity, normalized jerk score, mean angular velocity of shoulder, elbow, wrist and normalized jerk score of elbow and wrist improved significantlyin reaching movement of both comfortable and fast speed (p<0.05).
2	3309323	Movement time of the elbow	However, After pre- and post-training control group, mean velocity improved significantlyin reaching movement of only comfortable speed (p<0.05). Between two groups, movement time and mean angular velocity of the elbow at comfortable speed and normalized jerk score of the elbow at fast speed were statisticallysignificant (p<0.05).  
2	3309323	Mean angular velocity of the wrist	After pre- and post-training experimental group, movement time, mean velocity, normalized jerk score, mean angular velocity of shoulder, elbow, wrist and normalized jerk score of elbow and wrist improved significantlyin reaching movement of both comfortable and fast speed (p<0.05).
0	3597472	the rate of S. japonicum infection in humans, bovines, snails, cow dung and mice	Results showed that the rate of S. japonicum infection in humans, bovines, snails, cow dung and mice in the intervention group decreased from 3.41% in 2008 to 0.81% in 2011, 3.3% to none, 11 of 6,219 to none, 3.9% to none and 31.7% to 1.7%, respectively (P<0.001 for all comparisons).
0	3597472	infection risk in humans	Moreover, a generalized linear model showed that there was a higher infection risk in humans in the control group than in the intervention group (OR = 1.250, P = 0.001) and an overall significant downward trend in infection risk during the study period.  
0	3017527	LDL cholesterol levels	Compared to butter, administration of cold-pressed turnip rapeseed oil was followed by a reduction of total cholesterol by 8% (p < 0.001) and LDL cholesterol by 11% (p < 0.001).
1	3017527	Arterial elasticity	Minimal differences in arterial elasticity were not statistically significant.  
0	3017527	Oxidized LDL cholesterol	The level of oxidized LDL was 16% lower after oil period (p = 0.024).
0	3017527	Total cholesterol levels	Compared to butter, administration of cold-pressed turnip rapeseed oil was followed by a reduction of total cholesterol by 8% (p < 0.001) and LDL cholesterol by 11% (p < 0.001).
0	3271295	Appel amyotrophic lateral sclerosis rating scale slope speed	The slope of Appel ALS rating scale was 1.17 points/month lower while the patients were treated with ursodeoxycholic acid than with placebo (95% CI for difference 0.08-2.26, P = 0.037), whereas the slopes of ALSFRS-R and forced vital capacity did not show significant differences between treatments.
1	3271295	Forced vital capacity	The slope of Appel ALS rating scale was 1.17 points/month lower while the patients were treated with ursodeoxycholic acid than with placebo (95% CI for difference 0.08-2.26, P = 0.037), whereas the slopes of ALSFRS-R and forced vital capacity did not show significant differences between treatments.
2	3271295	Gastrointestinal adverse events	Gastrointestinal adverse events were more common with ursodeoxycholic acid (P < 0.05).
2	4440033	Serum interleukin-10	At week 12, serum interleukin-6 was reduced in both groups (p = 0.001), serum interleukin-10 was maintained in the Vitamin D + C group (p = 0.06) and was reduced in the Calcium group (p = 0.001).
1	4440033	Overall reduction in serum interleukin-6 after 12 weeks	At week 12, serum interleukin-6 was reduced in both groups (p = 0.001), serum interleukin-10 was maintained in the Vitamin D + C group (p = 0.06) and was reduced in the Calcium group (p = 0.001).
2	4101294	Overall response rate	RESULTS: The overall response rate and disease control rate in the combination group were significantly higher than in the chemotherapy group (23.53% vs 11.76% for overall response rate, P < .01; and 58.82% vs 35.29% for disease control rate, P < .01).
2	4101294	Disease control rate	RESULTS: The overall response rate and disease control rate in the combination group were significantly higher than in the chemotherapy group (23.53% vs 11.76% for overall response rate, P < .01; and 58.82% vs 35.29% for disease control rate, P < .01).
2	4101294	Progression-free survival	Compared with patients in the chemotherapy group, patients in the combination group had significantly longer progression-free survival (5.4 months vs 3.0 months, P < .01) and median survival (9.5 months vs 5.3 months, P < .01).
2	4101294	Median survival	Compared with patients in the chemotherapy group, patients in the combination group had significantly longer progression-free survival (5.4 months vs 3.0 months, P < .01) and median survival (9.5 months vs 5.3 months, P < .01).
1	2430614	the parasitological and clinical failure rate at day 28 post treatment	In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the Artesunate+amodiaquine group compared to the artemether-lumefantrine or Artesunate+chlorproguanil-dapsone groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005).
1	2430614	the parasitological and clinical failure rate at day 28 post treatment	However, the PCF28 corrected for re-infection was lower, though not significantly, in the Artesunate+amodiaquine group compared to the artemether-lumefantrine or the Artesunate+chlorproguanil-dapsone groups (Artesunate+amodiaquine 18.3%; artemether-lumefantrine 24.2%; Artesunate+chlorproguanil-dapsone 20.8%, p = 0.4)
2	5610854	intraocular pressure (IOP)-lowering medications	17 of the 38 eyes in group 1 (44.7%) required IOP-lowering medications as compared to seven of the 111 eyes in group 2 (6.3%).
1	4860224	Nonurgent Emergency Department visit	Most were Hispanic (68%), single (61%), primiparous (39%), and without high school diploma (44%). 35 (21%) neonates in the intervention group and 41 (27%) in the control group were brought at least once for a NUC to the Emergency Department (p = 0.12).
1	4860224	Change on knowledge scores	There was no statistically significant difference in within subject change on knowledge scores between the two study arms.
0	4079189	The consequently number of pads	The mean number of bleeding days significantly declined from 10.6 ± 2.7 days to 8.2 ± 1.9 days after 3 months treatment with the syrup (p = 0.01) and consequently the participants in the intervention group used fewer pads after 3 months (16.4 ± 10.7) compared with the number of pads used at the beginning of the treatment (22.7 ± 12.0, p = 0.01).
0	4079189	The number of bleeding days	The mean number of bleeding days significantly declined from 10.6 ± 2.7 days to 8.2 ± 1.9 days after 3 months treatment with the syrup (p = 0.01) and consequently the participants in the intervention group used fewer pads after 3 months (16.4 ± 10.7) compared with the number of pads used at the beginning of the treatment (22.7 ± 12.0, p = 0.01).
2	4883760	post-intervention test scores	Post-intervention test scores increased significantly from baseline (Game group: 29.3% gain, Didactic group: 31.5% gain; p<0.001 for each).
1	4883760	post-intervention test scores	Post-intervention test scores increased significantly from baseline (Game group: 29.3% gain, Didactic group: 31.5% gain; p<0.001 for each).
1	4621723	overactive bladder (overactive bladder) symptom scores (overactive bladder symptom scores)	Average OAB symptom scores (score 1) was determined as: 9.5 ± 2.8 for Group 1 and 10.7 ± 1.8 for Group 2 at week 0; 2.2 ± 1.2 (Group 1) and 2.4 ± 1.3 (Group 2) at week 4 (score 2); and 1.3 ± 0.5 for Group 1 and 1.3 ± 0.6 for Group 2 at week 12 (score 3). In addition, no statistically significant difference was found between the scores (p=0.062 (score 1), p=0.464 (score 2), and p=0.527 (score 3).
0	4621723	discontinuation of drugs due to side effects	The discontinuation rate of medication due to its side effects was 0 (0%) for Group 1, and 6 (10.2%) for Group 2.
0	4621723	discontinuation of drugs due to side effects	However, discontinuation of drugs due to side effects was more frequent in fesoterodine.
2	2681019	Adiponectin in women	Among women, adiponectin significantly increased after consuming red wine (29.8%, P < 0.05) and increased among men after ethanol solution (17.4%, P < 0.05) and consuming beer (16.1%, P < 0.05).
2	2681019	Adiponectin in men	Among women, adiponectin significantly increased after consuming red wine (29.8%, P < 0.05) and increased among men after ethanol solution (17.4%, P < 0.05) and consuming beer (16.1%, P < 0.05). De-alcoholized beverages had no substantial effect on adiponectin concentrations.  
2	4907713	3/4 grade nausea/vomiting/diarrhea - in axillary lymph node (LN)-positive early-stage breast cancer	Compared to 5-fluorouracil/epirubicin/cyclophosphamide, xeloda/epirubicin/cyclophosphamide was associated with more hand-foot syndrome (57% vs 11%, P<0.001) and 3/4 grade nausea/vomiting/diarrhea (30% vs 14%, P=0.034) but less phlebitis (3% vs 14%, P=0.035).
2	4907713	rate of pathological complete response in primary tumor - in axillary lymph node (LN)-positive early-stage breast cancer	Treatment with xeloda/epirubicin/cyclophosphamide led to an increased rate of pathological complete response in primary tumor (18% vs 6%, respectively, P=0.027) and objective remission rate (87% vs 73%, P=0.048) compared to 5-fluorouracil/epirubicin/cyclophosphamide.
2	4907713	hand-foot syndrome - in axillary lymph node (LN)-positive early-stage breast cancer	Compared to 5-fluorouracil/epirubicin/cyclophosphamide, xeloda/epirubicin/cyclophosphamide was associated with more hand-foot syndrome (57% vs 11%, P<0.001) and 3/4 grade nausea/vomiting/diarrhea (30% vs 14%, P=0.034) but less phlebitis (3% vs 14%, P=0.035).
2	4907713	objective remission rate - in axillary lymph node (LN)-positive early-stage breast cancer	Treatment with xeloda/epirubicin/cyclophosphamide led to an increased rate of pathological complete response in primary tumor (18% vs 6%, respectively, P=0.027) and objective remission rate (87% vs 73%, P=0.048) compared to 5-fluorouracil/epirubicin/cyclophosphamide.
1	4727651	mean motor score improvement - cases with incomplete traumatic spinal cord injury (traumatic spinal cord injury)	For incomplete traumatic spinal cord injury, the mean motor score improved from 77 (±22) to 92 (±12) in early, and from 68 (±22) to 82 (±16) in late surgery.
1	4727651	no motor improvement - cases with complete traumatic spinal cord injury (traumatic spinal cord injury)	Complete traumatic spinal cord injury patients had no motor improvement.
1	5971505	Mortality	We found no significant difference in the mortality or primary closure rates between the two groups.
1	5971505	Primary closure rates	We found no significant difference in the mortality or primary closure rates between the two groups.
2	3511948	Duration of analgesia	Duration of analgesia was longer in group M 17.5 ± 1.9 hours and SM 13.8 ± 1.6 hours than in group S 5.2 ± 1.2 hours.
2	3511948	Onset of action	Onset of action were at 7.6 ± 1.5 minutes in group S, 67.6 ± 1.5 minutes in group M and 12.2 ± 2.6 minutes in group SM.
2	3511948	Duration of analgesia	Duration of analgesia was longer in group M 17.5 ± 1.9 hours and SM 13.8 ± 1.6 hours than in group S 5.2 ± 1.2 hours.
0	4284021	Apolipoprotein B-100 (apo B)	At the highest dose (600 mg), evacetrapib significantly inhibited cholesteryl ester transfer protein activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
2	4145491	Quality of life total score	The findings showed that family empowerment model was effective in increasing the quality of life of children with chronic kidney diseases.
0	2674549	symptoms of rheumatoid arthritis	The addition of golimumab to methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy significantly reduced the signs and symptoms of rheumatoid arthritis and improved physical function.
2	2674549	physical function	The addition of golimumab to methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy significantly reduced the signs and symptoms of rheumatoid arthritis and improved physical function.
2	2674549	physical function	Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n  =  133), golimumab 100 mg injections plus placebo capsules (group 2, n  =  133), golimumab 50 mg injections plus methotrexate capsules (group 3, n  =  89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n  =  89).
2	2674549	physical function	At week 24, median improvements from baseline in health assessment questionnaire-disability index scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.
1	2674549	ACR20	The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p = 0.059) in the golimumab 100 mg plus placebo group, 55.1% (p = 0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group.
1	2674549	ACR20	Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n  =  133), golimumab 100 mg injections plus placebo capsules (group 2, n  =  133), golimumab 50 mg injections plus methotrexate capsules (group 3, n  =  89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n  =  89).
1	2674549	Median health assessment questionnaire-disability index score	At week 24, median improvements from baseline in health assessment questionnaire-disability index scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.
1	2674549	Median health assessment questionnaire-disability index score	Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n  =  133), golimumab 100 mg injections plus placebo capsules (group 2, n  =  133), golimumab 50 mg injections plus methotrexate capsules (group 3, n  =  89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n  =  89).
2	2674549	health assessment questionnaire-disability index score	Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n  =  133), golimumab 100 mg injections plus placebo capsules (group 2, n  =  133), golimumab 50 mg injections plus methotrexate capsules (group 3, n  =  89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n  =  89).
2	2674549	health assessment questionnaire-disability index score	At week 24, median improvements from baseline in health assessment questionnaire-disability index scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.
2	2674549	health assessment questionnaire-disability index score	Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n  =  133), golimumab 100 mg injections plus placebo capsules (group 2, n  =  133), golimumab 50 mg injections plus methotrexate capsules (group 3, n  =  89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n  =  89).
2	2674549	health assessment questionnaire-disability index score	At week 24, median improvements from baseline in health assessment questionnaire-disability index scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.
0	5101425	Thrombocytopenia rate	The analysis revealed that the rate of thrombocytopenia after surgery was higher in the control group (P = 0.012).  
1	5101425	Bleeding rate after surgery	No significant difference was noted between the groups regarding the rate of bleeding after surgery (359.3 ± 266.2 in group D vs. 406.3 ± 341.6 in group P (control group); P = 0.208).
1	5101425	Complications	There was no significant difference between the groups regarding age, gender, pump time, clamp time, duration of surgery, complications, and the changes in hemoglobin and coagulation test measurements (P > 0.05).
1	4050230	periodontal disease	There was no significant difference when the efficacy of triphala was compared with 0.2% chlorhexidine in hospitalized patients with periodontal disease.
1	4815882	Overall survival	No significant difference was observed between the two groups with respect to overall survival (median, 15.9 months (simvastatin) vs 19.9 months (placebo), P=0.826).
1	4815882	Toxicity	The addition of 40 mg simvastatin to the XELIRI/FOLFIRI regimens did not improve progression-free survival in patients with previously treated metastatic colorectal cancer nor did it increase toxicity.
1	4815882	Progression-free survival	The median progression-free survival was 5.9 months (95% CI, 4.5–7.3) in the XELIRI/FOLFIRI plus simvastatin group and 7.0 months (95% CI, 5.4–8.6) in the XELIRI/FOLFIRI plus placebo group (P=0.937).
0	5404432	Recurrence rates	Recurrence rates were 12% in the cone of pressure flap group and 60% in the conventional flap coverage group (P < 0.001).
2	3425422	U46619-induced fibrinogen binding	U46619-induced fibrinogen binding was unchanged after meal intake with placebo but was markedly enhanced (by ∼50–60%) after premeal insulin.
2	3425422	enhanced U46619-induced platelet P-selectin expression	The standardized meal enhanced U46619-induced platelet P-selectin expression by 23% after placebo; this response was more than doubled after premeal insulin.
1	3221331	Continuous abstinence at 6 months	Continuous abstinence at 6 months was 26.4% (29/110) in the intervention group and 27.6% (32/116) in the control group (P = .8).
2	3576910	drug cost	Compared with maintaining existing stimulant monotherapy, adding guanfacine extended release to existing stimulant monotherapy was associated with an incremental drug cost of $US1016 but a lower medical cost of $US124, resulting in a total incremental cost of $US892 at 1 year.
0	3576910	medical cost	Compared with maintaining existing stimulant monotherapy, adding guanfacine extended release to existing stimulant monotherapy was associated with an incremental drug cost of $US1016 but a lower medical cost of $US124, resulting in a total incremental cost of $US892 at 1 year.
2	4335628	peak oxygen consumption and workload at ventilatory threshold 1	No significant changes in homocysteine levels were observed in the experimental group (p > 0.05), but there was a significant increase in peak oxygen consumption and workload at ventilatory threshold 1 as well as a significant improvement in cholesterol, triglycerides, HDL, glucose, alkaline phosphatase, urea, T3, T4 and prostate-specific antigen compared with the control group (p < 0.05).  
1	4335628	homocysteine (homocysteine) levels	No significant changes in homocysteine levels were observed in the experimental group (p > 0.05), but there was a significant increase in peak oxygen consumption and workload at ventilatory threshold 1 as well as a significant improvement in cholesterol, triglycerides, HDL, glucose, alkaline phosphatase, urea, T3, T4 and prostate-specific antigen compared with the control group (p < 0.05).  
2	4335628	cognitive function	A significant improvement in cognitive function was observed in the experimental group compared with the control group (p < 0.05).
2	4836241	Kupperman menopausal index and hot flash/sweating score	At the 4th week after gonadotropin releasing hormone agonist therapy, Kupperman menopausal index and hot flash/sweating score results were as follows: Control group > Kuntai group > Tibolone group (P < 0.05); at the 8th and 12th week after gonadotropin releasing hormone agonist therapy, Kupperman menopausal index and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and Tibolone group (P > 0.05).
2	4836241	estradiol (E2) leve	After therapy, serum E2 level in Tibolone group was obviously higher than the other two groups (P < 0.05), while follicle-stimulating hormone and luteinizing hormone levels were obviously lower (P < 0.05).
0	4836241	follicle-stimulating hormone (follicle-stimulating hormone), luteinizing hormone (luteinizing hormone)	After therapy, serum E2 level in Tibolone group was obviously higher than the other two groups (P < 0.05), while follicle-stimulating hormone and luteinizing hormone levels were obviously lower (P < 0.05). (5) The incidence of vaginal bleeding, breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05).  
2	4836241	Kupperman menopausal index and hot flash/sweating score	ABSTRACT.RESULTS:. (1) Before gonadotropin releasing hormone agonist therapy, the baseline parameter results were comparable in the three groups (P > 0.05). (2) After gonadotropin releasing hormone agonist therapy, Kupperman menopausal index and hot flash/sweating scores in all the three groups increased significantly (P < 0.05).
0	4836241	follicle-stimulating hormone (follicle-stimulating hormone), luteinizing hormone (luteinizing hormone) and estradiol (E2) level and endometrial thickness	(4) The posttherapeutic serum follicle-stimulating hormone (follicle-stimulating hormone), luteinizing hormone (luteinizing hormone) and estradiol (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05).
2	4836241	incidence of vaginal bleeding, breast distending pain	(5) The incidence of vaginal bleeding, breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05).  
1	4836241	Kupperman menopausal index and hot flash/sweating score	At the 4th week after gonadotropin releasing hormone agonist therapy, Kupperman menopausal index and hot flash/sweating score results were as follows: Control group > Kuntai group > Tibolone group (P < 0.05); at the 8th and 12th week after gonadotropin releasing hormone agonist therapy, Kupperman menopausal index and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and Tibolone group (P > 0.05).
1	3106384	oxygen saturation (SpO2) or end-tidal carbon dioxide (EtCO2)	There were no statistically significant differences in oxygen saturation (SpO2) or end-tidal carbon dioxide (EtCO2) between the two groups before or during peritoneal insufflation.
2	1187893	Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months	In the exercise group, an improvement was seen at 6 weeks in the KOOS subscale quality of life compared to the control group (mean change 4.0 vs. -0.7, p = 0.05). The difference between groups was still persistent at 6 months (p = 0.02).  
1	1187893	Knee injury and Osteoarthritis Outcome Score	No significant differences in the KOOS subscales assessing pain, other symptoms, or function in daily life or in sport and recreation were seen at any time point between exercisers and controls.
1	1187893	Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 weeks	In the exercise group, an improvement was seen at 6 weeks in the KOOS subscale quality of life compared to the control group (mean change 4.0 vs. -0.7, p = 0.05).
0	4604289	Heart rate	The heart rate was significantly lower, immediately after extubation and 3, 5, and 10 minutes after extubation, in both magnesium and remifentanil groups, compared to normal saline (P < 0.001).
0	4604289	Heart rate	The heart rate was significantly lower, immediately after extubation and 3, 5, and 10 minutes after extubation, in both magnesium and remifentanil groups, compared to normal saline (P < 0.001).
0	4604289	Mean arterial pressure	The mean arterial pressure was also lower in magnesium and remifentanil groups, immediately after extubation and 3 minutes after extubation, in comparison to the normal saline group (P < 0.001).
0	4604289	Mean arterial pressure	The mean arterial pressure was also lower in magnesium and remifentanil groups, immediately after extubation and 3 minutes after extubation, in comparison to the normal saline group (P < 0.001).
2	4604289	Double burst time	Mean (± SD) double burst time 100% was significantly higher in magnesium group (30.2 ± 15.3) vs. remifenatnil (13.6 ± 6.8) and normal saline (13.5 ± 8.2) groups (P < 0.001).  
2	4604289	Double burst time	Mean (± SD) double burst time 100% was significantly higher in magnesium group (30.2 ± 15.3) vs. remifenatnil (13.6 ± 6.8) and normal saline (13.5 ± 8.2) groups (P < 0.001).  
2	2228375	Morning peak expiratory flow	The increase in morning peak expiratory flow with budesonide/formoterol pressurised metered-dose inhaler was significantly higher than with budesonide pressurised metered-dose inhaler (+28.7 l/min; p < 0.001).
1	2228375	Morning peak expiratory flow	Therapeutically equivalent increases in morning peak expiratory flow were observed with budesonide/formoterol pressurised metered-dose inhaler (29.3 l/min) and budesonide/formoterol dry-powder inhaler (32.0 l/min) (95% confidence interval: −10.4 to 4.9; p = 0.48).
2	4077042	improvement of QOLRAD-J (Japanese translation of Quality of Life in Reflux and Dyspepsia)	Omeprazole statistically significantly improved GERD-related quality of life from 30.8±0.7 to 33.0±0.5 (P<0.01) (QOLRAD-J, total) and from 6.0±0.2 to 6.6±0.1 (P<0.01) (QOLRAD-J, sleep-related) when administrated to patients with reflux symptoms.
2	4077042	improvement of Pittsburg Sleep Quality Index (Pittsburg Sleep Quality Index)	Omeprazole also improved insomnia significantly better than the placebo in patients with reflux symptoms; Pittsburg Sleep Quality Index, from 9.3±0.5 to 7.9±0.5 (P<0.01) and sleep diary, from 2.1±0.1 to 1.8±0.1 (P<0.01).
2	4077042	improvement of GERD-related quality of life (quality of life) and sleep disturbance	Omeprazole statistically significantly improved GERD-related quality of life from 30.8±0.7 to 33.0±0.5 (P<0.01) (QOLRAD-J, total) and from 6.0±0.2 to 6.6±0.1 (P<0.01) (QOLRAD-J, sleep-related) when administrated to patients with reflux symptoms. Omeprazole also improved insomnia significantly better than the placebo in patients with reflux symptoms; Pittsburg Sleep Quality Index, from 9.3±0.5 to 7.9±0.5 (P<0.01) and sleep diary, from 2.1±0.1 to 1.8±0.1 (P<0.01).
2	5793008	mindfulness	Mindfulness, aggression, and negative emotional regulation changed significantly for the Yoga Pranayama group, while mindfulness alone improved significantly for the Vedic Mathematics group.
2	5793008	mindfulness	Mindfulness, aggression, and negative emotional regulation changed significantly for the Yoga Pranayama group, while mindfulness alone improved significantly for the Vedic Mathematics group.
2	5793008	negative emotion control	Mindfulness, aggression, and negative emotional regulation changed significantly for the Yoga Pranayama group, while mindfulness alone improved significantly for the Vedic Mathematics group.
2	5793008	mindfulness	Mindfulness, aggression, and negative emotional regulation changed significantly for the Yoga Pranayama group, while mindfulness alone improved significantly for the Vedic Mathematics group.
0	5793008	agression	Mindfulness, aggression, and negative emotional regulation changed significantly for the Yoga Pranayama group, while mindfulness alone improved significantly for the Vedic Mathematics group.
0	3150311	LDL cholesterol	Plasma LDL cholesterol decreased (P < 0.05) with alternate day fasting (10 ± 4%) and calorie restriction (8 ± 4%), whereas HDL cholesterol increased (P < 0.05) with exercise (16 ± 5%).
2	3150311	HDL cholesterol	Plasma LDL cholesterol decreased (P < 0.05) with alternate day fasting (10 ± 4%) and calorie restriction (8 ± 4%), whereas HDL cholesterol increased (P < 0.05) with exercise (16 ± 5%).
1	3321403	Voiding symptoms	Intravesical resiniferatoxin instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale.  
1	3321403	Uroflowmetry	Intravesical resiniferatoxin instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale.  
2	3321403	Improvement in pain scores	Intravesical resiniferatoxin instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale.  
0	4215680	progression of chronic prostatitis plus irritable bowel syndrome toward chronic microbial prostate-vesiculitis (prostate-vesiculitis) or prostate-vesiculo-epididymitis (prostate-vesiculo-epididymitis) in infertile males	Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured chronic bacterial prostatitis plus irritable bowel syndrome.
0	5080766	total cholesterol and low-density lipoprotein cholesterol levels	Serum total cholesterol (total cholesterol) and low-density lipoprotein cholesterol (low-density lipoprotein cholesterol) in the high dose group significantly decreased over time during growth hormone therapy.
1	5864139	Cases of pancreatic cancer	Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%]) versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28–1.51], P = 0.32; 0.042 vs. 0.066 events/100 patient-years).
1	5864139	Cases of pancreatic cancer	Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%]) versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28–1.51], P = 0.32; 0.042 vs. 0.066 events/100 patient-years).
1	3496170	Learned irrelevance index	Biperiden had no effect on the behavioural Learned irrelevance measures, although prolonged reaction times were evident.
0	5077078	deactivation of the posterior regions of the default mode network	However, relatively reduced deactivation was found in Parkinson's disease patients in posterior regions of the default mode network, notably the precuneus and the posterior cingulate cortex.  
0	3653258	Systolic blood	After drinking commercial Citrus sinensis juice, diastolic and systolic blood pressure were significantly decreased (5.13%; P = 0.03 and -5.91%; P = 0.003, respectively). However, consumption of natural Citrus sinensis juice did not have significant effects on either diastolic or systolic blood pressure.  
0	3653258	Diastolic blood	After drinking commercial Citrus sinensis juice, diastolic and systolic blood pressure were significantly decreased (5.13%; P = 0.03 and -5.91%; P = 0.003, respectively). However, consumption of natural Citrus sinensis juice did not have significant effects on either diastolic or systolic blood pressure.  
0	3751685	Short Physical Performance Battery at 12 months	The score on the Short Physical Performance Battery, in which higher scores indicate better physical status, was stable in the intervention group and had declined in the control group; with the mean difference between groups being 1.44 (95% confidence interval, 0.80, 2.07; P <0.001) at 12 months.
2	4696975	required additional ablation	1) Among the post-procedural immediate recurrence of atrial premature beats provocation group, 33% showed immediate recurrence of atrial premature beats and required additional ablation with a longer procedure time (p=0.001) than those without immediate recurrence of atrial premature beats, without increasing the complication rate.
2	4696975	longer procedure time	1) Among the post-procedural immediate recurrence of atrial premature beats provocation group, 33% showed immediate recurrence of atrial premature beats and required additional ablation with a longer procedure time (p=0.001) than those without immediate recurrence of atrial premature beats, without increasing the complication rate.
1	4112798	Quality of life	No statistically significant quality of life differences were found.  
1	4112798	Overall survival	Median overall survival (overall survival) was 2.9 and 3.4 months in the placebo and erlotinib arms; HR 0.95 (95% CI = 0.58 to 1.55; P = .83).
1	4112798	Grade 3/4 adverse event	Grade 3/4 adverse event rates were similar between the two groups (70.0% in each arm), except for rash 20.0% (erlotinib) vs 5.0% (placebo), and fatigue 17.5% vs 35.0%.
1	4112798	Neurological progression-free survival	Median neurological progression-free survival was 1.6 months in both arms; neurological progression-free survival HR 0.95 (95% CI = 0.59 to1.54; P = .84).
2	4320624	peak forced expiratory volume in 1 s	Abediterol produced dose-dependent improvements in peak forced expiratory volume in 1 s from baseline compared with placebo, from 0.274 (95% CI 0.221, 0.327) to 0.405 L (95% CI 0.353, 0.458) for abediterol 0.313 to 2.5 μg, respectively (p < 0.0001 all doses).
2	4320624	Dose-dependent changes from baseline in trough forced expiratory volume in 1 s	Dose-dependent changes from baseline in trough forced expiratory volume in 1 s versus placebo were 0.219 (95% CI 0.136, 0.302) to 0.400 L (95% CI 0.317, 0.483) for abediterol 0.313 to 2.5 μg, respectively (p < 0.0001).
1	4320624	peak forced expiratory volume in 1 s	Abediterol 0.625, 1.25, and 2.5 μg had similar magnitude of peak forced expiratory volume in 1 s effect to salbutamol.
1	4320624	peak forced expiratory volume in 1 s	Abediterol 0.625–2.5 μg provided dose-dependent, clinically and statistically significant bronchodilation versus placebo in patients with asthma, with a peak effect similar to salbutamol and duration of action compatible with once-daily dosing.
2	5289138	1,5-anhydroglucitol	In addition, vildagliptin group showed a significant increase in 1,5-anhydroglucitol compared with the control group (4.5 ± 3.4 vs. 0.5 ± 4.1 μg/mL, P < 0.05).
0	5289138	hemoglobin A1c	Treatment with vildagliptin significantly reduced hemoglobin A1c from 8.1±0.7% at baseline to 7.1±0.7% (P < 0.01), while there was no significant change of hemoglobin A1c in the control group.
0	5289138	hemoglobin A1c	Vildagliptin group showed significant reduction of hemoglobin A1c compared with control group (-1.0±0.3% vs. 0.2±0.8%, P < 0.01).
2	5312688	HIV-related and antiretroviral treatment medication knowledge	Repeated-measures analysis showed that both HIV-related and antiretroviral treatment medication knowledge of the intervention group showed better improvement over time than those of the control group after the intervention (P<0.0001).
2	5312688	Visual Analog Scale mean score	For the adherence measures, compared with the control group, participants in the intervention group had significantly higher Visual Analog Scale mean score (Z=2.735, P=0.006) and lower suboptimal adherence rate (Z=2.208, P=0.027) at the end of the study.
0	4152682	Pulse rate during surgery	Pulse rate (95.9 ± 11.2 bpm vs. 102.9 ± 8.8 bpm, P = 0.001) systolic and diastolic BP were significantly higher in Group N. Median intraoperative fentanyl requirement was significantly higher in Group N (81 mcg vs. 114 mcg, P = 0.000).
2	4152682	Analgesia duration	Visual analog scale scores on emergence at rest (median Visual analog scale 3 mm vs 27 mm), with activity (median 8 mm vs. 35 mm) were significantly lower in Group B. Median duration of analgesia was significantly higher in Group B (290 min vs. 16 min, P = 0.000).
0	4152682	Requirement of fentanyl during surgery	Pulse rate (95.9 ± 11.2 bpm vs. 102.9 ± 8.8 bpm, P = 0.001) systolic and diastolic BP were significantly higher in Group N. Median intraoperative fentanyl requirement was significantly higher in Group N (81 mcg vs. 114 mcg, P = 0.000).
0	4152682	Visual analog scale scores	Visual analog scale scores on emergence at rest (median Visual analog scale 3 mm vs 27 mm), with activity (median 8 mm vs. 35 mm) were significantly lower in Group B. Median duration of analgesia was significantly higher in Group B (290 min vs. 16 min, P = 0.000).
2	2291568	Weight gain in not underweight children	At this final follow up, the albendazole-treated arm exhibited a similar height gain but a 35 (SE 5) % greater weight gain, equivalent to an extra 1 (SE 0.15) kg over 2 years (99% CI 0.6–1.4 kg, p = 10−11).  
2	2291568	Weight gain in not underweight children	In such urban slums in the 1990s, five 6-monthly rounds of single dose anthelmintic treatment of malnourished, poor children initially aged 1–5 years results in substantial weight gain.
2	2291568	Weight gain in underweight children	At this final follow up, the albendazole-treated arm exhibited a similar height gain but a 35 (SE 5) % greater weight gain, equivalent to an extra 1 (SE 0.15) kg over 2 years (99% CI 0.6–1.4 kg, p = 10−11).  
1	4046846	Self-efficacy	The benefits demonstrated at 4-months in the FACETS arm for fatigue severity and self-efficacy largely persisted, with a slight reduction in standardised effect sizes (standardised effect sizes) (−0.29, p = 0.06 and 0.34, p = 0.09, respectively). There was a significant difference on the multiple sclerosis Impact Scale favouring FACETS that had not been present at 4-months (standardised effect sizes −0.24, p = 0.046). No adverse events were reported.  
1	4046846	Fatigue severity	The benefits demonstrated at 4-months in the FACETS arm for fatigue severity and self-efficacy largely persisted, with a slight reduction in standardised effect sizes (standardised effect sizes) (−0.29, p = 0.06 and 0.34, p = 0.09, respectively). There was a significant difference on the multiple sclerosis Impact Scale favouring FACETS that had not been present at 4-months (standardised effect sizes −0.24, p = 0.046). No adverse events were reported.  
1	4046846	Adverse events	No adverse events were reported.  
0	4898395	respiratory rate	Heart rate (beats/min) (Ket = 119 ± 18; fentanyl-midazolam-medetomidine = 89 ± 17; p = 0.0066), systolic blood pressure (mmHg) (Ket = 109 ± 10; fentanyl-midazolam-medetomidine = 97 ± 10; p = 0.0313), and respiratory rate (breaths/min) (Ket = 39 ± 9; fentanyl-midazolam-medetomidine = 29 ± 10; p = 0.0416) were significantly lower in the fentanyl-midazolam-medetomidine group.
2	4898395	Recovery rate	Onset of a sufficient degree of sedation for safe handling was more rapid with ketamine (ketamine = 2.9 ± 1.4 min; fentanyl-midazolam-medetomidine = 7.9 ± 1.2 min; p = 0.0009), but fentanyl-midazolam-medetomidine recovery was faster (ketamine = 21.4 ± 13.4 min; fentanyl-midazolam-medetomidine = 9.1 ± 3.6 min; p = 0.0379) and of better quality (ketamine = 1.3 ± 0.9; fentanyl-midazolam-medetomidine = 7.4 ± 1.9; p = 0.0009) most probably because of the effectiveness of the reversal agents used.  
0	4898395	Heart rate	Heart rate (beats/min) (Ket = 119 ± 18; fentanyl-midazolam-medetomidine = 89 ± 17; p = 0.0066), systolic blood pressure (mmHg) (Ket = 109 ± 10; fentanyl-midazolam-medetomidine = 97 ± 10; p = 0.0313), and respiratory rate (breaths/min) (Ket = 39 ± 9; fentanyl-midazolam-medetomidine = 29 ± 10; p = 0.0416) were significantly lower in the fentanyl-midazolam-medetomidine group.
0	4898395	systolic blood pressure	Heart rate (beats/min) (Ket = 119 ± 18; fentanyl-midazolam-medetomidine = 89 ± 17; p = 0.0066), systolic blood pressure (mmHg) (Ket = 109 ± 10; fentanyl-midazolam-medetomidine = 97 ± 10; p = 0.0313), and respiratory rate (breaths/min) (Ket = 39 ± 9; fentanyl-midazolam-medetomidine = 29 ± 10; p = 0.0416) were significantly lower in the fentanyl-midazolam-medetomidine group.
1	4331314	injury severity score, revised trauma score, and trauma injury severity score	There were no significant differences between groups for matched data and prognostic scores: injury severity score, revised trauma score, and trauma injury severity score.
0	4331314	Ventilator time and overall hospital stay	Ventilator time (142 ± 224 versus 74 ± 125 hours, P = 0.026) and overall hospital stay (142 ± 224 versus 74 ± 125 hours, P = 0.026) were significantly lower for the surgical group after adjustment on prognostic scores.
1	4331314	ICU stay	There was a trend towards shorter ICU stay for operative patients (12.3 ± 8.5 versus 9.0 ± 4.3 days, P = 0.076).
1	3417877	Skin texture	The cellulose mask increased moisture levels in the skin significantly more than moist towels (P < 0.05) after a single application. No obvious effects on other skin characteristics were found.
2	3417877	Facial moisture	The cellulose mask increased moisture levels in the skin significantly more than moist towels (P < 0.05) after a single application. No obvious effects on other skin characteristics were found.
1	3417877	Sebum level	Skin moisture, sebum, elasticity, texture, dullness, and desquamation levels were assessed using a system used for routine skin counseling before applying the trial product and five minutes after its removal.
1	3417877	Sebum level	The cellulose mask increased moisture levels in the skin significantly more than moist towels (P < 0.05) after a single application. No obvious effects on other skin characteristics were found.
1	3417877	Elasticity	Skin moisture, sebum, elasticity, texture, dullness, and desquamation levels were assessed using a system used for routine skin counseling before applying the trial product and five minutes after its removal.
1	3417877	Elasticity	The cellulose mask increased moisture levels in the skin significantly more than moist towels (P < 0.05) after a single application. No obvious effects on other skin characteristics were found.
1	3944580	Obestatin	However, changes in obestatin and des-acyl ghrelin concentration were statistically insignificant (P > 0.05).
1	3944580	Obestatin	The data indicated that although acute treadmill exercise resulted in a significant change in acyl ghrelin and leptin levels, it had no effect on plasma obestatin and des-acyl ghrelin levels.
1	3944580	Des-acyl ghrelin	However, changes in obestatin and des-acyl ghrelin concentration were statistically insignificant (P > 0.05).
0	3944580	Acyl ghrelin	A two-way ANOVA revealed a significant (P < 0.05) interaction effect for leptin and acyl ghrelin.
0	3944580	Acyl ghrelin	The data indicated that although acute treadmill exercise resulted in a significant change in acyl ghrelin and leptin levels, it had no effect on plasma obestatin and des-acyl ghrelin levels.
1	2660282	Fat free mass	All 3 groups had significant gains in strength, averaging 47% in all major muscle groups and significant increases in fat free mass (2.6%), with no difference among groups.
1	2660282	Fat free mass	All 3 groups had significant gains in strength, averaging 47% in all major muscle groups and significant increases in fat free mass (2.6%), with no difference among groups.
1	2660282	Waist-to-hip ratio	Percent body fat and waist-to-hip ratio decreased significantly in all 3 groups an average of 8% and 2%, respectively, with no difference among groups.
1	2660282	Strength	All 3 groups had significant gains in strength, averaging 47% in all major muscle groups and significant increases in fat free mass (2.6%), with no difference among groups.
1	2660282	Body fat	Percent body fat and waist-to-hip ratio decreased significantly in all 3 groups an average of 8% and 2%, respectively, with no difference among groups.
1	2660282	Total serum cholesterol	Total serum cholesterol decreased significantly, again with no difference among groups.  
1	2660282	Strength	All 3 groups had significant gains in strength, averaging 47% in all major muscle groups and significant increases in fat free mass (2.6%), with no difference among groups.
2	5909776	The frequency of knowledge of elder abuse after the intervention	However, the frequency of high knowledge of elder abuse (94.8% in the intervention group and 46.6% in the control group), high self-efficacy (82.8% and 7.8%, respectively), high social support (97.0% and 10.3%, respectively) and high health promoting lifestyle (97.0% and 10.3%, respectively) was significantly higher (P<0.001) and the frequency of elder abuse risk (28.0% and 49.6%, respectively) was significantly less in the intervention group after the intervention.
2	5909776	The frequency of health promoting lifestyle after the intervention	However, the frequency of high knowledge of elder abuse (94.8% in the intervention group and 46.6% in the control group), high self-efficacy (82.8% and 7.8%, respectively), high social support (97.0% and 10.3%, respectively) and high health promoting lifestyle (97.0% and 10.3%, respectively) was significantly higher (P<0.001) and the frequency of elder abuse risk (28.0% and 49.6%, respectively) was significantly less in the intervention group after the intervention.
2	5909776	The frequency of social support after the intervention	However, the frequency of high knowledge of elder abuse (94.8% in the intervention group and 46.6% in the control group), high self-efficacy (82.8% and 7.8%, respectively), high social support (97.0% and 10.3%, respectively) and high health promoting lifestyle (97.0% and 10.3%, respectively) was significantly higher (P<0.001) and the frequency of elder abuse risk (28.0% and 49.6%, respectively) was significantly less in the intervention group after the intervention.
2	5909776	The frequency of self-efficacy after the intervention	However, the frequency of high knowledge of elder abuse (94.8% in the intervention group and 46.6% in the control group), high self-efficacy (82.8% and 7.8%, respectively), high social support (97.0% and 10.3%, respectively) and high health promoting lifestyle (97.0% and 10.3%, respectively) was significantly higher (P<0.001) and the frequency of elder abuse risk (28.0% and 49.6%, respectively) was significantly less in the intervention group after the intervention.
2	4976892	HIV-specific antibody response	We found that the DNA prime-rAd5 boost vaccine induced a significant cross-clade HIV-specific antibody response, which correlated with antibody neutralization efficiency.
1	5504600	Incidence of constipation	Safety: Vomiting on day 1 occurred in 11%, constipation in 35% of the tapentadol patients and in 16% and 30% of the oxycodone/naloxone patients (p = 0.60 and 0.33), respectively.
1	5504600	Incidence of Vomiting on day 1	Safety: Vomiting on day 1 occurred in 11%, constipation in 35% of the tapentadol patients and in 16% and 30% of the oxycodone/naloxone patients (p = 0.60 and 0.33), respectively.
1	5504600	Pain intensity during exercise in the first 24h of post operatory	Mean maximum pain intensity during exercise in the first 24 h after surgery was 3.8 ± 1.9 (tapentadol) and 3.8 ± 2.1 (oxycodone/naloxone). Statistically tapentadol was non-inferior but not superior to oxycodone/naloxone.
1	5504600	Total score of side effect events	The sum score of side effect events was 51% in the tapentadol vs. 49% in the oxycodone/naloxone group; risk difference 3% [95% CI, −8 to 14%]; p = 0.6).
1	1831486	Nicotine replacement therapy	Reporting of nicotine replacement therapy consumption was poor, with much missing data, but reporting of ratings of withdrawal symptom scores was nearly complete. However, these showed no significant changes or differences between groups for any week.  
1	1831486	Withdrawal symptom	Reporting of nicotine replacement therapy consumption was poor, with much missing data, but reporting of ratings of withdrawal symptom scores was nearly complete. However, these showed no significant changes or differences between groups for any week.  
2	3661239	Post-test scores	Improvement in post-test performance of group A was significantly greater than of group B, demonstrating the effectiveness of patient-oriented problem-solving.
2	4285787	Glycosuria	Canagliflozin increased urinary glucose excretion in a dose-dependent manner and produced statistically significant reductions in body weight compared with placebo (least squares mean percent changes from baseline of −2.2%, −2.9%, −2.7%, and −1.3% with canagliflozin 50, 100, and 300 mg and placebo; P < 0.05 for all comparisons).
1	4285787	Adverse events	Overall adverse event (adverse event) rates were similar across groups.
2	4285787	Body weight reduction	Canagliflozin increased urinary glucose excretion in a dose-dependent manner and produced statistically significant reductions in body weight compared with placebo (least squares mean percent changes from baseline of −2.2%, −2.9%, −2.7%, and −1.3% with canagliflozin 50, 100, and 300 mg and placebo; P < 0.05 for all comparisons).
2	5587697	Stress	Additionally, stress effects varied as a function of impulsivity traits. Individuals who lacked perseverance (i.e., had difficulty focusing on a difficult or boring task) gambled more after experiencing a loss in the stress condition than did those in the control condition.
2	3733184	Rate of error	Also, increase in sound pressure level increased the rate of error (P < 0.05).  
2	3733184	Speed of work	The results of this study showed that increasing sound pressure level from 65 to 95 dB in network 'A' increased the speed of work (P < 0.05).
1	4673066	extraneous or germane load	There was no significant difference in reported extraneous (p = 0.36) or germane (p = 0.42) cognitive load.  
0	4673066	intrinsic cognitive load	Schema-based instruction was associated with increased diagnostic performance on written questions (64 ± 22 % vs 44 ± 25 % p < 0.001) and reduced intrinsic cognitive load (mean difference = 15 %, standard error 3 %, p < 0.001).
0	3327628	Overall survey response rate	The response rate among the control group (no offer of continuing medical education credit) was 16.6%, while among those offered the continuing medical education opportunity, the response rate was 12.0% (p < 0.0001).  
1	5395856	Total K7-positive cells	No difference between the two groups could be observed regarding the proliferative hepatocyte number, proliferative K7-positive cells, or total K7-positive cells at the 4-week follow-up liver biopsy.
1	5395856	Proliferative hepatocyte number	No difference between the two groups could be observed regarding the proliferative hepatocyte number, proliferative K7-positive cells, or total K7-positive cells at the 4-week follow-up liver biopsy.
2	4510702	Time at target range	The proportion of time when sensor glucose was in the target range (3.9–8.0 mmol/l) overnight (between 24:00 and 08:00 hours) was 18.5% greater during closed‐loop insulin delivery than during sensor‐augmented therapy (p < 0.001).
0	4510702	Mean overnight sensor glucose	Closed‐loop therapy significantly reduced mean overnight glucose levels by 0.9 mmol/l (p < 0.001), with no difference in glycaemic variability, as measured by the standard deviation of sensor glucose.
0	4510702	Sensor hypoglycaemia	Closed‐loop therapy significantly reduced mean overnight glucose levels by 0.9 mmol/l (p < 0.001), with no difference in glycaemic variability, as measured by the standard deviation of sensor glucose.
2	4510702	Overnight insulin delivered	Lower mean overnight glucose levels during closed‐loop therapy were brought about by increased overnight insulin delivery (p < 0.001) without changes to the total daily delivery (p = 0.84).  
1	4270681	Patient awareness	The overall incidence of awareness in the Bispectral and routine monitoring groups were 5.5% and 4.1%, which was not significantly different.
1	4270681	Systolic blood pressure	There were no significant differences in hemodynamic indices including systolic blood pressure, diastolic blood pressure, heart rate, and SPO2 before induction of anesthesia between the two groups. These between-group differences in the studied indices remained insignificant at different time points after anesthesia induction as well as post ICU hospitalization.
1	5311860	Effective use of syndromic alerts after 1 year	Despite efforts to create standardized protocols and engage public health agencies in the process, no significant differences in the effective use of syndromic alerts were observed beyond year 1.
0	4067355	the risk of stroke, all-cause mortality	Compared to imputed placebo, all NOACs reduced the risk of stroke (odds ratios between 0.24 and 0.42, all p<0.001) and all-cause mortality (odds ratios between 0.55 and 0.59, all p<0.05).
0	4067355	The risk of major bleedings	The risk of major bleedings was lower with edoxaban 30 mg than any other NOAC, odds ratios (odds ratios) ranging between 0.45 and 0.67 (all p<0.001).  
0	4314171	after 10 days therapy - arterial BP level in patients who had stage I hypertension	Sulphate-sulphide mineral water "Mlječanica" caused significant (p<0.05) lowering of arterial BP level after 10 days of therapy in patients who had stage I hypertension.
0	3561645	risk of episodes of high reliever use	Budesonide/formoterol maintenance and reliever therapy significantly reduced the risk of episodes of high reliever use (>6 inhalations/day) vs. all alternative ICS/LABA regimens.
1	4093188	half carcasses	A comparison of half carcasses across the groups has shown no difference between the control group and the one with supplements, while the weight of half carcasses in the grazing group was smaller in comparison with groups C and S (p<0.001).
2	4093188	the weight of half carcasses	A comparison of half carcasses across the groups has shown no difference between the control group and the one with supplements, while the weight of half carcasses in the grazing group was smaller in comparison with groups C and S (p<0.001).
2	4093188	The fat of pelvic limb	The pelvic limb of grazing lambs contained less fat compared to the control and supplemented groups (p<0.001).
2	4093188	The fat of pelvic limb	The lambs from group G were grazed every day from May to July (2 months).
2	4093188	The concentrations of Se and ZnSO4 in the blood plasma of ram-lambs	The concentrations of Se and ZnSO4 in the blood plasma of ram-lambs from the supplemented group were significantly higher than for the control and grazing lambs.
1	3750227	Glomerular filtration rate increase	The mean e-GFR ranged 46.3 to 48.59 ml/mint/1.73 m2 in those treated with olmesartan and 46.8 to 48.3 ml/mint/1.73 m2 in those with enalapril and remained unchanged at the end of the study.
1	3750227	Microalbuminuria decrease	The decreases in microalbuminuria were also similar (23% in olmesartan and 29% in enalapril patients) in the 4 weeks time point.
1	3750227	Hyperkalemia higher than 5 mmol/L	The percentage of patients presenting hyperkalemia higher than 5 mmol/L did not differ between treatments: 37% for olmesartan and 40% for enalapril.
1	3750227	Urinary potassium	There were no appreciable changes in sodium and potassium urinary excretion.  
2	2001223	numbers of breast-conserving surgery	Significantly more letrozole-treated patients underwent breast-conserving surgery (45 vs. 35%, respectively; P = 0.022).
2	2001223	reducing tumor proliferation	Furthermore, when analyzed by Ki67 immunohistochemistry, letrozole was significantly more effective than tamoxifen in reducing tumor proliferation (P = 0.0009).
2	2001223	overall response rate	The overall response rate (overall response rate) was 55% for letrozole and 36% for tamoxifen (P < 0.001).
1	4323894	Improvement in Glasgow outcome score at 6 months post-trauma	Interestingly, the analysis at 6 months post-trauma disclosed mild-cooling-treated patients did better than no cooling (70% vs. 15.4% attained good Glasgow outcome score, P = 0.013) and apparently, the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).  
1	4323894	Improvement in Glasgow outcome score at 6 months post-trauma	Interestingly, the analysis at 6 months post-trauma disclosed mild-cooling-treated patients did better than no cooling (70% vs. 15.4% attained good Glasgow outcome score, P = 0.013) and apparently, the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).  
1	4323894	Improvement in Glasgow outcome score at 6 months post-trauma	There were 63.2% of patients in cooling group attained good Glasgow outcome score at 6 months compared to only 15.4% in noncooling group (P = 0.007).
2	4323894	Improvement in Glasgow outcome score at 6 months post-trauma	Interestingly, the analysis at 6 months post-trauma disclosed mild-cooling-treated patients did better than no cooling (70% vs. 15.4% attained good Glasgow outcome score, P = 0.013) and apparently, the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).  
0	3943081	Atelectasis	The frequency of atelectasis was lower in the case group who received prophylactic chest physiotherapy compared to the control group (16.6% vs. 40%).  
1	3214395	laryngoscopy duration, laryngospasm, bronchospasm, laryngoscopy failure, extremity movement, awakening	There were no differences in laryngoscopy duration and the occurrence of laryngospasm, bronchospasm, laryngoscopy failure, extremity movement and awakening time among three groups.  
0	3956949	the mean analgesic requirement	Statistically significant differences were noted in hospitalization for colic and analgesic requirement, which were less in group B than in group A. There were no serious adverse events.
1	3956949	stone expulsion rate	There was a higher expulsion rate (83.9% in group B and 74.2% in group A) and a lower time to expulsion in both treatment groups than in historical controls used in earlier studies. However, these results were not statistically significant (p=0.349, p=0.074, respectively).
1	3956949	mean expulsion time	There was a higher expulsion rate (83.9% in group B and 74.2% in group A) and a lower time to expulsion in both treatment groups than in historical controls used in earlier studies. However, these results were not statistically significant (p=0.349, p=0.074, respectively).
2	5236513	stool consistency	At the end of supplementation period, stool consistency in the Active group of the Intent to Treat population was significantly improved and classified as "normal" compared to Placebo (respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003).
0	3139306	Respiratory obstruction	Compared with placebo group, patients in the dexmedetomidine group required 52.7% less patient-controlled analgesia morphine during the first 24 hours postoperatively, with significantly better visual analogue scale scores, less incidence of respiratory obstruction (5 vs. 12 patients, respectively; P = .037) and longer time to first analgesic request (21 (11) vs. 9 (4) minutes; P = .002).
0	3139306	Nausea/vomiting	Fewer patients in group D experienced nausea and vomiting than those in group P (7 vs. 24 patients, respectively; P < .05).  
2	3139306	Time to first analgesic request	Compared with placebo group, patients in the dexmedetomidine group required 52.7% less patient-controlled analgesia morphine during the first 24 hours postoperatively, with significantly better visual analogue scale scores, less incidence of respiratory obstruction (5 vs. 12 patients, respectively; P = .037) and longer time to first analgesic request (21 (11) vs. 9 (4) minutes; P = .002).
0	3139306	Morphine usage at 24 hours	Compared with placebo group, patients in the dexmedetomidine group required 52.7% less patient-controlled analgesia morphine during the first 24 hours postoperatively, with significantly better visual analogue scale scores, less incidence of respiratory obstruction (5 vs. 12 patients, respectively; P = .037) and longer time to first analgesic request (21 (11) vs. 9 (4) minutes; P = .002).
2	3094237	L-lysine blood concentration	L-lysine treatment caused a significant increase in blood concentration of L-lysine and was well tolerated.
0	5506592	The mean expenditure on the products,	In 2012, after the intervention, the proportion of households who purchased anti-mosquito products in the last month was significantly lower in intervention clusters (47.8%; 2503/5293) than in control clusters (53.3%; 2707/5079) (difference − 0.05, 95% CIca −0.100 to −0.010).
0	5506592	the proportion of households who purchased anti-mosquito products in the last month	In 2012, after the intervention, the proportion of households who purchased anti-mosquito products in the last month was significantly lower in intervention clusters (47.8%; 2503/5293) than in control clusters (53.3%; 2707/5079) (difference − 0.05, 95% CIca −0.100 to −0.010).
2	4015738	IL-10	The balanced solution group exhibited higher circulating level of IL-10 and TIMP-1 and lower level of active matrix metalloproteinase 9.
0	4604314	Muscle tissue oxygenation	Nitrate supplementation further decreased muscle tissue oxygenation during 15 km time-trial cycling in hypoxia (p < 0.05).
1	4604314	Time to completing trial cycling	Hypoxia impaired time-to-completion during time-trial cycling (p < 0.05), while no improvements were observed with nitrate supplementation in normoxia or hypoxia (p > 0.05).  
1	4604314	Right ventricle to right atrium pressure gradient	Results: During steady state exercise, hypoxia elevated RV-RA gradient (p > 0.05), while oral nitrate supplementation did not alter RV-RA gradient (p > 0.05).
1	4604314	Time to completing trial cycling	Hypoxia impaired time-to-completion during time-trial cycling (p < 0.05), while no improvements were observed with nitrate supplementation in normoxia or hypoxia (p > 0.05).  
2	4604314	Right ventricle to right atrium pressure gradient	Results: During steady state exercise, hypoxia elevated RV-RA gradient (p > 0.05), while oral nitrate supplementation did not alter RV-RA gradient (p > 0.05).
2	5555437	overall survival 2 years	A 12% higher overall survival at 2 years in the once-daily group versus the twice-daily group was considered to be clinically significant to show superiority of the once-daily regimen.
2	5768344	anemia (anemia)	Whereas anemia was more frequent after ddAC (P < 0.001), TAC treated patients more often had peripheral neuropathy (P < 0.001).
2	5768344	peripheral neuropathy (peripheral neuropathy)	Whereas anemia was more frequent after ddAC (P < 0.001), TAC treated patients more often had peripheral neuropathy (P < 0.001).
0	4361464	mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing–remitting multiple sclerosis (relapsing–remitting multiple sclerosis)	In a subset of patients (MRI cohort), delayed-release dimethyl fumarate BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).
0	4361464	annualized relapse rate - patients newly diagnosed with relapsing–remitting multiple sclerosis (relapsing–remitting multiple sclerosis)	At 2 years, delayed-release dimethyl fumarate BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001), risk of relapse by 54% and 57% (both p < 0.0001), and risk of 12-week confirmed disability progression by 71% (p < 0.0001) and 47% (p = 0.0085) versus placebo.
0	4361464	annualized relapse rate - patients newly diagnosed with relapsing–remitting multiple sclerosis (relapsing–remitting multiple sclerosis)	At 2 years, delayed-release dimethyl fumarate BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001), risk of relapse by 54% and 57% (both p < 0.0001), and risk of 12-week confirmed disability progression by 71% (p < 0.0001) and 47% (p = 0.0085) versus placebo.
0	4361464	risk of relapse - patients newly diagnosed with relapsing–remitting multiple sclerosis (relapsing–remitting multiple sclerosis)	At 2 years, delayed-release dimethyl fumarate BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001), risk of relapse by 54% and 57% (both p < 0.0001), and risk of 12-week confirmed disability progression by 71% (p < 0.0001) and 47% (p = 0.0085) versus placebo.
0	4361464	mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing–remitting multiple sclerosis (relapsing–remitting multiple sclerosis)	In a subset of patients (MRI cohort), delayed-release dimethyl fumarate BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).
1	3790030	Heart rate	Systolic blood pressure, heart rate, and SpO2 were decreased, and Ramsay Sedation Scale score was increased significantly at both 20 min and 40 min after injection of dexmedetomidine in the three study groups compared to baseline, without significant differences between the groups.
1	3790030	Systolic blood pressure	Systolic blood pressure, heart rate, and SpO2 were decreased, and Ramsay Sedation Scale score was increased significantly at both 20 min and 40 min after injection of dexmedetomidine in the three study groups compared to baseline, without significant differences between the groups.
1	3790030	Ramsay Sedation Scale score	Systolic blood pressure, heart rate, and SpO2 were decreased, and Ramsay Sedation Scale score was increased significantly at both 20 min and 40 min after injection of dexmedetomidine in the three study groups compared to baseline, without significant differences between the groups.
1	3790030	Systolic blood pressure	Systolic blood pressure, heart rate, and SpO2 were decreased, and Ramsay Sedation Scale score was increased significantly at both 20 min and 40 min after injection of dexmedetomidine in the three study groups compared to baseline, without significant differences between the groups.
1	3790030	Ramsay Sedation Scale score	Systolic blood pressure, heart rate, and SpO2 were decreased, and Ramsay Sedation Scale score was increased significantly at both 20 min and 40 min after injection of dexmedetomidine in the three study groups compared to baseline, without significant differences between the groups.
1	5358282	Anxiety	We observed no differences in periprocedural pain perception (31% in the premedicated group versus 29% in the non-premedicated group; P = 0.75) or anxiety (59% in the premedicated group versus 50% in the non-premedicated group; P = 0.2).
1	5358282	Periprocedural pain perception	We observed no differences in periprocedural pain perception (31% in the premedicated group versus 29% in the non-premedicated group; P = 0.75) or anxiety (59% in the premedicated group versus 50% in the non-premedicated group; P = 0.2).
2	5358282	Local pain	Interestingly, local pain was more pronounced in the premedicated patients than in the non-premedicated patients (30% versus 16%, respectively; P = 0.018).
0	5630558	HbA1c	After 24 weeks of therapy, HbA1c values were significantly reduced at the endpoint in the vildagliptin add-on group.
1	5630558	Severe hypoglycemia	A severe hypoglycemic episode was not observed in either group.  
0	5630558	Glucose concentration	Continuous glucose monitoring data showed that patients with vildagliptin add-on therapy had a significantly lower 24-h mean glucose concentration and mean amplitude of glycemic excursion (mean amplitude of glycemic excursion).
0	5630558	Amplitude of glycemic excursion	Continuous glucose monitoring data showed that patients with vildagliptin add-on therapy had a significantly lower 24-h mean glucose concentration and mean amplitude of glycemic excursion (mean amplitude of glycemic excursion).
0	3053227	Shivering	A significant decrease over time in the hemodynamic values, respiratory rate, and shivering was seen in the active core-rewarming group when compared with the controls.
2	4342682	choosing the best treatment	A logistic regression analysis indicated that the odds of participants choosing the best treatment were 2.25 times higher in the unconscious-thought condition compared to the immediate-decision condition (b=.81, Wald=4.32, P=.04, 95% CI 1.048-4.836), and 2.39 times greater compared to the conscious-thought condition (b=.87, Wald=4.87, P=.027, 95% CI 1.103-5.186).
2	4342682	choosing the best treatment	A logistic regression analysis indicated that the odds of participants choosing the best treatment were 2.25 times higher in the unconscious-thought condition compared to the immediate-decision condition (b=.81, Wald=4.32, P=.04, 95% CI 1.048-4.836), and 2.39 times greater compared to the conscious-thought condition (b=.87, Wald=4.87, P=.027, 95% CI 1.103-5.186).
1	2837815	rotations or translations	The mean distal translation observed was −0.15 mm for SmartSet HV and −0.16 mm for Palacos R. The mean rotation around the longitudinal axis was 0.9° for SmartSet HV and 1.2° for Palacos R.
1	2837815	The mean distal translation	The mean distal translation observed was −0.15 mm for SmartSet HV and −0.16 mm for Palacos R.
1	2837815	The Merle d'Aubigne Postel score	The Merle d'Aubigne Postel score was the maximum of 18 points for all patients in both groups.  
2	4109867	gain:feed	Dietary SW supplementation significantly (p<0.05) improved average daily gain and gain:feed ratio as well as serum immunoglobulin G concentration.
0	4109867	Meat cholesterol concentration	Dietary SW significantly reduced meat cholesterol concentration (p<0.05).
1	4109867	saturated fatty acids (saturated fatty acids), unsaturated fatty acids, poly unsaturated fatty acid (poly unsaturated fatty acid) or mono unsaturated fatty acid content in muscles	Dietary SW supplementation had no effect on saturated fatty acids (saturated fatty acids), unsaturated fatty acids, poly unsaturated fatty acid (poly unsaturated fatty acid) or mono unsaturated fatty acid content in muscles.
2	4109867	average daily gain (ADG) of Hanwoo steers	Dietary SW supplementation significantly (p<0.05) improved average daily gain and gain:feed ratio as well as serum immunoglobulin G concentration.
2	4109867	concentration of stearic acid (C18:0) and linolenic acid (C18:3n-3)	Dietary SW supplementation significantly reduced the myristic acid (C14:0) and palmitoleic acid (C16:ln-7) concentration, while SW increased the concentration of stearic acid (C18:0) and linolenic acid (C18:3n-3) compared to control (p<0.05).
0	4109867	myristic acid (C14:0) and palmitoleic acid (C16:ln-7) concentration	Dietary SW supplementation significantly reduced the myristic acid (C14:0) and palmitoleic acid (C16:ln-7) concentration, while SW increased the concentration of stearic acid (C18:0) and linolenic acid (C18:3n-3) compared to control (p<0.05).
1	4171887	Success rate	There is no statistically significant difference between the success rates of the two methods at 3 months.
0	4696773	bradykinin (bradykinin) induced relaxation	bradykinin induced relaxation was reduced in LADs from occluded exercise trained and occluded-sedentary pigs (P<0.001), compared to non-occluded, non-exercised control, and exercise modestly increased responses to bradykinin (P<0.05).
0	4696773	Vasorelaxation to adenosine diphosphate (adenosine diphosphate) in LAD	Vasorelaxation to adenosine diphosphate was reduced in LADs from occluded-sedentary and occluded exercise trained pigs (P<0.001) as compared to non-occluded, non-exercised control pigs; however, occluded exercise trained pigs exhibited partial recovery (P<0.001) intermediate to the other two groups.
0	4696773	bradykinin (bradykinin) induced relaxation	bradykinin induced relaxation was reduced in LADs from occluded exercise trained and occluded-sedentary pigs (P<0.001), compared to non-occluded, non-exercised control, and exercise modestly increased responses to bradykinin (P<0.05).
0	4696773	Vasorelaxation to adenosine diphosphate (adenosine diphosphate) in LAD	Vasorelaxation to adenosine diphosphate was reduced in LADs from occluded-sedentary and occluded exercise trained pigs (P<0.001) as compared to non-occluded, non-exercised control pigs; however, occluded exercise trained pigs exhibited partial recovery (P<0.001) intermediate to the other two groups.
1	4696773	Vasorelaxation to sodium nitro-prusside (sodium nitro-prusside) in LAD	bradykinin induced relaxation was reduced in LADs from occluded exercise trained and occluded-sedentary pigs (P<0.001), compared to non-occluded, non-exercised control, and exercise modestly increased responses to bradykinin (P<0.05). In addition, sodium nitro-prusside, phenylephrine, Ang II, and endothelin-1 responses were not significantly different among the groups.
2	2864284	Superiority of treatment given by survival curves	The log-rank test comparing the survival curves confirmed the superiority of dihydroartemisinin-piperaquine over chloroquine (p = 0.003).
1	2864284	Serious adverse events	Both regimens were well tolerated and no serious adverse events were reported.  
1	4292865	Pancreatitis	The complications occurred in 20 (11.2%) patients from the Endocut mode group: pancreatitis in 6 (3.4%) and endoscopically evident bleeding in 14 (7.8%). In contrast, the complications occurred in 25 (13.8%) patients from the cut mode group: pancreatitis in 7 (3.9%) and endoscopically evident bleeding in 18 (9.9%), although these findings were not statistically significant.
1	4292865	Evident bleeding	The complications occurred in 20 (11.2%) patients from the Endocut mode group: pancreatitis in 6 (3.4%) and endoscopically evident bleeding in 14 (7.8%). In contrast, the complications occurred in 25 (13.8%) patients from the cut mode group: pancreatitis in 7 (3.9%) and endoscopically evident bleeding in 18 (9.9%), although these findings were not statistically significant.
1	4324609	Low cardiac output episode	The incidence rate of a low cardiac output episode in the perhexiline arm was 36.7% (51/139) vs 34.7% (51/147) in the control arm [odds ratio (odds ratio) 0.92, 95% confidence interval (confidence interval) 0.56–1.50, P = 0.74].
1	4324609	Troponin-T levels	There were no significant differences in myocardial injury with troponin-T or electrocardiogram, reoperation, renal dysfunction or length of stay.
1	4324609	Electrocardiographic signs of injury	There were no significant differences in myocardial injury with troponin-T or electrocardiogram, reoperation, renal dysfunction or length of stay.
0	4324609	Cardiac index at 6 h	Perhexiline was associated with a reduction in the cardiac index at 6 h [difference in means 0.19, 95% confidence interval 0.07–0.31, P = 0.001] and an increase in inotropic support in the first 12 h (odds ratio 0.55, 95% confidence interval 0.34–0.89, P = 0.015).
2	4324609	Need for inotropic support in the first 12 h	Perhexiline was associated with a reduction in the cardiac index at 6 h [difference in means 0.19, 95% confidence interval 0.07–0.31, P = 0.001] and an increase in inotropic support in the first 12 h (odds ratio 0.55, 95% confidence interval 0.34–0.89, P = 0.015).
1	4324609	Length of stay	There were no significant differences in myocardial injury with troponin-T or electrocardiogram, reoperation, renal dysfunction or length of stay.
1	3698473	Blood pressure	No significant differences were noted between conditions for blood pressure (P > 0.05), although systolic blood pressure increased approximately 6 mmHg with the supplement (diastolic blood pressure decreased approximately 4 mmHg).
2	3914313	Fastest heart rate	Results showed that the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of treatment (P < 0.05 or 0.01, resp.).
2	3914313	Fastest heart rate	Compared with pretreatment, the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group all increased significantly after treatment (P < 0.05 or 0.01, resp.).
2	3914313	Lowest heart rate	Results showed that the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of treatment (P < 0.05 or 0.01, resp.).
1	3914313	Severe adverse effects	No severe adverse effects were reported.
2	3914313	Improvement of symptom scores	Both the efficacy and the symptom scores in the trial group were significantly better than those in the control group after treatment (both having P < 0.01).
2	3914313	Mean heart rate	Results showed that the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of treatment (P < 0.05 or 0.01, resp.).
2	1839864	Death certificate completion score	Group I had a higher degree of improvement than group II (24±5 vs 19±5, p<0.001).
2	1839864	Postintervention score improvement	Participants were randomized into one of two educational interventions: either an interactive workshop (group I) or provided with printed instruction material (group II).
2	1839864	Postintervention score improvement	Participants were randomized into one of two educational interventions: either an interactive workshop (group I) or provided with printed instruction material (group II).
2	1839864	Postintervention score improvement	The death certificate score improved significantly in both group I (14±6 vs 24±5, p<0.001) and group II (14±5 vs 19±5, p<0.001) postintervention from baseline. Group I had a higher degree of improvement than group II (24±5 vs 19±5, p<0.001).
2	5697397	Phosphorylation of p70S6K 3 hours after exercise	Native whey ingestion induced a greater phosphorylation of p70S6K than milk 180 min after exercise (P = 0.03).
2	5697397	Leucine concentrations in blood	Native whey increased blood leucine concentrations more than WPC-80 and milk (P < 0.05).
2	5697397	Rates of muscle protein synthesis	Muscle protein synthesis rates were higher 1–5 h after exercise with native whey than with milk (0.112% vs. 0.064, P = 0.023).  
1	5697397	Phosphorylation of p70S6K and rates of muscle protein synthesis	Despite higher-magnitude increases in blood leucine concentrations with native whey, it was not superior to WPC-80 concerning effect on muscle protein synthesis and phosphorylation of p70S6K during a 5-h post-exercise period.
1	4757976	DHA	Following echium oil, final DHA was not greater compared to linseed oil.
0	2922723	Sputum expectoration during a single session	Significantly more sputum was expectorated during a single treatment session and over a 24 h period (mean difference 4.4 g and 6.9 g, respectively) with usual airway clearance techniques than with High frequency chest wall oscillation (p<0.001).
1	2922723	forced expiratory volume in 1 s%	No statistically significant change in forced expiratory volume in 1 s% or oxygen saturation was observed after either High frequency chest wall oscillation or usual airway clearance techniques compared with baseline.
1	2922723	O2 saturation	No statistically significant change in forced expiratory volume in 1 s% or oxygen saturation was observed after either High frequency chest wall oscillation or usual airway clearance techniques compared with baseline.
0	2922723	Sputum expectoration over a 24-hour period	Significantly more sputum was expectorated during a single treatment session and over a 24 h period (mean difference 4.4 g and 6.9 g, respectively) with usual airway clearance techniques than with High frequency chest wall oscillation (p<0.001).
2	4793173	Spermatozoa viability	All concentrations of sodium nitroprusside used was found to increase motility and viability of spermatozoa at 1, 2 and 3 hours after thawing, significantly (P<0.05), but there was no significant difference at zero time.
0	4053826	pain scores at rest at 8 hours and at 16 hours	Pain scores at rest were lower for the ropivacaine group and reached significance after 8 and 16 hours (P<0.01).
1	4053826	pain score on movement	There was no difference with respect to pain scores on movement, nor with respect to patient satisfaction.  
1	4053826	patient satisfaction	There was no difference with respect to pain scores on movement, nor with respect to patient satisfaction.  
2	5628593	Maximal voluntary isometric contraction	In the 30-Hz group, there was a significant increase in the maximal voluntary isometric contraction (p=0.039) and the concentric peak torque (p=0.018) of knee extensors and these changes were significant (p<0.05) compared with the 50-Hz group.
2	5628593	Concentric peak torque of knee extensors	In the 30-Hz group, there was a significant increase in the maximal voluntary isometric contraction (p=0.039) and the concentric peak torque (p=0.018) of knee extensors and these changes were significant (p<0.05) compared with the 50-Hz group.
1	5628593	Eccentric peak torque of knee extensors	In addition, the eccentric peak torque of knee extensors was increased significantly in both groups (p<0.05); however, there was no significant difference between the two groups (p=0.873).
1	4545550	hs-CRP	The yoga interventions performed in our study did not affect inflammatory biomarkers or metabolic risk factors associated with CVD in the study population of primary care patients with hypertension.
1	4545550	IL-6	We recorded no evidence that yoga altered inflammatory biomarkers or metabolic risk factors in our study population.
2	4704894	Engagement in Precontemplation and Contemplation groups	In Precontemplation and Contemplation groups, Decisional Balance posts generated above average engagement (P=.01 and P<.001).
0	4704894	Engagement in Contemplation group	In Contemplation groups, posts based on the TTM processes Dramatic Relief and Self-Liberation resulted in below average engagement (P=.01 and P=.005).
2	4704894	Engagement in Preparation group	In Preparation groups, posts based on Consciousness Raising generated above average engagement (P=.009).
1	4009088	Median frecuency on Rectus femoris	There was no significant difference between groups for Median frequency or mean power frequency in vastus medialis muscle and rectus femoris muscle.
1	4009088	Mean power frequency on Vastus medialis	There was no significant difference between groups for Median frequency or mean power frequency in vastus medialis muscle and rectus femoris muscle.
1	4009088	Mean power frequency on Rectus femoris	There was no significant difference between groups for Median frequency or mean power frequency in vastus medialis muscle and rectus femoris muscle.
1	4009088	Creatin kinase	The difference of creatine kinase level between the groups was also not significant.  
0	5264483	Energy intake	B420 and Litesse® Ultra polydextrose + B420 also significantly reduced energy intake compared to Placebo.
1	5264483	Adverse events	There were no differences between groups in the incidence of adverse events.  
0	5264483	Body fat mass	For relative change in body fat mass, Litesse® Ultra polydextrose + B420 showed a − 4.5% (− 1.4 kg, P = 0.02, N = 37) difference to the Placebo group, whereas Litesse® Ultra polydextrose (+ 0.3%, P = 1.00, N = 35) and B420 (− 3.0%, P = 0.28, N = 24) alone had no effect (overall ANOVA P = 0.095, Placebo N = 35).
1	5264483	Body fat mass	For relative change in body fat mass, Litesse® Ultra polydextrose + B420 showed a − 4.5% (− 1.4 kg, P = 0.02, N = 37) difference to the Placebo group, whereas Litesse® Ultra polydextrose (+ 0.3%, P = 1.00, N = 35) and B420 (− 3.0%, P = 0.28, N = 24) alone had no effect (overall ANOVA P = 0.095, Placebo N = 35).
1	5264483	Body fat mass	There were no significant differences between groups in body fat mass in the Intention-To-Treat population.
1	5264483	Body fat mass	For relative change in body fat mass, Litesse® Ultra polydextrose + B420 showed a − 4.5% (− 1.4 kg, P = 0.02, N = 37) difference to the Placebo group, whereas Litesse® Ultra polydextrose (+ 0.3%, P = 1.00, N = 35) and B420 (− 3.0%, P = 0.28, N = 24) alone had no effect (overall ANOVA P = 0.095, Placebo N = 35).
1	5264483	Body fat mass	There were no significant differences between groups in body fat mass in the Intention-To-Treat population.
0	5264483	Energy intake	B420 and Litesse® Ultra polydextrose + B420 also significantly reduced energy intake compared to Placebo.
0	4322313	low-density lipoprotein cholesterol	Simvastatin/ezetimibe reduced low-density lipoprotein cholesterol (3.49 (2.94 to 4.15) to 1.32 (1.02 to 1.69) vs 3.46 (2.92 to 4.08) to 3.34 (2.81 to 3.92) mmol/L) and high-sensitive C reactive protein (2.1 (0.9 to 4.1) to 1.2 (0.6 to 2.4) vs 2.2 (0.9 to 4.9) to 1.8 (0.85 to 4.35) mg/L, all p<0.05) during the first year of treatment.
0	4322313	high-sensitive C reactive protein	Simvastatin/ezetimibe reduced low-density lipoprotein cholesterol (3.49 (2.94 to 4.15) to 1.32 (1.02 to 1.69) vs 3.46 (2.92 to 4.08) to 3.34 (2.81 to 3.92) mmol/L) and high-sensitive C reactive protein (2.1 (0.9 to 4.1) to 1.2 (0.6 to 2.4) vs 2.2 (0.9 to 4.9) to 1.8 (0.85 to 4.35) mg/L, all p<0.05) during the first year of treatment.
0	5002172	Need for hysterectomy	The modified new technique was done in 80 patients with atonic postpartum hemorrhage and it was found to be superior to the classic technique with a success rate 95 % (4 cases needed hysterectomy as a lifesaving measure) compared to 85 % with the classic technique (in 12 cases, a life-saving hysterectomy was done).  
2	3445058	electromyographic (electromyographic) activity of anterior deltoid muscle	The upright-assisted exercises (95% confidence interval, 23% to 42% maximal voluntary isometric contraction) for the anterior deltoid generated more electromyographic activity than did the gravity-minimized exercises (95% confidence interval, 9% to 21% maximal voluntary isometric contraction) (P < .05).
1	4678179	progression-free-survival (progression-free-survival)	Median progression-free-survival was 4.0 and 2.5 months for GV and gemcitabine plus placebo arms, respectively (95% CI, 2.5 to 5.3 and 1.9 to 3.8, respectively; adjusted hazard ratio, 0.81; 95% CI, 0.54 to 1.21; P = .30).
1	4678179	Median overall survival (overall survival)	Median overall survival (overall survival) was 6.9 and 6.1 months for GV and gemcitabine plus placebo arms, respectively (95% CI, 5.8 to 8.0 and 5.0 to 8.0, respectively; adjusted hazard ratio, 1.04; 95% CI, 0.69 to 1.58; P = .84).
1	4678179	Response rates	Response rates were not significantly different.
0	5498715	Scores of external regulation and amotivation	The intervention group reported an increase in the scores of intrinsic motivation (p<0.001, ES=3.34), identified regulation (p<0.001, ES= 1.28), perceptions of competence (p<0.001, ES=0.81) and autonomy (p<0.001, ES=2.01), enjoyment (p<0.001, ES=0.98) and health motives (p<0.01, ES=0.19), health care climate (p<0.001, ES=4.6), and a decreased score of external regulation (p<0.01, ES=−0.55) and amotivation (p<0.01, ES= −0.56) over time, compared to the control group.  
0	5498715	Sedentary behavior and agility test	Four months after the intervention, an increase in the mean scores of total Physical activity (p<0.001, ES=4.77), physical fitness tests including flexibility (p<0.001, ES=1.59), muscular endurance (p<0.001, ES=2.0), cardiorespiratory endurance (p<0.001, ES=0.51), and a decrease in mean scores of agility test (p<0.001, ES= − 0.51) and sedentary behavior (p<0.01, ES=− 0.74) was observed in the intervention group compared to the control group.
2	5498715	Physical activity and physical fitness	Four months after the intervention, an increase in the mean scores of total Physical activity (p<0.001, ES=4.77), physical fitness tests including flexibility (p<0.001, ES=1.59), muscular endurance (p<0.001, ES=2.0), cardiorespiratory endurance (p<0.001, ES=0.51), and a decrease in mean scores of agility test (p<0.001, ES= − 0.51) and sedentary behavior (p<0.01, ES=− 0.74) was observed in the intervention group compared to the control group.
2	5498715	Scores of intrinsic motivation, perception of competence and autonomy, enjoyment, and health care climate	The intervention group reported an increase in the scores of intrinsic motivation (p<0.001, ES=3.34), identified regulation (p<0.001, ES= 1.28), perceptions of competence (p<0.001, ES=0.81) and autonomy (p<0.001, ES=2.01), enjoyment (p<0.001, ES=0.98) and health motives (p<0.01, ES=0.19), health care climate (p<0.001, ES=4.6), and a decreased score of external regulation (p<0.01, ES=−0.55) and amotivation (p<0.01, ES= −0.56) over time, compared to the control group.  
0	4544133	C-reactive protein levels	C-reactive protein levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001).
0	4544133	C-reactive protein levels	However, there was significant difference between the levels of C-reactive protein in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 ± 6.32 vs 23.07 ± 7.47, P < 0.05).
0	4888027	Branden score	The Branden score and area of pressure sore of the observation group were significantly lower than those of the control group (P<0.05).
0	4888027	Area of pressure sore	The Branden score and area of pressure sore of the observation group were significantly lower than those of the control group (P<0.05).
0	4888027	Average cost of hospitalization	The frequency and time of dressing change and the average cost of hospitalization of the observation group were significantly lower than those of the control group (P<0.001).
0	4888027	Dressing change time	The frequency and time of dressing change and the average cost of hospitalization of the observation group were significantly lower than those of the control group (P<0.001).
2	4888027	Improvement rate	The results showed that the improvement rate of the observation group was significantly higher than that of the control group (P<0.05).
0	4888027	Dressing change frequency	The frequency and time of dressing change and the average cost of hospitalization of the observation group were significantly lower than those of the control group (P<0.001).
1	5686687	Pain	After treatment, pain values were [3.9 (2.2 to 5); n = 22] and [3.2 (2.1 to 4.3); n = 22] in the placebo and resveratrol groups, respectively (P = 0.7; Mann-Whitney U test).
0	4871204	Incidence of digestive symptoms	The incidence of gastrointestinal symptoms including diarrhea was significantly higher in the control group than in the study group.
1	4871204	Acute rejection	There was no significant difference between the two groups in the incidence of acute rejection.
2	4871204	Improvement in renal function after 1 year	Renal function (estimated glomerular filtration rate and serum creatinine) was maintained in the control group whereas in the study group renal function gradually improved, with a statistical difference observed at 12 months.
1	4871204	Incidence of infection by cytomegalovirus	There was no significant difference in the incidence of cytomegalovirus infection and other adverse effects.  
0	4280721	severity of pain in primary dysmenorrhea	There was no significant difference in the mean of severity of dysmenorrhea during one cycle before the intervention between the four groups, but the difference was significant during two cycles after the intervention. Fennelin had similar effects as vitagnus on dysmenorrhea. Mefenamic acid had less effect than both the drugs (P <0.05).  
0	4280721	severity of pain in primary dysmenorrhea	There was no significant difference in the mean of severity of dysmenorrhea during one cycle before the intervention between the four groups, but the difference was significant during two cycles after the intervention. Fennelin had similar effects as vitagnus on dysmenorrhea. Mefenamic acid had less effect than both the drugs (P <0.05).  
0	4280721	severity of pain in primary dysmenorrhea	There was no significant difference in the mean of severity of dysmenorrhea during one cycle before the intervention between the four groups, but the difference was significant during two cycles after the intervention. Fennelin had similar effects as vitagnus on dysmenorrhea. Mefenamic acid had less effect than both the drugs (P <0.05).  
1	3774725	resolution rate	For patients resolving in the first three months, the adjusted Hazard Ratio (adjusted Hazard Ratio) was 0.85 (95% Confidence Interval [Confidence Interval]: 0.64-1.13) suggesting that patient navigation had no effect on resolution time during this period.
1	3774725	effect on resolution time in the first three months	For patients resolving in the first three months, the adjusted Hazard Ratio (adjusted Hazard Ratio) was 0.85 (95% Confidence Interval [Confidence Interval]: 0.64-1.13) suggesting that patient navigation had no effect on resolution time during this period.
2	3774725	effect on resolution time beyond first three months	Beyond three months, however, navigated patients resolved more quickly to diagnostic resolution compared with the control group (adjusted Hazard Ratio 2.8, 95%CI: 1.30-6.13).
2	3774725	effect on resolution time beyond first three months	For patients resolving in the first three months, the adjusted Hazard Ratio (adjusted Hazard Ratio) was 0.85 (95% Confidence Interval [Confidence Interval]: 0.64-1.13) suggesting that patient navigation had no effect on resolution time during this period.
2	4821313	serum creatinine	There was a significant increase in serum creatinine and a decrease in estimated glomerular filtration rate 48 hr post-intervention in group 1 (short regimen) with no statically difference regarding those parameters group 2 (long regimen).
1	4895420	Resolving disease	The proportion of GaM‐treated foals that resolved (70%; 14/20) was similar to that of foals treated with CLR+R (74%; 25/34), but we failed to demonstrate noninferiority for gallium maltolate relative to CLR+R; however, gallium maltolate was noninferior to CLR+R treatment when results from a noncompliant farm were excluded.  
1	4385682	efficacy in the reduction of dental biofilm after first use (t=1)	In measuring the time after use of mouthwash (t = 1), there was no difference between products (P = 0.602); that is, subjects in the study had a similar PI after the first use.
1	4385682	similar reduction in plaque	In measuring the time after use of mouthwash (t = 1), there was no difference between products (P = 0.602); that is, subjects in the study had a similar PI after the first use. After one week (t = 2), there was no difference between the four products evaluated (P = 0.674), so, all research individuals completed the study with a similar reduction in dental biofilm between themselves but it was different from initial state (Friedman test).
1	4385682	efficacy in the reduction of dental biofilm after one week	After one week (t = 2), there was no difference between the four products evaluated (P = 0.674), so, all research individuals completed the study with a similar reduction in dental biofilm between themselves but it was different from initial state (Friedman test).
1	4385682	preliminary time plaque index (PI)	After one week (t = 2), there was no difference between the four products evaluated (P = 0.674), so, all research individuals completed the study with a similar reduction in dental biofilm between themselves but it was different from initial state (Friedman test).
1	5928476	bulk-fill composite resin values and calcium silicate cement values	SureFil SDR and EverX Posterior bulk-fill composite resins' bond strengths were significantly higher than ProRoot MTA and Biodentine calcium silicate cements. However, no statistically significant differences were observed between bulk-fill composite resins values and calcium silicate cement values.    
0	3714520	Postprandial plasma glucose	Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0–2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0–6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO. Canagliflozin reduced AUC rates of appearance of oral glucose by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002).
0	3714520	Insulin fluctuations	Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0–2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0–6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO. Canagliflozin reduced AUC rates of appearance of oral glucose by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002).
2	3714520	Urinary glucose excretion	Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0–2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0–6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO. Canagliflozin reduced AUC rates of appearance of oral glucose by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002).
0	3714520	Appearance of oral glucose in plasma 0-1 h	Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0–2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0–6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO. Canagliflozin reduced AUC rates of appearance of oral glucose by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002).
0	3714520	Appearance of oral glucose in plasma 0-2 h	Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0–2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0–6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO. Canagliflozin reduced AUC rates of appearance of oral glucose by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002).
1	3476139	Cephalea relief at 24 hours	Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h. Side effects were noted in 9 patients in rizatriptan, 8 in ibuprofen and 3 in placebo, all of which were nonsignificant.
1	3476139	Side effects	Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h. Side effects were noted in 9 patients in rizatriptan, 8 in ibuprofen and 3 in placebo, all of which were nonsignificant.
2	3476139	Cephalea relief at 2 hours	Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h. Side effects were noted in 9 patients in rizatriptan, 8 in ibuprofen and 3 in placebo, all of which were nonsignificant.
2	3476139	Overall cephalea relief and improvement of associated symptoms	Rizatriptan is superior to ibuprofen in relieving headache, associated symptoms and functional disability.
2	3452313	headache relief for attacks occurring inside and outside the menstrual period (migraine attacks)	For the first attack, significantly more patients receiving sumatriptan than placebo reported headache relief for attacks occurring inside (67% vs. 33%, p=0.007) and outside (79% vs. 31%, p<0.001) the menstrual period.
0	3087029	Risk of coronary artery disease	Compared with non-randomised patients, randomised patients (n = 241) were younger (65 ± 11 vs. 69 ± 9 years, p = 0.004), had less coronary artery disease (9 vs. 20%, p = 0.018), previous TIA (1.7 vs. 7.2%, p = 0.029), atrial fibrillation during transoesophageal echocardiography (25 vs. 54%, p < 0.001), mitral incompetence (55 vs. 70%, p = 0.038), vitamin K antagonists use (69 vs. 82%, p = 0.032), had a lower mean CHADS2 score (1.2 ± 0.6 vs. 1.6 ± 1.0, p = 0.004), and left ventricular ejection fraction (59 ± 8 vs. 56 ± 8%, p = 0.016).  
0	3087029	Risk of atrial fibrillation during transoesophageal echocardiography	Compared with non-randomised patients, randomised patients (n = 241) were younger (65 ± 11 vs. 69 ± 9 years, p = 0.004), had less coronary artery disease (9 vs. 20%, p = 0.018), previous TIA (1.7 vs. 7.2%, p = 0.029), atrial fibrillation during transoesophageal echocardiography (25 vs. 54%, p < 0.001), mitral incompetence (55 vs. 70%, p = 0.038), vitamin K antagonists use (69 vs. 82%, p = 0.032), had a lower mean CHADS2 score (1.2 ± 0.6 vs. 1.6 ± 1.0, p = 0.004), and left ventricular ejection fraction (59 ± 8 vs. 56 ± 8%, p = 0.016).  
0	3087029	Risk of mitral incompetence	Compared with non-randomised patients, randomised patients (n = 241) were younger (65 ± 11 vs. 69 ± 9 years, p = 0.004), had less coronary artery disease (9 vs. 20%, p = 0.018), previous TIA (1.7 vs. 7.2%, p = 0.029), atrial fibrillation during transoesophageal echocardiography (25 vs. 54%, p < 0.001), mitral incompetence (55 vs. 70%, p = 0.038), vitamin K antagonists use (69 vs. 82%, p = 0.032), had a lower mean CHADS2 score (1.2 ± 0.6 vs. 1.6 ± 1.0, p = 0.004), and left ventricular ejection fraction (59 ± 8 vs. 56 ± 8%, p = 0.016).  
0	3087029	CHADS2 score	Compared with non-randomised patients, randomised patients (n = 241) were younger (65 ± 11 vs. 69 ± 9 years, p = 0.004), had less coronary artery disease (9 vs. 20%, p = 0.018), previous TIA (1.7 vs. 7.2%, p = 0.029), atrial fibrillation during transoesophageal echocardiography (25 vs. 54%, p < 0.001), mitral incompetence (55 vs. 70%, p = 0.038), vitamin K antagonists use (69 vs. 82%, p = 0.032), had a lower mean CHADS2 score (1.2 ± 0.6 vs. 1.6 ± 1.0, p = 0.004), and left ventricular ejection fraction (59 ± 8 vs. 56 ± 8%, p = 0.016).  
0	3087029	Left ventricular ejection fraction	Compared with non-randomised patients, randomised patients (n = 241) were younger (65 ± 11 vs. 69 ± 9 years, p = 0.004), had less coronary artery disease (9 vs. 20%, p = 0.018), previous TIA (1.7 vs. 7.2%, p = 0.029), atrial fibrillation during transoesophageal echocardiography (25 vs. 54%, p < 0.001), mitral incompetence (55 vs. 70%, p = 0.038), vitamin K antagonists use (69 vs. 82%, p = 0.032), had a lower mean CHADS2 score (1.2 ± 0.6 vs. 1.6 ± 1.0, p = 0.004), and left ventricular ejection fraction (59 ± 8 vs. 56 ± 8%, p = 0.016).  
0	3614647	Follicle Stimulating Hormone (follicle stimulating hormone) level in group APMM	Maca-GO significantly stimulated production of E2 (P<0.001) with a simultaneous suppression (P<0.05) of blood follicle stimulating hormone, increase (P<0.05) in HDL.
2	3614647	estradiol (E2) level in group APMM	Maca-GO significantly stimulated production of E2 (P<0.001) with a simultaneous suppression (P<0.05) of blood follicle stimulating hormone, increase (P<0.05) in HDL.
0	3614647	severity of individual menopausal symptoms (hot flushes and night sweating in particular)	Maca-GO significantly reduced both frequency and severity of individual menopausal symptoms (hot flushes and night sweating in particular) resulting in significant (P<0.001) alleviation of Kupperman's Index (from 22 to 10), thus, offering an attractive non-hormonal addition to the choices available to early-postmenopausal women in the form of a natural plant alternative to Hormone Replacement Therapy (Hormone Replacement Therapy) – hence, reducing dependence on hormone therapy programs.
2	3614647	High Density Lipoprotein (HDL) level	A total of 124 women concluded the study. Maca-GO significantly stimulated production of E2 (P<0.001) with a simultaneous suppression (P<0.05) of blood follicle stimulating hormone, increase (P<0.05) in HDL.
2	2584124	Venous glycerol concentration	At the same time, OBJECTIVE—Atrial natriuretic peptide induced lipolysis systemically (P < 0.05 vs. placebo) and locally in subcutaneous abdominal adipose tissue (P < 0.0001 vs. placebo), leading to a 50% increase in venous glycerol (P < 0.01) and free fatty acid (P < 0.05) concentrations compared with placebo.
2	2584124	Free fatty acid concentration	At the same time, OBJECTIVE—Atrial natriuretic peptide induced lipolysis systemically (P < 0.05 vs. placebo) and locally in subcutaneous abdominal adipose tissue (P < 0.0001 vs. placebo), leading to a 50% increase in venous glycerol (P < 0.01) and free fatty acid (P < 0.05) concentrations compared with placebo.
2	2584124	Postprandial energy expenditure	The increase in free fatty acid availability with OBJECTIVE—Atrial natriuretic peptide was paralleled by a 15% increase in lipid oxidation rates (P < 0.05 vs. placebo), driving a substantial increase in postprandial energy expenditure (P < 0.05 vs. placebo).  
2	2584124	Local lipolysis	At the same time, OBJECTIVE—Atrial natriuretic peptide induced lipolysis systemically (P < 0.05 vs. placebo) and locally in subcutaneous abdominal adipose tissue (P < 0.0001 vs. placebo), leading to a 50% increase in venous glycerol (P < 0.01) and free fatty acid (P < 0.05) concentrations compared with placebo.
2	2584124	Lipid oxidation rates	The increase in free fatty acid availability with OBJECTIVE—Atrial natriuretic peptide was paralleled by a 15% increase in lipid oxidation rates (P < 0.05 vs. placebo), driving a substantial increase in postprandial energy expenditure (P < 0.05 vs. placebo).  
0	2584124	Mean arterial blood pressure	RESULTS—OBJECTIVE—Atrial natriuretic peptide infusion decreased mean arterial blood pressure by 4 mmHg during the postprandial phase (P < 0.01 vs. placebo).
2	2584124	Systemic lipolysis	At the same time, OBJECTIVE—Atrial natriuretic peptide induced lipolysis systemically (P < 0.05 vs. placebo) and locally in subcutaneous abdominal adipose tissue (P < 0.0001 vs. placebo), leading to a 50% increase in venous glycerol (P < 0.01) and free fatty acid (P < 0.05) concentrations compared with placebo.
1	5018157	Five-minute Apgar score	The one-minute Apgar score was significantly lower for the preeclamptic parturients (8.4 ± 0.7 versus 7.2 ± 1.5) (P = 0.001), but there was no significant difference in the five-minute Apgar scores between the two groups.  
0	5018157	IV ephedrine total dosage	The total doses of IV ephedrine for treating hypotension were significantly lower among the preeclamptic patients (3.2 mg in preeclamptic patients versus 7.6 mg in normotensive patients) (P = 0.02).
0	5018157	One-minute Apgar score	The one-minute Apgar score was significantly lower for the preeclamptic parturients (8.4 ± 0.7 versus 7.2 ± 1.5) (P = 0.001), but there was no significant difference in the five-minute Apgar scores between the two groups.  
1	2992187	diabetes risk - metformin arm	Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32–4.15]) and lifestyle (2.48 [1.45–4.22]) arms, but not in the metformin arm (0.55 [0.25–1.19]).  
2	2992187	diabetes risk - lifestyle arm	Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32–4.15]) and lifestyle (2.48 [1.45–4.22]) arms, but not in the metformin arm (0.55 [0.25–1.19]).  
2	2992187	diabetes risk - placebo arm	Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32–4.15]) and lifestyle (2.48 [1.45–4.22]) arms, but not in the metformin arm (0.55 [0.25–1.19]).  
0	3730064	the preoperative corneal neovascularization (neovascularization) area	In group I, the preoperative corneal neovascularization area (8.75 ± 4.33%) was significantly decreased to 5.62 ± 3.86% one week after the injection and to 6.35 ± 3.02% one month after the injection (p = 0.012, 0.012, respectively).
0	5125190	pain	The intensity of pain was significantly less in patients receiving methylprednisolone and lignocaine than those receiving saline (P < 0.012).  
0	5125190	pain	The intensity of pain was significantly less in patients receiving methylprednisolone and lignocaine than those receiving saline (P < 0.012).  
0	3141615	Time spent on TV/DVD during the week (girls)	Time spent on TV/DVD (week p = 0.001, weekend p = 0.03) and computer/game-use (week p = 0.004, weekend p <.001), and the intake of sugar-sweetened beverages during weekend days (p = 0.04), were significantly lower among girls in the intervention group compared to the control group girls after 8 months.
0	3141615	Computer/game-use during the week (girls)	Time spent on TV/DVD (week p = 0.001, weekend p = 0.03) and computer/game-use (week p = 0.004, weekend p <.001), and the intake of sugar-sweetened beverages during weekend days (p = 0.04), were significantly lower among girls in the intervention group compared to the control group girls after 8 months.
0	3141615	Computer/game-use during the weekend (girls)	Time spent on TV/DVD (week p = 0.001, weekend p = 0.03) and computer/game-use (week p = 0.004, weekend p <.001), and the intake of sugar-sweetened beverages during weekend days (p = 0.04), were significantly lower among girls in the intervention group compared to the control group girls after 8 months.
0	3141615	Sugar-sweetened beverages intake during the weekend (girls)	Time spent on TV/DVD (week p = 0.001, weekend p = 0.03) and computer/game-use (week p = 0.004, weekend p <.001), and the intake of sugar-sweetened beverages during weekend days (p = 0.04), were significantly lower among girls in the intervention group compared to the control group girls after 8 months.
0	3141615	Time spent on TV/DVD during the weekend (girls)	Time spent on TV/DVD (week p = 0.001, weekend p = 0.03) and computer/game-use (week p = 0.004, weekend p <.001), and the intake of sugar-sweetened beverages during weekend days (p = 0.04), were significantly lower among girls in the intervention group compared to the control group girls after 8 months.
2	4379665	debris extrusion	The following post hoc Tukey's test confirmed that Group 2 (Self-adjusting file) exhibited significantly least (P < 0.01) debris extrusion between the three groups tested.  
0	4379665	debris extrusion	The following post hoc Tukey's test confirmed that Group 2 (Self-adjusting file) exhibited significantly least (P < 0.01) debris extrusion between the three groups tested.  
2	4379665	debris extrusion	The following post hoc Tukey's test confirmed that Group 2 (Self-adjusting file) exhibited significantly least (P < 0.01) debris extrusion between the three groups tested.  
2	4379665	debris extrusion	The following post hoc Tukey's test confirmed that Group 2 (Self-adjusting file) exhibited significantly least (P < 0.01) debris extrusion between the three groups tested.  
1	3492023	The severity of sensual pain at 8, 12, and 24 hours after menstruation	The severity of sensual pain at 8, 12, and 24 hours was non-significantly less in the heat Patch group.
2	4435702	≥50% reduction in mean pain	Patients receiving 8 mg VM202 per leg improved the most in all efficacy measures including a significant (P = 0.03) reduction at 3 months in the mean pain score and continued but not statistically significant reductions in pain at 6 and 9 months. Of these patients, 48.4% experienced a ≥50% reduction in pain compared to 17.6% of placebo patients.
1	4435702	Significant adverse events	There were no significant adverse events attributable to VM202.
1	5742644	Brain regions with adaptive coding	Finally, there were no adaptive coding effects in any brain regions.
1	5508614	improvement in cognitive dysfunction (schizophrenia patients)	D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia.
1	5508614	improvement in positive or negative symptoms (schizophrenia patients)	D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia.
1	3712961	HIV RNA <50 copies/mL	The average proportions with HIV RNA <50 copies/mL during the intervention phase were 0.51 in directly administered antiretroviral therapy and 0.40 in self-administered therapy (difference 0.11, 95% CI: −0.020 to 0.24).
1	4701182	Viral load improvement	At week 48, VL<50 copies/mL was 68.4%, 69.9%, and 72.4% in TPV/r100, TPV/r200, and lopinavir groups, respectively, and tipranavir groups showed non-inferiority to lopinavir.
1	5771358	Onset of turniquet pain	The mean onset of tourniquet pain in the two groups was not significantly different (P=0.443).
0	5771358	Time for pain after opening the tourniquet	In the ketorolac group, the onset of pain after opening the tourniquet was significantly longer than lidocaine group (p<0.001).
2	5771358	Postoperative pain	The mean postoperative pain score during the first 24 hours after surgery in the ketorolac group was significantly lower than lidocaine group (p<0.001).
2	5771358	Analgesia prescription	The average number of analgesia prescription during the 24 hours after operation was significantly lower in ketorolac group than lidocaine group (p<0.001).  
0	4608292	Need for transfusions	Lower number of patients receiving transfusion (4 (10 %) in GDFT vs. 17 (43 %) in CONTROL; p = 0.005) might contribute to this observation.
0	4608292	Postoperative infection	Reduced rate of postoperative infection and organ complications (22 (55 %) vs. 33 (83 %) patients; p = 0.016; relative risk 0.67 (0.49–0.91)) was observed in the GDFT group compared to CONTROL.
2	3266205	total sulfate, S-adenosylmethionine	Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (S-adenosylmethionine; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
0	3266205	glutathione, ratio of oxidized glutathione	Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (S-adenosylmethionine; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
2	3266205	nitrotyrosine, ATP , NADH , and NADPH	Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (S-adenosylmethionine; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
2	3266205	Parental Global Impressions-Revised, and on the subscores for Hyperactivity, Tantrumming , Overall , and Receptive Language	The supplement group had significantly greater improvements than the placebo group on the Parental Global Impressions-Revised (Parental Global Impressions-Revised, Average Change, p = 0.008), and on the subscores for Hyperactivity (p = 0.003), Tantrumming (p = 0.009), Overall (p = 0.02), and Receptive Language (p = 0.03).
0	4276527	Postprandial triglycerides	Short-term E2 reduced postprandial triglyceride and insulin, but had no effect on oxidation or storage of dietary fatty acids.
0	4276527	Postprandial triglycerides	Compared to premenopausal, healthy lean postmenopausal women had increased postprandial glucose and insulin and trend for higher triglyceride, but similar dietary fatty acids oxidation and storage.
0	4276527	Insulin	Short-term E2 reduced postprandial triglyceride and insulin, but had no effect on oxidation or storage of dietary fatty acids.
1	4276527	Storage of dietary fatty acids (fatty acids)	Short-term E2 reduced postprandial triglyceride and insulin, but had no effect on oxidation or storage of dietary fatty acids.
1	4052655	Fracture resistance	The mean fracture resistance values (N) were 402.8 (EX), 378.4 (EXR), 400.1 (DT), and 348.5 (DTF). Two-way analysis of variance test showed neither reinforcing method (P = 0.094), nor post composition (P = 0.462) had statistically significant differences on fracture resistance of the structurally compromised premolar teeth.
1	4052655	Fracture resistance	The mean fracture resistance values (N) were 402.8 (EX), 378.4 (EXR), 400.1 (DT), and 348.5 (DTF). Two-way analysis of variance test showed neither reinforcing method (P = 0.094), nor post composition (P = 0.462) had statistically significant differences on fracture resistance of the structurally compromised premolar teeth.
1	4052655	Fracture resistance	The mean fracture resistance values (N) were 402.8 (EX), 378.4 (EXR), 400.1 (DT), and 348.5 (DTF). Two-way analysis of variance test showed neither reinforcing method (P = 0.094), nor post composition (P = 0.462) had statistically significant differences on fracture resistance of the structurally compromised premolar teeth.
1	4052655	Fracture resistance	Two-way analysis of variance test showed neither reinforcing method (P = 0.094), nor post composition (P = 0.462) had statistically significant differences on fracture resistance of the structurally compromised premolar teeth.
1	4052655	Fracture resistance	The mean fracture resistance values (N) were 402.8 (EX), 378.4 (EXR), 400.1 (DT), and 348.5 (DTF). Two-way analysis of variance test showed neither reinforcing method (P = 0.094), nor post composition (P = 0.462) had statistically significant differences on fracture resistance of the structurally compromised premolar teeth.
1	4052655	Fracture resistance	The mean fracture resistance values (N) were 402.8 (EX), 378.4 (EXR), 400.1 (DT), and 348.5 (DTF). Two-way analysis of variance test showed neither reinforcing method (P = 0.094), nor post composition (P = 0.462) had statistically significant differences on fracture resistance of the structurally compromised premolar teeth.
0	3936610	QTc interval values	The QTc interval values after dexmedetomidine administration were significantly shorter compared to the QTc interval values just before dexmedetomidine administration.  
0	2639329	Hospitalization duration	By study design, the mean hospitalization duration was 34% shorter in the active than in the control group (P < 0.001), and Home-Monitoring facilitated the early detection of technical issues and detectable clinical anomalies.  
1	2639329	Treatment-related major adverse events	At least one treatment-related major adverse events was observed in 9.2% of patients (n = 17) assigned to the active group vs. 13.3% of patients (n = 26) in the control group (P = 0.21), a 4.1% absolute risk reduction (95% CI −2.2 to 10.4; P = 0.98).
0	4804082	Plasma homocysteine	Vitamin B-6 supplementation had a significant reducing effect on the change of plasma homocysteine (β = −2.4, p = 0.02) but not on the change of trolox equivalent antioxidant capacity level after adjusting for potential confounders.
1	4804082	Trolox equivalent antioxidant capacity	Vitamin B-6 supplementation had a significant reducing effect on the change of plasma homocysteine (β = −2.4, p = 0.02) but not on the change of trolox equivalent antioxidant capacity level after adjusting for potential confounders.
2	5472412	24-hour duration of action in relieving ocular itch	Olopatadine hydrochloride 0.77% was superior to vehicle (P<0.0001) at onset and 24-hour duration of action (difference in means: −1.14 to −1.52) and to olopatadine 0.2% (P=0.0009) at 24-hour duration of action in relieving ocular itch.
0	5472412	total redness at onset of action and 24 hours post-dosing	Additionally, olopatadine hydrochloride 0.77% substantially reduced conjunctival redness and total redness over vehicle and olopatadine 0.2% at onset and 24-hour duration of action.
0	5472412	conjunctival redness at onset and 24 hours	Additionally, olopatadine hydrochloride 0.77% substantially reduced conjunctival redness and total redness over vehicle and olopatadine 0.2% at onset and 24-hour duration of action.
0	5472412	total redness at onset of action and 24 hours post-dosing	Additionally, olopatadine hydrochloride 0.77% substantially reduced conjunctival redness and total redness over vehicle and olopatadine 0.2% at onset and 24-hour duration of action.
1	5472412	safety concerns	No safety concerns were identified.  
2	5472412	24-hour duration of action in relieving ocular itch	Olopatadine hydrochloride 0.77% was superior to vehicle (P<0.0001) at onset and 24-hour duration of action (difference in means: −1.14 to −1.52) and to olopatadine 0.2% (P=0.0009) at 24-hour duration of action in relieving ocular itch.
0	5472412	conjunctival redness at onset and 24 hours	Additionally, olopatadine hydrochloride 0.77% substantially reduced conjunctival redness and total redness over vehicle and olopatadine 0.2% at onset and 24-hour duration of action.
0	3663169	pigmentation, vascularity, pliability, and height	At the second month postoperatively, the silicone gel scars were scored lower when compared with the control scars. The differences were statistically significant in all parameters, including pigmentation (P = 0.001), Vascularity (P = 0.010), pliability (P = 0.001), and height (P = 0.010).  
0	3663169	pigmentation, vascularity, pliability, and height of the scar	The differences were statistically significant in all parameters, including pigmentation (P = 0.001), Vascularity (P = 0.010), pliability (P = 0.001), and height (P = 0.010).  
1	2836298	Continued abstinence at 1 year	Continued abstinence at 12 months confirmed through CO-oximetry was 7.4% in the intensive individual intervention, 5.4% in the intensive group intervention, and 1% in the minimal intervention. No significant differences were noted between intensive individual intervention and minimal intervention on the one hand, and between intensive group intervention and minimal intervention on the other [RR 7.04 (0.9-7.2) and RR 5.1 (0.6-41.9), respectively].
1	2836298	Continued abstinence at 1 year	No differences were noted between intensive group intervention and intensive individual intervention [RR 0.7 (0.2-2.2)].
1	2836298	Continued abstinence at 1 year	Continued abstinence at 12 months confirmed through CO-oximetry was 7.4% in the intensive individual intervention, 5.4% in the intensive group intervention, and 1% in the minimal intervention. No significant differences were noted between intensive individual intervention and minimal intervention on the one hand, and between intensive group intervention and minimal intervention on the other [RR 7.04 (0.9-7.2) and RR 5.1 (0.6-41.9), respectively].
1	2836298	Continued abstinence at 1 year	Continued abstinence at 12 months confirmed through CO-oximetry was 7.4% in the intensive individual intervention, 5.4% in the intensive group intervention, and 1% in the minimal intervention. No significant differences were noted between intensive individual intervention and minimal intervention on the one hand, and between intensive group intervention and minimal intervention on the other [RR 7.04 (0.9-7.2) and RR 5.1 (0.6-41.9), respectively].
2	2949642	Distant recurrence-free survival	Tamoxifen-treated patients with estrogen receptor-positive tumors expressing none or low levels of HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival (distant recurrence-free survival) (hazard ratio = 0.38, 95% confidence interval = 0.23 to 0.60, P = 0.000048).
2	2949642	Distant recurrence-free survival	Tamoxifen-treated patients with estrogen receptor-positive tumors expressing none or low levels of HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival (distant recurrence-free survival) (hazard ratio = 0.38, 95% confidence interval = 0.23 to 0.60, P = 0.000048).
1	2949642	Distant recurrence-free survival	However, for patients with a high or intermediate HOXB13 tumor expression, tamoxifen did not prolong the distant recurrence-free survival compared with the untreated patients (hazard ratio = 0.88, 95% confidence interval = 0.47 to 1.65, P = 0.69).
1	2949642	Distant recurrence-free survival	However, for patients with a high or intermediate HOXB13 tumor expression, tamoxifen did not prolong the distant recurrence-free survival compared with the untreated patients (hazard ratio = 0.88, 95% confidence interval = 0.47 to 1.65, P = 0.69).
1	5214464	forced inspiratory vital capacity (FIVC)	Forced inspiratory vital capacity demonstrated no significant difference within subjects (F(1, 17)= .073, p > .05), or between the two groups (F(1, 17)= 3.724, p= .073).
2	5214464	Maximal oxygen uptake (VO2max)	Within subjects, there was a significant increase in predicted VO2max (F(1,17)=7.376, P<.05).
1	5214464	forced vital capacity (FVC)	Similar to the VO2max results, forced vital capacity demonstrated a significant increase within subjects (F(1, 17)=6.201, p<.05), but there was no significant difference between the control and experimental groups (F(1,17)=3.562, p= .079).
0	4212559	cumulative incidence of type 2 diabetes mellitus (type 2 diabetes mellitus) among participants with baseline HbA1c levels ≥5.7%	The cumulative incidence of type 2 diabetes mellitus was significantly lower in the intensive lifestyle intervention group than in the usual care group among participants with HbA1c levels ≥5.7% (log-rank=3.52, p=0.06; Breslow=4.05, p=0.04; Tarone-Ware=3.79, p=0.05), while this was not found among participants with HbA1c levels <5.7%.  
2	3961877	the mean time to onset of mucositis	The mean duration of grade 3 or worse mucositis (grade 3 and grade 4) was significantly less (6.6 days vs. 9.2 days) in study arm with P < 0.001. Mean time of onset of mucositis was significantly delayed in patients who took glutamine in comparison to control arm with P < 0.001.  
0	3961877	Grade 3 or worse mucositis	Grade 3 mucositis (14.29%) and grade 4 mucositis (2.86%) in the study arm (who received oral glutamine) were significantly less (P = 0.02 and P = 0.04, respectively) in the glutamine arm.
1	3087256	sensory blockade	Sensory and motor blockade were identical in all three groups.
0	3087256	duration of analgesia	The addition of neostigmine resulted in significant longer duration of analgesia (dose independent) and sedation (dose dependent).
0	4450858	Need of oxytocin	Most women required oxytocin (77 %). The outpatient group were 24 % less likely to require oxytocin (risk difference −23.6 %, 95 % CI −43.8 to −3.5).
1	4450858	Failed induction	There were no failed inductions, infections or uterine hyperstimulation attributable to the catheter in either group.
1	4450858	Failed induction	Forty-eight women with low risk term pregnancies were randomised (2:1) to either outpatient (n = 33) or inpatient double-balloon catheter (n = 15) cervical ripening.
1	4450858	Infections	There were no failed inductions, infections or uterine hyperstimulation attributable to the catheter in either group.
0	3628802	Systolic blood pressure	Following alternate nostril breathing (ANYB) there was a significant decrease in systolic and diastolic blood pressure (p<0.001 and p<0.05), and an improvement in Purdue pegboard task scores for both hands (p<0.05), and for the right hand (p<.001).
0	3628802	Systolic blood pressure	Breath awareness (the control session) also showed a significant decrease in systolic blood pressure (p<0.05).
0	3628802	Diastolic blood pressure	Following alternate nostril breathing (ANYB) there was a significant decrease in systolic and diastolic blood pressure (p<0.001 and p<0.05), and an improvement in Purdue pegboard task scores for both hands (p<0.05), and for the right hand (p<.001).
1	5064802	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
1	5064802	activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-? in the human heart	No effect was observed of helium preconditioning, postconditioning or the combination thereof on activation of p38 MAPK, ERK 1/2 or levels of HSP27 and protein kinase C-epsilon in the human heart.
0	5556716	level of patients dissatisfaction	Likewise, among the Plane II fracture patients, those who underwent ultrasound-guided reduction were less dissatisfied than those who underwent blind reduction (p=0.043).  
2	5556716	surgeons graded outcomes for ultrasound-guided reduction	In a subgroup analysis consisting of Plane II fractures only, surgeons graded outcomes for ultrasound-guided reduction higher than that for the control group (p=0.007).
1	4355974	ER visits	Emergency room or acute visits to a physician for asthma did not significantly change in either group.
2	4355974	Knowledge	Knowledge of the purpose of controller medicine increased significantly in the intervention group, a statistically significant improvement over the control group.  
2	5904467	The median primary patency period	The median primary patency period was 9 months for paclitaxel-coated balloons and 2.5 months for the last previous procedure with conventional balloons (p < 0.001).  
2	4855961	25-hydroxyvitamin D	The postsupplementation levels of 25(OH)D were higher in Group 2K (42.86 ± 12.83) than in Group 1K (36.96 ± 10.56) with P value of 0.023.  
2	4855961	25-hydroxyvitamin D	We concluded that Vitamin D supplementation with 2000 IU/day or 60,000 IU/month is very effective and safe in achieving Vitamin D sufficiency in pregnant women.
1	3806324	operative time	Ventral urethrotomy group had considerably lesser operative time although the difference was not statistically significant.
1	3806324	complication rate	Operative time, success rate, satisfaction rate, and complications were compared between the two groups.
1	4895399	Time for ≥3 and ≥4 intragastric pH	Mean ± SD percentage of time intragastric pH was ≥3 and ≥4 was 67.0 ± 24.0% and 54.6 ± 26.4% for twice‐daily omeprazole, 24.4 ± 22.8% and 16.8 ± 19.3% for once‐daily omeprazole, 16.5 ± 9.0% and 9.6 ± 5.9% for ranitidine, and 9.4 ± 8.0% and 7.0 ± 6.6% for placebo administration.
1	4895399	Time for ≥3 and ≥4 intragastric pH	Twice‐daily omeprazole treatment significantly increased intragastric pH, whereas pH after once‐daily omeprazole and ranitidine treatments did not differ from that of placebo‐treated cats.  
2	4895399	Time for ≥3 and ≥4 intragastric pH	Mean ± SD percentage of time intragastric pH was ≥3 and ≥4 was 67.0 ± 24.0% and 54.6 ± 26.4% for twice‐daily omeprazole, 24.4 ± 22.8% and 16.8 ± 19.3% for once‐daily omeprazole, 16.5 ± 9.0% and 9.6 ± 5.9% for ranitidine, and 9.4 ± 8.0% and 7.0 ± 6.6% for placebo administration. Twice‐daily omeprazole treatment significantly increased intragastric pH, whereas pH after once‐daily omeprazole and ranitidine treatments did not differ from that of placebo‐treated cats.  
1	4895399	Time for ≥3 and ≥4 intragastric pH	Mean ± SD percentage of time intragastric pH was ≥3 and ≥4 was 67.0 ± 24.0% and 54.6 ± 26.4% for twice‐daily omeprazole, 24.4 ± 22.8% and 16.8 ± 19.3% for once‐daily omeprazole, 16.5 ± 9.0% and 9.6 ± 5.9% for ranitidine, and 9.4 ± 8.0% and 7.0 ± 6.6% for placebo administration. Twice‐daily omeprazole treatment significantly increased intragastric pH, whereas pH after once‐daily omeprazole and ranitidine treatments did not differ from that of placebo‐treated cats.  
0	3219777	Verbal numerical rating scales after incision	The Verbal numerical rating scales values at 1, 3, and 5 min after incision and Observer's Assessment of Alertness/Sedation scores at 5 min after remifentanil infusion, and 1, 3, and 5 min after incision were lower in the Ketamine group than in the Control group.
0	3219777	Observer's Assessment of Alertness/Sedation scores after incision	The Verbal numerical rating scales values at 1, 3, and 5 min after incision and Observer's Assessment of Alertness/Sedation scores at 5 min after remifentanil infusion, and 1, 3, and 5 min after incision were lower in the Ketamine group than in the Control group.
1	5655345	Artemether AUC0-8hr	Decreases of pharmacokinetic exposure [as estimated by AUC0-8hr (AUC0-8hr)] were marginally significant for artemether (by -46%, p = 0.08) and dihydroartemisinin (-22%, p = 0.06) in the children on nevirapine-based antiretroviral therapy, compared to when artemether-lumefantrine was administered alone.
1	5655345	Dihydroartemisinin AUC0-8hr	Decreases of pharmacokinetic exposure [as estimated by AUC0-8hr (AUC0-8hr)] were marginally significant for artemether (by -46%, p = 0.08) and dihydroartemisinin (-22%, p = 0.06) in the children on nevirapine-based antiretroviral therapy, compared to when artemether-lumefantrine was administered alone.
1	5655345	Artemether peak concentration	Similarly, peak concentration was decreased by 50% (p = 0.07) for artemether and 36% (p = 0.01) for dihydroartemisinin.
2	5288524	Improvement in swallowing solid and liquid consistencies	A significant improvement in swallowing, evaluated by clinical assessment, was observed in solid (p < 0.001) and liquid (p = 0.022) consistencies in EG when compared to OG and CG.
2	5288524	Improvement of frequency of symptoms domain in SWALQOL questionnaire	Patients in EG presented improvement in QoL, with the significant difference in comparison with the other groups, about domain frequency of symptoms (p = 0.029) in SWALQOL questionnaire.
2	5106877	serums Vit D level	There is no difference between serums Vit D level in case and control group at the beginning of the study, however at the end of the study serum Vit D level was significantly higher in the case group.
0	5106877	mean level of proteinuria	There is no difference in proteinuria between case and control group at the beginning and the end of the study, while a significant difference between the changes of proteinuria before and after the study was seen in two groups (P = 0.028).   
2	3977448	Relative and absolute flow-mediated dilation (flow mediated dilation)	Relative and absolute flow mediated dilation increased (before: 4.0 ± 0.5% versus after: 6.9 ± 0.6%, P < 0.05, and before: 0.14 ± 0.02 mm versus after: 0.23 ± 0.02 mm, P < 0.05, resp.), while body mass decreased (before: 86.9 ± 2.4 kg versus after: 81.1 ± 2.4 kg, P < 0.05) following the intervention.
1	3977448	interleukin-6, endothelin-1 levels	There were no changes in either blood marker (interleukin-6: before: 1.5 ± 0.2 pg/mL versus after: 1.5 ± 0.1 pg/mL, P > 0.05, and endothelin-1: before: 0.55 ± 0.05 pg/mL versus after: 0.59 ± 0.09 pg/mL, P > 0.05).
0	4659198	Bilirubin levels after 3 days	On the third day, the massage group showed significantly higher defecation frequency (p = 0.045) and significantly lower bilirubin levels (p = 0.03) compared with the control group.
2	4659198	Defecation frequency after 3 days	On the third day, the massage group showed significantly higher defecation frequency (p = 0.045) and significantly lower bilirubin levels (p = 0.03) compared with the control group.
1	4659198	Total food intake	No significant differences related to feeding amount or body weight were observed between the two groups.  
1	4659198	Body weight	No significant differences related to feeding amount or body weight were observed between the two groups.  
2	5336430	Treatment-emergent adverse events	Treatment-emergent adverse events, predominantly related to application- and administration-site reactions, were more common with 5-fluorouracil 0.5%/salicylic acid 10% than with vehicle (99.1% vs. 83.6%).  
2	5336430	The percentage of patients with complete clinical clearance (complete clinical clearance) 8 weeks after the end of treatment (primary endpoint)	At 8 weeks after the end of treatment, complete clinical clearance was significantly higher with 5-fluorouracil 0.5%/salicylic acid 10% than with vehicle [49.5% vs. 18.2%, respectively; odds ratio (odds ratio) 3.9 (95% CI) 1.7, 8.7; P = 0.0006].
2	5336430	the proportion of patients who achieved partial clearance of actinic keratosis lesions eight weeks after the end of treatment,	At 8 weeks after the end of treatment, complete clinical clearance was significantly higher with 5-fluorouracil 0.5%/salicylic acid 10% than with vehicle [49.5% vs. 18.2%, respectively; odds ratio (odds ratio) 3.9 (95% CI) 1.7, 8.7; P = 0.0006]. Significantly more patients achieved partial clearance of lesions with treatment than with vehicle [69.5% vs. 34.6%, respectively; odds ratio 4.9 (95% CI 2.3, 10.5); P < 0.0001].
2	4526979	Self-management as measured on the Osteoarthritis Quality Indicator, after 12 months	Following 12 months of exposure to the website, there were significant improvements for users compared to nonusers in self-management (absolute change score 15% vs 2%, P=.001) and weight reduction (absolute change scores 3% vs –6%, P=.03) measured on the Osteoarthritis Quality Indicator.  
1	4526979	Domains examined for the Health Evaluation Impact Questionnaire	With the exception of health service navigation, mean effect sizes from all other Health Evaluation Impact Questionnaire domains showed a positive trend for My Joint Pain users compared to the nonusers, although the differences between groups did not reach statistical significance.
2	4526979	Weight reduction as measured on the Osteoarthritis Quality Indicator, after 12 months	Following 12 months of exposure to the website, there were significant improvements for users compared to nonusers in self-management (absolute change score 15% vs 2%, P=.001) and weight reduction (absolute change scores 3% vs –6%, P=.03) measured on the Osteoarthritis Quality Indicator.  
1	4526979	Baseline demographics	Baseline demographics between groups were similar for gender (152/195, 77.9% female), age (mean 60, SD 9 years) and body mass index (mean 31.1, SD 6.8 kg/m2).
1	5412886	more effective for treating seasonal allergic conjunctivitis (seasonal allergic conjunctivitis) on day 15	On day 8 (±1 day) and day 15 (±2 days), all the antiallergic agents were found to be more effective than vehicle (p < 0.05) in terms of all the symptoms and signs. However, there was no statistical significance (p ≥ 0.05) shown among the treatment groups.
1	5412886	more effective for treating seasonal allergic conjunctivitis (seasonal allergic conjunctivitis) on day 15	On day 8 (±1 day) and day 15 (±2 days), all the antiallergic agents were found to be more effective than vehicle (p < 0.05) in terms of all the symptoms and signs.
1	5412886	more effective for treating seasonal allergic conjunctivitis (seasonal allergic conjunctivitis) on day 15	However, there was no statistical significance (p ≥ 0.05) shown among the treatment groups.
1	5412886	more effective for treating seasonal allergic conjunctivitis (seasonal allergic conjunctivitis) on day 15	On day 8 (±1 day) and day 15 (±2 days), all the antiallergic agents were found to be more effective than vehicle (p < 0.05) in terms of all the symptoms and signs. However, there was no statistical significance (p ≥ 0.05) shown among the treatment groups.
2	5412886	more effective for treating seasonal allergic conjunctivitis (seasonal allergic conjunctivitis) on day 8	On day 8 (±1 day) and day 15 (±2 days), all the antiallergic agents were found to be more effective than vehicle (p < 0.05) in terms of all the symptoms and signs.
2	5412886	more effective for treating seasonal allergic conjunctivitis (seasonal allergic conjunctivitis) on day 15	On day 8 (±1 day) and day 15 (±2 days), all the antiallergic agents were found to be more effective than vehicle (p < 0.05) in terms of all the symptoms and signs.
1	1261533	Adverse events	Both regimens were very well tolerated with no serious adverse events observed attributable to either combination.  
1	1261533	PCR-adjusted cure rates after 42 days	In both groups, the polymerase chain reaction adjusted cure rates by day 42 were high: 98.8% (95% CI 96.4, 99.6%) for artemether-lumefantrine and 96.3% (95% CI 93.1, 98.0%) for artesunate-mefloquine.
0	5927490	Matrix metalloproteinase-9 (Matrix metalloproteinase-9) level	The Bromelin group showed a significant decrement of Matrix metalloproteinase-9 level, from 6.02 ± 0.32 ng/ml before treatment to 5.50 ± 0.94 ng/ml after treatment (p = 0.028).
1	5927490	Matrix metalloproteinase-9 (Matrix metalloproteinase-9) level	There was a negative correlation between Matrix metalloproteinase-9 level and mRS (r= -0.03; p = 0.905) and a positive correlation toward BI (r = 0.039; p = 0.859), while the Standard group showed increased Matrix metalloproteinase-9 level from 5.82 ± 0.71 ng/ml to 5.91 ± 0.83 ng/ml (p = 0.616) which was correlated insignificantly to outcome.  
2	3406743	engaging in vigorous physical activity	A higher percentage (67%) of the enhanced intervention group was in the action/maintenance stage for vigorous physical activity at follow-up compared with baseline (47%).
2	3406743	readiness to engage in vigorous physical activity	A culturally tailored adaptation of the WISEWOMAN program that used community health workers significantly improved both self-reported readiness to engage in physical activity and vigorous physical activity among low-income Latinas.
2	4486927	The sustained virologic response rates if the patients had interleukin-28B rs8099917 TT genotype, and GT/GG genotype	Compared to patients treated for 24 weeks, the sustained virologic response rate in those treated for 48 weeks increased by 10.9% [95% CI: −5.9% to 27.7%] and 65.6% [95% CI: 44.5% to 86.7%] if they had interleukin-28B rs8099917 TT genotype, and GT/GG genotype, respectively (interaction P = 0.002).
1	4006506	Vomiting episodes during stay	Ten patients in ondansetron and 14 in placebo group had persistent vomiting during emergency department stay. After analyzing, there was no significant relation between vomiting in 4 and 48 hours and need for intra venous fluid therapy between the two groups although ondansetron generally decreased oral rehydration therapy failure (P=0.03).  
0	4006506	Overall oral rehydration therapy failure	After analyzing, there was no significant relation between vomiting in 4 and 48 hours and need for intra venous fluid therapy between the two groups although ondansetron generally decreased oral rehydration therapy failure (P=0.03).  
0	5450266	the risk of a first Clinically important deterioration' ('Clinically important deterioration') event	AB/FF 400/12 μg reduced the risk of a first 'Clinically important deterioration' event by 45% versus placebo (hazard ratio [hazard ratio] 0.55, p < 0.001), 18% versus μg/formoterol fumarate 12 μg (hazard ratio 0.82, p < 0.01), and 15% versus aclidinium bromide 400 μg (hazard ratio 0.85, p < 0.05).
0	5450266	the risk of a first 'Clinically important deterioration' event	AB/FF 400/12 μg reduced the risk of a first 'Clinically important deterioration' event by 45% versus placebo (hazard ratio [hazard ratio] 0.55, p < 0.001), 18% versus μg/formoterol fumarate 12 μg (hazard ratio 0.82, p < 0.01), and 15% versus aclidinium bromide 400 μg (hazard ratio 0.85, p < 0.05).
0	5450266	the risk of a first 'Clinically important deterioration' event	AB/FF 400/12 μg reduced the risk of a first 'Clinically important deterioration' event by 45% versus placebo (hazard ratio [hazard ratio] 0.55, p < 0.001), 18% versus μg/formoterol fumarate 12 μg (hazard ratio 0.82, p < 0.01), and 15% versus aclidinium bromide 400 μg (hazard ratio 0.85, p < 0.05).
0	5450266	the risk of a sustained 'Clinically important deterioration' event	Similarly, AB/FF 400/12 μg reduced the risk of a sustained 'Clinically important deterioration' event by 48% versus placebo (hazard ratio 0.52, p < 0.001) and 22% versus μg/formoterol fumarate 12 μg (hazard ratio 0.78, p < 0.01).
0	5450266	forced expiratory volume in 1 second (forced expiratory volume in 1 second) and Transition Dyspnea Index (Transition Dyspnea Index), first and sustained 'Clinically important deterioration'; St George's Respiratory Questionnaire (St George's Respiratory Questionnaire)	AB/FF 400/12 μg reduced the risk of a first or sustained 'Clinically important deterioration' event for all four components versus placebo (trough forced expiratory volume in 1 second and Transition Dyspnea Index, first and sustained 'Clinically important deterioration', all p < 0.001; St George's Respiratory Questionnaire first 'Clinically important deterioration' p < 0.001; St George's Respiratory Questionnaire sustained 'Clinically important deterioration', p < 0.01; exacerbations first and sustained 'Clinically important deterioration', both p < 0.05) and Transition Dyspnea Index and St George's Respiratory Questionnaire versus μg/formoterol fumarate 12 μg (Transition Dyspnea Index, first and sustained 'Clinically important deterioration' both p < 0.05; St George's Respiratory Questionnaire first 'Clinically important deterioration' p < 0.01), and St George's Respiratory Questionnaire versus aclidinium bromide 400 μg (first 'Clinically important deterioration', p < 0.05).  
0	5126873	Processed food intake	The UPBEAT intervention significantly reduced the Processed (−0.14; 95% CI −0.19, −0.08, P <0.0001) and Snacks (−0.24; 95% CI −0.31, −0.17, P <0.0001) pattern scores.
0	5126873	Snacks intake	The UPBEAT intervention significantly reduced the Processed (−0.14; 95% CI −0.19, −0.08, P <0.0001) and Snacks (−0.24; 95% CI −0.31, −0.17, P <0.0001) pattern scores.
1	1924504	Asthma Quality of Life Questionnaire score improvement at 52 weeks	The mean change from baseline in Asthma Quality of Life Questionnaire overall score was numerically greater with salmeterol/fluticasone propionate than formoterol/budesonide at week 28 and week 52, but did not reach statistical significance (p = 0.121 at Week 52).
2	1924504	Symptom-free days	The percentage of symptom-free days was significantly greater (58.8% vs 52.1%; p = 0.034) and the annual exacerbation rate was significantly lower (47%; p = 0.008) with stable-dose salmeterol/fluticasone propionate compared with formoterol/budesonide adjustable maintenance dosing.
0	1924504	Annual exacerbation rate	The percentage of symptom-free days was significantly greater (58.8% vs 52.1%; p = 0.034) and the annual exacerbation rate was significantly lower (47%; p = 0.008) with stable-dose salmeterol/fluticasone propionate compared with formoterol/budesonide adjustable maintenance dosing.
2	1924504	Asthma Quality of Life Questionnaire score improvement at 28 weeks	However, in a post hoc logistic regression analyses for any Asthma Quality of Life Questionnaire improvement, significant benefits with salmeterol/fluticasone propionate were seen at both time points (p = 0.038 and p = 0.009, respectively).
2	3904487	The duration of sedation	The duration of sedation in piperine receiving group was greater that the placebo group (188±59 vs. 102±43 min, p<0.0001).
2	3434899	Patient satisfaction	According to the results, patient satisfaction was also significantly higher in the group treated with narrowband UVB as compared with the systemic corticosteroids (p = 0.012).  
1	3994324	Adherence	No significant difference in mean adherence over the monitoring period was identified with 77.2% (CI, 73.0, 81.4) for the control group and 74.8% (CI, 69.7, 79.9) for the intervention group (p = 0.47).
1	3994324	Decrease in intraocular pressure	Similarly, there was no significant difference in percentage intraocular pressure reduction; 27.6% (CI, 23.5, 31.7) for the control group and 25.3% (CI, 21.06, 29.54) for the intervention group (p = 0.45).
2	3994324	Satisfaction with information given about travoprost	Participants in the intervention group were more satisfied with information about glaucoma medication with a mean score of 14.47/17 (CI, 13.85, 15.0) compared with control group which was 8.51 (CI, 7.72, 9.30).
0	5742508	Silness and Löe index	The Silness and Löe index was higher in the control group than in the experimental group, reaching a twofold difference between the groups (p < 0.0001).
0	5742508	Bleeding	The gingival bleeding index also supports this fact, since the bleeding was lower in the experimental group (p < 0.005).
2	5742508	Dental plaque	However, the dental plaque on the tooth surface according to the plaque index was 33% higher in the experimental group (p < 0.006).
2	5972262	The Steward recovery scores at T7 and T8	Compared with group C, the bispectral index values were significantly higher in group P at T5, T6, T7 and T8; and the Steward recovery scores at T7 and T8 were significantly higher in group P. The waking time, extubation time, consciousness recovery time and time in the postanaesthesia care unit were significantly shorter in group P compared with group C.  ABSTRACT.CONCLUSION. 
0	5972262	The time of waking, extubation, recovery of consciousness and time in the postanaesthesia care unit	Compared with group C, the bispectral index values were significantly higher in group P at T5, T6, T7 and T8; and the Steward recovery scores at T7 and T8 were significantly higher in group P. The waking time, extubation time, consciousness recovery time and time in the postanaesthesia care unit were significantly shorter in group P compared with group C.  ABSTRACT.CONCLUSION. 
1	4984916	complications	Overall, 54% of patients in the Hickman arm suffered one or more complications compared with 38% in the totally implantable venous access systems arm (one-sided P=0.068).
2	3459547	Itch control time	The suppressive effects of both the 5 mg and 10 mg olopatadine treatments on the visual analog scale itch score were more significant and longer lasting over a period of 4 weeks than the no-medication treatment.
0	4596416	transepidermal water loss (transepidermal water loss)	transepidermal water loss was 22.5; 95 %-confidence interval (%-confidence interval): 19.6-25.4 after P1, 16.3; 13.5–19.1 after P2, 16.4; 13.4–19.3 after P3, and 24.0; 21.1–27.0 after R; p < 0.0001.
1	4596416	transepidermal water loss (transepidermal water loss)	transepidermal water loss was 22.5; 95 %-confidence interval (%-confidence interval): 19.6-25.4 after P1, 16.3; 13.5–19.1 after P2, 16.4; 13.4–19.3 after P3, and 24.0; 21.1–27.0 after R; p < 0.0001.
2	4423288	Air-leak pressure	Results: The mean air-leak pressure was statistically higher in Group 3 than in Groups 1 and 2–95.2 ± 19.3 mmHg versus 72.5 ± 35.2 and 79.0 ± 24.5 mmHg (P < 0.05).
2	4423288	Air-leak pressure	Results: The mean air-leak pressure was statistically higher in Group 3 than in Groups 1 and 2–95.2 ± 19.3 mmHg versus 72.5 ± 35.2 and 79.0 ± 24.5 mmHg (P < 0.05).
2	4423288	Gastrotomy creation times	The gastrotomy creation times for Groups 1, 2, and 3 were 28.0 ± 10.1, 4.3 ± 1.4, and 20.1 ± 10.6 minutes, respectively, with significantly lower time in Group 2 (P < 0.001).
2	4423288	Gastrotomy creation times	The gastrotomy creation times for Groups 1, 2, and 3 were 28.0 ± 10.1, 4.3 ± 1.4, and 20.1 ± 10.6 minutes, respectively, with significantly lower time in Group 2 (P < 0.001).
2	4423288	Closure times	The closure times were 16.1 ± 6.1, 6.5 ± 1.2, and 5.3 ± 3.0 minutes, respectively, and significantly longer in the endoclip group (P < 0.001).
2	4423288	Closure times	The closure times were 16.1 ± 6.1, 6.5 ± 1.2, and 5.3 ± 3.0 minutes, respectively, and significantly longer in the endoclip group (P < 0.001).
0	3503942	The changes in visual analog scale	The changes in visual analog scale were estimated to be 6.86±0.90 before first therapy, 2.86±0.90 after first therapy, and 1.86±0.69 after third therapy in case of extracorporeal shock wave therapy group, whereas the figures were estimated to be 7.20±1.30 before first therapy, 4.60±0.55 after first therapy, and 2.80±0.84 after third therapy in case of TPI+TENS group, and the changes between the groups were significantly different (p=0.010).
1	3503942	The changes in McGill pain questionnaire	The changes in McGill pain questionnaire (p=0.816) and pain rating scale (p=0.644) between the groups were not significantly different.
1	3503942	neck range of motion	The changes in neck ROM were also not significantly different between the groups (p>0.05).  
0	3503942	pain threshold (lb/cm2)	The changes in pain threshold (lb/cm2) showed the values of 6.86±1.35 before first therapy, 11.43±0.27 after first therapy, and 12.57±0.72 after third therapy, while TPI+TENS group showed the values of 6.20±1.92 before first therapy, 8.80±0.48 after first therapy, and 9.60±2.19 after third therapy, and the changes between the groups were significantly different (p=0.045).
1	4914255	Mood	D-serine administration was not associated with any significant changes in the other cognitive tests or in the mood of older adults (p > 0.05).  
2	4538741	Physician Global Assessment (Physician Global Assessment)	Physician Global Assessment improved significantly in the fish oil group compared with the placebo group (p = 0.015).
1	4538741	The RAND SF-36 Energy/fatigue and Emotional well-being scores	The RAND SF-36 Energy/fatigue and Emotional well-being scores demonstrated improvement trends (p = 0.092 and 0.070).
1	4538741	Fatigue Severity Scale (Fatigue Severity Scale), Systemic Lupus Erythematosus Disease Activity Index (Systemic Lupus Erythematosus Disease Activity Index)	No clear difference was seen in Fatigue Severity Scale and SLE Disease Activity Index (p = 0.350 and p = 0.417).
0	4538741	Erythrocyte sedimentation rate	Erythrocyte sedimentation rate and serum IL-12 were reduced (p = 0.008 and p = 0.058); while serum IL-13 was increased by fish oil supplementation (p = 0.033).  
1	4538741	serum IL-12	Erythrocyte sedimentation rate and serum IL-12 were reduced (p = 0.008 and p = 0.058); while serum IL-13 was increased by fish oil supplementation (p = 0.033).  
2	4538741	serum IL-13	Erythrocyte sedimentation rate and serum IL-12 were reduced (p = 0.008 and p = 0.058); while serum IL-13 was increased by fish oil supplementation (p = 0.033).  
1	4538741	Emotional well-being	The RAND SF-36 Energy/fatigue and Emotional well-being scores demonstrated improvement trends (p = 0.092 and 0.070).
2	4483334	Amount of calcium and phosphate on enamel surface	The subjects of group D demonstrated a significant increase in the calcium and phosphate contents of enamel surface compared to those of groups A (P < 0.001, P < 0.001), B (P < 0.001, P < 0.001) and C (P = 0.024, P = 0.04), respectively.
2	4483334	Amount of calcium and phosphate on enamel surface	The subjects of group D demonstrated a significant increase in the calcium and phosphate contents of enamel surface compared to those of groups A (P < 0.001, P < 0.001), B (P < 0.001, P < 0.001) and C (P = 0.024, P = 0.04), respectively.
2	4483334	Amount of calcium and phosphate on enamel surface	The subjects of group D demonstrated a significant increase in the calcium and phosphate contents of enamel surface compared to those of groups A (P < 0.001, P < 0.001), B (P < 0.001, P < 0.001) and C (P = 0.024, P = 0.04), respectively.
1	2361806	Overall survival	For ILF and etoposide plus 5-FU/LV, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).
1	2361806	Time to treatment failure	For ILF and etoposide plus 5-FU/LV, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).
2	2361806	Overall response rates	Overall response rates over the entire treatment period for ILF and etoposide plus 5-FU/LV were 43 and 24%, respectively (risk ratio 0.56, 95% confidence interval 0.33–0.97; P=0.0467).
1	2361806	Clinical response rates at 14 weeks	The objective clinical response rates after 14 weeks treatment (primary end point) were 30% for ILF and 17% for etoposide plus 5-FU/LV (risk ratio (risk ratio) 0.57, 95% confidence interval (confidence interval) 0.29–1.13, P=0.0766).
1	4141807	reduction of hemoglobin A1c levels	The reduction of hemoglobin A1c levels and the proportion of patients with hemoglobin A1c of 6.5% or less were similar in the three groups after acarbose and metformin treatment.
2	4141807	In overweight group, fasting blood glucose (fasting blood glucose)	In overweight group, fasting blood glucose (fasting blood glucose) after metformin treatment showed greater decline compared to acarbose group at 48 weeks [−1.73 (−1.99 to −1.46) vs. −1.37 (−1.61 to −1.12), P<0.05), however the decrease of 2 h post-challenge blood glucose (post-challenge blood glucose) after acarbose treatment at 48 weeks was bigger compared to metformin group [−3.34 (−3.83 to−2.84) vs. −2.35 (−2.85 to −1.85), P<0.01 ].
0	5054596	Movement times	The indirect grasping group showed significantly shorter plateau times than the other training groups.
1	3491047	Long-term adherence to the program	No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.
1	3491047	Total adherence to the program	No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.
2	3491047	Short-term adherence to the program at 3 months	Short-term program adherence was greater in Walking and Behavioural intervention compared to control (p<0.012) after 3 months.
1	3491047	Total adherence to the program	No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.
1	3491047	Long-term adherence to the program	No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.
0	4310883	Costs	Costs were significantly lower in the alvimopan group than the control groups (2012 USD 32,443 vs. 40,604 p <0.001).
0	4310883	length of stay (length of stay)	Patients who received alvimopan experienced a shorter length of stay (length of stay) versus those in who did not receive alvimopan (10.5 vs. 8.6 days, p = 0.005, 95% CI 0.6–3.3).
1	2928344	Insulin requirements at 6, 12, and 24 months	At 6, 12, and 24 months follow-up, A1C and insulin requirement in the calcitriol group did not differ from the placebo group.
1	2928344	C-peptide response	At 6, 12, and 24 months follow-up, A1C and insulin requirement in the calcitriol group did not differ from the placebo group. C-peptide dropped significantly (P < 0.001) but similarly in both groups, with no significant differences at each time point.  
1	2928344	A1C levels at 6, 12, and 24 months	At 6, 12, and 24 months follow-up, A1C and insulin requirement in the calcitriol group did not differ from the placebo group.
2	3388481	Success of external cephalic version (External Cephalic Version) procedure	In the control group (n = 122) 27.3% (n = 33) had a statistically significant lower successful External Cephalic Version procedure than Neurolinguistic Programming (P = 0.05) and hypnosis and Neurolinguistic Programming (P = 0.03).  
1	4092926	goats body weight at slaughter	There was no influence of the treatments on any of the mean values of the evaluated measures (p>0.05): 21.78 kg (body weight at slaughter), 8.65 kg (hot carcass weight), 8.59 kg (cold carcass weight), 40.27% (hot carcass yield), 39.20% (cold carcass yield), 7.73 cm2(rib eye area), 46.74 cm (carcass outer length), 45.68 cm (carcass internal length), 36.92 cm (leg length), 26.04 cm (leg perimeter), 48.66 cm (hind perimeter), 58.62 cm (thoracic perimeter), 0.20 (carcass compactness index), 68.48% (total muscle of the leg), 2.79% (total leg fat), 55.19% (subcutaneous leg fat), 28.82% (total bone), 81.66 g (femur weight), 14.88 cm (femur length), 0.38 (leg muscularity index), 2.53 (muscle:bone ratio) and 33.42 (muscle:fat ratio).
2	3537701	Improvement in function and lumbar range of motion as well as endurance time	Improvement in function and lumbar range of motion as well as endurance time were significantly greater in the group receiving continuous ultrasound (P < .05).  
1	3537701	Lumbar range of motion (range of motion) as well as holding time during the Sorensen test and median frequency slope of all measured paravertebral muscles	Lumbar range of motion as well as holding time during the Sorensen test and median frequency slope of all measured paravertebral muscles did not change significantly in either group (P > .05).
0	4140547	By month 12, the proportion surviving with a functioning graft	By month 12, the proportion surviving with a functioning graft was higher with tacrolimus + mycophenolate mofetil (93%) and lower with belatacept low dose (67%) versus other groups (90%: basiliximab + belatacept high dose; 83%: belatacept high dose; 88%: tacrolimus).
2	4140547	The proportion of patients who met the primary end point (composite of acute rejection, graft loss, death by month 6)	All received corticosteroids. Demographic characteristics were similar among groups. The proportion of patients who met the primary end point (composite of acute rejection, graft loss, death by month 6) was higher in the belatacept groups (42–48%) versus tacrolimus groups (15–38%), with the highest number of deaths and grafts losses in the belatacept low dose group.
1	4577526	Home blood pressure	By HBPM, SBP dropped by 17±10.8 at week 6 and by 18±9. at week12.
1	4577526	Home blood pressure	There was no significant difference of BP reduction at week 6 between Original-xLosartan and Generic Losartan group.
1	4577526	Controlled office blood pressure	The percentage of patient whose Office BP <140/90 or HBPM <135/85 were not different among the two Losartan groups.
1	4192987	17-hydroxy progesterone and testosterone levels	The three different regimens were found to be similar in their ability to control 17-hydroxyprogesterone and testosterone levels.
1	5511020	forced expiratory volume in 1 second	All glycopyrronium bromide doses significantly increased from baseline forced expiratory volume in 1 second (forced expiratory volume in 1 second) area under the curve (AUC0–12h) and peak forced expiratory volume in 1 second, with a trend toward greater efficacy with higher glycopyrronium bromide dose.
1	2944158	phlebitis	There were no local infections or IVD-related bloodstream infections in either group.
1	2944158	intravenous device complications per person	Resite on clinical indication would allow one in two patients to have a single cannula per course of IV treatment, as opposed to one in five patients managed with routine resite; overall complication rates appear similar.
2	2944158	cost per patient	IV therapy duration did not differ between groups (P = 0.22), but more (P = 0.004) intravenous devices were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (P < 0.001).  
0	2944158	hospital costs per patient for the course of IV therapy	IV therapy duration did not differ between groups (P = 0.22), but more (P = 0.004) intravenous devices were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (P < 0.001).  
1	2944158	intravenous device comlication rates	intravenous device complication rates were 68 per 1,000 intravenous device days (clinically indicated) and 66 per 1,000 intravenous device days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).
1	2944158	time until first complication	Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).
1	2944158	infections	There were no local infections or IVD-related bloodstream infections in either group.
1	2944158	therapy duration	IV therapy duration did not differ between groups (P = 0.22), but more (P = 0.004) intravenous devices were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (P < 0.001).  
2	2944158	frequency of replacements	IV therapy duration did not differ between groups (P = 0.22), but more (P = 0.004) intravenous devices were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (P < 0.001).  
0	3446002	The duration of phototherapy	The duration of phototherapy was significantly shorter in clofibrate group (P<0.001).  
0	3446002	Total serum bilirubin level	The results show that total serum bilirubin was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001).
1	4960805	Treatment-related adverse events	The overall incidence of adverse events was numerically lower in ferumoxytol-treated patients compared to those treated with iron sucrose (42.4 vs. 50.2 %, respectively); the incidence of treatment-related adverse events was generally similar between the two treatment groups (13.6 vs. 16.0 %, respectively).
2	4960805	Increases in hemoglobin when GFR ≥90 mL/min	Mean increases in hemoglobin from Baseline to Week 5 were significantly greater with ferumoxytol than with iron sucrose treatment in the subgroup with an estimated glomerular filtration rate ≥90 mL/min (Least Squares mean difference = 0.53 g/dL; p < 0.001).
2	4917725	subscales on emotional and mental health and health change	A total of 50 of the 119 participants (42.0%) in the intervention group successfully reached their physical activity target and showed a significant improvement in quality of life compared to the control group for subscales on emotional and mental health (4.31 vs -0.72, respectively; P=.009) and health change (11.06 vs 2.03, respectively; P=.004).
1	4341495	Adjective Rating Scale for Withdrawal (Adjective Rating Scale for Withdrawal) score	The overall Adjective Rating Scale for Withdrawal (P value = 0.263) and Clinical Opiate Withdrawal Scale (P = 0.862) scores between the two groups were comparable.
1	4341495	Clinical Opiate Withdrawal Scale (Clinical Opiate Withdrawal Scale) score	(8.1), respectively (P = 0.462). The overall Adjective Rating Scale for Withdrawal (P value = 0.263) and Clinical Opiate Withdrawal Scale (P = 0.862) scores between the two groups were comparable. The differences in the Visual Analogue craving Scale score for craving between the two groups was marginally significant (P = 0.057).
1	4341495	Mean (SD) age	Mean (SD) age of the patients in methadone group and tramadol plus gabapentin group were 33.9 (7.1) and 32.4. (8.1), respectively (P = 0.462).
1	2845036	The geometric mean C-peptide area under the curve at 2 years	The geometric mean C-peptide area under the curve at 2 years was unaffected by mycophenolate mofetil alone or mycophenolate mofetil plus daclizumab versus placebo.
1	4183415	completion of each dose at the correct time	Although there was some improvement in dispenser knowledge, there was no difference between arms in adherence measured as completion of all doses (intervention 68.3%, control 69.8%, p [adjusted] = 0.6), or as completion of each dose at the correct time (intervention 33.1%, control 32.6%, p [adjusted] = 0.9). Further studies on the potential of text messages to improve adherence are needed.
1	4221638	Intracranial haemorrhage	Progressive intracranial haemorrhage was present in 21 (18%) of 120 patients allocated to Tranexamic acid and in 32 (27%) of 118 patients allocated to placebo. The difference was not statistically significant [RR = 0.65 (95% CI 0.40 to 1.05)].
1	4221638	Risk of death	There were no significant difference in the risk of death from all causes in patients allocated to Tranexamic acid compared with placebo [RR = 0.69 (95% CI 0.35 to 1.39)] and the risk of unfavourable outcome on the Glasgow Outcome Scale [RR = 0.76 (95% CI 0.46 to 1.27)].
1	4221638	Risk of thromboembolic events	There was no evidence of increased risk of thromboembolic events in those patients allocated to Tranexamic acid.  
1	4221638	Risk of unfavorable outcome on the Glasgow Outcome Score	There were no significant difference in the risk of death from all causes in patients allocated to Tranexamic acid compared with placebo [RR = 0.69 (95% CI 0.35 to 1.39)] and the risk of unfavourable outcome on the Glasgow Outcome Scale [RR = 0.76 (95% CI 0.46 to 1.27)].
2	3217852	FEV1 improvement	Each of the five Fluticasone furoate treatment groups produced a statistically significant improvement in pre-dose FEV1 compared with placebo (p < 0.05).
2	3217852	FEV1 improvement	Each of the five Fluticasone furoate treatment groups produced a statistically significant improvement in pre-dose FEV1 compared with placebo (p < 0.05).
2	3217852	FEV1 improvement	Each of the five Fluticasone furoate treatment groups produced a statistically significant improvement in pre-dose FEV1 compared with placebo (p < 0.05).
2	3217852	FEV1 improvement	Fluticasone furoate 400 mcg once daily in the evening and Fluticasone furoate 200 mcg twice daily produced similar placebo-adjusted improvements in evening pre-dose FEV1 at week 8 (240 ml vs. 235 ml). Fluticasone furoate 400 mcg once daily in the morning, although effective, resulted in a smaller improvement in morning pre-dose FEV1 than Fluticasone furoate 200 mcg twice daily at week 8 (315 ml vs. 202 ml). The incidence of oral candidiasis was low (0-4%) and UC excretion was comparable with placebo for all Fluticasone furoate groups.  
2	3217852	FEV1 improvement	Fluticasone furoate at total daily doses of 200 mcg or 400 mcg was significantly more effective than placebo.
1	3217852	Urinary cortisol excretion	The incidence of oral candidiasis was low (0-4%) and UC excretion was comparable with placebo for all Fluticasone furoate groups.  
1	3217852	Urinary cortisol excretion	The incidence of oral candidiasis was low (0-4%) and UC excretion was comparable with placebo for all Fluticasone furoate groups.  
0	3511947	24-h visual analog score	Overall 24-h visual analog score in group III was significantly less than in those who received fentanyl alone (P = 0.00).
2	3511947	Complete analgesia and effective analgesia duration	The durations of complete analgesia and effective analgesia were longer for all patients in group III compared with group II (P < 0.05) and group I (P < 0.005) patients.
2	3511947	Complete analgesia and effective analgesia duration	The durations of complete analgesia and effective analgesia were longer for all patients in group III compared with group II (P < 0.05) and group I (P < 0.005) patients.
0	3511947	Need of rescue analgesia	The total number of epidural top ups (rescue analgesia) required was less in group II (P < 0.05) and group III (P < 0.005) patients, compared with the control group.
0	3511947	Need of rescue analgesia	The total number of epidural top ups (rescue analgesia) required was less in group II (P < 0.05) and group III (P < 0.005) patients, compared with the control group.
2	3914427	Improvement in Sexual Intercourse Attempt diary scores	Significant improvements were noted in scores for the Sexual Intercourse Attempt diary, Erection Hardness Scale, Sexual Health Inventory of Men, and Aging Male Symptom scale (P < 0.05 for all).
2	3914427	Improvement in Sexual Health Inventory of Men	Significant improvements were noted in scores for the Sexual Intercourse Attempt diary, Erection Hardness Scale, Sexual Health Inventory of Men, and Aging Male Symptom scale (P < 0.05 for all).
2	3914427	Improvement in Aging Male Symptom scale	Significant improvements were noted in scores for the Sexual Intercourse Attempt diary, Erection Hardness Scale, Sexual Health Inventory of Men, and Aging Male Symptom scale (P < 0.05 for all).
2	3914427	Improvement in erectile hardness	Significant improvements were noted in scores for the Sexual Intercourse Attempt diary, Erection Hardness Scale, Sexual Health Inventory of Men, and Aging Male Symptom scale (P < 0.05 for all).
2	4831776	Time to exhaustion	TTE was increased after intake of CHO+PROT compared to CHO (63.5±4.4 vs 49.8±5.4 min; p<0.05).
0	4558976	extinction learning in a novel context (ABA condition)	The tiapride-treated group (tiapride-treated group) showed significantly impaired ABA extinction learning and a significant within-group difference between ABA and AAA extinction, compared to placebo (placebo).
2	3406192	PSA	Between two groups, post-biopsy PSA and PSA change ratio were statically significant differences. (p<0.001, <0.001) The effective cut-off value was 3.0, 3.5 and 4.0 according to receiver operating characteristic.
2	3406192	PSA	At receiver operating characteristic curve, PSA change ratio was statistically significant for diagnosis of prostate cancer. (AUC 0.800, p<0.001).  
2	2686715	Motor performance improvement	Highly significant improvements in motor performance were observed with methylphenidate compared to baseline ratings on all the 17 subtests of the MFNU 1–2 hr after administration of methylphenidate. There were no significant placebo effects.
1	4517417	implantation rate, chemical pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate, ectopic pregnancy rate, and miscarriage rate	Analysis of implantation rate (19.5 ± 27.7 vs. 21.7 ± 32.6; p = 0.6), chemical pregnancy rate (51 % vs. 50.5 %; p = 0.94), clinical pregnancy rate (35.7 % vs. 38.1 %; p = 0.73), ongoing pregnancy rate (31.6 % vs. 30.9 %; p = 0.92), ectopic pregnancy rate (8.6 % vs. 2.7 %; p = 0.35), and miscarriage rate (11.4 % vs. 16.2 %; 0.74) revealed comparable results for both groups.  
2	5125808	BP-lowering effects at Week 8	At Week 4, all groups showed significant antihypertensive effects but both CKD-828 combinations (CKD-828 2.5/40 mg and CKD-828 2.5/80 mg) exhibited superior BP-lowering effects to that of S-amlodipine 2.5 mg (sitDBP/SBP: P=0.0028/P=0.0001 and P<0.0001/P=0.0012, respectively).
2	5125808	BP-lowering effects at Week 8	At Week 8, the CKD-828 2.5/40 mg (sitDBP/SBP: P=0.0002/P<0.0001) and CKD-828 2.5/80 mg (sitDBP/SBP: P=0.0001/P<0.0001) showed superior BP-lowering effects to S-amlodipine 2.5 mg (P<0.001).
2	5125808	BP-lowering effects at Week 4	At Week 4, all groups showed significant antihypertensive effects but both CKD-828 combinations (CKD-828 2.5/40 mg and CKD-828 2.5/80 mg) exhibited superior BP-lowering effects to that of S-amlodipine 2.5 mg (sitDBP/SBP: P=0.0028/P=0.0001 and P<0.0001/P=0.0012, respectively).
2	5125808	BP-lowering effects at Week 8	At Week 4, all groups showed significant antihypertensive effects but both CKD-828 combinations (CKD-828 2.5/40 mg and CKD-828 2.5/80 mg) exhibited superior BP-lowering effects to that of S-amlodipine 2.5 mg (sitDBP/SBP: P=0.0028/P=0.0001 and P<0.0001/P=0.0012, respectively).
2	5125808	BP-lowering effects at Week 8	At Week 8, the CKD-828 2.5/40 mg (sitDBP/SBP: P=0.0002/P<0.0001) and CKD-828 2.5/80 mg (sitDBP/SBP: P=0.0001/P<0.0001) showed superior BP-lowering effects to S-amlodipine 2.5 mg (P<0.001).
2	5125808	BP-lowering effects at Week 4	At Week 4, all groups showed significant antihypertensive effects but both CKD-828 combinations (CKD-828 2.5/40 mg and CKD-828 2.5/80 mg) exhibited superior BP-lowering effects to that of S-amlodipine 2.5 mg (sitDBP/SBP: P=0.0028/P=0.0001 and P<0.0001/P=0.0012, respectively).
2	5125808	target blood pressure at Week 8	After the 8-week treatment, changes in sitDBP/systolic blood pressure (sitDBP/systolic BP) were −9.67±6.50/−12.89±11.78, −10.72±6.19/−13.79±9.41, and −4.93±7.26/−4.55±11.27 mmHg in the CKD-828 2.5/40 mg (P<0.0001/P<0.0001), CKD-828 2.5/80 mg (P<0.0001/P<0.0001), and S-amlodipine 2.5 mg (P<0.0001/P=0.0027) groups, respectively, which were all significant blood pressure reductions. At Week 8, the CKD-828 2.5/40 mg (sitDBP/SBP: P=0.0002/P<0.0001) and CKD-828 2.5/80 mg (sitDBP/SBP: P=0.0001/P<0.0001) showed superior BP-lowering effects to S-amlodipine 2.5 mg (P<0.001).
2	4610679	Physical activity	For example, 70% compared to 62% were physically active (odds ratio 1.43, 95% CI 1.16–1.77, p = 0.001), and 66% compared to 59% had influenza vaccinations in the past year (odds ratio 1.35, 95% CI 1.09–1.66, p = 0.005).
0	4610679	Mortality rate (after 8 years)	At 8 y, based on an intention-to-treat analysis, the estimated proportion alive was 77.9% in the intervention and 72.8% in the control group, for an absolute mortality difference of 4.9% (95% CI 1.3%–8.5%, p = 0.009; based on z-test for risk difference).
2	4610679	Influenza vaccinations	For example, 70% compared to 62% were physically active (odds ratio 1.43, 95% CI 1.16–1.77, p = 0.001), and 66% compared to 59% had influenza vaccinations in the past year (odds ratio 1.35, 95% CI 1.09–1.66, p = 0.005).
2	4610679	Influenza vaccinations	At 2 y, favourable health behaviours and use of preventive care were more frequent in the intervention than in the control group (based on z-statistics from generalised estimating equation models).
2	1784771	Infection	The combined therapy group had a higher infection rate than the prostaglandin-only group (59% vs. 12%, P = 0.003).
1	1784771	Baseline demographic differences	No demographic differences were noted between the groups.
2	1784771	Changes in Bishop score after 6 hours	After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007) and tended to have a shorter induction time (21.7 vs. 26.4 hours, P = 0.085).
1	1784771	Induction time	After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007) and tended to have a shorter induction time (21.7 vs. 26.4 hours, P = 0.085).
0	4565804	morphine doses	Dogs in the Placebo group received significantly more morphine doses than the Gabapentin group (P=0.021), despite no significant differences in pain scores. Perioperative gabapentin reduced the postoperative morphine requirements in dogs after mastectomy.
2	4026398	Reduction in levels and expression of matrix metalloproteinases	Our results revealed that sulodexide treatment is able to reduce both plasma levels and tissue expression of matrix metalloproteinases improving the clinical conditions in patients with mixed ulcers.  
1	4168417	effect on Berg Balance Scale score	Training programs conducted for both the telerehabilitation and conventional therapy groups showed significant effects within groups on the participant Berg Balance Scale as well as the total and self-care scores of Barthel Index. No significant difference between groups could be demonstrated.
1	4168417	System Environment Satisfaction and Perceived Satisfaction of System	The satisfaction of participants between the telerehabilitation and the conventional therapy groups also did not show significant difference.  
1	5960495	Quality of life	No differences in quality of life between groups could be detected but both groups had a substantially better quality of life postoperatively, as compared to before surgery.
1	5960495	Postoperative pain	There was no difference in pain between groups after surgery but a statistically significant difference concerning awareness of a groin lump and groin discomfort, favouring the lightweight group 1 year after surgery.
1	5960495	Impact on sex life	In the analysis of impact on sex life, no differences between mesh groups were found.  
1	5847600	Change in rates of alcohol consumption per week	There were no significant main effects of the intervention modules on change in weekly alcohol consumption or AUDIT score.
1	5847600	Score of Alcohol Use Disorders Identification Test	There were no significant main effects of the intervention modules on change in weekly alcohol consumption or AUDIT score.
1	3990364	Lumbar spine range of motion	We did not observe any significant difference in trained group's lumbar ranges of motion compared with control group after the training period (P>0.05).  
2	3990364	Spinal inclination	After the training period, trained group showed an increase in spinal inclination by 16.4% (P<0.05), in sacral/hip ranges of motion by 29.2% (P<0.05), and in thoracic ranges of motion by 22.5% (P>0.05) compared with control group from maximum extension position to maximum bending position.
2	3990364	Sacral/hip range of motion	After the training period, trained group showed an increase in spinal inclination by 16.4% (P<0.05), in sacral/hip ranges of motion by 29.2% (P<0.05), and in thoracic ranges of motion by 22.5% (P>0.05) compared with control group from maximum extension position to maximum bending position.
1	3990364	Thoracic range of motion	After the training period, trained group showed an increase in spinal inclination by 16.4% (P<0.05), in sacral/hip ranges of motion by 29.2% (P<0.05), and in thoracic ranges of motion by 22.5% (P>0.05) compared with control group from maximum extension position to maximum bending position.
2	3281242	continuous abstienence at week 12	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [odds ratio] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; odds ratio 4.4; 95% CI, 2.6–7.5; p < .0001).
2	3281242	continuous abstienence at 24 week follow up	Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [odds ratio] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; odds ratio 4.4; 95% CI, 2.6–7.5; p < .0001).
0	4411165	tympanic temperature from Pre to P20 (-0.28 ±0.11°C)	The WBC sessions caused an almost certain decrease in tympanic temperature from Pre to P20 (-0.28 ±0.11°C), while it only decreased at P20 (-0.14±0.05°C) after PBC sessions.
1	4411165	effects of cryostimulation on the autonomic nervous system	The main result of this study indicates that the head exposure to cold during whole-body cryostimulation may not be the main factor responsible for the effects of cryostimulation on the autonomic nervous system.
0	3893439	pAMPK/AMPK ratio in the hippocampus	Our results showed that environmental enrichment: (1) decreased the pro-inflammatory cytokines IL-1β and TNF-α and enhanced levels of the anti-inflammatory cytokine IL-10 after mild TBI; (2) mitigated mTBI-induced cognitive impairment; and (3) attenuated mTBI-induced downregulation in pAMPK/AMPK ratio and ubiquitous mitochondrial creatine kinase levels.  
0	3893439	Ubiquitous mitochondrial creatine kinase	Our results showed that environmental enrichment: (1) decreased the pro-inflammatory cytokines IL-1β and TNF-α and enhanced levels of the anti-inflammatory cytokine IL-10 after mild TBI; (2) mitigated mTBI-induced cognitive impairment; and (3) attenuated mTBI-induced downregulation in pAMPK/AMPK ratio and ubiquitous mitochondrial creatine kinase levels.  
0	4776542	postoperative nausea and vomiting (prevention of postoperative nausea and vomiting)	The incidence of prevention of postoperative nausea and vomiting was significantly smaller in group MO than group M and group O, while there was no significant difference between group M and group O during the first 24 h postoperatively.
1	4776542	postoperative nausea and vomiting (prevention of postoperative nausea and vomiting)	The incidence of prevention of postoperative nausea and vomiting was significantly smaller in group MO than group M and group O, while there was no significant difference between group M and group O during the first 24 h postoperatively.
0	3917884	Total cholesterol	There was a significant main effect of the Diet treatment, decreasing waist circumference (P = 0.001), total cholesterol (P = 0.007), LDL-cholesterol (P = 0.003) and fasting insulin (P = 0.042), at the end of the 12-wk treatment.
0	3917884	LDL cholesterol	There was a significant main effect of the Diet treatment, decreasing waist circumference (P = 0.001), total cholesterol (P = 0.007), LDL-cholesterol (P = 0.003) and fasting insulin (P = 0.042), at the end of the 12-wk treatment.
0	3917884	Waist circumference	There was a significant main effect of the Diet treatment, decreasing waist circumference (P = 0.001), total cholesterol (P = 0.007), LDL-cholesterol (P = 0.003) and fasting insulin (P = 0.042), at the end of the 12-wk treatment.
0	3917884	Fasting insulin	There was a significant main effect of the Diet treatment, decreasing waist circumference (P = 0.001), total cholesterol (P = 0.007), LDL-cholesterol (P = 0.003) and fasting insulin (P = 0.042), at the end of the 12-wk treatment.
2	5705350	Onychomycosis cured	At 16 weeks, the experimental group showed a significantly higher cumulative cure rate than the control group (71.88% vs. 20.31%, p<0.0001).
2	5705350	Patient satisfaction	The percent of "very satisfied" or "satisfied" responses was higher in the test group than the control group (81.25% vs. 23.44%).
2	4899895	Pre-exercise fat oxidation	Fat oxidation was significantly greater in the resting condition after green tea ingestion (p < 0.05) compared with the placebo.
2	4899895	Post-exercise fat oxidation	Fat oxidation was also significantly increased post-exercise in the green tea, compared with the placebo condition (p < 0.01).
2	4899895	Epinephrine levels during exercise in untrained people	Compared with the placebo, the plasma epinephrine levels were significantly higher for both groups in the green tea condition during and after exercise, however, norepinephrine levels were only significantly greater, p < 0.05, during and after exercise in the untrained group.  
2	4899895	Epinephrine levels after exercise in untrained people	Compared with the placebo, the plasma epinephrine levels were significantly higher for both groups in the green tea condition during and after exercise, however, norepinephrine levels were only significantly greater, p < 0.05, during and after exercise in the untrained group.  
1	5193306	irritable bowel syndrome (irritable bowel syndrome) symptoms (pain, bloating, constipation and diarrhoea)	All the participants in this study improved their irritable bowel syndrome symptoms (pain, bloating, constipation and diarrhoea) and physical functioning at the end of the treatment from baseline, but this was not significantly different across the treatment arms.  
1	5193306	irritable bowel syndrome (irritable bowel syndrome) symptoms (pain, bloating, constipation and diarrhoea)	All the participants in this study improved their irritable bowel syndrome symptoms (pain, bloating, constipation and diarrhoea) and physical functioning at the end of the treatment from baseline, but this was not significantly different across the treatment arms.  
1	5193306	irritable bowel syndrome (irritable bowel syndrome) symptoms (pain, bloating, constipation and diarrhoea)	Neither 'individualised' nor 'gut-directed' hypnotherapy is superior to relaxation therapy in irritable bowel syndrome.
0	3835502	Major adverse cardiac events rates	major adverse cardiac event rates were significantly different; 5.6% in paclitaxel-eluting stent and 2.5% in everolimus-eluting stent (P = 0.027).
1	3835502	Mortality	Rates of myocardial infarction (0.8% in paclitaxel-eluting stent vs 0.2% in everolimus-eluting stent, P = 0.308), all deaths (1.5% in paclitaxel-eluting stent vs 1.2% in everolimus-eluting stent, P = 0.739) and stent thrombosis (0.3% in paclitaxel-eluting stent vs 0.7% in everolimus-eluting stent, P = 0.325) were similar.
0	3835502	Ischemic-driven target vessel revascularization at 2 years	The clinical outcomes of everolimus-eluting stent are superior to paclitaxel-eluting stent, mainly due to a reduction in the rate of ischemia-driven target vessel revascularization.
1	3835502	Myocardial infarction	Rates of myocardial infarction (0.8% in paclitaxel-eluting stent vs 0.2% in everolimus-eluting stent, P = 0.308), all deaths (1.5% in paclitaxel-eluting stent vs 1.2% in everolimus-eluting stent, P = 0.739) and stent thrombosis (0.3% in paclitaxel-eluting stent vs 0.7% in everolimus-eluting stent, P = 0.325) were similar.
0	5920342	Time of hospitalization after the surgery	The length of postoperative hospital stay was shorter than that of the control group (P<0.05).
0	5920342	Operation time	Results showed that the operation time of the observation group was shorter than that of the control group (P<0.05), and the blood loss during the operation was less than that of the control group (P<0.05).
0	5920342	Loss of blood during surgery	Results showed that the operation time of the observation group was shorter than that of the control group (P<0.05), and the blood loss during the operation was less than that of the control group (P<0.05).
0	5920342	Soleus muscle latency and amplitude of H-reflex latency	The latency and amplitude of H-reflex latency in soleus muscle were significantly lower (P<0.05), and the height of intervertebral space in observation group was significantly higher than that in control group (P<0.05).
1	4761605	Prothrombin time	The two groups did not differ significantly in terms of prothrombin time, activated partial thromboplastin time, platelet number, blood loss, or operation duration.
1	4761605	Activated partial thromboplastin time	The two groups did not differ significantly in terms of prothrombin time, activated partial thromboplastin time, platelet number, blood loss, or operation duration.
1	4761605	Blood loss	The two groups did not differ significantly in terms of prothrombin time, activated partial thromboplastin time, platelet number, blood loss, or operation duration.
1	4761605	Platelet number	The two groups did not differ significantly in terms of prothrombin time, activated partial thromboplastin time, platelet number, blood loss, or operation duration.
1	4761605	Operation duration	The two groups did not differ significantly in terms of prothrombin time, activated partial thromboplastin time, platelet number, blood loss, or operation duration.
2	3329100	volume of O2 maximum (VO2max), systolic blood pressure (systolic blood pressure) , white blood cell (white blood cell) and diastolic blood pressure (diastolic blood pressure)	Findings of the study revealed a significant effect of the interval training program on VO2max, systolic blood pressure, and diastolic blood pressure and white blood cell count at P<0.05 and VO2max is negatively related to the white blood cell count (r=–0.339) at P<0.01.  
2	5491994	self-rated understanding of disease stat	Statistically significant improvements in patient ratings of their physician's explanation of their treatment options (p = 0.020), self-rated anatomical understanding (p = 0.043), self-rated understanding of disease state (p = 0.016), and effectiveness of the visualization (p = 0.007) were noted from the population that viewed the 3D education model, indicating it is an effective tool which Ear, Nose, and Throat surgeons may use to educate and interact with patients.
2	5491994	physician's explanation of their treatment	Statistically significant improvements in patient ratings of their physician's explanation of their treatment options (p = 0.020), self-rated anatomical understanding (p = 0.043), self-rated understanding of disease state (p = 0.016), and effectiveness of the visualization (p = 0.007) were noted from the population that viewed the 3D education model, indicating it is an effective tool which Ear, Nose, and Throat surgeons may use to educate and interact with patients.
2	5491994	effectiveness of the visualization	Statistically significant improvements in patient ratings of their physician's explanation of their treatment options (p = 0.020), self-rated anatomical understanding (p = 0.043), self-rated understanding of disease state (p = 0.016), and effectiveness of the visualization (p = 0.007) were noted from the population that viewed the 3D education model, indicating it is an effective tool which Ear, Nose, and Throat surgeons may use to educate and interact with patients.
2	4061186	White blood cell count	intensive insulin therapy + low molecular weight heparin noticeably increased the white blood cell count, hemodiastase level, serum albumin level and the arterial partial pressure of oxygen in the patients with severe acute pancreatitis (P<0.05).
1	5728078	Low-density lipoprotein cholesterol	In both groups triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting glucose, haemoglobin A1c, homeostasis model assessment index and diastolic blood pressure did not significantly change.
2	5728078	25-hydroxyvitamin D levels	In the Vitamin D group serum 25(OH)VitD levels significantly increased by 91% (from 16.0 (3.0–35.0) to 30.6 (8.4–67.0) ng/ml, p < 0.001), while in the control group no significant change was observed (from 10.0 (4.0–39.6) to 13.0 (3.5–37.0) ng/ml).
1	5728078	Triglycerides level	In the Vitamin D group serum 25(OH)VitD levels significantly increased by 91% (from 16.0 (3.0–35.0) to 30.6 (8.4–67.0) ng/ml, p < 0.001), while in the control group no significant change was observed (from 10.0 (4.0–39.6) to 13.0 (3.5–37.0) ng/ml). In both groups triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting glucose, haemoglobin A1c, homeostasis model assessment index and diastolic blood pressure did not significantly change.
1	5728078	High-density lipoprotein cholesterol	In both groups triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting glucose, haemoglobin A1c, homeostasis model assessment index and diastolic blood pressure did not significantly change. Systolic blood pressure decreased by 3.7% (from 134 ±14 to 129 ±13 mm Hg, p = 0.05) in the Vitamin D group, while it decreased by 1.5% (from 132 ±13 to 130 ±16 mm Hg, p = NS) in the control group (p = NS between groups).
1	5728078	Systolic blood pressure	In both groups triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting glucose, haemoglobin A1c, homeostasis model assessment index and diastolic blood pressure did not significantly change. Systolic blood pressure decreased by 3.7% (from 134 ±14 to 129 ±13 mm Hg, p = 0.05) in the Vitamin D group, while it decreased by 1.5% (from 132 ±13 to 130 ±16 mm Hg, p = NS) in the control group (p = NS between groups).
1	1468428	Puerperal and neonatal infection rates	We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66), and median labour time was similar between groups (515 min.
1	1468428	Median labour time	We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66), and median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).
1	1468428	Episiorraphy dehiscence rates	Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30).  
2	3916855	haemoglobin	The findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).
0	3916855	serum ferritin level	The findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).
2	3916855	serum iron	The findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).
2	3916855	transferrin saturation	The findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).
1	5746685	Weight rebound after 12 months	There was no significant weight rebound from the start of weight loss maintenance to 12 months for either group (mean: basic 1.3%, enhanced 1.5%) and limited change in secondary outcomes for either program.
1	5746685	Change in body mass index	There were no significant between-group differences in the primary outcome of change in body mass index (basic −0.5 (1.9) kg/m2, enhanced −0.5 (1.6) kg/m2, p = 0.93).
2	3551224	DAS28 improvement	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
2	3551224	Achieving normal functional status	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
2	3551224	ACR20 improvements	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
2	3551224	Clinical remissions	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
2	3551224	Stop of radiographic progression	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
0	270049	Participation	For the resistance exercise group, participation was 71% (p = 0.004) and adherence was 63% (p = 0.020). Participation and adherence for range of motion exercises was 96% and 95%, respectively.  
0	270049	Adherence	For the resistance exercise group, participation was 71% (p = 0.004) and adherence was 63% (p = 0.020). Participation and adherence for range of motion exercises was 96% and 95%, respectively.  
2	5486467	Time course of mean serum phosphorus levels	The change in serum phosphorus level was significantly greater in each PA21 group than in the placebo group (analysis of covariance: P < 0.001 for all groups).
2	5486467	Decrease in serum phosphorus levels	The change in serum phosphorus level was significantly greater in each PA21 group than in the placebo group (analysis of covariance: P < 0.001 for all groups). A dose-dependent change in serum phosphorus levels was observed in the PA21 groups. A notable decrease in mean serum phosphorus levels to the target level of ≤6 mg/dL was shown starting at Week 1 in all PA21 groups.
2	5486467	Decrease in serum phosphorus levels	ABSTRACT.CONCLUSIONS. PA21 was an effective and safe treatment that decreased serum phosphorus levels starting at 1 week of treatment when administered as one 250-mg tablet three times/day. PA21 demonstrated a dose-dependent phosphorus lowering effect up to 3000 mg/day.
0	4760045	visual analog scale score	Postoperative visual analog scale value at 18 h were significantly lower in group ropivacaine dexmedetomidine (P < 0.05).
0	4760045	required amount of diclofenac sodium injection as rescue analgesics in first 20 h of postoperative period	Sensory and motor block duration and time to first analgesic use were significantly longer and the total need for rescue analgesics was lower in group ropivacaine dexmedetomidine (P < 0.05) than group ropivacaine clonidine.
0	4760045	Onset of both sensory and motor block	Though with similar demographic profile in both groups, sensory and motor block in group ropivacaine dexmedetomidine (P < 0.05) was earlier than group ropivacaine clonidine.
1	2748072	outpatient clinic and admittance related costs, indirect costs, and total costs	There were no significant differences in the other direct cost categories (outpatient clinic and admittance related costs), indirect costs, and total costs.
2	2759629	radial-ulnar deviation	Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.
2	2759629	dorsiflexion	Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.
2	2759629	palmar flexion	Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.
2	2759629	pronation	Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.
2	2759629	radiological outcome	Radiological parameters were markedly better in the dorsiflexed group.
2	2759629	supination	Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.
0	4305224	Risk of preterm delivery	SPAZ reduced Low birthweight (risk ratio [risk ratio]: 0.74, 95% CI: 0.60–0.91, P = 0.005; absolute risk reduction (absolute risk reduction): 4.5%, 95% CI: 1.4–7.6; number needed to treat: 22), and preterm delivery (0.62, 95% CI: 0.43–0.89, P = 0.010), and increased mean birthweight (41.9 g, 95% CI: 0.2–83.6, P = 0.049).
2	4305224	Mean birthweight	SPAZ reduced Low birthweight (risk ratio [risk ratio]: 0.74, 95% CI: 0.60–0.91, P = 0.005; absolute risk reduction (absolute risk reduction): 4.5%, 95% CI: 1.4–7.6; number needed to treat: 22), and preterm delivery (0.62, 95% CI: 0.43–0.89, P = 0.010), and increased mean birthweight (41.9 g, 95% CI: 0.2–83.6, P = 0.049).
0	4305224	Risk of low birthweight	SPAZ reduced Low birthweight (risk ratio [risk ratio]: 0.74, 95% CI: 0.60–0.91, P = 0.005; absolute risk reduction (absolute risk reduction): 4.5%, 95% CI: 1.4–7.6; number needed to treat: 22), and preterm delivery (0.62, 95% CI: 0.43–0.89, P = 0.010), and increased mean birthweight (41.9 g, 95% CI: 0.2–83.6, P = 0.049).
0	4305224	Risk of active placental malaria	SPAZ reduced maternal parasitaemia (risk ratio: 0.57, 95% CI: 0.35–0.95, P = 0.029) and active placental malaria (0.68, 95% CI: 0.47–0.98, P = 0.037), and reduced carriage of gonorrhoea (0.66, 95% CI: 0.44–0.99, P = 0.041) at second visit.
1	4305224	Risk of adverse events	There were no treatment-related serious adverse events (serious adverse events), and the number of serious adverse events (intervention 13.1% [181/1,378], control 12.7% [174/1,374], P = 0.712) and AEs (intervention 10.5% [144/1,378], control 10.8% [149/1,374], P = 0.737) was similar.
0	4305224	Risk of maternal parasitaemia	SPAZ reduced maternal parasitaemia (risk ratio: 0.57, 95% CI: 0.35–0.95, P = 0.029) and active placental malaria (0.68, 95% CI: 0.47–0.98, P = 0.037), and reduced carriage of gonorrhoea (0.66, 95% CI: 0.44–0.99, P = 0.041) at second visit.
2	5884950	chemokines CXCL9	After 4 months of dietary intervention, CXCL9 was higher (p < 0.01) in the and Bifidobacterium breve M-16V group compared with control [and Bifidobacterium breve M-16V, 2.33 (1.99–2.89); controls, 1.95 (1.77–2.43) log 10 median (range)].
1	5697645	Hypoglycaemia	The overall incidence of adverse events, including hypoglycaemia, was similar in the 2 groups.  
1	4336131	Successful enteral feeding	The Rikkunshito group reached 50% of the target amount of enteral feeding significantly earlier than the metoclopramide group, although the proportion of patients in whom enteral feeding was successful did not differ significantly between the two groups.
1	4336131	Gastric discharge volume	The portions of enteral nutrition provided to the target amount and the quantity of gastric discharge were not statistically significantly different between the two groups.
2	4336131	Active ghrelin levels	Patients in the Rikkunshito group showed significantly higher plasma levels of active ghrelin compared to those in the metoclopramide group.  
2	4320136	Percent iron absorption	Percent iron absorption was significantly higher in raw bananas (49.3±21.3%) compared with cooked banana (33.9±16.2%) (p=0.035).
1	4320136	Total amount of absorbed iron	Total amount of iron absorbed from raw and cooked bananas was similar (0.77±0.33 mg vs. 0.86±0.41 mg, respectively).  
0	4320136	Iron content	Iron content in cooked bananas was significantly higher than raw bananas (0.53 mg/100 g bananas vs. 0.33 mg/100 mg bananas, respectively) (p<0.001).
2	4808872	1 repetition maximum	After the supplementation, the 1RM strength in the creatine group significantly increased (p < 0.05).
1	4808872	Jump performance	There was no significant difference in jump performance between the groups.
2	3636800	proportion of data points	A greater proportion of data points were completed with the native smartphone application in comparison to the SMS text-only implementation (β = -.25, SE=.11, P=.02), which also took significantly less time to complete (β =.78, SE= .09, P<.001).
1	3636800	the total quantitative feedback score	Although there were no significant differences in participants' quantitative feedback for the two delivery modalities, most participants reported preferring the native smartphone application (67%; n=16) and found it easier to use (71%; n=16). 33% of participants reported that they would be willing to complete mobile phone assessment for 5 weeks or longer.  
1	3191394	area under the curve (AUC) for pain	AUC for pain was not significantly different in the distant reiki and control groups (mean±SD; 212.1±104.7 vs 223.1±117.8; p=0.96).
1	3191394	opioid consumption or rate of healing	There were no significant differences in opioid consumption or rate of healing; however, the distant reiki group had a significantly lower heart rate (74.3±8.1 bpm vs 79.8±7.9 bpm, p=0.003) and blood pressure (106.4±9.7 mm Hg vs 111.9±11.0 mm Hg, p=0.02) post surgery.  
0	3191394	heart rate and blood pressure	There were no significant differences in opioid consumption or rate of healing; however, the distant reiki group had a significantly lower heart rate (74.3±8.1 bpm vs 79.8±7.9 bpm, p=0.003) and blood pressure (106.4±9.7 mm Hg vs 111.9±11.0 mm Hg, p=0.02) post surgery.  
0	5103151	Postoperative recovery agitation	Emergence of postoperative recovery agitation (WBS≥3) was observed more frequent in Group 2 (p<0.05) than Group 1.  ABSTRACT.CONCLUSION:. 
0	5490116	Mean visual analog scale	The mean Visual analog scale was significantly lower in the Group C for up to 24 h following the caudal block.
2	5056957	Weight and body mass index reduction at 12 months	At 12 months, there were group-by-time effects for weight (mean difference=–0.90 kg (95% confidence interval (CI)=–1.50, −0.30), P<0.01) and body mass index (−0.28 kg m−2 (−0.50, −0.06), P=0.01) in favour of the intervention group, but not for body mass index z-score (−0.05 (−0.11; 0.01), P=0.13).
1	5056957	body mass index z-score at 12months	At 12 months, there were group-by-time effects for weight (mean difference=–0.90 kg (95% confidence interval (CI)=–1.50, −0.30), P<0.01) and body mass index (−0.28 kg m−2 (−0.50, −0.06), P=0.01) in favour of the intervention group, but not for body mass index z-score (−0.05 (−0.11; 0.01), P=0.13).
2	4251615	improvements in quality of life (overall St. George's Hospital Respiratory Questionnaire and Clinical COPD Questionnaire)	Significant improvements in quality of life (overall St. George's Hospital Respiratory Questionnaire and Clinical COPD Questionnaire) were observed with arformoterol vs placebo (P < .05).  
0	4251615	first respiratory serious adverse event risk	Risk for first respiratory serious adverse event was 50% lower with arformoterol than placebo (P = .003).
2	4251615	Improvements in trough FEV1	Improvements in trough FEV1 and FVC were greater with arformoterol (least-squares mean change from baseline vs placebo: 0.051 L, P = .030 and 0.075 L, P = .018, respectively).
2	4251615	Improvements in FVC	Improvements in trough FEV1 and FVC were greater with arformoterol (least-squares mean change from baseline vs placebo: 0.051 L, P = .030 and 0.075 L, P = .018, respectively).
0	2841147	early (early response)	GSK256066 significantly reduced the early, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo.
0	2841147	fall in minimum and weighted mean FEV1	GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.
0	2841147	LAR (late response)	GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.
0	4673714	LDL-cholesterol	After the 12-months treatment period, LDL-cholesterol was significantly lower in the diet-plus-statin therapy group compared with the diet therapy group (diet vs diet-plus-statin: LDL-cholesterol, 126 ± 5 vs 83 ± 4 mg/dL, P < 0.001).
1	4673714	Albuminuria	On the other hand, the diet-plus-statin therapy did not significantly reduce albuminuria or delay the decline in eGFR compared with the diet therapy, and there was no relationship between the change in LDL-cholesterol and the change in eGFR or albuminuria.
1	4673714	eGFR decline	On the other hand, the diet-plus-statin therapy did not significantly reduce albuminuria or delay the decline in eGFR compared with the diet therapy, and there was no relationship between the change in LDL-cholesterol and the change in eGFR or albuminuria.
1	4673714	eGFR decline	Twenty eight patients were randomly assigned either to receive diet counseling alone (diet therapy group) or diet counseling plus pitavastatin (diet-plus-statin therapy group), to achieve the LDL-cholesterol (LDL-cholesterol) target of <100 mg/dl.  
1	4768887	use of right-sided approach	Compared to the /computed tomography group, the right-sided approach was more frequently used (42.6% versus 25.5%, P=0.065) in the PET/CT group in order to allow surgical access to radiographically suspicious lymph nodes inaccessible from the left, thus enabling the removal of more involved lymph nodes (2.83 versus 1.76; P=0.039) as well as their stations (1.65 versus 1.08; P=0.042).
2	4768887	Disease-free survival (disease-free survival)	Although the overall survival between the two groups was similar, the PET/CT group had a longer disease-free survival (disease-free survival) than the /computed tomography group (27.1 months versus 18.9 months; P=0.019), especially in the subgroup of node-positive patients (22.5 months versus 13.5 months; P=0.02).
2	4768887	removal of more involved lymph nodes, their stations	Compared to the /computed tomography group, the right-sided approach was more frequently used (42.6% versus 25.5%, P=0.065) in the PET/CT group in order to allow surgical access to radiographically suspicious lymph nodes inaccessible from the left, thus enabling the removal of more involved lymph nodes (2.83 versus 1.76; P=0.039) as well as their stations (1.65 versus 1.08; P=0.042).
1	4768887	Overall survival (OS)	Although the overall survival between the two groups was similar, the PET/CT group had a longer disease-free survival (disease-free survival) than the /computed tomography group (27.1 months versus 18.9 months; P=0.019), especially in the subgroup of node-positive patients (22.5 months versus 13.5 months; P=0.02).
2	4787139	bradycardia, hypotension and level 4 sedation	Dexmedetomidine full' group had a higher incidence of bradycardia, hypotension, level 4 sedation (Ramsay Sedation Scale) and lower surgeon satisfaction.
2	4282314	>5% weight loss	In terms of clinically relevant weight loss, 61% of participants lost 5% or more of their body weight with meal provision compared to 22% on the self-directed diet (P < 0.001).
2	4282314	Weight loss at 12 weeks	At 12 weeks [mean (SEM)], percentage weight loss in the meal provision group was 6.6% (0.5%) compared to 4.3% (0.6%) for those on the self-directed diet. In terms of clinically relevant weight loss, 61% of participants lost 5% or more of their body weight with meal provision compared to 22% on the self-directed diet (P < 0.001).
0	4282314	Attrition	Attrition was less apparent with 7% of those participants receiving meal provision withdrawing from the study compared to 41% of those following the self-directed diet (P < 0.001).  
0	5409664	The Disease Activity Score 28 (DAS 28 score)	Clinical and laboratory evaluations were done at the beginning and at the end of the study; (3) Results: The Disease Activity Score 28 (DAS 28 score), number of tender joints and visual analogue scale (visual analogue scale) score decreased notably after supplementation in groups I and II (p < 0.001).
0	5409664	phospholipids the n-6/n-3 fatty acids ratio	In plasma phospholipids the n-6/n-3 fatty acids ratio declined from 15.47 ± 5.51 to 10.62 ± 5.07 (p = 0.005), and from 18.15 ± 5.04 to 13.50 ± 4.81 (p = 0.005) in groups I and II respectively.
1	2194675	total cholesterol, LDL-cholesterol, or high-density lipoprotein (HDL)-cholesterol levels	There were no differences between PS-containing diet effects on total cholesterol, LDL-cholesterol, or high-density lipoprotein (HDL)-cholesterol levels.
2	2194675	plasma β-carotene concentrations	Consumption of PS-FO resulted in higher β-carotene (P = 0.0139) and retinol (P = 0.0425) levels than PS-SO and PS-OO, respectively.
0	2194675	plasminogen activator inhibitor 1 (plasminogen activator inhibitor 1) concentrations	In contrast, plasminogen activator inhibitor 1 (plasminogen activator inhibitor 1) concentrations were lower (P = 0.0282) in the PS-FO-fed than the PS-SO, but not the PS-OO (P = 0.7487) groups.  
1	2194675	plasminogen activator inhibitor 1 (plasminogen activator inhibitor 1) concentrations	In contrast, plasminogen activator inhibitor 1 (plasminogen activator inhibitor 1) concentrations were lower (P = 0.0282) in the PS-FO-fed than the PS-SO, but not the PS-OO (P = 0.7487) groups.  
0	2194675	fasting and postprandial triglyceride concentrations	However, PS-FO consumption resulted in markedly lower (P < 0.0001) fasting and postprandial triglyceride concentrations compared with PS-SO and PS-OO.
2	2194675	retinol concentrations	Consumption of PS-FO resulted in higher β-carotene (P = 0.0139) and retinol (P = 0.0425) levels than PS-SO and PS-OO, respectively.
2	4106715	attain 8 weeks continuous abstinence from weeks 19 through 26	3'AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).
1	4128609	UPDRS total score	Based on the UPDRS II + III score, pramipexole extended-release was non-inferior to pramipexole immediate-release.
1	4128609	UPDRS total score	Non-inferiority was based on the primary endpoint, the change from baseline to end of maintenance (week 18) in the UPDRS (Parts II + III) total score.  
1	4128609	UPDRS total score	For the primary endpoint, the adjusted mean changes (standard error) of UPDRS Parts II + III at week 18 were -13.81 (0.655) and -13.05 (0.643) for extended-release and immediate-release formulations, respectively, using ANCOVA adjusted for treatment and centre (fixed effect) and baseline (covariate).
1	4128609	Incidence of adverse events	The safety profiles of pramipexole extended-release and immediate-release were similar.
1	4202567	Working memory speed	There were also no statistically significant changes in speed of working memory [F(1,55)= 0.458,P=0.502] related to type or order of stimulation.  
1	4202567	Working memory speed	There were also no statistically significant changes in speed of working memory [F(1,55)= 0.458,P=0.502] related to type or order of stimulation.  
1	4286912	Serious adverse events	No serious adverse events considered causally related to vaccination were reported throughout the study.  
0	4397550	Analgesia duration	Median duration of analgesia was 16 h in group I and 20 h in group II (P = 0.002).
1	4397550	Demographic characteristics	Demographic data were comparable between the groups.
2	4397550	Visual Analog Score for post-operative pain	The maximum median Visual Analog Score was 4 in group I and 2 in group II (P = 0.002).
1	4418140	heart rate	There was no significant difference in heart rate between four groups (Pbaseline = 0.46, Ppreoperation = 0.55, P1 min = 0.86, P3 min = 0.30, P5 min = 0.63, P10 min = 0.74).
0	4418140	mean arterial pressures at 1, 3, and 5 minutes after intubation	Systolic, diastolic and mean arterial pressures were statistically significant less at 1, 3, and 5 minutes after intubation in comparison with other times of following-up in the three groups received MgSO4 than the control group.  
0	4418140	(SBP) systolic blood pressures at 1, 3, and 5 minutes after intubation	Systolic, diastolic and mean arterial pressures were statistically significant less at 1, 3, and 5 minutes after intubation in comparison with other times of following-up in the three groups received MgSO4 than the control group.  
0	4418140	(DBP) diastolic blood pressures at 1, 3, and 5 minutes after intubation	Systolic, diastolic and mean arterial pressures were statistically significant less at 1, 3, and 5 minutes after intubation in comparison with other times of following-up in the three groups received MgSO4 than the control group.  
1	3513028	effectiveness - combined type	Stratified analysis showed that the antihistamine was more effective for the sneezing/rhinorrhea type and the anti-leukotriene was more effective for the nasal blockage type, with no difference in effectiveness for the combined type.
1	3513028	effectiveness - combined type	This showed that antihistamine therapy was effective for the sneezing/rhinorrhea type and anti-leukotriene therapy was effective for the nasal blockage type, with no difference between the 2 drugs the combined type.
1	3513028	pollinosis symptoms	When either an anti-leukotriene (pranlukast) or an antihistamine was used for primal therapy of pollinosis, both drugs improved pollinosis symptoms and quality of life.
1	3513028	quality of life (quality of life)	When either an anti-leukotriene (pranlukast) or an antihistamine was used for primal therapy of pollinosis, both drugs improved pollinosis symptoms and quality of life.
0	3513028	effectiveness - sneezing/rhinorrhea type	Stratified analysis showed that the antihistamine was more effective for the sneezing/rhinorrhea type and the anti-leukotriene was more effective for the nasal blockage type, with no difference in effectiveness for the combined type.
2	3513028	effectiveness - nasal blockage type	Stratified analysis showed that the antihistamine was more effective for the sneezing/rhinorrhea type and the anti-leukotriene was more effective for the nasal blockage type, with no difference in effectiveness for the combined type.
2	3513028	effectiveness - nasal blockage type	This showed that antihistamine therapy was effective for the sneezing/rhinorrhea type and anti-leukotriene therapy was effective for the nasal blockage type, with no difference between the 2 drugs the combined type. For the nasal blockage type, symptoms and quality of life improved faster with anti-leukotriene than antihistamine therapy from the peak to the end of the pollen season.
0	3382640	the standard deviation of speed, mental effort, and subjective sleepiness	Similarly, the standard deviation of speed (p = 0.024; p = 0.001), mental effort (p = 0.003; p = 0.023), and subjective sleepiness (p = 0.001; p = 0.002) were reduced in both the first and second hour after consuming caffeinated coffee.
0	3382640	standard deviation of lateral position (standard deviation of lateral position) in the first and second hour after the break	The results showed that caffeinated coffee significantly reduced standard deviation of lateral position as compared to decaffeinated coffee, both in the first (p = 0.024) and second hour (p = 0.019) after the break.
2	4297469	unscheduled visits	Resource use with HM ON was clearly different: less follow-up visits (3.79 ± 1.67 vs. 5.53 ± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 ± 1.50 vs. 0.62 ± 1.25; P < 0.005), more non-office-based contacts (1.95 ± 3.29 vs. 1.01 ± 2.64; P < 0.001), more Internet sessions (11.02 ± 15.28 vs. 0.06 ± 0.31; P < 0.001) and more in-clinic discussions (1.84 ± 4.20 vs. 1.28 ± 2.92; P < 0.03), but with numerically fewer hospitalizations (0.67 ± 1.18 vs. 0.85 ± 1.43, P = 0.23) and shorter length-of-stay (6.31 ± 15.5 vs. 8.26 ± 18.6; P = 0.27), although not significant.
2	4297469	non-office-based contacts	Resource use with HM ON was clearly different: less follow-up visits (3.79 ± 1.67 vs. 5.53 ± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 ± 1.50 vs. 0.62 ± 1.25; P < 0.005), more non-office-based contacts (1.95 ± 3.29 vs. 1.01 ± 2.64; P < 0.001), more Internet sessions (11.02 ± 15.28 vs. 0.06 ± 0.31; P < 0.001) and more in-clinic discussions (1.84 ± 4.20 vs. 1.28 ± 2.92; P < 0.03), but with numerically fewer hospitalizations (0.67 ± 1.18 vs. 0.85 ± 1.43, P = 0.23) and shorter length-of-stay (6.31 ± 15.5 vs. 8.26 ± 18.6; P = 0.27), although not significant.
2	4297469	Internet sessions	Resource use with HM ON was clearly different: less follow-up visits (3.79 ± 1.67 vs. 5.53 ± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 ± 1.50 vs. 0.62 ± 1.25; P < 0.005), more non-office-based contacts (1.95 ± 3.29 vs. 1.01 ± 2.64; P < 0.001), more Internet sessions (11.02 ± 15.28 vs. 0.06 ± 0.31; P < 0.001) and more in-clinic discussions (1.84 ± 4.20 vs. 1.28 ± 2.92; P < 0.03), but with numerically fewer hospitalizations (0.67 ± 1.18 vs. 0.85 ± 1.43, P = 0.23) and shorter length-of-stay (6.31 ± 15.5 vs. 8.26 ± 18.6; P = 0.27), although not significant.
2	4297469	in-clinic discussions	Resource use with HM ON was clearly different: less follow-up visits (3.79 ± 1.67 vs. 5.53 ± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 ± 1.50 vs. 0.62 ± 1.25; P < 0.005), more non-office-based contacts (1.95 ± 3.29 vs. 1.01 ± 2.64; P < 0.001), more Internet sessions (11.02 ± 15.28 vs. 0.06 ± 0.31; P < 0.001) and more in-clinic discussions (1.84 ± 4.20 vs. 1.28 ± 2.92; P < 0.03), but with numerically fewer hospitalizations (0.67 ± 1.18 vs. 0.85 ± 1.43, P = 0.23) and shorter length-of-stay (6.31 ± 15.5 vs. 8.26 ± 18.6; P = 0.27), although not significant.
1	4297469	hospitalizations, shorter length-of-stay	Resource use with HM ON was clearly different: less follow-up visits (3.79 ± 1.67 vs. 5.53 ± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 ± 1.50 vs. 0.62 ± 1.25; P < 0.005), more non-office-based contacts (1.95 ± 3.29 vs. 1.01 ± 2.64; P < 0.001), more Internet sessions (11.02 ± 15.28 vs. 0.06 ± 0.31; P < 0.001) and more in-clinic discussions (1.84 ± 4.20 vs. 1.28 ± 2.92; P < 0.03), but with numerically fewer hospitalizations (0.67 ± 1.18 vs. 0.85 ± 1.43, P = 0.23) and shorter length-of-stay (6.31 ± 15.5 vs. 8.26 ± 18.6; P = 0.27), although not significant. For the whole study population, the total follow-up cost for providers was not different for HM ON vs. OFF [mean (95% CI): €204 (169–238) vs. €213 (182–243); range for difference (€−36 to 54), NS].
1	4297469	hospitalizations, shorter length-of-stay	From a payer perspective, FU-related costs were similar while the total cost per patient (including other physician visits, examinations, and hospitalizations) was numerically (but not significantly) lower.
1	4297469	total follow-up cost for providers	For the whole study population, the total follow-up cost for providers was not different for HM ON vs. OFF [mean (95% CI): €204 (169–238) vs. €213 (182–243); range for difference (€−36 to 54), NS].
0	4297469	follow-up (follow-up) visits	Resource use with HM ON was clearly different: less follow-up visits (3.79 ± 1.67 vs. 5.53 ± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 ± 1.50 vs. 0.62 ± 1.25; P < 0.005), more non-office-based contacts (1.95 ± 3.29 vs. 1.01 ± 2.64; P < 0.001), more Internet sessions (11.02 ± 15.28 vs. 0.06 ± 0.31; P < 0.001) and more in-clinic discussions (1.84 ± 4.20 vs. 1.28 ± 2.92; P < 0.03), but with numerically fewer hospitalizations (0.67 ± 1.18 vs. 0.85 ± 1.43, P = 0.23) and shorter length-of-stay (6.31 ± 15.5 vs. 8.26 ± 18.6; P = 0.27), although not significant.
2	4030328	Smooth pursuit saccadic frequency	Ketamine increased saccadic frequency and decreased velocity gain of smooth pursuit eye movements (all P<0.01) but had no significant effects on prosaccades or antisaccades (all P⩾0.07).
1	4480825	Probability for erectile function recovery	Showing a significant overall treatment effect (p = 0.038), the probability for EF-recovery was significantly higher for OaD versus placebo [hazard ratio (hazard ratio); 95 % CI 1.9; 1.2, 3.1; p = 0.011], but not for PRN versus placebo (p = 0.140).
2	4480825	Probability for erectile function recovery	Showing a significant overall treatment effect (p = 0.038), the probability for EF-recovery was significantly higher for OaD versus placebo [hazard ratio (hazard ratio); 95 % CI 1.9; 1.2, 3.1; p = 0.011], but not for PRN versus placebo (p = 0.140).
1	3608590	Walking time per day.	There were also larger improvements in adherence (2.16 points; 95% CI: 0.33–3.99), reductions in anxiety (0.96 points; 95% CI: 0.19–1.73), and a greater proportion engaging in beneficial physical activity (Odds Ratio 1.91, 95%CI: 1.01–3.61) in the internet-delivered Cognitive Behaviour Therapy participants but no effect upon disability, or walking time/day.
2	3608590	Adherence	There were also larger improvements in adherence (2.16 points; 95% CI: 0.33–3.99), reductions in anxiety (0.96 points; 95% CI: 0.19–1.73), and a greater proportion engaging in beneficial physical activity (Odds Ratio 1.91, 95%CI: 1.01–3.61) in the internet-delivered Cognitive Behaviour Therapy participants but no effect upon disability, or walking time/day.
2	3608590	Engagement in beneficial physical activity	There were also larger improvements in adherence (2.16 points; 95% CI: 0.33–3.99), reductions in anxiety (0.96 points; 95% CI: 0.19–1.73), and a greater proportion engaging in beneficial physical activity (Odds Ratio 1.91, 95%CI: 1.01–3.61) in the internet-delivered Cognitive Behaviour Therapy participants but no effect upon disability, or walking time/day.
1	3608590	Disability	In ITT analysis of 562 participants internet-delivered Cognitive Behaviour Therapy produced a greater decline in the mean PHQ-9 score compared to the attention control of 1.06 (95% CI: 0.23–1.89) points, with differences between the two arms increasing over the intervention period (time by treatment effect interaction p = .012). There were also larger improvements in adherence (2.16 points; 95% CI: 0.33–3.99), reductions in anxiety (0.96 points; 95% CI: 0.19–1.73), and a greater proportion engaging in beneficial physical activity (Odds Ratio 1.91, 95%CI: 1.01–3.61) in the internet-delivered Cognitive Behaviour Therapy participants but no effect upon disability, or walking time/day.
0	3608590	Patient Health Questionnaire 9 scores	In ITT analysis of 562 participants internet-delivered Cognitive Behaviour Therapy produced a greater decline in the mean PHQ-9 score compared to the attention control of 1.06 (95% CI: 0.23–1.89) points, with differences between the two arms increasing over the intervention period (time by treatment effect interaction p = .012).
1	4237335	Past week drinking	An intention to treat analysis found no difference between experimental groups for past week drinking (primary outcome) (5.6% increase associated with the intervention (95% CI −4.7% to 16.9%; p = .30)), AUDIT (measure of alcohol-related harm) and health utility (EQ-5D).  
1	4237335	EQ-5D index	An intention to treat analysis found no difference between experimental groups for past week drinking (primary outcome) (5.6% increase associated with the intervention (95% CI −4.7% to 16.9%; p = .30)), AUDIT (measure of alcohol-related harm) and health utility (EQ-5D).  
1	5763662	operative success rate	There was no significant difference between the two groups in the success rate and the time of cyst treatment (P>0.05).
0	5763662	postoperative complications	The incidence of intraoperative and postoperative complications of the observation group was significantly lower than that of the control group.
0	5763662	intraoperative complications	The incidence of intraoperative and postoperative complications of the observation group was significantly lower than that of the control group.
2	5763662	total effective rate	After 1 month follow-up, the total effective rate of the observation group was significantly higher than that of the control group, the difference was statistically significant (P<0.05).
1	5763662	time of cyst treatment	There was no significant difference between the two groups in the success rate and the time of cyst treatment (P>0.05).
2	3671204	pain scores after six weeks	After six weeks, pain scores increased from 5.3 to 6.6 (p=0.04).
1	3671204	pain scores after 12 weeks	After 12 weeks this difference disappeared (p=0.5).
1	4554239	ProTaper Next system maintained root canal curvature	Within the parameters of this study, there was no difference between the performance of path-finding files and ProTaper Next system maintained root canal curvature well and was safe to use either with path-finding files or alone.    
1	4554239	apical transportation values	No significant differences were found among groups regarding apical transportation (p>0.05).
1	4554239	performance of path-finding files	Within the parameters of this study, there was no difference between the performance of path-finding files and ProTaper Next system maintained root canal curvature well and was safe to use either with path-finding files or alone.    
1	4554239	performance of path-finding files	Within the parameters of this study, there was no difference between the performance of path-finding files and ProTaper Next system maintained root canal curvature well and was safe to use either with path-finding files or alone.    
1	4554239	ProTaper Next system safety	Within the parameters of this study, there was no difference between the performance of path-finding files and ProTaper Next system maintained root canal curvature well and was safe to use either with path-finding files or alone.    
1	4554239	performance of path-finding files	Within the parameters of this study, there was no difference between the performance of path-finding files and ProTaper Next system maintained root canal curvature well and was safe to use either with path-finding files or alone.    
1	4554239	performance of path-finding files	No significant differences were found among groups regarding apical transportation (p>0.05).
1	3441250	Reduction in FVC, FEV-1, and PEFR after surgery	A comparable reduction on post-operative FVC and FEV-1 and PEFR was observed in both groups.  
2	3441250	Nausea at 2 hours	At 2 hours the proportion of patients experiencing nausea (38.2 % vs 17.9%, P = 0.03) and the mean nausea score were increased in the colloid compared to crystalloid group respectively (1.49 ± 0.3 vs 0.68 ± 0.2, P = 0.028).
1	3441250	Incidence of vomiting	The incidence of vomiting and anti-emetic usage was low and did not differ between the groups.
1	3441250	Sore throat, dizziness, cephalea, and general well being	Sore throat, dizziness, headache and general well being were not different between the groups.
1	3441250	Use of anti-emetic drugs	The incidence of vomiting and anti-emetic usage was low and did not differ between the groups.
1	2882922	Event-free survival curves	Event-free survival was similar in both groups of patients.  
2	3504074	Improvement in Psoriasis Area and Severity Index ≥75% after 24 weeks	PASI 75 was significantly higher at week 24 for the combination therapy group compared with the monotherapy group (77·3% vs. 60·3%; P < 0·0001).
2	3504074	Improvement in Psoriasis Area and Severity Index ≥50% and ≥90% after 24 weeks	Other PASI improvement scores at week 12 [PASI 75, 70·2% vs. 54·3% (P = 0·01); PASI 50, 92·4% vs. 83·8% (P = 0·01); and PASI 90, 34·0% vs. 23·1% (P = 0·03)] showed similar results as did week 24 PASI 50 (91·6% vs. 84·6%; P = 0·01) and PASI 90 (53·8% vs. 34·2%; P = 0·01).
2	3504074	Physician's Global Assessment of clear/almost clear	Significantly more patients receiving combination therapy than monotherapy had static Physician's Global Assessment of clear/almost clear at week 12 (65·5% vs. 47·0%; P = 0·01) and week 24 (71·8% vs. 54·3%; P = 0·01).
2	3504074	Improvement in Psoriasis Area and Severity Index ≥50%, ≥ 75%, and ≥90% after 12 weeks	Other PASI improvement scores at week 12 [PASI 75, 70·2% vs. 54·3% (P = 0·01); PASI 50, 92·4% vs. 83·8% (P = 0·01); and PASI 90, 34·0% vs. 23·1% (P = 0·03)] showed similar results as did week 24 PASI 50 (91·6% vs. 84·6%; P = 0·01) and PASI 90 (53·8% vs. 34·2%; P = 0·01).
0	5655920	Nausea and vomiting	A 14% higher incidence of gastrointestinal adverse events and a 10% higher incidence of nausea and vomiting were seen with mild impairment vs normal function (P = .003 for both), but no significant differences were observed between the mild and moderate impairment categories (P = .99 and P = .57, respectively), or between the moderate impairment and normal categories (P = .16 and P = .65, respectively).
1	5655920	Hypoglycaemia	Additionally, the incidence of hypoglycaemia was similar in all categories.  
1	5655920	Hypoglycaemia	A 14% higher incidence of gastrointestinal adverse events and a 10% higher incidence of nausea and vomiting were seen with mild impairment vs normal function (P = .003 for both), but no significant differences were observed between the mild and moderate impairment categories (P = .99 and P = .57, respectively), or between the moderate impairment and normal categories (P = .16 and P = .65, respectively). Additionally, the incidence of hypoglycaemia was similar in all categories.  
1	5655920	Nausea and vomiting	A 14% higher incidence of gastrointestinal adverse events and a 10% higher incidence of nausea and vomiting were seen with mild impairment vs normal function (P = .003 for both), but no significant differences were observed between the mild and moderate impairment categories (P = .99 and P = .57, respectively), or between the moderate impairment and normal categories (P = .16 and P = .65, respectively).
1	5655920	Nausea and vomiting	A 14% higher incidence of gastrointestinal adverse events and a 10% higher incidence of nausea and vomiting were seen with mild impairment vs normal function (P = .003 for both), but no significant differences were observed between the mild and moderate impairment categories (P = .99 and P = .57, respectively), or between the moderate impairment and normal categories (P = .16 and P = .65, respectively).
0	5379203	Waiting time	The waiting time of patients with AHI ≥ 15/hr who were started on CPAP treatment from the first clinic consultation to the diagnostic sleep test, autoCPAP titration, and CPAP treatment was 189.6, 148.8 and 145.0 days shorter in group A than group B respectively. Home-based approach is non-inferior to hospital-based approach in managing patients with suspected OSAS, with shorter waiting time, and substantial cost savings.
0	5379203	Mean costs per patient	Modified intention-to-treat analysis of those with AHI ≥ 15/hr on CPAP (n = 86 vs 86) showed no difference in Epworth sleepiness score, the primary endpoint, but greater improvement in Sleep-Apnoea-Quality-of-Life-Index[difference 0.3,(95%CI 0.02, 0.6), p = 0.033] at 3 months in group A. The mean costs for the patients in group A and group B were HK$8479(989) and HK$22,248(2407) respectively. The mean difference between groups was HK$-13,769(USD 1770 equivalent) per patient with 95% CI. (−14324, −13213), p < 0.001.
0	3230393	Urinary 2-Hydroxynaphthalene	Postintervention measurements indicated an average reduction of 42% for hydroxylated metabolites of naphthalene, fluorene, phenanthrene, and pyrene on a whole-weight concentration basis (micrograms per liter of urine), and a 34% reduction on a creatinine-adjusted basis (micrograms per gram of creatinine).
0	5379843	calculus formation	Abhaibhubejhr and Total toothpaste groups show 20.51% and 38.46% significantly less calculus formation than the Cavity Protection toothpaste group (P < 0.05).
2	4493951	The sedation score recorded in the postanesthesia care unit (postanesthesia care unit) over the 2-h observation period	In the postanesthesia care unit, group H2 had a higher sedation score than groups H1 and H0 (P < 0.001).  
0	4493951	the incidence of postoperative nausea and vomiting (prevention of postoperative nausea and vomiting)	The total incidence of prevention of postoperative nausea and vomiting over 24 h was significantly lower in groups H1 (29 %) and H2 (24 %) than in group H0 (54 %; P = 0.003), but there was no significant difference between groups H1 and H2.
1	4493951	the incidence of postoperative nausea and vomiting (prevention of postoperative nausea and vomiting)	The total incidence of prevention of postoperative nausea and vomiting over 24 h was significantly lower in groups H1 (29 %) and H2 (24 %) than in group H0 (54 %; P = 0.003), but there was no significant difference between groups H1 and H2.
1	4190894	Brain-derived neurotrophic factor at skin closure	ABSTRACT.RESULTS..  Baseline plasma concentrations of brain-derived neurotrophic factor did not differ between group A and group B; 15 minutes after induction, concentrations of plasma brain-derived neurotrophic factor were significantly reduced in group A. Twenty-four hours after surgery, the concentration was still higher in group B than in group A. In contrast, plasma concentrations of brain-derived neurotrophic factor at other time points tested did not differ between the two groups.  
0	1913602	Systolic blood pressure	After adjusting for age, body mass index, an asset index, smoking, secondhand tobacco smoke, apparent temperature, season, day of week, time of day, and a random subject intercept, the improved stove intervention was associated with 3.7 mm Hg lower SBP [95% confidence interval (confidence interval), −8.1 to 0.6] and 3.0 mm Hg lower diastolic blood pressure (95% confidence interval, −5.7 to −0.4) compared with controls.
2	4338635	blood carboxyhaemoglobin concentrations	Compared to filtered air, exposure to wood smoke increased blood carboxyhaemoglobin concentrations (1.3% versus 0.8%; P < 0.001), but had no effect on arterial pressure, augmentation index or pulse wave velocity (P > 0.05 for all).
1	4338635	augmentation index	Compared to filtered air, exposure to wood smoke increased blood carboxyhaemoglobin concentrations (1.3% versus 0.8%; P < 0.001), but had no effect on arterial pressure, augmentation index or pulse wave velocity (P > 0.05 for all).
1	4338635	pulse wave velocity	Compared to filtered air, exposure to wood smoke increased blood carboxyhaemoglobin concentrations (1.3% versus 0.8%; P < 0.001), but had no effect on arterial pressure, augmentation index or pulse wave velocity (P > 0.05 for all).
2	4338635	vasodilatation to bradykinin	Following exposure to wood smoke, vasodilatation to bradykinin increased (P = 0.003), but there was no effect on bradykinin-induced tissue-plasminogen activator release, thrombus area or markers of platelet activation (P > 0.05 for all).  
1	4338635	effect on bradykinin-induced tissue-plasminogen activator release, thrombus area or markers of platelet activation	Following exposure to wood smoke, vasodilatation to bradykinin increased (P = 0.003), but there was no effect on bradykinin-induced tissue-plasminogen activator release, thrombus area or markers of platelet activation (P > 0.05 for all).  
0	4076897	Post treatment pain in temporomandibular joint (temporomandibular joint) disorders	Comparing with baseline measures, both groups had significantly improved post-treatment pain (P < 0.0001 for both groups) and mandibular opening (P value: 0.001 for glucosamine sulfate and 0.03 for ibuprofen). Post treatment pain and mandibular opening showed significantly more improvement in the glucosamine treated patients (P < 0.0001 and 0.01 respectively).
2	4076897	mandibular opening in temporomandibular joint (temporomandibular joint) disorders 60 days after starting treatment	Post treatment pain and mandibular opening showed significantly more improvement in the glucosamine treated patients (P < 0.0001 and 0.01 respectively).
2	4076897	mandibular opening in temporomandibular joint (temporomandibular joint) disorders 90 days after starting treatment	Post treatment pain and mandibular opening showed significantly more improvement in the glucosamine treated patients (P < 0.0001 and 0.01 respectively).
2	4061773	Post-ingestion bicarbonate and base excess	Post-ingestion bicarbonate and base excess were higher (P < 0.05) in both the acute and chronic trials compared to placebo showing adequate pre-exercise alkalosis.
1	4639684	Serum transferrin	Our results showed that there was no significant difference between the groups in terms of serum albumin, prealbumin or transferrin.
1	4639684	Serum albumin	Our results showed that there was no significant difference between the groups in terms of serum albumin, prealbumin or transferrin.
1	4639684	Serum prealbumin	Our results showed that there was no significant difference between the groups in terms of serum albumin, prealbumin or transferrin.
2	4639684	C3 levels	However, C3 and C4 levels were significantly higher in the enteral feeding group compared with the parenteral group, while hs-C-reactive protein level was significantly lower in the enteral feeding group.
2	4639684	C4 levels	However, C3 and C4 levels were significantly higher in the enteral feeding group compared with the parenteral group, while hs-C-reactive protein level was significantly lower in the enteral feeding group.
0	4639684	C- reactive protein	However, C3 and C4 levels were significantly higher in the enteral feeding group compared with the parenteral group, while hs-C-reactive protein level was significantly lower in the enteral feeding group.
2	3925077	probability of antibiotic prophylaxis being cost-effective from a societal perspective	If a decision-maker is willing to pay up to £25,000/QALY then there is a 66% probability of antibiotic prophylaxis being cost-effective from an NHS perspective, rising to 76% probability from a secondary, societal perspective.  
1	3925077	Cost of Prophylactic Antibiotics to Prevent Cellulitis of the Leg	Incremental costs of prophylaxis suggested a small cost saving but were not statistically significant, comparing the two groups.
2	3925077	probability of antibiotic prophylaxis being cost-effective from an NHS perspective	If a decision-maker is willing to pay up to £25,000/QALY then there is a 66% probability of antibiotic prophylaxis being cost-effective from an NHS perspective, rising to 76% probability from a secondary, societal perspective.  
1	5343026	Measures of gesture	Measures of gesture not differ over the course of the experiment for all the products under investigation  Conclusion: All cognitive measures attention, executive function and working memory are not influenced by the different electronic-cigarettes and gender showing that in general electronics cigarettes could become a strong support also from a cognitive point of view for those who decide to quit smoking.
1	5343026	rituals associated with smoking gestures	Measures of gesture not differ over the course of the experiment for all the products under investigation  Conclusion: All cognitive measures attention, executive function and working memory are not influenced by the different electronic-cigarettes and gender showing that in general electronics cigarettes could become a strong support also from a cognitive point of view for those who decide to quit smoking.
1	5343026	cognitive measures	Measures of gesture not differ over the course of the experiment for all the products under investigation  Conclusion: All cognitive measures attention, executive function and working memory are not influenced by the different electronic-cigarettes and gender showing that in general electronics cigarettes could become a strong support also from a cognitive point of view for those who decide to quit smoking.
1	5343026	cognitive measures	Results: Cognitive performance was not affected by "group condition." Within-group repeated measures analyses showed a significant time effect, indicating an increase of participants' current craving measure in group "usual classic cigarettes (group C)," "disposable cigalike electronic cigarette loaded with cartridges with 24 mg nicotine (group H), second generation electronic cigarette, personal vaporizer model Ego C, loaded with liquid nicotine 24 mg (group E).
1	3533739	number of clinic visits for cryotherapy	There was no evidence that the number of times salicylic acid was applied was different between the preference groups at one week (p=0.89) or at three weeks (p=0.24). Similarly, for the number of clinic visits for cryotherapy (p=0.71)  ABSTRACT.CONCLUSIONS. 
1	3533739	number of times salicylic acid was applied	There was no evidence that the number of times salicylic acid was applied was different between the preference groups at one week (p=0.89) or at three weeks (p=0.24).
0	5416724	Intubation difficulty scale (Intubation difficulty scale) score	The AirtraqTM laryngoscope significantly reduced the Intubation difficulty scale (mean − 0.43 ± 0.81) as compared with both McCoyTM (mean − 1.63 ± 1.49, P = 0.001) and Macintosh laryngoscope (mean −2.23 ± 1.92, P < 0.001) and improved the Cormack-Lehane glottic view (77% grade 1 view and no patients with grade 3 or 4 view).
1	2972641	time to bloody stools	In the full analysis set (n = 130), the proportion of patients without bloody stools was 76.9% in the pH-2.4 g and 69.2% in the Time-2.25 g, demonstrating the noninferiority of pH-2.4 g to Time-2.25 g. No statistically significant difference in time to bloody stools was found between the two formulations (P = 0.27, log-rank test), but the time to bloody stools tended to be longer in pH-2.4 g compared to Time-2.25 g, and a similar trend was observed with regard to the time to relapse.
1	2972641	time to bloody stools	In the full analysis set (n = 130), the proportion of patients without bloody stools was 76.9% in the pH-2.4 g and 69.2% in the Time-2.25 g, demonstrating the noninferiority of pH-2.4 g to Time-2.25 g. No statistically significant difference in time to bloody stools was found between the two formulations (P = 0.27, log-rank test), but the time to bloody stools tended to be longer in pH-2.4 g compared to Time-2.25 g, and a similar trend was observed with regard to the time to relapse.
1	2972641	safety profiles	No differences were observed between the safety profiles of the two formulations.  
2	5106769	Optical density of MPOD (MPOD)	MPOD for subjects in both supplementation groups increased significantly versus placebo at both 6- and 12-month visits (p < 0.001 for all).
2	5106769	disability glare (disability glare) performance	Increases in MPOD lead to significant improvements in photostress recovery times and disability glare thresholds.
2	5106769	disability glare (disability glare) performance	Additionally, photostress recovery times and disability glare thresholds improved significantly from baseline compared to placebo at 6- and 12-month visits (p < 0.001 for all).
2	5106769	repeated-exposure photostress recovery (photostress recovery)	Increases in MPOD lead to significant improvements in photostress recovery times and disability glare thresholds.
2	5106769	optical density of MPOD (MPOD)	MPOD for subjects in both supplementation groups increased significantly versus placebo at both 6- and 12-month visits (p < 0.001 for all).
1	3015551	The mean time to remove both tubal segments	The mean time to remove both tubal segments was not different between techniques (7 minutes, 21 seconds; range, 4 minutes, 25 seconds to 15 minutes, 43 seconds).
1	3015551	Postoperative pain at 6 hours	Postoperative pain at 6 hours was scored similarly (median, ligation 4.6, coagulation 4.0 of 10).
1	3015551	Outpatient recovery	Outpatient recovery was the same, unless pelvic pain required overnight observation (ligation, 4 patients; coagulation, 2 patients).  
0	2892494	Hospitalization	Compared with patients with Personal and Social Performance ≥ 71 group, the hazard for new hospitalization was 8.351 times greater (P = 0.0001) for patients with the poorest functioning (Personal and Social Performance 1 to 30) and 1.977 times greater (P = 0.0295) for patients with Personal and Social Performance of 31-70 compared to the ≥ 71 group.
2	2892494	Hospitalization	The hazard for new hospitalization was 5.457 times greater (P < 0.0001) for patients Positive and Negative Syndrome Scale ≥ 95 and 2.316 times greater (P = 0.0027) for the ≥ 75 to < 95 group compared with the < 75 group.
0	2892494	Discharge	For patients hospitalized at baseline, the Positive and Negative Syndrome Scale ≥ 95 patients had a discharge hazard that was 0.456 times lower than for the < 75 patients (P < 0.0001).
0	2892494	Hospitalization	Compared with patients with Personal and Social Performance ≥ 71 group, the hazard for new hospitalization was 8.351 times greater (P = 0.0001) for patients with the poorest functioning (Personal and Social Performance 1 to 30) and 1.977 times greater (P = 0.0295) for patients with Personal and Social Performance of 31-70 compared to the ≥ 71 group.
2	2892494	Discharge	The hazard for discharge was 0.646 times lower (P = 0.0012) for the Positive and Negative Syndrome Scale ≥ 75 to < 95 group compared with the < 75 group.
2	2892494	Hospitalization	The hazard for new hospitalization was 5.457 times greater (P < 0.0001) for patients Positive and Negative Syndrome Scale ≥ 95 and 2.316 times greater (P = 0.0027) for the ≥ 75 to < 95 group compared with the < 75 group.
2	4784207	Adequacy of consent index score	The mean adequacy of consent index score in Group B was higher than that of Group A (30.6 ± 4.6 [standard deviation (standard deviation)] vs. 27.9 ± 5.2 [standard deviation]) (P < 0.001).
2	4784207	Satisfaction with information about common side effects	The separate written consent had a positive impact on the patients' understanding of the nature and purpose of the intended anesthesia procedures (P = 0.04), satisfaction with the adequacy of information provided about common side effects (P < 0.001) and rare but serious complications (P = 0.008).  
2	4784207	Patients' understanding anesthesia procedure	The separate written consent had a positive impact on the patients' understanding of the nature and purpose of the intended anesthesia procedures (P = 0.04), satisfaction with the adequacy of information provided about common side effects (P < 0.001) and rare but serious complications (P = 0.008).  
2	4784207	Satisfaction with information rare complications	The separate written consent had a positive impact on the patients' understanding of the nature and purpose of the intended anesthesia procedures (P = 0.04), satisfaction with the adequacy of information provided about common side effects (P < 0.001) and rare but serious complications (P = 0.008).  
2	5148913	adjusted mean change of peak expiratory flow	The primary endpoint [change from baseline over the entire treatment period in average pre-dose morning peak expiratory flow (peak expiratory flow)] demonstrated the superiority of BDP/FF over BDP monotherapy, with an adjusted mean difference of 19 L/min, which is above the minimal important clinical difference reported for this parameter. Overall, BDP/FF and BDP showed a similar improvement of symptom-based parameters and of the use of rescue medication after 3-month treatment.
1	5148913	The mean average use of rescue medication	Overall, BDP/FF and BDP showed a similar improvement of symptom-based parameters and of the use of rescue medication after 3-month treatment.
2	4367028	Bispectral index values	During comparison between two groups with different angulations, Trendelenburg >30° showed a higher Bispectral index value than Trendelenburg <30°. This statistically significant (P < 0.05) trend was observed at all the 30, 60, 90, and 120th min interval.
0	2546382	Cost-effectiveness	Using the most conservative of assumptions, the cost-effectiveness ratio of exenatide vs. insulin glargine at the current UK NHS price was -£29,149/QALY (insulin glargine dominant) and thus exenatide is not cost-effective when compared with insulin glargine, at the current UK NHS price.  
0	4296355	Duration of motor and sensory block	There was a significant increase in duration of motor and sensory block and analgesia in Group B as compared to Group A patients (P < 0.0001).
1	4296355	Onset time of anesthesia	There was no significant difference in onset time in either group (P = 0.304).
1	4296355	Side effects	No significant side effects were noted.  
0	4171519	Blood glucose	In addition, raloxifene-treated rats had blood glucose levels significantly lower than both diabetic vehicle-treated rats as well as vehicle-treated rats that did not become diabetic.
2	4171519	Femoral toughness	Femoral toughness was greater in raloxifene-treated rats compared with both diabetic and non-diabetic vehicle-treated Zucker Diabetic Sprague-Dawley rats, due to greater energy absorption in the post-yield region of the stress-strain curve.
1	2571050	Time for reaching glucose predetermined values	Except for these differences, times to reach glucose ≤250 mg/dl, pH ≥7.3, and HCO3− ≥15 mEq/l did not differ significantly among the three groups.  
1	2571050	Time for reaching bicarbonate predetermined values	Except for these differences, times to reach glucose ≤250 mg/dl, pH ≥7.3, and HCO3− ≥15 mEq/l did not differ significantly among the three groups.  
2	4329963	mean post-test scores of health-promoting lifestyle scale, health-related quality of life scale, and all constructs of Pender's health promotion model (self-efficacy, perceived affect, perceived social support, and perceived barriers)	Analysis of covariance showed that after adjusting for effects of pretest scores, the difference between mean post-test scores of health-promoting lifestyle scale, health-related quality of life scale, and all constructs of Pender's health promotion model (self-efficacy, perceived affect, perceived social support, and perceived barriers) in the intervention group 1 and control group were significant (P< 0.0001). In addition, changes in mean scores of lifestyle scale (42.4 ± 13.6), quality of life scale (29.1 ± 14.2), self-efficacy (16.1 ± 2.6), perceived affect (16.1 ± 8), social support (35.4 ± 12.4), and barriers (17.2 ± 15.8) before and after intervention were significant in the intervention group 2 (P < 0.0001).  
0	5534500	The mean postoperative hospital stay, the mean time of removal of nasogastric tubes, the mean time of successful enteral feeding, the mean time for removal of intra-abdominal drains	The mean postoperative hospital stay was 4.49 ± 0.85 days vs. 13.31 ± 6.9 days (P < 0.001), the mean time of removal of nasogastric tubes was 0.77 ± 1.031 days vs. 3.26 ± 2.737 days (P < 0.001), the mean time of successful enteral feeding was 1.89 ± 1.13 days vs. 5.46 ± 1.67 days (P < 0.001), and the mean time for removal of intra-abdominal drains was 2.94 ± 1.056 days vs. 9.06 ± 3.757 days (P < 0.001) for the enhanced and the conventional groups, respectively.
0	5534500	Complications	Complications were significantly lower among patients in the enhanced group (25.7% vs. 65.7%) (P = 0.001).
0	4577567	internal work	Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001) and contact time (4.58%; p<0.001); inversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.
0	4577567	internal work	In RWF the effect of the training showed a decrease in stride length (1.18%; p<0.0001) and contact time (<1%; p<0.0001) with respect to baseline conditions and an increased stride frequency and internal work of 1.19% (p<0.0001).
2	4577567	contact time	Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001) and contact time (4.58%; p<0.001); inversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found. In RWF the effect of the training showed a decrease in stride length (1.18%; p<0.0001) and contact time (<1%; p<0.0001) with respect to baseline conditions and an increased stride frequency and internal work of 1.19% (p<0.0001).
0	4577567	stride frequency	Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001) and contact time (4.58%; p<0.001); inversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.
2	4577567	stride length	Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001) and contact time (4.58%; p<0.001); inversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.
0	2691927	Need for opiates	Differences regarding postoperative dosage of opiates and the visual analog scale (visual analog scale) for pain scoring system were in favor of the laparoscopic procedure.
1	2691927	Hospital permanence	Hospital stay was also comparable: 6.5 days in the laparoscopic group versus 8.0 days in the open group (P = 0.235).  
0	2691927	Visual analog scale pain score at day 3	The visual analog scale score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.
0	2691927	Visual analog scale pain score at day 1	The visual analog scale score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.
0	2691927	Visual analog scale pain score at day 7	The visual analog scale score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.
1	2691927	Postoperative complications	Complications were equally distributed.
2	2691927	Surgery duration	Operating time in the laparoscopy group was significantly longer than in the open group (75 min versus 50 min).
2	5176312	the Advanced-level subtotal Wheelchair Skills Test (Wheelchair Skills Test 4.1) - baseline, post-training	Participants in the Wheelchair Skills Training Program group improved their total and Advanced-level Wheelchair Skills Test 4.1 scores by 7.1% and 30.1% relative to baseline (p < 0.001) and retained their scores at one year follow-up.
2	4081799	long-term predictors for favorable course	Main long-term predictors for favorable course were adherence to relapse prevention, more spontaneity, and more ineffectiveness.
0	3346674	Improvement of rash sites	Although improvement in the severity of Diaper dermatitis was observed in both treatment groups (P < 0.001), patients receiving Calendula ointment had significantly fewer rash sites compared to Aloe group (P = 0.001).
1	3346674	Adverse effect	No adverse effect was reported from either of the medications.
0	5053082	Physical restraint use per week during training	The comparative effects of the two training conditions were assessed in terms of caregiver variables care recipient variable (number of aggressive events), and agency variables Results showed that Mindfulness-Based Positive Behavior Support was significantly more effective than Training-as-Usual in enabling the caregivers to manage their perceived psychological stress, and to reduce the use of physical restraints and stat medications for aggressive behavior of the individuals in their care.
0	5053082	Use of STAT medications per week after training	The comparative effects of the two training conditions were assessed in terms of caregiver variables care recipient variable (number of aggressive events), and agency variables Results showed that Mindfulness-Based Positive Behavior Support was significantly more effective than Training-as-Usual in enabling the caregivers to manage their perceived psychological stress, and to reduce the use of physical restraints and stat medications for aggressive behavior of the individuals in their care.
0	5053082	Perceived Stress	The comparative effects of the two training conditions were assessed in terms of caregiver variables care recipient variable (number of aggressive events), and agency variables Results showed that Mindfulness-Based Positive Behavior Support was significantly more effective than Training-as-Usual in enabling the caregivers to manage their perceived psychological stress, and to reduce the use of physical restraints and stat medications for aggressive behavior of the individuals in their care.
2	2806387	The intensity of an unpleasant sensation	The intensity of the unpleasant sensation was rated significantly higher after injection of saline from prefilled syringes compared to saline from polyethylene (p = 0.001).  
1	4240932	California verbal learning test (California verbal learning test), and symbol digit modality test (symbol digit modality test)	In the brief visual-spatial memory test revised, 13 patients (34.2%), who had already taken B. papyrifera, were shown to have significant improvement compared to the placebo group with no improvement (P < 0. 001). About 12 and 8 patients in the treatment and placebo groups in the symbol digit modality test, respectively (P = 0.200) and 17 and 12 patients in the treatment and placebo groups in the California verbal learning test, respectively (P = 0.170) had significant change values.   
1	5564101	the duration of anesthesia	However, the extent of pulpal anesthesia, surgical duration, and duration of soft tissue anesthesia were not significantly different.  
0	2995234	change in bowel frequency in patients with respiratory tract infection receiving antibiotics	However, the Lactobacillus group showed lower change in bowel frequency and consistency (50/103, 48.5%) than the placebo group (35/111, 31.5%) (P=0.01).
0	2995234	change in bowel consistency in patients with respiratory tract infection receiving antibiotics	However, the Lactobacillus group showed lower change in bowel frequency and consistency (50/103, 48.5%) than the placebo group (35/111, 31.5%) (P=0.01).
1	2995234	Antibiotic-associated diarrhea (Antibiotic-associated diarrhea) in patients with respiratory tract infection	Antibiotic-associated diarrhea developed in 4 (3.9%) of 103 patients in the Lactobacillus group and in 8 (7.2%) of 111 patients in the placebo group (P=0.44).
1	5565373	serum fibroblast growth factor 23 levels	However, both mean change and percentage change in the serum fibroblast growth factor 23 levels during the 8-week period were not significantly different between the two groups.
1	5565373	serum calcium level	Serum calcium level was increased significantly only in the combination treatment group. There was no significant difference in percentage change of serum calcium levels between the two groups.
1	5565373	serum phosphorus level	In addition, changes in serum levels of phosphate, 25(OH)D, or parathyroid hormone were not significantly different between the two groups.
1	5565373	concentrations of 25(OH)D	In addition, changes in serum levels of phosphate, 25(OH)D, or parathyroid hormone were not significantly different between the two groups.
1	5565373	serum parathyroid hormone (parathyroid hormone) levels	In addition, changes in serum levels of phosphate, 25(OH)D, or parathyroid hormone were not significantly different between the two groups.
2	3017961	Sattva improvement	The number of persons who showed improvement in Sattva and decrease in Tamas was significant in the Y but not in the physical exercises group (McNemar test).
2	3017961	Decrease in Tamas	The number of persons who showed improvement in Sattva and decrease in Tamas was significant in the Y but not in the physical exercises group (McNemar test).
2	3719224	the variables, knowledge	Despite the similarity of two groups of intervention (n = 53) and control (n = 59) at baseline, there were significant differences between the two groups in mean scores of the variables, knowledge (4.62 ± 1.38 vs. 3.53 ± 1.61), perceived susceptibility (14.05 ± 1.51 vs. 12.37 ± 2.11), and perceived benefits (28.41 ± 2.14 vs. 27.51 ± 3.05), at follow-up time after 3 months (P < 0.05).
2	3719224	perceived susceptibility	Despite the similarity of two groups of intervention (n = 53) and control (n = 59) at baseline, there were significant differences between the two groups in mean scores of the variables, knowledge (4.62 ± 1.38 vs. 3.53 ± 1.61), perceived susceptibility (14.05 ± 1.51 vs. 12.37 ± 2.11), and perceived benefits (28.41 ± 2.14 vs. 27.51 ± 3.05), at follow-up time after 3 months (P < 0.05).
2	3719224	perceived benefits	Despite the similarity of two groups of intervention (n = 53) and control (n = 59) at baseline, there were significant differences between the two groups in mean scores of the variables, knowledge (4.62 ± 1.38 vs. 3.53 ± 1.61), perceived susceptibility (14.05 ± 1.51 vs. 12.37 ± 2.11), and perceived benefits (28.41 ± 2.14 vs. 27.51 ± 3.05), at follow-up time after 3 months (P < 0.05).
2	4829247	P-wave duration	P-wave duration and Pd significantly increased during MM and ITH compared to BL in all subjects (+13.1ms and +13.8ms during MM; +11.7ms and +12.9ms during ITH; p<0.001 for all comparisons).
2	4829247	P-wave duration	P-wave duration and Pd significantly increased during MM and ITH compared to BL in all subjects (+13.1ms and +13.8ms during MM; +11.7ms and +12.9ms during ITH; p<0.001 for all comparisons).
2	4829247	P-wave dispersion	P-wave duration and Pd significantly increased during MM and ITH compared to BL in all subjects (+13.1ms and +13.8ms during MM; +11.7ms and +12.9ms during ITH; p<0.001 for all comparisons).
2	4829247	P-wave dispersion	P-wave duration and Pd significantly increased during MM and ITH compared to BL in all subjects (+13.1ms and +13.8ms during MM; +11.7ms and +12.9ms during ITH; p<0.001 for all comparisons).
0	4030092	Primary outcomes (cardiovascular disease deaths, nonfatal myocardial infarction, nonfatal stroke)	In the blood pressure trial, risk of the primary outcome was lower in the groups intensively treated for glycemia (hazard ratio [hazard ratio] 0.67; 95% CI 0.50–0.91), blood pressure (hazard ratio 0.74; 95% CI 0.55–1.00), or both (hazard ratio 0.71; 95% CI 0.52–0.96) compared with combined standard blood pressure and glycemia treatment.
1	4030092	Lipid levels	In the lipid trial, the general pattern of results showed no evidence of benefit of intensive regimens (whether single or combined) compared with combined standard lipid and glycemia treatment.
0	4030092	Any Myocardial infarction	For secondary outcomes, myocardial infarction was significantly reduced by intensive glycemia treatment and stroke by intensive blood pressure treatment; most other hazard ratios were neutral or favored intensive treatment groups.
0	4030092	Primary outcomes (cardiovascular disease deaths, nonfatal myocardial infarction, nonfatal stroke)	In the blood pressure trial, risk of the primary outcome was lower in the groups intensively treated for glycemia (hazard ratio [hazard ratio] 0.67; 95% CI 0.50–0.91), blood pressure (hazard ratio 0.74; 95% CI 0.55–1.00), or both (hazard ratio 0.71; 95% CI 0.52–0.96) compared with combined standard blood pressure and glycemia treatment.
0	4030092	Stroke	For secondary outcomes, myocardial infarction was significantly reduced by intensive glycemia treatment and stroke by intensive blood pressure treatment; most other hazard ratios were neutral or favored intensive treatment groups.
0	4030092	Primary outcomes (cardiovascular disease deaths, nonfatal myocardial infarction, nonfatal stroke)	In the blood pressure trial, risk of the primary outcome was lower in the groups intensively treated for glycemia (hazard ratio [hazard ratio] 0.67; 95% CI 0.50–0.91), blood pressure (hazard ratio 0.74; 95% CI 0.55–1.00), or both (hazard ratio 0.71; 95% CI 0.52–0.96) compared with combined standard blood pressure and glycemia treatment.
2	3790036	Improvement in PaO2 levels	The PaO2 levels and alveolar-arterial difference in oxygen tension (AaDO2) were improved in patients with positive end-expiratory pressures compared with patients in whom positive end-expiratory pressure was not used.
2	3790036	Improvement in alveolar-arterial difference in oxygen tension	The PaO2 levels and alveolar-arterial difference in oxygen tension (AaDO2) were improved in patients with positive end-expiratory pressures compared with patients in whom positive end-expiratory pressure was not used.
1	3790036	Heart rate, mean arterial pressure, and minute ventilation	There was a significant difference in central venous pressure between the groups, but there were no significant differences in heart rate, mean arterial pressure or minute ventilation between the groups.  
0	5525580	Mortality	The treatment protocol for all the participants followed the Sepsis Survival Campaign guidelines, and group B received total parenteral nutrition containing 100 ml of Omega-3 fatty acids (containing 10 g refined fish oil) per day in addition to the standard treatment applied in group A. Group B had a significantly lower mortality rate compared with group A (12.5 vs. 41.7%, P<0.05) during the 28-day follow-up.
0	5525580	Acute Physiology and Chronic Health Evaluation II scores	Group B also had lower Acute Physiology and Chronic Health Evaluation II scores (P<0.05) and lower Marshall scores (P<0.05) at day 7.
0	5525580	Marshall scores	Group B also had lower Acute Physiology and Chronic Health Evaluation II scores (P<0.05) and lower Marshall scores (P<0.05) at day 7.
2	5525580	CD4 to CD8 lymphocytes ratio	In addition, group B had a higher ratio of T helper to inducer lymphocytes as well as a higher ratio of CD4 to CD8 lymphocytes (P<0.01 for both) than group A. It was concluded that Omega-3 fatty acids improved T helper/inducer and CD4/CD8 ratios, and may have reduced mortality, among septic patients with intestinal dysfunction.
2	5525580	T helper to inducer lymphocytes ratio	In addition, group B had a higher ratio of T helper to inducer lymphocytes as well as a higher ratio of CD4 to CD8 lymphocytes (P<0.01 for both) than group A. It was concluded that Omega-3 fatty acids improved T helper/inducer and CD4/CD8 ratios, and may have reduced mortality, among septic patients with intestinal dysfunction.
2	5571924	advanced colorectal neoplasia (colorectal neoplasia)	The high-risk group had a 3.7-fold increased risk of advanced colorectal neoplasia compared to the low-risk group (1.1% vs. 4.0%, P < .001).
2	5571924	advanced colorectal neoplasia (colorectal neoplasia)	The discrimination performance of the present model for high-risk patients with advanced colorectal neoplasia was better than that of the Asia-Pacific Colorectal Screening score (AUC = 0.678, P < .001) and Schroy's CAN index (AUC = 0.672, P < .001).  
2	5571924	discrimination performance using AUC (Area under the receiver operating curve) for high risk patients	The developed model had good discrimination (AUC = 0.726) and was internally validated (AUC = 0.713). The high-risk group had a 3.7-fold increased risk of advanced colorectal neoplasia compared to the low-risk group (1.1% vs. 4.0%, P < .001). The discrimination performance of the present model for high-risk patients with advanced colorectal neoplasia was better than that of the Asia-Pacific Colorectal Screening score (AUC = 0.678, P < .001) and Schroy's CAN index (AUC = 0.672, P < .001).  
1	4674925	new metastases was associated with an increased risk of death - women with advanced/metastatic breast cancer (advanced/metastatic breast cancer)	In both clinical studies, development of new metastases was associated with an increased risk of death (p < 0.0001).
2	5292014	Improvement in mean scores of lifestyle-related vaginal health scale	analysis of covariance showed that after adjusting for effects of pretest scores, the difference between mean scores on the scale of lifestyle related to vaginal health in the intervention group (28.48 ± 0.38) and control group (23.65 ± 1.23) was significant (P < 0.001). Intervention has a positive significant effect on increasing the mean scores of lifestyle in the intervention group (P < 0.001).
2	5292014	Improvement in mean scores of lifestyle-related vaginal health scale	According to the findings, educational intervention is beneficial in promoting three aspects of women's lifestyle related to vaginal health.
1	2875419	improved A1C	Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).
1	2875419	number of patients with A1C <7%	Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).
2	2875419	number of patients with A1C <6.5%	Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).
1	2875419	Hypoglycemia	Hypoglycemia risk was similar.
2	2875419	Weight Gain	Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).
1	5094682	glomerular filtration rate (estimated glomerular filtration rate)	The mean changes in estimated glomerular filtration rate were 0 ± 14 and −7 ± 16 mL/min/1.73 m2 (p = 0.09, between groups) for the acarbose and pioglitazone groups, respectively.
1	5094682	urinary albumin-to-creatinine ratio (urinary albumin-to-creatinine ratio)	After 6 months of treatment, the mean changes in urinary albumin-to-creatinine ratio were −18 ± 104 and 12 ± 85 (p = 0.25, between groups) for the acarbose and pioglitazone groups, respectively.
2	4711101	Surgery time	Surgery time was significantly longer (p < 0.001) and there were significantly higher blood loss (p = 0.002) in the minimally invasive surgical technique group as compared to the conventional group.
2	4711101	Blood loss	Surgery time was significantly longer (p < 0.001) and there were significantly higher blood loss (p = 0.002) in the minimally invasive surgical technique group as compared to the conventional group.
1	4711101	Flexion/extension of the femur	There was no significant difference of component alignment between the two surgical groups with respect to flexion/extension (p = 0.269), varus/valgus (p = 0.653) or rotational alignment (p = 0.485) of the femur component and varus valgus alignment (p = 0.778) or posterior slope (p = 0.164) of the tibial component.  
2	4711101	Pain	Patients in the minimally invasive surgical technique group (3.97 ± 2.16) had significant more pain at 2 weeks than patients in the conventional group (2.77 ± 1.43) p = 0.003.
1	4711101	Rotational alignment of the femur	There was no significant difference of component alignment between the two surgical groups with respect to flexion/extension (p = 0.269), varus/valgus (p = 0.653) or rotational alignment (p = 0.485) of the femur component and varus valgus alignment (p = 0.778) or posterior slope (p = 0.164) of the tibial component.  
1	5820389	Number of absence days due to sickness at 6 months	We found no statistically significant difference between the programs in median number of sickness absence days at 6 and 12 months follow-up.
1	5820389	Number of absence days due to sickness at 12 months	We found no statistically significant difference between the programs in median number of sickness absence days at 6 and 12 months follow-up.
1	5820389	Sustainable return to work	In the outpatient program 57% of the participants achieved sustainable return to work (median time 7 months), in the inpatient program 49% (log rank, p = 0.167). The hazard ratio for sustainable return to work was 0.74 (95% CI 0.48–1.32, p = 0.165), in favor of the outpatient program.
1	4076224	Referral uptake	Actual referral uptake was 34% risk-assessment-only questionnaire, 26% RA+, OR 4.4, 95% CI (1.4–19.2), p = 0.31.
0	4076224	Risk of obstructive sleep apnea	The proportion of screened participants identified as being at risk of obstructive sleep apnea was significantly higher in the RA+ group (36% in risk-assessment-only questionnaire vs. 66% in RA+, OR 3.4, 95% CI (1.8–6.5), p<0.001).
0	4076224	Obstructive sleep apnea diagnosis rate	The obstructive sleep apnea diagnosis rate was higher in the RA+ arm (p = 0.01).
0	3556334	number of zones involved	After 12 weeks, the vitamin D supplemented arm demonstrated significantly greater mean weight gain (kg) + 3.75, (3.16 – 4.34) versus + 2.61 (95% CI 1.99 – 3.23) p 0.009 and lesser residual disease by chest radiograph; number of zones involved 1.35 v/s 1.82 p 0.004 (95% CI 0.15, 0.79) and 50% or greater reduction in cavity size 106 (89.8%) v/s 111 (94.8%), p 0.035.
2	3556334	mean weight gain	After 12 weeks, the vitamin D supplemented arm demonstrated significantly greater mean weight gain (kg) + 3.75, (3.16 – 4.34) versus + 2.61 (95% CI 1.99 – 3.23) p 0.009 and lesser residual disease by chest radiograph; number of zones involved 1.35 v/s 1.82 p 0.004 (95% CI 0.15, 0.79) and 50% or greater reduction in cavity size 106 (89.8%) v/s 111 (94.8%), p 0.035.
0	3556334	cavity size	After 12 weeks, the vitamin D supplemented arm demonstrated significantly greater mean weight gain (kg) + 3.75, (3.16 – 4.34) versus + 2.61 (95% CI 1.99 – 3.23) p 0.009 and lesser residual disease by chest radiograph; number of zones involved 1.35 v/s 1.82 p 0.004 (95% CI 0.15, 0.79) and 50% or greater reduction in cavity size 106 (89.8%) v/s 111 (94.8%), p 0.035.
0	4942591	resting heart rate (resting heart rate)	resting heart rate was lowered (P < 0.05) by 6 bpm after intervention (77 ± 1 to 71 ± 1 bpm).
2	4942591	Yo-Yo Intermittent Endurance test level 1 (Yo-Yo IE1) performance	Yo-Yo IE1 performance increased by 41% (540 ± 27 to 752 ± 45 m), while agility and postural balance were improved (P < 0.05) by ~6 and ~45%, respectively.
1	5431359	Stress	Stress, vital exhaustion and depression did not differ between the groups over time.
1	5431359	Depression	Stress, vital exhaustion and depression did not differ between the groups over time.
0	5431359	Somatic anxiety	The intervention had a positive effect on somatic anxiety (p < 0.05), reflecting a beneficial development over time compared with the controls.
1	5431359	Vital exhaustion	Stress, vital exhaustion and depression did not differ between the groups over time.
2	4763632	Demoscopic changes	Overall demoscopic changes were observed in 34/37 (91.8%) of the uncovered nevi compared to 16/37 (43.2%) of the covered nevi (P value 0.0001).
2	4763632	Demoscopic changes	Compared to narrowband ultraviolet B, dermoscopic changes were more frequent in both covered and uncovered nevi of the psoralen-ultraviolet A group. (P values 0.041 and 0.0172, respectively).
2	4763632	Formation of new dot-globule	New dot/globule formation was observed more frequently in the covered and uncovered nevi of psoralen-ultraviolet A group.  
0	4274545	incidence of suspected Necrotizing enterocolitis (Necrotizing enterocolitis)	short chain galacto-oligosaccharides/long chain fructo-oligosaccharides mixture significantly reduced the incidence of suspected Necrotizing enterocolitis, (1 [4.0%] vs. 11 [22.0%]; hazard ratio: 0.49 [95% confidence interval: 0.29-0.84]; P = 0.002), and time to full enteral feeds (11 [7-21] vs. 14 [8-36] days; P - 0.02].
0	4274545	Hospitalization time	Also duration of hospitalization was meaningfully shorter in the prebiotic group (16 [9-45] vs. 25 [11-80]; P - 0.004].
0	4374260	premature ejaculation (premature ejaculation).	premature ejaculation was successfully treated in only 2.4% of patients with placebo, in contrast to 53.6% and 85.6% with 50 and 100 mg tramadol, respectively (P < 0.001 for all comparisons).
0	4374260	premature ejaculation (premature ejaculation).	On multivariate logistic regression analysis, baseline Intra-vaginal ejaculatory latency time was the only predictor of successful treatment of premature ejaculation with both tramadol 50 mg (odds ratio [odds ratio]: 1.05, 95% confidence interval [confidence interval]: 1.03-1.07, P < 0.001) and tramadol 100 mg (odds ratio: 1.07, 95% confidence interval: 1.04-1.11, P < 0.001).
2	4374260	Weak scanty ejaculation	Weak scanty ejaculation was the main complaint in 7.2% versus 21.6% of those using 50 and 100 mg tramadol, respectively (P = 0.002).
2	4374260	Mean intra-vaginal ejaculatory latency time (Intra-vaginal ejaculatory latency time)	Mean Intra-vaginal ejaculatory latency time was 72 at presentation, 82 for placebo, 150 for tramadol 50 mg, and 272 for tramadol 100 mg (P < 0.001 for all comparisons).
2	3220090	thickness of the keratinized tissue (the keratinized tissue)	The changes from baseline to 6 months were significant in both the groups for PD, clinical attachment level, and recession height; however, for parameters such as recession width, height of the keratinized tissue, and the keratinized tissue significance was seen only in the experimental group. On comparison between two groups, only the keratinized tissue showed statistically significance.
2	3220090	thickness of the keratinized tissue (the keratinized tissue)	It can be concluded that the amount of root coverage obtained with acellular dermal matrix allograft + coronally positioned flap was superior compared to coronally positioned flap alone.
2	4359119	Functional ability	The adjusted between-group difference in the FFbH-R at 12 months was 6.58 (95% CI 3.38 to 9.78) using complete data and 3.56 (95% CI 0.45 to 6.67) using available da-ta, corresponding to significant small-to-medium effect sizes of d=0.42 (p<0.001) and d=0.10 (p=0.025) in favour of PASTOR.
2	4359119	Functional ability	Participants were assessed with self-report measures at baseline, discharge, and 12 months for functional ability (primary outcome) using the Hannover Functional Ability Questionnaire (FFbH-R) and vari-ous secondary outcomes (e.g. pain, health status, physical activity, pain coping, pain-related cognitions).  
1	3466198	detectable L. crispatus or L. jensenii	There were no significant changes in Lactobacillus crispatus or Lactobacillus jensenii in either group but there was a decrease in Gardnerella vaginalis in the Acidform group (p = 0.08).  
0	3466198	The median vaginal and cervical pH	The median vaginal and cervical pH was significantly lower 2 hours after application of Acidform and was associated with an increase in the bactericidal activity of cervicovaginal lavage against E. coli.
0	3466198	cervicovaginal lavage concentrations of lactoferrin and interleukin-1 receptor antagonist (interleukin-1 receptor antagonist), an anti-inflammatory protein,	While there was no increase in inflammatory cytokines or chemokines, cervicovaginal lavage concentrations of lactoferrin and interleukin-1 receptor antagonist (interleukin-1 receptor antagonist), an anti-inflammatory protein, were significantly lower following Acidform compared to hydroxyethylcellulose placebo gel application.
1	3466198	G. vaginalis	There were no significant changes in Lactobacillus crispatus or Lactobacillus jensenii in either group but there was a decrease in Gardnerella vaginalis in the Acidform group (p = 0.08).  
2	3466198	at least one local adverse event	However, 65% of women who received Acidform had at least one local adverse event compared with 11% who received placebo (p = 0.002).
1	5103733	Central venous pressure	No significant differences in hemodynamic parameters, including the central venous pressure and heart rate, were detected between patients in the two groups during the perioperative period or within the first 12 h post-surgery (P>0.05), except for the mean arterial pressure, which was higher in the esmolol group compared with the control group at 5 and 12 h post-surgery (P<0.05).
1	5103733	Heart rate	No significant differences in hemodynamic parameters, including the central venous pressure and heart rate, were detected between patients in the two groups during the perioperative period or within the first 12 h post-surgery (P>0.05), except for the mean arterial pressure, which was higher in the esmolol group compared with the control group at 5 and 12 h post-surgery (P<0.05).
2	5103733	Mean arterial pressure after the surgery	No significant differences in hemodynamic parameters, including the central venous pressure and heart rate, were detected between patients in the two groups during the perioperative period or within the first 12 h post-surgery (P>0.05), except for the mean arterial pressure, which was higher in the esmolol group compared with the control group at 5 and 12 h post-surgery (P<0.05).
0	5103733	Cardiac troponin I during the preoperative period	However, the serum level of cardiac troponin I was higher in patients of the control group compared with those of the esmolol group during the preoperative period (P<0.05).
1	4199615	Blood glucose concentrations over 7.5 hours	The areas under the curves for blood glucose and serum insulin concentrations over 7.5 h did not differ among the four trials.
1	4199615	Blood glucose concentrations over 7.5 hours	Three sessions of 30 min exercise (60% of VO2max) in moderate hypoxia over 7.5 h did not attenuate postprandial glucose and insulin responses in young, overweight men.
2	4199615	%carbohydrate contribution	Although exercise promoted carbohydrate oxidation in the NOR-Ex and HYP-Ex trials, %carbohydrate contribution during each exercise and post-exercise period were significantly higher in the HYP-Ex trial than in the NOR-Ex trial (P<0.05).  
1	4199615	Serum insuline concentrations over 7.5 hours	The areas under the curves for blood glucose and serum insulin concentrations over 7.5 h did not differ among the four trials.
1	3154934	Mortality rates in children who did not receive FU-VAS	Among children who had not received FU-VAS, mortality in the second and third year of life did not differ according to reception of neonatal vitamin A supplementation or placebo.
2	4213554	preeclampsia	Apgar score at 1 min < 7 was lower but preeclampsia was higher in the shared care than in the usual care.  
1	4213554	gestational weeks at delivery	Women in the shared care (n = 339) and usual care (n = 361) groups delivered their infants at similar gestational weeks.
0	4213554	birth weight	Birth weight of infants in the shared care group was lower than that in the usual care group (3469 vs. 3371 grams, P = 0.021).
0	3735552	The mean duration of antibiotic exposure in the subgroup of community-acquired pneumonia (CAP) patients	Mean duration of antibiotic exposure was reduced from 6.3 to 4.5 days under Serum-procalcitonin guidance (−1.8 days; 95% CI −3.1, −0.5; P = 0.039) for all lower respiratory tract infection and from 9.1 to 5.7 days for pneumonia (−3.4 days 95% CI −4.9, −1.7; P<0.001).
1	3735552	Antibiotic prescribing rates	Antibiotic prescribing rates were not significantly different in Serum-procalcitonin guided patients compared to controls (OR 1.26; 95% CI 0.81, 1.95).
2	4560512	IOP-lowering effect	Adjusting for these covariates, FCBT PF had a greater IOP-lowering effect (0.8–1.7 mmHg) in treatment-naïve patients than previously treated patients, which was statistically significant (P≤0.05) at seven of nine time points.  
1	4524824	Illness	None of the animals showed signs of illness 48 hours after the intraperitoneal gastrostomy tube placement.
0	5509647	mean and maximum potentiation	Alcohol consumption resulted in a significant impairment of mean (t = 2.456, df = 13, p = 0.029) and maximum potentiation (t = −2.945, df = 13, p = 0.011) compared to the placebo beverage in the dorsolateral prefrontal cortex and globally.
0	5509647	theta- gamma coupling following Paired associative stimulation	Additionally, the effect of alcohol on PAS-induced potentiation of theta-gamma coupling (an index associated with learning and memory) was examined prior to and following Paired associative stimulation.
0	5509647	theta- gamma coupling following Paired associative stimulation	Alcohol also suppressed the potentiation of theta-gamma coupling by Paired associative stimulation.
2	5506697	Parent rated emotional well being	OFC-treated patients demonstrated an improvement over placebo at endpoint with respect to mean change from baseline in the patient-rated KINDL-R Self-esteem subscale score (p = 0.028), and in the parent KINDL-R ratings of emotional well-being (p = 0.020), Self-esteem (p = 0.030), and Family (p = 0.006).
2	5506697	Parent rated self-esteem	OFC-treated patients demonstrated an improvement over placebo at endpoint with respect to mean change from baseline in the patient-rated KINDL-R Self-esteem subscale score (p = 0.028), and in the parent KINDL-R ratings of emotional well-being (p = 0.020), Self-esteem (p = 0.030), and Family (p = 0.006).
2	5506697	Patient rated self esteem	OFC-treated patients demonstrated an improvement over placebo at endpoint with respect to mean change from baseline in the patient-rated KINDL-R Self-esteem subscale score (p = 0.028), and in the parent KINDL-R ratings of emotional well-being (p = 0.020), Self-esteem (p = 0.030), and Family (p = 0.006).
2	5506697	Children's depression rating scale-revised total score improvement	olanzapine/fluoxetine combination showed significant improvement (p ≤ 0.05) versus placebo on the children's depression rating scale-revised total score and on 7 of the 17 children's depression rating scale-revised items.  
2	3856388	20% reduction in HAM-D score	At three months follow up 100% of the treatment group showed at least a 20% reduction in HAM-D score, while only 69% in the control arm showed at least a 20% reduction in HAM-D score (p<0.001).
0	5674649	Mean of postoperative pain score	Mean of postoperative pain score was significantly lower in ketamine group than others during 24 h after recovery (P < 0.001).
0	5674649	Mean of additive analgesic use during 12 h after recovery	Mean of additive analgesic use was significantly lower in ketamine group during 12 h after recovery (P < 0.001), but it was not significantly different during 12–24 h after recovery (P = 0.12).
1	5674649	Mean of additive analgesic use during 12-24 h after recovery	Mean of additive analgesic use was significantly lower in ketamine group during 12 h after recovery (P < 0.001), but it was not significantly different during 12–24 h after recovery (P = 0.12).
1	5674649	Mean of vomiting frequency and metoclopramide use	Mean of vomiting frequency and metoclopramide use was not different between groups (P > 0.05).
2	5674649	Excellent and good satisfaction score	Excellent and good satisfaction score were significantly higher in ketamine group than other groups (P = 0.04).  
2	5219826	Intermediate and near clarity-of-vision	extend depth-of-focus was significantly better than AOMF for HCVA at 40 cm (0.42 ± 0.18 vs. 0.48 ± 0.22, p = 0.024), stereopsis (98 ± 88 vs. 141 ± 114, p < 0.001), clarity-of-vision at intermediate (8.5 ± 1.6 vs. 7.7 ± 1.9, p = 0.006) and near (7.3 ± 2.5 vs. 6.2 ± 2.5, p = 0.005), lack-of-ghosting (p = 0.012), overall vision satisfaction (7.5 ± 1.7 vs. 6.4 ± 2.2, p < 0.001) and ocular comfort (9.0 ± 1.0 vs. 8.3 ± 1.7, p = 0.002).
2	5219826	High contrast visual acuity at 40 cms	extend depth-of-focus was significantly better than AOMF for HCVA at 40 cm (0.42 ± 0.18 vs. 0.48 ± 0.22, p = 0.024), stereopsis (98 ± 88 vs. 141 ± 114, p < 0.001), clarity-of-vision at intermediate (8.5 ± 1.6 vs. 7.7 ± 1.9, p = 0.006) and near (7.3 ± 2.5 vs. 6.2 ± 2.5, p = 0.005), lack-of-ghosting (p = 0.012), overall vision satisfaction (7.5 ± 1.7 vs. 6.4 ± 2.2, p < 0.001) and ocular comfort (9.0 ± 1.0 vs. 8.3 ± 1.7, p = 0.002).
2	5219826	Overall vision satisfaction and ocular comfort	extend depth-of-focus was significantly better than AOMF for HCVA at 40 cm (0.42 ± 0.18 vs. 0.48 ± 0.22, p = 0.024), stereopsis (98 ± 88 vs. 141 ± 114, p < 0.001), clarity-of-vision at intermediate (8.5 ± 1.6 vs. 7.7 ± 1.9, p = 0.006) and near (7.3 ± 2.5 vs. 6.2 ± 2.5, p = 0.005), lack-of-ghosting (p = 0.012), overall vision satisfaction (7.5 ± 1.7 vs. 6.4 ± 2.2, p < 0.001) and ocular comfort (9.0 ± 1.0 vs. 8.3 ± 1.7, p = 0.002).
2	5219826	Purchase preferance	Significantly more participants chose to only-purchase extend depth-of-focus (33% vs. 6%, p = 0.003).).
0	3843300	serum level of blood urea nitrogen (blood urea nitrogen) and creatinine (creatinine)	The serum level of blood urea nitrogen (blood urea nitrogen) and creatinine (creatinine) in the control group increased significantly (P < 0.05), and administration of N-acetylcysteine (150 mg/kg) decreased the serum levels of creatinine and blood urea nitrogen.
1	3843300	serum level of blood urea nitrogen (blood urea nitrogen)	The serum level of blood urea nitrogen (blood urea nitrogen) and creatinine (creatinine) in the control group increased significantly (P < 0.05), and administration of N-acetylcysteine (150 mg/kg) decreased the serum levels of creatinine and blood urea nitrogen. However, only the serum level of creatinine decreased significantly (P < 0.05).
0	3843300	the lung injury score	N-acetylcysteine did not improve kidney weight and damage; however, its low dose (150 mg/kg) attenuated the lung injury score (P < 0.05) when compared with the control group.
0	4461930	cerebrospinal fluid phosphorylated tau (phosphorylated tau)	Assignment to the active treatment arms was associated with reduction in plasma amyloid-β (amyloid-β) peptides, increase in ventricular volume, decrease in cerebrospinal fluid phosphorylated tau (phosphorylated tau) and several other laboratory measures and adverse event categories.
2	4461930	ventricular volume	Assignment to the active treatment arms was associated with reduction in plasma amyloid-β (amyloid-β) peptides, increase in ventricular volume, decrease in cerebrospinal fluid phosphorylated tau (phosphorylated tau) and several other laboratory measures and adverse event categories.
0	4461930	plasma amyloid-β (amyloid-β) peptides	Assignment to the active treatment arms was associated with reduction in plasma amyloid-β (amyloid-β) peptides, increase in ventricular volume, decrease in cerebrospinal fluid phosphorylated tau (phosphorylated tau) and several other laboratory measures and adverse event categories.
0	4059969	risk of malalignment - conventional total knee arthroplasty (total knee arthroplasty)	Patients operated with fluoroscopy assistance had (1) a lower risk of malalignment at the threshold of >3° (risk ratio, 0.7; 95 % CI, 0.13–1.2), (2) a mean fluoroscopic time of 3 s, and (3) a longer operative time (69 vs. 60 min, p < 0.001).
2	4059969	operative time - conventional total knee arthroplasty (total knee arthroplasty)	Patients operated with fluoroscopy assistance had (1) a lower risk of malalignment at the threshold of >3° (risk ratio, 0.7; 95 % CI, 0.13–1.2), (2) a mean fluoroscopic time of 3 s, and (3) a longer operative time (69 vs. 60 min, p < 0.001).
1	4059969	Knee Score - conventional total knee arthroplasty (total knee arthroplasty)	The American Knee Society Score was not different between the two groups at 1-year follow-up.  
0	5174811	Frequency of sputum production at night-time	In ACCORD, aclidinium reduced night-time cough frequency (−0.36 vs 0.1 for placebo; p<0.001) and severity (−0.24 vs −0.1 for placebo; p<0.05), and frequency of night-time sputum production (−0.37 vs 0.05 for placebo; p<0.001).  
0	5174811	Evaluating Respiratory Symptoms cough/sputum domain scores	Evaluating Respiratory Symptoms cough/sputum domain scores were significantly reduced with aclidinium 400 μg versus placebo in ATTAIN (−0.7 vs −0.3, respectively; p<0.01) and the active-comparator study (−0.6 vs −0.2, respectively; p<0.01).
0	5174811	Evaluating Respiratory Symptoms cough/sputum domain scores	Evaluating Respiratory Symptoms cough/sputum domain scores were significantly reduced with aclidinium 400 μg versus placebo in ATTAIN (−0.7 vs −0.3, respectively; p<0.01) and the active-comparator study (−0.6 vs −0.2, respectively; p<0.01).
0	5174811	Morning cough severity and phlegm	In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (−0.19 vs −0.02; p<0.01) and phlegm (−0.19 vs −0.02; p<0.05).
0	5174811	Night-time cough frequency and severity	In ACCORD, aclidinium reduced night-time cough frequency (−0.36 vs 0.1 for placebo; p<0.001) and severity (−0.24 vs −0.1 for placebo; p<0.05), and frequency of night-time sputum production (−0.37 vs 0.05 for placebo; p<0.001).  
1	5610548	Total Human milk oligosaccharides	Results: HMO and bioactive protein concentrations did not differ between groups (P > 0.10 for all comparisons).
2	3878739	proliferation index of γδ-T cells	The proliferation index of γδ-T cells in culture was almost five times higher after 10 wk of cranberry beverage consumption (p <0.001).
1	3539107	WBC counts	The site of abdominal pain, fever, signs of localized peritonitis, accompanying gastrointestinal symptoms, and white blood cell count showed no differences between the two groups.
2	3539107	mean age of patients	The mean age of patients in the diverticulitis group was significantly older than that of the appendicitis group (49.0 ± 15.2 years vs. 25.4 ± 14.2 years, P < 0.05).
2	3539107	perforation of appendix	Twenty-five patients (65.8%) of the diverticulitis group and 10 patients (10.2%) of the appendicitis group showed perforation of appendix (P < 0.05).
2	3539107	Mean operating time	Mean operating time and postoperative hospital stay were longer in the diverticulitis group (55.3 ± 28.8 minutes vs. 41.4 ± 17.8 minutes, 6.8 ± 3.4 days vs. 4.9 ± 1.5 days, P < 0.05).  
1	3539107	accompanying gastrointestinal symptoms	The site of abdominal pain, fever, signs of localized peritonitis, accompanying gastrointestinal symptoms, and white blood cell count showed no differences between the two groups.
1	3539107	fever	The site of abdominal pain, fever, signs of localized peritonitis, accompanying gastrointestinal symptoms, and white blood cell count showed no differences between the two groups.
2	3539107	Mean duration of preoperative symptoms	Mean duration of preoperative symptoms was longer in the diverticulitis group (3.6 ± 3.8 days vs. 1.8 ± 3.2 days, P < 0.05).
1	3539107	location of pain	The site of abdominal pain, fever, signs of localized peritonitis, accompanying gastrointestinal symptoms, and white blood cell count showed no differences between the two groups.
1	4751474	Medication persistence	In intent-to-treat analyses, intervention was not associated with significant improvement in primary adherence, medication persistence, or intermediate outcomes of care.
1	4751474	Intermediate outcomes of care	In intent-to-treat analyses, intervention was not associated with significant improvement in primary adherence, medication persistence, or intermediate outcomes of care.
1	4751474	LDL cholesterol improvement	This low-intensity intervention did not significantly improve medication adherence or control of glucose, blood pressure, or LDL cholesterol.
1	4751474	Primary adherence	In intent-to-treat analyses, intervention was not associated with significant improvement in primary adherence, medication persistence, or intermediate outcomes of care.
1	2876942	Vomiting	Drug palatability, vomiting, and onset of action of premedication; showed no significant differences between both groups.
1	2876942	Eye opening time	Time of eye opening after discontinuation of sevoflurane showed no significant differences between both groups.
0	2876942	Postoperative agitation	Postoperative agitation score and rescue fentanyl consumption were higher in group M than in group KM on admission to the PACU (P < 0.01).
0	2876942	Fentanyl consumption	Postoperative agitation score and rescue fentanyl consumption were higher in group M than in group KM on admission to the PACU (P < 0.01).
0	2876942	Time for discharge	The time of hospital discharge allowance in group M was longer than in group KM (P < 0.05).  
1	2876942	Palatability	Drug palatability, vomiting, and onset of action of premedication; showed no significant differences between both groups.
0	5820800	telomere length	Adjusted for potential baseline determinants and leukocyte composition, early parenteral nutrition was associated with telomere shortening during paediatric intensive care unit stay as compared with late parenteral nutrition (estimate early versus late parenteral nutrition –0.021 T/S-units, 95% CI −0.038; 0.004, P = 0.01).
1	4747995	AUCinf	Products' systemic exposures were comparable, with 90 % confidence intervals around ratios for AUCinf (0.96; 90 % CI 0.88–1.04) and Cmax (1.04; 90 % CI 0.98–1.11) within standard bioequivalence bounds (90 % CI 0.80–1.25).
1	4747995	Cmax	Products' systemic exposures were comparable, with 90 % confidence intervals around ratios for AUCinf (0.96; 90 % CI 0.88–1.04) and Cmax (1.04; 90 % CI 0.98–1.11) within standard bioequivalence bounds (90 % CI 0.80–1.25).
1	4747995	adverse events	Products' adverse events were similar and consistent with those previously reported.  
2	3599938	Enrollment into the randomized controlled trial	Enrollment into the RCT was also greater among patients followed-up by telephone (59/480, 12.3%) compared to those followed-up by mail (35/472, 7.4%) (relative risk 1.66, 95% confidence interval 1.11 to 2.47, P=0.01).  
2	3599938	Attendance for eligibility screening	Attendance for eligibility screening with the study nurse was more frequent when non-responders were followed-up by telephone (84/480, 17.5%) than by mail (43/472, 9.1%) (relative risk (relative risk) 1.92, 95% confidence interval (confidence interval) 1.36 to 2.71, P < 0.001).
1	5385703	Vitiligo Area Scoring Index score	Despite a continuous reduction in Vitiligo Area Scoring Index score in both groups, according to both physician (P = 0.13) and patient (P = 0.374) assessment oral simvastatin was not statistically more effective than conventional treatment of vitiligo.  
1	3376478	Open communication	Similar effects were found in both the intervention and control group models regarding open communication.
2	3094245	DPT-3/Hepatitis B completion rates	Multivariable analysis revealed a significant improvement of 39% (adjusted RR = 1.39; 95% CI: 1.06-1.81) in DPT-3/Hepatitis B completion rates in the intervention group.  
1	5419060	Sample rejection rate	The sample rejection rate was 0.79% (n = 60) at CHC A, 1.13% (n = 45) at CHC B, 1.64% (n = 38) at CDC C and 1.36% (n = 8) at CDC D pre-training. The rejection rate remained approximately the same post-training (p > 0.05).
2	5419060	Phlebotomy questionnaire score	The average score increased from 63% (95% CI 6.97‒17.03) to 96% (95% CI 16.91‒20.09) at CHC A (p = 0.039), 58% (95% CI 9.09‒14.91) to 93% (95% CI 17.64‒18.76) at CHC B (p = 0.006), 60% (95% CI 8.84‒13.13) to 97% (95% CI 16.14‒19.29) at CDC C (p = 0.001) and 63% (95% CI 9.81‒13.33) to 97% (95% CI 18.08‒19.07) at CDC D (p = 0.001).  
1	5419060	Techinque related rejections	The rejection rate remained approximately the same post-training (p > 0.05).
0	3573831	right breast exposure dose in lumbar spine imaging in both projections (anteroposterior (anteroposterior) and lateral)	On average, breast exposure dose in lumbar spine imaging in both projections (anteroposterior (anteroposterior) and lateral) was found reduced by approximately 80% (p < 0,001) when shielding with 0.5 mm lead equivalent was used (from 0.45±0.25 mGy to 0.09±0.07 mGy on the right and from 0.26±0.14 mGy to 0.06±0.04 mGy on the left breast). No correlation between the body mass index (body mass index) and the breast surface radiation dose was observed.  
0	3573831	left breast exposure dose in lumbar spine imaging in both projections (anteroposterior (anteroposterior) and lateral)	On average, breast exposure dose in lumbar spine imaging in both projections (anteroposterior (anteroposterior) and lateral) was found reduced by approximately 80% (p < 0,001) when shielding with 0.5 mm lead equivalent was used (from 0.45±0.25 mGy to 0.09±0.07 mGy on the right and from 0.26±0.14 mGy to 0.06±0.04 mGy on the left breast).
0	3573831	breast exposure dose in lumbar spine imaging	On average, breast exposure dose in lumbar spine imaging in both projections (anteroposterior (anteroposterior) and lateral) was found reduced by approximately 80% (p < 0,001) when shielding with 0.5 mm lead equivalent was used (from 0.45±0.25 mGy to 0.09±0.07 mGy on the right and from 0.26±0.14 mGy to 0.06±0.04 mGy on the left breast).
2	3159986	Improvement in respiratory endurance	Respiratory endurance time increased from 6.1 ± 0.8 to 20.3 ± 3.0 min (P < 0.001).
2	3159986	Improvement in myasthenia score	Myasthenia score improved from 0.71 ± 0.1 to 0.56 ± 0.1 (P = 0.007).
1	4365008	glutathione peroxidase (glutathione peroxidase) and superoxide dismutase (superoxide dismutase) levels	Similarly, the antioxidant enzymes glutathione peroxidase and superoxide dismutase activity were unchanged by treatments.
1	4365008	concentrations of zinc and selenium of studied groups.	Neither treatment was associated with significant differences in concentrations of zinc or selenium in blood plasma and erythocytes of studied groups.  
0	3972946	Patient's demand and pump's delivery count for bolus dose	Patient's demand and pump's delivery count for bolus dose in Group P were lower than in Group C in all measurement times.
0	3972946	Total analgesic requirements on postoperative 1st and 24th hours	Total analgesic requirements on postoperative 1st and 24th hours in Group P were lower than in Group C. Conclusion.
2	5852865	Macular pigment optical density	In this study, we compared the changes in macular pigment over a 24-week supplementation period for two groups of 24 subjects each assigned to either of two supplement formulations, 20 mg/day of lutein or 20 mg equivalent free carotenoids of a combination of diacetate esters of the macular carotenoids. The latter group responded with a larger increase (0.0666 ± 0.0481) in macular pigment optical density than the former group (0.0398 ± 0.0430), driven largely by the older subjects.
2	5852865	Macular pigment increase when baseline is high	There was a general trend towards smaller increases in macular pigment for those subjects whose baseline value was high. However, the trend was only significant (p < 0.05) for subjects in the diacetate group.
2	3781572	Probabilities of A1C <6.5%	Maintaining mean A1C <6.5% was more likely with glargine (odds ratio [odds ratio] 2.98 [95% CI 2.67–3.32], P < 0.001) than standard care after adjustment for other independent predictors.  
0	5127177	Sedentary habits	Compared with the other groups, the consistent Booster Break attendees had greater weekly pedometer counts (P < .001), significant decreases in sedentary behavior and self-reported leisure-time physical activity (P < .001), and a significant increase in triglyceride concentrations (P = .02) (levels remained within the normal range).
0	5127177	Self-reported leisure-time physical activity	Compared with the other groups, the consistent Booster Break attendees had greater weekly pedometer counts (P < .001), significant decreases in sedentary behavior and self-reported leisure-time physical activity (P < .001), and a significant increase in triglyceride concentrations (P = .02) (levels remained within the normal range).
2	5127177	Pedometer counts per week	Compared with the other groups, the consistent Booster Break attendees had greater weekly pedometer counts (P < .001), significant decreases in sedentary behavior and self-reported leisure-time physical activity (P < .001), and a significant increase in triglyceride concentrations (P = .02) (levels remained within the normal range).
2	4805129	Haemoglobin increase from baseline	Iron isomaltoside 1000 was both non-inferior to oral iron at Week 4 (P < 0.001) and sustained a superior increase in haemoglobin from Week 3 until the end of the study at Week 8 (P = 0.009 at Week 3).
2	4805129	Serum-ferritin	Serum-ferritin and transferrin saturation concentrations were also significantly increased with intravenous iron.
0	4221863	mucositis induced by chemoradiotherapy in head and neck cancer patients	A significant reduction in mucositis was seen among RJ-treated patients compared with controls (P < 0.001).
0	3133979	Pain	Pain (overall level) was significantly less in group A compared with group B (P = 0.004).
1	3133979	Hospital stay	The mean hospital stay was 1.52 ± 0.76 days in group A and 1.70 ± 1.06 days in group B (P = 0.294).
2	3133979	Operative duration	The mean operative duration in group A and B were 47.54 ± 12.82 min and 31.36 ± 11.43 min, respectively (P < 0.001).
1	3133979	Hematoma frequency	The two groups were comparable in terms of other postoperative complications, such as hematoma (P = 0.87), paralytic ileus (P = 0.086), urinary retention (P = 0.504), and wound infection (P = 0.134).  
1	3133979	Paralytic ileus	The two groups were comparable in terms of other postoperative complications, such as hematoma (P = 0.87), paralytic ileus (P = 0.086), urinary retention (P = 0.504), and wound infection (P = 0.134).  
1	3133979	Wound infection	The two groups were comparable in terms of other postoperative complications, such as hematoma (P = 0.87), paralytic ileus (P = 0.086), urinary retention (P = 0.504), and wound infection (P = 0.134).  
2	2635353	Pain reduction	The median pain reduction was significantly greater in the APT group (50.5) than in the PPT (39.2) or "act as usual" group (28.8).  
2	2635353	Improvement on median period of disability	After two months, patients in both the APT and PPT groups showed significant improvement in the median period of disability (active: 14 days; passive: 14 days) compared to the "act as usual" group (49 days).
1	2635353	Improvement in range of motion	After two months, patients in both the APT and PPT groups showed significant improvement in the median period of disability (active: 14 days; passive: 14 days) compared to the "act as usual" group (49 days). No group difference was observed with regard to median improvement in range of motion (active: 120°; passive: 108°; activity as usual: 70°).
1	2635353	Improvement in range of motion	No group difference was observed with regard to median improvement in range of motion (active: 120°; passive: 108°; activity as usual: 70°).
2	2635353	Pain reduction	The median pain reduction was significantly greater in the APT group (50.5) than in the PPT (39.2) or "act as usual" group (28.8).  
0	2867787	ineffective drainage	In Group A, 23 patients had tube malposition, 4 of whom developed associated ineffective drainage, while the patients in Group B had no insertion related complications (p = 0.001).
1	5409660	Vascular cell adhesion protein 1	Results: The mean differences between dry-cured ham and cooked ham followed by a time period adjustment for plasmatic P-selectin and interleukin 6 proteins slightly failed (p = 0.062 and p = 0.049, respectively), notably increased for MCP-1 levels (p = 0.023) while VCAM-1 was not affected.
1	5409660	P-selectin	Results: The mean differences between dry-cured ham and cooked ham followed by a time period adjustment for plasmatic P-selectin and interleukin 6 proteins slightly failed (p = 0.062 and p = 0.049, respectively), notably increased for MCP-1 levels (p = 0.023) while VCAM-1 was not affected.
2	5409660	Monocyte Chemoattractant Protein-1	Results: The mean differences between dry-cured ham and cooked ham followed by a time period adjustment for plasmatic P-selectin and interleukin 6 proteins slightly failed (p = 0.062 and p = 0.049, respectively), notably increased for MCP-1 levels (p = 0.023) while VCAM-1 was not affected.
1	4161265	activity of the hypothalamic area or the trigeminal nuclei	Contrary to earlier findings from animal studies, we could not find an effect of ASA on the trigeminal nuclei in the brainstem or within the hypothalamic area.  
2	4253794	Time needed to intubate	Intubation time was longer in the GlideScope® video-laryngoscope group (9.80 ± 1.27 s) than in the Macintosh direct laryngoscope group (8.20 ± 1.17 s) (P < 0.05).
0	4253794	Increase in Rate pressure product (First 3 minutes)	mean arterial blood pressure, pulse rate, and rate pressure product were lower in the GlideScope® video-laryngoscope than the Macintosh direct laryngoscope group after endotracheal intubation (P < 0.05).
0	4253794	Drop in pulse rate (first 3 minutes)	mean arterial blood pressure, pulse rate, and rate pressure product were lower in the GlideScope® video-laryngoscope than the Macintosh direct laryngoscope group after endotracheal intubation (P < 0.05).
2	4082484	flow-mediated vasodilation (flow-mediated vasodilation)	On the other hand, the consumption of the curry meal increased flow-mediated vasodilation from 5.2 ± 2.5% to 6.6 ± 2.0% (P = 0.001), and the postprandial flow-mediated vasodilation after the curry meal was higher than that after the control meal (P = 0.002).
2	4082484	postprandial flow-mediated vasodilation	On the other hand, the consumption of the curry meal increased flow-mediated vasodilation from 5.2 ± 2.5% to 6.6 ± 2.0% (P = 0.001), and the postprandial flow-mediated vasodilation after the curry meal was higher than that after the control meal (P = 0.002).
1	4082484	systemic and forearm hemodynamics, or any biochemical parameters including oxidative stress markers	Presence of spices in the curry did not alter significantly the systemic and forearm hemodynamics, or any biochemical parameters including oxidative stress markers measured.  
2	5045666	Mean serum levels of vitamin D	The mean serum levels of both high-density lipoprotein cholesterol and vitamin D showed a significant rise following the treatment in the study group (P = 0.007 and P < 0.001, respectively), whereas both variables decreased slightly in the control group (P = 0.27).
2	5045666	Mean serum levels of high-density lipoprotein cholesterol (high-density lipoprotein cholesterol)	The mean serum levels of both high-density lipoprotein cholesterol and vitamin D showed a significant rise following the treatment in the study group (P = 0.007 and P < 0.001, respectively), whereas both variables decreased slightly in the control group (P = 0.27).
1	4344586	energy intake	No differences were observed in lunch meal energy intake among breakfast meals in either trial.
2	4319300	clinical healing	The results of this study suggest that metronidazole and amoxicillin combination as an adjunct to scaling and root planning results in better clinical healing through restoring TIMP-1/MMP-1 balance.
1	4319300	Total MMP-1 levels at 3 months	Total MMP-1 levels were significantly decreased in both groups (P < 0.05) at 3 and 6 months.
1	4319300	Total MMP-1 levels at 6 months	Total MMP-1 levels were significantly decreased in both groups (P < 0.05) at 3 and 6 months.
2	4319300	TIMP-1/MMP-1 balance	TIMP-1/MMP-1 balance was restored in test group at 6 months significantly better than the control group (P < 0.05).  
2	4138383	Self-confidence in applying methods to deal with mental illness	Results four months after randomisation showed that patients with a contract for self-referral appeared to have more confidence in strategies to cope with mental illness and to apply more active cognitive strategies.
0	4138383	Negative feelings	Patients with a contract also expressed less resignation, hopelessness and powerlessness than patients without a contract.
0	3525032	serum cortisol levels after CO2 insufflation	Although no statistically significant differences were observed between and within groups when adrenalin, noradrenalin and dopamine values were compared, serum cortisol levels after CO2 insufflation in PLMA group were significantly lower than the ETT group (p = 0.024).
1	3525032	adrenalin, noradrenalin and dopamine values	Although no statistically significant differences were observed between and within groups when adrenalin, noradrenalin and dopamine values were compared, serum cortisol levels after CO2 insufflation in PLMA group were significantly lower than the ETT group (p = 0.024).
0	1618957	growth hormone	Mean (SE) GH levels were lower with lanreotide Autogel® than with lanreotide microparticles (3·8 (0·5) vs 4·3 (0·5) ng/ml; P < 0·001).
0	4874073	The mean heart rate	The mean heart rate was significantly lower in group D compared to groups E and N at all times of measurement (P < 0.05).
0	4874073	mean arterial pressure (mean arterial pressure)	The mean arterial pressure was found to be significantly lower in group D compared to groups E and N after infusion of study drugs, after induction, just after intubation and 5 min after intubation (P < 0.05).
2	4874073	The Ramsay Sedation Scores	The Ramsay Sedation Scores were significantly higher in group D (score 3 in 46%) when compared to group E (score 2 in 50%) and group N (score 2 in 54%) (P < 0.001).
2	3599792	AUC for the increment in plasma calcium	After repeated concentrations after supplementation with pentacalcium hydroxy-triphosphate administration, the AUC for the increment in plasma calcium concentration was significantly higher compared to placebo.  
2	3599792	Plasma calcium concentration after 240 minutes	concentrations after supplementation with pentacalcium hydroxy-triphosphate supplementation resulted in a significantly higher plasma calcium concentration after 240 min compared to placebo.
2	3599792	Plasma calcium concentration after 240 minutes	concentrations after supplementation with pentacalcium hydroxy-triphosphate supplementation resulted in a significantly higher plasma calcium concentration after 240 min compared to placebo.
0	4717319	risk of relapse	In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447–0.983); p=0.041).
2	4717319	time to relapse	In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447–0.983); p=0.041).
2	4230312	improvement of disorder	Improvements in mean MADRS total scores from baseline to week 8 were significantly greater with quetiapine 300 and 600 mg/day (−15.58 [n = 283] and −14.88 [n = 289]; p < 0.001) compared with placebo (−11.61 [n = 204]).
0	4335741	Vocal cords patency	Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the remifentanil and alfentanil groups and there were no significant differences, but vocal cords were significantly more patent in group remifentanil than those in group alfentanil (P = 0. 028).  
1	4335741	Scores for ease of laryngoscopy	Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the remifentanil and alfentanil groups and there were no significant differences, but vocal cords were significantly more patent in group remifentanil than those in group alfentanil (P = 0. 028).  
1	4335741	Baseline demographic characteristics	There were no demographic data differences between groups (age, weight, and sex).
1	4335741	Jaw relaxation scores	Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the remifentanil and alfentanil groups and there were no significant differences, but vocal cords were significantly more patent in group remifentanil than those in group alfentanil (P = 0. 028).  
1	4335741	Limb movement score	Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the remifentanil and alfentanil groups and there were no significant differences, but vocal cords were significantly more patent in group remifentanil than those in group alfentanil (P = 0. 028).  
1	3103853	Schirmer tear test I	There was no significant difference between groups in phase I.  In phase 2, there was no significant difference in Schirmer tear test I (Schirmer tear test I) results between the two groups, and both groups had a significant increase in Schirmer tear test I over time.
0	3896966	intestinal cholesterol absorption, blood non-HDL cholesterol, and hepatic cholesterol	In confirmation of diet formulation and compound delivery, both the phytosterols and ezetimibe treatments lowered (p < 0.05) intestinal cholesterol absorption (24 and 31%, respectively), blood non-HDL cholesterol (61 and 66%, respectively), and hepatic cholesterol (45 and 55%, respectively) compared with the HF-fed animals.
0	3896966	Blood triglycerides (triglycerides) concentrations	Blood triglycerides concentrations were lower (p < 0.05) in the phytosterols (49%) and ezetimibe (68%)-treated animals compared with the high fat group.
0	4760038	Score of needle visibility	Needle visibility score was better in group II (2.92 ± 0.26 vs. 1.9 ± 0.44, P < 0.0001).
2	4760038	Block performance time	Block performance time was shorter in group II (90.92 ± 15 vs. 128.25 ± 16s, P < 0.0001).
2	4760038	Number of needle passes	A number of needle passes were less in group II (1.27 ± 0.45 vs. 2.2 ± 0.68, P < 0.0001).
1	4760038	Complications	No differences were found regarding the duration of the block and incidence of complications between groups.  
0	4760038	Satisfaction of the patients and physicians	Doctor and patient satisfaction were better in group II (P = 0.015).
2	5868223	Visiting the ophthalmologist	These students, 97.9% in the experimental group and 58.1% in the control group underwent eye examinations from an ophthalmologist (P < 0.05).
2	5868223	Wearing sunglasses on sunny days	The students wearing glasses all in the experimental group and 53.3% in the control group were found to always wear their glasses after the education program was completed (P < 0.05).
0	4963027	Body mass index z-scores in Overweight kids	The body mass index z-score of Intervention group children decreased by -0.13 (95% CI -0.19 to -0.06) and -0.10 (95% CI -0.16 to -0.03), respectively, and the effect was greater in children with obesity.  
1	4134501	The safety profiles	The safety profiles were similar between arms and treatment was well tolerated.
2	5590362	Mean pain score	The lowest mean pain score recorded in the massage group (0.92) whereas it was 4.84 in the breastfeeding group and 6.16 in the control group.
0	5590362	Mean pain score	The lowest mean pain score recorded in the massage group (0.92) whereas it was 4.84 in the breastfeeding group and 6.16 in the control group.
0	2361654	Specificity	Specificity of the primary screening with sole high-risk human papillomavirus test (91.5–92.1%) was much lower than that with the cytology triage (98.7–99.3%), which was not quite as specific as screening with conventional cytology (99.2–99.6%).
0	3994428	Mortality	Six-month mortality was 6.5% in the Intracranial-pressure group and 9.1% in the control group (P < 0.05), and neurological outcome was better in the Intracranial-pressure group compared with the control group (P < 0.05).  
1	3994428	Hematoma enlargement	There was no significant between-group difference in the incidence of hematoma enlargement (control group, 38.6% vs. Intracranial-pressure monitoring group, 32.6%; P > 0.05).
0	3994428	Secondary brain herniation.	The incidence rate of secondary brain herniation in the Intracranial-pressure monitoring group was significantly lower compared with the control group (10.9% vs. 20.5%, P = 0.04).
1	5536130	Tissue coring with needle straight insertion	There was no significant difference in the incidence among different gauge needles, except for a difference in epidermis contamination between the 21-gauge and 23-gauge needles.
1	3298351	venous ulcer healing	However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).  
2	4598910	6-min walking test (6-min walking test) distance	Results showed statistically significant increase in 6-min walking test at the end of the training from 445.6 ± 22.99 to 491.06 ± 17.67 meters? (P < 0.001) and statistically significant decrease in dyspnea from 3.76 ± 0.64 to 1.13 ± 0.36 (P = 0.0001) in the training group but not in the control group.
2	4598910	exercise capacity	The values for exercise capacity and dyspnea improved after 8 weeks in group T in comparison with group C (P = 0.001 and P = 0.0001, respectively).
1	4598910	measure of pulmonary function	No changes were observed in any measure of pulmonary function in both groups.  
0	4293505	Nausea	Incidence of nausea and the need for rescue antiemetics, verbal rating scale (verbal rating scale) 1 hour pain value, ketorolac consumption, and incidence of shivering were significantly lower in group R and group RD, than in group C (P < 0.05).
0	4293505	Pain	Incidence of nausea and the need for rescue antiemetics, verbal rating scale (verbal rating scale) 1 hour pain value, ketorolac consumption, and incidence of shivering were significantly lower in group R and group RD, than in group C (P < 0.05).
0	4293505	Nausea	Incidence of nausea and the need for rescue antiemetics, verbal rating scale (verbal rating scale) 1 hour pain value, ketorolac consumption, and incidence of shivering were significantly lower in group R and group RD, than in group C (P < 0.05). Moreover, these parameters were significantly lower in group RD than in group R (P < 0.05).  
0	4293505	Ketorolac consumption	Incidence of nausea and the need for rescue antiemetics, verbal rating scale (verbal rating scale) 1 hour pain value, ketorolac consumption, and incidence of shivering were significantly lower in group R and group RD, than in group C (P < 0.05).
0	4293505	Ketorolac consumption	Moreover, these parameters were significantly lower in group RD than in group R (P < 0.05).  
0	4293505	Rescue antiemetics	Incidence of nausea and the need for rescue antiemetics, verbal rating scale (verbal rating scale) 1 hour pain value, ketorolac consumption, and incidence of shivering were significantly lower in group R and group RD, than in group C (P < 0.05).
1	2375877	increased ability to identify patients who have a high risk of severe asthma attacks	Post intervention, intervention arm general practitioners were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).
1	2375877	likelihood of providing a written asthma action plan to children	Post intervention, intervention arm general practitioners were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).
2	5928132	PAS-induced Long-term potentiation	Results: As predicted, L-DOPA and rivastigmine resulted in enhanced PAS-induced Long-term potentiation in the dorsolateral prefrontal cortex and dextromethorphan inhibited it compared to placebo.
0	5928132	PAS-induced Long-term potentiation	Results: As predicted, L-DOPA and rivastigmine resulted in enhanced PAS-induced Long-term potentiation in the dorsolateral prefrontal cortex and dextromethorphan inhibited it compared to placebo.
1	5928132	PAS-induced Long-term potentiation	In contrast, baclofen did not significantly suppress PAS-induced Long-term potentiation compared to placebo.  
2	3400348	mean reduction in blood pressure for both systolic blood pressure (SBP) and diastolic blood pressure (DBP)	Treatment with telmisartan-HCTZ induced significantly greater reductions in blood pressure (−31.1/−18.3 mm Hg) than valsartan-HCTZ (−28.4/−16.3 mm Hg; SBP P = 0.0265, diastolic blood pressure P = 0.0041).
1	4960789	Peripheral intravenous catheter failure rates per 1000 hours	peripheral intravenous catheter failure rates per 1000 hours were not significantly different for the volume intervention (4.84 [3 mL] versus 7.44 [10 mL], p = 0.06, log-rank).
1	4960789	Peripheral intravenous catheter failure rates per 1000 hours	peripheral intravenous catheter failure rates per 1000 hours were also not significantly different for the frequency intervention (5.06 [24 hour] versus 7.34 [6 hour], p = 0.05, log-rank).
1	4960789	Peripheral intravenous catheter failure rates per 1000 hours	peripheral intravenous catheter average dwell was 3.1 days. peripheral intravenous catheter failure rates per 1000 hours were not significantly different for the volume intervention (4.84 [3 mL] versus 7.44 [10 mL], p = 0.06, log-rank). peripheral intravenous catheter failure rates per 1000 hours were also not significantly different for the frequency intervention (5.06 [24 hour] versus 7.34 [6 hour], p = 0.05, log-rank).
1	5601935	Quality of fetuses	Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p>0.05).
1	5601935	Number of oocytes or M2 oocytes	Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p>0.05).
1	5601935	Number of follicles	Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p>0.05).
0	5601935	Total number of fetuses	Total number of fetuses were significantly higher in patients who received rFSH + human menopausal gonadotropin (p=0.02).
0	5601935	Fertility outcomes	Fertility outcomes consisted of: live birth rate, chemical pregnancy and clinical pregnancy rate were higher in rFSH + human menopausal gonadotropin group in comparison to rFSH +r-LH group (p<0.05).  
2	2784472	Improvement in Gastrointestinal Symptom Rating Scale (Gastrointestinal Symptom Rating Scale) abdominal pain subscore - in adults with post prandial intestinal gas-related symptoms and no gastrointestinal diagnoses	Measured against the placebo, subjects in the probiotic group achieved significant improvements in Gastrointestinal Symptom Rating Scale abdominal pain subscore (p = 0.046) and the Gastrointestinal Symptom Rating Scale total score (p = 0.048), with a strong trend for improvement on the Gastrointestinal Symptom Rating Scale abdominal distension subscore (p = 0.061).
2	2784472	Improvement in Gastrointestinal Symptom Rating Scale (Gastrointestinal Symptom Rating Scale) total score - in adults with post prandial intestinal gas-related symptoms and no gastrointestinal diagnoses	Measured against the placebo, subjects in the probiotic group achieved significant improvements in Gastrointestinal Symptom Rating Scale abdominal pain subscore (p = 0.046) and the Gastrointestinal Symptom Rating Scale total score (p = 0.048), with a strong trend for improvement on the Gastrointestinal Symptom Rating Scale abdominal distension subscore (p = 0.061).
1	2784472	Improvement in Gastrointestinal Symptom Rating Scale (Gastrointestinal Symptom Rating Scale) abdominal distension subscore - in adults with post prandial intestinal gas-related symptoms and no gastrointestinal diagnoses	Measured against the placebo, subjects in the probiotic group achieved significant improvements in Gastrointestinal Symptom Rating Scale abdominal pain subscore (p = 0.046) and the Gastrointestinal Symptom Rating Scale total score (p = 0.048), with a strong trend for improvement on the Gastrointestinal Symptom Rating Scale abdominal distension subscore (p = 0.061).
1	3118076	Rate of success	The success rate in group I was found to be 80%, which was lower than the success rate in group II which was found to be 90%. On comparison, there is no statistically significant difference in success rate between the two study groups.
1	3118076	Soft tissue parameters	There was no statistically significant difference between the groups over time in parameters like modified plaque index, modified bleeding index, ML and width of keratinized mucosa.
0	3118076	Papillary index score	The mean papillary index score in group II showed a significant increase from when compared to group I.  ABSTRACT.CONCLUSION:. 
1	4608185	Systolic blood pressure	Systolic and diastolic blood pressure did not change significantly over the study for either the ChiRunning or control groups.
1	4608185	Diastolic blood pressure	Systolic and diastolic blood pressure did not change significantly over the study for either the ChiRunning or control groups.
1	4608185	Body mass index	Changes in BMI over time were significantly different from zero in the ChiRunning group (p = 0.04) but not in the control group (slope for ChiRunning −0.05 [−0.1 to −0.002] vs. control −0.01 [−0.06 to 0.04], between slope difference, p = 0.22).
1	4608185	Injury incidence	Self-reported running-related injury (i.e. discomfort leading to a decrease in running) was similar between groups (ChiRunning, 4 [1.2 to 8.4] vs. control, 3 [0.7 to 7.1] injuries per 100 h of running, p = 0.72) although self-reported running-related discomfort (i.e. discomfort that does not lead to changes in running) trended higher in the ChiRunning group (ChiRunning, 10 [5.4 to 16.8] vs. control, 4 [1.5 to 9] reports of discomfort per 100 h of running, p = 0.06).  
1	4608185	Systolic blood pressure	Systolic and diastolic blood pressure did not change significantly over the study for either the ChiRunning or control groups.
1	4608185	Diastolic blood pressure	Systolic and diastolic blood pressure did not change significantly over the study for either the ChiRunning or control groups.
2	4354356	Subjective feelings of rush	Relative to the placebo treatment in patients, heroin significantly increased resting-state functional connectivity of the left putamen within the basal ganglia/limbic network, the extent of which correlated positively with patients' feelings of rush and with the plasma level of morphine.
0	3814649	cleavage and blastocyst rates	However, both cleavage and blastocyst rates were lower (P < 0.001) in the Vitrified group than in the Control, vitrification solution 1 and vitrification solution 1 + VS2 groups (40.9 and 1.6% vs 92.2 and 34.4%, 79.4 and 25.2%, and 80.2 and 20.8%, respectively in Experiment 1, and 25.0 and 1.7% vs 75.3 and 27.2%, 67.9 and 19.5%, and 62.7 and 22.5%, respectively in Experiment 2).  
0	3814649	Cleavage and blastocyst rates	However, both cleavage and blastocyst rates were lower (P < 0.001) in the Vitrified group than in the Control, vitrification solution 1 and vitrification solution 1 + VS2 groups (40.9 and 1.6% vs 92.2 and 34.4%, 79.4 and 25.2%, and 80.2 and 20.8%, respectively in Experiment 1, and 25.0 and 1.7% vs 75.3 and 27.2%, 67.9 and 19.5%, and 62.7 and 22.5%, respectively in Experiment 2).  
2	3608893	Loss in initial weight	Significantly more portion-controlled diet than diabetes self-management education participants lost ⩾5% of initial weight (54.0% vs 14.0%, P<0.0001) and ⩾10% (26.0% vs 6.0%, P<0.0001).
0	3608893	body weight over 6 months in obese patients with type 2 diabetes	While both groups produced significant improvements in weight and HbA1c after 6 months of treatment, portion-controlled diet participants lost 7.3 kg [95% confidence interval (confidence interval): −5.8 to −8.8 kg], compared with 2.2 kg (95% confidence interval: −0.7 to −3.7 kg) in the diabetes self-management education group (P<0.0001).
2	3608893	improvements in HbA1c after 6 months of treatment	HbA1c declined by 0.7% (95% confidence interval: −0.4 to −1.0%) in the portion-controlled diet group, compared with 0.4% (95% confidence interval: −0.1 to −0.7%) in diabetes self-management education (P<0.026).
1	3608893	larger weight losses were associated with greater reductions in HbA1c	Across both groups, larger weight losses were associated with greater reductions in HbA1c (r=0.52, P<0.0001).  
2	5680306	Serum 25(OH)D concentrations	Serum 25(OH)D concentrations increased with vitamin D supplementation compared to placebo (p < 0.001).
1	5680306	NF?B activity	Vitamin D and placebo groups did not differ in any inflammatory markers or nuclear factor kappa-B activity (all p > 0.05).
2	4241940	effect of endurance exercise on neointimal formation in balloon-injured rat	Neointiaml formation in Balloon-induced control was significantly higher than Sham-operated control, but it was significantly recovered in Balloon-induced exercise compared with Balloon-induced control.
2	4241940	effect of endurance exercise on neointimal formation in balloon-injured rat	These data suggest that endurance exercise inhibits neointimal formation and endothelial-dependent relaxation via FOXO expression in balloon-induce atherosclerosis rat model.
0	4241940	Body weight of rats	Body weight is significantly reduced in Balloon-induced exercise compared with Balloon-induced control.
1	4705007	Energy intake	From baseline to 18 months, participants showed statistically significantly lower mean weight (-4.2 kg [95% CI -6.0 to -2.4]; P<.001) and higher physical activity (mean 10.4 mins/day [95% CI 3.6-17.2]; P=.003), but no significant differences in energy intake (P=.200).
0	4705007	mean weight, physical activity	From baseline to 18 months, participants showed statistically significantly lower mean weight (-4.2 kg [95% CI -6.0 to -2.4]; P<.001) and higher physical activity (mean 10.4 mins/day [95% CI 3.6-17.2]; P=.003), but no significant differences in energy intake (P=.200).
2	4705007	physical activity	From baseline to 18 months, participants showed statistically significantly lower mean weight (-4.2 kg [95% CI -6.0 to -2.4]; P<.001) and higher physical activity (mean 10.4 mins/day [95% CI 3.6-17.2]; P=.003), but no significant differences in energy intake (P=.200).
2	5337766	The duration of stimulation	The duration of stimulation was significantly longer in group C than in groups A and D (P=0.030).
2	5337766	The serum estradiol level	The serum estradiol level was significantly higher in group D than in groups B and C (P=0.005).
0	5337766	The number of ampoules of Follicle Stimulating Hormone (FSG)	Group D patients required significantly fewer ampoules of FSH than did the women in groups A, B, and C (P=0.004).
1	4691672	association between flavonoid subclasses and site of colorectal cancer	Intakes of flavonoid subclasses were not associated with risk of colorectal cancer in either cohort.
1	4691672	Intakes of flavonoid subclasses associated with risk of colorectal cancer (CRC)	Intakes of flavonoid subclasses were not associated with risk of colorectal cancer in either cohort.
1	4744284	shoulder abduction, external rotation, internal rotation range of movements & Shoulder Pain and Disability Index (Shoulder Pain and Disability Index) after 5 weeks	After 5 weeks of intervention both groups made significant improvements in all outcome measures (p < 0.001). Intra group analysis showed no significant difference between two groups (p > 0.05).
0	2699080	The duration of analgesic requirement	The duration of analgesic requirement was also significantly less in laparoscopic group.
0	2699080	The postoperative hospital stay	The postoperative hospital stay in laparoscopic was mean 3.14 Days (2-7 days) significantly less than the open group mean of 8.29 days (7-11 days).  
0	3269087	Emotional symptoms	The total quality of life score in the two groups before therapy did not show any significant difference (P = 0.351); while 12 weeks after education there was a significant difference between the two groups (P < 0.001) in three items including abdominal symptoms (P = 0.01), worry (P < 0.001) and emotional factors (P < 0.001).
0	3269087	Abdominal symptoms	The total quality of life score in the two groups before therapy did not show any significant difference (P = 0.351); while 12 weeks after education there was a significant difference between the two groups (P < 0.001) in three items including abdominal symptoms (P = 0.01), worry (P < 0.001) and emotional factors (P < 0.001).
0	3269087	Worry	The total quality of life score in the two groups before therapy did not show any significant difference (P = 0.351); while 12 weeks after education there was a significant difference between the two groups (P < 0.001) in three items including abdominal symptoms (P = 0.01), worry (P < 0.001) and emotional factors (P < 0.001).
1	3269087	Activity	The other three items did not show a significant difference between the two groups.
1	3269087	Systemic symptoms	The other three items did not show a significant difference between the two groups.
1	4371718	Osteocalcin	Although serum levels of osteocalcin and alkaline phosphatase biomarkers and total serum calcium were not significantly different within and between study groups, their levels were increased in tail suspension model compared to control group.
1	4371718	Alkaline phosphatase	Although serum levels of osteocalcin and alkaline phosphatase biomarkers and total serum calcium were not significantly different within and between study groups, their levels were increased in tail suspension model compared to control group.
1	4371718	Alkaline phosphatase	The levels of these biomarkers were lower in those who were submitted to tail suspension model and received calcitriol supplementation compared to those who were only submitted to tail suspension (60.14 ± 11.73 ng/mL vs. 58.29 ± 2.69 ng/mL; p = 0.696 for osteocalcin and 381.86 ± 99.16 mU/mL vs. 362.57 ± 27.41 ng/mL; p = 0.635 for alkaline phosphatase).  
1	4371718	Alkaline phosphatase	The levels of these biomarkers were lower in those who were submitted to tail suspension model and received calcitriol supplementation compared to those who were only submitted to tail suspension (60.14 ± 11.73 ng/mL vs. 58.29 ± 2.69 ng/mL; p = 0.696 for osteocalcin and 381.86 ± 99.16 mU/mL vs. 362.57 ± 27.41 ng/mL; p = 0.635 for alkaline phosphatase).  
1	4371718	Calcium	Although serum levels of osteocalcin and alkaline phosphatase biomarkers and total serum calcium were not significantly different within and between study groups, their levels were increased in tail suspension model compared to control group.
1	4371718	Osteocalcin	Although serum levels of osteocalcin and alkaline phosphatase biomarkers and total serum calcium were not significantly different within and between study groups, their levels were increased in tail suspension model compared to control group.
2	4731919	Dental flossing	The intervention yielded effects on flossing frequency (p < 0.01) and flossing intentions (p < 0.01) at follow-up.
2	4731919	Flossing intentions	The intervention yielded effects on flossing frequency (p < 0.01) and flossing intentions (p < 0.01) at follow-up.
2	5346637	post-treatment vascular endothelial growth factor (vascular endothelial growth factor) levels	A significant post-treatment increase in vascular endothelial growth factor levels was observed in the PCR-B arm (29.77 to 57.05 pg/mL); in the PCR-B arm, lower baseline CCL-3 levels were significantly associated with achievement of complete remission (p = 0.01).
1	5346637	treatment-free survival (treatment-free survival)	Patients treated with PCR-B had a trend for a higher complete remission (complete remission) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).
1	5346637	treatment-free survival (treatment-free survival)	No differences in progression-free survival and treatment-free survival by IGHV mutational status were observed with the addition of bevacizumab.
0	5346637	CCL-3 levels with achievement of complete remission (complete remission)	A significant post-treatment increase in vascular endothelial growth factor levels was observed in the PCR-B arm (29.77 to 57.05 pg/mL); in the PCR-B arm, lower baseline CCL-3 levels were significantly associated with achievement of complete remission (p = 0.01).
1	5346637	progression-free survival and treatment-free survival by IGHV mutational status	No differences in progression-free survival and treatment-free survival by IGHV mutational status were observed with the addition of bevacizumab.
1	5346637	complete remission (complete remission) rate	Patients treated with PCR-B had a trend for a higher complete remission (complete remission) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).
1	5346637	progression-free survival (progression-free survival)	Patients treated with PCR-B had a trend for a higher complete remission (complete remission) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).
1	5346637	progression-free survival (progression-free survival)	In conclusion, the addition of bevacizumab to chemoimmunotherapy in chronic lymphocytic leukemia is generally well-tolerated and appears to prolong progression-free survival and treatment-free survival.
2	5448649	Progression�free survival	The PPV/CPA arm showed significantly better progression‐free survival (median time: 6.1 vs 2.9 months; hazard ratio (hazard ratio): 0.427; P = 0.008) and overall survival (median time: 12.1 vs 5.9 months; hazard ratio: 0.376; P = 0.004), compared to the personalized peptide vaccination alone arm.
0	5448649	IL�6	The personalized peptide vaccination alone arm, but not the PPV/CPA arm, showed significant increase in plasma IL‐6 after vaccinations, which might be associated with inhibition of antigen‐specific T cell responses.
2	5448649	Overall survival	The PPV/CPA arm showed significantly better progression‐free survival (median time: 6.1 vs 2.9 months; hazard ratio (hazard ratio): 0.427; P = 0.008) and overall survival (median time: 12.1 vs 5.9 months; hazard ratio: 0.376; P = 0.004), compared to the personalized peptide vaccination alone arm.
0	4923578	High-sensitivity C-reactive protein	After 12 weeks of treatment, plasma concentrations of high-sensitivity C-reactive protein (high-sensitivity C-reactive protein), interleukin-6 (interleukin-6), tumor necrosis factor-α (tumor necrosis factor-α), and matrix metalloproteinase-9 (matrix metalloproteinase-9) were significantly decreased in pioglitazone group compared to the Con group (P = 0.035, 0.011, 0.008, and 0.012, resp.).
0	4923578	Interleukin-6	After 12 weeks of treatment, plasma concentrations of high-sensitivity C-reactive protein (high-sensitivity C-reactive protein), interleukin-6 (interleukin-6), tumor necrosis factor-α (tumor necrosis factor-α), and matrix metalloproteinase-9 (matrix metalloproteinase-9) were significantly decreased in pioglitazone group compared to the Con group (P = 0.035, 0.011, 0.008, and 0.012, resp.).
0	4923578	Tumor necrosis factor-α	After 12 weeks of treatment, plasma concentrations of high-sensitivity C-reactive protein (high-sensitivity C-reactive protein), interleukin-6 (interleukin-6), tumor necrosis factor-α (tumor necrosis factor-α), and matrix metalloproteinase-9 (matrix metalloproteinase-9) were significantly decreased in pioglitazone group compared to the Con group (P = 0.035, 0.011, 0.008, and 0.012, resp.).
0	4923578	Matrix metalloproteinase-9	After 12 weeks of treatment, plasma concentrations of high-sensitivity C-reactive protein (high-sensitivity C-reactive protein), interleukin-6 (interleukin-6), tumor necrosis factor-α (tumor necrosis factor-α), and matrix metalloproteinase-9 (matrix metalloproteinase-9) were significantly decreased in pioglitazone group compared to the Con group (P = 0.035, 0.011, 0.008, and 0.012, resp.).
1	1868022	Cervicovaginal lavages levels of IL-8, IL-1β and IL-6	While CVL levels of IL-8, IL-1β and IL-6 remained unchanged following a Pap smear, markers of cell mediated immunity (IL-12 p70 and TNF-α) and T cell regulation (IL-10) were significantly elevated.
2	1868022	Levels of IL-12 p70 and TNF-α	While CVL levels of IL-8, IL-1β and IL-6 remained unchanged following a Pap smear, markers of cell mediated immunity (IL-12 p70 and TNF-α) and T cell regulation (IL-10) were significantly elevated.
2	1868022	Levels of IL-10	While CVL levels of IL-8, IL-1β and IL-6 remained unchanged following a Pap smear, markers of cell mediated immunity (IL-12 p70 and TNF-α) and T cell regulation (IL-10) were significantly elevated.
0	4610088	rescue analgesia (morphine) postoperatively	Saline group required more rescue analgesia (morphine) postoperatively (P < 0.001).
1	4610088	psychotomimetic symptoms	No significant psychotomimetic symptoms were noted in either group.  
1	4910973	Time until definitive deterioration of pain	Cox multivariate analysis showed no statistically significant difference in TUDD for most of the QLQ-C30 scales between treatments.
1	4910973	Time until definitive deterioration of insomnia	Cox multivariate analysis showed no statistically significant difference in TUDD for most of the QLQ-C30 scales between treatments.
1	5498096	pain intensity and functional disability	However, the result showed that there was no significant difference in the pain intensity and functional disability at the 8th week (P>0.05) of the treatment sessions across the three groups when compared.
2	5803937	knowledge score	In the experimental group, the knowledge score was increased significantly from 9 ± 2.2 at baseline to 23.6 ± 1.5 after the intervention.
2	3511173	Stools per week	The number of stools/week was 9.2 ± 3.2 (mean ± SD) in the PEG-only group and 7.8 ± 2.4 in the PEG-electrolyte group (p = 0.025); the number of days with stool was 22.4 ± 5.1 in the PEG-only group and 19.6 ± 7.2 in the PEG-electrolyte group (p = 0.034).  
2	3511173	Days with stools	The number of stools/week was 9.2 ± 3.2 (mean ± SD) in the PEG-only group and 7.8 ± 2.4 in the PEG-electrolyte group (p = 0.025); the number of days with stool was 22.4 ± 5.1 in the PEG-only group and 19.6 ± 7.2 in the PEG-electrolyte group (p = 0.034).  
1	3511173	Taking >80% of the prescribed dose	The difference between the percentage of subjects who took > 80% of the prescribed dose was in favour of the PEG-only group (98% vs. 88%), though it did not reach a conventional statistical level (p = 0.062).  
0	3511173	Difficulties associated with treatment	In the PEG-only group, 96% of patients did not demonstrate any difficulties associated with treatment, as compared with 52% of patients in the PEG-electrolyte group (p < 0.001).
2	3511173	Good taste	Also, the PEG-only formulation taste was better than that of PEG-electrolyte (p < 0.001).
1	4188585	The maximum difference in summed pain intensity differences (SPID)	No differences in SPID between treatments were observed at 2 and 3 months after patch application.
1	4188585	intraepidermal nerve fiber density (intraepidermal nerve fiber density) to 1 month	Changes in intraepidermal nerve fiber density on the pain side, from baseline to 1 month after patch application, did not differ between capsaicin and placebo treatment: 1.9 [−0.1 to 3.9] and 0.6 [−1.2 to 2.5] fibers/mm, respectively (P = 0.32).
2	5597285	bradykinin	Bradykinin increased at 45 min post-exercise only for 80% of LT (P=0.013), but was unrelated to the decrease in glucose (r=-0.16, P=0.642).
0	5597285	glucose level	Both exercise sessions elicited a parallel decrease in glucose level during exercise (P≤0.002), with a greater decrease being observed for 120%LT (P=0.005). Glucose decreased 22.7 mg/dL (95%CI=10.3 to 35, P=0.001) at the 45 min post-exercise recovery period for 80% of LT and decreased 31.2 mg/dL (95%CI=18.1 to 44.4, P<0.001) for 120%LT (P=0.004).
2	2500197	Ability to communicate about sex	Compared with controls at nine months, parents and adolescents in the intervention group reported greater ability to communicate with each other about sex (P<0.001) and more openness in communication about sex (P<0.001).  
2	2500197	Openness in communication about sex	Compared with controls at nine months, parents and adolescents in the intervention group reported greater ability to communicate with each other about sex (P<0.001) and more openness in communication about sex (P<0.001).  
2	2500197	Mean number of new sexual topics discussed	Results Differences between intervention and control groups were significant for the mean number of new sexual topics that parents and adolescents reported discussing between baseline and each follow-up (P<0.001 for each); intervention parents were less likely than controls to discuss no new topics (8% v 29%, 95% confidence interval for difference 16% to 24%) and more likely to discuss seven or more new topics (38% v 8%, 19% to 41%) at nine months.
2	2500197	Condom usage review	Some differences increased after completion of the programme: at one week after the programme, 18% of adolescents in the intervention group and 3% in the control group (6% to 30%) said that their parents had reviewed how to use a condom since baseline (P<0.001); this grew to 29% v 5% (13% to 36%) at nine months (P<0.001).
1	4260384	probing depth changes	Both the treatments resulted in significant recession depth reduction (P < 0.001), but the reduction was significantly greater (P < 0.01) for Group B than Group A. The probing depth changes were significant (P < 0.01) for both groups, but the difference was nonsignificant.
2	4260384	keratinized tissue	The width of keratinized tissue was also significantly (P < 0.001) increased in both groups, but the increase was significantly greater (P < 0.001) in group B (2.30 ± 1.06 mm) than in group A (1.21 ± 0.67 mm).  
1	5957406	gastrointestinal (gastrointestinal) side effects	No gastrointestinal (gastrointestinal) side effects were reported during the entire protocol.
2	5957406	The overall Fight Gone Bad (Fight Gone Bad)	The overall Fight Gone Bad performance improved under Sodium bicarbonate by ~6.1% (p<0.001) and it was ~3.1% higher compared to post placebo (PLApost) (p = 0.040).
2	5957406	maximum carbon dioxide production	Furthermore, the maximum carbon dioxide production increased under Sodium bicarbonate by ~4.8% (from ~3604 mL∙min-1 to ~3776 mL∙min-1, p = 0.049).
2	5957406	time to ventilatory threshold (ventilatory threshold), workload at ventilatory threshold and heart rate at ventilatory threshold in incremental cycling (incremental cycling)	Moreover, in incremental cycling, the time to ventilatory threshold (ventilatory threshold) (~8:25 min SBpost vs. ~8:00 min PLApost, p = 0.020), workload at ventilatory threshold (~218 W SBpost vs. ~208 W PLApost, p = 0.037) and heart rate at ventilatory threshold (~165 bpm SBpost vs. ~161 bpm PLApost, p = 0.030) showed higher SBpost than PLApost.
2	5957406	Pyruvate concentration and creatine kinase activity before incremental cycling (incremental cycling)	Pyruvate concentration and creatine kinase activity before incremental cycling showed higher SBpost than PLApost (~0.32 mmol∙L-1 vs. ~0.26 mmol∙L-1, p = 0.001; ~275 U∙L-1 vs. ~250 U∙L-1, p = 0.010, respectively).
0	2741450	Systolic blood pressure	However, there was a significant decrease in systolic blood pressure in the pedometer group (112.8 ± 2.44 mm Hg) compared to the control group (117.3 ± 2.03 mm Hg) (p = 0.003).  
1	5491162	Clinical remission rate	No significant differences were observed between the two groups with respect to primary and secondary outcomes.  
1	5491162	Clinical remission rate	Primary outcomes were the percentage reduction in urinary protein excretion from baseline and the rate of patients with hematuria disappearance 36 months after study initiation. Secondary outcomes were the rate of patients with proteinuria disappearance, clinical remission rate, absolute changes in estimated glomerular filtration rate from baseline, and the change in daily dose of prednisolone.
1	5491162	Changes in estimated glomerular filtration rate	No significant differences were observed between the two groups with respect to primary and secondary outcomes.  
1	5491162	Change in daily dose of prednisolone	No significant differences were observed between the two groups with respect to primary and secondary outcomes.  
1	5491162	Reduction in proteinuria	Secondary outcomes were the rate of patients with proteinuria disappearance, clinical remission rate, absolute changes in estimated glomerular filtration rate from baseline, and the change in daily dose of prednisolone. Forty-two patients were randomly assigned to Mizoribine (n = 21) and control groups (n = 21). Nine patients in Mizoribine group and 15 patients in the control group completed the study. No significant differences were observed between the two groups with respect to primary and secondary outcomes.  
1	4786378	Score on knowledge test	For the knowledge tests, there was no statistically significant difference between the groups (P = 0.14).
1	4786378	Assessment checklist score	Results: The median score on the assessment checklist was 75% for the intervention group and 70% for the control group (P = 0.32).
2	3890270	VO2max	The post intervention change in VO2max was +1.01 in the aerobic interval training, −0.06 in the maximal volitional interval training and −1.03 in the walking subgroups. The aerobic interval training subgroup increased VO2max compared to walking (p = 0.03).
1	4065461	Admission rates	ABSTRACT.RESULTS:. Patients who had received dexamethasone + epinephrine exhibited similar admission rates compared to placebo + epinephrine or salbutamol (P = 0.64).
1	4065461	Admission rates	Similarly, no statistically significant difference was observed in the rate of hospitalization for patients who received dexamethasone + salbutamol compared to those who received placebo + epinephrine or salbutamol (P = 0.51).
2	4065461	Heart rate	Treatment with dexamethasone + epinephrine resulted in a statistically significant change in HR over time (P < 0.005) compared to the other groups.  
1	4065461	Admission rates	ABSTRACT.RESULTS:. Patients who had received dexamethasone + epinephrine exhibited similar admission rates compared to placebo + epinephrine or salbutamol (P = 0.64).
1	4065461	Admission rates	ABSTRACT.RESULTS:. Patients who had received dexamethasone + epinephrine exhibited similar admission rates compared to placebo + epinephrine or salbutamol (P = 0.64).
2	4065461	Heart rate	Treatment with dexamethasone + epinephrine resulted in a statistically significant change in HR over time (P < 0.005) compared to the other groups.  
0	5648411	Vascular Endothelial Growth Factor (Vascular Endothelial Growth Factor)	Vascular Endothelial Growth Factor in intervention group significantly reduced compared to placebo group (Mean ± SD, 4.5±1.91 vs. 7.8±3.21; P<0.001).
1	5648411	interleukin-8 (interleukin-8)	Vascular Endothelial Growth Factor in intervention group significantly reduced compared to placebo group (Mean ± SD, 4.5±1.91 vs. 7.8±3.21; P<0.001). interleukin-8 in intervention group decreased compared to placebo group but not significant (2.7±1.91 vs. 3.2±3.20; P=0.49).
1	5741844	amount of the smear layer remaining in the coronal third	The results of the study showed the least amount of the smear layer at coronal, middle and apical thirds of the root canals in groups 2, which was not significantly different from the negative control group (P<0.5).  
1	5741844	amount of the smear layer at coronal, middle and apical thirds of the root canals	The results of the study showed the least amount of the smear layer at coronal, middle and apical thirds of the root canals in groups 2, which was not significantly different from the negative control group (P<0.5).  
2	4541185	duration of sensory and motor block	The duration of both sensory and motor block were significantly prolonged by clonidine (P < 0.001).
2	4541185	duration of analgesia	The duration of analgesia was also prolonged in patients receiving clonidine (613.10 ± 51.797 min vs. 878.33 ± 89.955 min).
1	3293068	measures of fluid retention	No differences were noted between coconut water (CW or coconut water from concentrate) and sport drink for any measures of fluid retention (p > 0.05).
1	3293068	fluid retention (based on body mass)	No differences were noted between coconut water (CW or coconut water from concentrate) and sport drink for any measures of fluid retention (p > 0.05).
0	5801479	gene expression of transforming growth factor beta (TGF-?), protein kinase C (protein kinase C), mitogen-activated protein kinases 1 (mitogen-activated protein kinases 1)	Results: Results of RT-PCR indicated that after the 12-week intervention, compared to the placebo, vitamin D supplementation downregulated gene expression of interleukin (IL)-1β (P = 0.02), tumor necrosis factor alpha (tumor necrosis factor alpha) (P = 0.02) and interferon gamma (interferon gamma) (P = 0.03) in peripheral blood mononuclear cells of diabetic hemodialysis patients. Additionally, vitamin D supplementation, compared to the placebo, downregulated gene expression of transforming growth factor beta (transforming growth factor beta) (P = 0.04), protein kinase C (protein kinase C) (P = 0.001), and mitogen-activated protein kinases 1 (mitogen-activated protein kinases 1) (P = 0.02) in peripheral blood mononuclear cells of diabetic hemodialysis patients.
1	5801479	nuclear factor kappa B (nuclear factor kappa B), interleukin (IL)-4, IL-6, and vascular endothelial growth factor (vascular endothelial growth factor)	Although not significant, vitamin D supplementation let to a reduction of nuclear factor kappa B (nuclear factor kappa B) (p = 0.75) expression in peripheral blood mononuclear cells isolated from diabetic patients compared to the placebo group. There was no statistically significant change following supplementation with vitamin D on gene expression of interleukin (IL)-4, IL-6, and vascular endothelial growth factor (vascular endothelial growth factor) in peripheral blood mononuclear cells of diabetic hemodialysis patients.  
0	5801479	gene expression of interleukin (interleukin), tumor necrosis factor alpha (TNF-?), interferon gamma (IFN-?)	Results: Results of RT-PCR indicated that after the 12-week intervention, compared to the placebo, vitamin D supplementation downregulated gene expression of interleukin (IL)-1β (P = 0.02), tumor necrosis factor alpha (tumor necrosis factor alpha) (P = 0.02) and interferon gamma (interferon gamma) (P = 0.03) in peripheral blood mononuclear cells of diabetic hemodialysis patients.
2	4868921	Performance in reverse Stroop	Results: Compared to WL, results revealed that LT improved inhibition performance in executive functions (Stroop: LT (Mean = 3.88) vs. WL (Mean = 1.22), adjusted p = 0.013 and reverse Stroop LT (Mean = 3.22) vs. WL (Mean = 1.59), adjusted p = 0.015), verbal episodic memory (Logical Memory (Logical Memory): LT (Mean = 4.59) vs. WL (Mean = 2.47), adjusted p = 0.015), focus attention (D-CAT: LT (Mean = 2.09) vs. WL (Mean = −0.59), adjusted p = 0.010) and processing speed compared to the WL control group (digit symbol coding: LT (Mean = 5.00) vs. WL (Mean = 1.13), adjusted p = 0.015 and Symbol Search (Symbol Search): LT (Mean = 3.47) vs. WL (Mean = 1.81), adjusted p = 0.014).  
2	4868921	Logical Memory	Results: Compared to WL, results revealed that LT improved inhibition performance in executive functions (Stroop: LT (Mean = 3.88) vs. WL (Mean = 1.22), adjusted p = 0.013 and reverse Stroop LT (Mean = 3.22) vs. WL (Mean = 1.59), adjusted p = 0.015), verbal episodic memory (Logical Memory (Logical Memory): LT (Mean = 4.59) vs. WL (Mean = 2.47), adjusted p = 0.015), focus attention (D-CAT: LT (Mean = 2.09) vs. WL (Mean = −0.59), adjusted p = 0.010) and processing speed compared to the WL control group (digit symbol coding: LT (Mean = 5.00) vs. WL (Mean = 1.13), adjusted p = 0.015 and Symbol Search (Symbol Search): LT (Mean = 3.47) vs. WL (Mean = 1.81), adjusted p = 0.014).  
2	4868921	Focus attention	Results: Compared to WL, results revealed that LT improved inhibition performance in executive functions (Stroop: LT (Mean = 3.88) vs. WL (Mean = 1.22), adjusted p = 0.013 and reverse Stroop LT (Mean = 3.22) vs. WL (Mean = 1.59), adjusted p = 0.015), verbal episodic memory (Logical Memory (Logical Memory): LT (Mean = 4.59) vs. WL (Mean = 2.47), adjusted p = 0.015), focus attention (D-CAT: LT (Mean = 2.09) vs. WL (Mean = −0.59), adjusted p = 0.010) and processing speed compared to the WL control group (digit symbol coding: LT (Mean = 5.00) vs. WL (Mean = 1.13), adjusted p = 0.015 and Symbol Search (Symbol Search): LT (Mean = 3.47) vs. WL (Mean = 1.81), adjusted p = 0.014).  
2	4868921	Performance in Stroop	Results: Compared to WL, results revealed that LT improved inhibition performance in executive functions (Stroop: LT (Mean = 3.88) vs. WL (Mean = 1.22), adjusted p = 0.013 and reverse Stroop LT (Mean = 3.22) vs. WL (Mean = 1.59), adjusted p = 0.015), verbal episodic memory (Logical Memory (Logical Memory): LT (Mean = 4.59) vs. WL (Mean = 2.47), adjusted p = 0.015), focus attention (D-CAT: LT (Mean = 2.09) vs. WL (Mean = −0.59), adjusted p = 0.010) and processing speed compared to the WL control group (digit symbol coding: LT (Mean = 5.00) vs. WL (Mean = 1.13), adjusted p = 0.015 and Symbol Search (Symbol Search): LT (Mean = 3.47) vs. WL (Mean = 1.81), adjusted p = 0.014).  
2	4868921	Digit symbol coding speed	Results: Compared to WL, results revealed that LT improved inhibition performance in executive functions (Stroop: LT (Mean = 3.88) vs. WL (Mean = 1.22), adjusted p = 0.013 and reverse Stroop LT (Mean = 3.22) vs. WL (Mean = 1.59), adjusted p = 0.015), verbal episodic memory (Logical Memory (Logical Memory): LT (Mean = 4.59) vs. WL (Mean = 2.47), adjusted p = 0.015), focus attention (D-CAT: LT (Mean = 2.09) vs. WL (Mean = −0.59), adjusted p = 0.010) and processing speed compared to the WL control group (digit symbol coding: LT (Mean = 5.00) vs. WL (Mean = 1.13), adjusted p = 0.015 and Symbol Search (Symbol Search): LT (Mean = 3.47) vs. WL (Mean = 1.81), adjusted p = 0.014).  
1	4967427	Average work incapacity	Results Average work incapacity over the 6-year follow-up, including contributions from daily allowances and permanent losses from disability, was slightly but insignificantly higher under intensive case management than under standardcase management (21.6 vs. 21.3 % of pre-accident work capacity).
2	4967427	Treatment costs	Treatment costs were 43,500 Swiss Francs (CHF) in intensive case management compared to 39,800 in standardcase management (+9.4 %, p = 0.01).
1	3208043	Pain relief at 24h - menstrually related migraine	At 24 h, 67 and 81% of frovatriptan-treated, and 61 and 74% of rizatriptan-treated patients were pain free and had pain relief, respectively (p = NS).
0	3208043	Recurrence at 24h - menstrually related migraine	Recurrence at 24 h was significantly (p < 0.01) lower with frovatriptan (10 vs. 32% rizatriptan).
1	3208043	Pain relief at 2h - menstrually related migraine	Rate of pain relief at 2 h was 58% for frovatriptan and 64% for rizatriptan (p = NS), while rate of pain free at 2 h was 31 and 34% (p = NS), respectively.
1	3616124	preeclampsia risk	Haptoglobin's phenotype does not influence preeclampsia risk, or identify a subset of women who may benefit from vitamin C and E supplementation to prevent preeclampsia.
1	3616124	risk of the primary outcome or preeclampsia	Vitamin supplementation did not reduce the risk of the primary outcome or preeclampsia in women of any phenotype.
0	4204994	percentages of migrated isoforms (percentages of migrated isoforms) on days 4 and 11	Low-dose Epoetin beta decreased percentages of migrated isoforms on days 4 and 11 to 46.0 (12.8)% (p<0.00001) and 46.1 (10.4)% (p<0.00001).
0	4204994	percentages of migrated isoforms (percentages of migrated isoforms) on day 25	In both recombinant human EPO groups, percentages of migrated isoforms on day 25 was still decreased (high-dose Epoetin beta: 72.9 (19.4)% (p = 0.029); low-dose Epoetin beta: 73.1 (17.8)% (p = 0.039)).
1	4251531	The sum CTC-NCI toxicity score	The sum CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group but significantly in the placebo group (P=0.05).
1	4251531	The sum CTC-NCI toxicity score	The sum CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group but significantly in the placebo group (P=0.05). The difference in increase between groups did not meet the level of significance (P=0.12). The sum toxicity score was reduced in the patients receiving 64 days of BP-C1 from 9.2 at screening to 8.9 at Day 48, but it increased again to 10.1 by Day 64 and 10.6 during the 28-day follow-up.
1	4251531	The sum CTC-NCI toxicity score	The difference in increase between groups did not meet the level of significance (P=0.12).
0	4251531	"Breast cancer-related pain and discomfort� and "Breast cancer treatment problem last week�	"Breast cancer-related pain and discomfort" and "Breast cancer treatment problem last week" were significantly reduced (P=0.02) in the BP-C1 group but increased slightly in the placebo group; between-group differences were significant in favor of BP-C1 (P=0.05).
0	4251531	The sum of target lesions	The sum of target lesions increased 2.4% in the BP-C1 group and 14.3% in the placebo group. Only the increase in the placebo group was significant (P=0.013).
2	4251531	Response Evaluation Criteria In Solid Tumors (Response Evaluation Criteria In Solid Tumors) classification	There was a significant difference (P=0.026) in favor of BP-C1 regarding Response Evaluation Criteria In Solid Tumors (Response Evaluation Criteria In Solid Tumors) classification.
0	4251531	"Breast cancer-related pain and discomfort� and "Breast cancer treatment problem last week�	"Breast cancer-related pain and discomfort" and "Breast cancer treatment problem last week" were significantly reduced (P=0.02) in the BP-C1 group but increased slightly in the placebo group; between-group differences were significant in favor of BP-C1 (P=0.05).
0	4251531	"Breast cancer related pain and discomfort�, "Breast cancer treatment problem last week,� and "Physical activity problem�	"Breast cancer related pain and discomfort", "Breast cancer treatment problem last week," and "Physical activity problem" were significantly reduced during the 64 days of BP-C1 treatment (P≤0.05).  
0	4251531	"Breast cancer related pain and discomfort�, "Breast cancer treatment problem last week,� and "Physical activity problem�	Breast cancer related pain and discomfort", "Breast cancer treatment problem last week," and "Physical activity problem" were significantly reduced during the 64 days of BP-C1 treatment (P≤0.05).  
0	2047288	Response rate after reminder	After the reminder, when the participant could chose between versions of the questionnaire, the total response rate for the Internet and paper-and-pencil group was 64.2% and 76.5%, respectively (risk difference 12.2%, P = .002).
2	2047288	Hospital Anxiety and Depression Scale completeness of questionnaire	For the Internet version, 97.8% filled in a complete questionnaire without missing data, while 63.4% filled in a complete questionnaire for the paper-and-pencil version (risk difference 34.5%, P < .001).  
0	2047288	Response rate before reminder	The response rate before the reminder was 17.9% for the Internet group compared to 73.2% for the paper-and-pencil group (risk difference 55.3%, P < .001).
2	2047288	Overall completeness of questionnaire	For the Internet version, 97.8% filled in a complete questionnaire without missing data, while 63.4% filled in a complete questionnaire for the paper-and-pencil version (risk difference 34.5%, P < .001).  
0	5501521	Mean arterial blood pressure	In the Lignocaine group, the average mean arterial pressure was 80.3 mmHg (SD: 4.9) compared to 85.1 mmHg (SD: 5.4) in the Saline group (95% CI 2.4–7.1, p < 0.001).
0	5501521	Sevoflurane concentration	The average end-tidal sevoflurane concentration was lower in the Lignocaine group compared to saline [1.49% (SD: 0.32) vs. 1.89% (SD: 0.29); 95% CI 0.26–0.5, p < 0.001].
0	5501521	Systolic blood pressure	Systolic blood pressure was also lower in the Lignocaine group: 121.7 mmHg (SD: 6.1) vs. 128.0 mmHg (SD: 6.4) in the Saline group; 95% CI 3.5–9.2, p < 0.001, as was the mean heart rate [Lignocaine group: 74.9 beats/min (SD: 1.8) vs. 81.5 beats/min (SD: 1.7) in the Saline group, 95% CI 4.1–9.1, p < 0.001].
2	5501521	Fluid requirements	Maintenance fluid requirements were higher in the Lignocaine group: 3281.1 mL (SD: 1094.6) vs. 2552.6 mL (SD: 1173.5) in the Saline group, 95% CI 206–1251, p = 0.007.
0	5501521	Heart rate	Systolic blood pressure was also lower in the Lignocaine group: 121.7 mmHg (SD: 6.1) vs. 128.0 mmHg (SD: 6.4) in the Saline group; 95% CI 3.5–9.2, p < 0.001, as was the mean heart rate [Lignocaine group: 74.9 beats/min (SD: 1.8) vs. 81.5 beats/min (SD: 1.7) in the Saline group, 95% CI 4.1–9.1, p < 0.001].
1	5012042	longitudinal strain	There were no differences in longitudinal strain (p = 0.38).  
1	5012042	navigator efficiency and signal-to-noise ratio (signal-to-noise ratio)	There was no difference in navigator efficiency (p = 0.90) or signal-to-noise ratio (p = 0.77) between untrained and trained participants for feedback game acquisitions.
1	5012042	navigator efficiency and signal-to-noise ratio (signal-to-noise ratio)	Using the feedback game improved average navigator efficiency from 33 ± 15 to 58 ± 13 % (p < 0.001) and improved signal-to-noise ratio by 5 % (p = 0.01) compared to acquisitions with no feedback.
2	5012042	signal-to-noise ratio (signal-to-noise ratio)	Using the feedback game improved average navigator efficiency from 33 ± 15 to 58 ± 13 % (p < 0.001) and improved signal-to-noise ratio by 5 % (p = 0.01) compared to acquisitions with no feedback.
2	3868679	cosmetic satisfaction	There was higher cosmetic satisfaction in group 1 (P < 0.05).  
0	5599918	Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries	Patients in the dIV-PCA and epidural patient-controlled analgesia groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the intravenous patient-controlled analgesia group.  
0	5599918	Pain intensity after surgery	The postoperative pain intensity was significantly lower in the dIV-PCA and epidural patient-controlled analgesia groups than in the intravenous patient-controlled analgesia group, but comparable between the dIV-PCA group and the epidural patient-controlled analgesia group.
1	5599918	Pain intensity after surgery	The postoperative pain intensity was significantly lower in the dIV-PCA and epidural patient-controlled analgesia groups than in the intravenous patient-controlled analgesia group, but comparable between the dIV-PCA group and the epidural patient-controlled analgesia group.
1	4632405	SF-36 questionnaire	compared with the control group (p< 0.05); the scores of SF-36 of two groups had no significant difference P> 0.05); finally the compliance of participants between the two groups had no signicant difference.
2	4632405	Pre-diabetes reversion	The clinical outcomes: the treatment group and control group had no significant statistical difference P> 0.05) on the baseline of situation; Jinqi Jiangtang tablet effectively reduced the incidence of diabetes mellitus and enhanced reversion rate. compared with the control group (p< 0.05); the scores of SF-36 of two groups had no significant difference P> 0.05); finally the compliance of participants between the two groups had no signicant difference.
0	4632405	Incidence of Diabetes	The clinical outcomes: the treatment group and control group had no significant statistical difference P> 0.05) on the baseline of situation; Jinqi Jiangtang tablet effectively reduced the incidence of diabetes mellitus and enhanced reversion rate. compared with the control group (p< 0.05); the scores of SF-36 of two groups had no significant difference P> 0.05); finally the compliance of participants between the two groups had no signicant difference.
1	4632405	Patient compliance	compared with the control group (p< 0.05); the scores of SF-36 of two groups had no significant difference P> 0.05); finally the compliance of participants between the two groups had no signicant difference.
1	4632405	Baseline values	The clinical outcomes: the treatment group and control group had no significant statistical difference P> 0.05) on the baseline of situation; Jinqi Jiangtang tablet effectively reduced the incidence of diabetes mellitus and enhanced reversion rate. compared with the control group (p< 0.05); the scores of SF-36 of two groups had no significant difference P> 0.05); finally the compliance of participants between the two groups had no signicant difference.
0	4030712	Rate of bone mineral density loss	Analysis of variance demonstrated an overall treatment effect on distal radius bone mineral density (p = 0.005), with the active treatment groups showing a lower rate of bone mineral density loss when compared to the placebo group.
0	5706318	Streptococcus mutans count	All the three mouth rinses have individually shown a statistically significant reduction in the salivary S. mutans counts.
0	5706318	Streptococcus mutans count	All the three mouth rinses have individually shown a statistically significant reduction in the salivary S. mutans counts.
0	5706318	Streptococcus mutans count	All the three mouth rinses have individually shown a statistically significant reduction in the salivary S. mutans counts.
1	3263860	HbA1c reduction	The primary outcome was achieved by 19% in the Continuous glucose monitoring group and 28% in the control group (P = 0.17).
1	3263860	HbA1c reduction	The primary outcome was reduction in HbA1c at 26 weeks by ≥0.5% without the occurrence of severe hypoglycemia.  
1	3263860	Severe hypoglycemia	Severe hypoglycemia rates were similarly low in both groups.
1	2944304	Adverse events	No serious drug-related adverse events occurred in either group.  
0	2944304	Geometric mean time to recovery of the train-of-four ratio to 0.9	Geometric mean time to recovery of the train-of-four ratio to 0.9 was 15-fold faster with sugammadex (4.5 minutes) compared with neostigmine (66.2 minutes; p < 0.0001) (median, 3.3 minutes with sugammadex versus 49.9 minutes with neostigmine).
0	2363753	Days with fever	In addition, a lower number of days with fever and a shortened duration of hospital stay were observed in the amifostine arm.
0	2363753	Hospital stay	In addition, a lower number of days with fever and a shortened duration of hospital stay were observed in the amifostine arm.
0	2363753	Grade III/IV stomatitis	Stomatitis grade III/IV occurred in 25% without versus 0% of patients with amifostine (P = 0.01).
0	2363753	Glomerular filtration rate fall	The median fall of the glomerular filtration rate (glomerular filtration rate) was 10% from baseline in the amifostine group (105 to 95 ml min−1) and 37% in the control patient group (107 to 67 ml min−1) (P< 0.01).
2	5515881	memory score	Moreover, the balance group significantly improved in memory and spatial cognition.
2	5515881	memory score	These results suggest that balance training is capable of improving particularly memory and spatial cognition.
2	3339723	headache intensity after 24 h	After 24 h, headache intensity was 3.77 ± 1.85 in conventionally treated group versus 0.94 ± 2.67 in hydrocortisone group (P < 0.0001), while it was 1.95 ± 1.12 in conventionally treated group versus 0.69 ± 1.64 in hydrocortisone group (P = 0.001) after 48 h.  ABSTRACT.CONCLUSIONS:. 
2	3339723	headache intensity after 48 h	After 24 h, headache intensity was 3.77 ± 1.85 in conventionally treated group versus 0.94 ± 2.67 in hydrocortisone group (P < 0.0001), while it was 1.95 ± 1.12 in conventionally treated group versus 0.69 ± 1.64 in hydrocortisone group (P = 0.001) after 48 h.  ABSTRACT.CONCLUSIONS:. 
2	3339723	headache intensity after 6 h	After 6 h, the mean headache intensity in patients treated conventionally was 6.02 ± 2.46, while it was 2.06 ± 1.98 in other patients who received additional hydrocortisone intravenous (P < 0.0001).
0	5712637	Nor-adrenaline plasma level	There was a decrease in nor-adrenaline plasma level in the religious music group (0.110 ng/mL) and the control group (0.013 ng/mL) when initial nor-adrenaline plasma level was compared to post extraction nor-adrenaline plasma level, whilst the classical music group showed an increase of 0.053 ng/mL. There were significant differences found between the religious Islamic music group and the classical music group (p = 0.041) as well as the control group (p = 0.028) for the difference between pre and post nor-adrenaline plasma level, of which the nor-adrenaline plasma level of the religious Islamic group participants were lower.  
0	5712637	Nor-adrenaline plasma level	There was a decrease in nor-adrenaline plasma level in the religious music group (0.110 ng/mL) and the control group (0.013 ng/mL) when initial nor-adrenaline plasma level was compared to post extraction nor-adrenaline plasma level, whilst the classical music group showed an increase of 0.053 ng/mL. There were significant differences found between the religious Islamic music group and the classical music group (p = 0.041) as well as the control group (p = 0.028) for the difference between pre and post nor-adrenaline plasma level, of which the nor-adrenaline plasma level of the religious Islamic group participants were lower.  
2	3215945	vertebral bone density	The change in vertebral bone mineral density in the zoledronic acid group (+7.93 ± 1.4%) was significantly (P < .05) greater than the change in the placebo group (+0.82 ± 1.7%) as was the change in left femoral neck bone mineral density (+5.05 ± 1.4% for the zoledronic acid group versus −0.48 ± 1.4% for the placebo group).
2	3215945	femoral neck bone density	The change in vertebral bone mineral density in the zoledronic acid group (+7.93 ± 1.4%) was significantly (P < .05) greater than the change in the placebo group (+0.82 ± 1.7%) as was the change in left femoral neck bone mineral density (+5.05 ± 1.4% for the zoledronic acid group versus −0.48 ± 1.4% for the placebo group).
2	3215945	The change in vertebral T-score	The change in vertebral bone mineral density in the zoledronic acid group (+7.93 ± 1.4%) was significantly (P < .05) greater than the change in the placebo group (+0.82 ± 1.7%) as was the change in left femoral neck bone mineral density (+5.05 ± 1.4% for the zoledronic acid group versus −0.48 ± 1.4% for the placebo group).
1	4323432	Gastric peristalsis events	A significantly higher number of gastric peristalsis events was observed in group A (0.49 vs. 0.08, p<0.001), but the difference was not clinically significant.
1	4323432	Duodenal peristalsis events	No significant difference between both groups was found in the occurrence of duodenal peristalsis events (1.79 vs. 1.63, p=0.569).
0	4323432	Dry mouth	The incidence of dry mouth was significantly higher with cimetropium bromide than with phloroglucin (50% vs. 15.1%, p<0.001).  
1	3176493	immune responsiveness of uninfected offspring	Despite strong effects on maternal infection intensity and maternal immune responses, praziquantel treatment of infected women during pregnancy had no effect on anti-schistosome immune responses among offspring by age one year.
2	3176493	IgG1	Praziquantel treatment during pregnancy showed no effect on cytokine responses or antibodies levels to SWA or SEA either in cord blood or at age one year, except for IgG1 to SWA, which was elevated in infants of treated mothers, reflecting maternal levels.
1	3176493	SWA-specific IgE	Praziquantel treatment during pregnancy showed no effect on cytokine responses or antibodies levels to SWA or SEA either in cord blood or at age one year, except for IgG1 to SWA, which was elevated in infants of treated mothers, reflecting maternal levels.
0	3259296	AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, and 0-90 min in study 2	In study 2, the test meal exhibited significantly lower AUCg and AUCi values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P = 0.0005), 0-60 min (P = 0.0002, P = 0.0025), and 0-90 min (P = 0.0396, P = 0.0246).
0	3259296	AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, 0-90 min, and 0-120 min in study 1	In study 1, the 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P < 0.0001), 0-60 min (P < 0.0001, P < 0.0001), 0-90 min (P < 0.0001, P < 0.0001) and 0-120 min (P = 0.0071, P = 0.0016).
0	3259296	concentrations of serum glucose at 15 min and 30 min in study 2	In study 2, the test meal exhibited significantly lower AUCg and AUCi values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P = 0.0005), 0-60 min (P = 0.0002, P = 0.0025), and 0-90 min (P = 0.0396, P = 0.0246).
1	4472776	Mean cost per patient	The mean cost difference per patient of €141 is not statistically significant (95% confidence interval: [€-975; €1,258]).
0	5588958	bradykinin-induced vasodilatation in people with type 2 diabetes mellitus (type 2 diabetes mellitus)	Bradykinin-induced vasodilatation was less during treatment with SRT2104 versus placebo (7.753vs9.044, respectively, mean difference=−1.291,(95% CI −2.296 to −0.285, p=0.012)).
0	5588958	bradykinin-induced vasodilatation in people with type 2 diabetes mellitus (type 2 diabetes mellitus)	Bradykinin-induced vasodilatation was less during treatment with SRT2104 versus placebo (7.753vs9.044, respectively, mean difference=−1.291,(95% CI −2.296 to −0.285, p=0.012)).
1	5588958	Lipid Profile in people with type 2 diabetes mellitus (type 2 diabetes mellitus)	Lipid profile and platelet-monocyte activation were similar in both treatment arms (p>0.05 for all).
1	5588958	platelet-monocyte activation in people with type 2 diabetes mellitus (type 2 diabetes mellitus)	Lipid profile and platelet-monocyte activation were similar in both treatment arms (p>0.05 for all).
2	5588958	HbA1c in people with type 2 diabetes mellitus (type 2 diabetes mellitus)	After 28 days, SRT2104 exposure was associated with weight reduction (−0.93 kg (95% CI −1.72 to −0.15), p=0.0236), and a rise in glycated haemoglobin (5 mmol/mol or 0.48% (0.26 to 0.70), p=0.004)  ABSTRACT.CONCLUSIONS. 
2	5614293	The mean score of final visual acuity	The mean score of final visual acuity was 0.293±0.11 in the intravitreal triamcinolone acetonide group, 0.25±0.10 in the intravitreal bevacizumab group and 0.48±0.15 in the IVB+IVT group. The differences between groups considering final visual acuity was significant (p<0.001).
2	5614293	The average of final visual acuity	The mean age of patients was 68.41±8.32 years. The mean score of final visual acuity was 0.293±0.11 in the intravitreal triamcinolone acetonide group, 0.25±0.10 in the intravitreal bevacizumab group and 0.48±0.15 in the IVB+IVT group. The differences between groups considering final visual acuity was significant (p<0.001).
0	5614293	The average of final macular thickness	The mean thickness of final macular was 383.33±97.70 micrometer in intravitreal triamcinolone acetonide group, 386.33±136.79 micrometers in intravitreal bevacizumab group and 307.33±110.79 micrometers in IVT+IVB group which were significant (p=0.014).  
0	4804276	The total and low-density lipoprotein cholesterol	Patients taking the nutraceutical combination had a significant reduction of total (−12%) and low-density lipoprotein cholesterol (−23%) compared to those who received noNC (p < 0.001 for both).
0	4804276	high sensitivity C-reactive protein (high sensitivity C-reactive protein) and endothelial microparticle (EMPs) levels	Also, high sensitivity C-reactive protein and EMPs were significantly reduced by the nutraceutical combination (−41% and −16%, respectively).
1	5976967	the amount of canal transportation	No significant difference was noted in the amount of canal transportation among the three groups (P > 0.05).
2	5741263	Stroke duration	In contrast to the reported positive effects of training on writing size, the current results showed increases in stroke duration and normalized jerk after amplitude training, which were absent in the placebo group.
1	5741263	Writing velocity	In contrast, velocity remained unchanged throughout the study.  
2	4359791	Performance	Children performed better on the Sniffin' Sticks than the University of Pennsylvania Smell Identification Test (65.3% versus 59.7%, p < .01).
0	5459273	Frequency distribution of catheter tip culture	Frequency distribution of catheter tip culture was significantly higher in the control group than that of the intervention group (p=0.03).  
1	4296330	Frequency of attempts	Regarding duration of insertion attempts, the difference between groups was significant (P < 0.05); while the number of insertion attempts was insignificant (P = 0.265).
1	4296330	Airway leak	Airway leak was assessed in both groups and data showed no significant difference (P = 0.662).
1	4344344	Overall safety at 96 weeks	At 96 weeks, both raltegravir and Control maintained efficacy greater than 75% and continued to demonstrate similar safety profiles.
1	4344344	VL <200 copies/mL at 96 weeks	VL <200 copies/mL at 96 weeks was: raltegravir 80.4%, Control 76.0% (difference: 4.4 [95%CI −2.6, 11.3]) and met non-inferiority criteria.
1	2974661	mean breathlessness change scores	There was no difference in mean breathlessness change scores between the hand-held fan (Borg change score: mean 0.6 (SD 2.10)) and the wristband (mean 0.8 (SD 2.67)) after two months (p = 0.90).  
1	2680972	AIDS progression/death	The difference in the primary endpoint did not reach statistical significance: AIDS progression/death was seen in 20 (14%) vs. 34 (24%); whereas no progression but with incomplete viral suppression was seen in 54 (38%) vs. 44 (31%); and no progression with optimal viral suppression in 67 (48%) vs 63 (45%) in the early vs. deferred arm, respectively (p = 0.22).
0	2680972	The time to a CD4+ count >50 cells/mm3	The early ART had shorter time to achieving a CD4 count above 50 cells/mL (p<0.001) and no increase in adverse events.  
1	2708184	Paretic step length ratio	No significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of training.
1	2708184	Self-selected overground walk velocity	No significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of training.
1	2442760	Pain reduction	Our trial showed no significant difference in pain relief after palliative radiotherapy with 1 or 10 fractions in Iranian patients.
1	2442760	Pain reduction	The mean reduction in pain was 1.1 in both groups.
1	2442760	Pain reduction	By logistic regression, patient sex, primary tumour, radiotherapy site, and type of treatment (single-fraction vs. multifraction) did not have any significant effect on pain reduction.
1	2442760	Response rates	The number of responders was 21 (78%) among those who received a single fraction and 20 (65%) among those who received multiple fractions (p > 0.1).
0	5719521	Cessation of injected drugs	Youth who had recently dealt drugs (adjusted hazard ration [adjusted hazard ration], 0.50; 95% confidence interval, 0.29–0.87), engaged in prohibited street-based income generation (adjusted hazard ration, 0.41; 95% confidence interval, 0.24–0.69), and engaged in illegal income generating activities (adjusted hazard ration, 0.19; 95% confidence interval, 0.06–0.61) were significantly less likely to report cessation of injection drug use.  
0	5719521	Cessation of injected drugs	Youth who had recently dealt drugs (adjusted hazard ration [adjusted hazard ration], 0.50; 95% confidence interval, 0.29–0.87), engaged in prohibited street-based income generation (adjusted hazard ration, 0.41; 95% confidence interval, 0.24–0.69), and engaged in illegal income generating activities (adjusted hazard ration, 0.19; 95% confidence interval, 0.06–0.61) were significantly less likely to report cessation of injection drug use.  
0	5719521	Cessation of injected drugs	Youth who had recently dealt drugs (adjusted hazard ration [adjusted hazard ration], 0.50; 95% confidence interval, 0.29–0.87), engaged in prohibited street-based income generation (adjusted hazard ration, 0.41; 95% confidence interval, 0.24–0.69), and engaged in illegal income generating activities (adjusted hazard ration, 0.19; 95% confidence interval, 0.06–0.61) were significantly less likely to report cessation of injection drug use.  
2	5341634	time before rescue analgesic	Although with similar demographic profile and block (sensory and motor) onset time, sensory and motor block duration and time to first analgesic use were significantly longer and the total need for rescue analgesics was lower in Group LN (P < 0.05) than Group LC.
0	5341634	Postoperative lower visual analog scale scale	Postoperative visual analog scale value at 24 h was significantly lower in Group LN (P < 0.05).
2	5341634	sensory and motor block duration	Although with similar demographic profile and block (sensory and motor) onset time, sensory and motor block duration and time to first analgesic use were significantly longer and the total need for rescue analgesics was lower in Group LN (P < 0.05) than Group LC.
1	5341634	onset of both sensory and motor blocks	Although with similar demographic profile and block (sensory and motor) onset time, sensory and motor block duration and time to first analgesic use were significantly longer and the total need for rescue analgesics was lower in Group LN (P < 0.05) than Group LC.
2	5341634	block duration	Although with similar demographic profile and block (sensory and motor) onset time, sensory and motor block duration and time to first analgesic use were significantly longer and the total need for rescue analgesics was lower in Group LN (P < 0.05) than Group LC.
2	5103331	Improvement of Rhinoconjunctivitis Quality of Life Questionnaire score after 8 weeks	However, the Rhinoconjunctivitis Quality of Life Questionnaire scores significantly differed between the two groups after 4 weeks of treatment completion (t = −2.045, P = 0.05) and this difference lasted until the end of 8-week follow-up (t = −2.246, P = 0.033).
1	5103331	Intake of relief medication	Throughout the treatment regimen, none of the participants took any relief medication, and no severe adverse events occurred.  
1	5103331	Rate of adverse events	Throughout the treatment regimen, none of the participants took any relief medication, and no severe adverse events occurred.  
1	5103331	Improvement of Rhinoconjunctivitis Quality of Life Questionnaire score after 4 weeks	However, the Rhinoconjunctivitis Quality of Life Questionnaire scores significantly differed between the two groups after 4 weeks of treatment completion (t = −2.045, P = 0.05) and this difference lasted until the end of 8-week follow-up (t = −2.246, P = 0.033).
1	5349672	median nausea ratings at rest	At rest (T0, T30), median nausea ratings were zero whether subjects were blindfolded or not.
1	5349672	nausea ratings at movement at T0	At rest (T0, T30), median nausea ratings were zero whether subjects were blindfolded or not.
1	1905915	Companion allowed	Despite an initial positive response from staff to the childbirth companion intervention, we detected no difference between intervention and control hospitals in relation to whether a companion was allowed by nursing staff, good obstetric practice or humanity of care.  
2	5074260	Overall confirmed hypoglycaemia	Confirmed hypoglycaemia rates were low in both groups, although higher with insulin degludec than with placebo (0.57 vs. 0.12 episodes/patient‐years of exposure; p = 0.0002).
0	5074260	Mean fasting plasma glucose at 26 weeks	At 26 weeks, the mean change in glycated haemoglobin level was greater in the insulin degludec add‐on to liraglutide arm (−1.04%) than in the placebo add‐on to liraglutide arm (−0.16%; p < 0.0001). Similarly, the mean fasting plasma glucose reduction was greater, and self‐measured plasma glucose values were lower at all eight time points, with insulin degludec add‐on versus placebo add‐on (both p < 0.0001).
1	5074260	Nocturnal confirmed hypoglycaemia	Nocturnal confirmed hypoglycaemia was infrequent in both groups, with no episodes of severe hypoglycaemia, and no marked differences in adverse events with either treatment approach.  
1	5074260	Adverse events	Nocturnal confirmed hypoglycaemia was infrequent in both groups, with no episodes of severe hypoglycaemia, and no marked differences in adverse events with either treatment approach.  
0	5529983	improvements in physical limitation , angina frequency and quality of life	Compared with standard care alone, CT coronary angiography was associated with less marked improvements in physical limitation (difference −1.74 (95% CIs, −3.34 to −0.14), p=0.0329), angina frequency (difference −1.55 (−2.85 to −0.25), p=0.0198) and quality of life (difference −3.48 (−4.95 to −2.01), p<0.0001) at 6 months.
1	3813126	Mild to borderline airway responsiveness	Changes in airway responsiveness categories (moderate to severe, mild, borderline, normal) after the intervention were not significant in atorvastatin group as in placebo group (p-value= 0.131 for atorvastatin group and p-value = 0.305 for placebo group).
1	3813126	Moderate to severe airway responsiveness	Changes in airway responsiveness categories (moderate to severe, mild, borderline, normal) after the intervention were not significant in atorvastatin group as in placebo group (p-value= 0.131 for atorvastatin group and p-value = 0.305 for placebo group).
1	3813126	Methacholine solution number which caused FEV1 decrease >20%	Also, changes in methacholine solution number (different concentrations of methacholine) which caused at least 20% decrease in FEV1 were not significant between groups (p-value = 0.089).
2	5489138	confirmed disability progression	confirmed disability progression rates defined by timed 25-foot walk or Expanded Disability Status Scale score were higher than those defined by 9-hole peg test score.
2	5489138	confirmed disability progression	ABSTRACT.RESULTS:. confirmed disability progression rates defined by a ≥20% increase in timed 25-foot walk were higher than those defined by Expanded Disability Status Scale score at 12 and 24 months.
2	4183968	Loss of weight	Compared to controls, intervention participants achieved significant weight loss (−6.3±1.0 kg versus +2.1±1.1 kg, P<0.001) and had increased activation for low-calorie food images with a composition consistent with that recommended in the behavioral intervention at 6 months versus baseline in the right ventral putamen (P=0.04), decreased activation for high-calorie images of typically consumed foods in the left dorsal putamen (P=0.01).
0	4183968	Hyperactivation of the reward system for high-calorie food cues	Compared to controls, intervention participants achieved significant weight loss (−6.3±1.0 kg versus +2.1±1.1 kg, P<0.001) and had increased activation for low-calorie food images with a composition consistent with that recommended in the behavioral intervention at 6 months versus baseline in the right ventral putamen (P=0.04), decreased activation for high-calorie images of typically consumed foods in the left dorsal putamen (P=0.01).
2	4183968	Hyperactivation of the reward system for low-calorie food cues	Compared to controls, intervention participants achieved significant weight loss (−6.3±1.0 kg versus +2.1±1.1 kg, P<0.001) and had increased activation for low-calorie food images with a composition consistent with that recommended in the behavioral intervention at 6 months versus baseline in the right ventral putamen (P=0.04), decreased activation for high-calorie images of typically consumed foods in the left dorsal putamen (P=0.01).
1	5107204	Adverse effects	The rates of adverse events (adverse events) were comparable between bilastine and placebo in both Part I and Part II.
0	2212351	fasting blood glucose (fasting blood glucose)	Similarly, fasting blood glucose (fasting blood glucose) levels decreased significantly between 1 and 12 months in group M (p<0.05), and decreased significantly during the entire 12 month period in group D (p<0.01).
0	2212351	fasting blood glucose (fasting blood glucose) levels	Similarly, fasting blood glucose (fasting blood glucose) levels decreased significantly between 1 and 12 months in group M (p<0.05), and decreased significantly during the entire 12 month period in group D (p<0.01).
0	2212351	HbA1c levels within 12 months	In group M, HbA1c levels decreased significantly from 8.2 ± 1.2% to 7.4 ± 0.8% after 12 months (p<0.05), while in group D, HbA1c levels decreased significantly throughout the entire 12 month period, from 8.5 ± 1.7% at baseline to 7.4 ± 1.1% at the endpoint.
0	2212351	HbA1c levels after 12 months	In group M, HbA1c levels decreased significantly from 8.2 ± 1.2% to 7.4 ± 0.8% after 12 months (p<0.05), while in group D, HbA1c levels decreased significantly throughout the entire 12 month period, from 8.5 ± 1.7% at baseline to 7.4 ± 1.1% at the endpoint.
2	4357072	improvement in symptom scores	On intergroup comparison, there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18) and erythematous area (P = 0.07), but there was a statistically highly significant improvement in reduction of clinical scoring (P < 0.01%).
1	4357072	reduction in erythematous area	On intergroup comparison, there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18) and erythematous area (P = 0.07), but there was a statistically highly significant improvement in reduction of clinical scoring (P < 0.01%).
1	4357072	reduction in burning sensation	On intergroup comparison, there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18) and erythematous area (P = 0.07), but there was a statistically highly significant improvement in reduction of clinical scoring (P < 0.01%).
1	3726903	Postoperative complications	The rates of postoperative complications and recurrences between the two groups showed no statistically significant difference (P = 0.688).
1	3726903	Ingrown toenails recurrence	The rates of postoperative complications and recurrences between the two groups showed no statistically significant difference (P = 0.688).
2	3726903	Time to return to normal daily activities	The time to return to normal daily activities was significantly shorter in Group II patients than in Group I patients (P < 0.05).  
1	5435062	Intragastric pH ≥4 mean percent time	Mean ± SD percent time intragastric pH was ≥3 and ≥4 was 58.9 ± 21.1% and 40.9 ± 17.3% for intravenous group, 75.8 ± 16.4% and 62.7 ± 17.7% for subcutaneous group, 88.2 ± 8.9% and 82.5 ± 7.7% for PO group, and 12.5 ± 3.6% and 3.7 ± 1.8% for baseline. The mean percent time with intragastric pH was ≥3 or ≥4 was significantly increased regardless of the dosing route (P < .05).  
1	5435062	Intragastric pH ≥4 mean percent time	Mean ± SD percent time intragastric pH was ≥3 and ≥4 was 58.9 ± 21.1% and 40.9 ± 17.3% for intravenous group, 75.8 ± 16.4% and 62.7 ± 17.7% for subcutaneous group, 88.2 ± 8.9% and 82.5 ± 7.7% for PO group, and 12.5 ± 3.6% and 3.7 ± 1.8% for baseline. The mean percent time with intragastric pH was ≥3 or ≥4 was significantly increased regardless of the dosing route (P < .05).  
2	4227298	Sample size requirements to estimate SDp from external pilot randomised controlled trials	We recommend that an external pilot study has at least 70 measured subjects (35 per group) when estimating the SDp for a continuous outcome.
2	4227298	Binary primary outcome	Hence if the primary outcome is binary a total of at least 120 subjects (60 in each group) may be required in the pilot trial.
2	4227298	Efficiency	It is very much more efficient to use a larger pilot study, than to guard against the lack of precision by using inflated estimates.
0	3917191	mean score of anxiety	However, after the intervention, mean score of anxiety were significantly lower in the experiment group than in the control group (P < 0.01).
0	3917191	mean score of anxiety	However, after the intervention, mean score of anxiety were significantly lower in the experiment group than in the control group (P < 0.01).
2	3831918	retrograde shear	Cuff inflation resulted in stepwise increases in retrograde shear rate (P < 0.05 for main effect).
1	3019750	Enamel wear	No significant differences were found between G1 and G2 for enamel hardness and wear.
1	3019750	Enamel hardness	No significant differences were found between G1 and G2 for enamel hardness and wear.
0	4274041	Rifaximin peak plasma concentration	For both dose levels, peak plasma concentration, area under the concentration-time curve, and cumulative urinary excretion were significantly higher after administration of amorphous rifaximin than rifaximin-α.
0	4274041	Area under curve 0-t	For both dose levels, peak plasma concentration, area under the concentration-time curve, and cumulative urinary excretion were significantly higher after administration of amorphous rifaximin than rifaximin-α.
0	4274041	Cumulative urinary excretion	For both dose levels, peak plasma concentration, area under the concentration-time curve, and cumulative urinary excretion were significantly higher after administration of amorphous rifaximin than rifaximin-α.
0	4274041	Rifaximin peak plasma concentration	For both dose levels, peak plasma concentration, area under the concentration-time curve, and cumulative urinary excretion were significantly higher after administration of amorphous rifaximin than rifaximin-α.
0	4274041	Cumulative urinary excretion	For both dose levels, peak plasma concentration, area under the concentration-time curve, and cumulative urinary excretion were significantly higher after administration of amorphous rifaximin than rifaximin-α.
0	4274041	Area under curve 0-t	For both dose levels, peak plasma concentration, area under the concentration-time curve, and cumulative urinary excretion were significantly higher after administration of amorphous rifaximin than rifaximin-α.
0	5808396	felt stigma after treatment	Participants receiving Cognitive Processing Therapy experienced moderate reductions in felt stigma relative to those in individual support (Cohen's D = 0.44, p = value = 0.02) following the end of treatment, though this difference was no longer significant six-months later (Cohen's D = 0.45, p = value = 0.12).
0	3570228	Eye opening time	Although group IV had shorter postoperative eye-opening and extubation times compared with the other groups (P<0.05), it also had higher restlessness and pain scores (P<0.01).
0	3570228	Eye opening time	Although group IV had shorter postoperative eye-opening and extubation times compared with the other groups (P<0.05), it also had higher restlessness and pain scores (P<0.01).
0	3570228	Extubation time	Although group IV had shorter postoperative eye-opening and extubation times compared with the other groups (P<0.05), it also had higher restlessness and pain scores (P<0.01).
2	5714973	Physical quality of life	The changes in quality of life in experiment group was significantly greater than control group for physical, psychological and social variables.  
2	5714973	Psychological quality of life	The changes in quality of life in experiment group was significantly greater than control group for physical, psychological and social variables.  
2	5714973	Social quality of life	The changes in quality of life in experiment group was significantly greater than control group for physical, psychological and social variables.  
2	5714973	Total quality of life	The changes in quality of life in experiment group was significantly greater than control group for physical, psychological and social variables.  
1	3564932	Vaginal birth rate	Vaginal birth rates (66% outpatient Foley catheter Vs. 71% inpatient vaginal PGE2), total induction to delivery time (33.5 hrs vs. 31.3 hrs) and total inpatient times (96 hrs outpatient Foley catheter Vs. 105 hrs inpatient vaginal PGE2) were similar.
1	3564932	Induction to delivery time	Vaginal birth rates (66% outpatient Foley catheter Vs. 71% inpatient vaginal PGE2), total induction to delivery time (33.5 hrs vs. 31.3 hrs) and total inpatient times (96 hrs outpatient Foley catheter Vs. 105 hrs inpatient vaginal PGE2) were similar.
2	3564932	Oxytocin requirements	outpatient Foley catheter group felt less pain (significant discomfort 26% Vs 58%, p = .003), and had more sleep (5.8 Vs 3.4 hours, p < .001), during cervical preparation, but were more likely to require oxytocin induction of labour (88 Vs 59%, p = .001).  
1	3564932	Total inpatient time	Vaginal birth rates (66% outpatient Foley catheter Vs. 71% inpatient vaginal PGE2), total induction to delivery time (33.5 hrs vs. 31.3 hrs) and total inpatient times (96 hrs outpatient Foley catheter Vs. 105 hrs inpatient vaginal PGE2) were similar.
0	3564932	Pain	outpatient Foley catheter group felt less pain (significant discomfort 26% Vs 58%, p = .003), and had more sleep (5.8 Vs 3.4 hours, p < .001), during cervical preparation, but were more likely to require oxytocin induction of labour (88 Vs 59%, p = .001).  
0	3564932	Achieving vaginal birth within 12 hours	outpatient Foley catheter group had shorter hospital stay prior to birth (21.3 vs. 32.4 hrs, p < .001), inpatient vaginal PGE2 were more likely to achieve vaginal birth within 12 hours of presenting to Birthing Unit (53% vs. 28%, p = .01).
1	1831737	Self-reported STI symptoms	No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities.
1	1831737	High-risk sexual behaviour	No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities.
1	1831737	HIV-1 incidence	Integrated peer education, condom distribution, and syndromic STI management did not reduce population-level HIV-1 incidence in a declining epidemic, despite reducing HIV-1 incidence in the immediate male target group.
1	1831737	HIV-1 incidence	Despite greater programme activity and knowledge in the intervention communities, the incidence rate ratio of HIV-1 was 1.27 (95% confidence interval [confidence interval] 0.92–1.75) compared to the control communities.
0	5040733	≥1 adjudicated symptomatic recurrent venous thromboembolism	Overall, fewer dalteparin-treated patients (2/74 [2.7 %]) experienced ≥1 adjudicated symptomatic recurrent VTE compared with VKA-treated patients (15/88 [17.0 %]; hazard ratio = 0.15 [95 % confidence interval 0.03–0.65]; p = 0.01).
1	5040733	Any bleeding	Bleeding event rates for both treatments were similar (p = 0.47).
2	3467590	medication intensification	For A1c control, medication intensification increased in both groups (intervention, pre 26.4% vs post 32.6%, p=0.022; control, pre 24.8% vs post 31.1%, p=0.033) (intervention, adjusted OR (adjusted OR) 1.37; 95% CI 1.06 to 1.76; control, adjusted OR 1.41 (95% CI 1.06 to 1.89)); however, we observed no incremental benefit solely due to the intervention (group-by-time interaction, p=0.948).
1	3467590	intensification of medications to control BP	A wide-reach, low-intensity, web-based interactive multicomponent intervention had no significant incremental effect on medication intensification for control of glucose, blood pressure or lipids for patients with diabetes of physicians practising in the rural Southeastern USA.  
1	3467590	intensification of medications to control LDL	A wide-reach, low-intensity, web-based interactive multicomponent intervention had no significant incremental effect on medication intensification for control of glucose, blood pressure or lipids for patients with diabetes of physicians practising in the rural Southeastern USA.  
1	3467590	incremental benefit	For A1c control, medication intensification increased in both groups (intervention, pre 26.4% vs post 32.6%, p=0.022; control, pre 24.8% vs post 31.1%, p=0.033) (intervention, adjusted OR (adjusted OR) 1.37; 95% CI 1.06 to 1.76; control, adjusted OR 1.41 (95% CI 1.06 to 1.89)); however, we observed no incremental benefit solely due to the intervention (group-by-time interaction, p=0.948).
0	3489577	total cholesterol and LDL-C	Total-, LDL-cholesterol and waist circumference decreased significantly in the oat group compared to the control.
2	3489577	dietary fiber	Dietary fiber intake increased significantly in the oat group compared to the control group at the end of the 6-week intervention.
1	3489577	plasma glucose levels	There were no significant changes in blood pressure, other anthropometric or laboratory measures between the two groups at the end of the intervention.  
0	3489577	Waist circumference	Total-, LDL-cholesterol and waist circumference decreased significantly in the oat group compared to the control.
1	3489577	blood pressure, other anthropometric or laboratory measures	There were no significant changes in blood pressure, other anthropometric or laboratory measures between the two groups at the end of the intervention.  
2	3489577	HDL-C	HDL-cholesterol decreased significantly in the control group versus the oat group.
0	5747102	Clinician's Interview-Based Impression of Change-Plus (Clinician's Interview-Based Impression of Change-Plus) values at 12-week treatment phase (T1) and 12-week follow-up period (T2)	The mean Clinician's Interview-Based Impression of Change-Plus values for the AG group at T1 and T2 were much lower than that for the DG group, and there were significant differences between the two groups (푃<0.05).
1	5747102	Activities of Daily Living Scales (ADAS-ADL23) and Neuropsychiatric Index (Neuropsychiatric Index)	There were no significant between-group differences in the scores of ADAS-ADL23 and Neuropsychiatric Index during the study period.
0	5747102	The Assessment Scale-Cognitive (Alzheimer's disease Assessment Scale-Cognitive) scores at 12-week follow-up period (T2)	The Alzheimer's disease Assessment Scale-Cognitive scores for AG group showed obvious decreases at T2 and ∆(T2-T0)when compared with DG group, and significant between-group differences were detected (all p < 0.05).
2	5245138	interleukin-2 and interferon-γ	After treatment, the levels of serum interleukin-2 (interleukin-2) and interferon-γ (interferon-γ) increased when compared to before, while levels of IL-4 and IL-6 decreased, and the observation group had more significant improvement.
0	5245138	IL-4 and IL-6	After treatment, the levels of serum interleukin-2 (interleukin-2) and interferon-γ (interferon-γ) increased when compared to before, while levels of IL-4 and IL-6 decreased, and the observation group had more significant improvement.
2	5245138	The effective rate and the degree of treatment	The effective rate and degree of treatment for the observation group were significantly higher than those of the control group and differences were statistically significant (P<0.05).
2	5003992	Insulin concentration	Results indicated: i) The growth performance of gilts were not affected by the addition of glucose, but the age of puberty onset was advanced significantly (p<0.05); ii) Compared with the starch group, the concentration of insulin significantly increased before puberty in high-dose group (p<0.05); iii) There was no difference in serum progesterone (progesterone) levels amongst the different feed groups, however, levels of estradiol (E2), luteinizing hormone, and follicle-stimulating hormone were significantly higher at puberty onset in high-dose group (p<0.05).
1	5003992	Serum progesterone	Results indicated: i) The growth performance of gilts were not affected by the addition of glucose, but the age of puberty onset was advanced significantly (p<0.05); ii) Compared with the starch group, the concentration of insulin significantly increased before puberty in high-dose group (p<0.05); iii) There was no difference in serum progesterone (progesterone) levels amongst the different feed groups, however, levels of estradiol (E2), luteinizing hormone, and follicle-stimulating hormone were significantly higher at puberty onset in high-dose group (p<0.05).
1	5003992	Serum progesterone	Results indicated: i) The growth performance of gilts were not affected by the addition of glucose, but the age of puberty onset was advanced significantly (p<0.05); ii) Compared with the starch group, the concentration of insulin significantly increased before puberty in high-dose group (p<0.05); iii) There was no difference in serum progesterone (progesterone) levels amongst the different feed groups, however, levels of estradiol (E2), luteinizing hormone, and follicle-stimulating hormone were significantly higher at puberty onset in high-dose group (p<0.05).
2	5003992	Follicle-stimulating hormone at puberty	Results indicated: i) The growth performance of gilts were not affected by the addition of glucose, but the age of puberty onset was advanced significantly (p<0.05); ii) Compared with the starch group, the concentration of insulin significantly increased before puberty in high-dose group (p<0.05); iii) There was no difference in serum progesterone (progesterone) levels amongst the different feed groups, however, levels of estradiol (E2), luteinizing hormone, and follicle-stimulating hormone were significantly higher at puberty onset in high-dose group (p<0.05).
2	5003992	Luteinizing hormone at puberty	Results indicated: i) The growth performance of gilts were not affected by the addition of glucose, but the age of puberty onset was advanced significantly (p<0.05); ii) Compared with the starch group, the concentration of insulin significantly increased before puberty in high-dose group (p<0.05); iii) There was no difference in serum progesterone (progesterone) levels amongst the different feed groups, however, levels of estradiol (E2), luteinizing hormone, and follicle-stimulating hormone were significantly higher at puberty onset in high-dose group (p<0.05).
2	5003992	Estradiol at puberty	Results indicated: i) The growth performance of gilts were not affected by the addition of glucose, but the age of puberty onset was advanced significantly (p<0.05); ii) Compared with the starch group, the concentration of insulin significantly increased before puberty in high-dose group (p<0.05); iii) There was no difference in serum progesterone (progesterone) levels amongst the different feed groups, however, levels of estradiol (E2), luteinizing hormone, and follicle-stimulating hormone were significantly higher at puberty onset in high-dose group (p<0.05).
0	5672307	AUC0–24 h for EPA	All plasma fatty acid levels reached baseline levels within 72 h. CCx (median = 2·987) had a significantly lower AUC0–24 h for EPA compared with liquid fish oil (median = 5·647, P = 0·043) and enriched kibbles (median = 5·119, P = 0·032) (F2,22 = 4·637, P = 0·021).
0	5672307	AUC0–24 h for EPA	All plasma fatty acid levels reached baseline levels within 72 h. CCx (median = 2·987) had a significantly lower AUC0–24 h for EPA compared with liquid fish oil (median = 5·647, P = 0·043) and enriched kibbles (median = 5·119, P = 0·032) (F2,22 = 4·637, P = 0·021).
0	5672307	AUC0–24 h for EPA	CCx (median = 2·471) AUC0–24 h for DHA was significantly lower compared with liquid fish oil (median = 4·837, Z = −2·56, P = 0·011) and enriched kibbles (median = 4·413, Z = −2·59, P = 0·01).
0	5672307	AUC0–24 h for DHA	CCx (median = 2·471) AUC0–24 h for DHA was significantly lower compared with liquid fish oil (median = 4·837, Z = −2·56, P = 0·011) and enriched kibbles (median = 4·413, Z = −2·59, P = 0·01).
0	5672307	AUC0–24 h for DHA	CCx (median = 2·471) AUC0–24 h for DHA was significantly lower compared with liquid fish oil (median = 4·837, Z = −2·56, P = 0·011) and enriched kibbles (median = 4·413, Z = −2·59, P = 0·01).
2	3635879	Probability of identifying 3 out of 5 Electrocardiogram diagnoses	Compared with formative assessments, summative assessments increased the odds of correctly identifying at least three out of five Electrocardiogram diagnoses (OR 5.14; 95% CI 3.26 to 8.09), of spending at least 2 h/week extra on Electrocardiogram self-study (OR 4.02; 95% CI 2.65 to 6.12) and of using additional learning material (OR 2.86; 95% CI 1.92 to 4.24).
2	3635879	Probability of self-studying 2 h/week extra	Compared with formative assessments, summative assessments increased the odds of correctly identifying at least three out of five Electrocardiogram diagnoses (OR 5.14; 95% CI 3.26 to 8.09), of spending at least 2 h/week extra on Electrocardiogram self-study (OR 4.02; 95% CI 2.65 to 6.12) and of using additional learning material (OR 2.86; 95% CI 1.92 to 4.24).
2	3635879	Probability of using additional learning material	Compared with formative assessments, summative assessments increased the odds of correctly identifying at least three out of five Electrocardiogram diagnoses (OR 5.14; 95% CI 3.26 to 8.09), of spending at least 2 h/week extra on Electrocardiogram self-study (OR 4.02; 95% CI 2.65 to 6.12) and of using additional learning material (OR 2.86; 95% CI 1.92 to 4.24).
0	3685599	plasminogen, sVCAM, d-dimer, and fibrinogen levels	At week 96, levels of interleukin-6, soluble vascular adhesion molecule-1, d-dimer, fibrinogen, and plasminogen were lower than baseline in both treatment groups, and the decrease was statistically significant for soluble vascular adhesion molecule-1 (fosamprenavir/ritonavir and efavirenz), d-dimer (fosamprenavir/ritonavir and efavirenz), fibrinogen (efavirenz), and plasminogen (efavirenz).
0	3685599	sVCAM and d-dimer	At week 96, levels of interleukin-6, soluble vascular adhesion molecule-1, d-dimer, fibrinogen, and plasminogen were lower than baseline in both treatment groups, and the decrease was statistically significant for soluble vascular adhesion molecule-1 (fosamprenavir/ritonavir and efavirenz), d-dimer (fosamprenavir/ritonavir and efavirenz), fibrinogen (efavirenz), and plasminogen (efavirenz).
0	3685599	Fibrinogen	At week 96, levels of interleukin-6, soluble vascular adhesion molecule-1, d-dimer, fibrinogen, and plasminogen were lower than baseline in both treatment groups, and the decrease was statistically significant for soluble vascular adhesion molecule-1 (fosamprenavir/ritonavir and efavirenz), d-dimer (fosamprenavir/ritonavir and efavirenz), fibrinogen (efavirenz), and plasminogen (efavirenz).
0	3685599	plasminogen at 96 week	At week 96, levels of interleukin-6, soluble vascular adhesion molecule-1, d-dimer, fibrinogen, and plasminogen were lower than baseline in both treatment groups, and the decrease was statistically significant for soluble vascular adhesion molecule-1 (fosamprenavir/ritonavir and efavirenz), d-dimer (fosamprenavir/ritonavir and efavirenz), fibrinogen (efavirenz), and plasminogen (efavirenz).
2	2981076	Preference	A total of 175 patients answered a preference question: 106 (61%) preferred orodispersible tablet and 48 (27%) preferred oral conventional tablet (P<0.001 adjusted for treatment sequence); 21 (12%) expressed no preference.
1	2981076	Compliance	Compliance as measured by tablet count was above 98% on both formulations.
1	2981076	Compliance	Compliance and drug attitude were measured using the Drug Attitude Inventory (DAI-10) and Medication Adherence Form (Medication Adherence Form) scales; tolerability and safety by Association for Methodology and Documentation in Psychiatry (AMDP-5) questionnaire and adverse event summary.
0	5354029	Mean percentage of scored days	First, the mean percentage of scored days per dog that were scored as diarrhea throughout their stay was 2.0% in the synbiotic group and 3.2% in the placebo group (P = .0022).
0	5354029	Occurrence of diarrhea within the first 14 days	Second, the occurrence of diarrhea within the first 14 days' stay was 18.8% in the synbiotic product group and 27.2% in the placebo group (P = .0008).
0	5354029	Occurrence of ≥2 consecutive days of diarrhea	Third, the occurrence of ≥2 consecutive days of diarrhea within the first 14 days' stay was 4.6% in the synbiotic product group and 8.0% in the placebo group (P = .0300).  
1	4648234	Agreement between Experts and Sponsors	Raw agreement between the expert group and sponsors was 0.74 in the concept and 0.78 in the ad hoc arm. Chance-corrected agreement was higher in the ad hoc (kappa: 0.34 (95% confidence interval = 0.10–0.58)) than in the concept arm (0.27 (0.06–0.50)), but the difference was not significant (p = 0.67).  
1	4648234	Kappa values	Chance-corrected agreement was higher in the ad hoc (kappa: 0.34 (95% confidence interval = 0.10–0.58)) than in the concept arm (0.27 (0.06–0.50)), but the difference was not significant (p = 0.67).  
2	4526336	proportion of words out of the total number of words	Results: Compared to those with normal cognitive function, mild cognitive impairment participants generated a greater proportion of words out of the total number of words during the timed conversation sessions (p=0.01).
0	4877819	Fatigue Severity Scores	Patients treated with A. paniculata showed a significant reduction in their Fatigue Severity Scores score as compared to the placebo, equivalent to a 44 % reduction at 12 months.
1	4877819	Relapse rate	No statistically significant differences were observed for relapse rate, Expanded Disability Status Scale or inflammatory parameters, with a trend in reducing new lesions among the A. paniculata group.
1	4877819	Inflammatory parameters	No statistically significant differences were observed for relapse rate, Expanded Disability Status Scale or inflammatory parameters, with a trend in reducing new lesions among the A. paniculata group.
1	4877819	Expanded Disability Status Scale	No statistically significant differences were observed for relapse rate, Expanded Disability Status Scale or inflammatory parameters, with a trend in reducing new lesions among the A. paniculata group.
1	3597059	Hypotension	Hypotension occurred in 3 patients in the C group and one each in the RS and HES group, respectively (P = 0.362).
2	3750766	reduction in acute induced pain	A single 30 minute session using one of 3 tested Repetitive transcranial magnetic stimulation coil configurations operated at 1 Hz consistently produced robust reduction (mean 70% on NRS scale) in evoked pain in volunteers.
0	3750766	pain perception in dorsal anterior cingulate cortex	A single 30 minute session using one of 3 tested Repetitive transcranial magnetic stimulation coil configurations operated at 1 Hz consistently produced robust reduction (mean 70% on NRS scale) in evoked pain in volunteers. In fibromyalgia patients, the 20 Repetitive transcranial magnetic stimulation sessions also produced a significant pain inhibition (43% reduction in NRS pain over last 24 hours), but only when operated at 10 Hz.
0	3590543	Insertion time	Mean insertion time for the I-gel (11.12 ± 1.814 sec) was significantly lower than that of the Proseal laryngeal mask airway (15.13 ± 2.91 sec) (P = 0.001).
0	3590543	Mean airway sealing pressure	Mean airway sealing pressure in the Proseal laryngeal mask airway group (29.55 ± 3.53 cm H2O) was significantly higher than in the I-gel group (26.73 ± 2.52 cm H2O; P = 0.001).
2	3590543	Ease of gastric tube insertion	Ease of gastric tube insertion was significantly higher in the I-gel group (P = 0.001).
0	2885597	alkaline phosphatase	The serum activities of alkaline phosphatase, gamma-glutamyl transpeptidase and alanine aminotranferase also decreased in this group compared with baseline (-32.6%; p=0.012, -44%; p=0.031 and -16.9%; p=0.029, respectively).
0	2885597	alanine aminotranferase	The serum activities of alkaline phosphatase, gamma-glutamyl transpeptidase and alanine aminotranferase also decreased in this group compared with baseline (-32.6%; p=0.012, -44%; p=0.031 and -16.9%; p=0.029, respectively).
0	2885597	gamma-glutamyl transpeptidase	The serum activities of alkaline phosphatase, gamma-glutamyl transpeptidase and alanine aminotranferase also decreased in this group compared with baseline (-32.6%; p=0.012, -44%; p=0.031 and -16.9%; p=0.029, respectively).
0	2885597	total cholesterol	Significant reductions in total cholesterol, triglycerides and non-high density lipoprotein cholesterol were observed in the combination treatment group.
0	2885597	triglycerides	Ten patients (57.2±13.3 years old) with primary biliary cirrhosis and persistent elevations of liver enzymes after treatment with ursodeoxycholic acid (600 mg/day) were randomized to continue ursodeoxycholic acid (4 patients) or to receive micronized fenofibrate (200 mg/day) plus ursodeoxycholic acid (6 patients) for 8 weeks. Significant reductions in total cholesterol, triglycerides and non-high density lipoprotein cholesterol were observed in the combination treatment group.
0	4155124	plasma cathepsin S levels	The Nordic diet significantly decreased cathepsin S levels (from 20.1 (+/-4.0 SD) to 19.7 μg/L (+/-4.3 SD)) compared with control group (from 18.2 (+/-2.9 SD) to 19.1 μg/L (+/-3.8 SD)).
1	3263163	uncorrected visual acuity or best corrected visual acuity	In this study, there was no statistical difference between uncorrected visual acuity, best corrected visual acuity, intraocular pressure, cataract incidence, contrast sensitivity, and specular microscopy, 1 year after surgery.
1	3263163	intraocular pressure (intraocular pressure)	In this study, there was no statistical difference between uncorrected visual acuity, best corrected visual acuity, intraocular pressure, cataract incidence, contrast sensitivity, and specular microscopy, 1 year after surgery.
1	5406030	Quality-adjusted life-years	There was no significant difference in the proportion of patients with unplanned rehospitalisations (mean difference 0.17%, 95% CI -8.85;8.51), and in quality-adjusted life-years (mean difference -0.0085, 95% CI -0.0170;0.0001).
1	5406030	Unplanned rehospitalisations	There was no significant difference in the proportion of patients with unplanned rehospitalisations (mean difference 0.17%, 95% CI -8.85;8.51), and in quality-adjusted life-years (mean difference -0.0085, 95% CI -0.0170;0.0001).
1	5406030	Total costs	Total costs for the COACH program were non-significantly lower than usual care (-€1160, 95% CI -3168;847).
2	5594766	The mean heart rate	Mean arterial pressure was well attenuated by pregabalin than others, and mean heart rate following laryngoscopy and intubation was attenuated by clonidine group significantly.  
0	5594766	the mean blood pressure	Mean arterial pressure was well attenuated by pregabalin than others, and mean heart rate following laryngoscopy and intubation was attenuated by clonidine group significantly.  
2	3932201	the duration of anesthesia	The duration of anesthesia in clonidine group (275.10 ± 96.09) was longer compared to the placebo (211.73 ± 74.80) and fentanyl (192.33 ± 30.36) groups.
2	3932201	the mean time to first analgesic request	Similarly, the mean time to first analgesic request was also longer in group C (519.44 ± 86.25) than in groups F (277.88 ± 94.25) and P (235.43 ± 22.35 min). This difference between group C versus F (P < 0.001) and P groups (P < 0.001) was significant.
1	5617873	Serious adverse effects	All patients randomized to aripiprazole completed the study, and no serious adverse events were reported.
2	5617873	Parent-rated Aberrant Behavior Checklis improvement	Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8.
2	5617873	Clinician-rated Clinical Global Impression-Improvement scores	Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8. Administration of aripiprazole provided significantly greater improvement in the mean clinician-rated Clinical Global Impression-Improvement scores than placebo from week 2 through week 8.
1	3696875	Suicide ideation after 12 months	Regardless of the intervention condition, participants showed significant reductions in suicidal ideation over 12 months (p<0.001).
2	3337377	Physician satisfaction	The ED group showed a lower failure rate, fewer cases of more than 2 attempts, a lesser time to identify the epidural space, and better ease and satisfaction scores of procedure than the C group, with statistical significance.  
0	3337377	Failing on first 2 attempts	The ED group showed a lower failure rate, fewer cases of more than 2 attempts, a lesser time to identify the epidural space, and better ease and satisfaction scores of procedure than the C group, with statistical significance.  
0	3337377	Time needed	The ED group showed a lower failure rate, fewer cases of more than 2 attempts, a lesser time to identify the epidural space, and better ease and satisfaction scores of procedure than the C group, with statistical significance.  
2	3337377	Ease of procedure	The ED group showed a lower failure rate, fewer cases of more than 2 attempts, a lesser time to identify the epidural space, and better ease and satisfaction scores of procedure than the C group, with statistical significance.  
0	3267522	body weight	Significant reductions were observed in body weight (−8.04 ± 2.31 kg), body mass index (−2.92 ± 0.85 kg/m2), and percent body fat (−4.44% ± 2.00%), as well as a small decrease in heart rate (−2.56 ± 2.85 beats per minute), but with no significant changes to diet over the course of the study.
0	3267522	body mass index (BMI)	Significant reductions were observed in body weight (−8.04 ± 2.31 kg), body mass index (−2.92 ± 0.85 kg/m2), and percent body fat (−4.44% ± 2.00%), as well as a small decrease in heart rate (−2.56 ± 2.85 beats per minute), but with no significant changes to diet over the course of the study.
0	3267522	percent body fat	Significant reductions were observed in body weight (−8.04 ± 2.31 kg), body mass index (−2.92 ± 0.85 kg/m2), and percent body fat (−4.44% ± 2.00%), as well as a small decrease in heart rate (−2.56 ± 2.85 beats per minute), but with no significant changes to diet over the course of the study.
0	3267522	percent body fat	Significant reductions were observed in body weight (−8.04 ± 2.31 kg), body mass index (−2.92 ± 0.85 kg/m2), and percent body fat (−4.44% ± 2.00%), as well as a small decrease in heart rate (−2.56 ± 2.85 beats per minute), but with no significant changes to diet over the course of the study.
1	5536158	Systolic blood pressure reduction	The reduction in systolic blood pressure was similar in both groups (Fixed:7.64±2.49%; Free: 7.81±4.00%, n.s.), while the reduction of diastolic blood pressure was greater in the Fixed group (Fixed: 14.22±2.03%; Free: 4.92±5.00%, p<0.05).
1	5536158	Reaching blood pressure target	After 3 months BP control was improved in both groups and BP targets were similarly reached in both groups (SBP; Fixed: 61.54%; Free 69.23%; n.s. DPB; Fixed: 80.77%; Free 84.62%; n.s.).
2	5536158	Diastolic blood pressure reduction	The reduction in systolic blood pressure was similar in both groups (Fixed:7.64±2.49%; Free: 7.81±4.00%, n.s.), while the reduction of diastolic blood pressure was greater in the Fixed group (Fixed: 14.22±2.03%; Free: 4.92±5.00%, p<0.05).
2	4495314	Use of midwife contacts	intervention group mothers used significantly more midwife contacts than control group mothers.
0	5789491	Pain	The mean pain score was 4.95 for patients in Group I, 4.15 for patients in Group II, and 2.18 for patients in Group III with statistically significant findings (F = 120.27, P < 0.001).
0	5789491	Pain	The mean pain score was 4.95 for patients in Group I, 4.15 for patients in Group II, and 2.18 for patients in Group III with statistically significant findings (F = 120.27, P < 0.001).
1	3089991	Inhibition of food cravings	With an improved sham control condition, prefrontal repetitive transcranial magnetic stimulation inhibited food cravings no better than sham repetitive transcranial magnetic stimulation.
1	3219771	pH	There were no significant differences in pH, PaCO2, the apparent strong ion difference, the strong ion gap, bicarbonate ion, or lactate between two groups throughout the whole investigation period. At T2, pH was decreased whereas PaCO2 was increased in both groups compared with T1 but these changes were not significantly different.
1	3219771	Strong ion difference	There were no significant differences in pH, PaCO2, the apparent strong ion difference, the strong ion gap, bicarbonate ion, or lactate between two groups throughout the whole investigation period.
1	3219771	PaCO2	There were no significant differences in pH, PaCO2, the apparent strong ion difference, the strong ion gap, bicarbonate ion, or lactate between two groups throughout the whole investigation period.
1	3219771	Strong ion gap	There were no significant differences in pH, PaCO2, the apparent strong ion difference, the strong ion gap, bicarbonate ion, or lactate between two groups throughout the whole investigation period.
1	3219771	Lactate	There were no significant differences in pH, PaCO2, the apparent strong ion difference, the strong ion gap, bicarbonate ion, or lactate between two groups throughout the whole investigation period.
0	5396972	Overall adverse cardiac events	There was a significant reduction in overall adverse cardiac events (myocardial injury, arrhythmias, angina, heart failure and nonfatal cardiac arrest) in patient controlled epidural analgesia group in comparison to patient controlled intravenous analgesia group.
0	5396972	Overall adverse cardiac events	Perioperative thoracic epidural analgesia in patients suffering from coronary artery disease subjected to major abdominal cancer surgery reduced significantly postoperative major adverse cardiac events with better pain control in comparison with perioperative intravenous analgesia.
0	5396972	Mean arterial pressure and heart rate during surgery	Regarding perioperative hemodynamics, there was a significant reduction in intra-operative mean arterial pressure (mean arterial pressure); and heart rate in patient controlled epidural analgesia group in comparison to patient controlled intravenous analgesia group at most of measured time points while there was not a significant reduction in postoperative mean arterial pressure and heart rate in the second and third postoperative days.
0	5396972	Dynamic visual analog scale pain score	Also, there was a significant reduction in dynamic visual analog scale pain score in group patient controlled epidural analgesia in comparison to patient controlled intravenous analgesia at all measured time points.
0	5396972	Postoperative complications	The incidence of other postoperative complications such as deep venous thrombosis, pneumonia and in hospital mortality were decreased in patient controlled epidural analgesia group.  
1	4124480	Mean SGRQ scores	SGRQ was not significantly changed.  
2	4124480	total weight lifted	The community-based exercise program group increased muscle strength (weight lifted) by 11.8 kilograms per subject per week of training (P < 0.001).
0	5753687	corticosteroid dosage, Crohn's disease activity index (Crohn's disease activity index), Harvey-Bradshaw index (Harvey-Bradshaw index)	Twelve months after treatment, the Crohn's disease activity index, Harvey-Bradshaw index, and corticosteroid dosage had decreased by 62.5±23.2, 3.4±1.2, and 4.2±0.84 mg/day, respectively, in the UC-MSC group and by 23.6±12.4, 1.2±0.58, and 1.2±0.35 mg/day, respectively, in the control group (p<0.01, p<0.05, and p<0.05 for UC-MSC vs control, respectively).
2	5395810	weight	Regarding to weight loss, the delayed-image group did consistently better in all analyses.
2	5395810	weight	At 24 weeks there was a significant change in weight overall (p < 0.0001), and a difference in rate of change between groups (delayed-image group: −0.60 kg, early-image group: −0.42 kg, p = 0.01).
1	4124476	the incidence of postoperative nausea and vomiting or need for rescue antiemetics 0–2 h postoperatively	There were no significant differences in the incidence of postoperative nausea and vomiting or need for rescue antiemetics 0–2 h postoperatively, but significant differences were observed in the incidence of postoperative nausea and vomiting and complete response among the three groups 2–48 h postoperatively.
0	4124476	The incidences of postoperative nausea and vomiting	The incidences of postoperative nausea and vomiting were lower (nausea, 14% vs. 59% and 41%, respectively; P  <  0.001; vomiting, P  =  0.048) and the incidence of complete response was higher (83% vs. 37% and 59%, respectively; P  <  0.001) in group C than in groups A and B at 48 h postoperatively.
2	4124476	incidence of complete response	The incidences of postoperative nausea and vomiting were lower (nausea, 14% vs. 59% and 41%, respectively; P  <  0.001; vomiting, P  =  0.048) and the incidence of complete response was higher (83% vs. 37% and 59%, respectively; P  <  0.001) in group C than in groups A and B at 48 h postoperatively.
2	5295074	serum 25(OH)D from baseline to study	Increases in 25(OH)D (median with interquartile range) from baseline to study end were 13.2 (5.9 to 20.7) nmol/L in the 200 international units group, and 35.8 (18.2 to 52.8) nmol/L in the 800 international units group (p < 0.001 for the between group difference).
2	4233044	Overall adverse events frequency	Adverse events were more frequent in the hyaluronic acid/carboxymethylcellulose powder group versus the no adhesion barrier group (63% vs. 39%; P <0.001), as were serious adverse events (28% vs. 11%; P <0.001).
2	4233044	Serious adverse events frequency	Adverse events were more frequent in the hyaluronic acid/carboxymethylcellulose powder group versus the no adhesion barrier group (63% vs. 39%; P <0.001), as were serious adverse events (28% vs. 11%; P <0.001).
1	4233044	Overall surgical site infections	There were no statistically significant differences between the hyaluronic acid/carboxymethylcellulose powder group and the no adhesion barrier group in surgical site infections (21% vs. 14%; P = 0.216) and serious surgical site infections (12% vs. 9%; P = 0.38), or in the most frequent serious surgical site infections of pelvic abscess (5% and 2%; significance not tested), anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).  
1	4233044	Serious surgical site infections	There were no statistically significant differences between the hyaluronic acid/carboxymethylcellulose powder group and the no adhesion barrier group in surgical site infections (21% vs. 14%; P = 0.216) and serious surgical site infections (12% vs. 9%; P = 0.38), or in the most frequent serious surgical site infections of pelvic abscess (5% and 2%; significance not tested), anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).  
1	4233044	Anastomotic fistula frequency	There were no statistically significant differences between the hyaluronic acid/carboxymethylcellulose powder group and the no adhesion barrier group in surgical site infections (21% vs. 14%; P = 0.216) and serious surgical site infections (12% vs. 9%; P = 0.38), or in the most frequent serious surgical site infections of pelvic abscess (5% and 2%; significance not tested), anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).  
1	4233044	Peritonitis frequency	There were no statistically significant differences between the hyaluronic acid/carboxymethylcellulose powder group and the no adhesion barrier group in surgical site infections (21% vs. 14%; P = 0.216) and serious surgical site infections (12% vs. 9%; P = 0.38), or in the most frequent serious surgical site infections of pelvic abscess (5% and 2%; significance not tested), anastomotic fistula (3% and 4%), and peritonitis (2% and 3%).  
2	4019890	median and mean peak IFN-γ T cell response	Median and mean peak IFN-γ T cell response by ELISPOT (spots per 104 CD8+ cells, Arm A/B/C) was 11/52/271 (A vs. C, p = 0.028) for medians and 37/148/248 (A vs. C, p = 0.032) for means. T cell responses developed or increased in 20%/60%/100% of pts in Arms A/B/C. Seven of the 19 patients remain alive at a minimum 32 months from trial initiation, including three with unresectable disease.  
2	4019890	median and mean peak IFN-γ T cell response	The T cell response in this randomized phase I trial was dose-dependent with the 1 mg carcinoembryonic antigen peptide dose eliciting the most robust T cell responses.
1	3907426	Gd-enhancing lesions on T1-weighted images	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
1	3907426	New lesions on T2-weighted images	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
1	3907426	Grey and white matter volumes	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
1	3907426	Number of relapse-free patients	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
1	3907426	Total lesion volume	All secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of Gd-enhancing lesions on T1-weighted images, volume of grey and white matter, EDSS, MSFC, relapse rate, number of relapse-free patients and neutralizing antibodies did not show significant differences either.
2	5807031	Shoulder stiffness	There were no significant differences between the hypofractionated and control groups for patient- and physician-assessed symptoms in START-A or START-B. In START-pilot, adverse effect rates were higher after 13 fractions of 3.3 Gy, consistent with effects reported in the breast/chest wall (significant for shoulder stiffness, HR 3.07, 95%CI 1.62–5.83, p = 0.001).  
1	5807031	Physician assessed symptoms	There were no significant differences between the hypofractionated and control groups for patient- and physician-assessed symptoms in START-A or START-B. In START-pilot, adverse effect rates were higher after 13 fractions of 3.3 Gy, consistent with effects reported in the breast/chest wall (significant for shoulder stiffness, HR 3.07, 95%CI 1.62–5.83, p = 0.001).  
1	5807031	Patient assessed symptoms	There were no significant differences between the hypofractionated and control groups for patient- and physician-assessed symptoms in START-A or START-B. In START-pilot, adverse effect rates were higher after 13 fractions of 3.3 Gy, consistent with effects reported in the breast/chest wall (significant for shoulder stiffness, HR 3.07, 95%CI 1.62–5.83, p = 0.001).  
2	5031764	decrease in the levels of impulsivity and aggressiveness in experimental group	Results: Statistical analyses showed a significant decrease in the levels of impulsivity and aggressiveness in the experimental group compared with the control group.
1	5634356	Pain	No significant difference was noted between the two groups in pain score and number of analgesics taken (p> 0.05).
0	5976903	Opioid requirement	Opioid requirement was lower in the PECS II than in the control group (43.8 ± 28.5 μg versus 77.0 ± 41.9 μg, p < 0.001).
1	5976903	Rescue analgesics frequency	However, the frequency of rescue analgesics did not differ between these groups.
0	5976903	Axilary numeric rating scale	The axillary Numerical Rating Scale was consistently lower through 24 hr in the PECS II group.   
2	3307993	responder rate in the subgroup of patients with gastroenteritis or antibiotics prior to irritable bowel syndrome onset	Altogether, the responder rate was higher in the Escherichia coli Nissle 1917 than in the placebo group. However, only after 10 and 11 weeks, the differences were significant (Δ 20.0% points [95% CI 2.6; 37.4], p = 0.01 and Δ 18.3% points [95% CI 1.0; 35.7], p = 0.02, respectively). The best response was observed in the subgroup of patients with gastroenteritis or antibiotics prior to irritable bowel syndrome onset (Δ 45.7% points, p = 0.029).
2	3307993	responder rate in the subgroup of patients with gastroenteritis or antibiotics prior to irritable bowel syndrome onset	The best response was observed in the subgroup of patients with gastroenteritis or antibiotics prior to irritable bowel syndrome onset (Δ 45.7% points, p = 0.029).
1	5936036	drop-out rates	(1) There was no significant difference among the drop-out rates in the three groups.
1	3263888	AIGR0–30 during the 4-year follow-up	Lifestyle intervention resulted in higher insulin sensitivity (P = 0.02) and lower unadjusted AIGR0–30 (P = 0.08) during the 4-year follow-up.
1	2630316	Healing after 3 months	No differences in 3-month healing rates: clinic 58.3% compared to home care at 56.7% (p = 0.5) or in secondary outcomes.  
1	2759981	Experience of childbirth	There were no statistically significant differences in the experience of childbirth or parental stress between the randomised groups, either in women or men.
1	2759981	Epidural analgesia	The epidural rate was 52% in both groups.
1	2759981	Parental stress	There were no statistically significant differences in the experience of childbirth or parental stress between the randomised groups, either in women or men.
2	4160145	Dose-sparing for idiopathic short stature	growth hormone dosing titrated to an insulin-like growth factor-I target of 0 SDS was the most dose-sparing treatment regimen for GH deficiency or idiopathic short stature children (mean±SE ΔHSDS/GH dose ratios 48·1 ± 4·4 and 32·5 ± 2·8, respectively) compared with conventional dosing (30·3 ± 6·6 and 21·3 ± 3·5, respectively; P = 0·02, P = 0·005) and IGF2T (32·7 ± 4·8 and 16·3 ± 2·8, respectively; P = 0·02, P < 0·0001).
2	4160145	Dose-sparing for growth hormone deficiency	growth hormone dosing titrated to an insulin-like growth factor-I target of 0 SDS was the most dose-sparing treatment regimen for GH deficiency or idiopathic short stature children (mean±SE ΔHSDS/GH dose ratios 48·1 ± 4·4 and 32·5 ± 2·8, respectively) compared with conventional dosing (30·3 ± 6·6 and 21·3 ± 3·5, respectively; P = 0·02, P = 0·005) and IGF2T (32·7 ± 4·8 and 16·3 ± 2·8, respectively; P = 0·02, P < 0·0001).
2	4160145	Dose-sparing for idiopathic short stature	growth hormone dosing titrated to an insulin-like growth factor-I target of 0 SDS was the most dose-sparing treatment regimen for GH deficiency or idiopathic short stature children (mean±SE ΔHSDS/GH dose ratios 48·1 ± 4·4 and 32·5 ± 2·8, respectively) compared with conventional dosing (30·3 ± 6·6 and 21·3 ± 3·5, respectively; P = 0·02, P = 0·005) and IGF2T (32·7 ± 4·8 and 16·3 ± 2·8, respectively; P = 0·02, P < 0·0001).
1	5985784	serum alarmin levels	No significant difference was found in alarmin levels between the mixed laparoscopy group and LPT groups. interleukin-6 was higher in the laparoscopy group group on day 2 (p=0.03) and day 3 (p=0.04).
2	5985784	interleukin-6 on day 2 and day 3	interleukin-6 was higher in the laparoscopy group group on day 2 (p=0.03) and day 3 (p=0.04).
2	5985784	S100A8 protein on day 1 and day 2, and S100A12 protein on day 2 in thecancer subgroup	Significantly higher S100A8 protein levels on day 1 (p=0.02) and day 2 (p=0.01) and higher S100A12 protein levels on day 2 (p=0.03) were obtained in the laparoscopy group cancer subgroup.
2	4138551	The overbite	At T3, the Quad Pendulum group maintained greater increase in lower anterior facial height and molar extrusion and decrease in overbite than the Segmented Pendulum group.  
2	4232010	Mobilization-Observation-Behaviour-Intensity-Dementia-2 score improvement after 8 weeks	The stepwise protocol of treating pain conferred significant benefit in Mobilization-Observation-Behaviour-Intensity-Dementia-2 scores compared with the control group [average treatment effect (average treatment effect) −1.388; p < 0.001] at week 8, and Mobilization-Observation-Behaviour-Intensity-Dementia-2 scores worsened during the washout period (average treatment effect = −0.701; p = 0.022).
2	4232010	Mobilization-Observation-Behaviour-Intensity-Dementia-2 score improvement after 8 weeks	The stepwise protocol of treating pain conferred significant benefit in Mobilization-Observation-Behaviour-Intensity-Dementia-2 scores compared with the control group [average treatment effect (average treatment effect) −1.388; p < 0.001] at week 8, and Mobilization-Observation-Behaviour-Intensity-Dementia-2 scores worsened during the washout period (average treatment effect = −0.701; p = 0.022).
2	4232010	Daily activities	Although there were no overall improvements in activities of daily living, an increase was seen in the group receiving acetaminophen (average treatment effect = +1.0; p = 0.022).  
2	4302388	whole-blood Se concentration	After adjustment, whole-blood Se concentration was higher in women consuming Brazil nuts (P= 0·040) and in those consuming more than two seafood portions per week (P= 0·054).
0	4302388	developing pre-eclampsia and pregnancy-induced hypertension (pre-eclampsia and pregnancy-induced hypertension)	On excluding non-compliers with Se treatment, Se supplementation also significantly reduced the OR for pre-eclampsia and pregnancy-induced hypertension (OR 0·30, 95 % CI 0·09, 1·00, P= 0·049).
0	2829413	Levels of LDL cholesterol after 6 weeks of treatment	After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), low-density lipoprotein cholesterol (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.
0	2829413	Apolipoprotein-B levels after 6 weeks of treatment	After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), low-density lipoprotein cholesterol (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.
2	2829413	Patients attaining the NCEP ATP III goal	Overall, the percentage of patients attaining the NCEP ATP III goal was higher with rosuvastatin as compared to atorvastatin (87.64 vs. 69.88%, p < 0.001).
0	2829413	Levels of non-high-density lipoprotein cholesterol after 6 weeks of treatment	After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), low-density lipoprotein cholesterol (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.
1	2829413	Changes in glucose and insulin levels	Overall, the percentage of patients attaining the NCEP ATP III goal was higher with rosuvastatin as compared to atorvastatin (87.64 vs. 69.88%, p < 0.001). Changes in glucose and insulin levels, and homeostasis model assessment of insulin resistance index were not significantly different between the two groups.
0	2829413	Total cholesterol after 6 weeks of treatment	After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), low-density lipoprotein cholesterol (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.
1	5343624	Volume reduction	Radiographic analysis revealed a volume reduction of the initial augmented bone substitute material (i.e. 100%) to 77.36 (±11.68) % in the BO-group, respectively, 75.82 (±22.28) % in the NB-group six months after augmentation. In both materials, the volume reduction was not significant.
2	4311411	Overall Neuropathy Limitations Scale improvement	The highest dose (highest dose) showed consistent evidence of improvement beyond stabilization. Charcot-Marie-Tooth Neuropathy Score and Overall Neuropathy Limitations Scale, with a significant improvement of respectively of 8% (0.4% - 16.2%) and 12.1% (2% - 23.2%) in the highest dose group versus the pool of all other groups, appear to be the most sensitive clinical endpoints to treatment despite their quasi-stability over one year under Placebo.
1	2800200	numbers needed to treat (NNTs)	NNTs for etoricoxib, celecoxib and naproxen were stable over 2–12 weeks.
1	2800200	numbers needed to treat (NNTs)	NNTs for etoricoxib, celecoxib and naproxen were stable over 2–12 weeks.
1	2800200	numbers needed to treat (NNTs)	NNTs for etoricoxib, celecoxib and naproxen were stable over 2–12 weeks.
1	3430047	visual analog scale scores for 24 hr	In addition, no significant difference was found in visual analog scale scores at the three evaluated times (p < 0.05).  
1	3430047	mean pain scores at 8 and 24h	Although pain scores were significantly reduced at 16 hours after the first subpleural instillation of bupivacaine 0.5% with patient-controlled analgesia, comparison between mean pain scores in the two groups at 8 and 24 hours after the first subpleural instillation of bupivacaine 0.5% revealed no significant difference.
2	4738038	reduction of all signs and symptoms of chronic tonsillitis	Statistically significant effects (p < 0.05) in the reduction of all signs and symptoms of chronic tonsillitis after Kumarabharana Rasa treatment were observed.
1	5320759	intubation time	Among the cases of successful intubation, the intubation time was not significantly different between the two groups (P > 0.05).
1	5320759	success rate of intubation	The overall success rate of intubation was not significantly different between the two groups (P > 0.05).
2	5320759	the frequencies of dry throat, sore throat and hoarseness	The incidences of dry throat, sore throat, and hoarseness were higher in the T group (all P < 0.05).  
1	5320759	The intubation success rates at the first, second, and third attempt	The intubation success rates at the first, second, and third attempts as well as the average intubation times were similar between the two groups (P > 0.05), but in patients receiving successful intubation at the second attempt, the intubation time was longer in the T group (P = 0.0006).
2	5320759	The intubation time at the second attempt	The intubation success rates at the first, second, and third attempts as well as the average intubation times were similar between the two groups (P > 0.05), but in patients receiving successful intubation at the second attempt, the intubation time was longer in the T group (P = 0.0006).
0	4697245	Changes in diastolic blood pressure 1 minute after induction of anaesthesia	Changes in diastolic blood pressure were significantly less in alfentanil group, 1 min after induction of anaesthesia and 1 min after endotracheal intubation.
0	4697245	Changes in diastolic blood pressure 1 minute after endotracheal extubation	Changes in diastolic blood pressure were significantly less in alfentanil group, 1 min after induction of anaesthesia and 1 min after endotracheal intubation.
0	4697245	Heart rate at 1 minute after induction of anesthesia and intubation	Changes in diastolic blood pressure were significantly less in alfentanil group, 1 min after induction of anaesthesia and 1 min after endotracheal intubation. Mean heart rate at 1 min after induction and at 1 and 5 min after intubation also reduced significantly in this group.  
2	2613135	Cmax	Detailed analyses showed that Cmax of Eudorlin® extra was higher than that of Nurofen® forte (36.62 vs. 32.92 μg/ml; p = 0.0014) and that of Migränin® (35.94 vs. 30.87 μg/ml; p < 0.0001).
0	2613135	The time to maximum plasma concentration (tmax)	The time to maximum plasma concentration (tmax) was shorter with Eudorlin® extra than with Nurofen forte (1.14 vs. 1.82 h; p < 0.0001) and Migränin (1.13 vs. 1.78 h; p = 0.0031).
1	3090298	Corrected distance visual acuity at 6 months	Significant differences were not found between treatment groups in contrast sensitivity (P ≥ 0.156) or corrected distance visual acuity (P = 0.800) at postoperative 6 months.
1	3090298	Contrast sensitivity	Significant differences were not found between treatment groups in contrast sensitivity (P ≥ 0.156) or corrected distance visual acuity (P = 0.800) at postoperative 6 months.
1	3090298	1 line or more of corrected distance visual acuity at 6 months	Significant differences were not found between treatment groups in contrast sensitivity (P ≥ 0.156) or corrected distance visual acuity (P = 0.800) at postoperative 6 months.
1	5781260	Exercise-induced Creatine kinase (CK)	Creatine kinase and IL-6 didn't show significant discrimmination between groups.  
0	5781260	exercise-related loss of muscle strength	Compared to placebo, lemon verbena extract receiving participants had significantly less exercise-related loss of muscle strength (p = 0.0311) over all timepoints, improved glutathione peroxidase activity by trend (p = 0.0681) and less movement induced pain (p = 0.0788) by trend.
1	5781260	Interleukin 6	Creatine kinase and IL-6 didn't show significant discrimmination between groups.  
2	3786549	Improvement in Vaginal Maturation Index	The Controlled phase results for a change in Vaginal Maturation Index demonstrated superiority of the 0.03 mg estriol–lactobacilli combination to placebo (p < 0.001).
1	4064756	Induction to abortion	The median induction-to-abortion interval was shorter in sublingual group (12/72 hours in sublingual and 14/67 hours in vaginal). There was no significant difference in the success rate at 24 and 48 hours and in side effects.
1	4064756	Success rate at 24 hours	There was no significant difference in the success rate at 24 and 48 hours and in side effects.
1	4064756	Success rate at 48 hours	There was no significant difference in the success rate at 24 and 48 hours and in side effects.
0	5954168	long-term biochemical progression free survival (biochemical progression free survival)	A positive biopsy was prognostic of worse biochemical progression free survival, going forward, compared with negative and suspicious biopsies, hazard ratio (hazard ratio) = 4.81 (95% confidence interval [confidence interval]: 2.50–9.26, p < 0.001).
2	4033571	Overall seizure median percent improvement	Median percent reduction was -28.7% for placebo, −38.2% (P = 0.08 vs placebo) for once-daily SPN-804 1200 mg, and −42.9% (P = 0.003) for SPN-804 2400 mg.
2	4033571	Overall seizure median percent improvement	When data were analyzed separately for study site clusters, a post hoc analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006) in the North American study site cluster.
1	4033571	Overall seizure median percent reduction	Median percent reduction was -28.7% for placebo, −38.2% (P = 0.08 vs placebo) for once-daily SPN-804 1200 mg, and −42.9% (P = 0.003) for SPN-804 2400 mg.
2	4033571	Seizure median percent improvement in North America	When data were analyzed separately for study site clusters, a post hoc analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006) in the North American study site cluster.
2	4033571	Seizure median percent improvement in North America	When data were analyzed separately for study site clusters, a post hoc analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006) in the North American study site cluster.
2	5633234	maintenance stage of smoking cessation	Within six months of follow-up, 20 persons (40%) of the intervention group reached the maintenance stage of smoking cessation, while no one from controls managed to do that.
0	5560591	Total need of morphine	Similarly, total morphine requirement was significantly lower in the Electroacupuncture group with the value of 21.38 (SD = 14.38) mg compared to the control group with the value of 33.94 (SD = 20.24) mg within 24 hours postoperatively.
0	5560591	Mean patient-controlled analgesia morphine demand	The mean PCA morphine demand was 27.28 (SD = 21.61) times pressed in the Electroacupuncture group and 55.25 (SD = 46.85) times pressed in the control group within 24 hours postoperatively, which showed a significant reduction in the Electroacupuncture group than the control group.
0	5560591	Incidence of nausea 30 min after surgery	Incidence of postoperative nausea also significantly reduced in the Electroacupuncture group at 30 minutes (15.6%) compared to the control group (46.9%).  
0	5560591	Postoperative numerical rating scale at 30 min and 2 hours	The mean numerical rating scale was 2.75 (SD = 2.34) at 30 minutes and 2.25 (SD = 1.80) at 2 hours postoperatively in the Electroacupuncture group that was significantly lower than the mean numerical rating scale in the control group as 4.50 (SD = 2.37) at 30 minutes and 3.88 (SD = 2.21) at 2 hours.
2	5976501	self-perception of effort spent	Next, we found that the intake of 5-aminolevulinic acid was significantly associated with improved coping ability (p = 0.004) and improved self-perception of effort spent (p = 0.002).
2	5976501	coping ability	In conclusion, after 12 weeks of taking 5-aminolevulinic acid, we found significant improvements in self-perception of effort spent, loneliness, and coping ability in prediabetic middle age and older adults.
2	5976501	coping ability	Next, we found that the intake of 5-aminolevulinic acid was significantly associated with improved coping ability (p = 0.004) and improved self-perception of effort spent (p = 0.002).
0	4880652	SpO2 at 5 minutes	In the fentanyl group, systolic blood pressures at 5, 10, 15, 20 minutes and diastolic blood pressure at 5 minutes and oxygen saturation at 5 minutes were significantly lower (p<0.05).  
1	4880652	the modified Aldrete scores at 60 minutes, systolic pressures at 0 minutes, oxygen saturation at 10, 15, 20 minutes, diastolic blood pressure at 10, 15, 20 minutes, heart rates, and visual analogue scores	When the modified Aldrete scores at 60 minutes, systolic pressures at 0 minutes, oxygen saturation at 10, 15, 20 minutes, diastolic blood pressure at 10, 15, 20 minutes, heart rates, and visual analogue scores were compared, there was no significant difference between groups (p>0.05).
0	4880652	systolic blood pressures at 5, 10, 15, and 20 minutes	In the fentanyl group, systolic blood pressures at 5, 10, 15, 20 minutes and diastolic blood pressure at 5 minutes and oxygen saturation at 5 minutes were significantly lower (p<0.05).  
0	4880652	Diastolic blood pressures at 5 minutes	In the fentanyl group, systolic blood pressures at 5, 10, 15, 20 minutes and diastolic blood pressure at 5 minutes and oxygen saturation at 5 minutes were significantly lower (p<0.05).  
1	5529957	Improvement of cardiac index in persistent/recurrent patients	Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6 L/min/m2 (95% CI 0.4 to 0.7; p<0.0001), while in persistent/recurrent patients the change was +0.2 L/min/m2 (95% CI −0.1 to 0.5; p=0.17).
0	5529957	Pulmonary vascular resistance	Riociguat decreased pulmonary vascular resistance (pulmonary vascular resistance) in inoperable (n=189; least-squares mean difference: −285 dyn s/cm5 (95% CI −357 to −213); p<0.0001) and persistent/recurrent (n=72; −131 dyn s/cm5 (95% CI −214 to −48); p=0.0025) patients.
0	5529957	Mean pulmonary artery pressure	Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(−4.7 mm Hg (95% CI −6.9 to −2.6; p<0.0001 and −4.8 mm Hg (–8.2 to −1.5; p=0.0055), respectively).
2	5529957	Improvement of cardiac index in inoperable patients	Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6 L/min/m2 (95% CI 0.4 to 0.7; p<0.0001), while in persistent/recurrent patients the change was +0.2 L/min/m2 (95% CI −0.1 to 0.5; p=0.17).
2	5856907	Test scores	The differences between pre- and post-test mean scores of the experimental and control groups were 24.53±5.74 and 20.63±5.58, respectively. The results of independent t-test showed that these differences in the two groups were significant (p=0.009).
1	4026558	Blood pressure	After 3 months, there were no significant changes in blood pressure or heart rate in both groups.
1	4026558	Heart rate	After 3 months, there were no significant changes in blood pressure or heart rate in both groups.
0	3210361	accuracy in the timing task	Critically, ketamine also impaired accuracy on the perceptual timing task while having no effect on performance of the colour perception task.
1	3210361	colour task	Critically, ketamine also impaired accuracy on the perceptual timing task while having no effect on performance of the colour perception task.
2	3877023	quantitative contour sharpness	Regarding all sequences, the relative differences were 39% for the mean overall qualitative image quality, 53% for the mean SNR values, and 34–37% for the quantitative contour sharpness (P<0.0001).
2	3877023	contrast-to-noise ratios (contrast-to-noise ratios)	The contrast-to-noise ratios values were also higher for images obtained with the short-bore magnetic resonance scanner.
2	3877023	Scanning times	Scanning times were significantly longer for examinations performed on the open magnetic resonance scanner (mean: 32±22 min versus 20±9 min; P<0.0001).  
1	4731528	Cytotoxicity	Cytotoxicity of the four materials was not significantly different from that of the control group at 24, 48 and 168 h (P>0.05).
1	4731528	Cytotoxicity	Cytotoxicity of the four materials was not significantly different from that of the control group at 24, 48 and 168 h (P>0.05).
1	4731528	Cytotoxicity	Cytotoxicity of the four materials was not significantly different from that of the control group at 24, 48 and 168 h (P>0.05).
1	4731528	Cytotoxicity	Cytotoxicity of the four materials was not significantly different from that of the control group at 24, 48 and 168 h (P>0.05).
2	3590739	Whole blood total antioxidant capacity	Results of the present study has shown that the total antioxidant capacity in whole blood in patients with periodontitis was significantly (P<0.005) lower than in control subjects.
2	3590739	Whole blood total antioxidant capacity	The study was conducted on 30 non-smoking volunteers with age ranging between 18-40 years. They were categorized into two groups; chronic periodontitis group and healthy group, respectively.
1	5559992	Anxiety	The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).  
1	5559992	Anxiety	The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).  
0	5559992	Anxiety	The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).  
0	5559992	Anxiety	The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).  
0	5559992	Anxiety	The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).  
1	5559992	Anxiety	The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).  
1	4282128	smoking cessation	Abstinence rates for bupropion (27.9%) and nicotine replacement therapy (24.2%) were not significantly different (odds ratio = 1.21, 95% confidence interval = 0.883–1.67), and the combination rate (24.2%) was similar to that for either treatment alone.
1	4282128	smoking cessation	Abstinence rates for bupropion (27.9%) and nicotine replacement therapy (24.2%) were not significantly different (odds ratio = 1.21, 95% confidence interval = 0.883–1.67), and the combination rate (24.2%) was similar to that for either treatment alone.
1	4282128	smoking cessation	There is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy and their combination when used with behavioural support in clinical practice.
1	4282128	smoking cessation	There is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy and their combination when used with behavioural support in clinical practice.
0	5754420	GLUT-4 expression	Muscle CS maximal activity increased (P < 0.05) by 18% in speed endurance training only, demonstrating larger (P < 0.05) improvement than small-sided game group, while HAD activity increased (P < 0.05) by 24% in both groups. Na+–K+ ATPase α1 subunit protein expression increased (P < 0.05) in speed endurance training and small-sided game group (19 and 37%, respectively), while MCT4 protein expression rose (P < 0.05) by 30 and 61% in speed endurance training and small-sided game group, respectively. SOD2 protein expression increased (P < 0.05) by 28 and 37% in speed endurance training and small-sided game group, respectively, while GLUT-4 protein expression increased (P < 0.05) by 40% in small-sided game group only.
2	5754420	Citrate synthase maximal activity	Muscle CS maximal activity increased (P < 0.05) by 18% in speed endurance training only, demonstrating larger (P < 0.05) improvement than small-sided game group, while HAD activity increased (P < 0.05) by 24% in both groups.
1	4839526	8 in the digit symbol substitution test (digit symbol substitution test)	Duloxetine was not significantly different from placebo on the digit symbol substitution test or UPSA, but was superior to placebo on the perceived deficits questionnaire, CGI-I, and MADRS.
2	4839526	8 in the digit symbol substitution test (digit symbol substitution test)	Vortioxetine was statistically superior to placebo on the digit symbol substitution test (P<0.05), perceived deficits questionnaire (P<0.01), CGI-I (P<0.001), MADRS (P<0.05), and UPSA (P<0.001).
1	4731690	hyperdense artery sign shrinkage and alteplase effect	There was no significant difference in hyperdense artery sign shrinkage with alteplase in proximal (vs distal) or more (vs less) extensive hyperdense artery sign (p = 0.516 and p = 0.580, respectively).
1	4731690	hyperdense artery sign shrinkage and alteplase effect	There was no significant difference in hyperdense artery sign shrinkage with alteplase in proximal (vs distal) or more (vs less) extensive hyperdense artery sign (p = 0.516 and p = 0.580, respectively).
2	4731690	6-month outcome (Oxford Handicap Scale [Oxford Handicap Scale])	ABSTRACT.RESULTS:. hyperdense artery sign presence (vs absence) independently predicted poor 6-month outcome (increased Oxford Handicap Scale [Oxford Handicap Scale]) on adjusted ordinal regression analysis (odds ratio [odds ratio] 0.66, p < 0.001). Outcome was worse in patients with more (vs less) extensive hyperdense artery sign (odds ratio 0.61, p = 0.027) but not in proximal (vs distal) hyperdense artery sign (p = 0.420).
1	4731690	6-month outcome (Oxford Handicap Scale [Oxford Handicap Scale])	Outcome was worse in patients with more (vs less) extensive hyperdense artery sign (odds ratio 0.61, p = 0.027) but not in proximal (vs distal) hyperdense artery sign (p = 0.420).
1	4284010	Snapshot response	There was no evidence of a difference in snapshot response between abacavir/lamivudine (ABC/3TC) and tenofovir/emtricitabine (TDF/FTC) overall [ABC/3TC 86%, TDF/FTC 85%, difference 1.1%, confidence interval (confidence interval) −1.8, 4.0 percentage points, P = 0.61] or at high viral loads (difference −2.5, 95% confidence interval −8.9, 3.8 percentage points, P = 0.42).  
1	4284010	High viral loads	There was no evidence of a difference in snapshot response between abacavir/lamivudine (ABC/3TC) and tenofovir/emtricitabine (TDF/FTC) overall [ABC/3TC 86%, TDF/FTC 85%, difference 1.1%, confidence interval (confidence interval) −1.8, 4.0 percentage points, P = 0.61] or at high viral loads (difference −2.5, 95% confidence interval −8.9, 3.8 percentage points, P = 0.42).  
2	4173437	Postoperatively hematocrit	Postoperatively hematocrit values were higher in the tranexamic acid group.
1	4173437	Complications	No complications or adverse effects were reported in the either group.  
1	4173437	Adverse effects	No complications or adverse effects were reported in the either group.  
0	4173437	Total blood loss	The tranexamic acid significantly reduced the quantity of total blood loss, 576 ± 53 mL in study group as compared to 823 ± 74 mL in the control group (P<0.01).
1	4173437	Coagulation profile	The coagulation profile did not differ between the groups, but D-dimer concentrations were increased in the control group.
2	5051624	Estimated median procedure time	Estimated median procedure time was 228 seconds in the conventional training group and 75 seconds in the simulator training group, with statistical significance (P=0.040).
1	5051624	The difficulty grading	The difficulty grading did not show any significant difference among groups (overall performance scale, 2 vs. 3; P=0.094).  
2	5579675	fatty acid oxidation (fatty acid oxidation)	Combining Yerba Maté intake with prolonged exercise at targeted "fat-loss"' intensities augments fatty acid oxidation and improves measures of satiety and mood state.
0	5579675	Hunger, Prospective eating, desire to eat (Pre, immediately before, after, and 30 min post exercise).	VAS scores for hunger, prospective eating, and desire to eat were all reduced (p < 0.05).
0	5579675	prospective eating score	VAS scores for hunger, prospective eating, and desire to eat were all reduced (p < 0.05).
2	2848004	FEV1 after one dose	Trough FEV1 after one dose was significantly higher with indacaterol than placebo (p < 0.001).
2	2848004	Standardised AUC measurements for FEV1 at Week 12	Standardised AUC measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.
2	2848004	forced expiratory volume in 1 s (FEV1) at Week 12	Trough FEV1 (LSM ± SEM) at Week 12 was 1.48 ± 0.018 L for indacaterol and 1.35 ± 0.019 L for placebo, a clinically relevant difference of 130 ± 24 mL (p < 0.001).
1	2848004	The overall rate of adverse events (ASs)	The overall rates of adverse events were comparable between the groups (indacaterol 49.3%, placebo 46.8%), with the most common adverse events being chronic obstructive pulmonary disease worsening (indacaterol 8.5%, placebo 12.2%) and cough (indacaterol 6.2%, placebo 7.3%).
0	3407716	mean fluid accumulation on day 2	There was significantly less mean fluid accumulated in the drain group on both day 1, 16.4 versus 25.1 ml (P-value = 0.005), and day 2, 18.4 versus 25.7 ml (P-value = 0.026), following surgery.
1	3407716	infections	There were four versus one wound infections in the drain versus no-drain groups. This finding was not statistically significant (P = 0.154).
0	3407716	mean fluid accumulation on day 1	There was significantly less mean fluid accumulated in the drain group on both day 1, 16.4 versus 25.1 ml (P-value = 0.005), and day 2, 18.4 versus 25.7 ml (P-value = 0.026), following surgery.
1	5493377	Pain	Pain reduced in both groups following treatment (active tDCS+exercise: p<0.001, partial η2 = 0.55; sham tDCS+exercise: p = 0.026, partial η2 = 0.18) but no between-group differences were observed (p = 0.18, partial η2 = 0.08).
2	5493377	Pressure pain thresholds improvement	active tDCS+exercise produced greater improvements in pressure pain thresholds than sham tDCS+exercise (p<0.05) (superolateral knee: partial η2 = 0.17; superior knee: partial η2 = 0.3; superomedial knee: partial η2 = 0.26).
1	5493377	Conditioned pain modulation	conditioned pain modulation only improved in the active tDCS+exercise group but no between-group difference was observed (p = 0.054, partial η2 = 0.158).
1	5493377	Function	Function improved in the active tDCS+exercise (p = 0.01, partial η2 = 0.22), but not the sham tDCS+exercise (p = 0.16, partial η2 = 0.08) group, between-group differences did not reach significance (p = 0.28, partial η2 = 0.052).
0	4845428	levels of decompression	The levels of decompression determined by magnetic resonance imaging + (paraspinal mapping or diffusion tensor imaging) in the experimental group were significantly less than that determined by magnetic resonance imaging + neurogenic examination in the control group (p = 0.000).
0	4845428	surgical time, blood loss, and surgical transfusion	The surgical time, blood loss, and surgical transfusion were significantly less in the experimental group (p = 0.001, p = 0.011, p = 0.001, respectively).
1	4845428	the visual analog scale back and leg pain (VAS-BP, VAS-LP) scores and Oswestry Disability Index (Oswestry Disability Index) scores at 2 weeks, 3 months, 6 months, and 12 months after operation	There were no differences in improvement of the visual analog scale back and leg pain (VAS-BP, VAS-LP) scores and Oswestry Disability Index (Oswestry Disability Index) scores at 2 weeks, 3 months, 6 months, and 12 months after operation between the experimental and control groups.  
1	3187863	Postpartum haemorrhage	There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.
1	3187863	Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth	There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.
0	3854508	Pain	The reported pain for all orthoses was lower than that of the placebo (P < 0.05).
0	3854508	Pain	The reported pain for all orthoses was lower than that of the placebo (P < 0.05).
1	3854508	Pain	There was no significant difference between a counterforce elbow band and a counterforce elbow sleeve (P = 0.23).
0	3854508	Pain	Pain reduction was significantly greater with a counterforce elbow band or a counterforce elbow sleeve compared to a wrist splint (P < 0.01).
0	3854508	Pain	The reported pain for all orthoses was lower than that of the placebo (P < 0.05). Pain reduction was significantly greater with a counterforce elbow band or a counterforce elbow sleeve compared to a wrist splint (P < 0.01).
0	3854508	Pain	Pain reduction was significantly greater with a counterforce elbow band or a counterforce elbow sleeve compared to a wrist splint (P < 0.01).
2	2671648	percentage of pregnant women who quitted smoking	The percentage of pregnant women who quitted smoking during the project was 46.1% in the intervention group and 23.4% among the controls (p < 0.001).
2	2671648	reduce smoking rate	In the intervention group, among the subjects who did not manage to quit smoking during pregnancy, the number of women who at least slightly reduced their smoking rate was twice as high as in the controls.
2	5015408	Probability for adequate oral anticoagulants prescription	Although the CHA 2 DS 2‐VASc score module was used in only 48 (10.5%) patients from the alert group, 100 (22.0%) patients from the alert group versus 69 (15.9%) from the control group received adequate oral anticoagulants prescription (relative risk 1.38; P=0.021).
0	3580622	Pleural opacity	The mean (± SD) change in pleural opacity was greater in the t-PA-DNase group than in the placebo group (-29.5 ± 23.3% vs. -17.2 ± 19.6%; difference, -7.9%; 95% confidence interval [confidence interval], -13.4 to -2.4; P = 0.005).
2	3580622	Surgical referral at 3 months	The frequency of surgical referral at 3 months was lower in the t-PA-DNase group than in the placebo group (2 of 48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for surgical referral, 0.17; 95% confidence interval, 0.03 to 0.87; P = 0.03) but was greater in the DNase group (18 of 46 patients [39%]) than in the placebo group (odds ratio, 3.56; 95% confidence interval, 1.30 to 9.75; P = 0.01).
0	3580622	Hospital stay	Combined t-PA-DNase therapy was associated with a reduction in the hospital stay, as compared with placebo (difference, -6.7 days; 95% confidence interval, -12.0 to -1.9; P = 0.006).
1	3580622	Pleural opacity	The change observed with tissue plasminogen activator alone and with DNase alone (-17.2 ± 24.3 and -14.7 ± 16.4%, respectively) was not significantly different from that observed with placebo.
0	3580622	Surgical referral at 3 months	The frequency of surgical referral at 3 months was lower in the t-PA-DNase group than in the placebo group (2 of 48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for surgical referral, 0.17; 95% confidence interval, 0.03 to 0.87; P = 0.03) but was greater in the DNase group (18 of 46 patients [39%]) than in the placebo group (odds ratio, 3.56; 95% confidence interval, 1.30 to 9.75; P = 0.01).
0	4006208	Plaque levels	There was a significant reduction on plaque in Aloe vera and chlorhexidine groups and no statistically significant difference was observed among them (p>0.05).
1	4006208	Plaque levels	There was a significant reduction on plaque in Aloe vera and chlorhexidine groups and no statistically significant difference was observed among them (p>0.05).
0	3963555	recurrent episodes of bronchiolitis in the first year	Infants born to mothers from the FeNO group were significantly less likely to have recurrent episodes of bronchiolitis in the first year of life (OR 0.08, 95% CI 0.01 to 0.62; p=0.016) as compared with the clinical group.  
1	4900317	Wound infection incidence	During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 ± 0.94 mg vs. 18.83 ± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 ± 10 min vs. 195 ± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in Intensive Care Unit or hospital stay duration.
0	4900317	Need of morphine during 48 hours after surgery	During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 ± 0.94 mg vs. 18.83 ± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 ± 10 min vs. 195 ± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in Intensive Care Unit or hospital stay duration.
0	4900317	Extubation time	During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 ± 0.94 mg vs. 18.83 ± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 ± 10 min vs. 195 ± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in Intensive Care Unit or hospital stay duration.
1	4525010	Severity of illness	Oseltamivir treatment did not reduce illness duration, severity, or duration of virus detection.
1	4525010	Duration of virus detection	Oseltamivir treatment did not reduce illness duration, severity, or duration of virus detection.
2	4776564	Quality of life score regarding satisfaction	The mean (standard deviation) overall quality of life score in the area of satisfaction significantly increased in the study group, compared to the controls, immediately [70.7 (8.5) vs. 59.2 (12.5)] and 1 month after the intervention [75.2 (7.4) vs. 59.4 (12.9)] (P < 0.05).
2	4776564	Quality of life score regarding importance	The mean (standard deviation) overall quality of life score in the area of satisfaction significantly increased in the study group, compared to the controls, immediately [70.7 (8.5) vs. 59.2 (12.5)] and 1 month after the intervention [75.2 (7.4) vs. 59.4 (12.9)] (P < 0.05). There was also a similar difference between the two groups in the area of importance immediately [73.6 (5.8) vs. 65.7 (7.5)] and 1 month after the intervention [76.3 (8.1) vs. 66.8 (8.5)] (P < 0.05).  
1	5139733	Frequency of bowel movements	There was no significant change in frequency of bowel movements or the dose of sennoside used.
0	5139733	Gas volume	The gas volume score was significantly decreased after the addition of TJ-100 (P < 0.05).  
2	5139733	Abdominal pain improvement	The addition of TJ-100 to sennoside resulted in significant improvement in bloating (P < 0.01) and abdominal pain (P < 0.05).
1	5139733	Sennoside needed	There was no significant change in frequency of bowel movements or the dose of sennoside used.
2	3387601	negative correlation between cerebrospinal fluid protein and duration of mechanical ventilation	There was a negative correlation between cerebrospinal fluid protein and duration of mechanical ventilation in the plasma exchange group (p = 0.037), but not in the intravenous immunoglobulin group (p = 0.132).  
1	3387601	Pediatric Intensive Care Unit (Pediatric Intensive Care Unit) stay	Those in the plasma exchange group had a tendency for a shorter Pediatric Intensive Care Unit (Pediatric Intensive Care Unit) stay (p = 0.094).  
0	3387601	Period of mechanical ventilation	Children in the plasma exchange group had a shorter period of mechanical ventilation (median 11 days, IQR 11.0 to 13.0) compared to intravenous immunoglobulin group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.  
1	3387601	could walk unaided within four weeks after Pediatric Intensive Care Unit discharge	A total of 20/21 (95.2%) and 18/20 (90%) children in the plasma exchange and intravenous immunoglobulin groups respectively could walk unaided within four weeks after Pediatric Intensive Care Unit discharge (p = 0.606).  
1	4317856	Median progression-free survival	In an efficacy analysis of 94 patients (DZ, 48; D, 46), the median progression-free survival was 2.7 months (95% confidence interval [confidence interval], 1.5–3.5 months) for the DZ group and 2.6 months (95% confidence interval, 1.5–3.4 months) for the D group (stratified log-rank test, P = 0.89).
1	4317856	Median overall survival	The median overall survival was 10.4 months (95% confidence interval, 7.0–15.8 months) for the DZ group and 9.7 months (95% confidence interval, 6.1–12.5 months) for the D group (stratified log-rank test, P = 0.62).
1	4317856	Grade 3 or 4 adverse events	There were no clinically relevant differences in the frequencies of grade 3 or 4 adverse events between the two groups.
0	5712123	postoperative pain	Neither Duloxetine nor etoricoxib individually had effect on pain with movement, while their combination revealed a significant reduction in pain scores over the entire postoperative period at rest and on movement.
0	5712123	morphine requirements	Etoricoxib showed a significant decrease in pain at all times at rest when compared with group P, while it showed significant pain decrease only at 0, 2 and 4 h when compared with group D. On the other hand duloxetine alone showed significant decrease in pain at rest at 24 h and 48 h when compared with group P. ConcerningMorphine requirement after 24 h.; it wassignificantly lower in the D/E group in comparison with groups P, E and D. It should be noted also that there was a significant decrease morphine requirement in both groups E and D.  ABSTRACT.CONCLUSION. 
1	5762965	Bone alkaline phosphatase	No differences were observed in bone turnover biomarkers and bone mineral density.
2	5756602	nursing satisfaction scores	The 28 d neonatal behavioral neurological assessment and nursing satisfaction scores in the observation group were higher than those in the control group, and the differences were statistically significant (P=0.017 and 0.008, respectively).  
2	5756602	total effective rate	The total effective rate in the observation group was increased and mortality was decreased, and the differences were statistically significant (P=0.029 and 0.033, respectively).
0	5756602	mortality	The total effective rate in the observation group was increased and mortality was decreased, and the differences were statistically significant (P=0.029 and 0.033, respectively).
2	5756602	28 d neonatal behavioral neurological assessment (NBNA)	The 28 d neonatal behavioral neurological assessment and nursing satisfaction scores in the observation group were higher than those in the control group, and the differences were statistically significant (P=0.017 and 0.008, respectively).  
0	2689169	Severity of dental compression	Both the Glidescope® and the AWS® performed better than the Macintosh, and demonstrate considerable promise in this context. The AWS® had the least number of dental compressions in all three scenarios, and in the cervical spine immobilization scenario it required fewer maneuvers to optimize the view of the glottis.  
2	5002324	the limits of stability (limits of stability) performance and one-leg stance (one-leg stance) tests	After training, participants in the balance-based exergaming group showed significant improvements in limits of stability performance, and in the eyes-closed condition of the one-leg stance test.
2	5002324	directional control in the limits of stability test	Furthermore, balance-based exergaming training resulted in significantly better performance in directional control in the limits of stability test (78.9 ± 7.65 %) compared with conventional balance training (70.6 ± 9.37 %).  
1	3278655	maximum total point motion (maximum total point motion)	maximum total point motion values were similar in the 2 groups (p = 0.9).
2	3278655	subsidence	The tibial monoblock component components had significantly greater subsidence than the cemented components (p = 0.001).
1	3278655	The proportion of "at risk" components at 5 years	The proportion of "at risk" components at 5 years was 2 of 18 in the cemented group and 0 of 27 in the tibial monoblock component group (p = 0.2).  
2	3972107	VO2peak	In the training group, VO2peak was significantly increased, and carotid β-stiffness was significantly decreased, after the intervention (P<0.05).
2	3972107	Plasma apelin	Moreover, plasma apelin and NOx levels were significantly increased in the training group after the intervention (P<0.05).
0	3972107	Carotid β-stiffness	Before and after the intervention, we evaluated plasma apelin and nitrite/nitrate (NOx) concentrations, VO2peak, and arterial stiffness index. In the training group, VO2peak was significantly increased, and carotid β-stiffness was significantly decreased, after the intervention (P<0.05).
2	3972107	Nitrite/nitrate (NOx) concentrations	Moreover, plasma apelin and NOx levels were significantly increased in the training group after the intervention (P<0.05).
1	5223669	low-density lipoprotein measured by longitudinal data analysis	The less efficient, longitudinal data analysis analysis yielded an low-density lipoprotein improvement of 7.2 mg/dL (95% CI −17.2 to 2.8; p=0.15) for Group Medical Clinics compared with usual care.  
0	5223669	low-density lipoprotein value measured by analysis of covariance and 'Constrained' longitudinal data analysis	With complete data (n=195), 95% CI coverage are equivalent for analysis of covariance and 'Constrained' longitudinal data analysis with an estimated 11.2 mg/dL (95% CI −19.2 to −3.3; p=0.006) lower mean low-density lipoprotein (low-density lipoprotein) cholesterol in Group Medical Clinics compared with usual care.
0	5223669	low-density lipoprotein value measured by analysis of covariance and 'Constrained' longitudinal data analysis	With all available data (n=233), applying the 'Constrained' longitudinal data analysis model yielded an low-density lipoprotein improvement of 8.9 mg/dL (95% CI −16.7 to −1.0; p=0.03) for Group Medical Clinics compared with usual care.
2	5119624	overall response rate (overall response rate)	overall response rate was also higher in the talimogene laherparepvec arm (40.5% versus 2.3%; P<0.0001), and 27 patients in the talimogene laherparepvec arm had a complete response, compared with none in GM-CSF-treated patients.
2	5119624	durable response rate (durable response rate)	Among 249 evaluated patients with stage IIIB–IVM1a melanoma, durable response rate was higher with talimogene laherparepvec compared with granulocyte-macrophage colony-stimulating factor (25.2% versus 1.2%; P<0.0001).
2	2778511	Patients preferense	Patients preferred 'opt-out plus' (43%) above 'one-time consent' (34%) or 'opt-out' (16%), whereas 8% indicated that they did not need to receive information about research with residual tissues or be given the opportunity to make a choice.  
0	3302141	BMI standard deviation score	An intervention effect after 1 year was found for adiposity (P=0.02 for body mass index-standard deviation score, P=0.03 for waist circumference (WC)-SDS), physical fitness (absolute measured peak value of oxygen uptake (ml min−1), standardized for age and gender (VO2peak-SDS), P<0.01) and insulin resistance (HOMA-SDS, P=0.04).
2	3302141	Physical fitness	An intervention effect after 1 year was found for adiposity (P=0.02 for body mass index-standard deviation score, P=0.03 for waist circumference (WC)-SDS), physical fitness (absolute measured peak value of oxygen uptake (ml min−1), standardized for age and gender (VO2peak-SDS), P<0.01) and insulin resistance (HOMA-SDS, P=0.04).
0	3302141	Insulin resistance	An intervention effect after 1 year was found for adiposity (P=0.02 for body mass index-standard deviation score, P=0.03 for waist circumference (WC)-SDS), physical fitness (absolute measured peak value of oxygen uptake (ml min−1), standardized for age and gender (VO2peak-SDS), P<0.01) and insulin resistance (HOMA-SDS, P=0.04).
1	3302141	Lipid profile	No significant intervention effect was found for serum lipid profile, high-sensitive C-reactive protein or for adiponectin.
1	3302141	High-sensitive C-reactive protein	No significant intervention effect was found for serum lipid profile, high-sensitive C-reactive protein or for adiponectin.
0	3302141	Waist circumference	An intervention effect after 1 year was found for adiposity (P=0.02 for body mass index-standard deviation score, P=0.03 for waist circumference (WC)-SDS), physical fitness (absolute measured peak value of oxygen uptake (ml min−1), standardized for age and gender (VO2peak-SDS), P<0.01) and insulin resistance (HOMA-SDS, P=0.04).
0	4624894	anemia rates - patients with chronic hepatitis C with hepatitis C virus genotype 6	More patients in the 48-week group had anemia (46.1% vs. 28.9%, P = 0.03), but other adverse events were comparable between the groups.
2	3343759	improvment in Amsterdam-Nijmegen everyday language test by day 21	Patients with a higher level of education (>12 years) improved more on Amsterdam-Nijmegen everyday language test by day 21 than those with <12 years of education (3.4 vs. 1.0, respectively).
1	3343759	communication ability	Very early intensive speech and language therapy with the Language Enrichment Therapy program over 21 days had no effect on the degree of aphasia in unselected acute aphasic stroke patients.
2	5771357	wall motion score - patients undergoing coronary artery bypass graft / coronary endarterectomy	However, wall mrotion score was significantly better in clopidogrel – aspirin patients in late (3 months) post operation (p<0.001).  
2	5771357	wall motion score - patients undergoing coronary artery bypass graft / coronary endarterectomy	Since warfarin has serious hemorrhagic complications and requires closed monitoring of serum drug activity by serial INR checking, it is recommended that clopidogrel – aspirin can be the preferred alternative anticoagulation therapy in coronary artery bypass graft / coronary endarterectomy patients.
2	4893099	ACR20 response rate	Peficitinib 50, 100 and 150 mg each showed statistically significantly higher ACR20 response rates compared with placebo, and response rates increased up to 150 mg with a statistically significant dose response.
1	4893099	Treatment-emergent adverse events	The total incidence of treatment-emergent adverse events (treatment-emergent adverse events) was similar between the placebo (64.3%) and peficitinib 25, 50, 100 and 150 mg groups (70.9%, 64.9%, 52.7% and 67.2%, respectively).
2	4893099	ACR20 response rate	Peficitinib 50, 100 and 150 mg each showed statistically significantly higher ACR20 response rates compared with placebo, and response rates increased up to 150 mg with a statistically significant dose response.
1	4893099	Treatment-emergent adverse events	The total incidence of treatment-emergent adverse events (treatment-emergent adverse events) was similar between the placebo (64.3%) and peficitinib 25, 50, 100 and 150 mg groups (70.9%, 64.9%, 52.7% and 67.2%, respectively).
2	4893099	ACR20 response rate	Peficitinib 50, 100 and 150 mg each showed statistically significantly higher ACR20 response rates compared with placebo, and response rates increased up to 150 mg with a statistically significant dose response.
1	4893099	Treatment-emergent adverse events	The total incidence of treatment-emergent adverse events (treatment-emergent adverse events) was similar between the placebo (64.3%) and peficitinib 25, 50, 100 and 150 mg groups (70.9%, 64.9%, 52.7% and 67.2%, respectively).
2	5721363	function without baseline	In covariate-adjusted models without accounting for baseline physical function, every 1-unit (Nm/kg) increase in knee extensor strength was associated with physical function improvement of 17 WOMAC units (95% confidence interval (confidence interval) −29 to −5).
2	3266642	Haemoglobin	multivitamins and minerals powder supplementation resulted in significant improvements in haemoglobin concentration and in the reduction of anaemia prevalence in the two treatment groups compared with the control group (p <0.001).
2	3266642	Haemoglobin	multivitamins and minerals powder supplementation resulted in significant improvements in haemoglobin concentration and in the reduction of anaemia prevalence in the two treatment groups compared with the control group (p <0.001).
0	3266642	Anaemia prevalence	multivitamins and minerals powder supplementation resulted in significant improvements in haemoglobin concentration and in the reduction of anaemia prevalence in the two treatment groups compared with the control group (p <0.001).
0	3266642	Anaemia prevalence	multivitamins and minerals powder supplementation resulted in significant improvements in haemoglobin concentration and in the reduction of anaemia prevalence in the two treatment groups compared with the control group (p <0.001).
1	4355443	Time to progression	Median progression-free survival (progression-free survival) was 180 days for Selective Internal Radiotherapy versus 216 days for TACE patients (p = 0.6193) with a median TTP of 371 days versus 336 days, respectively (p = 0.5764).
1	4355443	Overall survival	Median OS was 592 days for Selective Internal Radiotherapy versus 788 days for TACE patients (p = 0.9271).
1	4355443	Progression-free survival	Median progression-free survival (progression-free survival) was 180 days for Selective Internal Radiotherapy versus 216 days for TACE patients (p = 0.6193) with a median TTP of 371 days versus 336 days, respectively (p = 0.5764).
0	4834398	Somatic anxiety	The results of ANOVA on posttest scores showed that acupuncture had a significant effect on cognitive anxiety (p = 0.001) and somatic anxiety (p < 0.001) but not on self-confidence (p > 0.05).
0	4834398	Somatic anxiety	In conclusion, the results suggested that acupuncture has the capacity to decrease cognitive anxiety and somatic anxiety prior to competition in adolescent athletes, while this was accompanied by significant physiological changes.
0	4834398	Skin conductance	Furthermore, the results showed that acupuncture significantly decreased the skin conductance in acupuncture group compared to sham group (p = 0.006) and wait-list control group (p < 0.001).
1	4834398	Self-confidence	The results of ANOVA on posttest scores showed that acupuncture had a significant effect on cognitive anxiety (p = 0.001) and somatic anxiety (p < 0.001) but not on self-confidence (p > 0.05).
0	4834398	Skin conductance	Furthermore, the results showed that acupuncture significantly decreased the skin conductance in acupuncture group compared to sham group (p = 0.006) and wait-list control group (p < 0.001).
0	4834398	Cognitive anxiety	The results of ANOVA on posttest scores showed that acupuncture had a significant effect on cognitive anxiety (p = 0.001) and somatic anxiety (p < 0.001) but not on self-confidence (p > 0.05).
0	4834398	Cognitive anxiety	In conclusion, the results suggested that acupuncture has the capacity to decrease cognitive anxiety and somatic anxiety prior to competition in adolescent athletes, while this was accompanied by significant physiological changes.
1	5874977	intraocular pressure (intraocular pressure)	Mean changes in intraocular pressure were similar for the two protocols; the peak intraocular pressure was at the steep (peak) Trendelenburg position.
0	3775167	LDL cholesterol	Significant decrease in blood pressure (P < 0.01), total cholesterol (P = 0.02), LDL (P < 0.01), triglyceride (P < 0.01) and a better glycemic control (P < 0.01) was found in clopidogrel group.
2	5241452	H. pylori-positive rate	H. pylori-positive rate in group A was significantly higher than that in group B (98.2% versus 86.7%, p = 0.004).
2	5241452	The positive rate of H. pylori infection with each single biopsy taken from site 2 , and site 3	The positive rate of Rapid urease test was similar at each biopsy site but significantly increased if Rapid urease test results from 2 or 3 sites were combined (p < 0.05).
2	4356062	Viable follicles	Ovarian tissue frozen in CV7 solution showed a higher percentage of morphologically normal follicles or viable follicles than other cryoprotectant solutions P < 0.05.
2	4356062	Viable follicles	Ovarian tissue frozen in CV7 solution showed a higher percentage of morphologically normal follicles or viable follicles than other cryoprotectant solutions P < 0.05.
2	4356062	Viable follicles	Ovarian tissue frozen in CV7 solution showed a higher percentage of morphologically normal follicles or viable follicles than other cryoprotectant solutions P < 0.05.
2	4356062	Viable follicles	Ovarian tissue frozen in CV7 solution showed a higher percentage of morphologically normal follicles or viable follicles than other cryoprotectant solutions P < 0.05.
2	4590407	The body mass index-for-age	The body mass index-for-age increased after oral zinc supplementation in the experimental group (p=0.005).
2	3508963	Response to treatment	Pain score measured in two groups five minutes after the injection of lidocaine and morphine were 65 % and 53 % respectively (95% CI 0.60 - 0.69, CI 0.48 – 0.57, p = 0.0002).108 (90 %) patients (95 % CI 0.84 – 0.95) from group I and 84 (70%) patients (95 % CI 0.62 - 0.78) from group II responded appropriately at the end of the complete treatment. The difference was statistically significant (p = 0.0001).  
2	3508963	Pain score after 5 minutes	Pain score measured in two groups five minutes after the injection of lidocaine and morphine were 65 % and 53 % respectively (95% CI 0.60 - 0.69, CI 0.48 – 0.57, p = 0.0002).108 (90 %) patients (95 % CI 0.84 – 0.95) from group I and 84 (70%) patients (95 % CI 0.62 - 0.78) from group II responded appropriately at the end of the complete treatment.
1	3326921	Cure rate	Secnidazole had cure rate of 80.2% at 4 weeks (P=NS). Metronidazole showed a cure rate of 77.9% at 4 weeks, which is the lowest of all four drugs.  
2	3326921	Cure rate	At 1 week, the cure rate of tinidazole and ornidazole was 100% and at 4 weeks, it was 97.7% for both drugs (P<0.001).
1	3326921	Cure rate	At 1 week, the cure rate of tinidazole and ornidazole was 100% and at 4 weeks, it was 97.7% for both drugs (P<0.001).
2	5079608	oral disposition index (oral disposition index) - 10–17 years old with recent-onset type 2 diabetes and ≥80% adherence to metformin therapy for ≥8 weeks	No adherence threshold predicted the loss of glycemic control. Longitudinally, participants with high adherence had significantly greater insulin sensitivity and oral disposition index than those with low adherence.  
1	5079608	loss of glycemic control - 10–17 years old with recent-onset type 2 diabetes and ≥80% adherence to metformin therapy for ≥8 weeks	No adherence threshold predicted the loss of glycemic control.
0	5079608	significant depressive symptoms at baseline - 10–17 years old with recent-onset type 2 diabetes and ≥80% adherence to metformin therapy for ≥8 weeks	A greater percentage of participants with low adherence had clinically significant depressive symptoms at baseline (18% vs. 12%, P = 0.0415).
0	5013640	Progression-free survival	In the univariable analysis, higher insulin (HR = 0.81 [0.67, 0.98] p = 0.03) and C-peptide (HR = 0.62 [0.39, 1.00]; p = 0.05) levels were associated with a longer Progression-free survival, while higher Hepatocyte Growth Factor (HGF; HR = 1.63 [1.06, 2.51] p = 0.03) and Osteopontin (OPN; HR = 1.56 [1.13, 2.15]; p = 0.01) levels were associated with a shorter Progression-free survival.
2	5584005	Communication about mistakes	Improvement in attitudes toward patient safety was statistically significant in the intervention group in six domains: staff, training, and skill (p = 0.017); patient counseling (p = 0.043); communication about mistakes (p < 0.001); response to mistakes (p < 0.001); organizational learning – continuous improvement (p < 0.001); and overall patient safety perceptions (p = 0.033).
2	5584005	Patient counseling	Sixty-nine employees completed the questionnaire, a 43.9% response rate. Improvement in attitudes toward patient safety was statistically significant in the intervention group in six domains: staff, training, and skill (p = 0.017); patient counseling (p = 0.043); communication about mistakes (p < 0.001); response to mistakes (p < 0.001); organizational learning – continuous improvement (p < 0.001); and overall patient safety perceptions (p = 0.033).
2	5584005	Response to mistakes	Improvement in attitudes toward patient safety was statistically significant in the intervention group in six domains: staff, training, and skill (p = 0.017); patient counseling (p = 0.043); communication about mistakes (p < 0.001); response to mistakes (p < 0.001); organizational learning – continuous improvement (p < 0.001); and overall patient safety perceptions (p = 0.033).
2	5584005	Organizational learning and continuous improvement	Improvement in attitudes toward patient safety was statistically significant in the intervention group in six domains: staff, training, and skill (p = 0.017); patient counseling (p = 0.043); communication about mistakes (p < 0.001); response to mistakes (p < 0.001); organizational learning – continuous improvement (p < 0.001); and overall patient safety perceptions (p = 0.033).
2	5584005	Patient safety perceptions	Improvement in attitudes toward patient safety was statistically significant in the intervention group in six domains: staff, training, and skill (p = 0.017); patient counseling (p = 0.043); communication about mistakes (p < 0.001); response to mistakes (p < 0.001); organizational learning – continuous improvement (p < 0.001); and overall patient safety perceptions (p = 0.033).
2	4114003	beneficial preventive effects against neonatal conjunctivitis	Our data demonstrate the beneficial preventive effects of Colostrum against neonatal conjunctivitis (P = 0.036).  
0	4114003	frequency of conjunctivitis	Our data demonstrate the beneficial preventive effects of Colostrum against neonatal conjunctivitis (P = 0.036).  
0	5446455	Visual Analog Scale (Visual Analog Scale), Pain Disability Index (Pain Disability Index) and Headache Impact Tests (Headache Impact Tests)	When the groups were compared at the end of the study, a significant decrease was observed in Visual Analog Scale, Pain Disability Index and Headache Impact Tests values in the individuals in the Body Awareness Therapy and aerobic exercise groups.
2	4215531	alpha power	Effects on 10–13 Hz (alpha) power during the transition from neutral to emotional expressions were assessed via MEG based on previous findings that alpha power increase is related to facial affect recognition and is smaller in schizophrenia than in healthy subjects.
2	4215531	alpha power	Moreover, alpha power increase during the dynamic facial affect recognition task was larger after affect training than after treatment-as-usual, though similar to that after targeted perceptual–cognitive training, indicating somewhat nonspecific benefits.
2	1971065	amount of remission of Seasonal Affective Disorder (Seasonal Affective Disorder)	At trial end, the proportions of participants in remission (SIGH-SAD less than 9) were significantly greater (Fisher's exact test), and SIGH-SAD scores, as percent individual score at randomization, were significantly lower (t-test), with active treatment than with control, both in an intent-to-treat analysis and an observed cases analysis.
2	4045368	Mean knee scores at follow-up	The mean of knee scores was significantly higher in locking plate group than in nonlocking plate group at the follow-up time (80.20 ± 10.21 versus 72.52 ± 14.75, P = 0.039).
2	4045368	Mean functional score at follow-up	The mean of knee scores was significantly higher in locking plate group than in nonlocking plate group at the follow-up time (80.20 ± 10.21 versus 72.52 ± 14.75, P = 0.039).
0	4045368	Mean VAS pain score	Also, the mean VAS pain severity score was significantly lower in locking plate group compared with nonlocking plate group (4.45 ± 2.50 versus 6.00 ± 2.59, P = 0.046).
2	5047020	Level of base excess after therapy	In hydroxyethyl starch (Voluven) and normal saline groups, base excess level after solution therapy increased about 9.65 and 5.46 volumes, respectively, in which augmentation in hydroxyethyl starch (Voluven) group is significantly higher than normal saline group (P ≤ 0.001).  
0	5648980	Hospitalization time	The mechanical ventilation time, time for recovering from chest X-ray scan and hospitalization time of patients in the observation group were shorter than that of the control group, and the difference had statistical significance (P<0.05).
0	5648980	Mechanical ventilation time	The mechanical ventilation time, time for recovering from chest X-ray scan and hospitalization time of patients in the observation group were shorter than that of the control group, and the difference had statistical significance (P<0.05).
0	5648980	Oxygen index	The oxygen index of the patients in the observation group was significantly improved compared to that of the control group, and the difference had statistical significance (P<0.05).
1	5648980	Head circumference	The head circumference, height and weight of the patients in the observation group in the 3rd and 6th month were compared to those of the control group, suggesting no significant differences (P>0.05).
1	5648980	Height	The head circumference, height and weight of the patients in the observation group in the 3rd and 6th month were compared to those of the control group, suggesting no significant differences (P>0.05).
0	4119301	preference rates	There was a 50% difference in preference rates (in favour of silicone) (95%CI 32.7–67.3%, p < 0.0001).  
1	5019463	Appointment adherence, exemplified by the attendance of one or more follow-up visits	Appointment adherence, defined as attendance of ≥1 follow-up visit, was 69.8% (n=37/53) for G1, 82.5% (n=47/57) for G2, and 73.3% (n=33/45) for G3, (P=0.28).
1	5019463	number of follow-up appointments during the one year study period	The mean (±standard deviation) number of follow-up visits during the 1-year study period was 1.3 (±1.3) for G1, 1.6 (±1.3) for G2, and 1.3 (±1.1) for G3 (P=0.48).
1	5427603	Responders identification accuracy	However, the accuracy of these variables in identifying responders in each group was modest (62 and 53%, respectively).  
1	4652407	Liver enzymes	All other measurements (All other measurements, ALT, ALP, creatinine, CRP, eGFR) were normal and not significantly different between or within groups.  
1	4652407	Atherogenic index	No significant differences (p >0.05) in insulin, cholesterol measurements (total cholesterol, LDL-C, HDL-C, triglycerides and cholesterol ratios) and atherogenic index between or within groups were observed.
1	4652407	Fasting blood glucose	Both test groups elicited a non significant decrease in Fasting Blood Glucose following the intervention (group 1 - from 174 ± 14 to 160 ± 10 mg/dL; group 2 - from 183 ± 13 to 160 ± 7 mg/dL).
0	4652407	HbA1c levels	Therefore, both test groups (1 and 2) elicited a decrease in HbA1c compared to respective control groups.
1	4652407	Insulin and cholesterol levels	No significant differences (p >0.05) in insulin, cholesterol measurements (total cholesterol, LDL-C, HDL-C, triglycerides and cholesterol ratios) and atherogenic index between or within groups were observed.
0	3460347	hit rate in high - hallucinations/delusions (H-HD)	Both % hits and d′, as well as reaction time were poorer in H-HD (vs. L-HD) and while hit rate and d′ was increased by nicotine in H-HD, reaction time was slowed by ketamine in L-HD.
0	3460347	hit rate in high - hallucinations/delusions (H-HD)	Results: Ketamine significantly slowed mismatch negativity, and reduced mismatch negativity in H-HD, with amplitude attenuation being blocked by the co-administration of nicotine.
0	3460347	auditory event-related brain potential – mismatch negativity (mismatch negativity) in high - hallucinations/delusions (H-HD)	Results: Ketamine significantly slowed mismatch negativity, and reduced mismatch negativity in H-HD, with amplitude attenuation being blocked by the co-administration of nicotine.
0	3460347	d′ (weight hits and false alarms into a single measure) in high - hallucinations/delusions (H-HD)	Both % hits and d′, as well as reaction time were poorer in H-HD (vs. L-HD) and while hit rate and d′ was increased by nicotine in H-HD, reaction time was slowed by ketamine in L-HD.
2	60007	maximal T block	Mivacurium 250 μg/kg produced a maximal T block faster than 200 μg/kg, i.e. 2.4 ± 1.1 vs. 3.5 ± 1.4 min (p < 0.05).
1	60007	Spontaneous recovery time	Spontaneous recovery times were similar in both groups.
1	60007	heart rate (HR)	Heart rate was similar between doses while systolic and diastolic blood pressures were lower with the higher dose (p < 0.05).
0	5354681	expression of genes involved in wound healing and inflammation	Moreover, selenium was associated with down-regulated expression of genes involved in wound healing and inflammation; processes which are both related to epithelial-to-mesenchymal transition.
0	5354681	effect of selenium on the epithelial-to-mesenchymal transition (epithelial-to-mesenchymal transition)	This implies an inhibitory effect of selenium on the epithelial-to-mesenchymal transition (epithelial-to-mesenchymal transition).
2	5429471	bond strength	The control group showed the highest bond strength with significant differences with other groups (P<0.05).
1	5429471	bond strength	The control group showed the highest bond strength with significant differences with other groups (P<0.05). Among the experimental groups, the saline group had no significant difference with chlorhexidine (P=0.09) but it had significant differences with Smear Clear and NaOCl groups (P<0.05).
0	3748549	Symptoms after exercise	The comparison of the two groups showed that the mean scores of Premenstrual syndrome, for symptoms during and after exercise, were significantly different (P ≤ 0.001) and the percentages of scores Premenstrual syndrome changes, physical, and psychological symptoms of experimental and control groups had a significant difference (P ≤ 0.001) after 8 weeks of training.  
0	3748549	Symptoms during exercise	The comparison of the two groups showed that the mean scores of Premenstrual syndrome, for symptoms during and after exercise, were significantly different (P ≤ 0.001) and the percentages of scores Premenstrual syndrome changes, physical, and psychological symptoms of experimental and control groups had a significant difference (P ≤ 0.001) after 8 weeks of training.  
1	5897859	Erosive esophagitis recurrence rate after 24 weeks	In a post-hoc analysis, erosive esophagitis recurrence at Week 24 was significantly reduced with vonoprazan at both the 10 mg and the 20 mg dose vs lansoprazole 15 mg (5.1% vs 16.8%, P = 0.0002, and 2.0% vs 16.8%, P < 0.0001, respectively); by contrast, the erosive esophagitis recurrence rate did not differ significantly between the two doses of vonoprazan (P = 0.1090).
1	5897859	Erosive esophagitis recurrence rate after 24 weeks	Rates of erosive esophagitis recurrence during the 24-wk maintenance period were 16.8%, 5.1%, and 2.0% with lansoprazole 15 mg, vonoprazan 10 mg, and vonoprazan 20 mg, respectively.
0	5897859	Erosive esophagitis recurrence rate after 24 weeks	In a post-hoc analysis, erosive esophagitis recurrence at Week 24 was significantly reduced with vonoprazan at both the 10 mg and the 20 mg dose vs lansoprazole 15 mg (5.1% vs 16.8%, P = 0.0002, and 2.0% vs 16.8%, P < 0.0001, respectively); by contrast, the erosive esophagitis recurrence rate did not differ significantly between the two doses of vonoprazan (P = 0.1090).
1	5897859	Safety profiles	The safety profiles of vonoprazan 10 and 20 mg were similar to that of lansoprazole 15 mg in patients with healed erosive esophagitis.
2	4392900	mean percent weight loss of subjects with prediabetes and/or metabolic syndrome	At baseline, 475 subjects met the criteria for prediabetes and/or MetS. After 108 weeks, subjects with prediabetes and/or metabolic syndrome in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (intent-to-treat population using multiple imputation; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo.
0	4392900	incidence rate of type 2 diabetes	At baseline, 475 subjects met the criteria for prediabetes and/or MetS. After 108 weeks, subjects with prediabetes and/or metabolic syndrome in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (intent-to-treat population using multiple imputation; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo.
2	3778569	mean score of knowledge , attitude and practice	The results showed a significant increase in the knowledge (P < 0.001), attitude (P = 0.04) and practice (P = 0.01) in the intervention group 1 month after intervention compared with that before intervention, while such an increase was not seen in the control group.  
0	2409349	the prevalence of pathologic 24-hour esophageal reflux	The prevalence of pathologic 24-hour esophageal reflux in both studies was significantly higher when measured as time pH < 4 than when measured as integrated acidity.
1	4459874	Haemagglutination inhibition titers	haemagglutination inhibition titers against both influenza A strains as well as memory B-cell response were modestly higher in the antihelminthic treated group compared to the placebo group but the difference was not statistically significant.
2	3206382	improvement in Hb by month 1	Mean increases in Hb to months 1 and 4 with Iron polymaltose complex were 1.2 ± 0.9 g/dL and 2.3 ± 1.3 g/dL, respectively, (both P = 0.001 versus baseline) and 1.8 ± 1.7 g/dL and 3.0 ± 2.3 g/dL with ferrous sulfate (both P = 0.001 versus baseline) (n.s.
2	3206382	improvement in Hb by month 4	Mean increases in Hb to months 1 and 4 with Iron polymaltose complex were 1.2 ± 0.9 g/dL and 2.3 ± 1.3 g/dL, respectively, (both P = 0.001 versus baseline) and 1.8 ± 1.7 g/dL and 3.0 ± 2.3 g/dL with ferrous sulfate (both P = 0.001 versus baseline) (n.s.
2	4709811	Improvement in the composite score of vaginal symptoms	Improvement in urinary incontinence, dryness, maturation index (P<0.05) and composite score of vaginal symptoms (P<0.001) in the hyaluronic acid group was better than those in the Premarin group.  
2	4709811	Improvement in urinary incontinence	Urinary incontinence only showed improvement in the hyaluronic acid group (P<0.05).
2	4709811	Improvement in urinary incontinence	Urinary incontinence only showed improvement in the hyaluronic acid group (P<0.05). Improvement in urinary incontinence, dryness, maturation index (P<0.05) and composite score of vaginal symptoms (P<0.001) in the hyaluronic acid group was better than those in the Premarin group.  
2	4709811	Improvement in vaginal dryness	Improvement in urinary incontinence, dryness, maturation index (P<0.05) and composite score of vaginal symptoms (P<0.001) in the hyaluronic acid group was better than those in the Premarin group.  
2	5789513	incidence of clinical cure	Group II and Group III compared to Group I showed higher incidence of clinical cure (53.33% in Group II and 66.67% in Group III vs. 26.67% in Group I, P = 0.007).
0	5789513	ventilator days	Group II compared to Group I showed significant reduction in ventilator days (5.32 ± 1.86 vs. 7.3 ± 2.1 days, respectively, P < 0.001) and reduction in Intensive Care Unit days (11.87 ± 2.6 vs. 15.3 ± 3.1 days, respectively, P < 0.001).
0	5789513	ventilator days	Group III compared to Group II showed significant reduction in ventilator days (4.22 ± 1.32 vs. 5.32 ± 1.86, respectively, P = 0.011) and highly significant reduction in Intensive Care Unit days (9.21 ± 1.17 vs. 11.87 ± 2.6, respectively, P < 0.001).
0	5789513	Intensive Care Unit days	Group III compared to Group II showed significant reduction in ventilator days (4.22 ± 1.32 vs. 5.32 ± 1.86, respectively, P = 0.011) and highly significant reduction in Intensive Care Unit days (9.21 ± 1.17 vs. 11.87 ± 2.6, respectively, P < 0.001).
2	3678501	Quit smoking	According to the results, after education period, systolic blood pressure of the case group improves compared with control group (P < 0.05/P = 0.022), case group tends to quit smoking more than control group does (P = 0.013), cholesterol level of case group improves compared with control group (P < 0.0001), changes of body mass are more positive in case group compared with control group (P = 0.012), and anxiety of case group reduces compared with control group (P < 0.0001).
2	3678501	Body mass improvement	According to the results, after education period, systolic blood pressure of the case group improves compared with control group (P < 0.05/P = 0.022), case group tends to quit smoking more than control group does (P = 0.013), cholesterol level of case group improves compared with control group (P < 0.0001), changes of body mass are more positive in case group compared with control group (P = 0.012), and anxiety of case group reduces compared with control group (P < 0.0001).
0	3678501	Anxiety	According to the results, after education period, systolic blood pressure of the case group improves compared with control group (P < 0.05/P = 0.022), case group tends to quit smoking more than control group does (P = 0.013), cholesterol level of case group improves compared with control group (P < 0.0001), changes of body mass are more positive in case group compared with control group (P = 0.012), and anxiety of case group reduces compared with control group (P < 0.0001).
0	3678501	Systolic blood pressure	According to the results, after education period, systolic blood pressure of the case group improves compared with control group (P < 0.05/P = 0.022), case group tends to quit smoking more than control group does (P = 0.013), cholesterol level of case group improves compared with control group (P < 0.0001), changes of body mass are more positive in case group compared with control group (P = 0.012), and anxiety of case group reduces compared with control group (P < 0.0001).
0	3678501	Cholesterol	According to the results, after education period, systolic blood pressure of the case group improves compared with control group (P < 0.05/P = 0.022), case group tends to quit smoking more than control group does (P = 0.013), cholesterol level of case group improves compared with control group (P < 0.0001), changes of body mass are more positive in case group compared with control group (P = 0.012), and anxiety of case group reduces compared with control group (P < 0.0001).
1	4064763	induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation)	After intervention, variables including: induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation), in the two groups, were found to be the same (P < 0.05).
1	4064763	Number of postpartum hemorrhage	After intervention, variables including: induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation), in the two groups, were found to be the same (P < 0.05).
1	5294435	Pain relief	After therapeutic exercises, there was no significant difference between Pilates and McKenzie groups in pain relief (P = 0.327).
1	4464926	Trismus	No statistically significant differences were observed for pain (p<0.06), trismus (p<0.71) and swelling (p<0.05) between the test and the control group.
1	4464926	Rates of pain	No statistically significant differences were observed for pain (p<0.06), trismus (p<0.71) and swelling (p<0.05) between the test and the control group.
2	5014878	Mean antibody reactivity against the associated HPV	Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (median fluorescence intensity) pre-vaccination to 4690 median fluorescence intensity post-vaccination (p < 0.001).
1	2887201	Vomiting	The rates of vomiting, regurgitation, aspiration, and pneumonia were similar between the two groups.  
1	2887201	Pneumonia	The rates of vomiting, regurgitation, aspiration, and pneumonia were similar between the two groups.  
1	2887201	Energy requirements intake	In the before group, on average, patients received 58.8% of their energy and 61.2% of their protein requirements by enteral nutrition compared to 67.9% and 73.6% in the after group (P = 0.33 and 0.13).
0	2887201	Protein requirements intake	When the subgroup of patients prescribed to receive full volume feeds in the after group were evaluated (n = 18), they received 83.2% and 89.4% of their energy and protein requirements by enteral nutrition respectively (P = 0.02 for energy and 0.002 for protein compared to the before group).
0	2887201	Protein requirements intake	In the before group, on average, patients received 58.8% of their energy and 61.2% of their protein requirements by enteral nutrition compared to 67.9% and 73.6% in the after group (P = 0.33 and 0.13).
1	2887201	Regurgitation	The rates of vomiting, regurgitation, aspiration, and pneumonia were similar between the two groups.  
1	2887201	Aspiration	The rates of vomiting, regurgitation, aspiration, and pneumonia were similar between the two groups.  
1	4823346	Pain	Except for the difference in Foot and Ankle Outcome Score sport between the lace-up and the semi-rigid brace, there are no differences in any of the outcomes after 6-month follow-up.  
2	2858204	frequency of healed index ucler after 1 year	In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the hyperbaric oxygen therapy group and 12/42 (29%) in the placebo group (P = 0.03).
2	2858204	In the intention-to-treat analysis, complete healing of the index ulcer	In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the hyperbaric oxygen therapy group and 12/42 (29%) in the placebo group (P = 0.03).
2	2858204	complete healing of the index ulcer at 1-year of follow-up	In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the hyperbaric oxygen therapy group and 12/42 (29%) in the placebo group (P = 0.03).
2	3897937	mean villous area In HIV negative patients	In HIV negative patients given multiple micronutrient compared to placebo, mean villous height was 24.0% greater (293.3 v. 236.6 μm; 95% CI of difference 17.7–95.9 μm; P = 0.006), mean villous area was 27.6% greater (27623 v. 21650 μm2/100 μm; 95% CI of difference 818–11130 μm2/100 μm; P = 0.03), and median villous perimeter was 29.7% greater (355.0 v. 273.7 μm/100 μm; 95% CI of difference 16.3–146.2 μm/100 μm; P = 0.003).
2	3897937	median villous perimeter In HIV negative patients	In HIV negative patients given multiple micronutrient compared to placebo, mean villous height was 24.0% greater (293.3 v. 236.6 μm; 95% CI of difference 17.7–95.9 μm; P = 0.006), mean villous area was 27.6% greater (27623 v. 21650 μm2/100 μm; 95% CI of difference 818–11130 μm2/100 μm; P = 0.03), and median villous perimeter was 29.7% greater (355.0 v. 273.7 μm/100 μm; 95% CI of difference 16.3–146.2 μm/100 μm; P = 0.003).
1	3897937	crypt depth, villous width	There was no significant effect on crypt depth or villous width.
2	3897937	mean villous height In HIV negative patients	In HIV negative patients given multiple micronutrient compared to placebo, mean villous height was 24.0% greater (293.3 v. 236.6 μm; 95% CI of difference 17.7–95.9 μm; P = 0.006), mean villous area was 27.6% greater (27623 v. 21650 μm2/100 μm; 95% CI of difference 818–11130 μm2/100 μm; P = 0.03), and median villous perimeter was 29.7% greater (355.0 v. 273.7 μm/100 μm; 95% CI of difference 16.3–146.2 μm/100 μm; P = 0.003).
0	3848942	Likeliness to have temperature ≥37.5°C on day 4	Children in the intervention areas were also less likely to have temperature ≥37.5°C on day four (RR = 0.29, 95%CI = 0.11-0.78).
2	3848942	Likeliness to receive prompt and appropriate antibiotics for pneumonia	Children in the intervention areas were more likely to receive prompt and appropriate antibiotics for pneumonia symptoms compared to children in the control areas (RR = 3.51, 95%CI = 1.75-7.03).
0	3848942	Fast breathing	The decrease in fast breathing between day one and four was greater in the intervention (9.2%) compared to the control areas (4.2%, p-value = 0.01).  
1	3738485	Increase in serum albumin levels	Serum albumin level did not increase significantly within groups (P < 0.90 vs. P < 0.82) with no difference between groups (P = 0.39).
2	3738485	Decrease in human immunodeficiency virus viral load	Within each group, human immunodeficiency virus viral load significantly reduced at the end of the study (P < 0.001 and P = 0.04 for spirulina and soya beans groups respectively). Between the groups, the viral load was similar at baseline but significantly reduced in the spirulina group at the end of the study (P = 0.02).  
2	3738485	Increase in fat free body mass	But when compared between the two groups at the end of the trial, fat free mass was significantly higher in the spirulina group (42.2 vs. 39.0 Kg, P = 0.01).
1	3738485	Increment of the haemoglobin level	The haemoglobin level rose significantly within groups (P < 0.001 for each group) with no difference between groups (P = 0.77).
2	3738485	Increase in CD4 T lymphocyte count	The increase in CD4 cell count within groups was significant (P < 0.01 in both groups), with a significantly higher CD4 count in the spirulina group compared to subjects on soya beans at the end of the study (P = 0.02).
2	5228186	Vitamin D level	SNP rs11185644 near the RXRA was significantly associated with 25(OH)D dose-response (P = 1.01 × 10−4).
1	4593658	Serum creatinine	The serum creatinine increased and glomerular filtration rate decreased significantly during the intervention in three groups (P < 0.010). However, the amounts of these changes were equal between groups (P > 0.050).  
1	4593658	Glomerular filtration rate	The serum creatinine increased and glomerular filtration rate decreased significantly during the intervention in three groups (P < 0.010). However, the amounts of these changes were equal between groups (P > 0.050).  
2	5116111	Aesthetic appearance improvement by day 14	In all the recorded follow-ups (Day 7 p=0.001, and Day 14 p=0.01), the wound's aesthetic appearance was better in the EG.
1	5116111	Postoperative swelling	No significant findings were found regarding postoperative swelling and pain.
1	5116111	Pain	No significant findings were found regarding postoperative swelling and pain.
1	5116111	Tolerance	Overall treatment tolerance was satisfactory and similar in both groups.  
1	5116111	Infections	Neither of the groups displayed poor healing or infectious complications of the wound during the postoperative period.
2	5116111	Aesthetic appearance improvement by day 7	In all the recorded follow-ups (Day 7 p=0.001, and Day 14 p=0.01), the wound's aesthetic appearance was better in the EG.
2	4599047	subjects achieving the primary composite endpoint - moderate degenerative lumbar spinal stenosis.	At 3 years, the proportion of subjects achieving the primary composite endpoint was greater for Superion® (63/120, 52.5%) than for X-STOP® (49/129, 38.0%) (P=0.023) and the corresponding success rates exceeded 80% for each of the individual components of the primary endpoint in the Superion® group (range: 81%–91%).
2	4435250	relationship equity	Women in the Men's Health CoOp/Women's Health CoOp arm were more likely to report increases in relationship equity, relative to those in the Couples Health CoOp arm, and had a higher odds of reporting no victimization during the previous 3 months (Men's Health CoOp/Women's Health CoOp vs WHC: odds ratio =3.05, 95% confidence interval: 1.55, 6.0, P=0.001; Couples Health CoOp vs Men's Health CoOp/Women's Health CoOp: odds ratio =0.38, 95% confidence interval: 0.20, 0.74, P=0.004).  
2	4435250	relationship control, gender norms supporting female autonomy in relationships	Following the intervention, women in the Couples Health CoOp arm compared with those in the WHC arm were more likely to report an increase in relationship control (β=0.92, 95% confidence interval [confidence interval]: 0.02, 1.83, P=0.045) and gender norms supporting female autonomy in relationships (β=0.99, 95% confidence interval: 0.07, 1.91, P=0.035).
1	3515466	mental component score of the Short Form 36 (SF-36) questionnaire	There was a significant difference between the response of the physical component score of the SF-36, favouring the singing group +12.9(19.0) vs -0.25(11.9) (p=0.02), but no difference in response of the mental component score of the SF-36, breathing control measures, exercise capacity or daily physical activity.
1	3515466	mental component score of the Short Form 36 (SF-36) questionnaire	There was a significant difference between the response of the physical component score of the SF-36, favouring the singing group +12.9(19.0) vs -0.25(11.9) (p=0.02), but no difference in response of the mental component score of the SF-36, breathing control measures, exercise capacity or daily physical activity.
1	3515466	measures of breathing control, functional exercise capacity or daily physical activity	There was a significant difference between the response of the physical component score of the SF-36, favouring the singing group +12.9(19.0) vs -0.25(11.9) (p=0.02), but no difference in response of the mental component score of the SF-36, breathing control measures, exercise capacity or daily physical activity.
2	4069047	Instrumental Activities of Daily Living cognitive performance	Patients treated with prolonged-release melatonin (24 weeks) had significantly better cognitive performance than those treated with placebo, as measured by the Instrumental Activities of Daily Living (P=0.004) and Mini–Mental State Examination (P=0.044).
2	4069047	Mini–Mental State Examination cognitive performance	Patients treated with prolonged-release melatonin (24 weeks) had significantly better cognitive performance than those treated with placebo, as measured by the Instrumental Activities of Daily Living (P=0.004) and Mini–Mental State Examination (P=0.044).
2	4069047	Pittsburgh Sleep Quality Index sleep efficiency	Sleep efficiency, as measured by the Pittsburgh Sleep Quality Index, component 4, was also better with prolonged-release melatonin (P=0.017).
1	4069047	Adverse events	Differences were more significant at longer treatment duration. prolonged-release melatonin was well tolerated, with an adverse event profile similar to that of placebo.  
0	5104394	Binge number	sequential binge was associated with a 44% relative reduction in the planned food intake (p<0.001), a longer consecutive binge refractory period compared to regular binges (median: 48 hours versus 4 hours, p = 0.002) and an average relative reduction by 26% of binge number the day after each sequential binge (p = 0.004).
0	5104394	Planned food intake	sequential binge was associated with a 44% relative reduction in the planned food intake (p<0.001), a longer consecutive binge refractory period compared to regular binges (median: 48 hours versus 4 hours, p = 0.002) and an average relative reduction by 26% of binge number the day after each sequential binge (p = 0.004).
2	5104394	Consecutive binge refractory period	sequential binge was associated with a 44% relative reduction in the planned food intake (p<0.001), a longer consecutive binge refractory period compared to regular binges (median: 48 hours versus 4 hours, p = 0.002) and an average relative reduction by 26% of binge number the day after each sequential binge (p = 0.004).
2	5722122	Microcrack formation	There was a significant difference between Neolix and the control groups in microcrack formation (P=0.042).
2	5722122	Microcrack formation	No microcrack occurred in the control group.   
2	5299497	Percentage of patients achieving an systemic lupus erythematosus Responder Index 4	The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, versus placebo), with greater effect size in patients with a high interferon signature at baseline (13.2% in placebo‐treated patients versus 36.0% [P = 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, respectively.
2	5299497	British Isles Composite Lupus Assessment improvement	At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [P < 0.001] and 41.2% [P = 0.018], respectively), modified SRI(6) (28.4% versus 49.5% [P = 0.002] and 44.7% [P = 0.015], respectively), major clinical response (British Isles Lupus Assessment Group 2004 C or better in all organ domains from week 24 through week 52) (6.9% versus 19.2% [P = 0.012] and 17.3% [P = 0.025], respectively), and several other global and organ‐specific end points.
2	5299497	Percentage of patients achieving an systemic lupus erythematosus Responder Index 4	The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, versus placebo), with greater effect size in patients with a high interferon signature at baseline (13.2% in placebo‐treated patients versus 36.0% [P = 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, respectively.
2	5299497	Percentage of patients achieving an systemic lupus erythematosus Responder Index 4	At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [P < 0.001] and 41.2% [P = 0.018], respectively), modified SRI(6) (28.4% versus 49.5% [P = 0.002] and 44.7% [P = 0.015], respectively), major clinical response (British Isles Lupus Assessment Group 2004 C or better in all organ domains from week 24 through week 52) (6.9% versus 19.2% [P = 0.012] and 17.3% [P = 0.025], respectively), and several other global and organ‐specific end points.
2	5299497	Percentage of patients achieving an systemic lupus erythematosus Responder Index 6	At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [P < 0.001] and 41.2% [P = 0.018], respectively), modified SRI(6) (28.4% versus 49.5% [P = 0.002] and 44.7% [P = 0.015], respectively), major clinical response (British Isles Lupus Assessment Group 2004 C or better in all organ domains from week 24 through week 52) (6.9% versus 19.2% [P = 0.012] and 17.3% [P = 0.025], respectively), and several other global and organ‐specific end points.
1	5299497	Adverse events	Incidence of serious adverse events was similar between groups (18.8% versus 16.2% and 17.1%, respectively).  
2	5299497	Percentage of patients achieving an systemic lupus erythematosus Responder Index 6	At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [P < 0.001] and 41.2% [P = 0.018], respectively), modified SRI(6) (28.4% versus 49.5% [P = 0.002] and 44.7% [P = 0.015], respectively), major clinical response (British Isles Lupus Assessment Group 2004 C or better in all organ domains from week 24 through week 52) (6.9% versus 19.2% [P = 0.012] and 17.3% [P = 0.025], respectively), and several other global and organ‐specific end points.
1	5852701	Appetite area under the curve at day 2	Appetite AUC did not differ between interventions (standardised effect of RAB compared to sitting: Day 1: 0.11; 95% CI: −0.28, 0.06; p = 0.212; Day 2: 0.04; 95% CI: −0.15, 0.24; p = 0.648).
1	5852701	Appetite area under the curve at day 1	Appetite AUC did not differ between interventions (standardised effect of RAB compared to sitting: Day 1: 0.11; 95% CI: −0.28, 0.06; p = 0.212; Day 2: 0.04; 95% CI: −0.15, 0.24; p = 0.648).
0	5301992	Diastolic blood pressure	There was a statistically significant difference (P < 0.05) between the mean of systolic blood pressure (systolic blood pressure), diastolic blood pressures (diastolic blood pressures), and pulse rate (pulse rate) in the massage group prior to intervention (97.05 ± 20.7, 60.35 ± 16.69 and 95.45 ± 13.02 respectively) and on the fifth day (88.32 ± 16.58, 55.95 ± 12.7 and 90.45 ± 15.1 respectively).
1	5301992	Respiratory Rate	However, no difference was observed in mean respiratory rate (respiratory rate) in the massage group from the second day (17.55 ± 3.6) to fifth day (17.62 ± 3.27) (P = 0.096).
0	5301992	Anxiety	The mean of state of anxiety, which was 36.4 ± 5.1 before intervention, was reduced by the fifth day to 31.2 ± 5.1 in the massage group (P < 0.0001, t = 5.2).  
1	2710065	Microbiological and clinical parameters	No statistically significant difference was observed between these groups based on the microbiological and clinical parameters.  
0	3161280	Fasting glycemia	Fasting glycemia was lowered from 179.6 ± 7.5 to 117.6 ± 6.5 mg/dL (P < 0.001), and HbA1c levels declined from 8.4 ± 0.5 to 7.1 ± 0.2% (P = 0.0046).
0	3161280	HbA1c levels	Fasting glycemia was lowered from 179.6 ± 7.5 to 117.6 ± 6.5 mg/dL (P < 0.001), and HbA1c levels declined from 8.4 ± 0.5 to 7.1 ± 0.2% (P = 0.0046).
2	3161280	insulin and C-peptide responses to intravenous glucose administration	In contrast, insulin and C-peptide responses to intravenous glucose administration were significantly greater after the glargine treatment period (P < 0.0001, respectively).
2	3161280	first- and second-phase insulin secretion	Both first- and second-phase insulin secretion increased significantly after the glargine treatment period (P < 0.05, respectively).
1	3386590	follow up advised	None of the measured behavioral and cognitive variables were significantly associated with recall of screening examination results or whether follow-up was as advised.
0	4882374	Weight	In all tertiles, pramlintide resulted in greater reductions in glycated hemoglobin (HbA1c) and weight than placebo, with greater weight reductions and insulin sparing in tertiles 2 and 3.
1	4882374	Severe hypoglycemia	Event rates for severe hypoglycemia were similar for pramlintide and placebo and increased with longer duration of diabetes for both groups.
1	4610775	Amyloid betas 1-42	At 4 weeks after treatment, cognitive status in patients treated with Urinary kallidinogenase clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42.
2	4610775	Cognitive status improvement	At 4 weeks after treatment, cognitive status in patients treated with Urinary kallidinogenase clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42.
0	4610775	Amyloid betas 1-40	At 4 weeks after treatment, cognitive status in patients treated with Urinary kallidinogenase clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42.
0	2694465	pain intensity	The morphine group reported less pain intensity (evaluated using a visual numeric scale), especially when coughing (18 hours postoperatively: control group= 4.73 and morphine group= 1.80, p=0.001).
0	2694465	Cumulative morphine consumption	Cumulative morphine consumption was reduced after 18 hours in the morphine group (control group= 20.14 and morphine group= 14.20 mg, p=0.037).
0	2694465	The plasma morphine concentration	The plasma morphine concentration was also reduced in the morphine group 24 hours after surgery (control group= 15.87 ng.mL−1 and morphine group= 4.08 ng.mL−1, p=0.029).  
1	2694465	forced vital capacity (forced vital capacity), FEV1/FVC and PaO2/FiO2 ratio	Both groups experienced reduced forced vital capacity postoperatively (3.24 L to 1.38 L in control group; 2.72 L to 1.18 L in morphine FEV1 (p=0.085), group), with no significant decreases observed between groups. The two groups also exhibited similar results for FEV1/FVC (p=0.68) and PaO2/FiO2 ratio (p=0.08).
0	5589093	intraoperative fluid balance	Intraoperative fluid balance was 1005mL (475:1873) in the goal directed therapy group vs. 3300mL (2474:3874) in the usual care group (p<0.0001).
1	5589093	Postoperative complications	There were no significant differences in proportions of patients experiencing overall complications (p = 0.179); however, fewer complications occurred in the goal directed therapy group: 44 vs. 92 (Incidence Rate Ratio: 0.41; 95%CI 0.24 to 0.69, p = 0.001).
1	3224655	paco2	PaCO2 dropped significantly only in the Noninvasive ventilation group (Noninvasive ventilation: 55.4 [7.7] → 44.5 [4.70], P = 0.0076; control: 52.4 [6.0] → 47.6 [8.2], NS).
1	3224655	FEV1	In both groups there was a nonsignificant change in FEV1 (Noninvasive ventilation group 29.5 [9.0] to 38.5 [14.6] %pred, control group 30.5 [5.1] to 36.8 [8.7] mmHg).
1	4194359	tumour-size-related mortality reduction	In contrast, tumour-size-related mortality reduction reaches a maximum at 5–7 years and then regularly drops to very low values for patients of both trial arms.  
2	3671234	The duration of analgesia	We found that use of midazolam as adjuvant with the local anesthetic in spinal anaesthesia significantly increases the duration of analgesia (median 320 min versus 220 min) and motor block (median 255 min versus 195 min) but decreases the incidence of postoperative nausea-vomiting (postoperative nausea-vomiting).
2	4619975	Expression of substance P (substance P) and calcitonin gene-related peptide (calcitonin gene-related peptide)	In the EXPg, the substance P and calcitonin gene-related peptide exhibited statistically significant different levels.
2	4619975	Expression of substance P (substance P) and calcitonin gene-related peptide (calcitonin gene-related peptide)	substance P and calcitonin gene-related peptide were identified in dental pulp after seven days of controlled orthodontic intrusion movement, even in the absence of pain.
2	4619975	Expression of substance P (substance P) and calcitonin gene-related peptide (calcitonin gene-related peptide)	From each patient, two premolars (indicated for extraction due to orthodontic reasons) were randomly assigned to two different groups: the asymptomatic inflammation group (EXPg), which would undergo controlled intrusive force for seven days, and the control group (control group), which was used to determine the basal levels of each substance.
0	3933059	Systolic blood pressure (Systolic blood pressure), diastolic blood pressure (diastolic blood pressure)	Comparison of pre- vs. post-trial values revealed a significant reduction in both Systolic blood pressure (7%; P = 0.013) and diastolic blood pressure (6%; P < 0.010).
1	3933059	flow-mediated dilation (flow-mediated dilation)	However, changes in flow-mediated dilation (20%) as well as circulating levels of C-reactive protein, intracellular adhesion molecule-1, vascular cell adhesion molecule 1, E-selectin, and interleukin-6 did not reach statistical significance (P = 0.172).  
1	3933059	C-reactive protein (C-reactive protein), intracellular adhesion molecule-1 (intracellular adhesion molecule-1), vascular cell adhesion molecule 1 (vascular cell adhesion molecule 1), E-selectin and interleukin-6 (interleukin-6)	However, changes in flow-mediated dilation (20%) as well as circulating levels of C-reactive protein, intracellular adhesion molecule-1, vascular cell adhesion molecule 1, E-selectin, and interleukin-6 did not reach statistical significance (P = 0.172).  
2	4969982	Exogenous lactate clearance	Exogenous lactate clearance was significantly higher in the dexmedetomidine and esmolol groups.  
1	4969982	Muscle lactate production	The dexmedetomidine group exhibited lower epinephrine levels, but no difference in muscle lactate.
2	4969982	Exogenous lactate clearance	Exogenous lactate clearance was significantly higher in the dexmedetomidine and esmolol groups.  
2	2360030	Diarrhoea	Diarrhoea was prevalent in the uracil/tegafur/leucovorin combined with irinotecan arm (16%) vs TEGAFOX (4%).
1	5482825	low-density lipoprotein	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
1	5482825	mean arterial pressure	Low AGE diets did not change systolic (p = 0.2) and diastolic blood pressure (p = 0.3), mean arterial pressure (p = 0.8) and pulse pressure (p = 0.2) compared to high AGE diets.
1	5482825	total cholesterol	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
1	5482825	interleukin-6	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
1	5482825	C-reactive protein	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
1	5482825	systolic blood pressure	Low AGE diets did not change systolic (p = 0.2) and diastolic blood pressure (p = 0.3), mean arterial pressure (p = 0.8) and pulse pressure (p = 0.2) compared to high AGE diets.
1	5482825	pulse pressure	Low AGE diets did not change systolic (p = 0.2) and diastolic blood pressure (p = 0.3), mean arterial pressure (p = 0.8) and pulse pressure (p = 0.2) compared to high AGE diets.
1	5482825	tumour necrosis factor α	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
1	5482825	nuclear factor kappa beta	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
1	5482825	Diastolic BP	Low AGE diets did not change systolic (p = 0.2) and diastolic blood pressure (p = 0.3), mean arterial pressure (p = 0.8) and pulse pressure (p = 0.2) compared to high AGE diets.
1	5482825	high-density lipoprotein	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
1	5482825	triglycerides	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
1	5482825	monocyte chemoattractant protein-1	Change in total cholesterol (p = 0.3), low-density lipoprotein (p = 0.7), high-density lipoprotein (p = 0.2), and triglycerides (p = 0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (p = 0.6), monocyte chemoattractant protein-1 (p = 0.9), tumour necrosis factor α (p = 0.2), C-reactive protein (p = 0.6) and nuclear factor kappa beta (p = 0.2).
0	5513842	The total tramadol consumption	Twenty-four hours after surgery, median (25th–75th percentile) cumulative morphine consumption was 0 (0–2) vs 2.5 (2–4) mg (P<0.0001) and cumulative tramadol consumption was 200 (150–250) mg vs 300 (200–350) mg in the paravertebral and in the control group, respectively (P=0.003).
2	5513842	first analgesic request time	After surgery, the median (25th–75th percentile) first analgesic requirement time was prolonged in the paravertebral block group in statistically significant fashion (P<0.0001).  
0	4802087	COPD exacerbation	After the intervention, there were significant differences in FEV1 and the number of COPD exacerbation between the case and control group patients. Also, after the study, in the case group, FEV1 was increased and the number of COPD exacerbation was decreased significantly.  
2	4223943	Means scores of expectations and childbirth self-efficacy	While mean scores of the fear of childbirth, expectations and childbirth self-efficacy before the intervention between the two groups were not significantly different (P > 0.05), mean scores of childbirth in intervention group was reduced and expectation and childbirth self-efficacy had a significant increase after intervention (P < 0.05).
1	1774569	Risk of non-completion of detoxification	Risk of non-completion of detoxification was reduced if allocated buprenorphine (68% vs 88%, RR 0.58 CI 0.35–0.96, p = 0.065).
0	3267052	cumulative plaque scores	The % BOP (5 months) and cumulative plaque scores (8 months) were lowered more in the fruit/vegetable group (p < 0.05).  
0	4234788	Sedation score	Sedation score (3.47 vs. 3.93) and patient satisfaction score were better in Group I patients.
1	4234788	Oxygen saturation	There was no significant difference in intubation scores, grimace scores, oxygen saturation and level of recall when compared between the two groups (P > 0.05).  
2	4234788	Satisfaction score of the patients	Sedation score (3.47 vs. 3.93) and patient satisfaction score were better in Group I patients.
1	4234788	Intubation scores or grimace scores	There was no significant difference in intubation scores, grimace scores, oxygen saturation and level of recall when compared between the two groups (P > 0.05).  
0	5034497	Running time	Moreover significant reductions in the means of the running time were observed among these two groups.
2	5034497	Forced Vital Capacity	Interestingly, there was a significant increase in Forced Expiratory Volume in the first second and Forced Vital Capacity after inhalation for the both oils.
1	3284878	abscess size - females with breast abscess	The two groups were comparably in demographic characteristic and breast abscess size.
0	3284878	cost of procedure - females with breast abscess	Incision and drainage was found to be more costly than ultrasound guided aspiration (cost effective ratio of 2.85).  
1	3284878	demographic characteristic - females with breast abscess	The two groups were comparably in demographic characteristic and breast abscess size.
1	3284878	abscess healing rate - females with breast abscess	Survival analysis showed no difference in breast abscess healing rate between the two groups (Log rank 0.24 df 1 and P = 0.63).
0	5738810	Pain at manipulation	After 3 months of feeding, there was a significant reduction of pain at manipulation in the CCOT group, but not in the control group.
1	5738810	lameness, pain at palpation and joint mobility at T0 and T3	The three other parameters evaluated by veterinary subjective assessment (lameness, pain at palpation and joint mobility) did not show statistical differences.
2	5738810	PI change (∆ T3-T0) on the ability to rise to standing	No statistical difference was found for pain interference, except for the ability to rise to standing from lying down, which was significantly improved in the CCOT compared to the control group.
1	3557008	Systolic blood preasure	No significant differences were found in two groups in Systolic blood pressure before and after hospitalization in the intensive care unit (P > 0.05).
0	5009836	Use of phenylephrine	Significantly less phenylephrine (1077.5 ± 514 mcg) was used in the colloid group than the crystalloid group (1477 ± 591 mcg, P = 0.003).  
1	5009836	incidence of maternal nausea and vomiting	There was also no difference between groups with respect to bradycardia, APGAR scores, and nausea and vomiting.
1	5009836	elective cesarean delivery (cesarean delivery) reduction in spinal-induced hypotension (spinal-induced hypotension)	There was no statistical difference between groups with regards to the incidence of hypotension (10.8% in the colloid group vs. 27.0% in the crystalloid group, P = 0.12).
1	5009836	incidence of bradycardia	There was also no difference between groups with respect to bradycardia, APGAR scores, and nausea and vomiting.
1	4776972	Rate of mycologic cure by the end of the treatment	The Rates of mycologic cure and effective treatment with (Butenafine) were higher than with (Bifonazole) at cessation of treatment and 2 weeks later. However, no significant difference found between the two drugs (p> 0.05).
1	4776972	Rate of effective treatment by the end of the treatment	The Rates of mycologic cure and effective treatment with (Butenafine) were higher than with (Bifonazole) at cessation of treatment and 2 weeks later. However, no significant difference found between the two drugs (p> 0.05).
1	4776972	Rate of mycologic cure 2 weeks after the treatment	The Rates of mycologic cure and effective treatment with (Butenafine) were higher than with (Bifonazole) at cessation of treatment and 2 weeks later. However, no significant difference found between the two drugs (p> 0.05).
1	4776972	Rate of effective treatment 2 weeks after the treatment	And patients continued to improve for at least 2 weeks after treatment. The Rates of mycologic cure and effective treatment with (Butenafine) were higher than with (Bifonazole) at cessation of treatment and 2 weeks later. However, no significant difference found between the two drugs (p> 0.05).
0	4056784	Mean arterial pressure	Changing head of bed elevation from supine to 45° caused significant reductions in mean arterial pressure (from 83.8 mmHg to 71.1 mmHg, P < 0.001) and ScvO2 (76.1% to 74.3%, P < 0.001).
0	4056784	Central venous oxygen saturation	Changing head of bed elevation from supine to 45° caused significant reductions in mean arterial pressure (from 83.8 mmHg to 71.1 mmHg, P < 0.001) and ScvO2 (76.1% to 74.3%, P < 0.001).
1	4173506	Gastric pH level after tramadol	Similarly, no significant statistical difference was observed in the pH of the three tramadol groups during the subsequent three readings (pH1: 4.21 ± 0.93, 4.27 ± 0.95, 4.07 ± 0.82; pH2: 4.75 ± 1.00, 4.68 ± 0.94, 4.59 ± 0.78; pH3: 5.33 ± 0.86, 5.13 ± 0.95, 4.97 ± 0.78; P = 0.793, 0.876, and 0.490).
1	4173506	Baseline gastric pH level	There was no significant difference in the pH of the three groups before anesthesia (3.88 ± 0.75, 3.54 ± 0.73, and 3.75 ± 0.70; P = 0.393).
0	5149084	mean pain scores	A and L group showed a lower mean % of reduction in pain scores than laser and Amlexanox groups with a 22.2+10.5 and 43.4+15.8 mean % reduction in pain scores at day 2 and day 5 respectively.
0	5149084	mean ulcer size	Laser group showed the statistically highest mean percentage (%) of reduction in pain scores and ulcer size than the other groups. The mean % of reduction in pain scores was 43.3+20.0 at day 2 and 67.8+21.5 % at day 5 in the laser group while Amlexanox group demonstrated a 29.8 +11.3 and 61.9+24.5 mean % of reduction in pain scores at day 2 and 5 respectively.
0	5149084	mean ulcer size	All treatment modalities reduced pain and ulcer size than placebo group.
0	3821103	verbal pain rating score 1-hour post-operative scores	Meanwhile, verbal pain rating score scores did not differ significantly between the morphine and tramadol treated groups postoperatively, except for in the one-hour post-operative scores in which the tramadol-treated group experienced less pain (P < 0.007).
1	3821103	verbal pain rating score 6-hours post-operative scores	Meanwhile, verbal pain rating score scores did not differ significantly between the morphine and tramadol treated groups postoperatively, except for in the one-hour post-operative scores in which the tramadol-treated group experienced less pain (P < 0.007).
2	4916104	Balancing capacity	12-week study: Lower-limb muscle strength, balancing capacity, and whole body reaction time significantly improved in the exercise group.
2	4916104	Lower-limb muscle strength	12-week study: Lower-limb muscle strength, balancing capacity, and whole body reaction time significantly improved in the exercise group.
1	4181789	Adequate bowel preparation rates	Colon-cleansing efficiency was not significantly different between the two preparations.
0	4069273	the plaque index score and gingival index score	Participants in the intervention group had significantly lower glycosylated hemoglobin (HbA1c), fasting plasma glucose (fasting plasma glucose), plaque index score, gingival index score, pocket depth, clinical attachment level (clinical attachment level), and percentage of bleeding on probing (bleeding on probing) when compared to the control group.  
0	4069273	pocket depth, clinical attachment level (clinical attachment level), and percentage of bleeding on probing (bleeding on probing)	Participants in the intervention group had significantly lower glycosylated hemoglobin (HbA1c), fasting plasma glucose (fasting plasma glucose), plaque index score, gingival index score, pocket depth, clinical attachment level (clinical attachment level), and percentage of bleeding on probing (bleeding on probing) when compared to the control group.  
1	3268925	Locoregional disease-free survival	Locoregional disease-free survival did not statistically differ between the two operation methods for the patients who were planned for a mastectomy at the initial exam.  
0	3295238	Blood pressure	Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P < 0.001) as was total and LDL cholesterol (4.8 mg/dL; P = 0.495), while HDL was higher (3.6 mg/dL; P = 0.026).
0	3295238	Vasoconstriction to acetylcholine	In the most constricting segment, nifedipine reduced vasoconstriction to acetylcholine (14.0% vs. placebo 7.7%; P < 0.0088).
1	3295238	LDL cholesterol	Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P < 0.001) as was total and LDL cholesterol (4.8 mg/dL; P = 0.495), while HDL was higher (3.6 mg/dL; P = 0.026).
1	3295238	Change in plaque volume	The percentage change in plaque volume with nifedipine and placebo, respectively, was 1.0 and 1.9%, ns.  
2	3295238	HDL cholesterol	Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P < 0.001) as was total and LDL cholesterol (4.8 mg/dL; P = 0.495), while HDL was higher (3.6 mg/dL; P = 0.026).
0	2722000	rebleeding	The actuarial rebleeding rate in the prophylactic group was significantly lower than that in the ondemand group (33.9% vs. 62.1%, p=0.004).
1	4431324	Productivity losses	The infliximab group accumulated higher drug and healthcare costs (€27 487 vs €10 364; adjusted mean difference €16 956 (95% CI 14 647 to 19 162)), while productivity losses did not differ (€33 804 vs €29 220; €3961 (95% CI −3986 to 11 850)), resulting in higher societal cost compared to the conventional group (€61 291 vs €39 584; €20 916 (95% CI 12 800 to 28 660)).
1	4431324	Accumulated quality-adjusted life-years	Mean accumulated quality-adjusted life-years (quality-adjusted life-years) did not differ (1.10 vs 1.12; adjusted mean difference favouring infliximab treatment 0.01 (95% CI −0.07 to 0.08)).
2	4431324	Drug cost	The infliximab group accumulated higher drug and healthcare costs (€27 487 vs €10 364; adjusted mean difference €16 956 (95% CI 14 647 to 19 162)), while productivity losses did not differ (€33 804 vs €29 220; €3961 (95% CI −3986 to 11 850)), resulting in higher societal cost compared to the conventional group (€61 291 vs €39 584; €20 916 (95% CI 12 800 to 28 660)).
2	4431324	Societal cost	The infliximab group accumulated higher drug and healthcare costs (€27 487 vs €10 364; adjusted mean difference €16 956 (95% CI 14 647 to 19 162)), while productivity losses did not differ (€33 804 vs €29 220; €3961 (95% CI −3986 to 11 850)), resulting in higher societal cost compared to the conventional group (€61 291 vs €39 584; €20 916 (95% CI 12 800 to 28 660)).
2	4431324	Healthcare costs	The infliximab group accumulated higher drug and healthcare costs (€27 487 vs €10 364; adjusted mean difference €16 956 (95% CI 14 647 to 19 162)), while productivity losses did not differ (€33 804 vs €29 220; €3961 (95% CI −3986 to 11 850)), resulting in higher societal cost compared to the conventional group (€61 291 vs €39 584; €20 916 (95% CI 12 800 to 28 660)).
2	2429977	Bleeding complications	After adjustment for covariates and factors that may influence the bleeding risk, patients in group A were shown to have more likely bleeding complications when compared with group B (OR = 3.03; 95% CI 1.14–8.10; P = 0.027).  
1	2429977	Periprocedural troponin elevation	Periprocedural troponin elevation (>3× ULN) was detected in 2.6% group A vs. 3.3% group B (P = 0.475; 90% CI −2.5–1.0).
1	4608345	The incidence of fatigue , headache and dystonia	The incidence of fatigue (p=0.44), headache (p=0.58) and dystonia (p=0.06) had no significant difference in the two groups but the incidence of drowsiness and anxiety in the metoclopramide group was significantly higher (P < 0.001).   
0	4608345	severity of nausea	Administration of both ondansetron and metoclopramide significantly reduced the severity of nausea (P<0.001).
2	4608345	drowsiness and anxiety	The incidence of fatigue (p=0.44), headache (p=0.58) and dystonia (p=0.06) had no significant difference in the two groups but the incidence of drowsiness and anxiety in the metoclopramide group was significantly higher (P < 0.001).   
0	5389230	Emergence agitation	There was a significant difference in the incidence of Emergence agitation between Groups D and C (6.98% and 58%, respectively, with P = 0.001).
1	5389230	Discharge times	Extubation, emergence, and discharge times were comparable in both groups, and none of the subjects reported any adverse effects.  
0	5389230	Median scores of Face, Legs, Activity, Cry and Consolability pain	The median four-point agitation scales and the median scores of Face, Legs, Activity, Cry and Consolability pain scales of Group D were significantly lower than those of Group C at the all six time points with P < 0.05.
0	5129854	diurnal intraocular pressure (intraocular pressure)	At week 6, mean diurnal intraocular pressure with BBFC+PGA was lower than with vehicle+PGA (17.1±0.4 mm Hg vs 20.5±0.4 mm Hg; between-group difference, −3.4±0.5 mm Hg; P<0.0001; 95% confidence interval, −4.5 to −2.4 mm Hg).
0	4759876	Allogeneic transfusion requirements	Allogenic transfusion requirements between subcutaneous drainage group and intraarticular drainage groups (6.4% vs. 24.1%) were significantly different (P = 0.002).
1	1781578	C-reactive protein levels	RESULTS: There was no statistical difference between C-reactive protein levels at baseline (1.53 +/- 1.01 mg/l), after nine sessions of control autohemotherapy (1.48 +/- 0.96 mg/l), and after nine sessions of ozonated autohemotherapy (1.55 +/- 0.84 mg/l).
1	1781578	Interleukin-6 serum concentration	There was also no statistical difference between the interleukin-6 serum concentration at baseline (438 +/- 118 pg/ml), after nine sessions of control autohemotherapy (444 +/- 120 pg/ml), and after nine sessions of ozonated autohemotherapy (466 +/- 152 pg/ml).
2	4223523	sleep efficiency	A significant improvement in olanzapine-treated participants over placebo-treated participants was observed in secondary outcome measures, including sleep efficiency, total sleep time, and sleep latency.
1	4223523	Spatial Working Memory (Spatial Working Memory), Spatial Span (Spatial Span), and Reaction Time (Reaction Time) tasks	There was no significant difference between olanzapine- and placebo-treated participants in Spatial Working Memory, Spatial Span or Reaction Time tasks.  
2	3162205	Mean fusion mass volume	The fusion mass volumes and bone absorption percentage at 12 months postoperatively were 2.49 mL (58.4%) and 1.89 mL (69.5%) for the β-CPP and autograft groups, respectively, and mean fusion mass volume was significantly higher in the β-CPP group.  
1	3162205	Lenke scores at 12 months	The control sides treated with an autograft showed significantly better Lenke scores than the study sides treated with β-CPP at 3 and 6 months postoperatively, but there was no difference between the two sides at 12 months.
1	3162205	Fusion rates	The fusion rates (confirmed by 3 dimensional computed tomography) were 87.0% in the β-CPP group and 89.1% in the autograft group, which were not significantly different.
0	5592353	Waist circumference	Between group results obtained over the course of a year showed statistically significant mean differences between weight (–3.4 kg (95% CI –5.5, –1.3)), body mass index kg/m2 (–1.14 (95% CI –1.9, –0.41)), waist circumference (–4.6 cm (95% CI –6.8, –2.3)), hip circumference (–4.0 cm (95% CI –5.9, –2.0)) and fasting insulin (2.43 μU/ml (95% CI 0.6, 4.3)).
0	5592353	Hip circumference	Between group results obtained over the course of a year showed statistically significant mean differences between weight (–3.4 kg (95% CI –5.5, –1.3)), body mass index kg/m2 (–1.14 (95% CI –1.9, –0.41)), waist circumference (–4.6 cm (95% CI –6.8, –2.3)), hip circumference (–4.0 cm (95% CI –5.9, –2.0)) and fasting insulin (2.43 μU/ml (95% CI 0.6, 4.3)).
1	5592353	Glucose	Mean differences of changes in glucose and lipid levels were statistically non significant: fasting glucose (–0.01 mmol/l (95% CI –0.19, 0.17)), TC mmol/l (–0.04 mmol/l (95% CI –0.29, 0.21)), HDL-C (0.14 mmol/l (95% CI –0.65, 0.09)), LDL-C (–0.02 mmol/l (95% CI –0.22, 0.18)) and TG (0.23 mmol/l (95% CI –0.06, 0.52)).  
1	5592353	Total cholesterol	Mean differences of changes in glucose and lipid levels were statistically non significant: fasting glucose (–0.01 mmol/l (95% CI –0.19, 0.17)), TC mmol/l (–0.04 mmol/l (95% CI –0.29, 0.21)), HDL-C (0.14 mmol/l (95% CI –0.65, 0.09)), LDL-C (–0.02 mmol/l (95% CI –0.22, 0.18)) and TG (0.23 mmol/l (95% CI –0.06, 0.52)).  
0	5592353	Weight	Between group results obtained over the course of a year showed statistically significant mean differences between weight (–3.4 kg (95% CI –5.5, –1.3)), body mass index kg/m2 (–1.14 (95% CI –1.9, –0.41)), waist circumference (–4.6 cm (95% CI –6.8, –2.3)), hip circumference (–4.0 cm (95% CI –5.9, –2.0)) and fasting insulin (2.43 μU/ml (95% CI 0.6, 4.3)).
0	5592353	Weight	We found a statistically significant decrease in weight (2.4%), body mass index and waist circumference (4.8%) in the intervention group, while the control group showed a statistically non-significant increase in weight and body mass index and decrease in waist circumference.
0	5592353	body mass index	Between group results obtained over the course of a year showed statistically significant mean differences between weight (–3.4 kg (95% CI –5.5, –1.3)), body mass index kg/m2 (–1.14 (95% CI –1.9, –0.41)), waist circumference (–4.6 cm (95% CI –6.8, –2.3)), hip circumference (–4.0 cm (95% CI –5.9, –2.0)) and fasting insulin (2.43 μU/ml (95% CI 0.6, 4.3)).
0	5592353	body mass index	We found a statistically significant decrease in weight (2.4%), body mass index and waist circumference (4.8%) in the intervention group, while the control group showed a statistically non-significant increase in weight and body mass index and decrease in waist circumference.
2	5033379	Readiness for managing maternal sepsis	The providers in the intervention arm had better knowledge of active management of the third stage of labour (82.4% vs.35.8%, adjusted odds ratio (adjusted odds ratio) 10, 95% C.I 5.5 to 18.2); management of maternal sepsis (73.5% vs. 10.9%, adjusted odds ratio 36.1, 95% C.I 13.6 to 95.9); neonatal resuscitation (48.5% vs.11.7%, adjusted odds ratio 10.7, 95% C.I 4.6 to 25.0) and low birth weight newborn care (58.1% vs. 40.9%, adjusted odds ratio 2.4, 95% C.I 1.2 to 4.7).
2	5033379	Readiness for managing obstructed labour	A higher number of facilities in the intervention arm had all appropriate drugs, equipment and supplies to deal with gestational hypertension (19 vs.3, odds ratio (odds ratio) 9.2, 95% C.I 2.5 to33.6), postpartum haemorrhage (29 vs. 12, odds ratio 3.7, 95% C.I 1.6 to8.3); and obstructed labour (25 vs.9, odds ratio 3.4, 95% CI 1.6 to8.3).
2	5033379	Readiness for managing gestational hypertension	A higher number of facilities in the intervention arm had all appropriate drugs, equipment and supplies to deal with gestational hypertension (19 vs.3, odds ratio (odds ratio) 9.2, 95% C.I 2.5 to33.6), postpartum haemorrhage (29 vs. 12, odds ratio 3.7, 95% C.I 1.6 to8.3); and obstructed labour (25 vs.9, odds ratio 3.4, 95% CI 1.6 to8.3).
2	5033379	Readiness for managing postpartum hemorrhage	A higher number of facilities in the intervention arm had all appropriate drugs, equipment and supplies to deal with gestational hypertension (19 vs.3, odds ratio (odds ratio) 9.2, 95% C.I 2.5 to33.6), postpartum haemorrhage (29 vs. 12, odds ratio 3.7, 95% C.I 1.6 to8.3); and obstructed labour (25 vs.9, odds ratio 3.4, 95% CI 1.6 to8.3).
2	5033379	Knowledge on active management of third stage of labor	The providers in the intervention arm had better knowledge of active management of the third stage of labour (82.4% vs.35.8%, adjusted odds ratio (adjusted odds ratio) 10, 95% C.I 5.5 to 18.2); management of maternal sepsis (73.5% vs. 10.9%, adjusted odds ratio 36.1, 95% C.I 13.6 to 95.9); neonatal resuscitation (48.5% vs.11.7%, adjusted odds ratio 10.7, 95% C.I 4.6 to 25.0) and low birth weight newborn care (58.1% vs. 40.9%, adjusted odds ratio 2.4, 95% C.I 1.2 to 4.7).
2	1488892	Increase in CD4 T lymphocyte count	Compared to the control group, significant increases in CD4 cell count were observed for both interleukin-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 million international units dose groups, respectively.
2	1488892	Increase in CD4 T lymphocyte count	Compared to the control group, significant increases in CD4 cell count were observed for both interleukin-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 million international units dose groups, respectively.
2	1488892	Change in CD4 T lymphocyte count at 24 weeks	Area under curve (Area under curve) for change in the mean CD4 T lymphocyte count through 24 wk was 129 cells/mm3 for those assigned interleukin-2 (both dose groups combined) and 13 cells/mm3 for control participants (95% CI for difference, 51.3–181.2 cells/mm3; p = 0.0009).
1	1488892	Change in plasma HIV RNA	There were no significant differences between the interleukin-2 (0.13 log10 copies/ml) and control (0.09 log10 copies/ml) groups for Area under curve of change in plasma HIV RNA over the 24-wk period of follow-up (95% CI for difference, −0.17 to 0.26; p = 0.70).
0	5380326	Interferon gamma-induced protein 10	Our important finding revealed that upon correction of vitamin D insufficiency or deficiency, the serum gamma-induced protein 10 and DPP IV levels were decreased significantly as compare to the placebo group (delta changes; 83.27 vs -133.80; 95% CI [-326.910, -40.758], p = 0.0125, and 271.04 vs -518.69; 95% CI [-1179,15, -59.781], p = 0.0305, respectively.
2	5380326	Vitamin D levels	At the end of study, the mean 25(OH)D level in vitamin D group was significantly increased and normalised.
1	5380326	Th1/Th2 cytokines	There were no changes in the level of Th1/Th2 cytokines.
0	5380326	Dipeptidyl peptidase-4	Our important finding revealed that upon correction of vitamin D insufficiency or deficiency, the serum gamma-induced protein 10 and DPP IV levels were decreased significantly as compare to the placebo group (delta changes; 83.27 vs -133.80; 95% CI [-326.910, -40.758], p = 0.0125, and 271.04 vs -518.69; 95% CI [-1179,15, -59.781], p = 0.0305, respectively.
1	3585965	the rate and extent of absorption of GLPG0259	Food increased the bioavailability of GLPG0259 given in a solid dosage form. Co-administration of GLPG0259 with a single dose of methotrexate 7.5 mg did not result in any change in the pharmacokinetic profiles of either GLPG0259 or methotrexate.  
0	3806618	use of exogenous insulin - new-onset type 1 diabetes (type 1 diabetes)	We conclude that teplizumab treatment preserves insulin production and reduces the use of exogenous insulin in some patients with new-onset type 1 diabetes.
0	3806618	decline in C-peptide at 2 years - new-onset type 1 diabetes (type 1 diabetes)	In the intent to treat analysis of the primary end point, patients treated with teplizumab had a reduced decline in C-peptide at 2 years (mean −0.28 nmol/L [95% CI −0.36 to −0.20]) versus control (mean −0.46 nmol/L [95% CI −0.57 to −0.35]; P = 0.002), a 75% improvement.
2	3806618	insulin production - new-onset type 1 diabetes (type 1 diabetes)	We conclude that teplizumab treatment preserves insulin production and reduces the use of exogenous insulin in some patients with new-onset type 1 diabetes.
0	4283690	absenteeism and presenteeism	By week 24, employed certolizumab pegol patients reported an average of 1.0–1.8 and 3.0–3.9 fewer days of absenteeism and presenteeism, respectively, per month compared with 1.0 and 0.3 fewer days for placebo patients (p<0.05).
2	4283690	household work days	Within the home, by week 24, certolizumab pegol patients reported an average of 3.0–3.5 household work days gained per month versus 1.0 day for placebo (p<0.05).
2	4119719	effectiveness after early ischemic stroke	This study indicated that four-channel FES can improve motor function, balance, walking ability, and performance of activities of daily living in subjects with early ischemic stroke.
2	4119719	activities of daily living	This study indicated that four-channel FES can improve motor function, balance, walking ability, and performance of activities of daily living in subjects with early ischemic stroke.
1	3982948	birth characteristics, complications during the prenatal period, the need for mechanical ventilation during the first 5 days of life, use of surfactant	The routine (n=99) and continuous positive airway pressure (n=98) infants studied presented no statistically significant differences regarding birth characteristics, complications during the prenatal period, the need for mechanical ventilation during the first 5 days of life (19.2 vs 23.4%, P=0.50), use of surfactant (18.2 vs 17.3% P=0.92), or respiratory morbidity and mortality until discharge.
2	3982948	number of doses of surfactant	The continuous positive airway pressure group required a greater number of doses of surfactant (1.5 vs 1.0, P=0.02).
2	4889193	Achieving the predefined target	Patients following the rapid protocol reached higher doses of captopril (0.93±0.24 versus 0.57±0.38 mg/kg per dose, P<0.0001) and were more likely to have achieved the predefined target (88% versus 43%, P=0.002) and optimal ACEI doses (80% versus 29%, P=0.001) before discharge.  
1	4889193	Hypotension	There were no differences between the protocols in episodes of hypotension, symptomatic hypotension, or indices of renal function.
1	4889193	Symptomatic hypotension	There were no differences between the protocols in episodes of hypotension, symptomatic hypotension, or indices of renal function.
1	4889193	Renal function	There were no differences between the protocols in episodes of hypotension, symptomatic hypotension, or indices of renal function.
2	4889193	Captopril doses	Patients following the rapid protocol reached higher doses of captopril (0.93±0.24 versus 0.57±0.38 mg/kg per dose, P<0.0001) and were more likely to have achieved the predefined target (88% versus 43%, P=0.002) and optimal ACEI doses (80% versus 29%, P=0.001) before discharge.  
2	4889193	Achieving optimal ACE inhibitors doses	Patients following the rapid protocol reached higher doses of captopril (0.93±0.24 versus 0.57±0.38 mg/kg per dose, P<0.0001) and were more likely to have achieved the predefined target (88% versus 43%, P=0.002) and optimal ACEI doses (80% versus 29%, P=0.001) before discharge.  
2	5560514	pain reduction up to 3 weeks in patients with knee osteoarthritis - anteromedial subgroup	Greater pain reductions with Cingal up to 3 weeks were only significant in the anteromedial subgroup.
2	5560514	pain reduction up to 3 weeks in patients with knee osteoarthritis - anteromedial subgroup	Greater pain reductions with Cingal up to 3 weeks were only significant in the anteromedial subgroup.
2	5739798	Overall survival	The 3 years progression free survival and overall survival for SP vs. S were 71.9% vs. 46.9%, and 88.4% vs. 67.0%, respectively. Differences in progression free survival and overall survival between two treatment groups were significant with the p values of 0.0165 and 0.0191, respectively, using Log-Rank test.  
2	5739798	Overall survival	The hazard ratios after adjusting of age and disease stage (S vs. SP) of progression free survival and overall survival are 1.772 (95% CI, 1.102 to 2.848) and 2.047 (95% CI, 1.109 to 3.377), respectively.
0	5739798	Metastasis	Recurrence or metastasis (Recurrence or metastasis) after surgery were 24/82 (29.27%) in SP group and 37/81 (45.68%) in S group. The difference in the Recurrence or metastasis rate was statistically significant (p = 0.0304) by chi-square test.
2	5739798	Progression free survival	The hazard ratios after adjusting of age and disease stage (S vs. SP) of progression free survival and overall survival are 1.772 (95% CI, 1.102 to 2.848) and 2.047 (95% CI, 1.109 to 3.377), respectively. The 3 years progression free survival and overall survival for SP vs. S were 71.9% vs. 46.9%, and 88.4% vs. 67.0%, respectively. Differences in progression free survival and overall survival between two treatment groups were significant with the p values of 0.0165 and 0.0191, respectively, using Log-Rank test.  
1	3427491	Hepatic disorders and asthenia	Grades 3 and 4 neutropenia (p < 0.0001) and leukopenia (p = 0.028) were more common with the FOLFOX4 regimen, while hepatic disorders and asthenia were higher in TOMOX group (p = ns).
1	3427491	Progression-free survival	No statistically significant differences were observed in overall survival (15.6 and 17.2 months; p = 0.475); progression-free survival (7.7 and 8.7 months; p = 0.292), and response duration (6.4 and 7.6 months; p = 0.372) for TOMOX and FOLFOX4, respectively.
1	3427491	Survival rate	No statistically significant differences were observed in overall survival (15.6 and 17.2 months; p = 0.475); progression-free survival (7.7 and 8.7 months; p = 0.292), and response duration (6.4 and 7.6 months; p = 0.372) for TOMOX and FOLFOX4, respectively.
1	3427491	Response duration	No statistically significant differences were observed in overall survival (15.6 and 17.2 months; p = 0.475); progression-free survival (7.7 and 8.7 months; p = 0.292), and response duration (6.4 and 7.6 months; p = 0.372) for TOMOX and FOLFOX4, respectively.
0	3427491	Neutropenia and leukopenia	Grades 3 and 4 neutropenia (p < 0.0001) and leukopenia (p = 0.028) were more common with the FOLFOX4 regimen, while hepatic disorders and asthenia were higher in TOMOX group (p = ns).
2	3441280	concentrations of the final catabolic product of adenosine 5′-triphosphate, uric acid	In contrast, concentrations of the final catabolic product of adenosine 5′-triphosphate, uric acid, were significantly increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003) and naso-duodenal tube (P = 0.001), but not after administration via distal-release pellets.  
1	3441280	concentrations of the final catabolic product of adenosine 5′-triphosphate, uric acid	In contrast, concentrations of the final catabolic product of adenosine 5′-triphosphate, uric acid, were significantly increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003) and naso-duodenal tube (P = 0.001), but not after administration via distal-release pellets.  
2	3441280	concentrations of the final catabolic product of adenosine 5′-triphosphate, uric acid	In contrast, concentrations of the final catabolic product of adenosine 5′-triphosphate, uric acid, were significantly increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003) and naso-duodenal tube (P = 0.001), but not after administration via distal-release pellets.  
0	4630743	Pain on cervical dilatation	Only 3.61% patients complained of intolerable pain during dilatation in the study group while in control group 48.74% complained of intolerable pain and required anesthesia.
2	5325897	First 2 tests results	Mean scores of first and second evaluations were 10.24 ± 0.77, 17.73 ± 0.46 in feedback receivers and 9.73 ± 0.77 and 12.13 ± 0.47 in others (p < 0.001).
0	5852772	Serum Intact Parathyroid Hormone (intact parathyroid hormone) level at 20 weeks - severe secondary hyperparathyroidism (secondary hyperparathyroidism) hemodialysis (hemodialysis) patients	A significantly lower intact parathyroid hormone level was noted from the 20th week in the study group compared to the placebo group, and the target intact parathyroid hormone ≤ 300 pg/mL was achieved at the 24th week in the study group.
2	3652505	positive evaluation	If the drug effect was described as "of 100 patients taking this kind of medicine, 70 patients became better", people tended to make more positive evaluations, compared with described as "of 100 patients taking this kind of medicine, 30 patients didn't become better" (P < 0.01).
1	3395326	average total blood loss	Gender, BMI, ASA score, total and hidden blood losses, calculated blood loss, preop PLT, PT, PTT, and INR were similar between groups.
1	3395326	hidden blood loss	Gender, BMI, ASA score, total and hidden blood losses, calculated blood loss, preop PLT, PT, PTT, and INR were similar between groups.
1	4758401	Elevation of glucose and glucagon after 1 hour	All ratios reduced 0–3‐h glucose and glucagon increments by >50%.
1	4758401	Hypoglycemia after 24 hours	No hypoglycaemia occurred.
1	4780150	Total body stores of vitamin A	After intervention, total body stores (total body stores) and liver retinol concentrations did not differ between intervention and control groups; total body stores were 436 (SD 303) and 434 (SD 186) μmol, respectively, and estimated liver concentrations were 0·82 (SD 0·53) and 0·79 (SD 0·36) μmol/g liver, indicating adequate reserves in all children.  
1	4780150	Vitamin A concentrations in the liver	After intervention, total body stores (total body stores) and liver retinol concentrations did not differ between intervention and control groups; total body stores were 436 (SD 303) and 434 (SD 186) μmol, respectively, and estimated liver concentrations were 0·82 (SD 0·53) and 0·79 (SD 0·36) μmol/g liver, indicating adequate reserves in all children.  
1	4780150	Baseline modified relative dose response values	At baseline, the modified relative dose response values (95 % CI) for infants were comparable in the intervention and control groups: normal at 0·032 (SD 0·018) (0·025–0·038) and 0·031 (SD 0·018) (0·024–0·038), respectively.
1	5598124	mean use of nitroglycerin (TNG)	During the follow-up period, mean heart rate (P = 0.649) and TNG usage (P = 0.527) were similar in two groups.  
1	5598124	mean heart rate during follow-up period	In the lidocaine group, compared with the placebo group, mean systolic blood pressure, diastolic blood pressure, and mean arterial pressure significantly reduced after cannulation (P < 0.05). During the follow-up period, mean heart rate (P = 0.649) and TNG usage (P = 0.527) were similar in two groups.  
0	5598124	systolic blood pressure (systolic blood pressure)	In the lidocaine group, compared with the placebo group, mean systolic blood pressure, diastolic blood pressure, and mean arterial pressure significantly reduced after cannulation (P < 0.05).
0	5598124	mean arterial pressure (mean arterial pressure)	In the lidocaine group, compared with the placebo group, mean systolic blood pressure, diastolic blood pressure, and mean arterial pressure significantly reduced after cannulation (P < 0.05).
0	4477402	Length of intensive care units	Length of intensive care units stay was significantly higher in late extubation group (4.2 ± 1.2 days) than the Ultra fast-track extubation group (1.72 ± 1.5 days) (P = 0.02).
1	4477402	The length of survival	In survival analysis there was no significant difference between ultra-fast and late extubation groups (Log-rank test, P = 0.9).  
1	3705347	Anthropometric measurements	Subjects were analyzed for anthropometric measurements, bioelectric impedance with vectorial analysis (bioelectric impedance with vectorial analysis), IL-6 and TNF-α. A comparison between groups did not show any difference for the variables investigated.
1	2948428	nausea and vomiting	The number of patients reporting gastrointestinal adverse events did not increase following titration to higher doses of taspoglutide or when continuing the initial 20 mg regimen.
0	2948428	HbA1c	The proportion of subjects achieving HbA1c < 7.0% after 8 weeks of treatment was 72, 53 and 70% in the 20/20-, 20/30- and 20/40-mg arms, respectively, vs. 19% for placebo.  
2	5838916	Knowledge improvement	Knowledge scores in the intervention group at first, second, and third visits were 9.8 ± 1.8, 10.2 ± 1.6, and 11.0 ± 1.7, respectively. The knowledge scores in the control group at first, second, and third visits were 9.9 ± 1.7, 9.8 ± 1.6, and 10.0 ± 1.8, respectively. The change in knowledge score was statistically significant (P < 0.001) at third visit compared to first in the intervention group but not in the control group (P = 0.62).
2	5838916	Practice improvement	Practice score also improved significantly (P < 0.001) in the intervention group in the second visit but not in the control group.  
2	4231047	Minimal mean hepatic threshold dose 6 weeks after radiotherapy	Minimal mean hepatic threshold dose 6 weeks after radiotherapy (primary endpoint) was significantly higher in the study treatment-group compared with the control (19.1 Gy versus 14.6 Gy, p = 0.011).
1	4231047	Focal radiation-induced liver injury at 12 weeks	Qualitative evidence of focal radiation-induced liver injury by magnetic resonance imaging at 6 weeks was observed in 45.5% of patients in the treatment versus 90.9% of the control group. No significant differences between the groups were observed at the 12-week follow-up.  
2	4115605	Improvement in symptom-impact subscore	Improvement in symptom-impact subscore favored droxidopa by 1.06 units (p = 0.003), with maximum change for "standing a long time."
2	4115605	Mean standing systolic blood pressure (blood pressure), mean supine systolic blood pressure	Mean standing systolic blood pressure (blood pressure) increased by 11.2 vs 3.9 mm Hg (p < 0.001), and mean supine systolic blood pressure by 7.6 vs 0.8 mm Hg (p < 0.001).
1	4115605	adverse events	No patients discontinued double-blind treatment because of adverse events.  
2	4115605	Improvement Orthostatic Hypotension Questionnaire (Orthostatic Hypotension Questionnaire)	Improvement in Orthostatic Hypotension Questionnaire symptom subscore favored droxidopa by 0.73 units (p = 0.010), with maximum change in "dizziness/lightheadedness."
2	4115605	Improvement Orthostatic Hypotension Questionnaire (Orthostatic Hypotension Questionnaire)	From randomization to endpoint (n = 162), improvement in mean Orthostatic Hypotension Questionnaire composite score favored droxidopa over placebo by 0.90 units (p = 0.003).
1	4689520	Median endurance time	Median endurance time did not differ significantly; nitrate 5.65 (3.90–10.40) minutes vs. placebo 6.40 (4.01–9.67) minutes (p = 0.50).
0	4689520	Isotime oxygen consumption	However, isotime oxygen consumption (VO2) was lower following nitrate supplementation (16.6±6.0ml/min/kg nitrate vs. 17.2±6.0ml/min/kg placebo; p = 0.043), and consequently nitrate supplementation caused a significant lowering of the amplitude of the VO2-percentage isotime curve.  
0	4689520	Resting diastolic blood pressure	Resting diastolic blood pressure fell significantly with nitrate supplementation compared to placebo (-7±8mmHg nitrate vs. -1±8mmHg placebo; p = 0.008).
2	5091897	Household smoking bans	Participants assigned to the intervention condition were more likely than controls to report a full ban on smoking in the home at both 3- (38.1% vs 19.3%, p = < .001) and 6-month follow-up (43.2% vs 33.2%, p = .02).
2	4808543	Improvement of Total Nasal Symptom Score	Compared with the placebo, the experimental group showed significant improvement in Total Nasal Symptom Score, especially in nasal obstruction.
2	4808543	Improvement of fatigue level by Chalder Fatigue Scale	The aromatherapy group also showed significantly higher improvements in total score of Rhinoconjunctivitis Quality of Life Questionnaire and Chalder Fatigue Scale.
2	4808543	Improvement of Rhinoconjunctivitis Quality of Life Questionnaire scores	The aromatherapy group also showed significantly higher improvements in total score of Rhinoconjunctivitis Quality of Life Questionnaire and Chalder Fatigue Scale.
1	4993942	Peripapillary nerve fiber layer thickness	There was no difference between red and green laser considering subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increase after panretinal photocoagulation (P values: 0.184, 0.404, and 0.726, resp.).
1	4993942	Subfoveal choroidal thickness	There was no difference between red and green laser considering subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increase after panretinal photocoagulation (P values: 0.184, 0.404, and 0.726, resp.).
1	4993942	Central retinal thickness	There was no difference between red and green laser considering subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increase after panretinal photocoagulation (P values: 0.184, 0.404, and 0.726, resp.).
2	3349167	Exercise capacity	The merged lifestyle intervention resulted in statistically significant improvements in patients' systolic blood pressure, waist circumference, exercise capacity, glycaemic control, and some aspects of general health-related quality of life.
2	2720945	Quality of life	Improvement of lung function, dyspnea and quality of life as multiple criteria were statistically significant relative to placebo.
0	3144604	Social dysfunction (social dysfunction)	The General Health Questionnaire revealed that there was significant decrease in somatic symptoms, and insomnia, social dysfunction and severe depression in both Y and physical exercises groups (Wilcoxcon Singed Rank t test).
0	3144604	Severe depression (severe depression):	The General Health Questionnaire revealed that there was significant decrease in somatic symptoms, and insomnia, social dysfunction and severe depression in both Y and physical exercises groups (Wilcoxcon Singed Rank t test).
2	3144604	effect size in Sattva (gentle and controlled) subgroup	Sattva showed a significant difference within the groups and the effect size was more in the Y than in the physical exercises group.
2	3144604	effect size in Tamas (dull and uncontrolled)subgroup	Tamas showed significant reduction within the physical exercises group only.
1	1968469	change in anthropometric measurements, weight, performance status, energy, mood or pain	There was no change in anthropometric measurements, weight, performance status, energy, mood or pain in either group.
2	1968469	appetite between weeks 0 (pre-study) and 3 and 0 and 6	There was a significant improvement in appetite in the medroxyprogesterone acetate group between weeks 0 (pre-study) and 3 (P = 0.0002) and 0 and 6 (P = 0.015). There was no significant improvement in appetite in the placebo group.
2	1968469	serum thyroid binding pre-albumin and retinol binding protein	Supporting this finding was the significant increase in serum thyroid binding pre-albumin and retinol binding protein in the medroxyprogesterone acetate group between weeks 0 and 3 and 0 and 6 (P = 0.023 and P = 0.039 respectively). These two parameters showed no significant change in the placebo group.
0	4118506	Pain score	The median interquartile range pain score is worst for placebo group after LAI (5 [3-6]) and in the immediate postprocedure period (5 [4-5]) which was significantly attenuated by addition of fentanyl (3.5 [2-5] and 3 [2-4]) (P = 0.009 and 0.001 respectively).
1	4118506	Discomfort score, except after 10 minutes	Overall, fentanyl and placebo group were not statistically different with median discomfort score except at T10 (P = 0.047).  
1	3798206	Rates of myocardial infarction	Dabigatran had similar myocardial infarction rates when compared with enoxaparin or placebo.  
1	5684963	Glycemic response after dinner	Compared to the high glycemic index intervention, the low glycemic index intervention significantly reduced the glycemic response following breakfast (p = 0.02), lunch (p = 0.02) and dinner (p = 0.05).
2	5684963	Mean amplitude of glycemic excursion	The mean amplitude of glycemic excursion was significantly lower during the entire low glycemic index treatment (p = 0.03).  
2	5684963	Glycemic response after breakfast	Compared to the high glycemic index intervention, the low glycemic index intervention significantly reduced the glycemic response following breakfast (p = 0.02), lunch (p = 0.02) and dinner (p = 0.05).
2	5684963	Glycemic response after lunch	Compared to the high glycemic index intervention, the low glycemic index intervention significantly reduced the glycemic response following breakfast (p = 0.02), lunch (p = 0.02) and dinner (p = 0.05).
1	4639339	reduction in intussusception	Of 16 patients that received Midazolam, 15 patients demonstrated successful reduction; and of 16 patients that received distilled water, only 11 patients showed successful reduction (P=0.07).
1	4639339	The mean duration of a successful reduction	The mean duration of a successful reduction in the Midazolam group and placebo was 34.8±11.35 and 32.73±19.2 min, respectively (P=0.733).  
2	5331731	job satisfaction	Econometric analysis shows that Performance-based financing led to increased job satisfaction and decreased attrition on a subset of measures, with little effect on motivation.
2	3199060	Energy expenditure	An interaction was found such that in one pair, motion control (mean [SD] 0.96 [0.20] kcal · kg−1 · hr−1) produced 0.10 kcal · kg−1 · hr−1 (95% confidence interval 0.03 to 0.17) greater energy expenditure than traditional control (0.86 [0.17] kcal · kg−1 · hr−1, P =  .048).
1	5158040	Presence of diastolic dysfunction during hospitalization	Diastolic dysfunction was present in 11 (9%) of patients on metformin and 11 (9%) patients on placebo treatment (P = 0.98) during hospitalization.
1	5158040	Presence of diastolic dysfunction after 4 months	After 4 months 22 (19%) of patients with metformin and 18 (15%) patients with placebo (P = 0.47) had diastolic dysfunction.
1	5158040	Improvement of diastolic function echocardiographic markers	In addition, metformin did not improve any of the individual echocardiographic markers of diastolic function.  
1	5045523	response rate	The response rate for those receiving letters or postcards was similar (odds ratio 1.14, 95% CI 0.91-1.44, P=.26).  
1	5045523	response rate	Of those who were offered a book, 345/2973 (11.6%) responded compared with 106/993 (10.7%) who were not offered a book (odds ratio 1.10, 95% CI 0.87-1.38, P=.42).
1	3179725	Patient adherence	Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70).
1	3179725	Secondary outcomes including spontaneously expectorated sputum volume, and forced expired volume in 1 second	There were no significant differences in other secondary outcomes.  
2	3179725	Dyspnea improvement	After four treatments, a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04).
1	3179725	Patient satisfaction	Patient satisfaction was also similarly high in both groups.
2	5391070	The incidence of adverse events	The adverse event rate for Arm B (5.1%) was higher than for Arms A (2.8%) (P = 0.04) and C (1.9%) (P = 0.02).
2	5391070	The rate of H. pylori eradication	Intention-to-treat (Intention-to-treat) analysis showed that the rate of H. pylori eradication was significantly higher for Arms A (77.0%) and B (75.9%) compared to Arm C (58.6%) (P < 0.01), whereas there was no difference between Arms A and B (P = 0.90).
2	3215316	Blood transfusion interval	Statistically significant (P<0.01) result was obtained in Blood transfusion interval in group 'A' in comparison to group 'B'. Dhatri Avaleha may have a potential to increase blood transfusion interval and decrease secondary infection and thus it can be used as supportive therapy with modern medical management.
2	3423952	erythrocyte superoxide dismutase, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood	Exercise resulted in increased (P < 0.05) antioxidant defenses including erythrocyte superoxide dismutase, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1β in blood, and decreased plasma nitric oxide.
0	3423952	plasma nitric oxide	Exercise resulted in increased (P < 0.05) antioxidant defenses including erythrocyte superoxide dismutase, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1β in blood, and decreased plasma nitric oxide.
2	3423952	chondroitin sulfate-846 (CS) in synovial fluid (synovial fluid) and adjusted-PGE2,	Exercise increased (P < 0.05) synovial fluid CS and adjusted-PGE2, and higher (P < 0.05) CS and PGE2 were found in hock versus carpus joints.
1	3423952	erythrocyte superoxide dismutase, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood, and decreased plasma nitric oxide.	No treatment effects were detected.
1	3682900	Cystatin C	Contrast nephrotoxicity occurred in 22% of patients who received placebo (13/58) and 27% of patients who received N-acetylcysteine (14/52, p = 0.66). Ultra-high dose intravenous N-acetylcysteine did not alter creatinine or cystatin C levels.
1	3682900	Creatitine after 2 days	Ultra-high dose intravenous N-acetylcysteine did not alter creatinine or cystatin C levels.
1	3682900	Cystatin C after 10 days	Ultra-high dose intravenous N-acetylcysteine did not alter creatinine or cystatin C levels.
1	3682900	Creatitine after 4 days	Ultra-high dose intravenous N-acetylcysteine did not alter creatinine or cystatin C levels.
2	5551190	Distance ran	Distance ran, heart rate (heart rate) and five pre-and post-exercise emotional states were measured; (3) Results: Participants ran farther, and with higher heart rates, with self-selected entertainment compared to the two nature-based environment designs.
2	5551190	Heart rate	Distance ran, heart rate (heart rate) and five pre-and post-exercise emotional states were measured; (3) Results: Participants ran farther, and with higher heart rates, with self-selected entertainment compared to the two nature-based environment designs.
0	5551190	Happiness	Happiness increased during the two nature-based environment designs compared with self-selected entertainment;
1	5551190	Anxiety levels	Participants attained lowered anger, dejection, anxiety and increased excitement post exercise in all of the designed environments.
0	4764962	Wexner score	The results revealed a significant difference between the preoperative and postoperative Wexner scores of incontinence in all the 3 groups. Additionally, the difference between the preoperative and postoperative scores was significant only in Group I and Group III, but not in Group II. The reduction in the Wexner score was significantly less in Group III.
0	3702085	Systolic blood pressure	Overall, after the 12 weeks of allopurinol therapy, systolic and diastolic blood pressure also significantly decreased in allopurinol group, 15.8% (139 to 117, P < 0.0005) and 8.6% (81 to 74, P <.0005), respectively.
1	3702085	Creatinine	There were not significant changes in body mass index, blood urea nitrogen, creatinine, albumin, cholesterol, triglyceride, hemoglobin, liver enzymes and serum electrolytes level after treatment.
2	3702085	Quality of dialysis	Patients treated with allopurinol had a significant increase in the quality of dialysis (KT/V) (P: 0.043).  
0	3702085	Uric acid	Uric acid levels decreased significantly during the12 weeks of allopurinol therapy (7.71 ± 1.53 to 5.2 ± 1.2 P < 0.005).
0	3702085	Diastolic blood pressure	Overall, after the 12 weeks of allopurinol therapy, systolic and diastolic blood pressure also significantly decreased in allopurinol group, 15.8% (139 to 117, P < 0.0005) and 8.6% (81 to 74, P <.0005), respectively.
1	3702085	Blood urea nitrogen	There were not significant changes in body mass index, blood urea nitrogen, creatinine, albumin, cholesterol, triglyceride, hemoglobin, liver enzymes and serum electrolytes level after treatment.
1	4552663	Vasopressor use during the surgery	No significant differences existed between the groups regarding intraoperative vasopressor use during the surgery (p = 0.475).  
1	4552663	Quality of recovery after surgery	Results of the current study indicated that the preoperative administration of either CHO or oral rehydration solution did not improve the quality of recovery in patients undergoing minimally invasive body surface surgery.  
1	4552663	Quality of recovery after surgery	The median [interquartile range (interquartile range)] global Quality of Recovery 40 questionnaire scores 24 h after the surgery were 187 [177–197], 186 [171–200], and 184 [171–198] for the CHO, oral rehydration solution, and control groups, respectively (p = 0.916).
1	4552663	Quality of Recovery 40 questionnaire scores	The median [interquartile range (interquartile range)] global Quality of Recovery 40 questionnaire scores 24 h after the surgery were 187 [177–197], 186 [171–200], and 184 [171–198] for the CHO, oral rehydration solution, and control groups, respectively (p = 0.916).
1	2966708	Cortisol levels	The peak serum interleukin-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05), while the serum cortisol concentration showed a similar time course and changes and there were no significant difference between the groups.
0	2966708	interleukin-6 levels	The peak serum interleukin-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05), while the serum cortisol concentration showed a similar time course and changes and there were no significant difference between the groups.
0	2966708	interleukin-6 levels	The laparoscopic hysterectomy group demonstrated less of an inflammatory response in terms of the serum interleukin-6 and CRP responses than did the abdominal hysterectomy group, and the laparoscopic hysterectomy group had a shorter hospital stay (P < 0.05).
0	2966708	C-reactive protein	The peak serum interleukin-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05), while the serum cortisol concentration showed a similar time course and changes and there were no significant difference between the groups.
0	2966708	Hospital stay	The laparoscopic hysterectomy group demonstrated less of an inflammatory response in terms of the serum interleukin-6 and CRP responses than did the abdominal hysterectomy group, and the laparoscopic hysterectomy group had a shorter hospital stay (P < 0.05).
0	4513485	taking part in screening	Factors associated with non-uptake included: female gender (OR=0.64, p<0.001), older age (OR=0.73, p<0.001), current smoking (OR=0.70, p<0.001), lower socioeconomic group (OR=0.56, p<0.001) and higher affective risk perception (OR=0.52, p<0.001).
2	5426232	Late luminal loss	When comparing the drug-eluting balloon + bare metal stent results with the zotarolimus-eluting stent ones, late loss was 0.50 ± 0.46 mm in drug-eluting balloon + bare metal stent patients vs. 0.21 ± 0.44 mm in zotarolimus-eluting stent patients (P < 0.001).
2	2815285	Improvement in hemodynamic variables	Volume replacement produced transitory recovery in hemodynamic variables, including mean pulmonary artery pressure, pulmonary capillary wedge pressure and cardiac index, with significant increase in dogs treated with 32 mL/kg of Lactated Ringer's and 7.5% NaCl plus 6.0% dextran 70 (p<0.001, against no treatment), along with a decrease (p<0.001) in the systemic vascular resistance index.
0	4183888	Oral mucositis grade	The Oral Assessment Guide score, which was used as an index of oral mucositis, was also significantly lower in the professional oral health care group.
2	4676364	Overall willingness to eat vegetables	In the intervention kindergarten, the willingness to eat the samples increased significantly (p≤0.001, Wilcoxon and Friedman), while in the control kindergarten, no significant change was observed when all of the test samples were taken into account.
1	2361520	overall quality of life	There was no difference in overall quality of life or its individual domains between the two treatment strategies at baseline or at any subsequent time point.
1	2361520	Median survival	Median survival was not significantly better with immediate treatment (median 13.0 vs 11.0 months; hazard ratio, 1.15; 95% confidence interval (confidence interval) 0.79–1.72; P=0.49).
1	2361520	progression-free survival	There was no statistically significant difference in progression-free survival (time from randomisation until first evidence of progression after chemotherapy, 10.2 vs 10.8 months; hazard ratio, 1.08; 95% confidence interval 0.71–1.64; P=0.73).
0	3956097	physical pain after rehabilitation	Results: Our findings showed that there was a statistically significant increase in the mean score of the patients' life quality after rehabilitation. Also, the comparison of the scores of the eight aspects of patients' life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain.
2	3956097	improvement in the quality life of heart failure patients	Results: Our findings showed that there was a statistically significant increase in the mean score of the patients' life quality after rehabilitation. Also, the comparison of the scores of the eight aspects of patients' life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain. All differences were statistically significant yet, the difference regarding the aspects of psychological health and general well-being were not significant.    
2	3956097	social functioning	Also, the comparison of the scores of the eight aspects of patients' life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain. All differences were statistically significant yet, the difference regarding the aspects of psychological health and general well-being were not significant.    
2	3956097	limitation of physical health	Also, the comparison of the scores of the eight aspects of patients' life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain. All differences were statistically significant yet, the difference regarding the aspects of psychological health and general well-being were not significant.    
2	3956097	physical performance or functioning	Also, the comparison of the scores of the eight aspects of patients' life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain. All differences were statistically significant yet, the difference regarding the aspects of psychological health and general well-being were not significant.    
2	3956097	energy	Also, the comparison of the scores of the eight aspects of patients' life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain. All differences were statistically significant yet, the difference regarding the aspects of psychological health and general well-being were not significant.    
0	5207750	HbA1c	Intensive group participants had a mean six-month HbA1c (%) of 8.4 (95% CI: 8 to 8.9), while participants in the conventional education group had a mean six-month HbA1c (%) of 10.2 (95% CI: 9.8 to 10.7). The difference was statistically (P < 0.0001) and clinically significant, with intensive group participants having HbA1c outcomes on average -1.8 (95% CI: -2.4 to -1.2) percentage points lower than conventional group participants.
1	5835896	relapse-free survival (relapse-free survival) in metastatic colorectal cancer (colorectal cancer)	Three-year relapse-free survival was not significantly different between HLA-A*2402 matched and unmatched groups [67.8 vs. 73.6%, respectively; hazard ratio (HR)=1.254, 95% confidence interval (confidence interval): 0.48–4.63; P=0.706].
2	5835896	The 3-year elapse-free survival (relapse-free survival) in metastatic colorectal cancer (colorectal cancer)	Three-year relapse-free survival was significantly better in patients with positive CTL responses in the HLA-A*2402 matched group compared with those without (85.7 and 33.3%, respectively; HR=0.159, 95% confidence interval: 0.023–0.697; P=0.011).
1	2364533	Preterm delivery	Results: When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7).
1	2364533	Low birth weight	Results: When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7).
1	5338176	Shear bond strength	However, the difference between group A and C was insignificant, as was the difference between group A and B (p> 0.05).
2	5627563	Jaw relaxation	Jaw relaxation and ease of laryngeal mask airway insertion in the study group was significantly better than that of the control group (P = 0.02).
2	5627563	Laryngeal mask airway ease	Jaw relaxation and ease of laryngeal mask airway insertion in the study group was significantly better than that of the control group (P = 0.02).
0	5627563	Time to laryngeal mask airway placement	Average time needed for laryngeal mask airway placement in the study group (5/06 ± 0.52 second) was significantly lower than the control group (5/76 ± 0.67 second) (P = 0.001).
1	5627563	Hemodynamic response to laryngeal mask airway insertion	Hemodynamic response to laryngeal mask airway insertion was similar in both groups.
0	5627563	Sore throat at recovery	Sore throat at recovery and 24 h after surgery in the control group was significantly higher than that of the study group (3/30 vs. 10/30) (P = 0.01).  
0	5627563	Sore throat 24 hrs after surgery	Sore throat at recovery and 24 h after surgery in the control group was significantly higher than that of the study group (3/30 vs. 10/30) (P = 0.01).  
0	5541727	Tibial bone expansion	The MPC + hyaluronan group had reduced medial and lateral tibiofemoral joint space narrowing (p < 0.05), less tibial bone expansion (0.5% vs 4.0% over 26 weeks, p = 0.02), and a trend towards reduced tibial cartilage volume loss (0.7% vs –4.0% over 26 weeks, p = 0.10) than the hyaluronan controls.  
1	5541727	Treatment-related serious adverse events	No cell-related serious adverse effects were observed.
2	5541727	Activities of daily living	Compared with the hyaluronan group, MPC + HA-treated patients showed greater improvements in KOOS pain, symptom, activities of daily living, and SF-36 bodily pain scores (p < 0.05).
2	5541727	Symptom improvement	Compared with the hyaluronan group, MPC + HA-treated patients showed greater improvements in KOOS pain, symptom, activities of daily living, and SF-36 bodily pain scores (p < 0.05).
2	5541727	SF-36 bodily pain score improvement	Compared with the hyaluronan group, MPC + HA-treated patients showed greater improvements in KOOS pain, symptom, activities of daily living, and SF-36 bodily pain scores (p < 0.05).
1	5541727	Tibial cartilage volume loss	The MPC + hyaluronan group had reduced medial and lateral tibiofemoral joint space narrowing (p < 0.05), less tibial bone expansion (0.5% vs 4.0% over 26 weeks, p = 0.02), and a trend towards reduced tibial cartilage volume loss (0.7% vs –4.0% over 26 weeks, p = 0.10) than the hyaluronan controls.  
1	4858101	Complete response	Response was not different between groups (P = .56). None of the dogs showed complete response. In the mitoxantrone group, there were 2 (8%) partial responses (partial responses) and 18 (69%) dogs with stable disease (stable disease).
1	4858101	Progression‐free interval	The progression‐free interval was not significantly different between groups (mitoxantrone = 106 days; carboplatin = 73.5 days; P = .62; hazard ratio 0.86; 95% confidence interval 0.47–1.56).
2	4793655	Rate of improvement	However, the rate of improvement was greater for attractive versus repulsive cuing.  
1	2770415	Patients' perceptions of the therapeutic alliance	Patients' perceptions of the therapeutic alliance were very favorable at start of treatment, and no differences were found between intervention groups.
1	5450344	Adverse events	There were no adverse events.
0	5867479	Levels of S100B	The concentrations of serum S100B and nerve growth factor in dexmedetomidine group was lower than those in control group (P<0.01).
0	5867479	Levels of nerve growth factor	The concentrations of serum S100B and nerve growth factor in dexmedetomidine group was lower than those in control group (P<0.01).
2	5867479	Levels of brain-derived neurotrophic factor	The results of western blotting showed that the levels of serum brain-derived neurotrophic factor in control group and dexmedetomidine group were significantly lower than that in normal group (P<0.01), and it was higher in dexmedetomidine group than that in control group (P<0.01).
2	5867479	Scores of visual space, executive function, attention, and delayed memory	Besides, both Montreal cognitive assessment and attention network test results revealed that the visual space and executive function scores, attention scores, delayed memory scores, targeted network efficiency and executive control network efficiency in dexmedetomidine group were obviously higher than those in control group (P<0.01).
2	5867479	Targeted network efficiency and control network efficiency	Besides, both Montreal cognitive assessment and attention network test results revealed that the visual space and executive function scores, attention scores, delayed memory scores, targeted network efficiency and executive control network efficiency in dexmedetomidine group were obviously higher than those in control group (P<0.01).
2	4137650	Mean systolic arterial pressure after intubation	The mean arterial pressure was significantly increased in patients receiving placebo (P < 0.0001) and esmolol (P < 0.0001) after laryngoscopy and intubation compared with baseline value and Group D (P = 0.6294). The rise in Heart rate (P = 0.08481) and rate pressure product (P = 0.0666) at the time of intubation were minimal and was statistically significant up to 15 min in Group D.  ABSTRACT.CONCLUSIONS:. 
2	4137650	Mean arterial pressure after laryngoscopy and intubation	The mean arterial pressure was significantly increased in patients receiving placebo (P < 0.0001) and esmolol (P < 0.0001) after laryngoscopy and intubation compared with baseline value and Group D (P = 0.6294).
0	4052786	Duration of clinical symptoms	Compared to the placebo group, the treatment group showed a statistically significant decrease in duration of clinical symptoms (P = 0.044) and hospitalization (P = 0.004).
0	4052786	Duration of hospitalization	Compared to the placebo group, the treatment group showed a statistically significant decrease in duration of clinical symptoms (P = 0.044) and hospitalization (P = 0.004).
1	4610927	Demographic and anesthetic parameters	There was no significant difference among the three groups related to demographic and anesthetic parameters except the end-tidal concentration of desflurane.
2	4610927	Cumulative fentanyl dose	Additional analgesic consumption, numerical rating scale scores at 6 and 24 h, and cumulative fentanyl dose were significantly higher in group RH than in the other two groups.
0	4610927	Value of the Touch-Test sensory evaluation after surgery	The value difference of the Touch-Test sensory evaluation was significantly higher negative in group RH than in the other two groups.  
2	4610927	Pain scores as measured by the NRS at 6 hours and 24 hours after surgery	Additional analgesic consumption, numerical rating scale scores at 6 and 24 h, and cumulative fentanyl dose were significantly higher in group RH than in the other two groups.
2	4610927	Consumption of additional analgesics	Additional analgesic consumption, numerical rating scale scores at 6 and 24 h, and cumulative fentanyl dose were significantly higher in group RH than in the other two groups.
1	3487501	Leakage	There were no significant differences in impeding saliva leakage between the three experimental groups (P>0.05).  
1	3487501	Leakage	There were no significant differences in impeding saliva leakage between the three experimental groups (P>0.05).  
1	3487501	Leakage	There were no significant differences in impeding saliva leakage between the three experimental groups (P>0.05).  
2	4594140	Anaerobic power after 12 weeks	VO2max and anaerobic mean power in IJ (P < 0.05) and anaerobic power in RJ (P < 0.05) were significantly increased after 12-week training compared to CG.
2	4594140	Changes in epinephrine at 30-minute recovery	There was significantly higher changes in epinephrine of RJ compared to IJ at 30-minute recovery (P = 0.045).
1	4594140	Decrease in IgA levels	Along with increased physical stress, all groups showed reduced trend of IgA; however, there was no group difference based on different training methods.
0	3821116	Nausea	Nausea frequency was also higher in the placebo group than the pregabalin group (P = 0.003).  
0	3821116	Postoperative pain	Postoperative pain intensity in the pregabalin group at the time of recovery was significantly lower than that of the placebo group (P = 0.001) until 24 hours after the surgery.
0	3821116	Need for opioids	In the pregabalin group 17.5% of the patients received opioids while in the placebo group the figure was 52.5% (P = 0.001).
1	5453890	sedation scores	Changes in the anxiety and sedation scores on the day of surgery were not significantly different among groups, whereas the increases in systolic blood pressure and heart rate were significantly less in both triazolam groups.
1	5453890	anxiety scores	Changes in the anxiety and sedation scores on the day of surgery were not significantly different among groups, whereas the increases in systolic blood pressure and heart rate were significantly less in both triazolam groups.
0	5453890	systolic blood pressure	Changes in the anxiety and sedation scores on the day of surgery were not significantly different among groups, whereas the increases in systolic blood pressure and heart rate were significantly less in both triazolam groups.
0	5453890	heart rate	Changes in the anxiety and sedation scores on the day of surgery were not significantly different among groups, whereas the increases in systolic blood pressure and heart rate were significantly less in both triazolam groups.
1	4844154	Tinnitus related outcomes	No significant difference in tinnitus suppression was found between the standard clinical Corporation and the "Tinnitus Implant".  
1	4844154	Tinnitus suppression	No significant difference in tinnitus suppression was found between the standard clinical Corporation and the "Tinnitus Implant".  
0	5062234	The visual analog scale scores at rest and on coughing	The visual analog scale scores at rest and on coughing were significantly higher in the local infiltration group in the immediate postoperative period (P = 0.034 and P = 0.007, respectively).  
1	5062234	The 24 h morphine requirement	The 24 h morphine requirement (mean ± standard deviation) was 34.57 ± 14.64 mg in Transversus abdominis plane group and 32.76 ± 14.34 mg in local infiltration group (P = 0.688).
0	5062234	intraoperative supplemental fentanyl	The number of patients requiring intraoperative supplemental fentanyl in Transversus abdominis plane group was 8 and in local infiltration group was 16 (P = 0.028).
1	4173360	mean oxygen saturation	The upper airway morbidity and mean oxygen saturation are comparable in both the groups.
1	4173360	attenuation of hemodynamic responses	Intubating Laryngeal Mask Airway offers no advantage in attenuating the hemodynamic responses compared to direct laryngoscope.
1	4173360	success rate of intubation	The success rate of intubation through Intubating Laryngeal Mask is comparable with that of Direct Laryngoscopy.
1	4173360	upper airway morbidity	The upper airway morbidity and mean oxygen saturation are comparable in both the groups.
1	3642008	Gastrointestinal acute toxicity incidence	During the treatment comparing hypofractionation conformal treatment with C-ARM no differences was observed for gastrointestinal toxicity (grade 0–3; hypofractionation conformal treatment = 45.5%, 34%, 18.7% and 1.8% versus C-ARM = 47.6%, 35.2%, 17.2% and 0). For acute genitourinary toxicity no difference was detected between hypofractionation conformal treatment (grade 0–3; 22.3%, 54.5%, 18.7% and 4.5%) and C-ARM (grade 0–3; 25.8%, 53.3%, 17.1% and 3.8%).  
1	3642008	Genitourinary acute toxicity incidence	There was no difference between hypofractionation conformal treatment versus C-ARM for severity and incidence in genitourinary (genitourinary) and gastrointestinal (gastrointestinal) acute toxicity.
1	3642008	Genitourinary acute toxicity incidence	For acute genitourinary toxicity no difference was detected between hypofractionation conformal treatment (grade 0–3; 22.3%, 54.5%, 18.7% and 4.5%) and C-ARM (grade 0–3; 25.8%, 53.3%, 17.1% and 3.8%).  
1	3642008	Gastrointestinal acute toxicity severity	During the treatment comparing hypofractionation conformal treatment with C-ARM no differences was observed for gastrointestinal toxicity (grade 0–3; hypofractionation conformal treatment = 45.5%, 34%, 18.7% and 1.8% versus C-ARM = 47.6%, 35.2%, 17.2% and 0). For acute genitourinary toxicity no difference was detected between hypofractionation conformal treatment (grade 0–3; 22.3%, 54.5%, 18.7% and 4.5%) and C-ARM (grade 0–3; 25.8%, 53.3%, 17.1% and 3.8%).  
1	3642008	Genitourinary acute toxicity severity	There was no difference between hypofractionation conformal treatment versus C-ARM for severity and incidence in genitourinary (genitourinary) and gastrointestinal (gastrointestinal) acute toxicity.
1	2900076	Deep vein thrombosis	None of the patients in any of the groups developed deep vein thrombosis.
0	2900076	Units of PRBC needed	Control group patients received 26 units of PRBC as compared to 4 units in tranexamic acid groups (p<0.001).
0	2900076	Mean volume of drainage fluid	The mean volume of drainage fluid was 270 ml and 620 ml for unilateral(U/L) and bilateral(B/L) TKR patients in placebo group. Whereas it was 160ml and 286 ml respectively in unilateral(U/L) and bilateral(B/L) TKR patients who received tranexamic acid. This was considered statistically significant.
1	3878029	Smoking abstinence after 2 weeks	Smoking abstinence self-efficacy did not differ between the interventions (p = .14) at the 2-week follow-up, but non-smokers in the hypnosis group experienced reduced withdrawal (p = .02).
1	3878029	Cigarettes smoked per day	The intervention had no effect on smoking status (p = .73) or on the number of cigarettes smoked per day (p = .56).
1	3878029	Adverse reactions	Both interventions produced few adverse reactions (p = .81).  
1	3878029	Smoking status	The intervention had no effect on smoking status (p = .73) or on the number of cigarettes smoked per day (p = .56).
0	5426394	Pain	The lowest pain score related to endoscopy was obtained for oxymetazoline+lidocaine (P<0.001).
2	5426394	Nasal decongestion	Nasal decongestion was best achieved with NS+oxymetazoline (P<0.001).
2	5426394	Discomfort	The discomfort caused by lidocaine was significantly higher than that caused by the other sprays (P<0.001).
2	5426394	Discomfort	The discomfort caused by lidocaine was significantly higher than that caused by the other sprays (P<0.001).
1	5426394	Blood pressure	Statistically significant mean blood pressure changes were only seen with the application of NS+oxymetazoline (P<0.05). However, neither mean blood pressure nor pulse rate change was significant clinically.  
1	5426394	Heart rate	Statistically significant mean blood pressure changes were only seen with the application of NS+oxymetazoline (P<0.05). However, neither mean blood pressure nor pulse rate change was significant clinically.  
0	5426394	Endoscopy duration	Endoscopy duration was the shortest for oxymetazoline+ lidocaine (P<0.05).
1	4950066	Glycated hemoglobin	There was no effect of vitamin D supplementation on HbA1c: D2 versus placebo: −0.05% [95% confidence interval (confidence interval) −0.11, 0.02] or −0.51 mmol/mol (95% confidence interval −1.16, 0.14; p = 0.13); D3 versus placebo: 0.02% (95% confidence interval −0.04, 0.08) or 0.19 mmol/mol (95% confidence interval −0.46, 0.83; p = 0.57).
1	4950066	Glycated hemoglobin	There was no effect of vitamin D supplementation on HbA1c: D2 versus placebo: −0.05% [95% confidence interval (confidence interval) −0.11, 0.02] or −0.51 mmol/mol (95% confidence interval −1.16, 0.14; p = 0.13); D3 versus placebo: 0.02% (95% confidence interval −0.04, 0.08) or 0.19 mmol/mol (95% confidence interval −0.46, 0.83; p = 0.57).
0	4950066	Arterial Stiffness (Pulse Wave Velocity)	There were no clinically meaningful effects on secondary outcomes, except pulse wave velocity [D2 versus placebo: −0.68 m/s (95% confidence interval −1.31, −0.05); D3 versus placebo −0.73 m/s (95% confidence interval −1.42, −0.03)].
0	4950066	Arterial Stiffness (Pulse Wave Velocity)	There were no clinically meaningful effects on secondary outcomes, except pulse wave velocity [D2 versus placebo: −0.68 m/s (95% confidence interval −1.31, −0.05); D3 versus placebo −0.73 m/s (95% confidence interval −1.42, −0.03)].
0	3926947	Need for reminders	There was less need for reminders in the Interactive Voice Response group (p = 0.000).
2	3926947	Responsiveness	The response rate for complete answers was 65% in the Interactive Voice Response group and 38% in the postal survey group (p = 0.014).
1	5091022	Hematocrit after 72 hrs	Regarding the hematocrit, there were no differences between groups in measured periods (24, 48, and 72 h after surgery).
1	5091022	Total blood suctioned after 48 hrs	The total bleeding measured at the suction drains within 48 h was higher in Group II, with a statistically significant difference (p = 0.005); in the first 24 h, there was major bleeding in Group II (mean 893 mL), with a significant difference (p = 0.004). Between 24 and 48 h, there was no statistically significant difference in both groups (p = 0.710). The total estimated bleeding was higher in Group I, with mean of 463 mL, versus 409 mL in Group II, with no statistical significance (p = 0.394).  
0	5091022	Total blood suctioned after 24 hrs	The total bleeding measured at the suction drains within 48 h was higher in Group II, with a statistically significant difference (p = 0.005); in the first 24 h, there was major bleeding in Group II (mean 893 mL), with a significant difference (p = 0.004).
1	5091022	Hematocrit after 24 hrs	Regarding the hematocrit, there were no differences between groups in measured periods (24, 48, and 72 h after surgery).
1	5091022	Estimated blood loss	The total bleeding measured at the suction drains within 48 h was higher in Group II, with a statistically significant difference (p = 0.005); in the first 24 h, there was major bleeding in Group II (mean 893 mL), with a significant difference (p = 0.004). Between 24 and 48 h, there was no statistically significant difference in both groups (p = 0.710).
0	4511304	Glycated hemoglobin	In study 03-1, luseogliflozin significantly decreased glycated hemoglobin at the end of the 24-week double-blind period compared with the placebo (–0.88%, P < 0.001), and glycated hemoglobin reduction from baseline at week 52 was –0.63%.
0	4511304	Glycated hemoglobin	In study 03-1, luseogliflozin significantly decreased glycated hemoglobin at the end of the 24-week double-blind period compared with the placebo (–0.88%, P < 0.001), and glycated hemoglobin reduction from baseline at week 52 was –0.63%. In study 03-2, luseogliflozin added to other oral antidiabetic drugs significantly decreased glycated hemoglobin from baseline at week 52 (–0.52 to –0.68%, P < 0.001 for all oral antidiabetic drugs).
0	4511304	Glycated hemoglobin	In study 03-2, luseogliflozin added to other oral antidiabetic drugs significantly decreased glycated hemoglobin from baseline at week 52 (–0.52 to –0.68%, P < 0.001 for all oral antidiabetic drugs).
0	4511304	Glycated hemoglobin	In study 03-2, luseogliflozin added to other oral antidiabetic drugs significantly decreased glycated hemoglobin from baseline at week 52 (–0.52 to –0.68%, P < 0.001 for all oral antidiabetic drugs).
0	4511304	Glycated hemoglobin	In study 03-2, luseogliflozin added to other oral antidiabetic drugs significantly decreased glycated hemoglobin from baseline at week 52 (–0.52 to –0.68%, P < 0.001 for all oral antidiabetic drugs).
0	4511304	Glycated hemoglobin	In study 03-2, luseogliflozin added to other oral antidiabetic drugs significantly decreased glycated hemoglobin from baseline at week 52 (–0.52 to –0.68%, P < 0.001 for all oral antidiabetic drugs).
0	2772252	Catheter-associated urinary tract infection (Catheter-associated urinary tract infection)	Forty percent of the subjects in the control group developed Catheter-associated urinary tract infection, while none of the subjects in study group developed Catheter-associated urinary tract infection. (Fisher's exact test, P value < 0.001) Pseudomonas aeruginosa (51%) was the commonest pathogen.  
2	2912679	Positive And Negative Symptoms Scale (Positive And Negative Symptoms Scale)	Six weeks after switching to aripiprazole, patients showed improvements in Positive And Negative Symptoms Scale scores (P< 0.001), EPS, prolactin levels and weight over the baseline levels.
1	2912679	Extrapyramidal symptoms (EPS), prolactin levels and weight	Six weeks after switching to aripiprazole, patients showed improvements in Positive And Negative Symptoms Scale scores (P< 0.001), EPS, prolactin levels and weight over the baseline levels.
1	5126155	The effective pacing rate immediately after the procedure	Effective pacing rates of trial and control groups were comparable both in the full analysis set and the per protocol set (81.4% vs. 79.5%, P = 0.712 and 95.4% vs. 89.5%, P = 0.143, respectively).
2	3627033	Disease Activity Score 28 joints C-reactive protein (DAS28-CRP) and simplified disease activity index (simplified disease activity index) score	Most patients received combined 50 mg golimumab plus methotrexate (41/43). In these patients, the primary endpoint, clinical remission, was attained in 83 % of patients according to DAS28-CRP criteria (p < 0.001) and 69 % according to simplified disease activity index criteria (p < 0.001) by week 24.
0	5808274	Hospital stay	The mean hospital stay was less in group A (p<0.03), which was significant.  
2	5808274	Mean operative time	The mean operative time was less in group B than group A (74.83 min vs. 94.43 min) which was significant (p<0.001).
0	5808274	Postoperative complications	There were statistically significant differences in the post-operative pain scores, and postoperative complications compared to group B (p<0.001).
2	4776406	Probabilities of experiencing a good physical component summary	Subjects in the comprehensive care and interdisciplinary care groups were more likely to experience a good physical component summary scale trajectory (b = 0.99, odds ratio [odds ratio] = 2.69, confidence interval [confidence interval] = 7.24–1.00, p = 0.049, and b = 1.32, odds ratio = 3.75, confidence interval = 10.53–1.33, p = 0.012, respectively) than those who received usual care.
2	4776406	Probabilities of experiencing a good physical component summary	Subjects in the comprehensive care and interdisciplinary care groups were more likely to experience a good physical component summary scale trajectory (b = 0.99, odds ratio [odds ratio] = 2.69, confidence interval [confidence interval] = 7.24–1.00, p = 0.049, and b = 1.32, odds ratio = 3.75, confidence interval = 10.53–1.33, p = 0.012, respectively) than those who received usual care.
1	4776406	Probabilities of experiencing a good mental component summary	However, neither care model improved mental component summary scale.  
1	4776406	Probabilities of experiencing a good mental component summary	However, neither care model improved mental component summary scale.  
0	5003313	Symptom severity after 8 weeks	The symptom severity of this syndrome meaningfully changed eight weeks after intervention in the intervention group compared to the control group (P < 0.001).  
2	3528484	FEV1	All once-daily and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12.5 μg once-daily) to 160 mL (glycopyrronium bromide 50 μg BID).
2	3528484	FEV1	All once-daily and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12.5 μg once-daily) to 160 mL (glycopyrronium bromide 50 μg BID).
2	3199893	Alzheimer's disease Cooperative Study-Activities of Daily Living (Alzheimer's disease Cooperative Study-Activities of Daily Living) scale	Significant benefits were seen on the AD Cooperative Study-Activities of Daily Living in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, Vascular risk factors.
2	3199893	Alzheimer's disease Cooperative Study-Clinical Global Impression of Change (Alzheimer's disease Cooperative Study-Clinical Global Impression of Change) score	The AD Cooperative Study-Clinical Global Impression of Change significantly improved in capsule-treated patients with, and patch-treated patients without Vascular risk factors.
1	4306068	The mean timing to analgesic administration	The mean timing to analgesic administration for the displayed and non-displayed groups were 81.3 ± 41.2 (95% C.I 65.9, 96.7) and 88.7 ± 45.4 (95% C.I 69.0, 108.3), respectively (p > 0.05).  
1	4306068	The proportion of patients who received analgesics	The proportion of patients who received analgesics when pain score was displayed was 6.5% more than when pain score was not displayed. This difference was however not statistically significant.
2	3135864	Pittsburgh sleep quality index at the 6-month follow-up	State anxiety and trait anxiety, pain, quality of life and Pittsburgh sleep quality index were significantly higher in the intervention versus placebo group after the treatment period and at the 6-month follow-up.
1	4770250	Systemic adverse events	Dual release ciprofloxacin for inhalation was well tolerated with a similar incidence of systemic adverse events to the placebo group, but fewer pulmonary adverse events.  
2	4770250	CFU/g reduction in bacterial density of Pseudomona aeruginosa	Dual release ciprofloxacin for inhalation resulted in a mean (SD) 4.2 (3.7) log10 CFU/g reduction in P aeruginosa bacterial density at day 28 (vs −0.08 (3.8) with placebo, p=0.002).
2	4770250	Time to first pulmonary exacerbation	Dual release ciprofloxacin for inhalation treatment delayed time to first pulmonary exacerbation (median 134 vs 58 days, p=0.057 modified intention to treat, p=0.046 per protocol).
2	2801838	Mean lutein concentration at week 12	At week 12, the human milk group had a sixfold higher geometric mean serum lutein (69.3 mcg/l; 95% CI 40.3–119) than the unfortified formula group (11.3 mcg/l; 95% CI 8.1–15.8).
1	4365564	Major neurological complications	The rate of major neurological complications was similar between the 2 groups (investigational = 4.4%, control = 4.0%).
0	4913581	Oxidative stress index	Supplemented cows showed a lower risk for Oxidative stress, as reflected by a lower Oxidative stress index (P = .036), different areas under the curve for the concentrations of glucose (P < .01), insulin (P = .043), and nonesterified fatty acids (P = .041), more rapid elimination rates (P = .080, <.01 and .047 respectively), and shorter half‐lives (P = .040, <.01 and .032) of these metabolites.  
2	5653840	improving of Clothespin Relocation Task	Subjects performed a 6–8 week home trial using devices remains limited by conventional and pattern recognition control with a custom prostheses made from commercially available parts. Subjects showed statistically better performance in the Southampton Hand Assessment Procedure (p = 0.04) and the Clothespin relocation task (p = 0.02).
2	1414018	Intravenous colloid usage	The Goal-directed therapy group received more intravenous colloid (1,907 SD ± 878 ml versus 1,204 SD ± 898 ml; p < 0.0001) and dopexamine (55 patients (89%) versus 1 patient (2%); p < 0.0001).
2	1414018	Dopexamine usage	The Goal-directed therapy group received more intravenous colloid (1,907 SD ± 878 ml versus 1,204 SD ± 898 ml; p < 0.0001) and dopexamine (55 patients (89%) versus 1 patient (2%); p < 0.0001).
0	1414018	Patients with complications	Fewer Goal-directed therapy patients developed complications (27 patients (44%) versus 41 patients (68%); p = 0.003, relative risk 0.63; 95% confidence intervals 0.46 to 0.87).
0	1414018	Complications per patient	The number of complications per patient was also reduced (0.7 SD ± 0.9 per patient versus 1.5 SD ± 1.5 per patient; p = 0.002).
1	1414018	60-day mortality	There was no significant difference in mortality (seven patients (11.3%) versus nine patients (15%); p = 0.59).  
0	1414018	Hospital stay duration	The median duration of hospital stay in the Goal-directed therapy group was significantly reduced (11 days (IQR 7 to 15) versus 14 days (IQR 11 to 27); p = 0.001).
1	3137438	Microleakage after three months	In both group 1 and group 2, microleakage increased after three months but this increase was not statistically significant (P>.05).  
0	5122147	Monocyte chemoattractant protein-1	We found that metformin reduced the levels of IL-6 in blood and MCP-1 in urine, but increased IL-10 levels in blood of patients with type 2 diabetes.
0	5122147	Monocyte chemoattractant protein-1	Furthermore, compared to individual drug treatment, metformin significantly reduced the levels of serum IL-6 and TNF-α, as well as urine MCP-1.
2	4329409	maintaining clinical response to week 4 following a 16-week	In active rheumatoid arthritis patients with an incomplete methotrexate response, certolizumab pegol 200 mg every 2 weeks and 400 mg every 4 weeks were comparable and better than placebo for maintaining clinical response to week 4 following a 16-week, open-label run-in phase.
2	4329409	maintaining clinical response to week 4 following a 16-week	In active rheumatoid arthritis patients with an incomplete methotrexate response, certolizumab pegol 200 mg every 2 weeks and 400 mg every 4 weeks were comparable and better than placebo for maintaining clinical response to week 4 following a 16-week, open-label run-in phase.
1	4126186	5-hydroxy-vitamin D levels	There were no within or between group significant differences in 25(OH)D levels (atorvastatin: 21.7±1.9 ng/ml at baseline and 23.5±2.3 ng/ml at week 12; rosuvastatin: 25.3±1.8 and 27.0±2.4 ng/ml, respectively; p=0.172 and p=0.306 for between groups, respectively).
1	5273788	Plasmodial reverse transcription PCR	The proportion of plasmodial RT-PCR positive children was similar in both groups at week 16 (iron polymaltose group 16.6% vs placebo group 14.3%; P = 0.47).
1	5273788	Serum ferritin	Whereas iron polymaltose supplementation failed to increased haemoglobin or ferritin concentrations, the iron polymaltose group had a significantly higher rate of occurrence of microscopically detectable parasitaemia [hazard ratio 2.2, 95% C.I. 1.2–4.0; P = 0.01].
2	5273788	Microscopically detectable parasitaemia	Whereas iron polymaltose supplementation failed to increased haemoglobin or ferritin concentrations, the iron polymaltose group had a significantly higher rate of occurrence of microscopically detectable parasitaemia [hazard ratio 2.2, 95% C.I. 1.2–4.0; P = 0.01].
2	5244277	Preference for less running out of the nose	More patients stated a preference for fluticasone furoate nasal spray versus mometasone furoate nasal spray for the attributes of "less drip down the throat" (p < 0.001), "less run out of the nose" (p < 0.05), "more soothing" (p < 0.05), and "less irritating" (p < 0.001).
2	5244277	Overall preference	Overall, 56% of patients stated a preference for fluticasone furoate nasal spray versus 32% for mometasone furoate nasal spray (p < 0.001); the remaining 12% stated no preference.
2	5244277	Preference for less dripping	More patients stated a preference for fluticasone furoate nasal spray versus mometasone furoate nasal spray for the attributes of "less drip down the throat" (p < 0.001), "less run out of the nose" (p < 0.05), "more soothing" (p < 0.05), and "less irritating" (p < 0.001).
2	5244277	Preference for more soothing	More patients stated a preference for fluticasone furoate nasal spray versus mometasone furoate nasal spray for the attributes of "less drip down the throat" (p < 0.001), "less run out of the nose" (p < 0.05), "more soothing" (p < 0.05), and "less irritating" (p < 0.001).
2	5244277	Preference for less irritating	More patients stated a preference for fluticasone furoate nasal spray versus mometasone furoate nasal spray for the attributes of "less drip down the throat" (p < 0.001), "less run out of the nose" (p < 0.05), "more soothing" (p < 0.05), and "less irritating" (p < 0.001).
1	5941723	Needle pain intensity	There were no significant differences in number of sensations elicited, Massachusetts General Hospital Acupuncture Sensation Scale index, range of spreading, and intensity of needle pain for 5 mm penetration versus 1 mm skin press and 10 mm penetration versus 2 mm skin press.
1	5941723	Massachusetts General Hospital Acupuncture Sensation Scale index	There were no significant differences in number of sensations elicited, Massachusetts General Hospital Acupuncture Sensation Scale index, range of spreading, and intensity of needle pain for 5 mm penetration versus 1 mm skin press and 10 mm penetration versus 2 mm skin press.
1	5941723	Number of sensations elicited	There were no significant differences in number of sensations elicited, Massachusetts General Hospital Acupuncture Sensation Scale index, range of spreading, and intensity of needle pain for 5 mm penetration versus 1 mm skin press and 10 mm penetration versus 2 mm skin press.
1	5941723	Spreading range	There were no significant differences in number of sensations elicited, Massachusetts General Hospital Acupuncture Sensation Scale index, range of spreading, and intensity of needle pain for 5 mm penetration versus 1 mm skin press and 10 mm penetration versus 2 mm skin press.
2	4021263	active pulmonary tuberculosis adequate specimens collection	Among the active pulmonary tuberculosis, more adequate specimens were collected from saline nebulization in clinic (41/65, 63.1%) than either by self-expectoration (34/80, 42.5%) (p=0.01).
1	4021263	Bacteriological confirmation	Bacteriological confirmation was achieved in 14 (58.3%) patients in saline nebulization in clinic, and 13 (48.1%) in either by self-expectoration (p=0.46).
2	3549413	bone mineral density (bone mineral density)	There was also a significant difference (p < 0.05) in bone mineral density between the groups at Ward's triangle in favor of the geniVidaTM bone blend group.
2	4951371	Visual analogue scale score improvement	visual analogue scale scores improved post-intervention and at the 2-week and 4-week follow-up in the intervention group (p<0.05). Respective differences in visual analogue scale scores between baseline and post-intervention in the intervention and control groups were –1.69±1.90 and –0.45±0.79, respectively (p<0.05), between baseline and 2-week follow-up in the intervention and control groups were –1.60±1.74 and –0.34±0.70, respectively (p<0.05), and between baseline and 4-week follow-up in the intervention and control groups were –1.61±1.73 and –0.33±0.71, respectively (p<0.05).
2	3556012	The frequency of defecation	The frequency of defecation in cassia fistula emulsion group improved from 1.7 per week (before the study) to 10.6 per week (at the third week) while this parameter differed in mineral oil group from 2 to 6.1 (p < 0.001).
0	3556012	The severity of pain during defecation and consistency of stool	The severity of pain during defecation and consistency of stool improved significantly better in cassia fistula emulsion group than mineral oil group (p < 0.05), but there were not any significant differences between the two groups in fecal incontinence and retentive posturing.
1	3556012	fecal incontinence and retentive posturing	The severity of pain during defecation and consistency of stool improved significantly better in cassia fistula emulsion group than mineral oil group (p < 0.05), but there were not any significant differences between the two groups in fecal incontinence and retentive posturing.
1	3556012	Drug's compliances	Drug's compliances were not significantly different in the two groups.
0	5571493	Glycemic level	The mean glycemic level during the 4-h infusion was 83 ± 5 mg/dl without quinine versus 74 ± 5 ​​mg/dl with quinine (p < 0.001) using saline solute versus 92 ± 7 mg/dl without quinine versus 82 ± 5 mg/dl with quinine (p < 0.001) when associated with the glucose solute.
1	5571493	Glycemic level	Overall, quinine did not induce a significant change in blood glucose with glucose compared to saline.  
0	5571493	Glycemic level	The mean glycemic level during the 4-h infusion was 83 ± 5 mg/dl without quinine versus 74 ± 5 ​​mg/dl with quinine (p < 0.001) using saline solute versus 92 ± 7 mg/dl without quinine versus 82 ± 5 mg/dl with quinine (p < 0.001) when associated with the glucose solute.
1	5571493	QT interval	There were no signs of hypoglycemia or significant prolongation of the QT interval at the ECG.
1	5571493	QT interval	There were no signs of hypoglycemia or significant prolongation of the QT interval at the ECG.
1	5571493	Hypoglycemia	There were no signs of hypoglycemia or significant prolongation of the QT interval at the ECG.
0	4733710	Hemoglobin at day 1 after surgery	Only the Peri-operative Transfusion Trigger Score of Emergency group on the 1st postoperative day hemoglobin was lower than group control, P < 0.05.
0	4733710	Rates of utilization of allogeneic red blood cell, total allogeneic red blood cell and total red blood cell	There were no statistical differences in utilization rates of autologous blood of the two groups; the utilization rates of allogeneic red blood cell, total allogeneic red blood cell and total red blood cell were 48.48%, 51.5%, and 75.7% in Peri-operative Transfusion Trigger Score of Emergency group, which were lower than those of the control group (84.3%, 84.3%, and 96.8%) P < 0.05 or P < 0.01.
1	4733710	Rates of utilization of autologous blood	There were no statistical differences in utilization rates of autologous blood of the two groups; the utilization rates of allogeneic red blood cell, total allogeneic red blood cell and total red blood cell were 48.48%, 51.5%, and 75.7% in Peri-operative Transfusion Trigger Score of Emergency group, which were lower than those of the control group (84.3%, 84.3%, and 96.8%) P < 0.05 or P < 0.01.
1	4733710	Baseline characteristics	There was no statistical difference between the two groups for demography and baseline information.
1	4733710	Blood transfusion-related complications and mortality rates	There was also no statistical differences between the two groups in anesthesia time, intraoperative rehydration, staying time in postanesthetic care unit, emergency hospitalization, postoperative 72 h Acute Physiologic Assessment and Chronic Health Evaluation II scores, blood transfusion-related complications and mortality.
1	4478821	Laryngeal mask airway insertion attempts	However, number of attempts for laryngeal mask airway placement was comparable among the four groups (P - 0.766).  
1	4478821	Laryngeal mask airway insertion attempts	However, number of attempts for laryngeal mask airway placement was comparable among the four groups (P - 0.766).  
0	4478821	Need of atricurium	The need of atracurium due to unacceptable surgical conditions based on surgeon satisfaction score was statistically significant when compared among the groups being maximum in Group 0 (P < 0.001).
1	4734818	Intraocular pressure after 1 hour	intraocular pressure values with noncontact tonometry at 1, 2, 4, 24, and 48 hours were not statistically significant (P>0.05) for both the groups.  
2	4734818	Ocular viscosurgical devices removal time	Mean time for complete OVD evacuation and total surgical time were significantly higher in the hydroxypropylmethylcellulose group (P=0.00).
2	4734818	Total surgical time	Mean time for complete OVD evacuation and total surgical time were significantly higher in the hydroxypropylmethylcellulose group (P=0.00).
2	4078065	arginine and ornithine	Citrulline consumption brought about significant increases in plasma levels of citrulline and arginine.
0	5168897	mean intubation time - awake nasal intubation of oropharyngeal cancer patients with anticipated difficult intubation	ABSTRACT.RESULTS:. Intubation time in seconds was significantly shorter in Group G (70.85 ± 8.88 S) than in Group F (90.26 ± 9.41 S) with (P < 0.001).
1	5168897	incidence of sore throat - awake nasal intubation of oropharyngeal cancer patients with anticipated difficult intubation	After the ethical committee approval, we included 54 oropharyngeal cancer patients divided randomly into two equal groups: Group G and Group F. After pre-medication and pre-oxygenation, awake nasal intubation was performed using GlideScope® video laryngoscope in Group G and flexible fibre-optic bronchoscope in Group F. In both groups, we compared intubation time in seconds (mean ± standard deviation) (primary outcome), success rate of the first intubation attempt, percentage of Cormack and Lehane glottic score and incidence of complications.
1	5168897	incidence of sore throat - awake nasal intubation of oropharyngeal cancer patients with anticipated difficult intubation	We detected three cases of sore throat in each group.  
0	5447816	suturing test completion time	All participants then took a personality test, and their microsuture test scores and the time to complete the task were compared. The time to complete the task was significantly shorter in the simulator group than in the video-learning group.
2	3692346	forced expiratory volume in one second (FEV1)	The increase in FEV1 from baseline was greater in the higher-dose group than in the guidelines group, especially during the first month of treatment (304 ± 49 mL versus 148 ± 39 mL, respectively, P = 0.01).
2	3692346	Numbers of patients with completely or well controlled asthma	Numbers of patients with completely or well controlled asthma were higher in the higher-dose group than in the guidelines group (92.1% versus 81.1%, respectively, P = 0.03).
1	5320660	body composition	Consuming 30 g High-amylose maize resistant starch type 2 daily for 6 weeks can improve glucose homeostasis, lower leptin concentrations, and increase fasting peptide YY in healthy overweight adults without impacting body composition and may aid in the prevention of chronic disease.
1	5350209	Speed of alcohol consumption	We found that compared with the control condition, the beverage was consumed at a slower rate in the two health-warning conditions, which surprisingly did not differ from each other.
1	3897026	Recovery time	There were no differences in the recovery time (17.3 ± 3.4 in the case group vs. 16.3 ± 3 in the control group, P < 0.05), postoperative pain scores (5 ± 1 in the case group vs. 5.6 ± 2 in the control group, P < 0.05), the consumption of anesthetic (9376.9 ± 1245.8 in the case group vs. 9012.9 ± 1620 in the control group, P < 0.05), the analgesic requirements (1000 in the case group vs. 940.9 ± 135.6 in the control group, P < 0.05), and perioperative additional analgesic (63.4 ± 26.5 in the case group vs. 69.4 ± 25.6 in the control group, P < 0.05) between two groups.
1	3897026	Post-Surgical Pain	There were no differences in the recovery time (17.3 ± 3.4 in the case group vs. 16.3 ± 3 in the control group, P < 0.05), postoperative pain scores (5 ± 1 in the case group vs. 5.6 ± 2 in the control group, P < 0.05), the consumption of anesthetic (9376.9 ± 1245.8 in the case group vs. 9012.9 ± 1620 in the control group, P < 0.05), the analgesic requirements (1000 in the case group vs. 940.9 ± 135.6 in the control group, P < 0.05), and perioperative additional analgesic (63.4 ± 26.5 in the case group vs. 69.4 ± 25.6 in the control group, P < 0.05) between two groups.
1	3897026	Anesthetic usage	There were no differences in the recovery time (17.3 ± 3.4 in the case group vs. 16.3 ± 3 in the control group, P < 0.05), postoperative pain scores (5 ± 1 in the case group vs. 5.6 ± 2 in the control group, P < 0.05), the consumption of anesthetic (9376.9 ± 1245.8 in the case group vs. 9012.9 ± 1620 in the control group, P < 0.05), the analgesic requirements (1000 in the case group vs. 940.9 ± 135.6 in the control group, P < 0.05), and perioperative additional analgesic (63.4 ± 26.5 in the case group vs. 69.4 ± 25.6 in the control group, P < 0.05) between two groups.
1	3897026	Usage of analgesics	There were no differences in the recovery time (17.3 ± 3.4 in the case group vs. 16.3 ± 3 in the control group, P < 0.05), postoperative pain scores (5 ± 1 in the case group vs. 5.6 ± 2 in the control group, P < 0.05), the consumption of anesthetic (9376.9 ± 1245.8 in the case group vs. 9012.9 ± 1620 in the control group, P < 0.05), the analgesic requirements (1000 in the case group vs. 940.9 ± 135.6 in the control group, P < 0.05), and perioperative additional analgesic (63.4 ± 26.5 in the case group vs. 69.4 ± 25.6 in the control group, P < 0.05) between two groups.
0	3897026	Time for extubation	The extubation time in the case group (13.59 ± 4.83) was significantly shorter than in the control group (15.9 ± 3.6) (P = 0.01).  
0	4814821	ER visits for all causes	Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23 vs. 0.68/patient; p = 0.002) and emergency room visits (0.36 vs. 0.91/patient; p = 0.006).
2	4814821	the time to first re-admission for Chronic obstructive pulmonary disease exacerbation	During the follow-up period, time to first re-admission for Chronic obstructive pulmonary disease exacerbation was significantly increased in the telemonitoring group than in the usual care group (p = 0.026).
0	4814821	the number of all-cause re-admissions over a period of six months	Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23 vs. 0.68/patient; p = 0.002) and emergency room visits (0.36 vs. 0.91/patient; p = 0.006).
0	4814821	episodes of COPD-related re-admissions or ER visits per capita	Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23 vs. 0.68/patient; p = 0.002) and emergency room visits (0.36 vs. 0.91/patient; p = 0.006).
2	4307639	loneliness score	Compared with the no interest group, the committed with interest group were more likely to be personal computer users (odds ratio (odds ratio) = 2.78), physically active (odds ratio = 1.03) and had higher levels of loneliness (odds ratio = 1.16).  
2	4307639	physically active	Compared with the no interest group, the committed with interest group were more likely to be personal computer users (odds ratio (odds ratio) = 2.78), physically active (odds ratio = 1.03) and had higher levels of loneliness (odds ratio = 1.16).  
0	5911298	Remaining filling material	The mean percentage of remaining filling material was 12.96% for PR group and 24.26% for MR group (P=0.0056).
2	5911298	Dentin removed	The mean percentage of remaining filling material was 12.96% for PR group and 24.26% for MR group (P=0.0056). The percentage of dentin removal was greater in the PR group (5.02%) than MR group (1.36%) (P=0.0028).
1	3581780	Antiemetics use	No differences were observed in use of antiemetics and the side effects between the groups.  
0	3581780	Incidence of vomiting	However, the incidence of vomiting was lower in the palonosetron group than in the ondansetron group (18% vs. 4%, P = 0.025).
1	3581780	Rate of side-effects	No differences were observed in use of antiemetics and the side effects between the groups.  
1	3581780	Postoperative nausea and vomiting	There were no significant differences between the groups in the incidence of Postoperative nausea and vomiting during 72 h after operation.
1	3263438	Potassium	There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters.
1	3263438	Vital signs	There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters.
2	3263438	FEV1	The Fluticasone furoate/vilanterol group had statistically greater improvements compared with placebo in trough FEV1 (mean difference 183 ml) and 0–4 h postdose weighted mean FEV1 (mean difference 236 ml).  
1	3263438	Heart rate	The weighted mean heart rate 0–4 h postdose was similar between groups (difference: 0.6 beats per minute; 95% CI −3.9 to 5.1).
0	4975837	Transcutaneous oxygen	Comparing nasal high flow with long-term oxygen therapy: transcutaneous carbon dioxide (TcCO2) (43.3 vs 46.7 mm Hg, p<0.001), transcutaneous oxygen (TcO2) (97.1 vs 101.2 mm Hg, p=0.01), I:E ratio (0.75 vs 0.86, p=0.02) and respiratory rate (respiratory rate) (15.4 vs 19.2 bpm, p<0.001) were lower; and tidal volume (Vt) (0.50 vs 0.40, p=0.003) and end-expiratory lung volume (end-expiratory lung volume) (174% vs 113%, p<0.001) were higher.
2	4975837	Tidal volume	Comparing nasal high flow with long-term oxygen therapy: transcutaneous carbon dioxide (TcCO2) (43.3 vs 46.7 mm Hg, p<0.001), transcutaneous oxygen (TcO2) (97.1 vs 101.2 mm Hg, p=0.01), I:E ratio (0.75 vs 0.86, p=0.02) and respiratory rate (respiratory rate) (15.4 vs 19.2 bpm, p<0.001) were lower; and tidal volume (Vt) (0.50 vs 0.40, p=0.003) and end-expiratory lung volume (end-expiratory lung volume) (174% vs 113%, p<0.001) were higher.
0	4975837	Transcutaneous carbon dioxide	Comparing nasal high flow with long-term oxygen therapy: transcutaneous carbon dioxide (TcCO2) (43.3 vs 46.7 mm Hg, p<0.001), transcutaneous oxygen (TcO2) (97.1 vs 101.2 mm Hg, p=0.01), I:E ratio (0.75 vs 0.86, p=0.02) and respiratory rate (respiratory rate) (15.4 vs 19.2 bpm, p<0.001) were lower; and tidal volume (Vt) (0.50 vs 0.40, p=0.003) and end-expiratory lung volume (end-expiratory lung volume) (174% vs 113%, p<0.001) were higher.
0	4975837	Respiratory rate	Comparing nasal high flow with long-term oxygen therapy: transcutaneous carbon dioxide (TcCO2) (43.3 vs 46.7 mm Hg, p<0.001), transcutaneous oxygen (TcO2) (97.1 vs 101.2 mm Hg, p=0.01), I:E ratio (0.75 vs 0.86, p=0.02) and respiratory rate (respiratory rate) (15.4 vs 19.2 bpm, p<0.001) were lower; and tidal volume (Vt) (0.50 vs 0.40, p=0.003) and end-expiratory lung volume (end-expiratory lung volume) (174% vs 113%, p<0.001) were higher.
2	4975837	End-expiratory lung volume	Comparing nasal high flow with long-term oxygen therapy: transcutaneous carbon dioxide (TcCO2) (43.3 vs 46.7 mm Hg, p<0.001), transcutaneous oxygen (TcO2) (97.1 vs 101.2 mm Hg, p=0.01), I:E ratio (0.75 vs 0.86, p=0.02) and respiratory rate (respiratory rate) (15.4 vs 19.2 bpm, p<0.001) were lower; and tidal volume (Vt) (0.50 vs 0.40, p=0.003) and end-expiratory lung volume (end-expiratory lung volume) (174% vs 113%, p<0.001) were higher.
1	4173331	Hemodynamic parameters	The reduction of clonidine and fentanyl in the ropivacaine-fentanyl-clonidine group did not make any significant difference (P>0.05) in the analgesic properties of drug combination and hemodynamic parameters as compared to ropivacaine-clonidine and ropivacaine-fentanyl groups.
1	4173331	Analgesic properties	The reduction of clonidine and fentanyl in the ropivacaine-fentanyl-clonidine group did not make any significant difference (P>0.05) in the analgesic properties of drug combination and hemodynamic parameters as compared to ropivacaine-clonidine and ropivacaine-fentanyl groups.
1	4173331	Analgesic properties	The reduction of clonidine and fentanyl in the ropivacaine-fentanyl-clonidine group did not make any significant difference (P>0.05) in the analgesic properties of drug combination and hemodynamic parameters as compared to ropivacaine-clonidine and ropivacaine-fentanyl groups.
1	4173331	Hemodynamic parameters	The reduction of clonidine and fentanyl in the ropivacaine-fentanyl-clonidine group did not make any significant difference (P>0.05) in the analgesic properties of drug combination and hemodynamic parameters as compared to ropivacaine-clonidine and ropivacaine-fentanyl groups.
0	2871176	Postprandial plasma glucose	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (−1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
0	2871176	HbA1c level at 26 weeks	Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.
0	2871176	HbA1c level at 26 weeks	Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.
0	2871176	Postprandial plasma glucose	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (−1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
0	2871176	Fasting plasma glucose at week 26	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
0	2871176	Postprandial plasma glucose	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (−1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
0	2871176	Postprandial plasma glucose	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (−1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
0	2871176	Fasting plasma glucose at week 26	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
0	2871176	HbA1c level at 26 weeks	Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.
0	2871176	Fasting plasma glucose at week 26	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
0	2871176	Fasting plasma glucose at week 26	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
2	3571894	III-IV regimen-related toxicity	The incidence of total and III-IV regimen-related toxicity were 94.4% and 81.5% (P = 0.038), and 16.7% and 0.0% (P = 0.002), respectively, in busulfan plus cyclophosphamide and busulfan plus fludarabine group.
1	3137994	Mortality rate	There is no significant difference in the mortality rate between the "surgical" and non-"surgical" groups of  Iranian patients with Subarachnoid Haemorrhage.  
1	3137994	Rate of rebleeding	Difference of  rebleeding rate in the two therapeutic groups  was not significant; X2 = .014, P = .91.  
1	5711682	In-stent late lumen loss at 9 months	In-stent late lumen loss at 9 months was not significantly different between the 2 groups (0.11±0.25 vs. 0.16±0.43 mm, p=0.567).
1	5711682	no myocardial infarction (myocardial infarction)	There was no myocardial infarction or stent thrombosis in either group.
1	5711682	no target lesion revascularization (target lesion revascularization)	The rates of death (2.6% vs. 0%, p=0.494), target lesion revascularization (2.6% vs. 2.6%, p=1.000), and target vessel revascularization (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different.  
1	5711682	no stent thrombosis	There was no myocardial infarction or stent thrombosis in either group.
1	5711682	rates of death	The rates of death (2.6% vs. 0%, p=0.494), target lesion revascularization (2.6% vs. 2.6%, p=1.000), and target vessel revascularization (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different.  
0	5812048	BF%Bioelectrical impedance analysis (Bioelectrical impedance analysis) derived BF(Body Fat)% at PRE and 15-min	Repeated measures ANOVA revealed body fat percentage for caffeine was lower than the control and PLA conditions at PRE and 15-min (p < 0.001, p = 0.004), but not statistically significant for the remaining time points (i.e., 30-, 45-, 60-, 75-, and 90-min).
0	5812048	Bioelectrical impedance analysis (Bioelectrical impedance analysis) derived BF(Body Fat)% at PRE and 15-min	Repeated measures ANOVA revealed body fat percentage for caffeine was lower than the control and PLA conditions at PRE and 15-min (p < 0.001, p = 0.004), but not statistically significant for the remaining time points (i.e., 30-, 45-, 60-, 75-, and 90-min).
1	5812048	Bioelectrical impedance analysis (Bioelectrical impedance analysis) derived BF(Body Fat)% at 30-90 min	Repeated measures ANOVA revealed body fat percentage for caffeine was lower than the control and PLA conditions at PRE and 15-min (p < 0.001, p = 0.004), but not statistically significant for the remaining time points (i.e., 30-, 45-, 60-, 75-, and 90-min).
1	5812048	Bioelectrical impedance analysis (Bioelectrical impedance analysis) derived BF(Body Fat)% at 30-90 min	Repeated measures ANOVA revealed body fat percentage for caffeine was lower than the control and PLA conditions at PRE and 15-min (p < 0.001, p = 0.004), but not statistically significant for the remaining time points (i.e., 30-, 45-, 60-, 75-, and 90-min).
0	5784025	Central systolic blood pressure	Even with similar brachial blood pressure reduction, significantly lower central systolic blood pressure (atenolol; 146.5 ± 18.8 vs. valsartan; 133.5 ± 20.7 vs. fimasartan; 133.6 ± 19.8 mmHg, p = 0.017) and augmentation index values (89.8 ± 13.2 vs. 80.6 ± 9.2 vs. 79.2 ± 11.6%; p = 0.001) were seen in the angiotensin receptor blockers (angiotensin receptor blockers) groups.
0	5784025	Central systolic blood pressure	Even with similar brachial blood pressure reduction, significantly lower central systolic blood pressure (atenolol; 146.5 ± 18.8 vs. valsartan; 133.5 ± 20.7 vs. fimasartan; 133.6 ± 19.8 mmHg, p = 0.017) and augmentation index values (89.8 ± 13.2 vs. 80.6 ± 9.2 vs. 79.2 ± 11.6%; p = 0.001) were seen in the angiotensin receptor blockers (angiotensin receptor blockers) groups.
0	5784025	N-terminal pro b-type natriuretic peptide	Plasma N-terminal pro-brain natriuretic peptide level was also significantly decreased in ARB groups, especially for the fimasartan group (37.8 ± 50.6 vs. 29.2 ± 36.9 vs.19.2 ± 27.8 pg/mL; p = 0.006).
0	5784025	Transcranial Doppler pulsatility index	The pulsatility index on transcranial Doppler was significantly reduced in valsartan (p = 0.002) and fimasartan group (p = 0.008).
0	5784025	Transcranial Doppler pulsatility index	The pulsatility index on transcranial Doppler was significantly reduced in valsartan (p = 0.002) and fimasartan group (p = 0.008).
1	3546025	absolute amount of weight loss	By design, both groups lost ~7% of total body weight.
2	3546025	Skeletal muscle protein fractional synthesis rate	While EAAMR did not promote a significant preservation of lean tissue, the reduction in adipose tissue was greater in EAAMR compared to competitive meal replacement. Interestingly, these results corresponded to an increase in the acute skeletal muscle protein fractional synthesis rate.  
1	5551012	birthweight, incidence of congenital birth defect and mean Apgar scores	Intrapartum antibiotic exposure did not significantly affect the birthweight, incidence of congenital birth defect and mean Apgar scores.
0	5551012	mean Apgar	However, antibiotic use less than 24 h to delivery was associated with a decrease in mean APGAR score.
2	3980039	Beta cell glucose sensitivity	In Studies 1 and 2, both canagliflozin doses increased beta cell glucose sensitivity compared with placebo.
2	3980039	Beta cell glucose sensitivity	In Studies 1 and 2, both canagliflozin doses increased beta cell glucose sensitivity compared with placebo.
2	3479017	Physical activity levels	The intervention led to increased physical activity/fitness levels and an improved cardiovascular risk factor profile (reduced BMI and waist circumference).
0	4837818	Cure time	The cure time was 12.1 ± 4.3, 11.9 ± 4.0 weeks in negative control (placebo) group and positive control acyclovir group respectively (P = 0.991), which was longer than that in test ganciclovir group (8.6 ± 2.8 weeks) and there was a significant difference between test ganciclovir group and negative control (placebo) group or positive control acyclovir group (P = 0.000).
0	4837818	Recurrence rate	Furthermore, the recurrent rate was higher in negative control (placebo) group (47.3%) than that in positive control group acyclovir (26.7%) and test ganciclovir group (17.2%), and there was a great significant difference among the three groups (P = 0.007), but there was no significant difference between positive control acyclovir group and test ganciclovir group (P = 0.358).
0	4837818	Recurrence rate	Furthermore, the recurrent rate was higher in negative control (placebo) group (47.3%) than that in positive control group acyclovir (26.7%) and test ganciclovir group (17.2%), and there was a great significant difference among the three groups (P = 0.007), but there was no significant difference between positive control acyclovir group and test ganciclovir group (P = 0.358).
0	4837818	Cure time	The cure time was 12.1 ± 4.3, 11.9 ± 4.0 weeks in negative control (placebo) group and positive control acyclovir group respectively (P = 0.991), which was longer than that in test ganciclovir group (8.6 ± 2.8 weeks) and there was a significant difference between test ganciclovir group and negative control (placebo) group or positive control acyclovir group (P = 0.000).
1	4837818	Cure time	The cure time was 12.1 ± 4.3, 11.9 ± 4.0 weeks in negative control (placebo) group and positive control acyclovir group respectively (P = 0.991), which was longer than that in test ganciclovir group (8.6 ± 2.8 weeks) and there was a significant difference between test ganciclovir group and negative control (placebo) group or positive control acyclovir group (P = 0.000).
1	4837818	Recurrence rate	Furthermore, the recurrent rate was higher in negative control (placebo) group (47.3%) than that in positive control group acyclovir (26.7%) and test ganciclovir group (17.2%), and there was a great significant difference among the three groups (P = 0.007), but there was no significant difference between positive control acyclovir group and test ganciclovir group (P = 0.358).
2	4183082	sore throat 2 hours post–operation	Number of patients who developed sore throat was significantly higher in the Succinylcholine group (75%) compared to Cisatracurium group (27.5%) at the time of entrance to the recovery room (P = 0.001). These numbers decreased at 2 hours post–operation (42% versus 17.5%) but the difference was still statistically significant (P < 0.05).
2	4450462	Reduction in body weight after 20 weeks	After 20 weeks, body weight change with the intervention was −6.4 kg (95% confidence interval (confidence interval) −9.4 to −3.4, P<0.001) in an effect size analysis.
2	4450462	Improvement in pain score	The between-group difference in change in pain, as measured by the McGill pain questionnaire, was −8.2 points (95% confidence interval −16.1 to −0.3, P=0.04).
2	4450462	Changes in electrochemical skin conductance in the foot	Electrochemical skin conductance in the foot improved by an average of 12.4 microseimens (95% confidence interval 1.2–23.6, P=0.03) with the intervention in an effect size analysis.
1	3136370	Fibromyalgia Impact Questionnaire scores	Use of standard statistics with intent-to-treat analysis showed that total Fibromyalgia Impact Questionnaire scores decreased by 14% in the soy group (P = .02) and by 18% in the placebo group (P < .001). The difference in change in scores between the groups was not significant (P = .16). With the same analysis, Center for Epidemiologic Studies Depression Scale scores decreased in the soy group by 16% (P = .004) and in the placebo group by 15% (P = .05).
1	3136370	Center for Epidemiologic Studies Depression Scale score	With the same analysis, Center for Epidemiologic Studies Depression Scale scores decreased in the soy group by 16% (P = .004) and in the placebo group by 15% (P = .05). The change in scores was similar in the groups (P = .83).
1	3136370	Center for Epidemiologic Studies Depression Scale score	With the same analysis, Center for Epidemiologic Studies Depression Scale scores decreased in the soy group by 16% (P = .004) and in the placebo group by 15% (P = .05). The change in scores was similar in the groups (P = .83).
0	3136370	Fibromyalgia Impact Questionnaire scores	Use of standard statistics with intent-to-treat analysis showed that total Fibromyalgia Impact Questionnaire scores decreased by 14% in the soy group (P = .02) and by 18% in the placebo group (P < .001). The difference in change in scores between the groups was not significant (P = .16).
2	2744923	Effectiveness at day 28	chlorproguanil-dapsone was more effective than Sulphadoxine-pyrimethamine on day-28 (p = 0.01), but not day-42.  
1	2744923	Effectiveness at day 42	chlorproguanil-dapsone was more effective than Sulphadoxine-pyrimethamine on day-28 (p = 0.01), but not day-42.  
2	5514258	survival	Patients in the high-risk group had greater survival (hazard ratio [hazard ratio], 0.76; P = .002; 95% confidence interval [confidence interval], 0.64-0.91) if they received adjuvant radiation therapy.
1	5514258	survival	In contrast, patients in the intermediate- (hazard ratio, 1.01; P = .904; 95% confidence interval, 0.85-1.20) and low-risk groups (hazard ratio, 0.85; P = .427; 95% confidence interval, 0.57-1.26) did not experience a survival benefit with adjuvant radiation therapy.  
2	5307611	skin cancer preventive behaviors	However, significant differences were found between the scores of all the variables, as well as skin cancer preventive behaviors, in the two groups after the intervention (p<0.05).    
1	5119439	other significant differences in translations at 5 years	No other significant differences in translations or rotations were found between the 2 surgical techniques at 2 years (p > 0.4) and 5 years (p > 0.7) postoperatively.
1	5119439	other significant differences in rotations at 5 years	Results — Femoral stems in the compaction group had a higher degree of medio-lateral migration (0.21 mm, 95% CI: 0.03–0.40) than femoral stems in the broaching group at 5 years (p = 0.02). No other significant differences in translations or rotations were found between the 2 surgical techniques at 2 years (p > 0.4) and 5 years (p > 0.7) postoperatively.
1	5119439	other significant differences in translations at 2 years	No other significant differences in translations or rotations were found between the 2 surgical techniques at 2 years (p > 0.4) and 5 years (p > 0.7) postoperatively.
1	5119439	other significant differences in rotations at 2 years	No other significant differences in translations or rotations were found between the 2 surgical techniques at 2 years (p > 0.4) and 5 years (p > 0.7) postoperatively. There were no individual stems with continuous migration.
2	5119439	Femoral stems degree of medio-lateral migration at 5 years	Results — Femoral stems in the compaction group had a higher degree of medio-lateral migration (0.21 mm, 95% CI: 0.03–0.40) than femoral stems in the broaching group at 5 years (p = 0.02).
1	3830844	Area under the curve for the pain severity	The main outcome measure was the area under the curve (area under the curve) summarizing eight weeks of daily rated pain severity measured with a visual analogue scale (0 mm = no pain, 100 mm = worst imaginable pain). No significant differences between groups were observed for the area under the curve (individualized acupuncture mean: 1768.7 (95% CI, 1460.4; 2077.1); standardized acupuncture 1482.9 (1177.2; 1788.7); group difference, 285.8 (−33.9; 605.5) P = 0.080).
2	5404992	Ever practicing floor tummy time	Infant activity: 82.6% ever practiced tummy time; 32.0% practiced tummy time on the floor; 34.4% reported unrestrained floor time; 56.4% reported >1 hour/day in movement restricting devices. Inadequate health literacy was associated with reduced tummy time and unrestrained floor time. The intervention group reported more floor tummy time (OR 2.16, 95% CI 1.44–3.23) and unrestrained floor time (OR 1.69, 95% CI 1.14–2.49) compared to controls.
2	5404992	Practicing tummy time mostly on the floor	456 mothers completed 3-month assessments. Infant activity: 82.6% ever practiced tummy time; 32.0% practiced tummy time on the floor; 34.4% reported unrestrained floor time; 56.4% reported >1 hour/day in movement restricting devices. Inadequate health literacy was associated with reduced tummy time and unrestrained floor time. The intervention group reported more floor tummy time (OR 2.16, 95% CI 1.44–3.23) and unrestrained floor time (OR 1.69, 95% CI 1.14–2.49) compared to controls.
1	3391000	Colon cleanliness	Adding bisacodyl to g of PEG caused more abdominal bloating/cramps (P<0.01) and did not result in a cleaner colon (P=0.66) compared with g of PEG without bisacodyl.
1	3391000	Boston Bowel Preparation Scale score	The Boston Bowel Preparation Scale scores in both the g of PEG arms and NuLYTELY arm were not significantly different (P=0.19).
0	3391000	Gastrointestinal problems and discomfort	Compared with subjects in the NuLYTELY arm, subjects in the g of PEG without bisacodyl arm had less nausea (P<0.04), vomiting (P<0.02), abdominal pain (P<0.02), bloating (P<0.005), difficulty drinking the liquid (P<0.0001), and found the overall preparation easier to tolerate (P<0.0001).
0	3391000	Levels of blood electrolytes and BUN	Subjects in the combined g of PEG arms had a lower serum sodium (P<0.0007), chloride (P<0.007), and BUN (P<0.0001) levels than those in the NuLYTELY arm, but this did not cause any clinical symptoms.  
1	4396730	Urine albumin	Mean changes of urinary albumin were 15.05 ± 30.09 μg/mg Cr (P = 0.038) in the placebo group and 13.89 ± 32.25 μg/mg Cr (P = 0.069) in the sulodexide group.
0	4396730	Change in urine TGF-beta1	Urinary TGF-beta1 increased significantly in the placebo group but did not change significantly in the sulodexide group. Additionally, the mean change of urine TGF-beta1 in the placebo group was significantly higher than that in the sulodexide group (8.44 ± 9.21 versus 2.17 ± 6.96 pg/mg Cr, P = 0.02).
2	2784386	treatment success in non-ICU subjects	In non-ICU subjects, treatment success was significantly higher for micafungin versus liposomal amphotericin B (85% (n = 108/127) versus 72.1% (n = 98/136); P = 0.0113).
1	2784386	treatment success in intensive care unit subjects	However, for intensive care unit subjects, treatment success rates for micafungin versus liposomal amphotericin B were similar (62.5% (n = 75/120) versus 66.4% (n = 73/110); P = 0.5828).
2	2784386	renal function in intensive care unit and non-ICU subjects	Renal function was significantly better in micafungin versus liposomal amphotericin B subjects: a difference (liposomal amphotericin B - micafungin in mean peak change in estimated glomerular filtration rate (ml/minute/1.73 m2) of -18.2 (P < 0.0001) and -17.7 (P = 0.0124) in non-ICU and intensive care unit subjects, respectively.  
1	4682450	Wake time after sleep onset improvement	In the second study, the naproxen sodium 440 mg/DPH 25 mg combination failed to show any significant improvements vs. either component alone.  
1	4682450	Wake time after sleep onset improvement	In the second study, the naproxen sodium 440 mg/DPH 25 mg combination failed to show any significant improvements vs. either component alone.  
2	4682450	Wake time after sleep onset improvement	In the first study, only the naproxen sodium 440 mg/DPH 50 mg combination showed significant improvements in both wake time after sleep onset vs. naproxen sodium alone (−70.3 min p = 0.0002) and sleep latency vs. diphenhydramine alone (25.50 and 41.50 min respectively, p < 0.0001).
2	4682450	Sleep latency improvement	In the first study, only the naproxen sodium 440 mg/DPH 50 mg combination showed significant improvements in both wake time after sleep onset vs. naproxen sodium alone (−70.3 min p = 0.0002) and sleep latency vs. diphenhydramine alone (25.50 and 41.50 min respectively, p < 0.0001).
0	3276929	Morning stiffness in participants with OA knees	Morning stiffness decreased more (P<0.001) in yoga (post 1=68.6% and post 2=98.1%) than control group (post 1=38.6% and post 2=71.6%).
0	3276929	Diastolic blood pressure	Diastolic blood pressure reduced (P<0.001) better in yoga group (post 1=−7.6% and post 2=−16.4%) than the control group (post 1=−2.1% and post 2=−5.0%).
0	3276929	Resting pain in participants with OA knees	Resting pain (numerical rating scale) reduced better (P<0.001, Mann–Whitney U test) in yoga group (post 1=33.6% and post 2=71.8%) than control group (post 1=13.4% and post 2=37.5%).
0	3276929	State anxiety in participants with OA knees	State anxiety (STAI-1) reduced (P<0.001) by 35.5% (post 1) and 58.4% (post 2) in the yoga group and 15.6% (post 1) and 38.8% (post 2) in the control group; trait anxiety (STAI 2) reduced (P<0.001) better (post 1=34.6% and post 2=57.10%) in yoga than control group (post 1=14.12% and post 2=34.73%).
0	3276929	Systolic blood pressure	Systolic blood pressure reduced (P<0.001) better in yoga group (post 1=−7.93% and post 2=−15.7%) than the control group (post 1=−1.8% and post 2=−3.8%).
0	3276929	Pulse rate	Pulse rate reduced (P<0.001) better in yoga group (post 1=−8.41% and post 2=−12.4%) than the control group (post 1=−5.1% and post 2=−7.1%).  
1	4223972	HbA1c variation - effect of cognitive-behavioral group therapy on depressive symptoms in people with type 2 diabetes	The results showed that HbA1c variation was statistically significant before and after the intervention in both groups (P ≤ 0.001).
1	4223972	HbA1c variation - effect of cognitive-behavioral group therapy on depressive symptoms in people with type 2 diabetes	However, the mean variation of HbA1c was not statistically significant between the groups (P = 0.473).  
0	3712888	Recurrence of bacterial vaginosis after 6 months	Considering a 6-month treatment period, the recurrence rate in the vitamin C group (16.2%) was significantly lower (P = 0.024) than in the placebo group (32.4%).
2	3712888	Probability of being free of bacterial vaginosis relapse (survival analysis of Kaplan Meyer)	Moreover, at the same time point, the survival analysis of Kaplan Meyer was significant in favour of the vitamin C group compared with the placebo group (P = 0.029).  
1	3227609	Overall adverse events	There was no difference in the incidence of adverse events between the two formula groups.  
1	3227609	Daily stool frequency	The prebiotic and control groups showed similar mean weight, length and head circumference, skin fold thicknesses, arm circumference gains and stool frequency at each study point.
0	3227609	Stool consistency	The stool consistency in the prebiotic group was softer than in the control group at 8, 16 and 24 weeks (p<0.001) and closer to that of the breastfeeding group.
1	3227609	Serious adverse events	There was no difference in the incidence of adverse events between the two formula groups.  
0	3892495	Fat oxidation rate	The fat oxidation rate in the CHO was significantly lower than the CON while walking for 5~15, 25~35 and 45~55 min.
0	3892495	Free fatty acid	Plasma free fatty acid levels were also significantly lower in the CHO compared to the CON at 30, 45 and 60 min.
2	3892495	Human growth hormone	Plasma human growth hormone concentrations were significantly higher in subjects who received CHO compared to those who received CON at 15 and 30 min.
0	3892495	Plasma glucose	Plasma glucose levels in the CHO were significantly lower while plasma insulin levels were significantly higher than in the CON at 15 and 30 min.
1	5846302	Serious adverse events within 30 days post-surgery	Serious adverse events within 30 days post-surgery were experienced by 12/44 (27.3%) patients treated with VerisetTM hemostatic patch and 10/45 (22.2%) in the TachoSil® group (p=0.6295).
0	5846302	Median time to hemostasis	Median time to hemostasis was 1.5 min with VerisetTM hemostatic patch, compared to 3.0 min with TachoSil® (p<0.0001).
1	3056193	Hamilton Rating Scale for Depression (HAM-D) and the Montgomery-Asberg Rating Scale (MADRS)	There was no significant difference between placeboxetine and sertraline groups on either HAM-D or MADRS at any visit.
2	4766670	Symptom severity improvement	The adherence therapy group reported significantly greater improvements in symptom severity (p < 0.003), insight into illness/treatment (p < 0.001), functioning (p < 0.005), duration of re-hospitalisations (p < 0.005), and medication adherence (p < 0.005) over 18 months follow-up, when compared with usual care alone.  
2	4766670	Insight into illness/treatment	The adherence therapy group reported significantly greater improvements in symptom severity (p < 0.003), insight into illness/treatment (p < 0.001), functioning (p < 0.005), duration of re-hospitalisations (p < 0.005), and medication adherence (p < 0.005) over 18 months follow-up, when compared with usual care alone.  
2	4766670	Functioning improvement	The adherence therapy group reported significantly greater improvements in symptom severity (p < 0.003), insight into illness/treatment (p < 0.001), functioning (p < 0.005), duration of re-hospitalisations (p < 0.005), and medication adherence (p < 0.005) over 18 months follow-up, when compared with usual care alone.  
0	4766670	Duration of re-hospitalisations	The adherence therapy group reported significantly greater improvements in symptom severity (p < 0.003), insight into illness/treatment (p < 0.001), functioning (p < 0.005), duration of re-hospitalisations (p < 0.005), and medication adherence (p < 0.005) over 18 months follow-up, when compared with usual care alone.  
2	4766670	Medication adherence	The adherence therapy group reported significantly greater improvements in symptom severity (p < 0.003), insight into illness/treatment (p < 0.001), functioning (p < 0.005), duration of re-hospitalisations (p < 0.005), and medication adherence (p < 0.005) over 18 months follow-up, when compared with usual care alone.  
0	4166382	Vomiting	The incidence of postoperative nausea and vomiting 24 hours postoperatively was significantly lower in the continuous palonosetron infusion group than the single-injection palonosetron group (31.8 vs. 56.1%, P = 0.009).  
0	4280425	duration of hospitalization	The results favour laparoscopy within the group with ASA 1–3 in terms of several parameters, namely: duration of hospitalization – 7.7 days in the case of laparoscopic intervention, vs. 10.6 days for conventional surgery (p < 0.05); and duration of operation – 61 min vs. 85.1 min respectively (p < 0.05).
0	4280425	Total morbidity	Total morbidity was 27.5% in the case of patients with conventional surgery, vs. 10.9% with laparoscopic intervention (p < 0.05). The sample of patients with ASA 4–5 suffered a high mortality of 82.7%.  
0	4280425	duration of operation	The results favour laparoscopy within the group with ASA 1–3 in terms of several parameters, namely: duration of hospitalization – 7.7 days in the case of laparoscopic intervention, vs. 10.6 days for conventional surgery (p < 0.05); and duration of operation – 61 min vs. 85.1 min respectively (p < 0.05).
2	5626376	At 18 months, the higher improvement in total WOMAC	At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by platelet-rich plasma (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).
2	5626376	At 18 months, the higher improvement in total WOMAC	At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by platelet-rich plasma (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).
0	4206289	Systolic blood pressure	After the three months' intervention period, the net reduction in SBP/DBP in the intervention group in comparison to the control group was −8.2/−3.4 mmHg (all p<0.05) in Per protocol analysis, after adjusting for baseline blood pressure and other variables.
2	4206289	Adequate blood pressure control	intention to treat analysis showed the net reduction in SBP/DBP at −7.6/−3.5 mmHg with multiple imputations (all p<0.05). Furthermore, the whole distribution of blood pressure showed an overall decline in SBP/DBP and the proportion of patients with blood pressure under control (SBP/DBP<140 mmHg) was significantly higher in salt-substitute group in comparison to the regular salt group (19.2% vs. 8.8%, p = 0.027).  
0	4206289	Diastolic blood pressure	After the three months' intervention period, the net reduction in SBP/DBP in the intervention group in comparison to the control group was −8.2/−3.4 mmHg (all p<0.05) in Per protocol analysis, after adjusting for baseline blood pressure and other variables.
2	4445854	storage time had significant effect on bond strength	The results of the t-test indicated that storage time only had significant effect on bond strength of Clearfil SE Bond with no Epigallocatechin gallate (p= 0.017).
0	3424202	Incidence of new infections	The dihydroartemisinin-piperaquine combination exerted a significant post-treatment prophylactic effect, and compared with A + M a significant reduction in the incidence of new infections for dihydroartemisinin-piperaquine was observed (respectively 17.1% versus 7.5% of patients experienced new infection within follow up).
2	3984416	Total work of trained athletes	Total work done was significantly increased following supplementation in both NTBA (p = 0.03) and TBA (p = 0.002), and it was significantly reduced in NTPL (p = 0.03) with no difference for TPL (p = 0.73).
2	3984416	Total work of non-trained athletes	Total work done was significantly increased following supplementation in both NTBA (p = 0.03) and TBA (p = 0.002), and it was significantly reduced in NTPL (p = 0.03) with no difference for TPL (p = 0.73).
0	5863632	Suicidal ideas	Results indicated that Aussie Optimism with teacher training plus coaching was associated with the best outcomes: a significant increase in student-reported pro-social behavior from pre-test to post-test 1 (maintained at post-test 2) and significantly lower incidence rates from suicidal ideation at post-test 2 and follow-up.
2	2652457	Level of enjoyment	Students who watched the computer assisted learning package had superior retention performance percentage scores (p = 0.02, 95% CI = 0.83–12.19, effect size = 0.8) and level of enjoyment (p = 0.04, 95% CI = 0.03–2.75, effect size = 0.7) compared with students who read the information leaflet.
2	2652457	Treatment retention performance percentage scores	Students who watched the computer assisted learning package had superior retention performance percentage scores (p = 0.02, 95% CI = 0.83–12.19, effect size = 0.8) and level of enjoyment (p = 0.04, 95% CI = 0.03–2.75, effect size = 0.7) compared with students who read the information leaflet.
1	2652457	Level of confidence to identify a child with autism	However, there was no significant difference in level of confidence to identify a child with autism (p = 0.39, 95% CI = -1.80–0.72, effect size = -0.3).  
2	2652457	Co-morbidities retention performance percentage scores	Students who watched the computer assisted learning package had superior retention performance percentage scores (p = 0.02, 95% CI = 0.83–12.19, effect size = 0.8) and level of enjoyment (p = 0.04, 95% CI = 0.03–2.75, effect size = 0.7) compared with students who read the information leaflet.
2	2375236	Information recall	Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.
0	2375236	Anxiety	Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.
2	2375236	Prognosis information given	Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients.
2	2375236	Prognosis enquiry	Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients.
0	5154016	24 h drainage volume	In our study, drainage volume in the first 24 h of patients in Group A and B is significantly smaller, as well as total postoperative volumes of drainage (p < 0.05) during their hospital stay.
1	5154016	Second 24 h drainage volume	The drainage volumes in the second 24 h were similar in the 3 groups.
1	5154016	Second 24 h drainage volume	The drainage volumes in the second 24 h were similar in the 3 groups.
0	5154016	Total drainage volume	In our study, drainage volume in the first 24 h of patients in Group A and B is significantly smaller, as well as total postoperative volumes of drainage (p < 0.05) during their hospital stay.
0	5154016	Total drainage volume	In our study, drainage volume in the first 24 h of patients in Group A and B is significantly smaller, as well as total postoperative volumes of drainage (p < 0.05) during their hospital stay.
2	3827502	retesting was recommended after chlamydia treatment	More practice nursess than general practitioners knew that retesting was recommended after chlamydia treatment (93% vs 87%, P=0.027); and the recommended timeframe was 3 months (66% vs 26%, P<0.01).
2	3827502	Aboriginal or Torres Strait Islander male with a sore throat - testing opportunities to asymptomatic patients aged ≤25 years	More practice nursess than general practitioners would offer testing opportunistically to asymptomatic patients aged ≤25 years; women having a pap smear (84% vs 55%, P<0.01); antenatal checkup (83% vs 44%, P<0.01) and Aboriginal men with a sore throat (79% vs 33%, P<0.01), but also to patients outside of the guideline age group at the time of the survey; 26 year old males presenting for a medical check (78% vs 30%, P = <0.01) and 33 year old females presenting for a pill prescription (83% vs 55%, P<0.01).
2	3827502	antenatal checkup - testing opportunities to asymptomatic patients aged ≤25 years	More practice nursess than general practitioners would offer testing opportunistically to asymptomatic patients aged ≤25 years; women having a pap smear (84% vs 55%, P<0.01); antenatal checkup (83% vs 44%, P<0.01) and Aboriginal men with a sore throat (79% vs 33%, P<0.01), but also to patients outside of the guideline age group at the time of the survey; 26 year old males presenting for a medical check (78% vs 30%, P = <0.01) and 33 year old females presenting for a pill prescription (83% vs 55%, P<0.01).
2	3827502	women having a pap smear - testing opportunities to asymptomatic patients aged ≤25 years	More practice nursess than general practitioners would offer testing opportunistically to asymptomatic patients aged ≤25 years; women having a pap smear (84% vs 55%, P<0.01); antenatal checkup (83% vs 44%, P<0.01) and Aboriginal men with a sore throat (79% vs 33%, P<0.01), but also to patients outside of the guideline age group at the time of the survey; 26 year old males presenting for a medical check (78% vs 30%, P = <0.01) and 33 year old females presenting for a pill prescription (83% vs 55%, P<0.01).
2	5508798	maximal voluntary isometric contraction (maximal voluntary isometric contraction) torque - after the exercise	Compared with the control group, M-wave latency was significantly shorter in the fish oil group immediately after exercise (p = 0.040), maximal voluntary isometric contraction torque was significantly higher at 1 day after exercise (p = 0.049), range of motion was significantly greater at post and 2 days after exercise (post; p = 0.006, day 2; p = 0.014), and there was significantly less delayed onset muscle soreness at 1 and 2 days after exercise (day 1; p = 0.049, day 2; p = 0.023).  
0	5508798	M-wave latency	Compared with the control group, M-wave latency was significantly shorter in the fish oil group immediately after exercise (p = 0.040), maximal voluntary isometric contraction torque was significantly higher at 1 day after exercise (p = 0.049), range of motion was significantly greater at post and 2 days after exercise (post; p = 0.006, day 2; p = 0.014), and there was significantly less delayed onset muscle soreness at 1 and 2 days after exercise (day 1; p = 0.049, day 2; p = 0.023).  
2	5508798	maximal voluntary isometric contraction (maximal voluntary isometric contraction) torque - 1 day after the exercise	Compared with the control group, M-wave latency was significantly shorter in the fish oil group immediately after exercise (p = 0.040), maximal voluntary isometric contraction torque was significantly higher at 1 day after exercise (p = 0.049), range of motion was significantly greater at post and 2 days after exercise (post; p = 0.006, day 2; p = 0.014), and there was significantly less delayed onset muscle soreness at 1 and 2 days after exercise (day 1; p = 0.049, day 2; p = 0.023).  
2	5508798	decrease in range of motion (range of motion)	Compared with the control group, M-wave latency was significantly shorter in the fish oil group immediately after exercise (p = 0.040), maximal voluntary isometric contraction torque was significantly higher at 1 day after exercise (p = 0.049), range of motion was significantly greater at post and 2 days after exercise (post; p = 0.006, day 2; p = 0.014), and there was significantly less delayed onset muscle soreness at 1 and 2 days after exercise (day 1; p = 0.049, day 2; p = 0.023).  
2	5971365	clinically meaningful improvement at week 144 (⩾3-point increase on the Symbol Digit Modalities Test)	At week 96, significantly greater mean improvement from baseline in Symbol Digit Modalities Test was observed with daclizumab beta versus intramuscular interferon beta-1a (p = 0.0274). Significantly more patients treated with daclizumab beta showed clinically meaningful improvement in Symbol Digit Modalities Test (increase from baseline of ⩾3 points (p = 0.0153) or ⩾4 points (p = 0.0366)), and significantly fewer patients showed clinically meaningful worsening (decrease from baseline of ⩾3 points (p = 0.0103)). Odds representing risk of worsening versus stability or improvement on Symbol Digit Modalities Test were significantly smaller for daclizumab beta (p = 0.0088 (3-point threshold); p = 0.0267 (4-point threshold)). In patients completing 144 weeks of treatment, the effects of daclizumab beta were generally sustained.  
2	5971365	Symbol Digit Modalities Test (Symbol Digit Modalities Test) score at week 144 in limited patients	At week 96, significantly greater mean improvement from baseline in Symbol Digit Modalities Test was observed with daclizumab beta versus intramuscular interferon beta-1a (p = 0.0274). Significantly more patients treated with daclizumab beta showed clinically meaningful improvement in Symbol Digit Modalities Test (increase from baseline of ⩾3 points (p = 0.0153) or ⩾4 points (p = 0.0366)), and significantly fewer patients showed clinically meaningful worsening (decrease from baseline of ⩾3 points (p = 0.0103)). Odds representing risk of worsening versus stability or improvement on Symbol Digit Modalities Test were significantly smaller for daclizumab beta (p = 0.0088 (3-point threshold); p = 0.0267 (4-point threshold)). In patients completing 144 weeks of treatment, the effects of daclizumab beta were generally sustained.  
2	5971365	clinically meaningful improvement at week 96 (⩾3-point increase on the Symbol Digit Modalities Test)	At week 96, significantly greater mean improvement from baseline in Symbol Digit Modalities Test was observed with daclizumab beta versus intramuscular interferon beta-1a (p = 0.0274).
2	5971365	Symbol Digit Modalities Test (Symbol Digit Modalities Test) score at week 96	At week 96, significantly greater mean improvement from baseline in Symbol Digit Modalities Test was observed with daclizumab beta versus intramuscular interferon beta-1a (p = 0.0274).
0	5971365	clinically meaningful worsening at week 96 (⩾3-point decrease on the Symbol Digit Modalities Test)	Significantly more patients treated with daclizumab beta showed clinically meaningful improvement in Symbol Digit Modalities Test (increase from baseline of ⩾3 points (p = 0.0153) or ⩾4 points (p = 0.0366)), and significantly fewer patients showed clinically meaningful worsening (decrease from baseline of ⩾3 points (p = 0.0103)).
2	5440538	intact parathyroid hormone reductions of ≥30%	Thirty-six children were randomized to paricalcitol or placebo; 27.8% of the paricalcitol group achieved two consecutive intact parathyroid hormone reductions of ≥30% from baseline versus none of the placebo group (P = 0.045).
0	5440538	Adverse effects	Adverse events were higher in children who received placebo than in those administered paricalcitol during the double-blind treatment (88.9 vs. 38.9%; P = 0.005).
2	5440538	intact parathyroid hormone reduction from baseline	Thirty-six children were randomized to paricalcitol or placebo; 27.8% of the paricalcitol group achieved two consecutive intact parathyroid hormone reductions of ≥30% from baseline versus none of the placebo group (P = 0.045).
2	4262215	quality of life of patients - (individuals diagnosed with a malignant tumor)	For individuals diagnosed with a malignant tumor, using a mental health clinical nursing pathway can effectively decrease the degree of suicidal ideation and positively impact the quality of life.
1	4262215	scores of sleep factor before reatment (individuals diagnosed with malignant tumor)	There were no statistical differences in the scores of despair factor, optimistic factor, sleep factor, and cover factor between the two groups before the treatment (P>0.05). After different styles of nursing, the former four factors of patients in the study group were significantly lower than those in the control group (P<0.01), while there were no significant differences in the score of cover factor between the two groups (P>0.05).
1	4262215	scores of optimistic factor - before the treatment (individuals diagnosed with a malignant tumor)	There were no statistical differences in the scores of despair factor, optimistic factor, sleep factor, and cover factor between the two groups before the treatment (P>0.05).
2	4262215	Karnofsky Performance Status (Karnofsky Performance Status) of patients - (individuals diagnosed with a malignant tumor)	The Karnofsky Performance Status of patients receiving mental clinical nursing pathway care was higher than those receiving usual nursing care, and there was a statistical significant difference between the two groups (P<0.01).
0	4262215	degree of suicidal ideation of patients - (individuals diagnosed with a malignant tumor)	For individuals diagnosed with a malignant tumor, using a mental health clinical nursing pathway can effectively decrease the degree of suicidal ideation and positively impact the quality of life.
1	4262215	scores of despair factor - before the treatment (individuals diagnosed with a malignant tumor)	There were no statistical differences in the scores of despair factor, optimistic factor, sleep factor, and cover factor between the two groups before the treatment (P>0.05).
1	3612585	Complete response (no emesis + no rescue medication)	Acute complete response rates were 73.5, 76.3, 74.1, and 70.4 % for all patients receiving the palonosetron 0.25, 0.50, and 0.75 mg oral doses, and for IV palonosetron 0.25 mg, respectively; delayed complete response (24–120 h) rates were 59.4, 62.5, 60.1, and 65.4 %, and overall complete response (0–120 h) rates were 53.5, 58.8, 53.2, and 59.3 %, respectively.
2	3316967	Score: improvement in visual analogue scale (visual analogue scale) for dyspnea - COPD patients due to exposure to sulfur mustard (sulfur mustard) and refractory to conventional therapies	The scores of visual analogue scale for dyspnea, cough and quality of life and also respiratory rate, heart rate, and night time awaking due to dyspnea and night time awaking due to cough improved significantly after morphine nebulization without any major adverse events.
2	3316967	Score: cough improvement - COPD patients due to exposure to sulfur mustard (sulfur mustard) and refractory to conventional therapies	The scores of visual analogue scale for dyspnea, cough and quality of life and also respiratory rate, heart rate, and night time awaking due to dyspnea and night time awaking due to cough improved significantly after morphine nebulization without any major adverse events.
2	3316967	Score: quality of life - COPD patients due to exposure to sulfur mustard (sulfur mustard) and refractory to conventional therapies	The scores of visual analogue scale for dyspnea, cough and quality of life and also respiratory rate, heart rate, and night time awaking due to dyspnea and night time awaking due to cough improved significantly after morphine nebulization without any major adverse events.
2	3316967	Score: night time awaking due to dyspnea improvement - COPD patients due to exposure to sulfur mustard (sulfur mustard) and refractory to conventional therapies	The scores of visual analogue scale for dyspnea, cough and quality of life and also respiratory rate, heart rate, and night time awaking due to dyspnea and night time awaking due to cough improved significantly after morphine nebulization without any major adverse events.
2	3316967	Score: night time awaking due to cough improvement - COPD patients due to exposure to sulfur mustard (sulfur mustard) and refractory to conventional therapies	The scores of visual analogue scale for dyspnea, cough and quality of life and also respiratory rate, heart rate, and night time awaking due to dyspnea and night time awaking due to cough improved significantly after morphine nebulization without any major adverse events.
0	5038569	central macular thickness (central macular thickness) at 1 month and at 4 months	The mean ± standard deviation central macular thickness decreased from 604±199 μm at baseline to 319±115 μm (P=0.001) at 1 month and to 351±205 μm (P=0.026) at 4 months.
0	5038569	central macular thickness (central macular thickness) at 1 month and at 4 months	The mean best-corrected visual acuity did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits.
1	5038569	The mean best-corrected visual acuity (best-corrected visual acuity) at 1 month, and at 4 months	The mean best-corrected visual acuity did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits.
2	4488551	neutrophil count	The increase in neutrophil count and hs-CRP level was found only in placebo group, indicating a significant blunting of the systemic inflammatory response in the subjects taking astaxanthin.
1	4488551	neutrophil count	The increase in neutrophil count and hs-CRP level was found only in placebo group, indicating a significant blunting of the systemic inflammatory response in the subjects taking astaxanthin.
2	4488551	high sensitivity C-reactive protein (hs-CRP)	The plasma muscle enzymes levels were reduced significantly by astaxanthin supplementation and by regular training. The increase in neutrophil count and hs-CRP level was found only in placebo group, indicating a significant blunting of the systemic inflammatory response in the subjects taking astaxanthin.
2	5047648	interstitial concentrations of pyruvate	Fibromyalgia syndrome was associated with significantly increased interstitial concentrations of glutamate, pyruvate, and lactate.
2	5047648	interstitial concentrations of lactate	Fibromyalgia syndrome was associated with significantly increased interstitial concentrations of glutamate, pyruvate, and lactate.
2	5047648	interstitial concentrations of glutamate	Fibromyalgia syndrome was associated with significantly increased interstitial concentrations of glutamate, pyruvate, and lactate.
2	4339981	disability (Neck Disability Index)	Disability showed a significant improvement of 24.6% from a mean (SD) of 28.2 (13.08) at baseline to 16.88 (11.62) at the end of the 8-week intervention.
2	4339981	Mental Health State	All secondary outcome variables were observed to show significant, clinically relevant improvements with increase ranges between 13.0% and 16.3% from a mean of 0.70 (0.2) at baseline to 0.83 (0.2), for EuroQoL-5D, and from a mean of 40.6 (12.7) at baseline to 56.9 (9.5), for mental health state, at the end of the 8-week intervention.  
2	4339981	Quality of Life (5 dim) EuroQoL	All secondary outcome variables were observed to show significant, clinically relevant improvements with increase ranges between 13.0% and 16.3% from a mean of 0.70 (0.2) at baseline to 0.83 (0.2), for EuroQoL-5D, and from a mean of 40.6 (12.7) at baseline to 56.9 (9.5), for mental health state, at the end of the 8-week intervention.  
1	5844554	working memory capacity of individuals who rated higher levels of attachment avoidance	In other words, the subliminal priming of the security led to increased working memory capacity of individuals who rated higher levels of attachment anxiety. This effect, however, was not observed for higher levels of attachment avoidance.
2	5844554	working memory capacity of individuals who rated higher levels of attachment anxiety	In other words, the subliminal priming of the security led to increased working memory capacity of individuals who rated higher levels of attachment anxiety.
0	3846239	The analgesic requirement	The analgesic requirement was significantly lower in the B+D group compared with the B group.
0	3846239	At 1, 2, 4, 6, and 12 h post surgery, visual analog scale pain scores	At 1, 2, 4, 6, and 12 h post surgery, visual analog scale pain values were significantly lower in the B+D group than in the B group.
0	3503752	Staff training costs	The training costs for the lay-trainers were greater than nurses (£36 versus £18 respectively per patient, p<0.001), however, the consultation cost for lay-trainers were lower than nurses (£6 per patient versus £24, p<0.001).
1	3503752	Overall costs	The total costs (delivery and unscheduled healthcare) were £202 per patient for nurses versus £178 for lay-trainers, (mean difference £24, [95%CI = −£100, £147, p = 0.707]).  
1	3503752	Unscheduled health care usage	One year data (n = 418) showed that 29% (61/205) of the nurse group required unscheduled healthcare (177 events) compared with 30.5% (65/213) for lay-trainers (178 events).  
1	3503752	Unscheduled health care usage	There were no significant differences in the cost of training and healthcare delivery between nurse and lay trainers, and no significant difference in the cost of unscheduled health care use.
1	4266769	Pain at movement	For pain at movement and at rest, no significant differences were found between the paracetamol/naproxen group and either the paracetamol/CR oxycodone for 24 hours group (β = 2.6 [4.9]; P = 0.597) or the paracetamol/CR oxycodone for 48 hours (β = –1.7 [5.1]; P = 0.736).
1	4266769	Pain at rest	For pain at movement and at rest, no significant differences were found between the paracetamol/naproxen group and either the paracetamol/CR oxycodone for 24 hours group (β = 2.6 [4.9]; P = 0.597) or the paracetamol/CR oxycodone for 48 hours (β = –1.7 [5.1]; P = 0.736).
1	4266769	Pain at rest	For pain at movement and at rest, no significant differences were found between the paracetamol/naproxen group and either the paracetamol/CR oxycodone for 24 hours group (β = 2.6 [4.9]; P = 0.597) or the paracetamol/CR oxycodone for 48 hours (β = –1.7 [5.1]; P = 0.736).
1	4266769	Compliance	Compliance was comparable across the groups.
1	4266769	Pain at movement	For pain at movement and at rest, no significant differences were found between the paracetamol/naproxen group and either the paracetamol/CR oxycodone for 24 hours group (β = 2.6 [4.9]; P = 0.597) or the paracetamol/CR oxycodone for 48 hours (β = –1.7 [5.1]; P = 0.736).
1	4266769	Mayor adverse effects	No major adverse effects of study medication were registered and satisfaction with postoperative pain treatment was high in all groups.
2	5919699	moderate physical activity	A total of 57 participants (79.2%) completed the trial. Intention-to-treat analysis indicated that moderate physical activity level increased significantly by 269.4 ± 260.6 minutes per week in the exercise group (mean between-group difference, 254.6 minutes; 95% confidence interval, 172.7–434.7; p < 0.001).
0	3687261	peak blood glucose	Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (placebo < 0.01 for each) and were lowest after SX (placebo < 0.05 for each), while overall blood glucose was lower after SX than PC (placebo < 0.05).
0	3687261	amplitude of glycemic excursion	Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (placebo < 0.01 for each) and were lowest after SX (placebo < 0.05 for each), while overall blood glucose was lower after SX than PC (placebo < 0.05).
2	3687261	plasma glucagon-like peptide-1 before consuming the meal	Plasma glucagon-like peptide-1 concentrations were higher after d-xylose than control only before the meal (placebo < 0.05) but were sustained postprandially when combined with sitagliptin (placebo < 0.05).  
0	3687261	overall blood glucose	Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (placebo < 0.01 for each) and were lowest after SX (placebo < 0.05 for each), while overall blood glucose was lower after SX than PC (placebo < 0.05).
1	4644305	Decrease in 10-point numerical rating scale (numerical rating scale) at the first follow-up evaluation - Painful diabetic peripheral neuropathy (diabetic peripheral neuropathy)	In both groups, the numerical rating scale rating significantly decreased after treatment, with a marked pain reduction observed at the first follow-up evaluation.
2	4644305	superior efficacy	However, pulsed radiofrequency lumbar sympathectomy seems to have a superior efficacy.
0	4608626	Raven's Colored Progressive Matrice completion time	In the music therapy group, the time for completion of the Japanese Raven's Colored Progressive Matrices was significantly reduced (p = 0.026), and the results obtained from interviewing the patients' caregivers revealed a significant decrease in the Neuropsychiatric Inventory score (p = 0.042) and a prolongation of the patients' sleep time (p = 0.039).
0	4608626	Neuropsychiatric Inventory score	In the music therapy group, the time for completion of the Japanese Raven's Colored Progressive Matrices was significantly reduced (p = 0.026), and the results obtained from interviewing the patients' caregivers revealed a significant decrease in the Neuropsychiatric Inventory score (p = 0.042) and a prolongation of the patients' sleep time (p = 0.039).
2	4608626	Sleep time	In the music therapy group, the time for completion of the Japanese Raven's Colored Progressive Matrices was significantly reduced (p = 0.026), and the results obtained from interviewing the patients' caregivers revealed a significant decrease in the Neuropsychiatric Inventory score (p = 0.042) and a prolongation of the patients' sleep time (p = 0.039).
1	5614960	Time to failure	No differences emerged between implementation intention and control participants regarding time to failure and performance quality.
2	5614960	Perceived exertion	Compared to the control condition, participants in the implementation intention condition reported substantially greater increases in Ratings of perceived exertion during the second half of the task and reached higher total values of Ratings of perceived exertion before task termination.
2	4227976	mean score of sexual satisfaction	A significant difference between the two groups regarding sexual satisfaction after the intervention (p=0.003) compared to the beginning of the study (p=0.356).
2	4396724	Duration of vigorous physical activity weekly	Minutes spent in vigorous physical activity per week measured by accelerometer were higher in High-intensity interval training (24 ± 18) as compared to moderate-intensity continuous training (11 ± 10) at one-month follow-up (P = 0.049, Cohen's d = 0.92).
2	4396724	Adherence to training after 1 month	Individuals in High-intensity interval training (89 ± 11%) adhered to their prescribed protocol to a greater extent than individuals in moderate-intensity continuous training (71 ± 31%) as determined by training logs completed over one-month follow-up (P = 0.05, Cohen's d = 0.75).
1	3410988	Test scores on measures of episodic and spatial memory	Although no significant differences were observed between the memantine and placebo groups on the two primary outcome measures, we found a significant improvement in the memantine group in one of the secondary measures associated with the primary hypothesis.
2	5217809	weight of infants	The weight of infants in the intervention group was significantly higher than that of those in the control group (p<0.001).  
2	3575357	EQ-5D quality of life in men	This pilot study had a significant impact on the quality of life (p = 0.05) in men, which increased.
1	3575357	EQ-5D quality of life in women	However, the quality of life in women did not improve.
1	3620559	The number of oocytes per the number of aspirated follicles	The standard diameter needle was used to collect a total of 215 oocytes from 355 aspirated follicles (60.6%) compared to 203 oocytes from 352 aspirated follicles (57.7%) with the thinner needle (p = 0.23).
1	3620559	oocyte yield among women with normal ovarian reserve	Stratifying outcomes by anti-Müllerian hormone (anti-Müllerian hormone), as indicator of ovarian reserve, and by body mass index (body mass index) the oocyte yields, still, did not differ (anti-Müllerian hormone, r (17) = −0.20, p = 0.44; body mass index, r (17) =0.02, p = 0.96).
2	3620559	Operating time	Operating time was, however, significantly increased by 3.3 minutes per ovary (z = −3.08, p = 0.002) with the thinner needle.  
1	3620559	oocyte yields among women with diminished ovarian reserve	Stratifying outcomes by anti-Müllerian hormone (anti-Müllerian hormone), as indicator of ovarian reserve, and by body mass index (body mass index) the oocyte yields, still, did not differ (anti-Müllerian hormone, r (17) = −0.20, p = 0.44; body mass index, r (17) =0.02, p = 0.96).
1	3620559	Oocyte yield	Stratifying outcomes by anti-Müllerian hormone (anti-Müllerian hormone), as indicator of ovarian reserve, and by body mass index (body mass index) the oocyte yields, still, did not differ (anti-Müllerian hormone, r (17) = −0.20, p = 0.44; body mass index, r (17) =0.02, p = 0.96).
0	1332199	Post operative pain scores	Results: Post operative pain scores were significantly lower in the fentanyl and sufentanil groups compared to remifentanil group (55 ± 15, and 60 ± 10 versus 78± 12, P < 0.05).
2	1332199	length of stay in postoperative care unit (postoperative care unit)	Patients in the remifentanil group stayed longer in the postoperative care unit 108± 37 min versus 78±31 and 73 ± 25 min, (P< 0.05).
2	2808793	patients reaching remission	The remission rate (7 and below in Hamilton Rating Scales for Depression) of the forest group was 61% (14/23), significantly higher than both the hospital group (21%, 4/19) and the controls (5%, 1/21).
0	2808793	Montgomery-Asberg Depression Rating Scale (Montgomery-Asberg Depression Rating Scales) scores	Montgomery-Asberg Depression Rating Scales (Montgomery-Asberg Depression Rating Scales) scores of the forest group were significantly decreased compared with both the hospital group and the controls.
2	2808793	patients reaching remission	The remission rate (7 and below in Hamilton Rating Scales for Depression) of the forest group was 61% (14/23), significantly higher than both the hospital group (21%, 4/19) and the controls (5%, 1/21).
0	2808793	Hamilton Rating Scales for Depression (Hamilton Rating Scales for Depression) scores	Hamilton Rating Scales for Depression (Hamilton Rating Scales for Depression) scores of the forest group were significantly decreased after 4 sessions compared with controls.
0	2808793	Montgomery-Asberg Depression Rating Scale (Montgomery-Asberg Depression Rating Scales) scores	Hamilton Rating Scales for Depression (Hamilton Rating Scales for Depression) scores of the forest group were significantly decreased after 4 sessions compared with controls. Montgomery-Asberg Depression Rating Scales (Montgomery-Asberg Depression Rating Scales) scores of the forest group were significantly decreased compared with both the hospital group and the controls.
2	2762969	Use of statins and anti-platelet therapy at 18 months	When comparing users and non-users of the interdisciplinary diabetes care teams (irrespective of the intervention arm) and after 18 months of intervention the use of the interdisciplinary diabetes care teams was significantly associated with improvements in HbA1c, LDL-cholesterol, an increase in statins and anti-platelet therapy as well as the number of targets that were reached.
2	2762969	Improvements in levels of HbA1c and LDL-cholesterol at 18 months	When comparing users and non-users of the interdisciplinary diabetes care teams (irrespective of the intervention arm) and after 18 months of intervention the use of the interdisciplinary diabetes care teams was significantly associated with improvements in HbA1c, LDL-cholesterol, an increase in statins and anti-platelet therapy as well as the number of targets that were reached.
1	4132637	major bleeding	Major bleeding rate was similar between treatment groups (13.4 vs. 12.6%; hazard ratio 1.07; 95% confidence interval = 0.95–1.19), but ticagrelor was associated with an increase in non-CABG major bleeding (4.8 vs. 3.8%; hazard ratio 1.28; 95% confidence interval = 1.05–1.56).
2	4132637	non-CABG-related major bleeding	Major bleeding rate was similar between treatment groups (13.4 vs. 12.6%; hazard ratio 1.07; 95% confidence interval = 0.95–1.19), but ticagrelor was associated with an increase in non-CABG major bleeding (4.8 vs. 3.8%; hazard ratio 1.28; 95% confidence interval = 1.05–1.56).
1	5446739	Weight bearing pain	Mean changes of weight-bearing pain at 12 weeks after the last injection were −33.3 mm with XLHA and −29.2 mm with HMWHA, proving non-inferiority of XLHA to HMWHA as the lower bound of 95% CI (−1.9 mm, 10.1 mm) was well above the predefined margin (−10 mm).
2	3984795	Lipid profile improvement	The probiotic (VSL#3) supplemented group had significant reduction in total cholesterol, triglyceride, LDL, and VLDL and had increased HDL (P < 0.05) value.
1	2936735	decrease in infection - effect of multimodality chest physiotherapy in intensive care units for prevention of ventilator-associated pneumonia (ventilator-associated pneumonia) in intubated and mechanically ventilated patients	The Clinical Pulmonary infection Score (Clinical Pulmonary infection Score) Score showed significant decrease at the end of extubation/successful outcome or discharge in both the groups (P = 0.00).
0	2936735	mortality rates - effect of multimodality chest physiotherapy in intensive care units for prevention of ventilator-associated pneumonia (ventilator-associated pneumonia) in intubated and mechanically ventilated patients	In addition, significant decrease in mortality rate was noted in the study group (24%) as compared to the control group (49%) (P = 0.007).  
1	2223531	Toxicity	Toxicities of oral etoposide phosphate were not different from those known for etoposide.
1	2223531	Median AUC(inf)	The median AUC(inf) (area under the concentration vs time curve from zero to infinity) of etoposide was 77.7 mg l(-1) h after etoposide phosphate (95% CI 61.3-100.5) and 62.0 mg l(-1) h after oral etoposide (95% CI 52.2-76.9). The difference in favour of etoposide phosphate was borderline significant: median 9.9 mg l(-1) h (95% CI 0.1-32.8 mg l(-1) h; P = 0.05).
1	2223531	Median AUC(inf)	In conclusion, oral etoposide phosphate does not offer a clinically relevant benefit over oral etoposide.
2	5168495	Adherence at 3 months	There was a statistically significant improvement in adherence in the intervention group compared to control at 3 months (mean Medication Adherence Questionnaire score 0.42: 95% CI (0.27 to 0.57) vs 1.58: 95% CI (1.42 to 1.75); p<0.001).
2	5168495	Adherence at 6 months	The significant improvement in Medication Adherence Questionnaire score in the intervention group compared to control was sustained at 6 months (0.48: 95% CI (0.31 to 0.65) vs 1.48: 95% CI (1.27 to 1.69); p<0.001).  
1	5168495	Baseline demographics and mean Medication Adherence Questionnaire score	The mean Medication Adherence Questionnaire score at baseline in the intervention and control were similar (1.58: 95% CI (1.38 to 1.78) and 1.60: 95% CI (1.43 to 1.77), respectively).
1	3842830	Daily OFF time	ResultsThe change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, P = .003) and istradefylline 40 mg/day (−0.96 hours, P = .003) groups compared with the placebo group (−0.23 hours).
0	3842830	Daily OFF time	ResultsThe change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, P = .003) and istradefylline 40 mg/day (−0.96 hours, P = .003) groups compared with the placebo group (−0.23 hours).
1	2972614	Severity of pain	In group I, statistically significant improvements in pain severity, range of motion except internal and external rotation and SPADI scores were observed compared to baseline scores after the therapy (p<0.05). In Group II, all parameters except range of motion of external rotation were improved (p<0.05). However, no significant differences were recorded between the groups (p>0.05).  
1	2972614	Shoulder Pain and Disability Index score	In group I, statistically significant improvements in pain severity, range of motion except internal and external rotation and SPADI scores were observed compared to baseline scores after the therapy (p<0.05). In Group II, all parameters except range of motion of external rotation were improved (p<0.05). However, no significant differences were recorded between the groups (p>0.05).  
1	2972614	Motion range	In group I, statistically significant improvements in pain severity, range of motion except internal and external rotation and SPADI scores were observed compared to baseline scores after the therapy (p<0.05). In Group II, all parameters except range of motion of external rotation were improved (p<0.05). However, no significant differences were recorded between the groups (p>0.05).  
1	2972614	Motion range	The Low level laser therapy seems to have no superiority over placebo laser therapy in reducing pain severity, range of motion and functional disability.
0	5045904	Serum neuron-specific enolase level after 7 days	After the 7-day treatment, patients in the magnesium sulfate treatment group, compared with those in the control group, had a lower serum neuron-specific enolase level (25.40±6.66 vs 29.58±7.32, respectively, P=0.001) and higher Glasgow coma scale score (8.23±2.72 vs 7.05±2.64, respectively, P=0.016).
1	5045904	Mortality rate	Although the length of stay and mortality did not differ between the groups in the intensive care unit, Glasgow outcome scale score was significantly lower in the magnesium sulfate treatment group at discharge (3.30±1.35 vs 3.90±1.10, P=0.004) and 3 months after discharge (2.95±1.48 vs 3.66±1.44, P=0.009).  
0	5045904	Glasgow outcome scale score at discharge and 3 months after discharge	Although the length of stay and mortality did not differ between the groups in the intensive care unit, Glasgow outcome scale score was significantly lower in the magnesium sulfate treatment group at discharge (3.30±1.35 vs 3.90±1.10, P=0.004) and 3 months after discharge (2.95±1.48 vs 3.66±1.44, P=0.009).  
2	5045904	Glasgow coma scale scores after 7 days	After the 7-day treatment, patients in the magnesium sulfate treatment group, compared with those in the control group, had a lower serum neuron-specific enolase level (25.40±6.66 vs 29.58±7.32, respectively, P=0.001) and higher Glasgow coma scale score (8.23±2.72 vs 7.05±2.64, respectively, P=0.016).
1	5045904	Lenght of stay in the ICU	Although the length of stay and mortality did not differ between the groups in the intensive care unit, Glasgow outcome scale score was significantly lower in the magnesium sulfate treatment group at discharge (3.30±1.35 vs 3.90±1.10, P=0.004) and 3 months after discharge (2.95±1.48 vs 3.66±1.44, P=0.009).  
2	5842771	The Mini Mental State Examination (Mini Mental State Examination)	But, compared to the control group, the experimental group had a significantly higher average Mini Mental State Examination score (p<0.00001), lower average Activities of Daily Living score (p=0.00002), and lower average Clinical Dementia Rating Scale score (p=0.030).
1	3984270	short-term graft function	Thus, in a porcine experimental model α-MSH did not reduce renal inflammation and did not improve short-term graft function following deceased brain dead kidney transplantation.
2	3984270	primary dysfunction after kidney transplant	α-MSH treatment reduced urine flow and impaired recovery of glomerular filtration rate (glomerular filtration rate) compared to controls.
1	3984270	inflammation after kidney transplant	α-MSH did not affect expression of inflammatory markers.
0	5720557	Use of non�coplanar beams	The use of non‐coplanar beams was more common with Perspecta plans (82% vs. 27%). The mean target dose differed by less than 2% between rival plans.
1	5720557	Plan preference, planner, or planning institution	About 57% of normal organs received less dose from Perspecta plans. No statistically significant association was found between plan preference and planning institution or planner.  
2	5846971	Quality of life after 3 months	After 3 months, there was an intervention effect on environmental quality of life (group × time p = .048).
2	5846971	Sense of coherence	Sense of coherence increased in RT2 compared to the control group and RT3 (group × time p = .032).  
2	5129050	Peer support	Compared with control, intervention students reported greater peer support 0.5 (0.1 to 0.9) p=0.03, well-being 1.8 (0.1 to 3.4) p=0.04 but no difference in shyness/sociability.
2	5129050	Well-being	Compared with control, intervention students reported greater peer support 0.5 (0.1 to 0.9) p=0.03, well-being 1.8 (0.1 to 3.4) p=0.04 but no difference in shyness/sociability.
1	5129050	Sociability	Compared with control, intervention students reported greater peer support 0.5 (0.1 to 0.9) p=0.03, well-being 1.8 (0.1 to 3.4) p=0.04 but no difference in shyness/sociability.
2	4667406	Progressive pain relief	Clinical response rates and pain relief were significantly better at 1, 4, and 12 weeks for those receiving local anaesthetic injections than ischemic compression via physical therapy. The pain relief of women treated with local anaesthetic injections progressively improved at 1, 4, and 12 weeks after intervention.
0	3800406	stain intensity after 21 days	Group II showed significantly less stain intensity in comparison with group I after 14 and 21 days (P values 0.025 and 0.005, respectively).
0	3800406	stain intensity after 14 days	Group II showed significantly less stain intensity in comparison with group I after 14 and 21 days (P values 0.025 and 0.005, respectively).
0	3800406	amount of plaque formed at end of week 1 and 2	The plaque formation was significantly less in groups II and III than group I at 7, 14, and 21 days.  
2	3678237	Consciousness Commands improvement	This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).  
2	3678237	Facial palsy score improvement	This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).  
2	3678237	Motor arm Score improvement	This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).  
2	3678237	Best language score improvement	This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).  
2	3678237	Sensory score improvement	Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in National Institutes of Health Stroke Scale (P= 0.0001). This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).  
2	3678237	Motor leg Score improvement	Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in National Institutes of Health Stroke Scale (P= 0.0001). This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).  
2	5225252	Gag-specific IFN-? enzyme-linked immunospot–determined response rates and geometric mean responses	Gag-specific IFN-γ enzyme-linked immunospot–determined response rates and geometric mean responses were higher (96% and 248 spot-forming units, respectively) in groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) than those after a single dose of Ad35-GRIN (56% and 54 spot-forming units, respectively) or SeV-Gag (55% and 59 spot-forming units, respectively); responses persisted for ≥8 months after completion of the prime-boost regimen.
2	5225252	Functional CD8+ T-cell responses with greater breadth, magnitude, and frequency in a viral inhibition assay	Functional CD8+ T-cell responses with greater breadth, magnitude, and frequency in a viral inhibition assay were also seen in the SLA and SHA groups after Ad35-GRIN boost, compared with those who received either vaccine alone.
1	3916852	Perioperative fever	Results: There were no differences in perioperative fever (>38 °C), infectious complications, length of hospital stay (>14 days), length of critical care stay (>2 days), time for oral food intake, and in-hospital mortality between the two groups.
1	3916852	In-hospital mortality	Results: There were no differences in perioperative fever (>38 °C), infectious complications, length of hospital stay (>14 days), length of critical care stay (>2 days), time for oral food intake, and in-hospital mortality between the two groups.
2	3916852	IgG levels	The test group showed a higher increase in IgG level compared with the medium chain triglyceride/long chain triglyceride group (p = 0.028).
2	3916852	IgG levels	The test group was given enteral nutrition (enteral nutrition) with parenteral nutrition containing olive oil-based lipid emulsion after tumor resection for ≥7 days, and the patients in the control group were supported by enteral nutrition with medium chain triglyceride/long chain triglyceride emulsion-based parenteral nutrition after surgery for the same time period.
1	3585302	global composition of the microbiota in colicky infants	L. reuteri DSM 17938 did not affect the global composition of the microbiota.
1	3585302	global composition of the microbiota in colicky infants	Treatment with L. reuteri DSM 17938 did not change the global composition of the microbiota, but when comparing responders with non-responders the group responders had an increased relative abundance of the phyla Bacteroidetes and genus Bacteroides at day 21 compared with day 0.
2	5772830	blind-side detection	P-prisms improved blind-side detection from 42% to 56%, which further improved after training to 72% (all P < 0.001).
2	5772830	blind-side detection	P-prisms improved blind-side detection from 42% to 56%, which further improved after training to 72% (all P < 0.001).
0	4258972	consumption of propofol	A significant reduction in consumption of propofol with the use of midazolam (P < 0.001) and clonidine (P < 0.001) was observed.
0	4258972	consumption of propofol	A significant reduction in consumption of propofol with the use of midazolam (P < 0.001) and clonidine (P < 0.001) was observed.
0	5724392	Iron burden	Iron burden decreased more in the Alternative Arm, with ferritin difference −1047 ng/mL (−1524, −570), p<0.001 and liver iron difference −4.3 mg Fe/gm dry weight (−6.1, −2.5), p=0.001.  
1	5129820	The Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Ovarian Symptom Index (FACT/NCCN Ovarian Symptom Index)	There were no statistically significant differences in time to worsening or improvement rates of Trial Outcome Index, FACT/NCCN Ovarian Symptom Index and FACT-Ovarian scores in the overall, BRCA1/2 mutation and germline BRCA1/2 mutation populations.  
1	5129820	Trial Outcome Index (Trial Outcome Index)	There were no statistically significant differences in time to worsening or improvement rates of Trial Outcome Index, FACT/NCCN Ovarian Symptom Index and FACT-Ovarian scores in the overall, BRCA1/2 mutation and germline BRCA1/2 mutation populations.  
1	5442201	Pain	No statistically significant difference in perceived pain between the instruments used was found.  
1	5442201	Pain	The average visual analogue scale for the test device Piezon Master 700 with NO PAIN technology was 3.16 ± 2.10, and for the control device Mini Piezon without NO PAIN technology 3.40 ± 2.59 (p = 0.490).
1	3658388	Connected Speech Test (CST) rau score	No statistically significant differences were found between groups for any of the auditory tests.
0	3484141	Risk of prostate cancer	Men with serum higher thyroid-stimulating hormone had a decreased risk of prostate cancer compared to men with lower thyroid-stimulating hormone (Q5 vs. Q1–4: Odds ratios = 0.70, 95% confidence intervals: 0.51–0.97, p = 0.03).
1	3480782	Immediate efficacy	There was no statistically significant difference in immediate efficacy.
0	3480782	Preferred intranasal corticosteroid	Patients (58% males; pooled median age 32 years [Interquartile range, IQR, 25–41]; pooled median symptom duration 24 months [IQR 12–72]) preferred fluticasone propionate over ciclesonide nasal spray overall (55.41% vs. 25.68%, P = 0.007) and also with respect to attributes of scent, soothing feel, and nasal irritation.
0	3480782	Preferred intranasal corticosteroid	fluticasone propionate was preferred over ciclesonide with respect to scent, soothing feel and nasal irritation, and also overall.
0	4856346	viewing times	As expected, negative tweets drew longer viewing times and elicited more attention to themselves than positive tweets.
1	3662597	Lipid parameters	There was no group × time interaction for heart rate, blood pressure, blood glucose, lipids, NOx, high sensitivity C-reactive protein, cortisol concentrations or body fat.
1	3662597	Levels of nitrate/nitrite (NOx), cortisol, and high sensitivity C-reactive protein (high sensitivity C-reactive protein)	There was no group × time interaction for heart rate, blood pressure, blood glucose, lipids, NOx, high sensitivity C-reactive protein, cortisol concentrations or body fat.
1	3662597	Body fat	There was no group × time interaction for heart rate, blood pressure, blood glucose, lipids, NOx, high sensitivity C-reactive protein, cortisol concentrations or body fat.
1	3662597	Cardiovascular health parameters	There was no group × time interaction for heart rate, blood pressure, blood glucose, lipids, NOx, high sensitivity C-reactive protein, cortisol concentrations or body fat.
1	3662597	Cardiovascular health parameters	Six weeks of multi-ingredient performance supplements ingestion and periodized resistance training does not alter cardiovascular health parameters or blood indices of health or body fat more than a Placebo treatment in healthy, resistance-trained men.
2	3662597	Total body mass and fat-free mass	Six weeks of multi-ingredient performance supplements ingestion and periodized resistance training does not alter cardiovascular health parameters or blood indices of health or body fat more than a Placebo treatment in healthy, resistance-trained men. However, multi-ingredient performance supplements significantly increased fat, fat-free mass more than Placebo.
2	3376522	Revisiting the program	Finally, using a proactive strategy influenced sustained use, with people from the prompting condition being more likely to revisit the program (odds ratio 28.92, 95% confidence interval 10.65–78.52; P < .001).  
1	5655938	Feedback provided	Despite this stereotype activation, student ethnicity had no influence on examiners' scores; on the feedback examiners gave; or on examiners' memories for one performance.  
1	3311713	Decrease in lumbar spine mineral density (bone mineral density)	Hip (p=0.007) and lumbar spine (p=0.05) bone mineral density decreased with weight loss, and remained reduced after weight regain with or without exercise.
1	3311713	Decrease in Hip bone mineral density (bone mineral density)	Hip (p=0.007) and lumbar spine (p=0.05) bone mineral density decreased with weight loss, and remained reduced after weight regain with or without exercise.
1	3311713	changes in Osteocalcin (OC)	Likewise, the weight-loss-associated increases in osteocalcin (p<0.001) and C-terminal peptide of type I collagen (p<0.001) persisted following weight regain, independent of exercise.  
1	3953439	Pain visual analogue scale	All pre-post-treatment differences were significant; however, there was no significant difference between the treatment group and the control group.
1	3953439	Pain visual analogue scale	VAS decreased from 58.3 ± 18.2 to 42.2 ± 21.1 (treatment group) and from 51.8 ± 18.8 to 30.6 ± 21.9 (control group).
1	3953439	Oswestry disability index	All pre-post-treatment differences were significant; however, there was no significant difference between the treatment group and the control group.
1	3953439	Roland-Morris questionnaire score	Roland-Morris questionnaire value decreased from 9.8 ± 5.1 to 6.4 ± 4.4 (treatment group), and from 9.3 ± 5.5 to 6.1 ± 4.6 (control group).
1	3953439	Roland-Morris questionnaire score	All pre-post-treatment differences were significant; however, there was no significant difference between the treatment group and the control group.
2	4030121	Root mean square of the successive differences	Student t test indicated significantly higher SNDD values (60.46 ms vs. 37.42 ms, P=0.003) and root mean square of the successive differences (57.90 ms vs. 26.92 ms, P=0.000) in the patient group than in the control group. In the patient group, root mean square of the successive differences (80.41 ms vs. 45.89 ms, P=0.015) and normalized high frequency (61.18 ms vs. 43.19 ms, P=0.022) were significantly higher in adolescents, whereas normalized low frequency (38.81 ms vs. 56.76 ms, P=0.022) and low frequency to high frequency ratio ratio (0.76 vs. 1.89, P=0.041) were significantly lower in adolescents. In contrast, the control group did not have significant differences in heart rate variability values between adolescents and preadolescents.  
2	4030121	Average R-R intervals SD	Student t test indicated significantly higher SNDD values (60.46 ms vs. 37.42 ms, P=0.003) and root mean square of the successive differences (57.90 ms vs. 26.92 ms, P=0.000) in the patient group than in the control group.
2	5442667	Medication appropriateness index improvement	The targeted Medication therapy management intervention resulted in statistically significant clinical dementia rating adjusted differences between groups with regard to improved medication appropriateness index (change score of 3.6 (1.1) for the Medication therapy management group as compared with 1.0 (0.9) for the control group, p = 0.04) and anticholinergic drug scale (change score of 1.0 (0.3) for the Medication therapy management group as compared with 0.2 (0.3) for the control group, p = 0.03).  
2	5442667	Anticholinergic drug scale improvement	The targeted Medication therapy management intervention resulted in statistically significant clinical dementia rating adjusted differences between groups with regard to improved medication appropriateness index (change score of 3.6 (1.1) for the Medication therapy management group as compared with 1.0 (0.9) for the control group, p = 0.04) and anticholinergic drug scale (change score of 1.0 (0.3) for the Medication therapy management group as compared with 0.2 (0.3) for the control group, p = 0.03).  
0	5461594	Low density lipoprotein (LDL)	High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively, P < 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001).
0	5461594	Time between menstrual cycles	The interval between periods in omega-3 was significantly shorter than control (29.83 ± 4.68 vs. 47.11 ± 8.72 days, respectively, P < 0.001).  
2	5461594	High density lipoprotein (HDL)	High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively, P < 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001).
0	5461594	Triglycerides	High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively, P < 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001).
0	5461594	Cholesterol	High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively, P < 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001).
0	5461594	Waist circumference	After 6 months' intervention, waist circumference (waist circumference) was significantly lower in omega-3 as compared to control (81.18 ± 2.87 vs. 84.22 ± 2.61 cm, respectively, P < 0.0001).
2	2363617	N1 and N2 groups	The former 1987 N1 and N2 group were significantly split into three new N 1997 groups (P = 0.006, respectively P< 0.0005).
2	2363617	better prognosticator	In addition, the new TNM stage was also a better prognosticator.
2	2363617	requirement for the examination of nodes for N0	A second change is the requirement for the examination of at least 15 nodes to justify the N0 status.
1	4509558	Glycated hemoglobin A1c (hemoglobin A1c)	At the end point, 22 patients (78.6 %) in sleeve gastrectomy group and 23 patients (85.2 %) in Roux-en-Y gastric bypass group achieved complete remission of diabetes mellitus with hemoglobin A1c < 6.0 % (P = 0.525) and without taking diabetic medications, and 25 patients in each group (89.3 % vs. 92.6 %) gained successful treatment of diabetes with HbA1c≦6.5 % (P = 0.100).
1	4509558	hemoglobin A1c, fasting blood glucose and C peptid	Change in hemoglobin A1c, fasting blood glucose and C peptide were comparable in the two groups.
0	4794897	beta-isomer of carboxy-terminal telopeptide of type I collagen	pyridinoline and CTX-I decreased significantly in arm A. PINP can be considered as a complementary tool for prediction of local response, and PINP as well as bone alkaline phosphatase for avoidance of skeletal-related events.  
0	3329225	Change of total Genant-modified Sharp score	Change of total Genant-modified Sharp score was lower in patients receiving tocilizumab than placebo (tocilizumab: 0.29±0.96; placebo: 0.90±1.92; p=0.0007).
0	3329225	Difference in radiographic progression	Change of total Genant-modified Sharp score was lower in patients receiving tocilizumab than placebo (tocilizumab: 0.29±0.96; placebo: 0.90±1.92; p=0.0007). In patients receiving placebo, the correlation with total Genant-modified Sharp score change was significant for baseline scores of the simplified disease activity index (simplified disease activity index; r=0.18, p=0.047) and swollen joint count 28 (r=0.22, p=0.019), with similar trends for C-reactive protein. Similar correlations were seen for simplified disease activity index, clinical disease activity index, disease activity score 28 at 1 year with x-ray change during that year (r=0.26–0.28, p=0.002–0.006).
0	4796524	Urinary leakage	Urinary leakage was 3.3% overall, that all of them occurred in separate stent group, 37.5% vs. 0% in the linked stent group. Stent crustation in separate stent was 25% compared with 0% in the linked stent.  
0	4796524	Stent crustation	Urinary leakage was 3.3% overall, that all of them occurred in separate stent group, 37.5% vs. 0% in the linked stent group. Stent crustation in separate stent was 25% compared with 0% in the linked stent.  
1	4796524	UTI after 2 weeks	Second week and fourth week UTI reported 25.6%, 2.3% in study group versus 34.9%, 4.7% in control group (P value 0.48 and 0.5).
1	4796524	UTI after 4 weeks	Second week and fourth week UTI reported 25.6%, 2.3% in study group versus 34.9%, 4.7% in control group (P value 0.48 and 0.5).
1	4796524	UTI during discharge	Second week and fourth week UTI reported 25.6%, 2.3% in study group versus 34.9%, 4.7% in control group (P value 0.48 and 0.5).
1	4796524	UTI during discharge	Low complications rate in linked stent group, despite the lack of significant statistical differences, but indicate the effectiveness and success of the new technique.
2	4094569	forced expiratory volume in 1 second	Olodaterol significantly improved forced expiratory volume in 1 second area under the curve from 0–3 hours versus placebo in both studies (with olodaterol 5 μg, 0.151 L and 0.129 L; with olodaterol 10 μg, 0.165 L and 0.154 L; for all comparisons P<0.0001) and forced expiratory volume in 1 second trough responses versus placebo (0.053–0.085 L; P<0.01), as did formoterol.
2	4094569	forced expiratory volume in 1 second	Olodaterol significantly improved forced expiratory volume in 1 second area under the curve from 0–3 hours versus placebo in both studies (with olodaterol 5 μg, 0.151 L and 0.129 L; with olodaterol 10 μg, 0.165 L and 0.154 L; for all comparisons P<0.0001) and forced expiratory volume in 1 second trough responses versus placebo (0.053–0.085 L; P<0.01), as did formoterol.
2	4094569	forced expiratory volume in 1 second AUC from 0–3 hours	Olodaterol significantly improved forced expiratory volume in 1 second area under the curve from 0–3 hours versus placebo in both studies (with olodaterol 5 μg, 0.151 L and 0.129 L; with olodaterol 10 μg, 0.165 L and 0.154 L; for all comparisons P<0.0001) and forced expiratory volume in 1 second trough responses versus placebo (0.053–0.085 L; P<0.01), as did formoterol.
1	4094569	Transition dyspnea index focal score	Primary analysis revealed no significant difference in transition dyspnea index focal score for any active treatment versus placebo.
2	4094569	forced expiratory volume in 1 second	Olodaterol significantly improved forced expiratory volume in 1 second area under the curve from 0–3 hours versus placebo in both studies (with olodaterol 5 μg, 0.151 L and 0.129 L; with olodaterol 10 μg, 0.165 L and 0.154 L; for all comparisons P<0.0001) and forced expiratory volume in 1 second trough responses versus placebo (0.053–0.085 L; P<0.01), as did formoterol.
1	3987287	glucose uptake across the forearm muscle	HAM-RS2 resulted in significantly lower postprandial glucose concentrations (P=0.045) and a trend for greater glucose uptake across the forearm muscle (P=0.077); however, there was no effect of HAM-RS2 on hepatic or peripheral insulin sensitivity, or on HbA1c.
2	3987287	fasting plasma triglyceride (triglyceride) concentrations	Fasting triglyceride (triglyceride) concentrations and soleus intramuscular triglyceride concentrations were significantly higher following the consumption of HAM-RS2 (P=0.039 and P=0.027 respectively).
2	3987287	differential suppression of non-esterified fatty acid by insulin during the two-step clamp	Fasting non-esterified fatty acid (non-esterified fatty acid) concentrations were significantly lower (P=0.004) and non-esterified fatty acid suppression was greater during the clamp with HAM-RS2 (P=0.001).
0	3987287	Fasting GLP1 concentrations	Although fasting GLP1 concentrations were significantly lower following HAM-RS2 consumption (P=0.049), postprandial GLP1 excursions during the meal tolerance test were significantly greater (P=0.009).
0	3283075	Mature oocytes amount	The numbers of mature oocytes, fertilized oocytes and grade I, II embryos were significantly lower in group 2 than in group 1 or 3.
0	3283075	Fertilized oocytes	The numbers of mature oocytes, fertilized oocytes and grade I, II embryos were significantly lower in group 2 than in group 1 or 3.
0	3283075	Fertilized oocytes	The numbers of mature oocytes, fertilized oocytes and grade I, II embryos were significantly lower in group 2 than in group 1 or 3.
1	3283075	Clinical pregnancy rate	There were no significant differences in the clinical pregnancy rate and implantation rate among three groups.  
2	5372977	plasma and salivary nitrate and nitrite concentrations	Six days of BR ingestion increased plasma and salivary nitrate and nitrite concentrations in comparison to PLA (p < 0.001), and enhanced Yo-Yo IR1 test performance by 3.4 ± 1.3% (from 1574 ± 47 to 1623 ± 48 m; p = 0.027).
0	5372977	Mean heart rate	Mean heart rate was lower in the BR (172 ± 2) vs. PLA trial (175 ± 2; p = 0.014).
2	5372977	High-intensity intermittent running performance as assessed by the Yo-Yo IR1	Six days of BR ingestion effectively improves high-intensity intermittent type exercise performance in trained soccer players.
2	3425748	positive attitudes towards mental health issues in post-test period	The data analysis indicated a significant improvement in the Primary Health Care physicians' attitude after the course (P<0.0001).
2	3425748	changes in the attitude of Primary Health Care (Primary Health Care) physicians towards mental illnesses after a short-term training course	The data analysis indicated a significant improvement in the Primary Health Care physicians' attitude after the course (P<0.0001).
1	3422059	Shear bond strength	The mean shear bond strength obtained with an Er:YAG laser operated at 1W or 1.5W is approximately similar to that of conventional etching.
0	2952311	State-Trait Anxiety Inventory-I	Verbal rating scale, Neck Disability Index, State-Trait Anxiety Inventory and muscle hardness values decreased after acupressure in the LP and the distal acupuncture points group.
1	5502308	effects on renal function	Migalastat and enzyme replacement therapy had similar effects on renal function.
1	3557743	Rate of minor and major complications	There was no 30-day mortality and no significant difference in major complication rate (0% after Roux-en-Y gastric bypass and 8.3% after Laparoscopic sleeve gastrectomy, p > 0.05) or minor complication rate (16.6% after Roux-en-Y gastric bypass and 10.1% after Laparoscopic sleeve gastrectomy, p > 0.05).
1	3557743	Comorbidities	There was no significant difference in the overall prevalence of comorbidities and nutritional deficiencies.  
1	3557743	Early reoperations	There were no early reoperations after Roux-en-Y gastric bypass and 2 after Laparoscopic sleeve gastrectomy (5.5%) (p > 0.05).
1	3557743	Weight loss at 6 and 12 months	Weight loss was significant after Roux-en-Y gastric bypass and Laparoscopic sleeve gastrectomy but there was no difference between both groups at 6 and 12 months of follow-up.
2	5315239	Quality-of-life improvement after 3 months	Quality-of-life differences between values at 3 and 6 months versus baseline increased significantly more in the study group (P = .05 and .03, respectively), and so did general health perception differences at 6 months (P = .018).  
2	5315239	General health perception improvement after 6 months	Quality-of-life differences between values at 3 and 6 months versus baseline increased significantly more in the study group (P = .05 and .03, respectively), and so did general health perception differences at 6 months (P = .018).  
2	5315239	Quality-of-life improvement after 6 months	Quality-of-life differences between values at 3 and 6 months versus baseline increased significantly more in the study group (P = .05 and .03, respectively), and so did general health perception differences at 6 months (P = .018).  
1	5662512	Microhardness	Pairwise comparisons of the groups revealed that there was no significant difference between groups C and proanthocyanidin, proanthocyanidin and CP, F and PAF, F and FCP, PAF and FCP, and PACP and FPACP (P>0.05); but significant differences were observed between other groups (P<0.05).  
1	5662512	Microhardness	Pairwise comparisons of the groups revealed that there was no significant difference between groups C and proanthocyanidin, proanthocyanidin and CP, F and PAF, F and FCP, PAF and FCP, and PACP and FPACP (P>0.05); but significant differences were observed between other groups (P<0.05).  
1	5662512	Microhardness	Pairwise comparisons of the groups revealed that there was no significant difference between groups C and proanthocyanidin, proanthocyanidin and CP, F and PAF, F and FCP, PAF and FCP, and PACP and FPACP (P>0.05); but significant differences were observed between other groups (P<0.05).  
1	5662512	Microhardness	Pairwise comparisons of the groups revealed that there was no significant difference between groups C and proanthocyanidin, proanthocyanidin and CP, F and PAF, F and FCP, PAF and FCP, and PACP and FPACP (P>0.05); but significant differences were observed between other groups (P<0.05).  
2	5636088	2D healing at 8 weeks	Continuous rPTH1-34 significantly increased 2D healing and callus volumes at 4-weeks versus Placebo, and sustained the significant increase in cortical union at 8-week (p<0.05).
2	5636088	callus volumes at 4 weeks	Continuous rPTH1-34 significantly increased 2D healing and callus volumes at 4-weeks versus Placebo, and sustained the significant increase in cortical union at 8-week (p<0.05).
2	5636088	2D healing at 4 weeks	Continuous rPTH1-34 significantly increased 2D healing and callus volumes at 4-weeks versus Placebo, and sustained the significant increase in cortical union at 8-week (p<0.05).
1	4348728	Urinary Retention relief	Respectively, 59.5%, 71.4%, and 7.1% of patients in the hot pack, the soaked gauze, and the control groups experienced relief from urinary retention and the bladder was emptied. There was a significant difference among study groups in percentage of patients who experienced urinary retention relief. However, the difference between the two experimental groups was not significant.
2	4348728	Urinary Retention relief	Respectively, 59.5%, 71.4%, and 7.1% of patients in the hot pack, the soaked gauze, and the control groups experienced relief from urinary retention and the bladder was emptied. There was a significant difference among study groups in percentage of patients who experienced urinary retention relief.
2	5619630	Improvement in the Hamilton Rating Scale for Depression at 24 weeks	The medication-plus-exercise group showed significantly more improvement at 12 and 24 weeks than the medication-only group.
2	5963741	living conditions in perimenopausal women	Mild moxibustion significantly improved physical condition, living conditions, and emotional status compared to the control group after treatment (P<0.05).
2	5963741	emotional status in premenopausal women	Mild moxibustion significantly improved physical condition, living conditions, and emotional status compared to the control group after treatment (P<0.05).
2	5963741	emotional status in premenopausal women	Physical condition (P<0.01) and living conditions (P<0.05) improved significantly in post-menopausal women, while living conditions and emotional status were improved in pre-menopausal women (P<0.05).
2	5963741	E2 (estradiol) levels	Serum estradiol level was significantly higher after moxibustion, especially for pre-menopausal women (P<0.01).  
0	4222010	headache severity	The results of the LSD post-hoc test indicated that there were significant differences in the frequency, severity, and duration of pain among experimental groups and the control group.
0	4222010	primary headaches in healthcare providers	The results from the analysis of covariance showed that treatment with neurofeedback behavioural therapy and transcutaneous electrical nerve stimulation had caused significant decrease in the frequency, severity, and duration of headache in experimental groups. The results of the LSD post-hoc test indicated that there were significant differences in the frequency, severity, and duration of pain among experimental groups and the control group.
0	3681374	the reintubation rates related to noninvasive ventilation (noninvasive ventilation) failure	Considering only the subgroup of patients that used noninvasive ventilation, the reintubation rates related to noninvasive ventilation failure were significantly lower in the study group when compared with controls; two patients (6%) versus 13 (33%); P < 0.05, respectively.
0	3681374	duration of invasive mechanical ventilation	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under mechanical ventilation; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.
0	3681374	the reintubation rate	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under mechanical ventilation; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.
1	3681374	total ICU length of stay	No differences were found in the total ICU length of stay.  
0	2575601	Refractory intracranial pressure	Uncontrollable intracranial pressure occurred in 11 patients (50%) in the thiopental treatment group and in 18 patients (82%) in the pentobarbital group (P = 0.03).
1	2575601	Infection	There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.  
1	2575601	Hypotension	There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.  
2	2575601	Intracranial pressure control	Under logistic regression analysis – undertaken in an effort to adjust for the cranial tomography characteristics, which were unfavourable for pentobarbital – thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; P = 0.027).
0	2806530	Transcallosal inhibition in women	Results showed significant reductions in transcallosal inhibition after alcohol administration in female participants exclusively.  
0	5135478	Pain interference with function after 3 days	Pain interference with function scores were also significantly lower in the parecoxib/valdecoxib group, compared with placebo, on Day 2 (−29%, P<0.001) and Day 3 (−28%, P=0.013).
0	5135478	Pain after 2 days	Pain scores were reduced in the parecoxib/valdecoxib group (n=98), relative to placebo (n=97), on Day 2 (−21%, P<0.001) and Day 3 (−23%, P=0.004).
0	5135478	Pain after 3 days	Pain scores were reduced in the parecoxib/valdecoxib group (n=98), relative to placebo (n=97), on Day 2 (−21%, P<0.001) and Day 3 (−23%, P=0.004).
0	5135478	Pain interference with function after 2 days	Pain interference with function scores were also significantly lower in the parecoxib/valdecoxib group, compared with placebo, on Day 2 (−29%, P<0.001) and Day 3 (−28%, P=0.013).
0	5135478	Morphine consumption after 1 day	Consumption of supplemental morphine was significantly lower in the parecoxib/valdecoxib group relative to placebo at 24 hours (−37%, P=0.010) and trended lower at 48 (−28%) and 72 hours (−26%).
1	5135478	Morphine consumption after 2 days	Consumption of supplemental morphine was significantly lower in the parecoxib/valdecoxib group relative to placebo at 24 hours (−37%, P=0.010) and trended lower at 48 (−28%) and 72 hours (−26%).
1	4199180	Chance of survival	Though survival probability is higher among Group 1 patients but the difference is not statistically significant.  
2	4636656	Warwick Edinburgh Mental Wellbeing Scale (Warwick Edinburgh Mental Wellbeing Scale) scores intervention effect	Warwick Edinburgh Mental Wellbeing Scale scores fell from 50.4–49.0 in the control (n=59) and 51.0–49.9 in the intervention (n=225), giving an intervention effect of 0.5 (95% CI −3.2 to 4.2).
0	3269796	Mean procedure time	An objectively determined secondary endpoint; mean procedure time, skin-to-skin; also favored the OnControl Bone Marrow group (175 s) versus the standard bone marrow group (292 s), P<0.007.
2	3269796	Mean length of the specimens	The mean length of the marrow biopsy specimens was significantly longer (56%) for the OnControl Bone Marrow group (15.3 mm) than for the standard bone marrow (standard bone marrow) group (9.8 mm), P<0.003.
2	4415132	The average readings for the systolic blood pressure and diastolic blood pressure	The average readings for the systolic BP and diastolic BP were higher in the forearm than in the upper arm by approximately 3 mmHg. There was a statistically significant difference in both systolic BP and diastolic BP.  
1	4821226	femoral head necrosis (femoral head necrosis)	In contrast to that, we could not perceive any significant change in the volume of femoral head necrosis in both treatment groups related to the longitudinal course after treating.
1	4821226	the head survival rate	Over the period of two years there was no significant difference between the head survival rate between both groups.
1	4821226	clinical outcome	However, there was no difference in the clinical outcome between the two study groups.
0	4121491	Core temperature	The final core temperature was significantly higher in group 2 (35.4 ± 0.7°C) than in group 1 (34.9 ± 0.5°C).
2	5316445	Berg Balance Scale score improvement 8 weeks	Intent-to-treat analysis showed a significantly greater improvement in Berg Balance Scale in the exercise group (6.0; 95% CI, 5.1–6.9) compared to the control group (0.5; 95% CI, −0.3–1.3) at 8 weeks (average intergroup difference (95% CI), 5.5 (4.3–6.7), p < 0.001) after adjusting for baseline.
1	5316445	Adverse events	There were no study-related adverse events.
1	3664086	achieving pathologic complete response	Five patients in the rh-endostatin plus chemotherapy arm achieved pathologic complete response compared with 2 in the chemotherapy arm (P = 0.428).
1	3664086	quality of life score and side effects	No significant difference was identified in quality of life score and side effects (P > 0.05).  
2	5886394	Attention improvement	Results of linear mixed effects models indicated that the IOT+GOT showed significant improvements in verbal memory (p <0.01), working memory (p = 0.02), verbal fluency (p < 0.01), attention (p < 0.01), and composite score (p < 0.01) on the Brief Assessment of Cognition in Schizophrenia Japanese version; interest/enjoyment (p < 0.01), value/usefulness (p < 0.01), perceived choice (p < 0.01), and Intrinsic Motivation Inventory Japanese version total (p < 0.01) on the Intrinsic Motivation Inventory Japanese version; Morisky Medication Adherence Scale-8 score (p < 0.01) compared with the group OT alone.
2	5886394	Sense of Value	Results of linear mixed effects models indicated that the IOT+GOT showed significant improvements in verbal memory (p <0.01), working memory (p = 0.02), verbal fluency (p < 0.01), attention (p < 0.01), and composite score (p < 0.01) on the Brief Assessment of Cognition in Schizophrenia Japanese version; interest/enjoyment (p < 0.01), value/usefulness (p < 0.01), perceived choice (p < 0.01), and Intrinsic Motivation Inventory Japanese version total (p < 0.01) on the Intrinsic Motivation Inventory Japanese version; Morisky Medication Adherence Scale-8 score (p < 0.01) compared with the group OT alone.
2	5886394	Verbal fluency improvement	Results of linear mixed effects models indicated that the IOT+GOT showed significant improvements in verbal memory (p <0.01), working memory (p = 0.02), verbal fluency (p < 0.01), attention (p < 0.01), and composite score (p < 0.01) on the Brief Assessment of Cognition in Schizophrenia Japanese version; interest/enjoyment (p < 0.01), value/usefulness (p < 0.01), perceived choice (p < 0.01), and Intrinsic Motivation Inventory Japanese version total (p < 0.01) on the Intrinsic Motivation Inventory Japanese version; Morisky Medication Adherence Scale-8 score (p < 0.01) compared with the group OT alone.
2	5886394	Interest/enjoyment	Results of linear mixed effects models indicated that the IOT+GOT showed significant improvements in verbal memory (p <0.01), working memory (p = 0.02), verbal fluency (p < 0.01), attention (p < 0.01), and composite score (p < 0.01) on the Brief Assessment of Cognition in Schizophrenia Japanese version; interest/enjoyment (p < 0.01), value/usefulness (p < 0.01), perceived choice (p < 0.01), and Intrinsic Motivation Inventory Japanese version total (p < 0.01) on the Intrinsic Motivation Inventory Japanese version; Morisky Medication Adherence Scale-8 score (p < 0.01) compared with the group OT alone.
2	5886394	Working memory improvement	Results of linear mixed effects models indicated that the IOT+GOT showed significant improvements in verbal memory (p <0.01), working memory (p = 0.02), verbal fluency (p < 0.01), attention (p < 0.01), and composite score (p < 0.01) on the Brief Assessment of Cognition in Schizophrenia Japanese version; interest/enjoyment (p < 0.01), value/usefulness (p < 0.01), perceived choice (p < 0.01), and Intrinsic Motivation Inventory Japanese version total (p < 0.01) on the Intrinsic Motivation Inventory Japanese version; Morisky Medication Adherence Scale-8 score (p < 0.01) compared with the group OT alone.
0	4674480	Body weight	At end of study, differences between IDegLira and basal–bolus or up-titrated insulin glargine, respectively, were as follows: reduction in HbA1c −0.30%, 95% confidence interval (–0.58; −0.01) and −0.65% (−0.83; −0.47); change in body weight −6.89 kg (−7.92; −5.86) and −4.04 kg (−4.69; −3.40) all in favor of IDegLira.
0	4674480	Hypoglycemia	Confirmed hypoglycemia rate was 122.8 (90.7; 166.1), 1060.8 (680.2; 1654.4), and 286.1 (231.1; 354.1) events/100 patient-years for IDegLira, basal–bolus, and up-titrated insulin glargine, respectively.
0	4065280	Total lesion count	There was a significant mean reduction in total lesion count in the pantothenic acid group versus placebo at week 12 (P = 0.0197).
0	4065280	Inflammatory lesions	Mean reduction in inflammatory lesions was also significantly reduced and Dermatology Life Quality Index scores were significantly lower at week 12 in the pantothenic acid group versus placebo.
0	4065280	Dermatology Life Quality Index scores	Mean reduction in inflammatory lesions was also significantly reduced and Dermatology Life Quality Index scores were significantly lower at week 12 in the pantothenic acid group versus placebo.
2	5761719	discrimination	The PROMISE minimal-risk tool improved discrimination compared with the CAD Consortium model (c-statistic 0.785 vs 0.730, p < 0.001) and was improved further following re-estimation of covariate coefficients (c-statistic 0.805, p < 0.001).
